
<html lang="en"     class="pb-page"  data-request-id="ddad0e70-3720-419f-bab6-0376d72607b6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/jm301085w;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2012.55.issue-24;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors" /></meta><meta name="dc.Creator" content="Francesca  Musumeci" /></meta><meta name="dc.Creator" content="Marco  Radi" /></meta><meta name="dc.Creator" content="Chiara  Brullo" /></meta><meta name="dc.Creator" content="Silvia  Schenone" /></meta><meta name="dc.Description" content="The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future onco..." /></meta><meta name="Description" content="The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future onco..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 6, 2012" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301085w" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301085w" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301085w" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301085w" /></link>
        
    
    

<title>Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301085w" /></meta><meta property="og:title" content="Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0019.jpeg" /></meta><meta property="og:description" content="The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncologic therapy. In this Perspective we briefly report the inhibitors that are in clinical use, while we dedicate two wider sections to the compounds that are in clinical trials and to the new derivatives appearing in the literature. We especially consider the medicinal chemistry aspect of the topic and report the structure–activity relationship studies and the binding mode of some inhibitors as well as the biological data of the compounds discovered in the past 5 years." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301085w"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301085w">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301085w&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301085w&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301085w&amp;href=/doi/10.1021/jm301085w" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 10797-10822</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm301182j" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Musumeci">Francesca Musumeci</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marco++Radi">Marco Radi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chiara++Brullo">Chiara Brullo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Schenone">Silvia Schenone</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Dipartimento di Farmacia, University of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Dipartimento Famaceutico, University of Parma, Viale delle Scienze, 27/A, I-43124 Parma, Italy</span></div><div class="corresp-info"><strong>*</strong>Phone: +39 010 3538866. Fax: +39 010 3538358. E-mail: <a href="/cdn-cgi/l/email-protection#196a7a717c776a7075596c77707e7c37706d"><span class="__cf_email__" data-cfemail="c7b4a4afa2a9b4aeab87b2a9aea0a2e9aeb3">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301085w&amp;href=/doi/10.1021%2Fjm301085w" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 10797–10822</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 25, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 July 2012</li><li><span class="item_label"><b>Published</b> online</span>6 November 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 December 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301085w" title="DOI URL">https://doi.org/10.1021/jm301085w</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10797%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DFrancesca%2BMusumeci%252C%2BMarco%2BRadi%252C%2BChiara%2BBrullo%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D24%26contentID%3Djm301085w%26title%3DVascular%2BEndothelial%2BGrowth%2BFactor%2B%2528VEGF%2529%2BReceptors%253A%2BDrugs%2Band%2BNew%2BInhibitors%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10822%26publicationDate%3DDecember%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301085w"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5153</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">105</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301085w" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Musumeci&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;Radi&quot;},{&quot;first_name&quot;:&quot;Chiara&quot;,&quot;last_name&quot;:&quot;Brullo&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Schenone&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;10797-10822&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301085w&quot;},&quot;abstract&quot;:&quot;The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncologic therapy. In this Perspective we briefly report the inhibitors that are in clinical use, while we dedicate two wider sections to the compounds that are in clinical trials and to the new derivatives appearing in the literature. We especially consider the medicinal chemistry aspect of the topic and report the structure–activity relationship studies and the binding mode of some inhibitors as well as the biological data of the compounds discovered in the past 5 years.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301085w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301085w" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301085w&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301085w" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301085w&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301085w" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301085w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301085w&amp;href=/doi/10.1021/jm301085w" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301085w" /></input><a href="/doi/pdf/10.1021/jm301085w" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301085w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301085w%26sid%3Dliteratum%253Aachs%26pmid%3D23098265%26genre%3Darticle%26aulast%3DMusumeci%26date%3D2012%26atitle%3DVascular%2BEndothelial%2BGrowth%2BFactor%2B%2528VEGF%2529%2BReceptors%253A%2BDrugs%2Band%2BNew%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D24%26spage%3D10797%26epage%3D10822%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jmcmar.2012.55.issue-24/production/jmcmar.2012.55.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0019.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncologic therapy. In this Perspective we briefly report the inhibitors that are in clinical use, while we dedicate two wider sections to the compounds that are in clinical trials and to the new derivatives appearing in the literature. We especially consider the medicinal chemistry aspect of the topic and report the structure–activity relationship studies and the binding mode of some inhibitors as well as the biological data of the compounds discovered in the past 5 years.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Angiogenesis is the process consisting of blood vessel formation sprouting or splitting from pre-existing vessels. This process begins with dilatation of pre-existing capillaries and venules, followed by an increase of vascular permeability. Endothelial cells, which constitute the vessels, become activated, detach, migrate, and proliferate to form new sprouts.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Normal angiogenesis occurs during ovulation, wound healing, and reproduction.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In these physiological conditions, angiogenesis is stimulated by a wide range of endogenous molecules, including growth factors, adhesion factors (integrins, cadherins), proteinases (matrix metalloproteinases, urokinase plasminogen activators), extracellular matrix proteins (fibronectins, collagens), transcription factors (hypoxia inducible factor, nuclear factor κB), and signaling molecules (mTOR, Akt, PKA, COX-2). A number of other molecules, including thrombospondin-1, TIMP-1 (tissue inhibitor of metalloproteinase-1), interleukin 10, angiostatins, and endostatins are antiangiogenic factors present in the organism.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Physiological angiogenesis is tightly controlled by a complex balance among endogenous proangiogenic and antiangiogenic factors.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Aberrant angiogenesis is present in a wide range of diseases including retinopathies, arthritis, endometriosis, atherosclerosis, and cancer.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Starting from Folkman’s studies in the early 1970s,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> it has been demonstrated that the growth of primary tumors and their subsequent metastasis are angiogenesis-dependent processes. In fact, in order to grow beyond a size of 1–2 mm, tumors need new blood capillaries to create their own nutrient supply to remove metabolic waste and to facilitate metastasis formation.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Tumor-derived factors promote angiogenesis, causing an imbalance between proangiogenic and antiangiogenic factors. Hypoxic conditions in the center of the tumor mass stimulate the release of proangiogenic factors from tumor cells that are located in the proximity of pre-existing blood vessels and lead to the formation of new capillaries around the tumor mass.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In these situations, endothelial progenitor cells are mobilized from the bone marrow, differentiate into endothelial cells, and participate in the angiogenic process, stimulating neovascularization of ischemic tissues.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Perivascular progenitor cells also differentiate into perivascular mural cells, which cover and stabilize vessels in tumor.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p last">In 1989 Ferrara and colleagues published the amino acid sequence of a peptide, VEGF, later identified as VEGF-A, which stimulates endothelial cell mitosis.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Subsequent studies demonstrated that this growth factor is a potent angiogenesis stimulator and is a member of a family consisting of five homodimeric glycoprotein members, VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placenta growth factor (PlGF).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">VEGF Receptors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">VEGF family members bind in an overlapping pattern to three different but structurally correlated VEGF receptors (VEGFRs), which are transmembrane tyrosine kinases (TKs). VEGFR-1 (Flt-1) is critical for hematopoietic cell development, VEGFR-2 (human KDR or murine Flk-1) for vascular endothelial cell development, and VEGFR-3 (Flt-4) for lymphatic endothelial cell development. The expression of VEGFR-3 is associated with the dissemination of tumor cells to regional lymph nodes.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> VEGFRs are type III transmembrane kinase receptors and share a common structure that has been extensively described elsewhere.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Briefly, these receptors consist of an extracellular part composed of an N-terminal signal sequence and seven immunoglobulin-like domains followed by a single transmembrane segment. The intracellular portion of the receptor is constituted by a juxtamembrane (JM) segment, a TK domain, which is divided into proximal and distal kinase domains by an insert domain of about 70 amino acid residues, and a carboxy-terminal tail (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><div class="NLM_p">The binding of VEGFs to VEGFRs induces receptor dimerization, causing modification in the intracellular domain conformation. These conformational changes lead to the exposure of the ATP-binding site, followed by ATP binding and auto- or transphosphorylation on specific tyrosine residues on the receptor dimers<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and on downstream signal transducer proteins.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This mechanism leads to the initiation of a typical receptor signal transduction cascade, which activates several downstream enzymatic pathways, including p38MAPK, Raf/MEK/ERK, and PI3K/PKB pathways.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Tyrosine phosphorylation on VEGFRs is tightly regulated both by internalization and degradation and by dephosphorylation through different protein tyrosine phospatases.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of VEGER structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The biological and pathological roles of VEGFRs have been extensively studied and continue to be investigated.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> VEGFR-1 is a 180–185 kDa glycoprotein activated by the binding of VEGF-A, VEGF-B, and PlGF. The crystal structure of the receptor binding domain of VEGF bound to the second Ig loop of VEGFR-1 indicates that hydrophobic interactions stabilize the ligand–receptor dimers.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> VEGFR-1 is mainly expressed in vascular endothelial cells but is also present in nonendothelial cells, including monocytes, macrophages, renal mesangial cells, vascular smooth muscle cells, and dendritic cells. VEGFR-1 has been shown to mediate monocyte migration, recruitment of endothelial cell progenitors, hematopoietic stem cell survival, and release of growth factors from liver endothelial cells.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">The precise role of VEGFR-1 functions is still emerging, and it has been difficult to link the activation of VEGFR-1 to specific biological responses in cells that endogenously express this receptor. However, several studies in recent years have suggested that this receptor may play both negative and positive roles in angiogenesis. In fact, VEGFR-1 has negative functions, probably trapping VEGF-A in the embryo, and yet it shows a positive role in adulthood in a tyrosine-kinase-dependent manner.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Moreover, VEGFR-1 acts primarily as a decoy receptor, modulating the availability of VEGF-A and reducing its bioavailability to other receptors, in particular to VEGFR-2, which is the principal receptor in VEGF signaling.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Importantly, VEGFR-1-dependent signaling was shown to play a role in the angiogenesis of certain tumors as well as in the progression of rheumatoid arthritis and atherosclerosis.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> VEGFR-1 is up-regulated in several tumor cell lines, including malignant prostate cells,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> pancreatic cancer cells,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> malignant melanoma cells,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and lung adenocarcinoma cells.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Importantly VEGFR-1 is involved in tumor metastasis.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Thus, blocking the activity of VEGFR-1 has emerged as an antimetastasis strategy to target angiogenesis, cancer cell survival, and migration. In addition, it has the potential to reduce the recruitment of tumor-growth-promoting bone-marrow-derived cells. However, it seems that selective inhibition of VEGFR-1 activity does not change the rate of spontaneous metastasis formation after surgical removal of primary tumors.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> VEGFR-1 and VEGFR-2 also exist in soluble forms that are involved in angiogenesis and in different human diseases. High levels of soluble VEGFR-1 have been detected in several cancers, including breast, pancreatic, lung, and ovarian cancers and leukemias. On the other hand, administration of soluble VEGFR-1 has demonstrated antitumor effects, probably because the soluble receptor intercepts VEGF-A.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">VEGFR-2 is a 210–230 kDa glycoprotein that binds VEGF-A with a 10-fold lower affinity than VEGFR-1. It is expressed in vascular endothelial cells and also in hematopoietic stem cells.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> VEGFR-2 is the major regulator of VEGF-driven responses in endothelial cells, including permeability, proliferation, invasion, and migration. Moreover, it is considered to be a crucial signal transducer in both physiologic and pathologic angiogenesis. Its signaling pathways are relatively well understood, with Y1175 and Y1214 in human VEGFR-2 being the main autophosphorylation sites following VEGF binding. Autophosphorylated VEGFR-2 is required for activation of several downstream pathways, including PI3K, p38MAPK, FAK, Src, Akt, which are usually hyperactivated in several tumors.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> VEGFR-2 is overexpressed in several malignancies, including ovarian<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and thyroid cancer,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> melanoma,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and medulloblastoma.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> VEGFR-2 and VEGFR-3 are primarily located and significantly up-regulated on the tumor vasculature (blood and/or lymphatic) that supports the majority of solid cancers. Moreover, the signal intensity of both receptors is significantly higher in vessels associated with malignant colorectal, lung, and breast tumor tissues than in adjacent nontumor tissues.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p last">VEGFR-3 is synthesized as a precursor protein of 195 kDa. The precursor is proteolytically cleaved in the fifth Ig-like domain, generating an N-terminal peptide that remains disulfide-bonded to the mother protein. VEGFR-3 is activated by the binding of VEGF-C and VEGF-D.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> VEGFR-3 is deeply involved in the establishment and maintenance of the lymphatic system. Its expression in the adult seems to be largely restricted to lymphatic endothelial cells.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Furthermore, VEGFR-3 is strongly expressed in several human malignancies, including lung, cervical, breast, and colorectal cancers. Its higher levels are correlated with increased metastasis formation and shorter patient survival,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> since the lymphatic vessels surrounding the tumor play important roles in metastasis formation.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">VEGFR Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73473" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73473" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Therapeutic strategies based on the inhibition of VEGF or its receptor signaling systems are an attractive approach for the treatment of different diseases, primarily tumors. TK inhibitors that target VEGFRs, reducing angiogenesis and/or lymphangiogenesis, have been shown to possess anticancer activity. Generally they are small synthetic molecules that act with an ATP-competitive mechanism by binding the ATP pocket of the protein kinase domain.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> As a result of the similarity shared by VEGFR-1, -2, and -3, VEGFR inhibitors often target more than one member of the VEGFR family. However, this lack of selectivity among VEGFRs may be an advantage, since probably both VEGFR-1 and VEGFR-2 must be simultaneously inhibited to prevent tumor metastasis.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Furthermore the up-regulation of VEGFR-3 on tumor blood vessels indicates a potential additional antiangiogenic effect for dual VEGFR-2/VEGFR-3 inhibitors.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The lymphatic spread of malignancy may also be reduced by targeting VEGFR-3. A number of receptor TK families, such as PDGFRs, CSFR, c-Kit, and FLT3, share a substantial sequence homology with VEGFRs in their catalytic domains. For this reason, several compounds are not selective for VEGFRs. These often display high affinity for other TKs and are defined as multikinase inhibitors. Their poor selectivity among different TK families seems to offer different opportunities in cancer treatment. Several independent biological pathways that are vital for tumor proliferation and metastasis can be disrupted by these compounds.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Additionally, during VEGF inhibition, a hypoxic environment can drive a shift from VEGF dependent signaling to other proangiogenic pathways. For this reason, the use of multitargeted inhibitors should be of great therapeutic benefit.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Indeed, tumor angiogenesis is regulated by a number of proangiogenic factors other than VEGF, including FGFs (fibroblast growth factors), hepatocyte growth factor (HGF), and interleukin 8 (IL-8).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Even if the blockage of the VEGF/VEGFR signaling pathway alone has potent antitumor activity in animal models, this approach showed a reduced effect on some human tumors.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> For example, a switch from VEGF-dependent angiogenesis to FGF-2-dependent angiogenesis has been clearly demonstrated in pancreatic islet tumors in response to chronic blockade of VEGF signaling.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Angiopoietin-Tie receptors, ephrin-Eph receptors, and Delta-Notch pathways have also been identified as other major angiogenesis regulators.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_p">These insights in angiogenesis regulation strongly support the rationale for the use of multitargeted TK inhibitors, which have been shown to be more useful from a therapeutic point of view than selective VEGFR inhibitors.</div><div class="NLM_p">Therapies based on targeted antiangiogenic agents are supposed to be less toxic for chronic administration than conventional chemotherapy, since angiogenesis is a process usually restricted to the growing tumors.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Beside its antiangiogenic effects, VEGFR inhibition may help to normalize tumor vasculature. In fact, because of elevated VEGF expression, the tumor vessels are abnormal and inefficient with many blind ends, and it is difficult for conventional drugs to gain access to the tumor tissue. Moreover, drug penetration is diminished by the high interstitial pressure of many tumors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> VEGFR inhibitors, producing vascular normalization, lead to a decrease of vascular volume and interstitial pressure, enhancing the delivery of chemotherapeutic agents.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> A recent study is at odds with this hypothesis. Indeed, Van der Veldt and colleagues, using PET and radiolabeled docetaxel in NSCLC (non-small-cell lung cancer) patients receiving avastin (a monoclonal antibody inhibitor of VEGF-A) and docetaxel combination therapy, showed that there was no improvement in drug delivery to tumors.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> On the other hand, it has been demonstrated that antiangiogenic drugs prevent a rapid tumor cell repopulation after cytotoxic chemotherapy,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> strengthening the rationale for the combined use of conventional chemotherapeutic agents and VEGFR inhibitors.</div><div class="NLM_p">VEGFR inhibitors ultimately target endothelial cells that are genetically stable in comparison with the genetically more labile tumor cells.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Consequently, this type of drug should be less prone to inducing enzymatic mutations that confer resistance to the drug itself.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> This is in contrast to other TK inhibitors, such as the Bcr-Abl inhibitor imatinib used for chronic myeloid leukemia therapy,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> which frequently leads to drug resistance. However, it has been observed that some tumors can also become resistant to antiangiogenic drugs.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Some possible reasons for this resistance include the overexpression of different angiogenic factors during tumor progression, mainly in response to antiangiogenic treatment or the development of tumor cell clones that may better survive in hypoxic tumors after angiogenesis inhibition.<a onclick="showRef(event, 'ref11 ref57'); return false;" href="javascript:void(0);" class="ref ref11 ref57">(11, 57)</a> Several studies have highlighted the possibility that VEGFR inhibitors can promote an invasive metastatic switch, in part by creating an increasingly hypoxic tumor microenvironment. Consequently, although the therapy based on VEGFR inhibitors has demonstrated delayed tumor progression, leading to progression-free survival and overall survival benefits compared with standard chemotherapy, a significant number of patients either do not respond to antiangiogenic agents or develop resistance to them. Moreover, some cancers, once they develop resistance, become more invasive or lead to metastatic disease.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p">Another issue is the toxicity associated with the use of VEGFR inhibitors. Adverse event profiles are generally acceptable and can be classified in on-target adverse events caused by VEGFR inhibition and in off-target adverse events. The latter events are more frequent with multitargeted-kinase inhibitors<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and are due to the simultaneous inhibition of kinases different from VEGFRs. Off-target effects are more dependent on the characteristics of patients, comorbidities, and the stage of the disease.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> However, VEGFR inhibitors are generally less toxic than conventional chemotherapeutic agents, with the most common adverse effects being thromboembolic events, congestive heart failure, gastrointestinal perforation, and hypertension.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Particular attention must therefore be devoted to the toxicity evaluation of therapeutic protocols using associations of VEGFR inhibitors and conventional cytotoxic agents.</div><div class="NLM_p">In this Perspective the inhibitors already in clinical use are briefly reported, since there are plenty of articles focused on clinical aspects of each single drug, while two wider sections are dedicated to the compounds that are in clinical trials and to the new derivatives appearing in the literature. We especially consider the medicinal chemistry aspect of the topic and report the structure–activity relationship (SAR) studies and the binding mode of some inhibitors as well as the biological (enzymatic, in vitro and in vivo) data of all the compounds.</div><div class="NLM_p">Enzymatic data are given for each single kinase when available from the literature. For cell data and especially for in vivo data it is very difficult to determine the contribution of the inhibition of every single enzyme to the global activity of the drug (or inhibitor).</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> VEGFR Inhibitors Approved for Clinical Use</h3><div class="NLM_p">Targeting VEGF receptors represents one approach that has enjoyed a great therapeutic success. At the time of writing, five drugs targeting VEGFRs and usually also other kinases have been approved for clinical use. The literature on these compounds is very extensive, and studies on their use for different tumors are ongoing. An overview of the compounds currently used in clinical settings is given below in order to provide a basis for comparison with other inhibitors that have appeared more recently in the literature.</div><div class="NLM_p">Sorafenib, <b>1</b> (BAY-439006) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), trade name Nexavar, codeveloped and comarketed by Bayer and Onyx Pharmaceuticals, is a biarylurea multitargeted kinase inhibitor. It inhibits, among others, VEGFR-2 and VEGFR-3, PDGFRβ, c-Kit, and Raf .<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Importantly, it is the only approved drug shown to inhibit Raf, which is a critical component of the Ras pathway, a fundamental enzymatic cascade for cell division. Sorafenib was approved by U.S. FDA in 2005 for the treatment of advanced renal cell carcinoma (RCC) and in 2007 for the treatment of hepatocellular carcinoma (HCC).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> All the drugs reported in this section have been approved for RCC but only sorafenib for HCC. Probably the positive clinical trial results that led to sorafenib’s approval for HCC are due to the inhibitory activity of this drug on Raf. Indeed, overexpression of Raf and its pathway are frequently observed in HCC.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63, 64)</a> However, further efforts to understand the complete role of sorafenib in the treatment of HCC are still necessary.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Sunitinib, <b>2</b> (SU11248) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), trade name Sutent, by Sugen-Pfizer, is a multikinase indol-2-one inhibitor targeting VEGFR-1 and VEGFR-2, PDGFRβ, and other kinases, including FLT3, which has been shown to be involved, especially in mutated forms, in acute leukemia.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> It also inhibits c-Kit, hyperactivated by mutations in gastrointestinal stromal tumor (GIST). Sunitinib was approved in 2006 by the FDA for the treatment of RCC and of GIST.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">Pazopanib, <b>3</b> (GW-786034) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), trade name Votrient, by GlaxoSmithKline, is a potent pan-VEGFR inhibitor (indeed it inhibits VEGFR-1, -2, and -3). Its chemical structure is quite unusual among kinase inhibitors, bearing a 2,4-pyrimidinediamine core substituted by an indazole ring and a 2-methylbenzenesulfonamide moiety.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Pazopanib also inhibits PDGFRα/β and c-Kit. In 2009 it was approved by the FDA for RCC and in April 2012 for soft tissue sarcoma. Pazopanib also appears to be effective in the treatment of ovarian and in NSCLC.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">Vandetanib, <b>4</b> (ZD6474) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), trade name Caprelsa, previously called Zactima, produced by AstraZeneca, inhibits VEGFR-2, VEGFR-3, EGFR, and RET.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> It is an anilinoquinazoline derivative bearing a water-solubilizing basic side chain. In April 2011, vandetanib became the first drug to be approved by the FDA for treatment of late-stage (metastatic) medullary thyroid cancer in adult patients who are ineligible for surgery.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> This therapeutic activity is likely caused by inhibition of RET, a TK hyperactivated by mutations in medullary thyroid cancer.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><div class="NLM_p">Axitinib, <b>5</b> (AG013736) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), trade name Inlyta, is an indazole derivative developed by Pfizer as a mutikinase inhibitor. It is active on VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and c-Kit.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Pfizer researchers studied the effects of the juxtamembrane (JM) domain on VEGFR-2 enzymatic activity, autophosphorylation, and inhibition by axitinib, using kinetic, biophysical, and structural methods. In particular they obtained highly purified preparations of the VEGFR-2 catalytic domain without (VEGFR-2-CD) and with (VEGFR-2-CD/JM) the JM and showed that although the catalytic parameters for both constructs were similar, the autophosphorylation rate of VEGFR-2-CD/JM was faster than that of VEGFR-2-CD. Axitinib was found to have 40-fold enhanced biochemical potency toward VEGFR-2-CD/JM compared to VEGFR-2-CD, which correlates better with cellular potency. This study, identifying potential functions for the VEGFR-2 JM domain, emphasizes the importance of selecting the proper protein construct for mechanistic studies of receptor TKs and for the design of their inhibitors.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p">On January 2012, the U.S. FDA approved axitinib for use in patients with RCC that had failed to respond to a previous treatment.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. VEGFR/multitargeted inhibitors approved for clinical use.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among these drugs, sorafenib, sunitinib, and pazopanib are administered as salts tosylate, malate, and hydrochloride, respectively. Common doses, <i>T</i><sub>1/2</sub>, and <i>T</i><sub>max</sub> of the five inhibitors are reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Importantly, all these compounds are administered per os, different from other chemotherapeutic agents that need iv administration.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Comparison of Some Pharmacokinetic Parameters for Approved Compounds<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">pharmacokinetics</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">trade name</th><th class="colsep0 rowsep0" align="center">administration</th><th class="colsep0 rowsep0" align="center">salt</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub></th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b>, sorafenib</td><td class="colsep0 rowsep0" align="left">Nexavar</td><td class="colsep0 rowsep0" align="left">400 mg orally twice daily</td><td class="colsep0 rowsep0" align="left">tosylate</td><td class="colsep0 rowsep0" align="left">25–48 h</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b>, sunitinib</td><td class="colsep0 rowsep0" align="left">Sutent</td><td class="colsep0 rowsep0" align="left">50 mg orally once daily</td><td class="colsep0 rowsep0" align="left">malate</td><td class="colsep0 rowsep0" align="left">40–60 h</td><td class="colsep0 rowsep0" align="left">6–12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b>, pazopanib</td><td class="colsep0 rowsep0" align="left">Votrient</td><td class="colsep0 rowsep0" align="left">800 mg orally once daily</td><td class="colsep0 rowsep0" align="left">hydrochloride</td><td class="colsep0 rowsep0" align="left">30.9 h</td><td class="colsep0 rowsep0" align="left">2–4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>, vandetanib</td><td class="colsep0 rowsep0" align="left">Caprelsa</td><td class="colsep0 rowsep0" align="left">300 mg orally once daily</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">19 days</td><td class="colsep0 rowsep0" align="left">4–10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b>, axitinib</td><td class="colsep0 rowsep0" align="left">Inlyta</td><td class="colsep0 rowsep0" align="left">5 mg orally twice daily</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.5–6.1 h</td><td class="colsep0 rowsep0" align="left">2.5–4.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Data from <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm" class="extLink">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</a>.</p></div></div></div><div class="NLM_p last">Further insights on each drug can be found in several articles that have recently appeared in the literature, where detailed information on all that is known about these inhibitors, especially from the biological and medical perspectives, is reported.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> VEGFR Inhibitors in Clinical Trials</h3><div class="NLM_p">A number of VEGFR and multitargeted inhibitors that have entered clinical trials are reported in this section. Emphasis has been placed on chemical structures and on the most important biological results obtained with their use. Data are from the past 5 years. In all the figures the superscript number refers to the main bibliografic reference for the compounds.</div><div class="NLM_p">The quinazoline and the quinoline moieties bearing C4 anilino or C4 oxy substituents and C6, C7 oxy substitents are present in several TK inhibitors, including vandetanib <b>4</b>, already reported, and the EGFR (ErbB1) kinase inhibitor gefitinib, approved by FDA in 2003 for the treatment of NSCLC, and in many Src/Abl dual inhibitors.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><div class="NLM_p">Cediranib, <b>6</b> (AZD2171) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) (tentative trade name Recentin), from AstraZeneca, is a 4,6,7-trioxyquinazoline, a potent oral inhibitor of VEGFRs, showing IC<sub>50</sub> values of 5, 1, and 3 nM toward VEGFR-1, -2, and -3, respectively. It is also active toward PDGFRβ and c-Kit with similar potencies and possesses good selectivity over a panel of other tyrosine and serine/threonine kinases.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> This inhibitor reduces VEGF-induced angiogenesis in vivo and shows activity in mice implanted with human tumor xenografts. It is currently in several phase 2/3 trials, alone or in combination with other antineoplastic agents, for the treatment of various solid tumors and leukemias, particularly acute myeloid leukemia (AML).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Results from a phase 2 clinical trial using cediranib monotherapy at a dose of 45 mg/day for recurrent glioblastoma showed encouraging proportions of radiographic response and 6-month progression-free patient survival, with manageable toxicity.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Unfortunately, it has been successively reported that recurrent glioblastomas relapse after initial response to cediranib treatment. Probably the tumor escapes antiangiogenic therapy by switching to VEGFR-independent pathways and can grow using blood vessels with normal molecular expression and morphology without a second wave of angiogenesis.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> However, it has been very recently determined that a judicious application of antiangiogenic therapy in glioblastomas may normalize the structure and function of the tumor vasculature, promoting an improved blood perfusion. These findings offer direct clinical evidence in support of the hypothesis that vascular normalization can increase tumor drug perfusion and help improve glioblastoma patient survival.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Results from a phase 2 clinical trial indicated that cediranib monotherapy demonstrates significant evidence of antitumor activity in patients with advanced RCC. The adverse event profile is consistent with previous studies of cediranib 45 mg/day and includes diarrhea, hypertension, and fatigue.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Cediranib monotherapy has modest single-agent activity in malignant pleural mesothelioma after platinum-based therapy. However, some tumors are highly sensitive to cediranib. This study provides a rationale for further testing of cediranib plus chemotherapy in mesothelioma patients,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> whereas the compound is not an effective treatment in patients with unresectable or metastatic HCC, due to its high toxicity in this type of patients.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> In a phase 1 study cediranib was generally well tolerated and shows preliminary evidence of activity as a monotherapy in patients with AML.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">Cabozantinib, <b>7</b> (XL184, BMS-907351) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), invented at Exelixis, later developed by Bristol-Myers Squibb and then returned to Exelixis in 2010, is a quinoline derivative bearing a cyclopropane-1,1-dicarboxylic acid amide substituent. It is a multikinase inhibitor that targets VEGFR-2, MET, and RET. The drug also inhibits Kit, FLT3, and Tek with IC<sub>50</sub> values in the low nanomolar range in enzymatic assays. Preclinical studies demonstrate that cabozantinib potently inhibits multiple receptor TKs in various cancer cell lines and animal xenograft models, with significant oral bioavailability and blood–brain barrier penetration. Cabozantinib is also a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with deregulated VEGFR, MET, and RET signaling. For these reasons it is a potential candidate for the oral treatment of medullary thyroid cancer, glioblastoma, and NSCLC.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The compound is being tested in several phase 1/2 trials for different malignancies and in phase 3 trials in patients with medullary thyroid and prostate cancer.<a onclick="showRef(event, 'ref85 ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref85 ref86 ref87">(85-87)</a> Cabozantinib was granted orphan-drug status by the FDA in 2011. This status will support its development for treatment against various cancers in the U.S., particularly NSCLC, glioblastomas, and medullary thyroid cancer, which are listed as rare diseases by the Office of Rare Diseases of the National Institutes of Health.</div><div class="NLM_p">Foretinib, <b>8</b> (GSK1363089, XL880) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), was synthesized at Exelixis and then licensed by GSK in 2007. It is a cabozantinib derivative in which the 7-methoxy group of the quinoline ring has been substituted by the 3-morpholin-4-yl-propoxy group as a solubilizing basic side chain. It is a multitargeted inhibitor that is especially active on VEGFR and MET and shows IC<sub>50</sub> values of 0.8, 6.8, and 2.8 nM against VEGFR-1, VEGFR-2, and VEGFR-3, respectively, and of 0.5 nM on MET. It also inhibits PDGFRs and the angiopoietin-1 receptor Tie-2, shows modest activity on FGFR and EGFR, and is inactive against 50 serine/threonine kinases. In human umbilical vein endothelial cells (HUVEC), it reduces VEGFR-2 phosphorylation with an IC<sub>50</sub> of 16 nM.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Foretinib blocks tumorigenesis and reduces invasive tumor growth in different models of ovarian cancer by affecting several critical tumor functions. This provides the rationale for its further clinical development for the treatment of ovarian cancer.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The significant antitumor activities in patient-derived HCC xenograft models, which it demonstrates, justifies its clinical investigation in patients with advanced HCC.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Foretinib is being tested in phase 1–2 clinical trials on solid malignancies. In a phase 1 clinical trial, the recommended dose of foretinib is 240 mg, given on the first 5 days of a 14-day cycle.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><div class="NLM_p">Tivozanib, <b>9</b> (KRN951, AV-951) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), was originally synthesized at Kirin Brewery, now Kyowa Hakko Kirin, then licensed to AVEO in 2007, which in turn licensed the compound to Astellas in 2011. It is a quinoline derivative bearing a urea moiety in turn substituted with an isoxazolyl group. The urea function is often present in kinase inhibitors, since it is a suitable group for hydrogen binding interactions with amino acids of the kinase catalytic cleft.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Tivozanib is a potent inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, showing IC<sub>50</sub> values of 0.21, 0.16, and 0.24 nM, respectively, and nanomolar activity values on PDGFRβ and c-Kit. It displays antitumor activity in a variety of human tumor xenografts, such as lung, breast, colon, ovarian, pancreas, and prostate cancer.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Tivozanib is undergoing clinical trial investigation for the treatment of solid tumors<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94, 95)</a> at a recommended daily dose of 1.5 mg in a 4-week-on and 2-week-off dosing regimen.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Phase 2 results suggest that tivozanib is active and well tolerated in patients with advanced RCC. These data support additional development of tivozanib in advanced RCC.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Phase 3 results on advanced RCC suggest a 30% or 3 months improvement in progression free survival compared to sorafenib.</div><div class="NLM_p">Lenvatinib, <b>10</b> (E7080) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), also possesses a urea moiety, whereas the C6 methoxy group present in the previously reported quinolines has been replaced with an amide group. The compound produced by Eisai Co. is a potent dual inhibitor of VEGFR-2 (IC<sub>50</sub> = 4.0 nM) and of VEGFR-3 (IC<sub>50</sub> = 5.2 nM). In preclinical assays lenvatinib suppresses lymph node and lung metastases of human breast tumor MDA-MB-231 via inhibition of angiogenesis and lymphangiogenesis.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Treatment with lenvatinib potently inhibits the proliferation of malignant pleural mesothelioma cell lines, markedly prolongs mouse survival, and is associated with fewer tumor vessels and proliferating cells in the tumor.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The compound also shows activity on human sarcoma xenografs.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> It is being tested in phase 1–2 clinical trials against solid tumors, including HCC, melanoma, and thyroid cancer of medullary, papillary, and follicular subtypes.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Results from phase 1 studies indicate that lenvatinib has manageable toxicity up to 13 mg b.i.d. when administered in a 2-week-on/1-week-off cycle. It also shows preliminary activity for durable disease control. Biomarker analysis suggests that its antiangiogenic activity is correlated with antitumor activity in patients with a wide range of solid tumors.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Results have been promising in patients with melanoma and RCC.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p"><b>11</b> (E-3810) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) is a dual inhibitor of VEGFR and FGFR. It shows IC<sub>50</sub> values of 7, 25, and 10 nM on VEGFR-1, -2, and -3, respectively, and of 17.5 and 82.5 nM on FGFR-1 and -2, respectively, whereas it possesses low activity on PDGFRs and on c-Kit. The compound suppresses phosphorylation of VEGFR-2 and FGFR-1 in HUVEC growth at nanomolar concentrations. In a variety of tumor xenograft models, <b>11</b> exhibits antitumor properties at well-tolerated oral doses administered daily, making it a potent antiangiogenic agent with a favorable pharmacokinetic profile and broad spectrum antitumor activity.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The compound is being tested in a phase 1 clinical trial. A high-performance liquid chromatography–tandem mass spectrometry method has been developed and validated to evaluate <b>11</b> pharmacokinetics in cancer patients with solid tumors who are receiving daily oral doses of the drug during the phase 1 trial.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><div class="NLM_p">Dovitinib, <b>12</b> (CHIR-258, TKI258) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), developed by Novartis/Chiron,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> is a benzymidazolhydroquinolinone multitargeted inhibitor active on VEGFR-1, -2, -3, FGFR, PDGFRβ, c-Kit, and FLT3 with IC<sub>50</sub> values in the low nanomolar range. Renhowe and colleagues developed a homology model to study the interaction of dovitinib with the catalytic site of VEGFR-2. Briefly, the compound binds to the active and so-called “in” conformation of the enzyme in an ATP-competitive fashion and forms three hydrogen bonds to the hinge region (to Glu917-CO, Cys919-NH, and Cys919-CO). Moreover, it makes a pattern of van der Waals interactions with other amino acids, including Val916, which is the gatekeeper residue of the catalytic site, and with some residues in the purine pocket. The good pharmacokinetic profile and the pharmacological activity in preclinical models have prompted further investigation on this compound.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Dovitinib shows antiangiogenic activity in vivo and, when orally administered, inhibits tumor growth in colon cancer animal models in a dose dependent manner.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Because of its action against FLT3, a TK mutated in AML, it is also active in experimental tumor xenograft models of this disease<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> and in orthotopic multiple myeloma models in mice.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Despite its preclinical activity on hematologic malignancies, at the moment dovitinib is in clinical trials for solid tumor treatment only. In a phase 3 trial dovitinib activity is compared with that of sorafenib in patients with metastatic RCC, whereas in other phase 2 trials it is being tested on HCC, breast cancer, GIST, endometrial cancer, and melanoma. In the latter tumor, treatment with 400 mg/die of dovitinib showed an acceptable safety profile but limited clinical benefit.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Quinazoline and quinoline derivatives in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Orantinib, <b>13</b> (SU6668, TSU-68) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), synthesized by Sugen, is an indolin-2-one structurally similar to sunitinib<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> but bearing an acid group on the pyrrole moiety. It is a soluble and orally bioavailable nanomolar inhibitor of VEGFR-2, PDGFRβ, and FGFR-1. In animal models it produces tumor vascular normalization because of its antiangiogenic effect.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> It also reduces chondrosarcoma growth in severe combined immunodeficient (SCID) mice<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> and prevents liver metastasis of colon cancer xenografts.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> The compound is currently being tested in phase 1–2 clinical trials for the treatment of solid tumors, especially HCC. At a dose of 200 mg b.i.d. it shows promising preliminary efficacy with a high safety profile in patients with HCC who had been heavily pretreated<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> and satisfactory activity against breast cancer in combination with other antineoplastic agents.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><div class="NLM_p">Nintedanib (or intenanib), <b>14</b> (BIBF 1120) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), Vargatef, is a 6-methoxycarbonyl-substituted indolinone reported by Boehringer Ingelheim Pharma GmbH & Co. and defined as a triple angiokinase inhibitor targeting VEGFR, PDGFR, and FGFR. It shows IC<sub>50</sub> values of 104, 5, and 5 nM for VRGFR-1, -2, and -3, respectively, and of 38 and 18 nM for FGFR-1 and PDGFRα, respectively, in enzymatic assays. The compound is an ATP-competitive inhibitor, as indicated by the homology model of a similar derivative in the VEGFR-2 kinase domain. The typical canonical hydrogen bonds are formed between the lactam moiety and the hinge region (Glu917 and Cys919). In addition, the carbonyl oxygen of the C6 group can form an additional hydrogen bond with Lys868, probably accounting for the high potency of this family of compounds. Nintedanib shows antiproliferative activity on VEGF-related endothelial cell with additional efficacy on pericyctes and smooth muscle cells. However, no direct inhibition of tumor cell proliferation is observed. It is orally available and displays encouraging efficacy in in vivo tumor models while being well tolerated. It is currently in phase 3 clinical trials for the treatment of NSCLC.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118, 119)</a> Current phase 2 trials are investigating the effect of the compound in ovarian cancer<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> and on other solid malignancies.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div><div class="NLM_p">Vatalanib, <b>15</b> (PTK787, ZK222584) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), a phthalazino derivative disclosed by Novartis and Schering AG in 1998, is one of the most potent and selective first-generation VEGFR kinase inhibitors, with IC<sub>50</sub> values of 110, 43, 195 nM against VEGFR-1, -2, and -3, respectively. It also inhibits other kinases, including PDGFRβ and c-Kit, but at higher concentrations. Vatalanib is an ATP competitive inhibitor. Docking studies indicate that it does not form direct hydrogen bonds with the backbone of the hinge region as many reported TK inhibitors do. In detail, the aniline moiety is located in a hydrophobic pocket, and the phthalazine bicycle also makes hydrophobic contacts with other amino acids. Although no direct hydrogen bond with the hinge region is established, the aniline NH group forms water-mediated hydrogen bonds with Glu915 and Cys917 of the hinge region, and the pyridyl nitrogen is assumed to form a hydrogen bond with Lys1060, a residue of the kinase activation loop.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The compound has been extensively investigated in phase 1 and 2 clinical trials for the treatment of solid tumors and hematological malignancies. Results from a phase 2 trial on mesothelioma patients show partial responses in 6% of patients and stable disease in 72% of patients, with mild toxicity.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> It has been shown to be quite active in metastatic GIST,<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> NSCLC,<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> and melanoma patients, although in the last cancer overall survival is disappointing.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The compound is being tested in a number of phase 3 trials in advanced colorectal cancer. Results from two phase 3 studies (CONFIRM 1 and 2) evaluating vatalanib in the first- and second-line treatment of advanced colorectal cancer indicated that the addition of vatalanib to standard treatment did not result in improved outcomes.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div><div class="NLM_p">Telatinib, <b>16</b> (BAY 57-9352) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), is characterized by a furo[2,3-<i>d</i>]pyridazine scaffold, isoster to the phthalazinic one present in vatalanib. It has been patented by Bayer as a potent inhibitor of VEGFR, PDGFR, and c-Kit, with IC<sub>50</sub> values of 6 and 4 nM in enzymatic assays for the inhibition of VEGFR-2 and VEGFR-3, respectively. It inhibits HUVEC growth in proliferation assays, although it is not directly active against tumor cells, possessing a purely antiangiogenic mechanism of action. In in vivo assays, telatinib is orally active at a dose of 2.5–60 mg/kg in different xenograft models<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> and has been tested in a number of phase 1 trials for the treatment of advanced solid tumors. Telatinib is safe and well tolerated up to 1500 mg twice daily. On the basis of pharmacodynamic and pharmacokinetic end points, telatinib 900 mg twice daily is the recommended dose for subsequent phase 2 studies.<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129, 130)</a> A phase 2 study on telatinib used in combination with chemotherapy as first-line therapy in subjects with advanced gastric cancer has been just completed, but the results are not yet available.</div><div class="NLM_p">Motesanib, <b>17</b> (AMG 706) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), produced by Amgen, is derived from the anthranilamide class of VEGFR inhibitors. The anthranilamide scaffold, where an intramolecular H-bond between NH and CO forms a “pseudo ring”, mimics the phthalazine binding mode, giving the same type of interactions with the enzyme.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Motesanib is a multikinase inhibitor that possesses IC<sub>50</sub> values of 2, 3, 6 nM for VEGFR-1, -2, -3 and is also active on PDGFR, c-Kit, and RET. Oral administration of the compound potently inhibits VEGF-induced angiogenesis in the rat corneal model and induces regression of established A431 xenografts.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The compound also shows antitumor activity in breast cancer,<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> medullary thyroid cancer xenografts,<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> and GIST,<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> and it is currently being studied in clinical trials for the treatment of thyroid cancer and other advanced solid tumors.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Unfortunately, a 2011 report indicated that a phase 3 trial did not show benefit for advanced NSCLC.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p"><b>18</b> (OSI-930) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), patented by OSI Pharmaceuticals in 2004,<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> is a thiophene isoster of anthranilamide derivatives and bears a quinoline group, which constitutes the hinge-region binding element. It potently inhibits VEGFR-2 with an IC<sub>50</sub> of 9 nM, together with c-Kit, c-Raf, and Lck (IC<sub>50</sub> values of 10, 41, 22 nM, respectively) in different enzymatic assays and in intact cells, including HUVECs. More importantly, it has been found to be active in different tumor xenograft models when administered daily at the maximally efficacious dose of 200 mg/kg.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Phase 1 dose escalation studies of <b>18</b> in healthy volunteer patients have been completed, and a phase 1 dose escalation study in cancer patients is ongoing.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Other derivatives in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Bristol-Myers Squibb reported a series of 4-(4-fluoro-1<i>H</i>-indol-5-yloxy)pyrrolotriazines as VEGFR-1, VEGFR-2, and FGFR-1 inhibitors, including <b>19</b> (BMS-540215) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), endowed with good kinase selectivity and potent in vivo efficacy versus H3396 and L2987 human lung carcinoma xenografts implanted in athymic mice.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> On the other hand, the compound showed suboptimal physicochemical and pharmacokinetic properties and particularly low aqueous solubility that presumably contributed to dissolution rate-limited absorption. To overcome this potential development issue, a prodrug approach has been investigated and led to the preparation of brivanib alaninate, <b>20</b> (BMS-582664) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), in which the secondary alcohol of <b>19</b> was linked to alanine through a metabolically labile ester linkage. Brivanib alaninate is converted in vivo to the active compound <b>19</b> and demonstrates excellent pharmaceutical properties and significant antitumor activity against L2987 human lung carcinoma xenografts.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Brivanib alaninate is also very active in other preclinical models,<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> including in mouse models of human HCC,<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> and has entered clinical trials for the treatment of solid malignancies.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Unfortunately, the failure of brivanib in a phase 3 head to head study with nexavar has been very recently reported. Brivanib demonstrates promising antitumor activity and a manageable safety profile as first-line therapy in patients with advanced, unresectable HCC. In a phase 2 open-label study, brivanib was administered orally at a dose of 800 mg once daily as second-line therapy in patients with advanced HCC who had failed prior antiangiogenic treatment. Results of this trial showed that brivanib has a manageable safety profile and is one of the first agents to possess promising antitumor activity in advanced HCC patients treated with prior sorafenib.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> At the time of writing, the compound is being tested in a phase 3 study with the same objective as the phase 2 study just reported.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Other derivatives in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>21 (</b>BMS-690514) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) is another pyrrolotriazine by Bristol-Myers Squibb. The compound is a pan HER/VEGFR orally active inhibitor that also targets other kinases, including FLT3 and Lck. It exerts antiproliferative and proapoptotic effects on NSCLC cell lines, with prominent efficacy on cells expressing the T790M mutation that confers resistance to the EGFR inhibitor erlotinib.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Moreover, it shows antitumor activity on NSCLC xenografts and induces synergistic effect with radiation.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The potency and selectivity of <b>21</b> have been successively evaluated by using an extensive array of enzymatic assays, as well as cellular assays, whereas the antitumor activity was evaluated by using multiple xenograft models. The antiangiogenic properties of the compound were assessed in a matrigel plug assay, and the effect on tumor blood flow was measured by dynamic contrast-enhanced magnetic resonance imaging. Overall, the results demonstrated that <b>21</b> is a novel targeted agent that disrupts signaling in the tumor and its vasculature.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> The preclinical ADME properties of <b>21</b> suggest good oral bioavailability in humans and metabolism by multiple pathways including oxidation and glucuronidation. On the basis of the preliminary results on compound pharmacokinetics, the efficacious dose for humans is predicted to be in the range of 100–200 mg.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Considering the submicromolar plasma concentration at the anticipated clinical dose of 200 mg, <b>21</b> is unlikely to cause clinically relevant drug–drug interactions when coadministered with other medications. In addition, because multiple enzymatic clearance pathways are available for the compound, inhibition of an individual metabolic pathway either via coadministered drugs or gene polymorphisms is not expected to cause pronounced increases in <b>21</b> exposure.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The compound is currently being tested in different phase 1 clinical trials on solid tumors and in a phase 2 trial on NSCLC.</div><div class="NLM_p">Linifanib, <b>22</b> (ABT-869) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), is a multitargeted indazolyldiphenylurea inhibitor, developed by Abbott, which potently inhibits VEGFR-2 and PDGFRβ with IC<sub>50</sub> values of 4 and 2 nM, respectively, and shows a similar behavior against FLT3 and CSF1-R in both enzymatic and cell assays.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> It possesses antiproliferative and apoptotic effects on kinase-dependent cancer cell lines and favorable pharmacokinetic profiles across different species and displays significant tumor growth inhibition in multiple xenograft models, including human fibrosarcoma, breast, colon, and lung carcinomas.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Similar to other urea-based kinase inhibitors, the compound forms three hydrogen bonds with the catalytic site of VEGFR-2 (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), more specifically between the urea external NH and Glu885 carboxylate, between the 3-amino group of the indazole and Glu917 backbone carbonyl, and between the ring nitrogen (N2) and Cys919 NH.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic representation of hydrogen bonds (dotted lines) between <b>22</b> and VEGFR-2 catalytic site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antiangiogenic activity of the compound has been recently confirmed in HT1080 fibrosarcoma and SW620 colon carcinoma cells<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> and in an orthotopic rat glioma model.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Linifanib is currently being tested in a number of phase 1–2 clinical trials for the treatment of solid tumors, including colorectal cancer and NSCLC and hematological malignancies. Some results have been published indicating that the compound is well tolerated and shows promising preliminary clinical activity in Japanese patients with solid tumors,<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> in patients with advanced RCC after sunitinib failure,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> and in advanced NSCLC patients as second- or third-line therapy. Increased adverse event rates were observed at a dose of 0.25 mg/kg once daily, whereas lower doses are quite well tolerated.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><div class="NLM_p"><b>23</b> (AEE788) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) is a 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine synthesized by Novartis as a dual inhibitor of EGFR and VEGFR. It shows IC<sub>50</sub> values of 2, 77, 59 nM toward EGFR-2, VEGFR-2, and VEGFR-1, respectively, in enzymatic assays. Orally administered, <b>23</b> shows favorable pharmacokinetic properties and potent antitumor and antiangiogenic activity in different animal models of cancer.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> As an example, <b>23</b> reduces tumor growth by inhibiting proliferation and vascularization in human HCC xenografts in nude mice<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> and shows growth-suppressive activities in chemosensitive and chemoresistant medulloblastoma cells in vitro and in xenografts.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> The compound is in phase 1/2 clinical trials on patients with advanced cancer or recurrent glioblastoma. Unfortunately, it has been very recently reported that once-daily <b>23</b> was associated with unacceptable toxicity and minimal activity for the treatment of recurrent glioblastoma. This finding led to the premature discontinuation of the trial.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><div class="NLM_p"><b>24</b> (TAK-593) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), an imidazo[1,2-<i>b</i>]pyridazine derivative by Takeda Pharmaceuticals, potently inhibits TKs from the VEGFR and PDGFR families, specifically VEGFR-1, -2, and -3 with IC<sub>50</sub> values of 3.2, 0.95, and 1.1 nM, respectively. <b>24</b> is selective for these families, with IC<sub>50</sub> > 1 μM when tested against more than 200 protein and lipid kinases. It displays competitive inhibition for ATP and binds to the inactive conformation of the enzyme, behaving as a type II kinase inhibitor.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> The authors, studying its kinetic and interaction with VEGFR-2, concluded that the compound binds the enzyme in a way similar to that recently reported for axitinib, interacting also with the juxtamembrane region.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> This inhibitor targets the enzyme with a two-step slow binding mechanism, and this accounts for the longest residence times of any VEGFR inhibitor yet reported, probably ensuring a prominent and durable effect at very low doses in vivo. It has been tested in a phase 1 clinical and pharmacokinetic study in subjects with nonhematologic advanced cancer, but no result is available.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></div><div class="NLM_p"><b>25</b> (CEP-11981) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) is an indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazolone, very recently reported by Cephalon as a potent multitargeted inhibitor, being especially active on Tie-2, VEGFR-1, -2, and -3 and FGFR-1. In detail, it shows IC<sub>50</sub> values of 4 and 22 nM on VEGFR-2 and Tie-2, respectively, and less than 10 nM in VEGFR-2 cells. The compound shows antiangiogenic activity on ex vivo rat aortic ring explant cultures and in vitro HUVEC capillary-tube formation bioassays, as well as reduced tumor growth of glioblastoma and melanoma xenografts in nude mice. Its inhibitory activity on Tie-2 seems to play important roles in the antiangiogenic activity.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Indeed, Tie-1 and Tie-2, together with their ligands, the angiopoietins, have been implicated in vessel stabilization, maturation, remodeling, and organization of the rudimentary vasculature. The inhibition of tumor angiogenesis and vascular remodeling by modulating the angiopoietin/Tie-2 axis and the VEGF/VEGFR-2 axis has been demonstrated using different approaches against a variety of human tumors in preclinical studies.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a><b>25</b> possesses favorable pharmacokinetic properties; a clinical phase 1 study assessing its safety and pharmacokinetics has been recently completed. Phase 2 proof-of-concept studies are planned in select genotyped cancer patient populations to fully assess the therapeutic potential of this compound.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></div><div class="NLM_p"><b>26</b> (CP-547,632) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), produced by Pfizer, is a substituted isothiazoleurea identified as a potent, ATP-competitive, reversible inhibitor of VEGFR-2 and FGFRβ, with IC<sub>50</sub> values in enzymatic assays of 11 and 9 nM, respectively, and of 6 nM in VEGFR-2 cells. It possesses antiangiogenic activity, assessed in vivo by functional assays. The compound, orally administered to athymic mice bearing human xenografts, inhibits tumor growth by 85% and is well tolerated. It is currently in phase 2 clinical trials for the treatment of refractory solid tumors.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></div><div class="NLM_p">Regorafenib, <b>27</b> (BAY 73-4506) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), is a fluoro derivative of sorafenib, developed by Bayer.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> It inhibits angiogenic kinases (VEGFR-1/3, PDGFRβ, FGFR1, and Tie-2) and the mutant oncogenic kinases Kit, RET, and B-Raf with IC<sub>50</sub> values in the low nanomolar range. The compound shows antiproliferative effects on different cancer cell lines and is active in various preclinical human xenograft models in mice, where it also demonstrated antiangiogenic activity.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Regorafenib is currently being tested in several phase 1/2 clinical trials. The first results indicate that it is active in patients with advanced solid tumors<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> and in particular with metastatic colorectal cancer.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><div class="NLM_p">VEGFR inhibitors currently in clinical trials for the treatment of different cancers are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> (data from <a href="http://clinicaltrials.gov" class="extLink">clinicaltrials.gov</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Compounds in Clinical Trials</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">clinical trial</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">common name</th><th class="colsep0 rowsep0" align="center">chemical class</th><th class="colsep0 rowsep0" align="center">phase 1/phase 2</th><th class="colsep0 rowsep0" align="center">phase 3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD2171 (<b>6</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>)</td><td class="colsep0 rowsep0" align="left">cediranib</td><td class="colsep0 rowsep0" align="left">quinazoline</td><td class="colsep0 rowsep0" align="left">alone or in combination for hematological and solid tumors</td><td class="colsep0 rowsep0" align="left">in combination for solid tumors (glioblastoma, colorectal, ovarian, and lung cancers)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XL184, BMS-907351 (<b>7</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>)</td><td class="colsep0 rowsep0" align="left">cabozantinib</td><td class="colsep0 rowsep0" align="left">quinoline</td><td class="colsep0 rowsep0" align="left">alone or in combination for hematological and solid tumors</td><td class="colsep0 rowsep0" align="left">alone for prostate and medullary thyroid cancers</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XL880, GSK1363089 (<b>8</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>)</td><td class="colsep0 rowsep0" align="left">foretinib</td><td class="colsep0 rowsep0" align="left">quinoline</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KRN951, AV-951 (<b>9</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>)</td><td class="colsep0 rowsep0" align="left">tivozanib</td><td class="colsep0 rowsep0" align="left">quinoline</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left">alone for RCC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E7080 (<b>10</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>)</td><td class="colsep0 rowsep0" align="left">lenvatinib</td><td class="colsep0 rowsep0" align="left">quinoline</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left">alone for refractory differentiated thyroid cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E-3810 (<b>11</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">quinoline</td><td class="colsep0 rowsep0" align="left">alone for solid tumors</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHIR-258, TKI258 (<b>12</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>)</td><td class="colsep0 rowsep0" align="left">dovitinib</td><td class="colsep0 rowsep0" align="left">quinolin-2-one</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left">alone for metastatic RCC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SU6668, TSU-68 (<b>13</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>)</td><td class="colsep0 rowsep0" align="left">orantinib</td><td class="colsep0 rowsep0" align="left">indolinone</td><td class="colsep0 rowsep0" align="left">alone for solid tumors</td><td class="colsep0 rowsep0" align="left">in combination for HCC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BIBF 1120 (<b>14</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>)</td><td class="colsep0 rowsep0" align="left">nintedanib, intenanib</td><td class="colsep0 rowsep0" align="left">indolinone</td><td class="colsep0 rowsep0" align="left">alone or in combination for hematological and solid tumors</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors (ovarian, lung and liver cancers)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTK787, ZK222584 (<b>15</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>)</td><td class="colsep0 rowsep0" align="left">vatalanib</td><td class="colsep0 rowsep0" align="left">phtalazine</td><td class="colsep0 rowsep0" align="left">alone or in combination for hematological and solid tumors</td><td class="colsep0 rowsep0" align="left">in combination for metastatic colorectal cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BAY 57-9352 (<b>16</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>)</td><td class="colsep0 rowsep0" align="left">telatinib</td><td class="colsep0 rowsep0" align="left">furopyridazine</td><td class="colsep0 rowsep0" align="left">in combination for gastric cancer</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AMG 706 (<b>17</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>)</td><td class="colsep0 rowsep0" align="left">motesanib</td><td class="colsep0 rowsep0" align="left">2-aminonicotinamide</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors or lymphoma</td><td class="colsep0 rowsep0" align="left">in combination for NSCLC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">OSI-930 (<b>18</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3-aminothiophene-2-carboxamide</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-540215 (<b>19</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pyrrolotriazine</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors (liver and colorectal cancers)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-582664 (<b>20</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left">brivanib alaninate</td><td class="colsep0 rowsep0" align="left">pyrrolotriazine</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors (liver and colorectal cancers)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-690514 (<b>21</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pyrrolotriazine</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABT-869 (<b>22</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left">linifanib</td><td class="colsep0 rowsep0" align="left">indazole</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left">alone for advanced HCC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AEE788 (<b>23</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pyrrolopyrimidine</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TAK-593 (<b>24</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">imidazopyridazine</td><td class="colsep0 rowsep0" align="left">alone for solid tumors</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CEP-11981 (<b>25</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">indazolopyrrolocarbazolone</td><td class="colsep0 rowsep0" align="left">alone for solid tumors</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CP-547,632 (<b>26</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">isothiazole</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BAY 73-4506 (<b>27</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>)</td><td class="colsep0 rowsep0" align="left">regorafenib</td><td class="colsep0 rowsep0" align="left">diphenylurea</td><td class="colsep0 rowsep0" align="left">alone or in combination for solid tumors (e.g., colorectal cancer)</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> VEGFR Inhibitors Recently Published</h3><div class="NLM_p">A high number of VEGFR inhibitors have recently been reported, highlighting the interest of medicinal chemists from both academia and pharmaceutical companies in this class of therapeutic agents. This final section of the article deals with synthetic VEGFR inhibitors that have appeared in the literature over the past few years, with an emphasis on medicinal chemistry in terms of chemical structure, mechanisms of action, and SAR. Even if experience frequently shows a decrease of inhibitor activity when passing from in vitro to in vivo assays, preliminary data on the biological profile of some of these compounds are extremely interesting. Some of the compounds described below are derived from minor chemical modifications of lead compounds already approved or in clinical trials. It is likely that the majority of the new inhibitors will prove to be less active than their parent drugs as the biological evaluation continues. On the other hand, the introduction of a small substituent on a suitable chemical scaffold can lead to surprising results. The most famous example is imatinib, the first kinase inhibitor approved for clinical use and the first drug of choice for chronic myeloid leukemia (CML) treatment. It is derived from an optimization process on phenylaminopyrimidine derivatives active as protein kinase C (PKC) and other kinase inhibitors. The introduction of a simple methyl group (often referred to as the “magic methyl”) at position 6 of the diaminophenyl ring abolished PKC inhibitory activity and retained, or even enhanced, activity against protein tyrosine kinases, thus giving rise to imatinib that is active on Abl, the TK etiologic agent of CML.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> It is impossibile to rule out a similar advance in the field of VEGFR/multitargeted inhibitors. Regorafenib, a close analogue of sorafenib, which bears only one fluorine atom more than its parent, appears to be doing surprisingly well in clinical trials, especially for metastatic colorectal cancer.</div><div class="NLM_p">The complex nature of the interactions between a small molecule drug and a protein target is very difficult to fully determinate a priori, even using advanced techniques such as X-ray crystallography or molecular modeling studies. So it is impossible to predict whether or not a very small change in a molecule will give rise to a large variation in its biological activity. It is important to point out that, besides the possible structural drug–target collaboration just mentioned, a small variation of chemical structure can lead to a different solubility or permeability and consequently to a different biological behavior, especially when the compound in question is an apolar molecule, as several TKs inhibitors are.</div><div class="NLM_p">In our opinion, the search for new TK inhibitors endowed with antiangiogenic activity is still an open road. Systematic and sophisticated procedures for designing the inhibitor provide opportunity for further promising results, as does serendipity.</div><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Pyrimidine Derivatives</h4><div id="sec3_3_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i11" class="anchor-spacer"></div><h5 class="article-section__title" id="_i11"> Quinazolines</h5><div class="NLM_p">The quinazoline scaffold is present in potent VEGFR inhibitors, including vandetanib, <b>4</b>, and cediranib, <b>6</b>. Garofalo and colleagues reported a series of quinazolineurea derivatives as VEGFR-2 inhibitors. The molecules are derived from a previously synthesized series of quinolines active as dual EGFR/VEGFR-2 inhibitors, modified following the suggestion of computational studies performed by the same authors. Compound <b>28</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) shows an IC<sub>50</sub> of 40 nM on VEGFR-2, whereas it is almost inactive on EGFR (IC<sub>50</sub> > 10 μM) and exerts antiproliferative activity on PC3 prostate cancer cells, HT29 colon cancer cells, and MCF-7 breast cancer cells with IC<sub>50</sub> values of about 9 μM.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></div><div class="NLM_p"><b>29</b> (SKLB1002) (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), a quinoline substituted with a (5-methyl-1,3,4-thiadiazol-2-yl)thio group in C4, is a VEGFR-2-selective inhibitor (IC<sub>50</sub> = 32 nM) while exhibiting reduced or little activity against other kinases. It is an effective antiangiogenic agent, showing 98% inhibition of HUVEC tube formation at 10 μM and 80% inhibition of zebrafish embryos intersegmental vessel growth at 2.5 μM. The compound suppresses SW620- and HepG2-derived tumor growth in mice (by 72% and 63%, respectively, in 18 days at 100 mg kg<sup>–1</sup> day<sup>–1</sup>).<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Moreover, <b>29</b> induces vascular normalization and enhances anticancer drug delivery, which is associated with a synergistic effect in vivo.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Quinazolines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Yu and colleagues prepared a series of 4-aminoquinazoline VEGFR inhibitors based on the vandetanib, <b>4</b>, structure. The newer compounds, however, lack the C6 methoxy group and bear a urea group at the para position of the C4 anilino moiety. Compound <b>30</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) was found to be 6-fold more potent than the positive control <b>4</b>, showing IC<sub>50</sub> values of 5.5 and 9.6 nM for VEGFR-2 and VEGFR-3, respectively, and a good selectivity on a panel of other kinases. It is also efficacious in HepG2 human tumor xenograft model in BALB/c-nu mice.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></div><div class="NLM_p last">AstraZeneca researchers further expanded the quinazoline family of kinase inhibitors and very recently reported <b>31</b> (AZD2932) (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) as a high affinity inhibitor of VEFGR-2 and PDGFR. The N1-alkylated 4-aminopyrazole in the amide portion leads to compounds with a balanced ∼1:1 ratio of activity vs both VEGFR-2 and PDGFRβ, including <b>31</b>, which shows IC<sub>50</sub> values of 8 and 4 nM against the two enzymes, respectively. It is also active on c-Kit and FLT3 with good selectivity on a panel of kinases. The pharmacokinetic behavior and the preclinical antitumor activity in nude mice bearing C6 rat glial tumors indicate that <b>31</b> has the potential to become an antiangiogenic agent in the clinic.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div></div><div id="sec3_3_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i12" class="anchor-spacer"></div><h5 class="article-section__title" id="_i12"> Other Fused Pyrimidines</h5><div class="NLM_p">Two families of pyrrolo[3,2-<i>d</i>]pyrimidine derivatives have been published by Oguro and colleagues at Takeda Pharmaceuticals, as VEGFR-2 kinase inhibitors. Incorporation of a diphenylurea moiety at the C4-position of the pyrrolopyrimidine core via an oxygen linker resulted in compounds that are type II inhibitors, binding to the inactive conformation of VEGFR<b>-</b>2 kinase.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pyrrolopyrimidines and other fused pyrimidines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>32</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) shows IC<sub>50</sub> values of 6.2, 15, 35, and 96 nM against VEGFR-2, VEFGR-1, PDGFRα, and PDGFRβ, respectively. It also inhibits Tie-2 with good selectivity on a panel of kinases. In order to confirm the binding mode of such compound, the crystal structure of the complex between <b>32</b> and VEGFR-2 was solved (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VHE">3VHE</a>). The kinase adopts an inactive conformation (DFG-out) so that the urea portion occupies the back hydrophobic pocket with additional hydrogen-bonding interactions. The N1 of the pyrrolo[3,2-<i>d</i>]pyrimidine core interacts with the main chain NH group of Cys919 in the hinge region. The urea moiety binds to the protein through two hydrogen-bonding interactions: both urea NH groups interact with Glu885, and the carbonyl interacts with Asp1046. The external 3-(trifluoromethyl)phenyl moiety occupies the hydrophobic pocket created by the conformational rearrangement of Phe1047 (DFG-out) (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). The compound inhibits HUVEC cell proliferation with an IC<sub>50</sub> of 4.4 nM, possessing good pharmacokinetic parameters. Oral administration of its hydrochloride salt inhibits tumor growth in a DU145 human prostate cancer cell xenograft nude mouse model.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Graphical representation of the binding mode of compound <b>32</b> (sticks) into the ATP binding site of VEGFR-2. For sake of clarity, only a few residues are labeled, nonpolar hydrogen atoms are omitted, and hydrogen bond interactions are represented by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further modifications, performed using the cocrystal structure analysis of VEGFR-2 and <b>32</b>, led to the identification of potent dual VEGFR-2/FGFR-1 inhibitors. Among these compounds the urea derivative <b>33</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>), having a piperazine moiety on the terminal benzene ring, shows IC<sub>50</sub> values of 9.3 and 14 nM, respectively, for the two enzymes. A binding model of <b>33</b> complexed with VEGFR-2 suggested that the piperazine moiety forms additional interactions with Ile1025 and His1026. Compound <b>33</b> shows strong inhibitory activities against both VEGF- and FGF-stimulated HUVEC proliferation and improved solubility. Since FGF-FGFR signaling has been shown not only to influence tumor angiogenesis but also to directly contribute to tumor growth and survival, simultaneous inhibition of these receptor TKs may be useful for the antitumor activity.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></div><div class="NLM_p">The isoster heterocyclic scaffold, i.e., the pyrrolo[2,3-<i>d</i>]pyrimidine, also provided interesting VEGFR-2 inhibitors. Gangjiee and colleagues prepared a series of <i>N</i><sup>4</sup>-phenyl-substituted-6-(2,4-dichlorophenylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-2,4-diamines, among which compound <b>34</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) inhibits VEGFR-2 with an IC<sub>50</sub> of 100 nM and shows an excellent selectivity on EGFR, VEGFR-1, and PDGFβ, which are inhibited only at doses of >300 μM. The compound was further evaluated in a mouse orthotopic model of melanoma and showed significant inhibition of tumor growth, angiogenesis, and metastasis formation.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></div><div class="NLM_p">Among fused pyrimidine derivatives, other potent TK inhibitors are present. 7-Aminopyrazolo[1,5-<i>a</i>]pyrimidines, again substituted with a urea function, gave different VEGFR and PDGFR inhibitors. Several of these compounds were selective for VEGFR-2. For example, <b>35</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) shows IC<sub>50</sub> values of 3 and 0.7 nM in enzymatic and in cell assays, respectively. Compound <b>35</b> possesses a favorable pharmacokinetic and oral efficacy in the estradiol-induced murine uterine edema assay, an in vivo model of VEGF-induced vascular permeability. Modeling and SAR studies suggest that this compound binds in the ATP pocket of the enzyme with the 7-aminopyrazolo[1,5-<i>a</i>]pyrimidine core forming a bidentate hydrogen bonding interaction with the hinge region, in particular between the exocyclic amine and Glu917 backbone carbonyl and between the N1 of the pyrazolopyrimidine and Cys919 NH. The the <i>N</i>,<i>N</i>′-diarylurea occupies the hydrophobic pocket. Asp1046 and Phe1047 of the “DFG” motif are in the inactive conformation (“DFG-out”).<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><div class="NLM_p last">Egert-Schmidt and colleagues developed a family of dual polo-like kinase 1 (PLK1)/VEGFR-2 inhibitors.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> The serine/threonine kinase PLK1 is an important regulator of the cell cycle, involved in the formation of the mitotic spindle and in the activation of CDK/cyclin complexes during M-phase of the cycle. Experimental evidence demonstrated that PLK1 is a valid biological target for potential anticancer agents.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Accordingly, dual PLK1/VEGFR-2 inhibitors should display an improved antitumor activity compared with selective VEGFR inhibitors. 2-Anilino-9-methoxy-5,7-dihydro-6<i>H</i>-pyrimido[5,4-<i>d</i>][1]benzazepin-6-ones consist of the seven-membered lactam structure present in the paullone basic scaffold, which might serve as a suitable hinge-binder template for the design of dual VEGFR-2/PLK1 inhibitors. Among these, compound <b>36</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) shows IC<sub>50</sub> values of 11 and 360 nM against VEGFR-2 and PKL1, respectively, inhibitory activity in a cellular angiogenesis model and antiproliferative activity on cancer cell lines in vitro.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></div></div><div id="sec3_3_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i13" class="anchor-spacer"></div><h5 class="article-section__title" id="_i13"> Nonfused Pyrimidines</h5><div class="NLM_p">The isolated pyrimidine ring is present in a number of VEGFR-2 inhibitors. A series of 4-aryl-5-cyano-2-aminopyrimidines shows potent VEGFR-2 kinase inhibitory activity. The phenylethylmorpholino derivative <b>37</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) has an IC<sub>50</sub> of 27 nM on the isolated enzyme and is orally active in the corneal micropocket assay, suggesting the inhibition of in vivo neovascularisation.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><div class="NLM_p">Optimization of a series of pyrimidine derivatives bearing a urea function and a malonamide type group, where one amido group is substituted with the amide isostere triflouoroethylamine unit, led to potent and selective VEGFR-2 inhibitors. These include <b>38</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) (IC<sub>50</sub> = 40 nM), which reduces VEGF-dependent HUVEC proliferation. In an in vitro angiogenesis assay it significantly affects tubule growth and branch formation and inhibits tubule growth and junction formation.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></div><div class="NLM_p">4-Aminopyrimidine-5-carbaldehydeoximes bearing a phenylurea function on C4 were good and selective VEGFR-2 inhibitors when tested on a panel of 13 kinases. Derivative <b>39</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) shows an IC<sub>50</sub> of 11 nM in the enzymatic assay and is active against a variety of xenografts in mice. It demonstrates good bioavailability and no evident toxicity in animals.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Nonfused pyrimidines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Pyridine Derivatives</h4><div id="sec3_3_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15"> Quinolines</h5><div class="NLM_p">The quinoline ring, often bearing C6 and C7 methoxy or oxy groups, is the most represented scaffold among different kinase inhibitors. A C4 oxy substituent is commonly present in VEGFR inhibitor structures. <b>40</b> (Ki23057) (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) is a multitargeted receptor-TK, active on VEGFR-2, PDGFRβ, FGFR-2, and c-Kit (IC<sub>50</sub> values in the range 69–100 nM) but not on EGFR, IGF1R, or MET. The compound inhibits VEGF-induced proliferation of HUVECs, whereas no inhibitory effect on the proliferation of three colon cancer cell lines (LM-H3, LoVo, and LS174T) was observed. On the other hand, <b>40</b> inhibits the growth of the xenografted LM-H3 tumors and the spreading of cancer cells to the liver. Fewer microvessels are present in the xenograft tumors treated with <b>40</b> compared with controls, indicating the antiangiogenic activity of the compound.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Quinolines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Amgen Inc. researchers synthesized different series of quinolines, two of them bearing C4 naphthamide substituents. Among the first series, one of the most active compounds is the 4-chlorophenyl derivative <b>41</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) which shows IC<sub>50</sub> values of 0.5 and 8 nM in enzymatic test and in HUVEC cells, respectively, and significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice. Authors obtained a X-ray cocrystal structure of VEGFR-2 with naphthamide <b>41</b>. As illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>, the compound binds to the ATP binding site of VEGFR-2 and forces the protein to adopt a “DFG-out” conformation, enabling the <i>p</i>-chlorophenyl ring to penetrate into the extended hydrophobic pocket (PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8Q">3B8Q</a>). A conserved hydrogen-bond interaction is formed between the backbone amide NH of Cys919 and the nitrogen of the quinoline ring; the carbonyl and NH groups of the amide form critical hydrogen bonds with the backbone NH of Asp1046 and the side chain of Glu885, respectively.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Graphical representation of the binding mode of compound <b>41</b> (sticks) into the ATP binding site of VEGFR-2. For sake of clarity, only a few residues are labeled, nonpolar hydrogen atoms are omitted, and hydrogen bond interactions are represented by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The same group synthesized a series of <i>N-</i>alkyl and N-unsubstituted naphthamides, with the aim of obtaining more selective compounds, lacking the Aurora B and Lck activity characteristic of <b>41</b>. The new compounds target the hydrophobic pocket of the enzyme and behave as type I inhibitors. Indeed, the enzyme is maintained in a “DFG-in” conformation after inhibitor binding, typical of the active kinase. One of the most active compounds of the new series is the unsubstituted naphthamide <b>42</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>), which shows IC<sub>50</sub> values of 0.9 and 2.1 nM in enzymatic and cell assays, respectively, and exhibits good pharmacokinetics. Once-daily oral administration of <b>42</b> for 14 days led to 85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a></div><div class="NLM_p">More soluble compounds have been obtained by the substitution of the naphthalene moiety with a 2,3-dihydro-1,4-benzoxazine group, which retains the shape and contact elements with the protein while improving the solubility. Compound <b>43</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) shows IC<sub>50</sub> values of 0.5 and 4 nM for VEGFR-2 and HUVEC cells, respectively, and is also quite selective, inhibiting MET, Tie-2, and Lck with IC<sub>50</sub> values in the range 20–100 nM.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></div><div class="NLM_p">6,7-Dimethoxyquinolines bearing an indazole moiety proved to be potent VEGFR-2 inhibitors. Among these, the <i>m</i>-trifluorophenyl derivative <b>44</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) has IC<sub>50</sub> values of 1 and 9 nM in enzymatic and HUVEC cell assays, respectively, and inhibits VEGFR-induced vascular permeability in a dose-dependent fashion. Tested on a small panel of kinases, the compound is quite selective for VEGFR-2. Aurora-1 is the only other kinase significantly inhibited by <b>44</b>.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a></div><div class="NLM_p">A series of <i>N</i>-(4-(6,7-disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3 phenylimidazolidine-1-carboxamides was found to target MET and VEGFR-2 with IC<sub>50</sub> values in the low nanomolar range. Since MET cooperates synergistically with the VEGFRs in tumor angiogenesis and its deregulation is associated with tumorigenesis, such dual inhibitors represent a promising approach to cancer treatment. Compound <b>45</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>), which also demonstrates good bioavailability within this series, was evaluated for its ability to inhibit the proliferation of several human cancer cell lines and showed potent antiproliferative effects. This compound was active in a mouse xenograft model bearing tumors derived from the MET-driven MNNG-Hos cells.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a></div><div class="NLM_p last">Quinoline amides, e.g., <b>46</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>),<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> and quinolylthienyl chalcones, e.g., <b>47</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>),<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> made up of a differently decorated quinoline ring, are active as VEGFR-2 inhibitors in enzymatic and in cell assays.</div></div><div id="sec3_3_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16"> Other Fused Pyridines</h5><div class="NLM_p">The pyridine ring fused with a number of eterocycle moieties has provided VEGFR/multitargeted inhibitors. A family of dual MET/VEGFR-2 targeted molecules, including compound <b>48</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>), is structurally and biologically similar to <b>44</b> but is based on a substituted thieno[3,2-<i>b</i>]pyridine scaffold instead of the quinolinic one.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> A further development of such derivatives is a series of arylmalonamides, in particular <b>49</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>), characterized by the introduction of a cyclopropyl moiety at the methylene unit of the malonamide fragment. This side chain is present in cabozantinib and foretinib, which have been discussed elsewhere in this paper. Compound <b>49</b> shows IC<sub>50</sub> values of 8 and 24 nM for VEGFR-2 and MET, respectively, and is efficacious in different human tumor xenograft models.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Fused pyridines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pyrrolopyridinepyridone derivatives such as <b>50</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>) are multitargeted inhibitors active in the low nanomolar range on VEGFR-2, FLT3, and MET, metabolically stable, and endowed with good efficacy in a GTL-16 human gastric carcinoma xenograft model.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><div class="NLM_p last">Aminopyrazolo[3,4-<i>b</i>]pyridineureas, aza analogues of <b>22</b>, were shown to be VEGFR/PDGFR inhibitors, but were not active on other structurally nonrelated kinases, such as Fyn and Src. Compound <b>51</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>) inhibits VEGFR-2 with IC<sub>50</sub> values of 1.7 and 2.6 nM in enzymatic and cell assays, respectively, and is orally active in an estradiol-induced mouse uterine edema model.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a></div></div><div id="sec3_3_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> Nonfused Pyridines</h5><div class="NLM_p">A number of VEGFR inhibitors with structures miming the anthranilamide moiety and containing a nonfused pyridine ring have been synthesized in the past few years, including 3,4-disubstituted isothiazoles such as <b>52</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>)<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> and (1,2,3-triazol-4-yl)benzenamines such as <b>53</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>),<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> both reported by Kiselyov and colleagues. These compounds are potent VEGFR-1 and -2 inhibitors with activity comparable to that of vatalanib in enzymatic and cell assays.</div><div class="NLM_p">A more recent example of this type of VEGFR inhibitors is represented by <b>54</b> (BRN-103) (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>), a nicotinamide derivative that inhibits VEGF-induced migration, proliferation, capillary-like tube formation of HUVECs, and vessel sprouting from mouse aortic rings, in a dose dependent fashion. <b>54</b> was found to suppress the VEGF-induced phosphorylation of VEGFR-2 and the activation of AKT and eNOS.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></div><div class="NLM_p">A differently structured compound containing the isolated pyridine ring is the <i>N</i>-methyl-4-(4-(3-(trifluoromethyl)benzamido)phenoxy)picolinamide <b>55</b> (SKLB610) (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>), a multitargeted inhibitor active on VEGFR-2 and FGFR-2. The derivative has antiangiogenic effects, inhibiting HUVEC capillary-tube formation and the subintestinal vein formation of zebrafish in vivo. It has antiproliferative effects, especially on human NSCLC cell line A549 and human colorectal cancer cell line HCT116, and is also active on tumor xenografts in nude mice without evident toxicity.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Nonfused pyridines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Pyrrolocarbazoles, Indolopyrrolones, and Indolinones</h4><div class="NLM_p">Cephalon Inc. synthesized different families of dihydroindazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole derivatives active as dual Tie-2/VEGFR-2 inhibitors, including <b>56</b>, <b>57</b>, and <b>58</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>),<a onclick="showRef(event, 'ref200 ref201 ref202'); return false;" href="javascript:void(0);" class="ref ref200 ref201 ref202">(200-202)</a> bearing different C3 groups. These studies led very recently to the identification of <b>25</b>,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> currently in clinical trials and discussed elsewhere in this paper. All these compounds are derived from modifications/simplifications of staurosporine, one of the first pan-kinase inhibitors.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Pyrrolocarbazoles, indolopyrrolones, and indolinones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The pyrrol-2-one <b>59</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>), derived from a further simplification on dihydroindazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole structure of <b>56</b>–<b>58</b>, is a potent VEGFR-2/3 inhibitor showing IC<sub>50</sub> values of 31 and 37 nM, respectively, and specificity over a panel of other 22 proteine kinases. The inhibitor forms the two canonical hydrogen bonds to the hinge region, whereas the indole ring is located in the hydrophobic region I with π–π stacking interactions to Phe1047 (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>). It demonstrates a strong in vivo activity in the human lung derived microvascular endothelial cells sprouting assay at 1.3 μM and induction of apoptosis in the human dermal microvascular endothelial cells assay at 2.6 μM. Thus, in light of the high in vitro activity, selectivity, and good bioavailability in the cellular models, <b>59</b> may have potential for clinical development as an antiangiogenic drug.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Schematic representation of hydrogen bonds (dotted lines) between <b>59</b> and VEGFR-2 catalytic site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A number of 2-indolinone derivatives synthesized in the past few years are multikinase inhibitors that are also active on VEGFR-2. Among them, some compounds substituted with pyrrolo-fused six- and seven-membered heterocycles, including <b>60</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>), are potent inhibitors of VEGFR-2, PDGFR, and c-Kit both enzymatically (<50 nM) and cellularly (<50 nM). Moreover, compound <b>60</b> possesses a favorable pharmacokinetic profile and demonstrates good efficacy against human HT-29 cell colon tumor engrafts in nude mice.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a></div><div class="NLM_p last">Derivative <b>61</b> (SIM010603) (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>) inhibits VEGFR-2, PDGFR, c-Kit, RET, and FLT3 with IC<sub>50</sub> values in the range from 5 to 68 nM. It also inhibits endothelial cell proliferation and chemotaxis, corneal angiogenesis, and tumor growth in animal models, in particular reducing microvascular density in a T241-VEGF-A tumor engraft model.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a></div></div><div id="sec3_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Miscellaneous Compounds</h4><div class="NLM_p">Two series of pyrrolotriazine derivatives, similar to the Bristol-Myers Squibb clinical candidate brivanib alaninate <b>20</b>, have been reported by the same company. Compound <b>62</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>), bearing the 2,4-difluoro-5-(cyclopropylcarbamoyl)phenylamino group at the C4 position and a substituted 1,3,5-oxadiazole ring appended to the C6 position of the pyrrolo[2,1-<i>f</i>][1,2,4]triazine scaffold, is a low nanomolar inhibitor of VEGFR-2, showing IC<sub>50</sub> values of 11 and 25 nM in enzymatic and HUVEC assays, respectively. Furthermore, antitumor efficacy was observed with this derivative against L2987 human lung carcinoma xenografts in athymic mice.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Compound <b>63</b> (BMS-645737) (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>) and its congeners, substituted in C4 with a pyrrolo[2,3-<i>b</i>]pyridin-5-yl moiety, are nanomolar VEGFR-2 inhibitors. Derivative <b>63</b> possesses good preclinical in vivo activity against human tumor xenograft models.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a></div><div class="NLM_p">Abbott synthesized a series of benzo[<i>d</i>]isoxazoles incorporating a <i>N</i>,<i>N</i>′-diphenylurea moiety at the 4-position as receptor TK inhibitors. In particular, compound <b>64</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>) potently inhibits VEGFR-2 with IC<sub>50</sub> values of 11 and 31 nM in enzymatic and cell assays, respectively, and FLT3 and Kit in the nanomolar range. This inhibitor is orally bioavailable and has a promising pharmacokinetic profile. It demonstrates in vivo efficacy in models of VEGF-stimulated vascular permeability, i.e., the uterine edema model. Moreover, it inhibits tumor growth in the human fibrosarcoma (HT1080) model by 81% at a dose of 10 mg kg<sup>–1</sup> day<sup>–1</sup>.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a></div><div class="NLM_p">The tetrasubstituted pyrazole <b>65</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>) and its analogues, derived from a family of p38MAPK inhibitors, are potent multikinase inhibitors active in the nanomolar range against Src, B-Raf wt, B-Raf V600E, EGFRs, and VEGFR-2. The last is inhibited by <b>65</b> with an IC<sub>50</sub> of 34 nM.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Miscellaneous compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The admission into clinical use of five VEGFR inhibitors in 8 years, the last drug being pazopanib, approved in April 2012, has strongly indicated the therapeutic value of these agents and the importance of research in the field of angiogenesis inhibitors for future oncology therapy.</div><div class="NLM_p">Even if their initial uses in cancer treatment are currently restricted to advanced and metastatic renal-cell carcinoma, gastrointestinal stromal tumors, and hepatocellular carcinoma, ongoing investigations into different malignancies are likely to lead to the use of such compounds in other tumors as well.</div><div class="NLM_p">However, there are undoubtedly many issues that are not yet fully explored, from both the clinical and biochemical perspectives. As to the clinical aspect, it has been reported in several reviews that the toxicity profile of VEGFR inhibitors is usually acceptable and manageable, considering the severity of the diseases in which such drugs are used. Some effects are, however, sufficiently severe or life-threatening to require discontinuation of therapy. VEGFR inhibitors are being tested in several combinations with conventional chemotherapy, which should improve patient outcomes and permit reduced doses of cytotoxic chemotherapy, although particular attention should be paid to the use of combination regimens in order to avoid risks of severe effects. Future studies will help to fine-tune the delicate balance between efficacy and tolerability.</div><div class="NLM_p">From the biochemical point of view, much evidence indicates that VEGFR inhibition alone is not usually sufficient to block and eradicate the tumor. This aspect of the problem is partially mitigated by the fact that the most active compounds that have been mentioned in this article are multitargeted inhibitors and inhibit other kinases involved in angiogenesis or in cell growth. As an example, a number of potential drugs block both the VEGF/VEGFRs and angiopietin/Tie-2 pathways, which are both involved in angiogenesis. Manipulating these interacting pathways may make possible even more potent and targeted inhibition.</div><div class="NLM_p">While in the recent past the research was focused on the discovery of selective agents that inhibited only one tyrosine or serine/threonine kinase, the more recent trend is to address the rational design of compounds active on multiple protein targets. Especially in the field of cancer treatment, nonselective drugs acting on more than one kinase and inhibiting different cell pathways can sometimes be more effective than a drug specific for one kinase, as indicated by the principles of multitargeted pharmacology.<a onclick="showRef(event, 'ref210 ref211'); return false;" href="javascript:void(0);" class="ref ref210 ref211">(210, 211)</a> The continuous development of new technologies in the chemical, computational, and biological fields, all applied to systems biology, will offer new means for discovering other molecules as potential new drugs. On the other hand, efforts to obtain inhibitors selective for VEGFRs or, preferably, for each member of the VEGFR family are very challenging and worthwhile, since the identification of VEGFR specific signaling pathways and gene expression remains to be fully understood.</div><div class="NLM_p last">In conclusion, the large number of studies and publications in the field of angiogenesis inhibitors shows a significant interest in VEGFR/multikinase inhibitors on the part of academic and pharmaceutical researchers. Several compounds are in advanced clinical trials, and very recently synthesized molecules, which have just entered preclinical study, could offer further opportunities to develop other drugs that are active on hematological and solid malignancies.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm301085w" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Schenone</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Farmacia, University
of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#99eafaf1fcf7eaf0f5d9ecf7f0fefcb7f0ed"><span class="__cf_email__" data-cfemail="51223239343f22383d11243f3836347f3825">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Musumeci</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Farmacia, University
of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco Radi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Famaceutico, University of Parma, Viale delle Scienze, 27/A, I-43124
Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiara Brullo</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Farmacia, University
of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Francesca Musumeci</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Francesca Musumeci</b> graduated from the University of Genoa, Italy, in 2008 (marks, 110/110 cum laude), specializing in Medicinal Chemistry. In the same year, she received a fellowship for “new synthetic approaches toward interesting therapeutic molecules”, working at the Department of Chemistry and Industrial Chemistry at University of Genoa. In 2012, she obtained a Ph.D. in Medicinal Chemistry at University of Genoa, working at synthesis of heterocycles compounds as protein kinases inhibitors. During her Ph.D. studies, she spent a period at National University of Ireland in Galway, working on “deuteration and functionalization of resorcylic acid lactones (RALs)”. Since January 2012 she has a postdoctoral position at University of Genoa. She is coauthor of nine publications on international journals, a patent, and three oral communications to Congress.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Marco Radi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Marco Radi</b> graduated cum laude (November 2000) and was later awarded a Ph.D. in Medicinal Chemistry from the University of Siena, Italy (2004). He spent 1 year as Postdoctoral Research Associate at the University of Georgia (U.S.) under the supervision of Prof. David C. K. Chu. From January 2006 to January 2010 he worked as Postdoctoral Research Associate at the University of Siena, Italy, in collaboration with Prof. Maurizio Botta. From July 2010 to December 2011, he worked at the University of Siena. Since December 2011, he has been Assistant Professor at the Faculty of Pharmacy of the University of Parma, Italy. His research is in the field of synthesis of anti-infective and anticancer agents. He is author of 47 papers, 2 book chapters, and 6 patents.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Chiara Brullo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chiara Brullo</b> received her Bachelors degree in Pharmaceutical Chemistry at the University of Genoa, Italy, in 1999 (marks, 110/110 cum laude). In 2003 she received a Ph.D. in Pharmaceutical Science, and from 2003 to 2009 she held five research fellowships at the University of Genoa, working on the synthesis of adenosine receptor ligands and on the synthesis of neutrophil chemotaxis. Since 2010 she has had a contract from the Department of Pharmaceutical Sciences, University of Genoa. Since November 2010 she has been a researcher at the Department of Pharmaceutical Sciences at the University of Genoa. She is the author of 39 scientific publications on international journals, 30 posters, 2 patents, and a book chapter.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Silvia Schenone</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=bio4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Silvia Schenone</b> obtained a degree in Medicinal Chemistry in 1987 and in Pharmacy in 1988, both with laude at the University of Genoa, Italy. In 1992 she received her Ph.D. in Medicinal Chemistry. Since 2001 she has been Associate Professor of Medicinal Chemistry at the same university. She is the author of 115 publications and 4 patents. Currently she is involved in the synthesis of pyrazolopyridine derivatives as adenosine antagonists and of heterocyclic derivatives as tyrosine kinases inhibitors. Prof. Schenone’s group is also involved in structural studies on biological macromolecules (enzymes, receptors, growth factors) and molecular modeling application on medicinal subjects.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i25" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i25"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i26" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i26"> Abbreviations Used</h2><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">TIMP-1</td><td class="NLM_def"><p class="first last">tissue inhibitor of metalloproteinase 1</p></td></tr><tr><td class="NLM_term">PlGF</td><td class="NLM_def"><p class="first last">placenta growth factor</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">TK</td><td class="NLM_def"><p class="first last">tyrosine kinase</p></td></tr><tr><td class="NLM_term">Flt</td><td class="NLM_def"><p class="first last">fms-like tyrosine kinase</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain</p></td></tr><tr><td class="NLM_term">Flk</td><td class="NLM_def"><p class="first last">fetal liver kinase</p></td></tr><tr><td class="NLM_term">JM</td><td class="NLM_def"><p class="first last">juxtamembrane</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen activated protein kinase</p></td></tr><tr><td class="NLM_term">Raf</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen activated protein kinase/extracellular signal-regulated kinase kinase</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">CSFR</td><td class="NLM_def"><p class="first last">colony stimulating factor receptor</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms-like tyrosine kinase receptor 3</p></td></tr><tr><td class="NLM_term">FGF</td><td class="NLM_def"><p class="first last">fibroblast growth factor</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">IL-8</td><td class="NLM_def"><p class="first last">interleukin 8</p></td></tr><tr><td class="NLM_term">Tie-2</td><td class="NLM_def"><p class="first last">tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 2</p></td></tr><tr><td class="NLM_term">Eph</td><td class="NLM_def"><p class="first last">erythropoietin-producing human hepatocellular carcinoma receptor</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">Bcr-Abl</td><td class="NLM_def"><p class="first last">breakpoint cluster region Abelson tyrosine kinase</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">catalytic domain</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cell</p></td></tr><tr><td class="NLM_term">HER</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">Lck</td><td class="NLM_def"><p class="first last">lymphoid cell kinase</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">adsorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">PLK1</td><td class="NLM_def"><p class="first last">polo-like kinase 1</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin dependent kinase</p></td></tr><tr><td class="NLM_term">eNOS</td><td class="NLM_def"><p class="first last">endothelial nitric oxide synthase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 211 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Folkman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amore, P.</span><span> </span><span class="NLM_article-title">Blood vessel formation: what is its molecular basis?</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1996&pages=1153-1155&author=J.+Folkmanauthor=P.+D%E2%80%99Amore&title=Blood+vessel+formation%3A+what+is+its+molecular+basis%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%26atitle%3DBlood%2520vessel%2520formation%253A%2520what%2520is%2520its%2520molecular%2520basis%253F%26jtitle%3DCell%26date%3D1996%26volume%3D87%26spage%3D1153%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Risau, W.</span><span> </span><span class="NLM_article-title">Mechanisms of angiogenesis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2F386671a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=9109485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADyaK2s3mtlGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=1997&pages=671-674&author=W.+Risau&title=Mechanisms+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of angiogenesis</span></div><div class="casAuthors">Risau W</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">6626</span>),
    <span class="NLM_cas:pages">671-4</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">After the developing embryo has formed a primary vascular plexus by a process termed vasculogenesis, further blood vessels are generated by both sprouting and non-sprouting angiogenesis, which are progressively pruned and remodelled into a functional adult circulatory system.  Recent results, particularly from the study of mice lacking some of the signalling systems involved, have greatly improved our understanding of the molecular basis underlying these events, and may suggest new approaches for treating conditions such as cancer that depend on angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRN2kGUT2MdEH3Rlp_k91zfW6udTcc2eao_stWqDbarrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3mtlGksg%253D%253D&md5=748146a1cf56ccaf4894573d0687a402</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F386671a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F386671a0%26sid%3Dliteratum%253Aachs%26aulast%3DRisau%26aufirst%3DW.%26atitle%3DMechanisms%2520of%2520angiogenesis%26jtitle%3DNature%26date%3D1997%26volume%3D386%26spage%3D671%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Klagsbrun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moses, M. A.</span><span> </span><span class="NLM_article-title">Molecular angiogenesis</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">R217</span><span class="NLM_x">–</span> <span class="NLM_lpage">R224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2FS1074-5521%2899%2980081-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=10421764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVynsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=R217-R224&author=M.+Klagsbrunauthor=M.+A.+Moses&title=Molecular+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular angiogenesis</span></div><div class="casAuthors">Klagsbrun, Michael; Moses, Marsha A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">R217-R224</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">A review with 70 refs.  New insights into the mechanisms by which blood vessels develop (angiogenesis) have been gained recently, primarily by the identification of factors that inhibit and promote this process.  Angiogenesis-stimulating factors are being used to promote growth of new blood vessels in ischemic disease.  In contrast, anti-angiogenesis factors are being used as inhibitors of neovascularization to control tumor growth and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol1lP42oGX-7Vg90H21EOLACvtfcHk0ljtSlGjcs0HYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVynsLk%253D&md5=7deec4953a842556064ce4d002b72d6d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2899%2980081-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252899%252980081-7%26sid%3Dliteratum%253Aachs%26aulast%3DKlagsbrun%26aufirst%3DM.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26atitle%3DMolecular%2520angiogenesis%26jtitle%3DChem.%2520Biol.%26date%3D1999%26volume%3D6%26spage%3DR217%26epage%3DR224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, B. M.</span><span> </span><span class="NLM_article-title">An overview of small-molecule inhibitors of VEGFR signalling</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">569</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrclinonc.2009.130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19736552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=569-579&author=S.+P.+Ivyauthor=J.+Y.+Wickauthor=B.+M.+Kaufman&title=An+overview+of+small-molecule+inhibitors+of+VEGFR+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of small-molecule inhibitors of VEGFR signaling</span></div><div class="casAuthors">Ivy, S. Percy; Wick, Jeannette Y.; Kaufman, Bennett M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">569-579</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The VEGFR small-mol. inhibitors of angiogenesis show promise for oncol. patients.  These rationally designed inhibitors are being tailored for use in specific malignancies and will have a pivotal role in personalized medicine.  The authors discuss the potential of these agents for treating tumors such as metastatic renal-cell carcinoma, GIST and hepatocellular carcinoma.  VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma, gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a no. of other oncol. indications, including colorectal cancer, non-small-cell lung cancer, pancreatic cancer, thyroid malignancies, ovarian cancer, breast cancer and sarcomas.  This Review outlines the structure-activity relationships of the 44 VEGFR inhibitors currently in development.  An overview of the pharmacokinetic profile of each mol. and its stage in development is provided.  Phase III clin. trials being conducted for licensing of these agents for specific indications and phase III developmental efficacy trials are described in detailed tables that include the disease studied, trial design including combination therapy, study end points, and projected or final accrual.  The relative frequency of on-target and off-target adverse events obsd. in 3,060 patients is described for a subset of agents in development in clin. trials sponsored by the National Cancer Institute.  No interagent comparisons were undertaken and no data from pharmaceutical pharmacovigilance databases were used.  The on-target effects seem to be mechanistically based and predicted by VEGFR inhibition.  Small-mol. inhibitors of angiogenesis are active in a wide variety of malignancies and fill a unique niche for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN-w_SDT-UfrVg90H21EOLACvtfcHk0lh5WJ18wXiVuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbI&md5=6ae67a681df0729bda1fa06a2aa391eb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2009.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2009.130%26sid%3Dliteratum%253Aachs%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DWick%26aufirst%3DJ.%2BY.%26aulast%3DKaufman%26aufirst%3DB.%2BM.%26atitle%3DAn%2520overview%2520of%2520small-molecule%2520inhibitors%2520of%2520VEGFR%2520signalling%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D6%26spage%3D569%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor as a target for anticancer therapy</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=2-10&author=N.+Ferrara&title=Vascular+endothelial+growth+factor+as+a+target+for+anticancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520as%2520a%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DOncologist%26date%3D2004%26volume%3D9%26spage%3D2%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Potente, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhardt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Basic and therapeutic aspects of angiogenesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">887</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2011&pages=873-887&author=M.+Potenteauthor=H.+Gerhardtauthor=P.+Carmeliet&title=Basic+and+therapeutic+aspects+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPotente%26aufirst%3DM.%26aulast%3DGerhardt%26aufirst%3DH.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DBasic%2520and%2520therapeutic%2520aspects%2520of%2520angiogenesis%26jtitle%3DCell%26date%3D2011%26volume%3D146%26spage%3D873%26epage%3D887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Tumor angiogenesis: therapeutic implications</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">1182</span><span class="NLM_x">–</span> <span class="NLM_lpage">1186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1056%2FNEJM197111182852108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=4938153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1971&pages=1182-1186&author=J.+Folkman&title=Tumor+angiogenesis%3A+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor angiogenesis: therapeutic implications</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1182-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA0C6odtE1LPxQvRxYU81tfW6udTcc2eYo26MNSkJgGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D&md5=efdddcba0c04be542edd51fef2ef27b9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJM197111182852108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197111182852108%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DTumor%2520angiogenesis%253A%2520therapeutic%2520implications%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1971%26volume%3D285%26spage%3D1182%26epage%3D1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1996&pages=353-364&author=D.+Hanahanauthor=J.+Folkman&title=Patterns+and+emerging+mechanisms+of+the+angiogenic+switch+during+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DPatterns%2520and%2520emerging%2520mechanisms%2520of%2520the%2520angiogenic%2520switch%2520during%2520tumorigenesis%26jtitle%3DCell%26date%3D1996%26volume%3D86%26spage%3D353%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Tumor angiogenesis: past, present and the near future</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">–</span> <span class="NLM_lpage">515</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=501-515&author=R.+S.+Kerbel&title=Tumor+angiogenesis%3A+past%2C+present+and+the+near+future"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DTumor%2520angiogenesis%253A%2520past%252C%2520present%2520and%2520the%2520near%2520future%26jtitle%3DCarcinogenesis%26date%3D2000%26volume%3D21%26spage%3D501%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Sharpe, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maupin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teleron, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pyle, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. P.</span><span> </span><span class="NLM_article-title">VEGF and PIGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularisation</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1495</span><span class="NLM_x">–</span> <span class="NLM_lpage">1497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=1495-1497&author=E.+E.+Sharpeauthor=A.+B.+Maupinauthor=A.+A.+Teleronauthor=A.+L.+Pyleauthor=P.+Carmelietauthor=P.+P.+Young&title=VEGF+and+PIGF+promote+adult+vasculogenesis+by+enhancing+EPC+recruitment+and+vessel+formation+at+the+site+of+tumor+neovascularisation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharpe%26aufirst%3DE.%2BE.%26aulast%3DMaupin%26aufirst%3DA.%2BB.%26aulast%3DTeleron%26aufirst%3DA.%2BA.%26aulast%3DPyle%26aufirst%3DA.%2BL.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DP.%2BP.%26atitle%3DVEGF%2520and%2520PIGF%2520promote%2520adult%2520vasculogenesis%2520by%2520enhancing%2520EPC%2520recruitment%2520and%2520vessel%2520formation%2520at%2520the%2520site%2520of%2520tumor%2520neovascularisation%26jtitle%3DFASEB%2520J.%26date%3D2006%26volume%3D20%26spage%3D1495%26epage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Angiogenesis in life, disease and medicine</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnature04478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16355210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=932-936&author=P.+Carmeliet&title=Angiogenesis+in+life%2C+disease+and+medicine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in life, disease and medicine</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">7070</span>),
    <span class="NLM_cas:pages">932-936</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair.  An imbalance in this process contributes to numerous malignant, inflammatory, ischemic, infectious and immune disorders.  Recently, the first anti-angiogenic agents have been approved for the treatment of cancer and blindness.  Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5NqkaUGRfrVg90H21EOLACvtfcHk0lh5WJ18wXiVuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF&md5=e196d7203fa60d5ecd9182fa023cd30e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature04478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04478%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAngiogenesis%2520in%2520life%252C%2520disease%2520and%2520medicine%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D932%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Leung, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cachianes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goeddel, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor is a secreted angiogenic mitogen</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">246</span><span class="NLM_x">, </span> <span class="NLM_fpage">1306</span><span class="NLM_x">–</span> <span class="NLM_lpage">1309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1989&pages=1306-1309&author=D.+W.+Leungauthor=G.+Cachianesauthor=W.+J.+Kuangauthor=D.+V.+Goeddelauthor=N.+Ferrara&title=Vascular+endothelial+growth+factor+is+a+secreted+angiogenic+mitogen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DD.%2BW.%26aulast%3DCachianes%26aufirst%3DG.%26aulast%3DKuang%26aufirst%3DW.%2BJ.%26aulast%3DGoeddel%26aufirst%3DD.%2BV.%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520is%2520a%2520secreted%2520angiogenic%2520mitogen%26jtitle%3DScience%26date%3D1989%26volume%3D246%26spage%3D1306%26epage%3D1309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Holmes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, M. J.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.cellsig.2007.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17658244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=2003-2012&author=K.+Holmesauthor=O.+L.+Robertsauthor=A.+M.+Thomasauthor=M.+J.+Cross&title=Vascular+endothelial+growth+factor+receptor-2%3A+structure%2C+function%2C+intracellular+signalling+and+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span></div><div class="casAuthors">Holmes, Katherine; Roberts, Owain Ll; Thomas, Angharad M.; Cross, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2003-2012</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a no. of receptors.  VEGFR-1 is required for the recruitment of hematopoietic stem cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function.  Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signaling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response.  Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a no. of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTYxPMokVV57Vg90H21EOLACvtfcHk0ljU92pJpEuAhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D&md5=44a935f36d29b000d2a9ff514709e9c2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2007.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2007.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DO.%2BL.%26aulast%3DThomas%26aufirst%3DA.%2BM.%26aulast%3DCross%26aufirst%3DM.%2BJ.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-2%253A%2520structure%252C%2520function%252C%2520intracellular%2520signalling%2520and%2520therapeutic%2520inhibition%26jtitle%3DCell.%2520Signalling%26date%3D2007%26volume%3D19%26spage%3D2003%26epage%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Stuttfeld, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballmer-Hofer, K.</span><span> </span><span class="NLM_article-title">Structure and function of VEGF receptors</span> <span class="citation_source-journal">IUBMB Life</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=915-922&author=E.+Stuttfeldauthor=K.+Ballmer-Hofer&title=Structure+and+function+of+VEGF+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStuttfeld%26aufirst%3DE.%26aulast%3DBallmer-Hofer%26aufirst%3DK.%26atitle%3DStructure%2520and%2520function%2520of%2520VEGF%2520receptors%26jtitle%3DIUBMB%2520Life%26date%3D2009%26volume%3D61%26spage%3D915%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">VEGF receptor protein-tyrosine kinases: structure and regulation</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2008&pages=287-291&author=R.+Roskoski&title=VEGF+receptor+protein-tyrosine+kinases%3A+structure+and+regulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DVEGF%2520receptor%2520protein-tyrosine%2520kinases%253A%2520structure%2520and%2520regulation%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2008%26volume%3D375%26spage%3D287%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Koch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tugues, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gualandi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claesson-Welsh, L.</span><span> </span><span class="NLM_article-title">Signal transduction by vascular endothelial growth factor receptors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">437</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1042%2FBJ20110301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21711246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFSmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=437&publication_year=2011&pages=169-183&author=S.+Kochauthor=S.+Tuguesauthor=X.+Liauthor=L.+Gualandiauthor=L.+Claesson-Welsh&title=Signal+transduction+by+vascular+endothelial+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction by vascular endothelial growth factor receptors</span></div><div class="casAuthors">Koch, Sina; Tugues, Sonia; Li, Xiujuan; Gualandi, Laura; Claesson-Welsh, Lena</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">437</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-183</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  VEGFs (vascular endothelial growth factors) control vascular development during embryogenesis and the function of blood vessels and lymphatic vessels in the adult.  There are five related mammalian ligands, which act through three receptor tyrosine kinases.  Signaling is modulated through neuropilins, which act as VEGF co-receptors.  Heparan sulfate and integrins are also important modulators of VEGF signaling.  Therapeutic agents that interfere with VEGF signaling have been developed with the aim of decreasing angiogenesis in diseases that involve tissue growth and inflammation, such as cancer.  The present review will outline the current understanding and consequent biol. of VEGF receptor signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeC7nB3SWcmrVg90H21EOLACvtfcHk0ljU92pJpEuAhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFSmtbo%253D&md5=fa31c9c345be1b5004c9d8052f6d29ae</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1042%2FBJ20110301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110301%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DTugues%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGualandi%26aufirst%3DL.%26aulast%3DClaesson-Welsh%26aufirst%3DL.%26atitle%3DSignal%2520transduction%2520by%2520vascular%2520endothelial%2520growth%2520factor%2520receptors%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D437%26spage%3D169%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Morabito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Maio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normanno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, F.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=753-764&author=A.+Morabitoauthor=E.+De+Maioauthor=M.+Di+Maioauthor=N.+Normannoauthor=F.+Perrone&title=Tyrosine+kinase+inhibitors+of+vascular+endothelial+growth+factor+receptors+in+clinical+trials%3A+current+status+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorabito%26aufirst%3DA.%26aulast%3DDe%2BMaio%26aufirst%3DE.%26aulast%3DDi%2BMaio%26aufirst%3DM.%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DPerrone%26aufirst%3DF.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptors%2520in%2520clinical%2520trials%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DOncologist%26date%3D2006%26volume%3D17%26spage%3D753%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kappert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böhmer, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostman, A.</span><span> </span><span class="NLM_article-title">Tyrosine phosphatases in vessel wall signaling</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.cardiores.2004.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=15664385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsVKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=587-598&author=K.+Kappertauthor=K.+G.+Petersauthor=F.+D.+B%C3%B6hmerauthor=A.+Ostman&title=Tyrosine+phosphatases+in+vessel+wall+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine phosphatases in vessel wall signaling</span></div><div class="casAuthors">Kappert, Kai; Peters, Kevin G.; Boehmer, Frank D.; Oestman, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-598</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are crit. regulators of cellular processes like migration, proliferation and differentiation that are involved in physiol. and pathol. vessel wall function.  In this review, we summarize the biochem. of this enzyme family, discuss the present knowledge concerning the identity and involvement of PTPs in vascular cells and in pathways of relevance to cardiovascular diseases.  We also briefly introduce ongoing efforts to develop inhibitors of PTPs, and finally point to some opportunities for use of such agents in novel treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYLeFet4ZcbVg90H21EOLACvtfcHk0lh7kSClzhh0nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsVKmuw%253D%253D&md5=87f37d332a2b6f60fbade9fedb9c7b4c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2004.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2004.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DKappert%26aufirst%3DK.%26aulast%3DPeters%26aufirst%3DK.%2BG.%26aulast%3DB%25C3%25B6hmer%26aufirst%3DF.%2BD.%26aulast%3DOstman%26aufirst%3DA.%26atitle%3DTyrosine%2520phosphatases%2520in%2520vessel%2520wall%2520signaling%26jtitle%3DCardiovasc.%2520Res.%26date%3D2005%26volume%3D65%26spage%3D587%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Bruce, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, P. H.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: Where do we go from here?</span> <span class="citation_source-journal">Cell Commun. Adhes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22017472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsF2ltbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=85-103&author=D.+Bruceauthor=P.+H.+Tan&title=Vascular+endothelial+growth+factor+receptors+and+the+therapeutic+targeting+of+angiogenesis+in+cancer%3A+Where+do+we+go+from+here%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?</span></div><div class="casAuthors">Bruce, David; Tan, Peng H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Communication & Adhesion</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">85-103</span>CODEN:
                <span class="NLM_cas:coden">CCAEBH</span>;
        ISSN:<span class="NLM_cas:issn">1541-9061</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Vascular Endothelial Growth Factor receptors (VEGFRs), the interactions with their ligands and the subsequent signalling pathways are known to play a vital role in tumor angiogenesis.  Initial clin. trials of VEGFR inhibitors were disappointing but over the past decade some therapies have been successfully brought to market.  At present, VEGFR inhibitors appear to be most promising as adjuvants to conventional chemotherapy.  However, several interacting signalling mols. and downstream pathways have recently been shown to interact with VEGFR signalling and provide promising novel targets, such as the platelet-derived growth factor (PDGF), epithelial growth factor (EGF), human epithelial receptor-2, (HER-2) Tie-2 and estrogen receptors.  Elucidation of this web of signalling pathways may identify new therapeutic strategies which may be used in combination with VEGFR inhibitors to augment the efficacy of anti-angiogenic cancer treatments.  This review assesses the role of modulating VEGFR activity in cancer and systematically examines current evidence and trials in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS2hGQkpX8wbVg90H21EOLACvtfcHk0lh7kSClzhh0nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsF2ltbnE&md5=e1e997c8fdb55c025ff5d5bb4afd72cb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DP.%2BH.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptors%2520and%2520the%2520therapeutic%2520targeting%2520of%2520angiogenesis%2520in%2520cancer%253A%2520Where%2520do%2520we%2520go%2520from%2520here%253F%26jtitle%3DCell%2520Commun.%2520Adhes.%26date%3D2011%26volume%3D18%26spage%3D85%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christinger, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vos, A. M.</span><span> </span><span class="NLM_article-title">Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2FS0092-8674%2800%2980456-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=9393862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1997&pages=695-704&author=C.+Wiesmannauthor=G.+Fuhauthor=H.+W.+Christingerauthor=C.+Eigenbrotauthor=J.+A.+Wellsauthor=A.+M.+de+Vos&title=Crystal+structure+at+1.7+%C3%85+resolution+of+VEGF+in+complex+with+domain+2+of+the+Flt-1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor</span></div><div class="casAuthors">Wiesmann, Christian; Fuh, Germaine; Christinger, Hans W.; Eigenbrot, Charles; Wells, James A.; De Vos, Abraham M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-704</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) is a homodimeric hormone that induces proliferation of endothelial cells through binding to the kinase domain receptor and the Fms-like tyrosine kinase receptor (Flt-1), the extracellular portions of which consist of seven Ig domains.  We show that the second and third domains of Flt-1 are necessary and sufficient for binding VEGF with near-native affinity, and that domain 2 alone binds only 60-fold less tightly than wild-type.  The crystal structure of the complex between VEGF and the second domain of Flt-1 shows domain 2 in a predominantly hydrophobic interaction with the "poles" of the VEGF dimer.  Based on this structure and on mutational data, we present a model of VEGF bound to the first four domains of Flt-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZYD3KG--Kg7Vg90H21EOLACvtfcHk0lh7kSClzhh0nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWrtr4%253D&md5=0775fe6ced8d68e2db5d2900a2d5c3e4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980456-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980456-0%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DFuh%26aufirst%3DG.%26aulast%3DChristinger%26aufirst%3DH.%2BW.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26atitle%3DCrystal%2520structure%2520at%25201.7%2520%25C3%2585%2520resolution%2520of%2520VEGF%2520in%2520complex%2520with%2520domain%25202%2520of%2520the%2520Flt-1%2520receptor%26jtitle%3DCell%26date%3D1997%26volume%3D91%26spage%3D695%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Maharaj, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saint-Geniez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maldonado, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amore, P. A.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor localization in the adult</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">168</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2353%2Fajpath.2006.050834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16436677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1agu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2006&pages=639-648&author=A.+S.+Maharajauthor=M.+Saint-Geniezauthor=A.+E.+Maldonadoauthor=P.+A.+D%E2%80%99Amore&title=Vascular+endothelial+growth+factor+localization+in+the+adult"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor localization in the adult</span></div><div class="casAuthors">Maharaj, Arindel S. R.; Saint-Geniez, Magali; Maldonado, Angel E.; D'Amore, Patricia A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">639-648</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Although vascular endothelial growth factor (VEGF) has been well studied in both developmental and pathol. angiogenesis, its role in mature blood vessels is poorly understood.  A growing body of observations, including the side effects of anti-VEGF therapies as well as the role of sol. VEGFR1 in preeclampsia, points to an important role for VEGF in maintenance of stable blood vessels.  To better understand the potential function of VEGF in mature vessels, a survey of VEGF localization in adult mice was conducted.  In adult VEGF-lacZ mice, VEGF was expressed in a cell-specific manner by cells overlying fenestrated and sinusoidal blood vessels, including podocytes, choroid plexus epithelium, and hepatocytes, as well as in tissues with high metabolic demands or with secretory functions, such as cardiac and skeletal myocytes, Leydig cells, prostatic epithelium, and salivary serous epithelium.  VEGF was not detected in most endothelium but was specifically expressed by aortic endothelial cells where VEGFR2 was found to be phosphorylated, indicating an autocrine loop.  Addnl., VEGFR2 was constitutively phosphorylated in the liver, lung, adipose, and kidney in vivo, providing evidence consistent with a role for VEGF in adult tissues.  These observations support the concept that VEGF acts in the adult to stabilize mature vessels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnrvmXDoCBbVg90H21EOLACvtfcHk0ljZ_BCs0R7CBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1agu7c%253D&md5=eaab361f5f9a869b528202b7845519dc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2006.050834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2006.050834%26sid%3Dliteratum%253Aachs%26aulast%3DMaharaj%26aufirst%3DA.%2BS.%26aulast%3DSaint-Geniez%26aufirst%3DM.%26aulast%3DMaldonado%26aufirst%3DA.%2BE.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520localization%2520in%2520the%2520adult%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2006%26volume%3D168%26spage%3D639%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Shibuya, M.</span><span> </span><span class="NLM_article-title">Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1177%2F1947601910392987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21779435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFamt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=1119-1123&author=M.+Shibuya&title=Tyrosine+kinase+receptor+Flt%2FVEGFR+family%3A+its+characterization+related+to+angiogenesis+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer</span></div><div class="casAuthors">Shibuya, Masabumi</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ligands and their tyrosine kinase (TK) receptors regulate a variety of biol. systems in animals.  Vascular endothelial growth factor (VEGF) and its receptor (Flt/VEGFR family) system play a crucial role not only in physiol. but also in most parts of pathol. angiogenesis including cancer.  Flt-1/VEGFR-1 and KDR/VEGFR-2 bind VEGF-A but have different functions on angiogenesis at early embryogenesis: Flt-1 has a neg. role by trapping ligands, whereas KDR (Flk1 in mice) exerts a strong pos. signal, resulting in a balance in blood vessel formation.  At adult stages, however, both VEGFRs contribute to pathol. angiogenesis either directly or through stimulation of migration/activation of macrophage lineage cells and stimulate tumor growth, metastasis, and inflammation.  VEGFRs activate downstream signaling of the phospholipase Cγ-protein kinase C-MAP kinase pathway but not Ras pathway for cell proliferation.  The VEGF-C/D and Flt-4/VEGFR-3 system regulates lymphangiogenesis.  Thus, VEGFs as well as these receptor TKs are attractive targets for suppressing pathol. angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0TbJ-wxIJY7Vg90H21EOLACvtfcHk0ljZ_BCs0R7CBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFamt7g%253D&md5=320ffe17a8a3d4d5468d5784e428a8f3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F1947601910392987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601910392987%26sid%3Dliteratum%253Aachs%26aulast%3DShibuya%26aufirst%3DM.%26atitle%3DTyrosine%2520kinase%2520receptor%2520Flt%252FVEGFR%2520family%253A%2520its%2520characterization%2520related%2520to%2520angiogenesis%2520and%2520cancer%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26spage%3D1119%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Rahimi, N.</span><span> </span><span class="NLM_article-title">VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy</span> <span class="citation_source-journal">Front. Biosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2741%2F1839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16146773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=818-829&author=N.+Rahimi&title=VEGFR-1+and+VEGFR-2%3A+two+non-identical+twins+with+a+unique+physiognomy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy</span></div><div class="casAuthors">Rahimi, Nader</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">818-829</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Angiogenesis involves endothelial cell differentiation, proliferation, migration and cord formation, which lead to tubulogenesis to form vessels.  One group of growth factor receptors implicated in angiogenesis is the VEGFR family of receptor tyrosine kinases.  VEGFR-1 and VEGFR-2 are closely related receptor tyrosine kinases and have both common and specific ligands.  VEGFR-1 is a kinase-impaired RTK whereas VEGFR-2 is a highly active kinase.  Despite their differential kinase activation potentials, both VEGFR-1 and VEGFR-2 are required for normal development and angiogenesis.  VEGFR-1 regulates angiogenesis by mechanisms that involve ligand-trapping, receptor homo- and heterodimerization.  VEGFR-2 stimulates variety of signaling pathways and broad biol. responses in vitro.  The mechanisms that govern VEGFR-2 activation, its ability to recruit signaling proteins and to undergo downregulation are highly regulated by its carboxyl terminus.  This review highlights recent insights into the mechanism of activation of VEGFR-1 and VEGFR-2, and focuses on the signaling pathways employed by VEGFR-1 and VEGFR-2 that regulate angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxIaYxenHinbVg90H21EOLACvtfcHk0ljZ_BCs0R7CBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrurnN&md5=36552ed71bde50aa5e04a7180e6101d7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2741%2F1839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F1839%26sid%3Dliteratum%253Aachs%26aulast%3DRahimi%26aufirst%3DN.%26atitle%3DVEGFR-1%2520and%2520VEGFR-2%253A%2520two%2520non-identical%2520twins%2520with%2520a%2520unique%2520physiognomy%26jtitle%3DFront.%2520Biosci.%26date%3D2006%26volume%3D11%26spage%3D818%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moons, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Compernolle, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Mol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Palma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewerchin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalmans, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandendriessche, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponten, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foidart, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaper, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charnock Jones, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persico, M. G.</span><span> </span><span class="NLM_article-title">Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2F87904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=11329059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVakurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=575-583&author=P.+Carmelietauthor=L.+Moonsauthor=A.+Luttunauthor=V.+Vincentiauthor=V.+Compernolleauthor=M.+De+Molauthor=Y.+Wuauthor=F.+Bonoauthor=L.+Devyauthor=H.+Beckauthor=D.+Scholzauthor=T.+Ackerauthor=T.+Di+Palmaauthor=M.+Dewerchinauthor=A.+Noelauthor=I.+Stalmansauthor=A.+Barraauthor=S.+Blacherauthor=T.+Vandendriesscheauthor=A.+Pontenauthor=U.+Erikssonauthor=K.+H.+Plateauthor=J.+M.+Foidartauthor=W.+Schaperauthor=D.+S.+Charnock+Jonesauthor=D.+J.+Hicklinauthor=J.+M.+Herbertauthor=D.+Collenauthor=M.+G.+Persico&title=Synergism+between+vascular+endothelial+growth+factor+and+placental+growth+factor+contributes+to+angiogenesis+and+plasma+extravasation+in+pathological+conditions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions</span></div><div class="casAuthors">Carmeliet, Peter; Moons, Lieve; Luttun, Aernout; Vincenti, Valeria; Compernolle, Veerle; De Mol, Maria; Wu, Yan; Bono, Francoise; Devy, Laetitia; Beck, Heike; Scholz, Dimitri; Acker, Till; DiPalma, Tina; Dewerchin, Mieke; Noel, Agnes; Stalmans, Ingeborg; Barra, Adriano; Blacher, Sylvia; Vandendriessche, Thierry; Ponten, Annica; Eriksson, Ulf; Plate, Karl H.; Foidart, Jean-Michel; Schaper, Wolfgang; Charnock-Jones, D. Stephen; Hicklin, Daniel J.; Herbert, Jean-Marc; Collen, Desire; Persico, M. Graziella</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">575-583</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating VEGF receptor-2 (VEGFR-2).  The role of its homolog, placental growth factor (PIGF), remains unknown.  Both VEGF and PIGF bind to VEGF receptor-1 (VEGFR-1), but it is unknown whether VEGFR-1, which exists as a sol. or a membrane-bound type, is an inert decoy or a signaling receptor for PIGF during angiogenesis.  Here, we report that embryonic angiogenesis in mice was not affected by deficiency of PIGF (Pgf-/-).  VEGF-B, another ligand of VEGFR-1, did not rescue development in Pgf-/- mice.  However, loss of PIGF impaired angiogenesis, plasma extravasation and collateral growth during ischemia, inflammation, wound healing and cancer.  Transplantation of wild-type bone marrow rescued the impaired angiogenesis and collateral growth in Pgf-/- mice, indicating that PIGF might have contributed to vessel growth in the adult by mobilizing bone-marrow-derived cells.  The synergism between PIGF and VEGF was specific, as PIGF deficiency impaired the response to VEGF, but not to bFGF or histamine.  VEGFR-1 was activated by PIGF, given that anti-VEGFR-1 antibodies and a Src-kinase inhibitor blocked the endothelial response to PIGF or VEGF/PIGF.  By upregulating PIGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the "angiogenic switch" in many pathol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsnFRJnUk7e7Vg90H21EOLACvtfcHk0ljZ_BCs0R7CBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVakurc%253D&md5=ae49f22810ca45ba84f02a8238d7b5a4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2F87904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F87904%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DMoons%26aufirst%3DL.%26aulast%3DLuttun%26aufirst%3DA.%26aulast%3DVincenti%26aufirst%3DV.%26aulast%3DCompernolle%26aufirst%3DV.%26aulast%3DDe%2BMol%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DDevy%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DH.%26aulast%3DScholz%26aufirst%3DD.%26aulast%3DAcker%26aufirst%3DT.%26aulast%3DDi%2BPalma%26aufirst%3DT.%26aulast%3DDewerchin%26aufirst%3DM.%26aulast%3DNoel%26aufirst%3DA.%26aulast%3DStalmans%26aufirst%3DI.%26aulast%3DBarra%26aufirst%3DA.%26aulast%3DBlacher%26aufirst%3DS.%26aulast%3DVandendriessche%26aufirst%3DT.%26aulast%3DPonten%26aufirst%3DA.%26aulast%3DEriksson%26aufirst%3DU.%26aulast%3DPlate%26aufirst%3DK.%2BH.%26aulast%3DFoidart%26aufirst%3DJ.%2BM.%26aulast%3DSchaper%26aufirst%3DW.%26aulast%3DCharnock%2BJones%26aufirst%3DD.%2BS.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DCollen%26aufirst%3DD.%26aulast%3DPersico%26aufirst%3DM.%2BG.%26atitle%3DSynergism%2520between%2520vascular%2520endothelial%2520growth%2520factor%2520and%2520placental%2520growth%2520factor%2520contributes%2520to%2520angiogenesis%2520and%2520plasma%2520extravasation%2520in%2520pathological%2520conditions%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D575%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egashira, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiasa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishibashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeshita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunagawa, K.</span><span> </span><span class="NLM_article-title">Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury</span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2284</span><span class="NLM_x">–</span> <span class="NLM_lpage">2289</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1161%2F01.ATV.0000147161.42956.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=15472126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVaisrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=2284-2289&author=Q.+Zhaoauthor=K.+Egashiraauthor=K.+Hiasaauthor=M.+Ishibashiauthor=S.+Inoueauthor=K.+Ohtaniauthor=C.+Tanauthor=M.+Shibuyaauthor=A.+Takeshitaauthor=K.+Sunagawa&title=Essential+role+of+vascular+endothelial+growth+factor+and+Flt-1+signals+in+neointimal+formation+after+periadventitial+injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of vascular endothelial growth factor and Flt-1 Signals in neointimal formation after periadventitial injury</span></div><div class="casAuthors">Zhao, Qingwei; Egashira, Kensuke; Hiasa, Ken-ichi; Ishibashi, Minako; Inoue, Shujiro; Ohtani, Kisho; Tan, Chunyan; Shibuya, Masabumi; Takeshita, Akira; Sunagawa, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2284-2289</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) is upregulated after arterial injury.  Its role in the pathogenesis of neointimal formation after periadventitial injury, however, has not been addressed.  Expression of VEGF and its receptors but not that of placental growth factor markedly increased with the development of neointimal formation in hypercholesterolemic mice after cuff-induced periarterial injury.  Transfection with the murine sol. Flt-1 (sFlt-1) gene to block VEGF in vivo in mice inhibited early inflammation and later neointimal formation.  The sFlt-1 gene transfer did not affect plasma lipid levels but attenuated increased expression of VEGF, Flt-1, Flk-1, monocyte chemoattractant protein-1, and other inflammation-promoting factors.  Mice with Flt-1 kinase deficiency also displayed reduced neointimal formation.  Thus, inflammatory changes mediated by VEGF and Flt-1 signals play an important role in the pathogenesis of neointimal formation after cuff-induced periadventitial injury.  VEGF might promote neointimal formation by acting as a proinflammatory cytokine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuWZSmJhFVALVg90H21EOLACvtfcHk0li4Q-pk_7s9WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVaisrvM&md5=8a48242d9808c10de0cab0e775048067</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1161%2F01.ATV.0000147161.42956.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.ATV.0000147161.42956.80%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DEgashira%26aufirst%3DK.%26aulast%3DHiasa%26aufirst%3DK.%26aulast%3DIshibashi%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DOhtani%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DSunagawa%26aufirst%3DK.%26atitle%3DEssential%2520role%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520and%2520Flt-1%2520signals%2520in%2520neointimal%2520formation%2520after%2520periadventitial%2520injury%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D2284%26epage%3D2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Jackson, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckford, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricciardelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsfall, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tilley, W. D.</span><span> </span><span class="NLM_article-title">A potential autocrine role for vascular endothelial growth factor in prostate cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">854</span><span class="NLM_x">–</span> <span class="NLM_lpage">859</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=854-859&author=M.+W.+Jacksonauthor=J.+S.+Robertsauthor=S.+E.+Heckfordauthor=C.+Ricciardelliauthor=J.+Stahlauthor=C.+Choongauthor=D.+J.+Horsfallauthor=W.+D.+Tilley&title=A+potential+autocrine+role+for+vascular+endothelial+growth+factor+in+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DM.%2BW.%26aulast%3DRoberts%26aufirst%3DJ.%2BS.%26aulast%3DHeckford%26aufirst%3DS.%2BE.%26aulast%3DRicciardelli%26aufirst%3DC.%26aulast%3DStahl%26aufirst%3DJ.%26aulast%3DChoong%26aufirst%3DC.%26aulast%3DHorsfall%26aufirst%3DD.%2BJ.%26aulast%3DTilley%26aufirst%3DW.%2BD.%26atitle%3DA%2520potential%2520autocrine%2520role%2520for%2520vascular%2520endothelial%2520growth%2520factor%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D854%26epage%3D859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Yang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camp, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somcio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L. M.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=46-51&author=A.+D.+Yangauthor=E.+R.+Campauthor=F.+Fanauthor=L.+Shenauthor=M.+J.+Grayauthor=W.+Liuauthor=R.+Somcioauthor=T.+W.+Bauerauthor=Y.+Wuauthor=D.+J.+Hicklinauthor=L.+M.+Ellis&title=Vascular+endothelial+growth+factor+receptor-1+activation+mediates+epithelial+to+mesenchymal+transition+in+human+pancreatic+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DA.%2BD.%26aulast%3DCamp%26aufirst%3DE.%2BR.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSomcio%26aufirst%3DR.%26aulast%3DBauer%26aufirst%3DT.%2BW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DEllis%26aufirst%3DL.%2BM.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-1%2520activation%2520mediates%2520epithelial%2520to%2520mesenchymal%2520transition%2520in%2520human%2520pancreatic%2520carcinoma%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D46%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Frank, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schatton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saab, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osherov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widlund, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waaga-Gasser, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupper, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, M. H.</span><span> </span><span class="NLM_article-title">VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1474</span><span class="NLM_x">–</span> <span class="NLM_lpage">1485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1474-1485&author=N.+Y.+Frankauthor=T.+Schattonauthor=S.+Kimauthor=Q.+Zhanauthor=B.+J.+Wilsonauthor=J.+Maauthor=K.+R.+Saabauthor=V.+Osherovauthor=H.+R.+Widlundauthor=M.+Gasserauthor=A.+M.+Waaga-Gasserauthor=T.+S.+Kupperauthor=G.+F.+Murphyauthor=M.+H.+Frank&title=VEGFR-1+expressed+by+malignant+melanoma-initiating+cells+is+required+for+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DN.%2BY.%26aulast%3DSchatton%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DQ.%26aulast%3DWilson%26aufirst%3DB.%2BJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DSaab%26aufirst%3DK.%2BR.%26aulast%3DOsherov%26aufirst%3DV.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26aulast%3DGasser%26aufirst%3DM.%26aulast%3DWaaga-Gasser%26aufirst%3DA.%2BM.%26aulast%3DKupper%26aufirst%3DT.%2BS.%26aulast%3DMurphy%26aufirst%3DG.%2BF.%26aulast%3DFrank%26aufirst%3DM.%2BH.%26atitle%3DVEGFR-1%2520expressed%2520by%2520malignant%2520melanoma-initiating%2520cells%2520is%2520required%2520for%2520tumor%2520growth%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1474%26epage%3D1485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Roybal, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thilaganathan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saintigny, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurie, J. M.</span><span> </span><span class="NLM_article-title">miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1</span> <span class="citation_source-journal">Mol Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1541-7786.MCR-10-0497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21115742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=25-35&author=J.+D.+Roybalauthor=Y.+Zangauthor=Y.+H.+Ahnauthor=Y.+Yangauthor=D.+L.+Gibbonsauthor=B.+N.+Bairdauthor=C.+Alvarezauthor=N.+Thilaganathanauthor=D.+D.+Liuauthor=P.+Saintignyauthor=J.+V.+Heymachauthor=C.+J.+Creightonauthor=J.+M.+Kurie&title=miR-200+Inhibits+lung+adenocarcinoma+cell+invasion+and+metastasis+by+targeting+Flt1%2FVEGFR1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1</span></div><div class="casAuthors">Roybal, Jonathon D.; Zang, Yi; Ahn, Young-Ho; Yang, Yanan; Gibbons, Don L.; Baird, Brandi N.; Alvarez, Cristina; Thilaganathan, Nishan; Liu, Diane D.; Saintigny, Pierre; Heymach, John V.; Creighton, Chad J.; Kurie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-35</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The microRNA-200 (miR-200) family is part of a gene expression signature that predicts poor prognosis in lung cancer patients.  In a mouse model of K-ras/p53-mutant lung adenocarcinoma, miR-200 levels are suppressed in metastasis-prone tumor cells, and forced miR-200 expression inhibits tumor growth and metastasis, but the miR-200 target genes that drive lung tumorigenesis have not been fully elucidated.  Here, we scanned the genome for putative miR-200 binding sites and found them in the 3'-untranslated region (3'-UTR) of 35 genes that are amplified in human cancer.  Mining of a database of resected human lung adenocarcinomas revealed that the levels of one of these genes, Flt1/VEGFR1, correlate inversely with duration of survival.  Forced miR-200 expression suppressed Flt1 levels in metastasis-prone lung adenocarcinoma cells derived from K-ras/p53-mutant mice, and neg. regulated the Flt1 3'-UTR in reporter assays.  Cancer-assocd. fibroblasts (CAFs) isolated from murine lung adenocarcinomas secreted abundant VEGF and enhanced tumor cell invasion in coculture studies.  CAF-induced tumor cell invasion was abrogated by VEGF neutralization or Flt1 knockdown in tumor cells.  Flt1 knockdown decreased the growth and metastasis of tumor cells in syngeneic mice.  We conclude that miR-200 suppresses lung tumorigenesis by targeting Flt1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_JXl7KJozGbVg90H21EOLACvtfcHk0lj5hf3NaICUsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGruw%253D%253D&md5=d7400afc42a03a43f016a583c8cd50e2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-10-0497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-10-0497%26sid%3Dliteratum%253Aachs%26aulast%3DRoybal%26aufirst%3DJ.%2BD.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DY.%2BH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DBaird%26aufirst%3DB.%2BN.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DThilaganathan%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DD.%2BD.%26aulast%3DSaintigny%26aufirst%3DP.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DKurie%26aufirst%3DJ.%2BM.%26atitle%3DmiR-200%2520Inhibits%2520lung%2520adenocarcinoma%2520cell%2520invasion%2520and%2520metastasis%2520by%2520targeting%2520Flt1%252FVEGFR1%26jtitle%3DMol%2520Cancer%2520Res.%26date%3D2011%26volume%3D9%26spage%3D25%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Kaplan, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riba, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharoulis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bramley, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shido, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Port, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altorki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Port, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shmelkov, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyden, D.</span><span> </span><span class="NLM_article-title">VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">820</span><span class="NLM_x">–</span> <span class="NLM_lpage">827</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=820-827&author=R.+N.+Kaplanauthor=R.+D.+Ribaauthor=S.+Zacharoulisauthor=A.+H.+Bramleyauthor=L.+Vincentauthor=C.+Costaauthor=D.+D.+MacDonaldauthor=D.+K.+Jinauthor=K.+Shidoauthor=S.+A.+Kernsauthor=Z.+Zhuauthor=D.+Hicklinauthor=Y.+Wuauthor=J.+L.+Portauthor=N.+Altorkiauthor=E.+R.+Portauthor=D.+Ruggeroauthor=S.+V.+Shmelkovauthor=K.+K.+Jensenauthor=S.+Rafiiauthor=D.+Lyden&title=VEGFR1-positive+haematopoietic+bone+marrow+progenitors+initiate+the+pre-metastatic+niche"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaplan%26aufirst%3DR.%2BN.%26aulast%3DRiba%26aufirst%3DR.%2BD.%26aulast%3DZacharoulis%26aufirst%3DS.%26aulast%3DBramley%26aufirst%3DA.%2BH.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DMacDonald%26aufirst%3DD.%2BD.%26aulast%3DJin%26aufirst%3DD.%2BK.%26aulast%3DShido%26aufirst%3DK.%26aulast%3DKerns%26aufirst%3DS.%2BA.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DPort%26aufirst%3DJ.%2BL.%26aulast%3DAltorki%26aufirst%3DN.%26aulast%3DPort%26aufirst%3DE.%2BR.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DShmelkov%26aufirst%3DS.%2BV.%26aulast%3DJensen%26aufirst%3DK.%2BK.%26aulast%3DRafii%26aufirst%3DS.%26aulast%3DLyden%26aufirst%3DD.%26atitle%3DVEGFR1-positive%2520haematopoietic%2520bone%2520marrow%2520progenitors%2520initiate%2520the%2520pre-metastatic%2520niche%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D820%26epage%3D827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Premetastatic lung “niche”: Is vascular endothelial growth factor receptor 1 activation required?</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">5670</span><span class="NLM_x">–</span> <span class="NLM_lpage">5673</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=5670-5673&author=D.+G.+Dudaauthor=R.+K.+Jain&title=Premetastatic+lung+%E2%80%9Cniche%E2%80%9D%3A+Is+vascular+endothelial+growth+factor+receptor+1+activation+required%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DPremetastatic%2520lung%2520%25E2%2580%259Cniche%25E2%2580%259D%253A%2520Is%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25201%2520activation%2520required%253F%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D5670%26epage%3D5673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Wu, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanini, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mac Gabhann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontos, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annex, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popel, A. S.</span><span> </span><span class="NLM_article-title">A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use</span> <span class="citation_source-journal">J. Cell. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19840194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1yktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=528-552&author=F.+T.+Wuauthor=M.+O.+Stefaniniauthor=F.+Mac+Gabhannauthor=C.+D.+Kontosauthor=B.+H.+Annexauthor=A.+S.+Popel&title=A+systems+biology+perspective+on+sVEGFR1%3A+its+biological+function%2C+pathogenic+role+and+therapeutic+use"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use</span></div><div class="casAuthors">Wu, Florence T. H.; Stefanini, Marianne O.; MacGabhann, Feilim; Kontos, Christopher D.; Annex, Brian H.; Popel, Aleksander S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">528-552</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-1838</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is the growth of new capillaries from pre-existent microvasculature.  A wide range of pathol. conditions, from atherosclerosis to cancer, can be attributed to either excessive or deficient angiogenesis.  Central to the physiol. regulation of angiogenesis is the vascular endothelial growth factor (VEGF) system - its ligands and receptors (VEGFRs) are thus prime mol. targets of pro-angiogenic and anti-angiogenic therapies.  Of growing interest as a prognostic marker and therapeutic target in angiogenesis-dependent diseases is sol. VEGF receptor-1 (sVEGFR1, also known as sFlt-1) - a truncated version of the cell membrane-spanning VEGFR1.  For instance, it is known that sVEGFR1 is involved in the endothelial dysfunction characterizing the pregnancy disorder of pre-eclampsia, and sVEGFR1's therapeutic potential as an anti-angiogenic agent is being evaluated in pre-clin. models of cancer.  This mini review begins with an examn. of the protein domain structure and biomol. interactions of sVEGFR1 in relation to the full-length VEGFR1.  A synopsis of known and inferred physiol. and pathol. roles of sVEGFR1 is then given, with emphasis on the utility of computational systems biol. models in deciphering the mol. mechanisms by which sVEGFR1's purported biol. functions occur.  Finally, we present the need for a systems biol. perspective in interpreting circulating VEGF and sVEGFR1 concns. as surrogate markers of angiogenic status in angiogenesis-dependent diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAGxoi9cHujLVg90H21EOLACvtfcHk0lgWfMEUX81hUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1yktr4%253D&md5=dc58194306c54f32e12cdc7c55194fe8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.%2BT.%26aulast%3DStefanini%26aufirst%3DM.%2BO.%26aulast%3DMac%2BGabhann%26aufirst%3DF.%26aulast%3DKontos%26aufirst%3DC.%2BD.%26aulast%3DAnnex%26aufirst%3DB.%2BH.%26aulast%3DPopel%26aufirst%3DA.%2BS.%26atitle%3DA%2520systems%2520biology%2520perspective%2520on%2520sVEGFR1%253A%2520its%2520biological%2520function%252C%2520pathogenic%2520role%2520and%2520therapeutic%2520use%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2010%26volume%3D14%26spage%3D528%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kowanetz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor signaling pathways: therapeutic perspective</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">5018</span><span class="NLM_x">–</span> <span class="NLM_lpage">5022</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-06-1520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16951216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XovF2huro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5018-5022&author=M.+Kowanetzauthor=N.+Ferrara&title=Vascular+endothelial+growth+factor+signaling+pathways%3A+therapeutic+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective</span></div><div class="casAuthors">Kowanetz, Marcin; Ferrara, Napoleone</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5018-5022</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The establishment of a vascular supply is one of the earliest and most important events occurring during embryonic development.  Growth and maturation of a functional vascular network are complex and still incompletely understood processes involving orchestrated activation of vascular progenitors in the early stages of embryonic development followed by vasculogenesis and angiogenesis.  These processes require a tightly regulated activation of several growth factors and their receptors.  The role of vascular endothelial growth factors (VEGF) and their receptors has been studied extensively due to their prominent role during blood vessel formation.  Mice deficient in various VEGF ligands or receptors show serious defects in vascular formation and maturation.  Moreover, members of the VEGF family are involved in other significant biol. processes, including lymphangiogenesis, vascular permeability, and hematopoiesis.  Importantly, VEGF is released by tumor cells and induces tumor neovascularization.  It is now well established that the VEGF axis represents an important target for antitumor therapy.  Aberrant VEGF signaling is also a feature of several other pathol. conditions, such as age-related macular degeneration and rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDW6gq9KzrR7Vg90H21EOLACvtfcHk0lgWfMEUX81hUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovF2huro%253D&md5=6b7523714e6d601ffc9c9b0a8f8edd44</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1520%26sid%3Dliteratum%253Aachs%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520signaling%2520pathways%253A%2520therapeutic%2520perspective%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5018%26epage%3D5022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Wang, F. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barfield, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pua, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishman, D. A.</span><span> </span><span class="NLM_article-title">VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.ygyno.2009.08.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=414-423&author=F.+Q.+Wangauthor=E.+Barfieldauthor=S.+Duttaauthor=T.+Puaauthor=D.+A.+Fishman&title=VEGFR-2+silencing+by+small+interference+RNA+%28siRNA%29+suppresses+LPA-induced+epithelial+ovarian+cancer+%28EOC%29+invasion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2009.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2009.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%2BQ.%26aulast%3DBarfield%26aufirst%3DE.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DPua%26aufirst%3DT.%26aulast%3DFishman%26aufirst%3DD.%2BA.%26atitle%3DVEGFR-2%2520silencing%2520by%2520small%2520interference%2520RNA%2520%2528siRNA%2529%2520suppresses%2520LPA-induced%2520epithelial%2520ovarian%2520cancer%2520%2528EOC%2529%2520invasion%26jtitle%3DGynecol.%2520Oncol.%26date%3D2009%26volume%3D15%26spage%3D414%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Rodríguez-Antona, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero-Conde, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglada-Pérez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelblanco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leskelä, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leandro-García, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Jiménez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letón, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascón, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carralero, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauricio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cigudosa, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matias-Guiu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robledo, M.</span><span> </span><span class="NLM_article-title">Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=7-16&author=C.+Rodr%C3%ADguez-Antonaauthor=J.+Pallaresauthor=C.+Montero-Condeauthor=L.+Inglada-P%C3%A9rezauthor=E.+Castelblancoauthor=I.+Landaauthor=S.+Leskel%C3%A4author=L.+J.+Leandro-Garc%C3%ADaauthor=E.+L%C3%B3pez-Jim%C3%A9nezauthor=R.+Let%C3%B3nauthor=A.+Casc%C3%B3nauthor=E.+Lermaauthor=M.+C.+Martinauthor=M.+C.+Carraleroauthor=D.+Mauricioauthor=J.+C.+Cigudosaauthor=X.+Matias-Guiuauthor=M.+Robledo&title=Overexpression+and+activation+of+EGFR+and+VEGFR2+in+medullary+thyroid+carcinomas+is+related+to+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez-Antona%26aufirst%3DC.%26aulast%3DPallares%26aufirst%3DJ.%26aulast%3DMontero-Conde%26aufirst%3DC.%26aulast%3DInglada-P%25C3%25A9rez%26aufirst%3DL.%26aulast%3DCastelblanco%26aufirst%3DE.%26aulast%3DLanda%26aufirst%3DI.%26aulast%3DLeskel%25C3%25A4%26aufirst%3DS.%26aulast%3DLeandro-Garc%25C3%25ADa%26aufirst%3DL.%2BJ.%26aulast%3DL%25C3%25B3pez-Jim%25C3%25A9nez%26aufirst%3DE.%26aulast%3DLet%25C3%25B3n%26aufirst%3DR.%26aulast%3DCasc%25C3%25B3n%26aufirst%3DA.%26aulast%3DLerma%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DM.%2BC.%26aulast%3DCarralero%26aufirst%3DM.%2BC.%26aulast%3DMauricio%26aufirst%3DD.%26aulast%3DCigudosa%26aufirst%3DJ.%2BC.%26aulast%3DMatias-Guiu%26aufirst%3DX.%26aulast%3DRobledo%26aufirst%3DM.%26atitle%3DOverexpression%2520and%2520activation%2520of%2520EGFR%2520and%2520VEGFR2%2520in%2520medullary%2520thyroid%2520carcinomas%2520is%2520related%2520to%2520metastasis%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2010%26volume%3D17%26spage%3D7%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Graells, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinyals, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llorens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoval, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabra, A.</span><span> </span><span class="NLM_article-title">Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1151</span><span class="NLM_x">–</span> <span class="NLM_lpage">1161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2004&pages=1151-1161&author=J.+Graellsauthor=A.+Vinyalsauthor=A.+Figuerasauthor=A.+Llorensauthor=A.+Morenoauthor=J.+Marcovalauthor=F.+J.+Gonzalezauthor=A.+Fabra&title=Overproduction+of+VEGF+concomitantly+expressed+with+its+receptors+promotes+growth+and+survival+of+melanoma+cells+through+MAPK+and+PI3K+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGraells%26aufirst%3DJ.%26aulast%3DVinyals%26aufirst%3DA.%26aulast%3DFigueras%26aufirst%3DA.%26aulast%3DLlorens%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DA.%26aulast%3DMarcoval%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DF.%2BJ.%26aulast%3DFabra%26aufirst%3DA.%26atitle%3DOverproduction%2520of%2520VEGF%2520concomitantly%2520expressed%2520with%2520its%2520receptors%2520promotes%2520growth%2520and%2520survival%2520of%2520melanoma%2520cells%2520through%2520MAPK%2520and%2520PI3K%2520signaling%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2004%26volume%3D123%26spage%3D1151%26epage%3D1161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Blom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roselli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Häyry, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tynninen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartiovaara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korja, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordfors, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haapasalo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nupponen, N. N.</span><span> </span><span class="NLM_article-title">Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs11060-009-0014-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19779861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFygsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2010&pages=217-224&author=T.+Blomauthor=A.+Roselliauthor=V.+H%C3%A4yryauthor=O.+Tynninenauthor=K.+Wartiovaaraauthor=M.+Korjaauthor=K.+Nordforsauthor=H.+Haapasaloauthor=N.+N.+Nupponen&title=Amplification+and+overexpression+of+KIT%2C+PDGFRA%2C+and+VEGFR2+in+medulloblastomas+and+primitive+neuroectodermal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors</span></div><div class="casAuthors">Blom, Tea; Roselli, Annariikka; Haeyry, Valtteri; Tynninen, Olli; Wartiovaara, Kirmo; Korja, Miikka; Nordfors, Kristiina; Haapasalo, Hannu; Nupponen, Nina N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Medulloblastomas (MB) and primitive neuroectodermal tumors (PNET) are the most common malignant brain tumors in children.  These two tumor types are histol. similar, but have different genetic backgrounds and clin. outcomes.  Other brain tumors, such as gliomas, frequently have coamplification and overexpression of receptor tyrosine kinases KIT, platelet-derived growth factor receptor alpha (PDGFRA), and vascular endothelial growth factor receptor 2 (VEGFR2).  We investigated protein expression and gene copy nos. of KIT, PDGFRA, and VEGFR2 in 41 MB and 11 PNET samples by immunohistochem. (IHC) and chromogenic in situ hybridization (CISH).  KIT and PDGFRA expression was detected in both MBs and PNETs, whereas VEGFR2 expression was weak in these tumors.  KIT, PDGFRA, and VEGFR2 amplifications were all present in 4% of MBs/PNETs, and KIT amplification was assocd. with concurrent PDGFRA and VEGFR2 amplifications (P ≤ 0.001).  Most strikingly, increased gene copy no. of PDGFRA was assocd. with poor overall survival (P = 0.027).  We suggest that coamplification of PDGFRA or VEGFR2 with KIT may be clin. useful novel mol. markers in MBs and PNETs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJe7WLUMZwdLVg90H21EOLACvtfcHk0lhaUdSg9mYEVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFygsLc%253D&md5=4642469bca80265ef2c6f3e5b1bed5ce</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs11060-009-0014-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-009-0014-2%26sid%3Dliteratum%253Aachs%26aulast%3DBlom%26aufirst%3DT.%26aulast%3DRoselli%26aufirst%3DA.%26aulast%3DH%25C3%25A4yry%26aufirst%3DV.%26aulast%3DTynninen%26aufirst%3DO.%26aulast%3DWartiovaara%26aufirst%3DK.%26aulast%3DKorja%26aufirst%3DM.%26aulast%3DNordfors%26aufirst%3DK.%26aulast%3DHaapasalo%26aufirst%3DH.%26aulast%3DNupponen%26aufirst%3DN.%2BN.%26atitle%3DAmplification%2520and%2520overexpression%2520of%2520KIT%252C%2520PDGFRA%252C%2520and%2520VEGFR2%2520in%2520medulloblastomas%2520and%2520primitive%2520neuroectodermal%2520tumors%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2010%26volume%3D97%26spage%3D217%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratcliffe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womack, C.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3548</span><span class="NLM_x">–</span> <span class="NLM_lpage">3561</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-09-2797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20606037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovVansb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3548-3561&author=N.+R.+Smithauthor=D.+Bakerauthor=N.+H.+Jamesauthor=K.+Ratcliffeauthor=M.+Jenkinsauthor=S.+E.+Ashtonauthor=G.+Sproatauthor=R.+Swannauthor=N.+Grayauthor=A.+Ryanauthor=J.+M.+J%C3%BCrgensmeierauthor=C.+Womack&title=Vascular+endothelial+growth+factor+receptors+VEGFR-2+and+VEGFR-3+are+localized+primarily+to+the+vasculature+in+human+primary+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers</span></div><div class="casAuthors">Smith, Neil R.; Baker, Dawn; James, Neil H.; Ratcliffe, Kirsty; Jenkins, Martin; Ashton, Susan E.; Sproat, Graham; Swann, Ruth; Gray, Neil; Ryan, Anderson; Juergensmeier, Juliane M.; Womack, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3548-3561</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Vascular endothelial growth factor (VEGF) signaling is key to tumor angiogenesis and is an important target in the development of anticancer drugs.  However, VEGF receptor (VEGFR) expression in human cancers, particularly the relative expression of VEGFR-2 and VEGFR-3 in tumor vasculature vs. tumor cells, is poorly defined.  Exptl. Design: VEGFR-2- and VEGFR-3-specific antibodies were identified and used in the immunohistochem. anal. of human primary cancers and normal tissue.  The relative vascular localization of both receptors in colorectal and breast cancers was detd. by coimmunofluorescence with vascular markers.  RESULTS: VEGFR-2 and VEGFR-3 were expressed on vascular endothelium but not on malignant cells in 13 common human solid tumor types (n > 400, bladder, breast, colorectal, head and neck, liver, lung, skin, ovarian, pancreatic, prostate, renal, stomach, and thyroid).  The signal intensity of both receptors was significantly greater in vessels assocd. with malignant colorectal, lung, and breast than adjacent nontumor tissue.  In colorectal cancers, VEGFR-2 was expressed on both intratumoral blood and lymphatic vessels, whereas VEGFR-3 was found predominantly on lymphatic vessels.  In breast cancers, both receptors were localized to and upregulated on blood vessels.  CONCLUSIONS: VEGFR-2 and VEGFR-3 are primarily localized to, and significantly upregulated on, tumor vasculature (blood and/or lymphatic) supporting the majority of solid cancers.  The primary clin. mechanism of action of VEGF signaling inhibitors is likely to be through the targeting of tumor vessels rather than tumor cells.  The upregulation of VEGFR-3 on tumor blood vessels indicates a potential addnl. antiangiogenic effect for dual VEGFR-2/VEGFR-3-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHdbIUcIe27Vg90H21EOLACvtfcHk0lhaUdSg9mYEVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovVansb4%253D&md5=8a2b2d865a14202dfd539a74ec700e3f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-2797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-2797%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DRatcliffe%26aufirst%3DK.%26aulast%3DJenkins%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DSproat%26aufirst%3DG.%26aulast%3DSwann%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DA.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DWomack%26aufirst%3DC.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptors%2520VEGFR-2%2520and%2520VEGFR-3%2520are%2520localized%2520primarily%2520to%2520the%2520vasculature%2520in%2520human%2520primary%2520solid%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3548%26epage%3D3561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Mäkinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veikkola, T</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustjoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karpanen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catimel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nice, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerjaschki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stacker, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Achen, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4762</span><span class="NLM_x">–</span> <span class="NLM_lpage">4773</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=4762-4773&author=T.+M%C3%A4kinenauthor=T+Veikkolaauthor=S.+Mustjokiauthor=T.+Karpanenauthor=B.+Catimelauthor=E.+C.+Niceauthor=L.+Wiseauthor=A.+Mercerauthor=H.+Kowalskiauthor=D.+Kerjaschkiauthor=S.+A.+Stackerauthor=M.+G.+Achenauthor=K.+Alitalo&title=Isolated+lymphatic+endothelial+cells+transduce+growth%2C+survival+and+migratory+signals+via+the+VEGF-C%2FD+receptor+VEGFR-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A4kinen%26aufirst%3DT.%26aulast%3DVeikkola%26aufirst%3DT%26aulast%3DMustjoki%26aufirst%3DS.%26aulast%3DKarpanen%26aufirst%3DT.%26aulast%3DCatimel%26aufirst%3DB.%26aulast%3DNice%26aufirst%3DE.%2BC.%26aulast%3DWise%26aufirst%3DL.%26aulast%3DMercer%26aufirst%3DA.%26aulast%3DKowalski%26aufirst%3DH.%26aulast%3DKerjaschki%26aufirst%3DD.%26aulast%3DStacker%26aufirst%3DS.%2BA.%26aulast%3DAchen%26aufirst%3DM.%2BG.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DIsolated%2520lymphatic%2520endothelial%2520cells%2520transduce%2520growth%252C%2520survival%2520and%2520migratory%2520signals%2520via%2520the%2520VEGF-C%252FD%2520receptor%2520VEGFR-3%26jtitle%3DEMBO%2520J.%26date%3D2001%26volume%3D20%26spage%3D4762%26epage%3D4773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Su, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuang, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, M. L.</span><span> </span><span class="NLM_article-title">The role of the VEGF-C/VEGFR-3 axis in cancer progression</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fsj.bjc.6603487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17164762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvV2jsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=541-545&author=J.+L.+Suauthor=C.+J.+Yenauthor=P.+S.+Chenauthor=S.+E.+Chuangauthor=C.+C.+Hongauthor=I.+H.+Kuoauthor=H.+Y.+Chenauthor=M.+C.+Hungauthor=M.+L.+Kuo&title=The+role+of+the+VEGF-C%2FVEGFR-3+axis+in+cancer+progression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the VEGF-C/VEGFR-3 axis in cancer progression</span></div><div class="casAuthors">Su, J.-L.; Yen, C.-J.; Chen, P.-S.; Chuang, S.-E.; Hong, C.-C.; Kuo, I.-H.; Chen, H.-Y.; Hung, M.-C.; Kuo, M.-L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">541-545</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C, which promotes cancer progression.  The VEGF-C/VEGFR-3 axis is expressed not only by lymphatic endothelial cells but also by a variety of human tumor cells.  Activation of the VEGF-C/VEGFR-3 axis in lymphatic endothelial cells can facilitate metastasis by increasing the formation of lymphatic vessels (lymph angiogenesis) within and around tumors.  The VEGF-C/VEGFR-3 axis plays a crit. role in leukemic cell proliferation, survival, and resistance to chemotherapy.  Moreover, activation of the VEGF-C/VEGFR-3 axis in several types of solid tumors enhances cancer cell mobility and invasion capabilities, promoting cancer cell metastasis.  In this review, we discuss the novel function and mol. mechanism of the VEGF-C/VEGFR-3 axis in cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_-GCr7Ijs7Vg90H21EOLACvtfcHk0ljJCpHkA5OB_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvV2jsbg%253D&md5=5e18e8c62f846a218e9275352fbc307f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603487%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DJ.%2BL.%26aulast%3DYen%26aufirst%3DC.%2BJ.%26aulast%3DChen%26aufirst%3DP.%2BS.%26aulast%3DChuang%26aufirst%3DS.%2BE.%26aulast%3DHong%26aufirst%3DC.%2BC.%26aulast%3DKuo%26aufirst%3DI.%2BH.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DKuo%26aufirst%3DM.%2BL.%26atitle%3DThe%2520role%2520of%2520the%2520VEGF-C%252FVEGFR-3%2520axis%2520in%2520cancer%2520progression%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D96%26spage%3D541%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Achen, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stacker, S. A.</span><span> </span><span class="NLM_article-title">Targeting lymphangiogenesis to prevent tumour metastasis</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fsj.bjc.6603120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16641900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=1355-1360&author=M.+G.+Achenauthor=G.+B.+Mannauthor=S.+A.+Stacker&title=Targeting+lymphangiogenesis+to+prevent+tumour+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting lymphangiogenesis to prevent tumour metastasis</span></div><div class="casAuthors">Achen, M. G.; Mann, G. B.; Stacker, S. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1355-1360</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent studies involving animal models of cancer and clinicopathol. analyses of human tumors suggest that the growth of lymphatic vessels (lymphangiogenesis) in or nearby tumors is assocd. with the metastatic spread of cancer.  The best validated mol. signalling system for tumor lymphangiogenesis involves the secreted proteins vascular endothelial growth factor-C (VEGF-C) and VEGF-D that induce growth of lymphatic vessels via activation of VEGF receptor-3 (VEGFR-3) localized on the surface of lymphatic endothelial cells.  In this review, we discuss the evidence supporting a role for this signalling system in the spread of cancer and potential approaches for blocking this system to prevent tumor metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOLXx0f0rdcbVg90H21EOLACvtfcHk0ljJCpHkA5OB_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKnur0%253D&md5=9e5d3355aec24711990a68992e587c15</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603120%26sid%3Dliteratum%253Aachs%26aulast%3DAchen%26aufirst%3DM.%2BG.%26aulast%3DMann%26aufirst%3DG.%2BB.%26aulast%3DStacker%26aufirst%3DS.%2BA.%26atitle%3DTargeting%2520lymphangiogenesis%2520to%2520prevent%2520tumour%2520metastasis%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D94%26spage%3D1355%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Boyer, S. J.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F1568026023393273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=12171566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVOitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=973-1000&author=S.+J.+Boyer&title=Small+molecule+inhibitors+of+KDR+%28VEGFR-2%29+kinase%3A+an+overview+of+structure+activity+relationships"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships</span></div><div class="casAuthors">Boyer, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">973-1000</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Kinase insert Domain contg. Receptor (KDR), alternatively referred to as VEGFR-2, is a receptor for Vascular Endothelial Growth Factors (VEGFs) and functions as a key regulator of angiogenesis, the process by which new capillaries are created from preexisting blood vessels.  The induction of angiogenesis, or the "angiogenic switch," is a crit. step in tumor progression, and inhibitors of KDR have been demonstrated both to induce tumor regression and reduce metastatic potential in preclin. models.  In the last few years, medicinal chemists have expanded the kinase selectivity profile of known inhibitor classes to include KDR, and also identified novel classes of KDR inhibitors.  This review presents structure activity relationships (SAR) of small mol. inhibitors of KDR, with an emphasis on the pharmacophore elements of the scaffolds employed.  Binding hypotheses based on x-ray crystallog. analyses will also be described.  Addnl., the efficacy of representative compds. in in vitro and in vivo models of tumor progression and angiogenesis are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8iX5xdLgktLVg90H21EOLACvtfcHk0ljJCpHkA5OB_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVOitbw%253D&md5=4c4445eac589bded1baed3140b918be8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F1568026023393273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026023393273%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DS.%2BJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520KDR%2520%2528VEGFR-2%2529%2520kinase%253A%2520an%2520overview%2520of%2520structure%2520activity%2520relationships%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2002%26volume%3D2%26spage%3D973%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondavalli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Antiangiogenic agents: an update on small molecule VEGFR inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2495</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F092986707782023622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17979703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKqtrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=2495-2516&author=S.+Schenoneauthor=F.+Bondavalliauthor=M.+Botta&title=Antiangiogenic+agents%3A+an+update+on+small+molecule+VEGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic agents: an update on small molecule VEGFR inhibitors</span></div><div class="casAuthors">Schenone, S.; Bondavalli, F.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2495-2516</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels sprouting from pre-existing microvasculature and occurs in limited physiol. conditions or under pathol. situations such as retinopathies, arthritis, endometriosis and cancer.  Blockade of angiogenesis is an attractive approach for the treatment of such diseases.  Particularly in malignancies, antiangiogenic therapy should be less toxic in comparison with conventional treatments such as chemotherapy, as angiogenesis is a process relatively restricted to the growing tumor.  Vascular endothelial growth factor (VEGF) is one of the most important inducers of angiogenesis and exerts its cellular effects mainly by interacting with two high-affinity transmembrane tyrosine kinase receptors: VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1).  It has been proven that inhibition of VEGF receptor activity reduces angiogenesis.  For these reasons, the inhibition of VEGF or its receptor signaling system is an attractive target for therapeutic intervention.  The most studied and developed inhibitors are monoclonal antibodies that neutralize VEGF, ribozymes, and small mol. VEGFR kinase inhibitors.  Many important reviews dealing with VEGF-induced angiogenesis and its inhibition through the block of VEGF receptors have been reported, esp. from a biol. point of view.  Here, we will review small synthetic VEGFR inhibitors that have appeared in literature in the last few years, focusing our attention on their medicinal chem. in terms of chem. structure, mechanisms of action and structure-activity relationships.  In fact, there have been an increased no. of tyrosine kinase inhibitors in the most recent literature reports; their biol. profile is extremely interesting and could be of great importance to medicinal chemists working in this area in improving their efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7o_mKLGN1mLVg90H21EOLACvtfcHk0ljJCpHkA5OB_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKqtrbN&md5=1cb7ea6cf7867e796f2333e5d304220c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F092986707782023622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707782023622%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBondavalli%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DAntiangiogenic%2520agents%253A%2520an%2520update%2520on%2520small%2520molecule%2520VEGFR%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D2495%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Gille, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidenreich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehme, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henschler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breier, G.</span><span> </span><span class="NLM_article-title">Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation</span> <span class="citation_source-journal">Int. J. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">1899</span><span class="NLM_x">–</span> <span class="NLM_lpage">908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1002%2Fijc.22531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17230507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVCqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2007&pages=1899-908&author=J.+Gilleauthor=R.+Heidenreichauthor=A.+Pinterauthor=J.+Schmitzauthor=B.+Boehmeauthor=D.+J.+Hicklinauthor=R.+Henschlerauthor=G.+Breier&title=Simultaneous+blockade+of+VEGFR-1+and+VEGFR-2+activation+is+necessary+to+efficiently+inhibit+experimental+melanoma+growth+and+metastasis+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation</span></div><div class="casAuthors">Gille, Jens; Heidenreich, Regina; Pinter, Andreas; Schmitz, Judith; Boehme, Beatrice; Hicklin, Daniel J.; Henschler, Reinhard; Breier, Georg</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1899-1908</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Metastasis continues to be the major cause of morbidity and mortality in malignant melanoma.  In our study, we explored whether inhibition of VEGFR-1 or VEGFR-2 signaling conveys distinct suppressive effects on B16 melanoma s.c. growth and metastasis formation.  The inhibition of VEGFR-1 or -2 alone had no significant influence on both melanoma growth and metastasis formation.  In contrast, simultaneous blockade of VEGFR-1 and -2 signaling strongly suppressed progression in both B16 tumor models.  There was no expression of VEGFR-1 or -2 detectable on the B16 cells used, excluding the melanoma cells as direct therapeutic targets.  Analyzing the contribution of progenitor-like cells during melanoma metastasis formation, we obsd. an enhanced proliferation and mobilization of VEGFR-1+ myeloid and VEGFR-2+ endothelial cells with progenitor potential by the induction of melanoma lung metastasis, which was not influenced by interference with VEGFR signaling.  These results indicate that the antimetastatic effects exerted by combined inhibition of VEGFR-1 and -2 signaling were mediated via targeting cell populations other than progenitors only.  Sole inhibition of VEGFR-1 signaling led to a strong redn. of the CD45-pos. inflammatory infiltrate in the tumor tissue.  However, the formation of lung metastasis was not affected, indicating that inhibition of the inflammatory response was not sufficient to efficiently block B16 melanoma metastasis development.  Taken together,these data suggest that in the utilized B16 tumor models the blockade of both the inflammatory and the VEGFR-2-dependent angiogenic response are necessary to effectively inhibit solid tumor growth and formation of lung metastasis by B16 melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1p1K_RkddibVg90H21EOLACvtfcHk0lis2M90fHoNgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVCqsLw%253D&md5=6b304bd8a5792206c910c8bbe1db4445</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fijc.22531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22531%26sid%3Dliteratum%253Aachs%26aulast%3DGille%26aufirst%3DJ.%26aulast%3DHeidenreich%26aufirst%3DR.%26aulast%3DPinter%26aufirst%3DA.%26aulast%3DSchmitz%26aufirst%3DJ.%26aulast%3DBoehme%26aufirst%3DB.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DHenschler%26aufirst%3DR.%26aulast%3DBreier%26aufirst%3DG.%26atitle%3DSimultaneous%2520blockade%2520of%2520VEGFR-1%2520and%2520VEGFR-2%2520activation%2520is%2520necessary%2520to%2520efficiently%2520inhibit%2520experimental%2520melanoma%2520growth%2520and%2520metastasis%2520formation%26jtitle%3DInt.%2520J.%2520Cancer.%26date%3D2007%26volume%3D120%26spage%3D1899%26epage%3D908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">Clinical applications of angiogenic growth factors and their inhibitors</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2F70928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=10581076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADyaK1MXnvFCqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=1359-1364&author=N.+Ferraraauthor=K.+Alitalo&title=Clinical+applications+of+angiogenic+growth+factors+and+their+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical applications of angiogenic growth factors and their inhibitors</span></div><div class="casAuthors">Ferrara, Napoleone; Alitalo, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1359-1364</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">A review with 97 refs. is given on promoting the formation of new collateral vessels in ischemic tissues (therapeutic angiogenesis) using angiogenic factors like vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) and inhibition of key regulators of angiogenesis as an approach for the treatment of solid tumors and intraocular neovascular syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-M0EbeAZm8LVg90H21EOLACvtfcHk0lis2M90fHoNgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnvFCqtrw%253D&md5=2c16b63492d564151b64a8a75151cbe3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2F70928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F70928%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DClinical%2520applications%2520of%2520angiogenic%2520growth%2520factors%2520and%2520their%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D1999%26volume%3D5%26spage%3D1359%26epage%3D1364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Kanda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanetake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smithgall, T. E.</span><span> </span><span class="NLM_article-title">Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17549397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1KqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=113-121&author=S.+Kandaauthor=Y.+Miyataauthor=H.+Kanetakeauthor=T.+E.+Smithgall&title=Non-receptor+protein-tyrosine+kinases+as+molecular+targets+for+antiangiogenic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review)</span></div><div class="casAuthors">Kanda, Shigeru; Miyata, Yasuyoshi; Kanetake, Hiroshi; Smithgall, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-121</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Molecular Medicine</span>)
        </div><div class="casAbstract">A review.  Antiangiogenic therapy, including blockade of vascular endothelial growth factor (VEGF) signaling, was highly anticipated to improve the prognosis for patients with advanced cancers following the success of preclin. animal models.  However, antiangiogenic monotherapy with VEGF antagonists has produced disappointing results in clin. trials to date.  One of the reasons for this poor outcome is that angiogenesis is not solely regulated by VEGF.  Inhibition of VEGF signaling, therefore, may select for tumor cell populations that stimulate angiogenesis through VEGF-independent pathways.  Successful antiangiogenic therapy, therefore, may require simultaneous blockade of signaling downstream from multiple proangiogenic factor receptors.  Recently, we found that non-receptor protein-tyrosine kinases, including members of the Src and Fes families, play vital roles in the responses of cultured endothelial cells to several proangiogenic factors.  In this review, we summarize the contributions of these kinase families to angiogenic pathways in endothelial cells, and discuss the potential of these kinases as new targets for antiangiogenic drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpljqPGMyZFIrVg90H21EOLACvtfcHk0lis2M90fHoNgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1KqtLo%253D&md5=a223598e45fe1982b33886d630432c36</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DS.%26aulast%3DMiyata%26aufirst%3DY.%26aulast%3DKanetake%26aufirst%3DH.%26aulast%3DSmithgall%26aufirst%3DT.%2BE.%26atitle%3DNon-receptor%2520protein-tyrosine%2520kinases%2520as%2520molecular%2520targets%2520for%2520antiangiogenic%2520therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2007%26volume%3D20%26spage%3D113%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Casanovas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span> </span><span class="NLM_article-title">Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=299-309&author=O.+Casanovasauthor=D.+J.+Hicklinauthor=G.+Bergersauthor=D.+Hanahan&title=Drug+resistance+by+evasion+of+antiangiogenic+targeting+of+VEGF+signaling+in+late-stage+pancreatic+islet+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasanovas%26aufirst%3DO.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBergers%26aufirst%3DG.%26aulast%3DHanahan%26aufirst%3DD.%26atitle%3DDrug%2520resistance%2520by%2520evasion%2520of%2520antiangiogenic%2520targeting%2520of%2520VEGF%2520signaling%2520in%2520late-stage%2520pancreatic%2520islet%2520tumors%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D299%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Shibuya, M.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis</span> <span class="citation_source-journal">BMB Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.5483%2FBMBRep.2008.41.4.278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18452647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFelsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=278-286&author=M.+Shibuya&title=Vascular+endothelial+growth+factor-dependent+and+-independent+regulation+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis</span></div><div class="casAuthors">Shibuya, Masabumi</div><div class="citationInfo"><span class="NLM_cas:title">BMB Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">278-286</span>CODEN:
                <span class="NLM_cas:coden">BRMEC2</span>;
        ISSN:<span class="NLM_cas:issn">1976-6696</span>.
    
            (<span class="NLM_cas:orgname">Korean Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review on the roles of VEGF and VEGFRs for formation, maintenance, and pathol. of blood vessels, the clin. application of VEGF-VEGFR inhibitors to treat cancer and macular degeneration, the adverse effects of and resistance to VEGF-VEGFR inhibitors.  The author also discussed VEGF-independent regulation of angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnudmVpbvuMbVg90H21EOLACvtfcHk0liSafxqmi-QeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFelsL0%253D&md5=691e39eebfae3534a2a9772816cb392a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.5483%2FBMBRep.2008.41.4.278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5483%252FBMBRep.2008.41.4.278%26sid%3Dliteratum%253Aachs%26aulast%3DShibuya%26aufirst%3DM.%26atitle%3DVascular%2520endothelial%2520growth%2520factor-dependent%2520and%2520-independent%2520regulation%2520of%2520angiogenesis%26jtitle%3DBMB%2520Rep.%26date%3D2008%26volume%3D41%26spage%3D278%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyhack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1697</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=17-27&author=P.+W.+Manleyauthor=G.+Boldauthor=J.+Bruggenauthor=G.+Fendrichauthor=P.+Furetauthor=J.+Mestanauthor=C.+Schnellauthor=B.+Stolzauthor=T.+Meyerauthor=B.+Meyhackauthor=W.+Starkauthor=A.+Straussauthor=J.+Wood&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+VEGF-R+kinase+inhibitors+for+the+treatment+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DStolz%26aufirst%3DB.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DMeyhack%26aufirst%3DB.%26aulast%3DStark%26aufirst%3DW.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520VEGF-R%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520angiogenesis%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2004%26volume%3D1697%26spage%3D17%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrd3455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21629292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvVegurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=417-427&author=P.+Carmelietauthor=R.+K.+Jain&title=Principles+and+mechanisms+of+vessel+normalization+for+cancer+and+other+angiogenic+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases</span></div><div class="casAuthors">Carmeliet, Peter; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417-427</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite having an abundant no. of vessels, tumors are usually hypoxic and nutrient-deprived because their vessels malfunction.  Such abnormal milieu can fuel disease progression and resistance to treatment.  Traditional anti-angiogenesis strategies attempt to reduce the tumor vascular supply, but their success is restricted by insufficient efficacy or development of resistance.  Preclin. and initial clin. evidence reveal that normalization of the vascular abnormalities is emerging as a complementary therapeutic paradigm for cancer and other vascular disorders, which affect more than half a billion people worldwide.  Here, we discuss the mechanisms, benefits, limitations and possible clin. translation of vessel normalization for cancer and other angiogenic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodLcTmRH7e2bVg90H21EOLACvtfcHk0liSafxqmi-QeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvVegurs%253D&md5=e32f1e9d69ff314d20af6bdcca745981</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrd3455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3455%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DPrinciples%2520and%2520mechanisms%2520of%2520vessel%2520normalization%2520for%2520cancer%2520and%2520other%2520angiogenic%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D417%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Rosen, L. S.</span><span> </span><span class="NLM_article-title">VEGF-targeted therapy: therapeutic potential and recent advances</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">382</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=382-391&author=L.+S.+Rosen&title=VEGF-targeted+therapy%3A+therapeutic+potential+and+recent+advances"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DL.%2BS.%26atitle%3DVEGF-targeted%2520therapy%253A%2520therapeutic%2520potential%2520and%2520recent%2520advances%26jtitle%3DOncologist%26date%3D2005%26volume%3D10%26spage%3D382%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Van der Veldt, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubberink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walraven, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Boer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greuter, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrikse, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windhorst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postmus, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheul, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serné, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammertsma, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span> </span><span class="NLM_article-title">Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=82-91&author=A.+A.+Van+der+Veldtauthor=M.+Lubberinkauthor=I.+Bahceauthor=M.+Walravenauthor=M.+P.+de+Boerauthor=H.+N.+Greuterauthor=N.+H.+Hendrikseauthor=J.+Erikssonauthor=A.+D.+Windhorstauthor=P.+E.+Postmusauthor=H.+M.+Verheulauthor=E.+H.+Sern%C3%A9author=A.+A.+Lammertsmaauthor=E.+F.+Smit&title=Rapid+decrease+in+delivery+of+chemotherapy+to+tumors+after+anti-VEGF+therapy%3A+implications+for+scheduling+of+anti-angiogenic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BVeldt%26aufirst%3DA.%2BA.%26aulast%3DLubberink%26aufirst%3DM.%26aulast%3DBahce%26aufirst%3DI.%26aulast%3DWalraven%26aufirst%3DM.%26aulast%3Dde%2BBoer%26aufirst%3DM.%2BP.%26aulast%3DGreuter%26aufirst%3DH.%2BN.%26aulast%3DHendrikse%26aufirst%3DN.%2BH.%26aulast%3DEriksson%26aufirst%3DJ.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3DVerheul%26aufirst%3DH.%2BM.%26aulast%3DSern%25C3%25A9%26aufirst%3DE.%2BH.%26aulast%3DLammertsma%26aufirst%3DA.%2BA.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26atitle%3DRapid%2520decrease%2520in%2520delivery%2520of%2520chemotherapy%2520to%2520tumors%2520after%2520anti-VEGF%2520therapy%253A%2520implications%2520for%2520scheduling%2520of%2520anti-angiogenic%2520drugs%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D82%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Antiangiogenic therapy: a universal chemosensitization strategy for cancer?</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1175</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2006&pages=1171-1175&author=R.+S.+Kerbel&title=Antiangiogenic+therapy%3A+a+universal+chemosensitization+strategy+for+cancer%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DAntiangiogenic%2520therapy%253A%2520a%2520universal%2520chemosensitization%2520strategy%2520for%2520cancer%253F%26jtitle%3DScience%26date%3D2006%26volume%3D312%26spage%3D1171%26epage%3D1175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Kerbel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Clinical translation of angiogenesis inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrc905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=12360276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVGrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=727-739&author=R.+Kerbelauthor=J.+Folkman&title=Clinical+translation+of+angiogenesis+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical translation of angiogenesis inhibitors</span></div><div class="casAuthors">Kerbel, Robert; Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">727-739</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply.  The successful translation of angiogenesis inhibitors to clin. application depends partly on the transfer of expertise from scientists who are familiar with the biol. of angiogenesis to clinicians.  What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDKNdHthr-NrVg90H21EOLACvtfcHk0liGqtxWouERtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVGrtb0%253D&md5=db07af200e8842cc5a66a1bb41c6cd57</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrc905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc905%26sid%3Dliteratum%253Aachs%26aulast%3DKerbel%26aufirst%3DR.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DClinical%2520translation%2520of%2520angiogenesis%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D727%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1220</span><span class="NLM_x">–</span> <span class="NLM_lpage">1245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F092986710790936310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20166937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFeht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1220-1245&author=S.+Schenoneauthor=C.+Brulloauthor=M.+Botta&title=New+opportunities+to+treat+the+T315I-Bcr-Abl+mutant+in+chronic+myeloid+leukaemia%3A+tyrosine+kinase+inhibitors+and+molecules+that+act+by+alternative+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms</span></div><div class="casAuthors">Schenone, S.; Brullo, C.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1220-1245</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Resistance to the Bcr-Abl inhibitors approved for the treatment of chronic myeloid leukemia (CML) may arise from different mechanisms, including Bcr-Abl amino acid mutations, gene amplification and mechanisms independent of Bcr-Abl.  The T315I mutation at the gatekeeper residue is very frequent in advanced phases of the disease and is one of the main causes of resistance, disrupting important contact points between the inhibitors and the enzyme.  Different strategies have been implemented to overcome this resistance, including the synthesis of new Bcr-Abl ATP-competitive or non-ATP-competitive inhibitors, dual Aurora/Bcr-Abl inhibitors and multi-targeted kinase inhibitors.  An alternative approach is the use of other compds. that do not bind directly to the Bcr-Abl protein; instead, these mols. act on several downstream pathways, regulated by or linked in different ways to Bcr-Abl, that lead to the malignant transformation of the cells.  For this reason, farnesyl transferase inhibitors, MAPK inhibitors, Rac guanosine triphosphatase inhibitors, PI3K inhibitors, JAK inhibitors, Hsp90 inhibitors, mTOR inhibitors, PP2A activators and apoptosis inducers have been tested, alone or in combination with ATP-competitive inhibitors, against CML cell lines.  This review discusses compds. that act on Bcr-Abl or different cell pathways and reports on the mols. active against the T315I mutation, particularly the most recent findings in this field.  New mols. that are claimed by recent patents to be active on this mutation are also reported.  When possible, the review will focus on medicinal chem. in terms of chem. structure, mechanism of action and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzJF4D0f3TnrVg90H21EOLACvtfcHk0liGqtxWouERtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFeht7k%253D&md5=b169ec458fa04fd2870501e42753381e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F092986710790936310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710790936310%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DNew%2520opportunities%2520to%2520treat%2520the%2520T315I-Bcr-Abl%2520mutant%2520in%2520chronic%2520myeloid%2520leukaemia%253A%2520tyrosine%2520kinase%2520inhibitors%2520and%2520molecules%2520that%2520act%2520by%2520alternative%2520mechanisms%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D1220%26epage%3D1245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Marx, J.</span><span> </span><span class="NLM_article-title">Cancer research. Obstacle for promising cancer therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">1444</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2002&pages=1444&author=J.+Marx&title=Cancer+research.+Obstacle+for+promising+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarx%26aufirst%3DJ.%26atitle%3DCancer%2520research.%2520Obstacle%2520for%2520promising%2520cancer%2520therapy%26jtitle%3DScience%26date%3D2002%26volume%3D295%26spage%3D1444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Lee, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouhi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl Jensen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauptmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span> </span><span class="NLM_article-title">Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">19485</span><span class="NLM_x">–</span> <span class="NLM_lpage">19490</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=19485-19490&author=S.+L.+Leeauthor=P.+Rouhiauthor=L.+Dahl+Jensenauthor=D.+Zhangauthor=H.+Jiauthor=G.+Hauptmannauthor=P.+Inghamauthor=Y.+Cao&title=Hypoxia-induced+pathological+angiogenesis+mediates+tumor+cell+dissemination%2C+invasion%2C+and+metastasis+in+a+zebrafish+tumor+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BL.%26aulast%3DRouhi%26aufirst%3DP.%26aulast%3DDahl%2BJensen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DHauptmann%26aufirst%3DG.%26aulast%3DIngham%26aufirst%3DP.%26aulast%3DCao%26aufirst%3DY.%26atitle%3DHypoxia-induced%2520pathological%2520angiogenesis%2520mediates%2520tumor%2520cell%2520dissemination%252C%2520invasion%252C%2520and%2520metastasis%2520in%2520a%2520zebrafish%2520tumor%2520model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D19485%26epage%3D19490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Rapisarda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melillo, G.</span><span> </span><span class="NLM_article-title">Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrclinonc.2012.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22525710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVSgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=378-390&author=A.+Rapisardaauthor=G.+Melillo&title=Overcoming+disappointing+results+with+antiangiogenic+therapy+by+targeting+hypoxia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia</span></div><div class="casAuthors">Rapisarda, Annamaria A.; Melillo, Giovanni G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">378-390</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer cells rely on angiogenesis to fulfil their need for oxygen and nutrients; hence, agents targeting angiogenic pathways and mediators have been investigated as potential cancer drugs.  However, a significant no. of patients either do not respond to antiangiogenic agents or fairly rapidly develop resistance to them, which raises questions about how resistance develops and how it can be overcome.  In this Review, the authors examine the evidence linking antiangiogenic agents and intratumor hypoxia by providing an overview of the preclin. and clin. data, focusing on the possibility of exploiting intratumor hypoxia as a means to improve the therapeutic response to antiangiogenic agents.  Cancer cells rely on angiogenesis to fulfil their need for oxygen and nutrients; hence, agents targeting angiogenic pathways and mediators have been investigated as potential cancer drugs.  Although this strategy has demonstrated delayed tumor progression-leading to progression-free survival and overall survival benefits compared with std. therapy-in some patients, the results are more modest than predicted.  A significant no. of patients either do not respond to antiangiogenic agents or fairly rapidly develop resistance to them, which raises questions about how resistance develops and how it can be overcome.  Furthermore, whether cancers, once they develop resistance, become more invasive or lead to metastatic disease remains unclear.  Several mechanisms of resistance have been recently proposed and emerging evidence indicates that, under certain exptl. conditions, antiangiogenic agents increase intratumor hypoxia by promoting vessel pruning and inhibiting neoangiogenesis.  Indeed, several studies have highlighted the possibility that inhibitors of VEGF (and its receptors) can promote an invasive metastatic switch, in part by creating an increasingly hypoxic tumor microenvironment.  As a potential remedy, a no. of therapeutic approaches have been investigated that target the hypoxic tumor compartment to improve the clin. outcome of antiangiogenic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXtTq_ScREzrVg90H21EOLACvtfcHk0liGqtxWouERtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVSgt74%253D&md5=a0362341d4f472cc25b778a1effb765f</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.64%26sid%3Dliteratum%253Aachs%26aulast%3DRapisarda%26aufirst%3DA.%26aulast%3DMelillo%26aufirst%3DG.%26atitle%3DOvercoming%2520disappointing%2520results%2520with%2520antiangiogenic%2520therapy%2520by%2520targeting%2520hypoxia%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D378%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Force, T.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2010&pages=21-34&author=H.+Chengauthor=T.+Force&title=Molecular+mechanisms+of+cardiovascular+toxicity+of+targeted+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DForce%26aufirst%3DT.%26atitle%3DMolecular%2520mechanisms%2520of%2520cardiovascular%2520toxicity%2520of%2520targeted%2520cancer%2520therapeutics%26jtitle%3DCirc.%2520Res.%26date%3D2010%26volume%3D106%26spage%3D21%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Jain, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeffler, J. S.</span><span> </span><span class="NLM_article-title">Lessons from phase III clinical trials on anti-VEGF therapy for cancer</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fncponc0403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16407877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVynsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=24-40&author=R.+K.+Jainauthor=D.+G.+Dudaauthor=J.+W.+Clarkauthor=J.+S.+Loeffler&title=Lessons+from+phase+III+clinical+trials+on+anti-VEGF+therapy+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from phase III clinical trials on anti-VEGF therapy for cancer</span></div><div class="casAuthors">Jain, Rakesh K.; Duda, Dan G.; Clark, Jeffrey W.; Loeffler, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-40</span>CODEN:
                <span class="NLM_cas:coden">NCPOB5</span>;
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer.  In one approach, the addn. of bevacizumab, a VEGF-specific antibody, to std. chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients.  In the second approach, multitargeted tyrosine kinase inhibitors that block VEGF receptor and other kinases in both endothelial and cancer cells, demonstrated survival benefit in gastrointestinal stromal tumor and renal-cell-carcinoma patients.  By contrast, adding bevacizumab to chemotherapy failed to increase survival in patients with previously treated and refractory metastatic breast cancer.  Furthermore, addn. of vatalanib, a kinase inhibitor developed as a VEGF receptor-selective agent, to chemotherapy did not show a similar benefit in metastatic colorectal cancer patients.  These contrasting responses raise crit. questions about how these agents work and how to combine them optimally.  We summarize three of the many potential mechanisms of action of anti-VEGF agents, and also discuss progress relating to the identification of potential biomarkers for anti-VEGF-agent efficacy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzdONgbUWNUrVg90H21EOLACvtfcHk0lhV6H7FkSDbmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVynsL0%253D&md5=dfcfbf8ab8060df6b65c359b0bf8ef77</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fncponc0403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0403%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DLoeffler%26aufirst%3DJ.%2BS.%26atitle%3DLessons%2520from%2520phase%2520III%2520clinical%2520trials%2520on%2520anti-VEGF%2520therapy%2520for%2520cancer%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2006%26volume%3D3%26spage%3D24%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0lhV6H7FkSDbmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Woo, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, J.</span><span> </span><span class="NLM_article-title">Sorafenib in liver cancer</span> <span class="citation_source-journal">Exp. Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1059</span><span class="NLM_x">–</span> <span class="NLM_lpage">1067</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1517%2F14656566.2012.679930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22519770" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1059-1067&author=H.+Y.+Wooauthor=J.+Heo&title=Sorafenib+in+liver+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1517%2F14656566.2012.679930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2012.679930%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DH.%2BY.%26aulast%3DHeo%26aufirst%3DJ.%26atitle%3DSorafenib%2520in%2520liver%2520cancer%26jtitle%3DExp.%2520Opin.%2520Pharmacother.%26date%3D2012%26volume%3D13%26spage%3D1059%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Calvisi, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conner, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Factor, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorgeirsson, S. S.</span><span> </span><span class="NLM_article-title">Ubiquitous activation of Ras and Jak/Stat pathways in human HCC</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1128</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2006&pages=1117-1128&author=D.+F.+Calvisiauthor=S.+Laduauthor=A.+Gordenauthor=M.+Farinaauthor=E.+A.+Connerauthor=J.+S.+Leeauthor=V.+M.+Factorauthor=S.+S.+Thorgeirsson&title=Ubiquitous+activation+of+Ras+and+Jak%2FStat+pathways+in+human+HCC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCalvisi%26aufirst%3DD.%2BF.%26aulast%3DLadu%26aufirst%3DS.%26aulast%3DGorden%26aufirst%3DA.%26aulast%3DFarina%26aufirst%3DM.%26aulast%3DConner%26aufirst%3DE.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DFactor%26aufirst%3DV.%2BM.%26aulast%3DThorgeirsson%26aufirst%3DS.%2BS.%26atitle%3DUbiquitous%2520activation%2520of%2520Ras%2520and%2520Jak%252FStat%2520pathways%2520in%2520human%2520HCC%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D130%26spage%3D1117%26epage%3D1128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Gedaly, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creasy, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spear, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hundley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daily, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, B. M.</span><span> </span><span class="NLM_article-title">The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2531</span><span class="NLM_x">–</span> <span class="NLM_lpage">2536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22753710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aks73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=2531-2536&author=R.+Gedalyauthor=P.+Anguloauthor=C.+Chenauthor=K.+T.+Creasyauthor=B.+T.+Spearauthor=J.+Hundleyauthor=M.+F.+Dailyauthor=M.+Shahauthor=B.+M.+Evers&title=The+role+of+PI3K%2FmTOR+inhibition+in+combination+with+sorafenib+in+hepatocellular+carcinoma+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment</span></div><div class="casAuthors">Gedaly, Roberto; Angulo, Paul; Chen, Changguo; Creasy, Kate Townsend; Spear, Brett T.; Hundley, Jonathan; Daily, Michael F.; Shah, Malay; Evers, B. Mark</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2531-2536</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Deregulated RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC).  This study aimed to test the inhibitory effects of PI-103 (a small mol. inhibitor of PI3K and mTOR) and sorafenib as single agents and in combination on HCC tumorigenesis in an in vivo xenograft model.  Materials and Methods: In vitro study: Huh7 proliferation was assayed by 3H-thymidine incorporation and by thiazolyl blue tetrazolium bromide (MTT) assay.  Western blots were used to detect phosphorylation of the key enzymes in the two pathways.  In vivo study: Human HCC cell line Huh7 was inoculated into nude mice s.c. and the mice were treated with sorafenib (20 mg/kg/day) and PI-103 (5 mg/kg, every 4 days).  Tumor size was measured every other day.  Tumors were isolated for western blot and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay detection of apoptosis and signaling pathway enzymes.  Results: Our in vitro study found that combination of sorafenib and PI-103 additively inhibited Huh7 proliferation as compared to single-agent treatment.  Sorafenib and PI-103 as single agents differentially inhibited or activated key enzymes (MEK, ERK, AKT, mTOR, and S6K) in P13K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.  Combination of sorafenib and PI-103 inhibited all the key enzymes in the two pathways.  Our in vivo study demonstrated significant differences between control group, mono-drug groups and drug-combination group (p<0.05).  Combination of Sorafenib and PI-103 more efficiently inhibited tumorigenesis as compared to mono-drug treatments (p<0.032).  Conclusion: The combination of PI-103 and sorafenib has the advantage over mono-drug therapy on inhibition of HCC cell proliferation and tumorigenesis by inhibiting both PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCZFrpeD720LVg90H21EOLACvtfcHk0liBQ55uWIS2ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aks73I&md5=921829aacb25e09d9261364e3806b111</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGedaly%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCreasy%26aufirst%3DK.%2BT.%26aulast%3DSpear%26aufirst%3DB.%2BT.%26aulast%3DHundley%26aufirst%3DJ.%26aulast%3DDaily%26aufirst%3DM.%2BF.%26aulast%3DShah%26aufirst%3DM.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DThe%2520role%2520of%2520PI3K%252FmTOR%2520inhibition%2520in%2520combination%2520with%2520sorafenib%2520in%2520hepatocellular%2520carcinoma%2520treatment%26jtitle%3DAnticancer%2520Res.%26date%3D2012%26volume%3D32%26spage%3D2531%26epage%3D2536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Small molecules ATP-competitive inhibitors of FLT3: a chemical overview</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3113</span><span class="NLM_x">–</span> <span class="NLM_lpage">3132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F092986708786848613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19075657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptV2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=3113-3132&author=S.+Schenoneauthor=C.+Brulloauthor=M.+Botta&title=Small+molecules+ATP-competitive+inhibitors+of+FLT3%3A+a+chemical+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules ATP-competitive inhibitors of FLT3: a chemical overview</span></div><div class="casAuthors">Schenone, S.; Brullo, C.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3113-3132</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3 is a tyrosine kinase (TK), member of the class III TK receptor family, normally expressed in hematopoietic, immune and neural systems, also playing an important role in the pathogenesis of acute leukemias, particularly acute myeloid leukemia (AML), where it is present in constitutively activated mutated forms, correlated with poor prognosis, in a notable percentage of patients.  For these reasons FLT3 soon appeared as a promising target for the therapeutic intervention for this severe and aggressive malignancy; the recent detn. of the crystal structure of the autoinhibited form of FLT3 gave new trend for the design and the synthesis of potent inhibitors.  Small mols. tyrosine kinase inhibitors represent one of the largest drug family currently targeted by pharmaceutical companies for the treatment of cancer.  Exciting examples of such mols. have reached advanced clin. trials and have been recently approved by FDA for the treatment of different solid or hematol. tumors.  Usually TK inhibitors share common features, namely two hydrophobic/arom. regions bearing one or more hydrogen bonding substituents.  These two regions can be connected by different spacers and almost all the mols. contain a component resembling the ATP purine structure.  This review will deal with FLT3 synthetic inhibitors, reporting not only the most important mols. that are in clin. trials, but also the new compds. that have appeared in literature in the last few years.  Our attention will be focused on chem. structures, mechanisms of action and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMaEJysVaMAbVg90H21EOLACvtfcHk0liBQ55uWIS2ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptV2gsA%253D%253D&md5=f0d577bdb45e35fb063b98f35d9329d1</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2174%2F092986708786848613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708786848613%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520ATP-competitive%2520inhibitors%2520of%2520FLT3%253A%2520a%2520chemical%2520overview%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D3113%26epage%3D3132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=323-328&author=R.+Roskoski&title=Sunitinib%3A+a+VEGF+and+PDGF+receptor+protein+kinase+and+angiogenesis+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DSunitinib%253A%2520a%2520VEGF%2520and%2520PDGF%2520receptor%2520protein%2520kinase%2520and%2520angiogenesis%2520inhibitor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D356%26spage%3D323%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boloor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epperly, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N. ,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudeman, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-dimethyl-2<i>H</i>-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4632</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.++Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28pazopanib%29%2C+a+novel+and+potent+vascular+endothelial+growth+factor+receptor+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528pazopanib%2529%252C%2520a%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Pazopanib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=17-18&author=R.+M.+Bukowskiauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Pazopanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DPazopanib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D17%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Morabito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccirillo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandomenico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carillio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryce, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotenuto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rocca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normanno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, F.</span><span> </span><span class="NLM_article-title">Vandetanib: an overview of its clinical development in NSCLC and other tumors</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1358%2Fdot.2010.46.9.1516989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Wms7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=683-698&author=A.+Morabitoauthor=M.+C.+Piccirilloauthor=R.+Costanzoauthor=C.+Sandomenicoauthor=G.+Carillioauthor=G.+Danieleauthor=P.+Giordanoauthor=J.+Bryceauthor=P.+Carotenutoauthor=A.+La+Roccaauthor=M.+Di+Maioauthor=N.+Normannoauthor=G.+Roccoauthor=F.+Perrone&title=Vandetanib%3A+an+overview+of+its+clinical+development+in+NSCLC+and+other+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib: an overview of its clinical development in NSCLC and other tumors</span></div><div class="casAuthors">Morabito, A.; Piccirillo, M. C.; Costanzo, R.; Sandomenico, C.; Carillio, G.; Daniele, G.; Giordano, P.; Bryce, J.; Carotenuto, P.; La Rocca, A.; Di Maio, M.; Normanno, N.; Rocco, G.; Perrone, F.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">683-698</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Vandetanib is an oral inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR) and Ret tyrosine kinases involved in tumor growth, progression and angiogenesis.  Phase I studies indicated that the recommended dose of vandetanib as a single agent is 300 mg/day.  Rash, diarrhea, hypertension and asymptomatic Q-Tc prolongation were the most common adverse events.  Four randomized phase III clin. trials evaluated the efficacy of vandetanib in non-small cell lung cancer (NSCLC) in combination with docetaxel (ZODIAC), pemetrexed (ZEAL) or as a single agent (ZEST and ZEPHYR).  Only the ZODIAC trial met its primary endpoint (progression-free survival [PFS]), while no study showed an advantage in overall survival with vandetanib.  No significant antitumor activity has been obsd. in small cell lung cancer, advanced ovarian, colorectal, breast, prostate cancer and multiple myeloma.  In advanced metastatic medullary thyroid cancer, one randomized phase III clin. trial has demonstrated that vandetanib can significantly improve response rate, PFS and time to worsening of pain.  Several key questions remain to be addressed regarding the identification of clin. or mol. biomarkers predictive of response, the choice of the optimal dose or schedule of vandetanib and the safety of long-term administration.  The results of ongoing trials in untreated patients with advanced NSCLC and other tumors should better define the optimal clin. application of vandetanib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeMQRrol1lKbVg90H21EOLACvtfcHk0ljyU1WMIKp8tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Wms7vE&md5=fed11f7d0dfbe7e6717384d5de86fa77</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1358%2Fdot.2010.46.9.1516989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2010.46.9.1516989%26sid%3Dliteratum%253Aachs%26aulast%3DMorabito%26aufirst%3DA.%26aulast%3DPiccirillo%26aufirst%3DM.%2BC.%26aulast%3DCostanzo%26aufirst%3DR.%26aulast%3DSandomenico%26aufirst%3DC.%26aulast%3DCarillio%26aufirst%3DG.%26aulast%3DDaniele%26aufirst%3DG.%26aulast%3DGiordano%26aufirst%3DP.%26aulast%3DBryce%26aufirst%3DJ.%26aulast%3DCarotenuto%26aufirst%3DP.%26aulast%3DLa%2BRocca%26aufirst%3DA.%26aulast%3DDi%2BMaio%26aufirst%3DM.%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DRocco%26aufirst%3DG.%26aulast%3DPerrone%26aufirst%3DF.%26atitle%3DVandetanib%253A%2520an%2520overview%2520of%2520its%2520clinical%2520development%2520in%2520NSCLC%2520and%2520other%2520tumors%26jtitle%3DDrugs%2520Today%26date%3D2010%26volume%3D46%26spage%3D683%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Commander, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteside, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, C.</span><span> </span><span class="NLM_article-title">Vandetanib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2165%2F11595310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21770481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlakurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1355-1365&author=H.+Commanderauthor=G.+Whitesideauthor=C.+Perry&title=Vandetanib%3A+first+global+approval"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib: first global approval</span></div><div class="casAuthors">Commander, Helen; Whiteside, Glenn; Perry, Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1355-1365</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC).  Regulatory submissions for this indication have been filed in the EU and Canada, with clin. development in malignant MTC ongoing in several other countries.  Vandetanib is being developed by AstraZeneca, and is also in phase II development for biliary, breast and prostate cancer.  Earlier, AstraZeneca withdrew regulatory filings for non-small cell lung cancer (NSCLC) in the US and EU, and later discontinued development.  This article summarizes the milestones in the development of vandetanib leading to this first approval in malignant MTC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsc9DGAyJOZ7Vg90H21EOLACvtfcHk0ljyU1WMIKp8tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlakurzJ&md5=ffb345f58f8c488b3752dc43554054af</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2165%2F11595310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11595310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DCommander%26aufirst%3DH.%26aulast%3DWhiteside%26aufirst%3DG.%26aulast%3DPerry%26aufirst%3DC.%26atitle%3DVandetanib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D1355%26epage%3D1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjaer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibáñez, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span> </span><span class="NLM_article-title">Structure and chemical inhibition of the RET tyrosine kinase domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">33577</span><span class="NLM_x">–</span> <span class="NLM_lpage">33587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kjaerauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ib%C3%A1%C3%B1ezauthor=N.+Q.+McDonald&title=Structure+and+chemical+inhibition+of+the+RET+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0ljyU1WMIKp8tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520chemical%2520inhibition%2520of%2520the%2520RET%2520tyrosine%2520kinase%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Ho, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonasch, E.</span><span> </span><span class="NLM_article-title">Axitinib in the treatment of metastatic renal cell carcinoma</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2217%2Ffon.11.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22044199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=1247-1253&author=T.+H.+Hoauthor=E.+Jonasch&title=Axitinib+in+the+treatment+of+metastatic+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Axitinib in the treatment of metastatic renal cell carcinoma</span></div><div class="casAuthors">Ho, Thai H.; Jonasch, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1247-1253</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Axitinib, an oral small-mol. tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma.  Common side effects include hypertension, fatigue and dysphonia.  Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma.  Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9XhyXJ5T84LVg90H21EOLACvtfcHk0lhomJ2u_UmbOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtbrI&md5=60a0a2879cb1fb633c9fb84d89e8c07c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2217%2Ffon.11.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.11.107%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BH.%26aulast%3DJonasch%26aufirst%3DE.%26atitle%3DAxitinib%2520in%2520the%2520treatment%2520of%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DFuture%2520Oncol.%26date%3D2011%26volume%3D7%26spage%3D1247%26epage%3D1253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobbs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7019</span><span class="NLM_x">–</span> <span class="NLM_lpage">7031</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900522y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=7019-7031&author=J.+Solowiejauthor=S.+Bergqvistauthor=M.+A.+McTigueauthor=T.+Marroneauthor=T.+Quenzerauthor=M.+Cobbsauthor=K.+Ryanauthor=R.+S.+Kaniaauthor=W.+Diehlauthor=B.+W.+Murray&title=Characterizing+the+effects+of+the+juxtamembrane+domain+on+vascular+endothelial+growth+factor+receptor-2+enzymatic+activity%2C+autophosphorylation%2C+and+inhibition+by+axitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fbi900522y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900522y%26sid%3Dliteratum%253Aachs%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DMarrone%26aufirst%3DT.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DCobbs%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCharacterizing%2520the%2520effects%2520of%2520the%2520juxtamembrane%2520domain%2520on%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520enzymatic%2520activity%252C%2520autophosphorylation%252C%2520and%2520inhibition%2520by%2520axitinib%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D7019%26epage%3D7031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musumeci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Novel dual Src/Abl inhibitors for hematologic and solid malignancies</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">931</span><span class="NLM_x">–</span> <span class="NLM_lpage">945</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=931-945&author=S.+Schenoneauthor=C.+Brulloauthor=F.+Musumeciauthor=M.+Botta&title=Novel+dual+Src%2FAbl+inhibitors+for+hematologic+and+solid+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DNovel%2520dual%2520Src%252FAbl%2520inhibitors%2520for%2520hematologic%2520and%2520solid%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D931%26epage%3D945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boffey, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilburn, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span> </span><span class="NLM_article-title">AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4389</span><span class="NLM_x">–</span> <span class="NLM_lpage">4400</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4389-4400&author=S.+R.+Wedgeauthor=J.+Kendrewauthor=L.+F.+Hennequinauthor=P.+J.+Valentineauthor=S.+T.+Barryauthor=S.+R.+Braveauthor=N.+R.+Smithauthor=N.+H.+Jamesauthor=M.+Dukesauthor=J.+O.+Curwenauthor=R.+Chesterauthor=J.+A.+Jacksonauthor=S.+J.+Boffeyauthor=L.+L.+Kilburnauthor=S.+Barnettauthor=G.+H.+Richmondauthor=P.+F.+Wadsworthauthor=M.+Walkerauthor=A.+L.+Bigleyauthor=S.+T.+Taylorauthor=L.+Cooperauthor=S.+Beckauthor=J.+M.+Jurgensmeierauthor=D.+J.+Ogilvie&title=AZD2171%3A+a+highly+potent%2C+orally+bioavailable%2C+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DValentine%26aufirst%3DP.%2BJ.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DChester%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DJ.%2BA.%26aulast%3DBoffey%26aufirst%3DS.%2BJ.%26aulast%3DKilburn%26aufirst%3DL.%2BL.%26aulast%3DBarnett%26aufirst%3DS.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DWadsworth%26aufirst%3DP.%2BF.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DBigley%26aufirst%3DA.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%2BT.%26aulast%3DCooper%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DJurgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26atitle%3DAZD2171%253A%2520a%2520highly%2520potent%252C%2520orally%2520bioavailable%252C%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4389%26epage%3D4400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Lindsay, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacPherson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassidy, J.</span><span> </span><span class="NLM_article-title">Current status of cediranib: the rapid development of a novel anti-angiogenic therapy</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2217%2Ffon.09.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19450171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtF2qu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=421-432&author=C.+R.+Lindsayauthor=I.+R.+MacPhersonauthor=J.+Cassidy&title=Current+status+of+cediranib%3A+the+rapid+development+of+a+novel+anti-angiogenic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of Cediranib: the rapid development of a novel anti-angiogenic therapy</span></div><div class="casAuthors">Lindsay, Colin R.; MacPherson, Iain RJ; Cassidy, Jim</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">421-432</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and metastasis, is a pivotal event in tumorigenesis.  It is tightly regulated by the VEGF system.  Cediranib (AZD2171, Recentin; AstraZeneca, London, UK) is a novel and potent small-mol. inhibitor of VEGF signaling, with activity against the three VEGF receptors, as well as other targets.  This article provides a comprehensive and up-to-date synopsis of all pertinent preclin. and clin. studies detailing this promising new therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj-x6JwTlXIbVg90H21EOLACvtfcHk0lhCBgpfcE9JZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtF2qu7c%253D&md5=0f60b2d1bb1ac6379dcee0787d220830</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.2217%2Ffon.09.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.09.18%26sid%3Dliteratum%253Aachs%26aulast%3DLindsay%26aufirst%3DC.%2BR.%26aulast%3DMacPherson%26aufirst%3DI.%2BR.%26aulast%3DCassidy%26aufirst%3DJ.%26atitle%3DCurrent%2520status%2520of%2520cediranib%253A%2520the%2520rapid%2520development%2520of%2520a%2520novel%2520anti-angiogenic%2520therapy%26jtitle%3DFuture%2520Oncol.%26date%3D2009%26volume%3D5%26spage%3D421%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Batchelor, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">di Tomaso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancukiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotkin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichler, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drappatz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochberg, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chea, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Exarhopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeffler, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moses, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2817</span><span class="NLM_x">–</span> <span class="NLM_lpage">2823</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2009.26.3988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20458050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFKmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2817-2823&author=T.+T.+Batchelorauthor=D.+G.+Dudaauthor=E.+di+Tomasoauthor=M.+Ancukiewiczauthor=S.+R.+Plotkinauthor=E.+Gerstnerauthor=A.+F.+Eichlerauthor=J.+Drappatzauthor=F.+H.+Hochbergauthor=T.+Bennerauthor=D.+N.+Louisauthor=K.+S.+Cohenauthor=H.+Cheaauthor=A.+Exarhopoulosauthor=J.+S.+Loefflerauthor=M.+A.+Mosesauthor=P.+Ivyauthor=A.+G.+Sorensenauthor=P.+Y.+Wenauthor=R.+K.+Jain&title=Phase+II+study+of+cediranib%2C+an+oral+pan-vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+in+patients+with+recurrent+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma</span></div><div class="casAuthors">Batchelor, Tracy T.; Duda, Dan G.; di Tomaso, Emmanuelle; Ancukiewicz, Marek; Plotkin, Scott R.; Gerstner, Elizabeth; Eichler, April F.; Drappatz, Jan; Hochberg, Fred H.; Benner, Thomas; Louis, David N.; Cohen, Kenneth S.; Chea, Houng; Exarhopoulos, Alexis; Loeffler, Jay S.; Moses, Marsha A.; Ivy, Percy; Sorensen, A. Gregory; Wen, Patrick Y.; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2817-2823</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF).  We performed a phase II study of cediranib in patients with recurrent glioblastoma.  Methods: Cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, was administered (45 mg/d) until progression or unacceptable toxicity to patients with recurrent glioblastoma.  The primary end point was the proportion of patients alive and progression free at 6 mo (APF6).  We performed magnetic resonance imaging (MRI) and plasma and urinary biomarker evaluations at multiple time points.  Results: Thirty-one patients with recurrent glioblastoma were accrued.  APF6 after cediranib was 25.8%.  Radiog. partial responses were obsd. by MRI in 17 (56.7%) of 30 evaluable patients using three-dimensional measurements and in eight (27%) of 30 evaluable patients using two-dimensional measurements.  For the 15 patients who entered the study taking corticosteroids, the dose was reduced (n = 10) or discontinued (n = 5).  Toxicities were manageable.  Grade 3/4 toxicities included hypertension (four of 31; 12.9%); diarrhea (two of 31; 6.4%); and fatigue (six of 31; 19.4%).  Fifteen (48.4%) of 31 patients required at least one dose redn. and 15 patients required temporary drug interruptions due to toxicity.  Drug interruptions were not assocd. with outcome.  Changes in plasma placental growth factor, basic fibroblast growth factor, matrix metalloproteinase (MMP) -2, sol. VEGF receptor 1, stromal cell-derived factor-1α, and sol. Tek/Tie2 receptor and in urinary MMP-9/neutrophil gelatinase-assocd. lipocalin activity after cediranib were assocd. with radiog. response or survival.  Conclusion: Cediranib monotherapy for recurrent glioblastoma is assocd. with encouraging proportions of radiog. response, 6-mo progression-free survival, and a steroid-sparing effect with manageable toxicity.  We identified early changes in circulating mols. as potential biomarkers of response to cediranib.  The efficacy of cediranib and the predictive value of these candidate biomarkers will be explored in prospective trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJbFlYzveoHrVg90H21EOLACvtfcHk0lhCBgpfcE9JZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFKmu78%253D&md5=b8f902095ea92608bdd4ef376acbfb50</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.3988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.3988%26sid%3Dliteratum%253Aachs%26aulast%3DBatchelor%26aufirst%3DT.%2BT.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3Ddi%2BTomaso%26aufirst%3DE.%26aulast%3DAncukiewicz%26aufirst%3DM.%26aulast%3DPlotkin%26aufirst%3DS.%2BR.%26aulast%3DGerstner%26aufirst%3DE.%26aulast%3DEichler%26aufirst%3DA.%2BF.%26aulast%3DDrappatz%26aufirst%3DJ.%26aulast%3DHochberg%26aufirst%3DF.%2BH.%26aulast%3DBenner%26aufirst%3DT.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DCohen%26aufirst%3DK.%2BS.%26aulast%3DChea%26aufirst%3DH.%26aulast%3DExarhopoulos%26aufirst%3DA.%26aulast%3DLoeffler%26aufirst%3DJ.%2BS.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DSorensen%26aufirst%3DA.%2BG.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DPhase%2520II%2520study%2520of%2520cediranib%252C%2520an%2520oral%2520pan-vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D2817%26epage%3D2823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">di Tomaso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snuderl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamoun, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auluck, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazlollahi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andronesi, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frosch, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotkin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley-Whyte, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=19-28&author=E.+di+Tomasoauthor=M.+Snuderlauthor=W.+S.+Kamounauthor=D.+G.+Dudaauthor=P.+K.+Auluckauthor=L.+Fazlollahiauthor=O.+C.+Andronesiauthor=M.+P.+Froschauthor=P.+Y.+Wenauthor=S.+R.+Plotkinauthor=E.+T.+Hedley-Whyteauthor=A.+G.+Sorensenauthor=T.+T.+Batchelorauthor=R.+K.+Jain&title=Glioblastoma+recurrence+after+cediranib+therapy+in+patients%3A+lack+of+%E2%80%9Crebound%E2%80%9D+revascularization+as+mode+of+escape"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Ddi%2BTomaso%26aufirst%3DE.%26aulast%3DSnuderl%26aufirst%3DM.%26aulast%3DKamoun%26aufirst%3DW.%2BS.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3DAuluck%26aufirst%3DP.%2BK.%26aulast%3DFazlollahi%26aufirst%3DL.%26aulast%3DAndronesi%26aufirst%3DO.%2BC.%26aulast%3DFrosch%26aufirst%3DM.%2BP.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DPlotkin%26aufirst%3DS.%2BR.%26aulast%3DHedley-Whyte%26aufirst%3DE.%2BT.%26aulast%3DSorensen%26aufirst%3DA.%2BG.%26aulast%3DBatchelor%26aufirst%3DT.%2BT.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DGlioblastoma%2520recurrence%2520after%2520cediranib%2520therapy%2520in%2520patients%253A%2520lack%2520of%2520%25E2%2580%259Crebound%25E2%2580%259D%2520revascularization%2520as%2520mode%2520of%2520escape%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D19%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Sorensen, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emblem, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polaskova, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancukiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=402-407&author=A.+G.+Sorensenauthor=K.+E.+Emblemauthor=P.+Polaskovaauthor=D.+Jenningsauthor=H.+Kimauthor=M.+Ancukiewiczauthor=M.+Wangauthor=P.+Y.+Wenauthor=P.+Ivyauthor=T.+T.+Batchelorauthor=R.+K.+Jain&title=Increased+survival+of+glioblastoma+patients+who+respond+to+antiangiogenic+therapy+with+elevated+blood+perfusion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DA.%2BG.%26aulast%3DEmblem%26aufirst%3DK.%2BE.%26aulast%3DPolaskova%26aufirst%3DP.%26aulast%3DJennings%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DAncukiewicz%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DBatchelor%26aufirst%3DT.%2BT.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DIncreased%2520survival%2520of%2520glioblastoma%2520patients%2520who%2520respond%2520to%2520antiangiogenic%2520therapy%2520with%2520elevated%2520blood%2520perfusion%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D402%26epage%3D407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Mulders, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jong, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osanto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porfiri, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protheroe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Herpen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mookerjee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M. E.</span><span> </span><span class="NLM_article-title">Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=527-537&author=P.+Muldersauthor=R.+Hawkinsauthor=P.+Nathanauthor=I.+de+Jongauthor=S.+Osantoauthor=E.+Porfiriauthor=A.+Protheroeauthor=C.+M.+van+Herpenauthor=B.+Mookerjeeauthor=L.+Pikeauthor=J.+M.+J%C3%BCrgensmeierauthor=M.+E.+Gore&title=Cediranib+monotherapy+in+patients+with+advanced+renal+cell+carcinoma%3A+results+of+a+randomised+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMulders%26aufirst%3DP.%26aulast%3DHawkins%26aufirst%3DR.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3Dde%2BJong%26aufirst%3DI.%26aulast%3DOsanto%26aufirst%3DS.%26aulast%3DPorfiri%26aufirst%3DE.%26aulast%3DProtheroe%26aufirst%3DA.%26aulast%3Dvan%2BHerpen%26aufirst%3DC.%2BM.%26aulast%3DMookerjee%26aufirst%3DB.%26aulast%3DPike%26aufirst%3DL.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DGore%26aufirst%3DM.%2BE.%26atitle%3DCediranib%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520renal%2520cell%2520carcinoma%253A%2520results%2520of%2520a%2520randomised%2520phase%2520II%2520study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2012%26volume%3D48%26spage%3D527%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Garland, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chansky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verschraegen, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dasilva, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandara, D. R.</span><span> </span><span class="NLM_article-title">Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1945</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1097%2FJTO.0b013e318229586e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21964533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADC%252BC3MbhvVCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1938-1945&author=L.+L.+Garlandauthor=K.+Chanskyauthor=A.+J.+Wozniakauthor=A.+S.+Tsaoauthor=S.+M.+Gadgeelauthor=C.+F.+Verschraegenauthor=M.+A.+Dasilvaauthor=M.+Redmanauthor=D.+R.+Gandara&title=Phase+II+study+of+cediranib+in+patients+with+malignant+pleural+mesothelioma%3A+SWOG+S0509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509</span></div><div class="casAuthors">Garland Linda L; Chansky Kari; Wozniak Antoinette J; Tsao Anne S; Gadgeel Shirish M; Verschraegen Claire F; Dasilva Marco A; Redman Mary; Gandara David R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1938-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Malignant pleural mesothelioma (MPM) tumors express vascular epithelial growth factor (VEGF) and VEGF receptors.  We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy.  METHODS:  Patients with MPM previously treated with a platinum-containing chemotherapy regimen and a performance status 0 to 2 were eligible for enrollment.  Cediranib 45 mg/d was administered until progression or unacceptable toxicity.  The primary end point was response rate.  Tumor measurements were made by RECIST criteria, with a subset analysis conducted using modified RECIST.  A two-stage design with an early stopping rule based on response rate was used.  RESULTS:  Fifty-four patients were enrolled.  Of 47 evaluable patients, 4 patients (9%) had objective responses, 16 patients (34%) had stable disease, 20 patients (43%) had disease progression, 2 patients (4%) had symptomatic deterioration, and 1 patient (2%) had early death.  The most common toxicities were fatigue (64%), diarrhea (64%), and hypertension (70%); 91% of patients required a dose reduction.  Median overall survival was 9.5 months, 1-year survival was 36%, and median progression-free survival was 2.6 months.  CONCLUSION:  Cediranib monotherapy has modest single-agent activity in MPM after platinum-based therapy.  However, some patient tumors were highly sensitive to cediranib.  This study provides a rationale for further testing of cediranib plus chemotherapy in MPM and highlights the need to identify a predictive biomarker for cediranib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbY1bR_QwPCLZpSb_XWfMrfW6udTcc2ebUk5tYlR6VT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbhvVCmug%253D%253D&md5=4b201c6827c3aed78d507efae97800e5</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e318229586e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e318229586e%26sid%3Dliteratum%253Aachs%26aulast%3DGarland%26aufirst%3DL.%2BL.%26aulast%3DChansky%26aufirst%3DK.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DTsao%26aufirst%3DA.%2BS.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVerschraegen%26aufirst%3DC.%2BF.%26aulast%3DDasilva%26aufirst%3DM.%2BA.%26aulast%3DRedman%26aufirst%3DM.%26aulast%3DGandara%26aufirst%3DD.%2BR.%26atitle%3DPhase%2520II%2520study%2520of%2520cediranib%2520in%2520patients%2520with%2520malignant%2520pleural%2520mesothelioma%253A%2520SWOG%2520S0509%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D1938%26epage%3D1945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Alberts, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitch, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morlan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakhil, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, S.</span><span> </span><span class="NLM_article-title">Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II north central cancer treatment troup clinical trial</span> <span class="citation_source-journal">Am. J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1097%2FCOC.0b013e3182118cdf" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21422991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=329-333&author=S.+R.+Albertsauthor=T.+R.+Fitchauthor=G.+P.+Kimauthor=B.+W.+Morlanauthor=S.+R.+Dakhilauthor=H.+M.+Grossauthor=S.+Nair&title=Cediranib+%28AZD2171%29+in+patients+with+advanced+hepatocellular+carcinoma%3A+a+phase+II+north+central+cancer+treatment+troup+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial</span></div><div class="casAuthors">Alberts, Steven Robert; Fitch, Tom R.; Kim, George P.; Morlan, Bruce W.; Dakhil, Shaker R.; Gross, Howard M.; Nair, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">329-333</span>CODEN:
                <span class="NLM_cas:coden">AJCODI</span>;
        ISSN:<span class="NLM_cas:issn">0277-3732</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objectives: Vascular endothelial growth factor has been shown to be overexpressed in several studies of hepatocellular carcinoma (HCC).  Cediranib is a potent inhibitor of vascular endothelial growth factor signaling.  We assessed the efficacy and toxicity of cediranib in patients with HCC.  Methods: Twenty-eight patients with unresectable or metastatic HCC were enrolled in this study.  Patients received 45 mg of cediranib orally, once daily, for 28-day cycles.  The primary objective of this phase II study was to assess 6-mo survival.  Secondary objectives were to assess tumor response, time to progression, and toxicity.  Results: All 28 patients were evaluable for efficacy outcomes.  Twelve patients (42.9%) survived 6 mo, 15 (53.6%) died within 6 mo, and 1 (3.6%) was lost to follow-up before 6 mo.  The median overall survival was 5.8 mo (95% confidence interval, 3.4-7.3 mo).  No patients experienced confirmed response.  The median time to progression was 2.8 mo (95% confidence interval, 2.3-4.4 mo).  Twenty-six patients (93%) experienced a grade 3+ adverse event with the most common adverse event s being fatigue (46%), anorexia (25%), hypertension (21%), and elevated alanine aminotransferase (18%).  Conclusions: Owing to the toxicity, cediranib at this dose and schedule is not an effective treatment in patients with unresectable or metastatic HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgnvCvkgPvtrVg90H21EOLACvtfcHk0ljhKfYk_WnErQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOjsbfL&md5=1f23cf888e84d1af813d1f154c5c2c7b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1097%2FCOC.0b013e3182118cdf&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOC.0b013e3182118cdf%26sid%3Dliteratum%253Aachs%26aulast%3DAlberts%26aufirst%3DS.%2BR.%26aulast%3DFitch%26aufirst%3DT.%2BR.%26aulast%3DKim%26aufirst%3DG.%2BP.%26aulast%3DMorlan%26aufirst%3DB.%2BW.%26aulast%3DDakhil%26aufirst%3DS.%2BR.%26aulast%3DGross%26aufirst%3DH.%2BM.%26aulast%3DNair%26aufirst%3DS.%26atitle%3DCediranib%2520%2528AZD2171%2529%2520in%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%253A%2520a%2520phase%2520II%2520north%2520central%2520cancer%2520treatment%2520troup%2520clinical%2520trial%26jtitle%3DAm.%2520J.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D35%26spage%3D329%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesters, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehninger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zirrgiebel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puchalski, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span> </span><span class="NLM_article-title">An open-label, phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">196</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.leukres.2009.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19674789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=196-202&author=W.+Fiedlerauthor=R.+Mestersauthor=M.+Heuserauthor=G.+Ehningerauthor=W.+E.+Berdelauthor=U.+Zirrgiebelauthor=J.+D.+Robertsonauthor=T.+A.+Puchalskiauthor=B.+Collinsauthor=J.+M.+J%C3%BCrgensmeierauthor=H.+Serve&title=An+open-label%2C+phase+I+study+of+cediranib+%28RECENTIN%29+in+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia</span></div><div class="casAuthors">Fiedler, Walter; Mesters, Rolf; Heuser, Michael; Ehninger, Gerhard; Berdel, Wolfgang E.; Zirrgiebel, Ute; Robertson, Jane D.; Puchalski, Tom A.; Collins, Barbara; Juergensmeier, Juliane M.; Serve, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-202</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">VEGFR and c-Kit signaling pathways may contribute to the pathophysiol. of acute myeloid leukemia (AML).  Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of ≤30 mg/day.  The most common adverse events were diarrhea, hypertension and fatigue.  Six patients experienced an objective response (3 each at 20 and 30 mg).  Dose- and time-dependent redns. in sVEGFR-2 were obsd., and there was a pos. correlation between cediranib exposure and the change in plasma VEGF levels from baseline.  Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNJ2lmgszE5LVg90H21EOLACvtfcHk0ljhKfYk_WnErQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgt7c%253D&md5=110f783b4ed226182786615af2860586</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2009.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2009.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DMesters%26aufirst%3DR.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DZirrgiebel%26aufirst%3DU.%26aulast%3DRobertson%26aufirst%3DJ.%2BD.%26aulast%3DPuchalski%26aufirst%3DT.%2BA.%26aulast%3DCollins%26aufirst%3DB.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DServe%26aufirst%3DH.%26atitle%3DAn%2520open-label%252C%2520phase%2520I%2520study%2520of%2520cediranib%2520%2528RECENTIN%2529%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2010%26volume%3D34%26spage%3D196%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2298</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0lgdpEyJVZMOng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guessous, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kofman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abounader, R.</span><span> </span><span class="NLM_article-title">XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20127563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1ylt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=112-121&author=Y.+Zhangauthor=F.+Guessousauthor=A.+Kofmanauthor=D.+Schiffauthor=R.+Abounader&title=XL-184%2C+a+MET%2C+VEGFR-2+and+RET+kinase+inhibitor+for+the+treatment+of+thyroid+cancer%2C+glioblastoma+multiforme+and+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC</span></div><div class="casAuthors">Zhang, Ying; Guessous, Fadila; Kofman, Alex; Schiff, David; Abounader, Roger</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-121</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  XL-184 (BMS-907351), under development by Exelixis Inc and Bristol-Myers Squibb Co, is a pan-tyrosine kinase inhibitor for the potential oral treatment of medullary thyroid cancer, glioblastoma multiforme and NSCLC.  The prinicipal targets of XL-184 are MET, VEGFR-2 and RET, but the drug is also reported to display inhibitory activity against KIT, FLT3 and TEK.  Preclin. studies demonstrated that XL-184 potently inhibited multiple receptor tyrosine kinases in various cancer cell lines and animal xenograft models, and that the drug exhibited significant oral bioavailability and blood-brain barrier penetration.  A phase I clin. trial in patients with advanced solid malignancies indicated that XL-184 accumulated dose-dependently in the plasma and had a long terminal half-life.  A phase II trial in patients with progressive or recurrent glioblastoma revealed modest but promising median progression-free survival.  Toxicity and side effects for the drug have generally been of low-to-moderate severity.  At the time of publication, three addnl. trials of XL-184 were recruiting patients, including a phase I trial in combination with std. of care in patients with glioblastoma, a phase I/II trial in combination with erlotinib in patients with NSCLC, and a phase III trial in patients with medullary thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Fd_mnBA3mrVg90H21EOLACvtfcHk0lgdpEyJVZMOng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1ylt7s%253D&md5=fe00ddc171497cc2dff787db6d430208</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuessous%26aufirst%3DF.%26aulast%3DKofman%26aufirst%3DA.%26aulast%3DSchiff%26aufirst%3DD.%26aulast%3DAbounader%26aufirst%3DR.%26atitle%3DXL-184%252C%2520a%2520MET%252C%2520VEGFR-2%2520and%2520RET%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520thyroid%2520cancer%252C%2520glioblastoma%2520multiforme%2520and%2520NSCLC%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D112%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Bowles, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span> </span><span class="NLM_article-title">Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib)</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">868</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1358%2Fdot.2011.47.11.1688487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsleitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=857-868&author=D.+W.+Bowlesauthor=E.+R.+Kesslerauthor=A.+Jimeno&title=Multi-targeted+tyrosine+kinase+inhibitors+in+clinical+development%3A+focus+on+XL-184+%28cabozantinib%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib)</span></div><div class="casAuthors">Bowles, D. W.; Kessler, E. R.; Jimeno, A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">857-868</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">XL-184 (cabozantinib) is a novel, small-mol., multi-targeted receptor tyrosine kinase inhibitor with particular activity against hepatocyte growth factor receptor (tyrosine-protein kinase Met), vascular endothelial growth factor receptor 2 (VEGFR-2) and proto-oncogene tyrosine-protein kinase receptor Ret.  There is ample evidence of Met, VEGFR-2 and Ret signaling in several tumor types.  Preclin. data suggest that XL-184 has activity in tumors derived from both epithelial and mesenchymal origins.  Phase I and II clin. studies support significant antitumor activity, particularly in medullary thyroid cancer and cancers metastatic to the bone.  This review will evaluate XL-184's preclin. pharmacol., pharmacokinetics, drug interactions and clin. activity in phase I through phase III studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonPoiYaPWFU7Vg90H21EOLACvtfcHk0lgdpEyJVZMOng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsleitL0%253D&md5=02ecf3a4628b7204e8cd74a48b62a0a3</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1358%2Fdot.2011.47.11.1688487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2011.47.11.1688487%26sid%3Dliteratum%253Aachs%26aulast%3DBowles%26aufirst%3DD.%2BW.%26aulast%3DKessler%26aufirst%3DE.%2BR.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DMulti-targeted%2520tyrosine%2520kinase%2520inhibitors%2520in%2520clinical%2520development%253A%2520focus%2520on%2520XL-184%2520%2528cabozantinib%2529%26jtitle%3DDrugs%2520Today%26date%3D2011%26volume%3D47%26spage%3D857%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Durante, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrienti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filetti, S.</span><span> </span><span class="NLM_article-title">XL184 (cabozantinib) for medullary thyroid carcinoma</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">413</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=407-413&author=C.+Duranteauthor=D.+Russoauthor=A.+Verrientiauthor=S.+Filetti&title=XL184+%28cabozantinib%29+for+medullary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurante%26aufirst%3DC.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DVerrienti%26aufirst%3DA.%26aulast%3DFiletti%26aufirst%3DS.%26atitle%3DXL184%2520%2528cabozantinib%2529%2520for%2520medullary%2520thyroid%2520carcinoma%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D407%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Zillhardt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, I. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montag, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengyel, E.</span><span> </span><span class="NLM_article-title">Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4042</span><span class="NLM_x">–</span> <span class="NLM_lpage">4051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-3387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21551255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4042-4051&author=M.+Zillhardtauthor=S.+M.+Parkauthor=I.+L.+Romeroauthor=K.+Sawadaauthor=A.+Montagauthor=T.+Krauszauthor=S.+D.+Yamadaauthor=M.+E.+Peterauthor=E.+Lengyel&title=Foretinib+%28GSK1363089%29%2C+an+orally+available+multikinase+inhibitor+of+c-Met+and+VEGFR-2%2C+blocks+proliferation%2C+induces+anoikis%2C+and+impairs+ovarian+cancer+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis</span></div><div class="casAuthors">Zillhardt, Marion; Park, Sun-Mi; Romero, Iris L.; Sawada, Kenjiro; Montag, Anthony; Krausz, Thomas; Yamada, S. Diane; Peter, Marcus E.; Lengyel, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4042-4051</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Currently, there are no approved targeted therapies for the treatment of ovarian cancer, despite the fact that it is the most lethal gynecol. malignancy.  One proposed target is c-Met, which has been shown to be an important prognostic indicator in a no. of malignancies, including ovarian cancer.  The objective of this study was to det. whether an orally available multikinase inhibitor of c-Met and vascular endothelial growth factor receptor-2 (foretinib, GSK1363089) blocks ovarian cancer growth.  Exptl. Design: The effect of foretinib was tested in a genetic mouse model of endometrioid ovarian cancer, several ovarian cancer cell lines, and an organotypic 3D model of the human omentum.  RESULTS: In the genetic mouse model, treatment with foretinib prevented the progression of primary tumors to invasive adenocarcinoma.  Invasion through the basement membrane was completely blocked in treated mice, whereas in control mice, invasive tumors entirely replaced the normal ovary.  In 2 xenograft mouse models using human ovarian cancer cell lines, the inhibitor reduced overall tumor burden (86% inhibition, P < 0.0001) and metastasis (67% inhibition, P < 0.0001).  The mechanism of inhibition by foretinib involved (a) inhibition of c-Met activation and downstream signaling, (b) redn. of ovarian cancer cell adhesion, (c) a block in migration and invasion, (d) reduced proliferation mediated by a G2-M cell-cycle arrest, and (e) induction of anoikis.  CONCLUSIONS: This study shows that foretinib blocks tumorigenesis and reduces invasive tumor growth in different models of ovarian cancer by affecting several crit. tumor functions.  We believe that it provides a rationale for the further clin. development of foretinib for the treatment of ovarian cancer.  Clin Cancer Res; 17(12); 4042-51.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWG7ScxztDR7Vg90H21EOLACvtfcHk0lhoATbJkd5yHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKgt70%253D&md5=c38fa90e323957636493972d340cad83</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3387%26sid%3Dliteratum%253Aachs%26aulast%3DZillhardt%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DS.%2BM.%26aulast%3DRomero%26aufirst%3DI.%2BL.%26aulast%3DSawada%26aufirst%3DK.%26aulast%3DMontag%26aufirst%3DA.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DS.%2BD.%26aulast%3DPeter%26aufirst%3DM.%2BE.%26aulast%3DLengyel%26aufirst%3DE.%26atitle%3DForetinib%2520%2528GSK1363089%2529%252C%2520an%2520orally%2520available%2520multikinase%2520inhibitor%2520of%2520c-Met%2520and%2520VEGFR-2%252C%2520blocks%2520proliferation%252C%2520induces%2520anoikis%252C%2520and%2520impairs%2520ovarian%2520cancer%2520metastasis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4042%26epage%3D4051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Huynh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, K. C.</span><span> </span><span class="NLM_article-title">Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma</span> <span class="citation_source-journal">Angiogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=59-70&author=H.+Huynhauthor=R.+Ongauthor=K.+C.+Soo&title=Foretinib+demonstrates+anti-tumor+activity+and+improves+overall+survival+in+preclinical+models+of+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuynh%26aufirst%3DH.%26aulast%3DOng%26aufirst%3DR.%26aulast%3DSoo%26aufirst%3DK.%2BC.%26atitle%3DForetinib%2520demonstrates%2520anti-tumor%2520activity%2520and%2520improves%2520overall%2520survival%2520in%2520preclinical%2520models%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DAngiogenesis%26date%3D2012%26volume%3D15%26spage%3D59%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock-Bryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3507</span><span class="NLM_x">–</span> <span class="NLM_lpage">3516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-0574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20472683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3507-3516&author=J.+P.+Ederauthor=G.+I.+Shapiroauthor=L.+J.+Applemanauthor=A.+X.+Zhuauthor=D.+Milesauthor=H.+Keerauthor=B.+Cancillaauthor=F.+Chuauthor=S.+Hitchcock-Bryanauthor=L.+Shermanauthor=S.+McCallumauthor=E.+I.+Heathauthor=S.+A.+Boernerauthor=P.+M.+LoRusso&title=A+phase+I+study+of+foretinib%2C+a+multi-targeted+inhibitor+of+c-Met+and+vascular+endothelial+growth+factor+receptor+2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2</span></div><div class="casAuthors">Eder, Joseph Paul; Shapiro, Geoffrey I.; Appleman, Leonard J.; Zhu, Andrew X.; Miles, Dale; Keer, Harold; Cancilla, Belinda; Chu, Felix; Hitchcock-Bryan, Suzanne; Sherman, Laurie; McCallum, Stewart; Heath, Elisabeth I.; Boerner, Scott A.; Lo Russo, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3507-3516</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor.  We conducted a phase I, first-time-in-human, clin. trial using escalating doses of oral foretinib.  The primary objectives are to identify a max. tolerated dose and det. the safety profile of foretinib.  Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity.  Exptl. Design: Patients had histol. confirmed metastatic or unresectable solid tumors for which no std. measures exist.  All patients received foretinib orally for 5 consecutive days every 14 days.  Dose escalation followed a conventional "3+3" design.  RESULTS: Forty patients were treated in eight dose cohorts.  The max. tolerated dose was defined as 3.6 mg/kg, with a max. administered dose of 4.5 mg/kg.  Dose-limiting toxicities included grade 3 elevations in aspartate aminotransferase and lipase.  Addnl. non-dose-limiting adverse events included hypertension, fatigue, diarrhea, vomiting, proteinuria, and hematuria.  Responses were obsd. in two patients with papillary renal cell cancer and one patient with medullary thyroid cancer.  Stable disease was identified in 22 patients.  Foretinib pharmacokinetics increased linearly with dose.  Pharmacodynamic evaluation indicated inhibition of MET phosphorylation and decreased proliferation in select tumor biopsies at submaximal doses.  CONCLUSIONS: The recommended dose of foretinib was detd. to be 240 mg, given on the first 5 days of a 14-day cycle.  This dose and schedule were identified as having acceptable safety and pharmacokinetics, and will be the dose used in subsequent phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LAL1xiRe-rVg90H21EOLACvtfcHk0lhoATbJkd5yHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D&md5=d37b24383a08fdde5f78ed40b077963b</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0574%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DKeer%26aufirst%3DH.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DHitchcock-Bryan%26aufirst%3DS.%26aulast%3DSherman%26aufirst%3DL.%26aulast%3DMcCallum%26aufirst%3DS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520foretinib%252C%2520a%2520multi-targeted%2520inhibitor%2520of%2520c-Met%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3507%26epage%3D3516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Dumas, J.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors from the urea class</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">718</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2002&pages=718-727&author=J.+Dumas&title=Protein+kinase+inhibitors+from+the+urea+class"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDumas%26aufirst%3DJ.%26atitle%3DProtein%2520kinase%2520inhibitors%2520from%2520the%2520urea%2520class%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2002%26volume%3D5%26spage%3D718%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bichat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilbaud, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span> </span><span class="NLM_article-title">KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9134</span><span class="NLM_x">–</span> <span class="NLM_lpage">9142</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9134-9142&author=K.+Nakamuraauthor=E.+Taguchiauthor=T.+Miuraauthor=A.+Yamamotoauthor=K.+Takahashiauthor=F.+Bichatauthor=N.+Guilbaudauthor=K.+Hasegawaauthor=K.+Kuboauthor=Y.+Fujiwaraauthor=R.+Suzukiauthor=K.+Kuboauthor=M.+Shibuyaauthor=T.+Isoe&title=KRN951%2C+a+highly+potent+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases%2C+has+antitumor+activities+and+affects+functional+vascular+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DTaguchi%26aufirst%3DE.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DBichat%26aufirst%3DF.%26aulast%3DGuilbaud%26aufirst%3DN.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DKRN951%252C%2520a%2520highly%2520potent%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%252C%2520has%2520antitumor%2520activities%2520and%2520affects%2520functional%2520vascular%2520properties%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9134%26epage%3D9142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Eskens, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span> </span><span class="NLM_article-title">An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2034</span><div class="note"><p class="first last">; Asco Meeting Abstracts</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2034&author=F.+A.+Eskensauthor=A.+Plantingauthor=L.+Van+Doornauthor=T.+Isoeauthor=K.+Hayashiauthor=S.+Hussainauthor=L.+Ekmanauthor=H.+Burgerauthor=J.+Verweij&title=An+open-label+phase+I+dose+escalation+study+of+KRN951%2C+a+tyrosine+kinase+inhibitor+of+vascular+endothelial+growth+factor+receptor+2+and+1+in+a+4+week+on%2C+2+week+off+schedule+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%26aulast%3DPlanting%26aufirst%3DA.%26aulast%3DVan%2BDoorn%26aufirst%3DL.%26aulast%3DIsoe%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DEkman%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DVerweij%26aufirst%3DJ.%26atitle%3DAn%2520open-label%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520KRN951%252C%2520a%2520tyrosine%2520kinase%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520and%25201%2520in%2520a%25204%2520week%2520on%252C%25202%2520week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">De Luca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normanno, N.</span><span> </span><span class="NLM_article-title">Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20799147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGjurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=636-645&author=A.+De+Lucaauthor=N.+Normanno&title=Tivozanib%2C+a+pan-VEGFR+tyrosine+kinase+inhibitor+for+the+potential+treatment+of+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors</span></div><div class="casAuthors">De Luca, Antonella; Normanno, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">636-645</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Tivozanib (AV-951; KRN-951), being developed by AVEO Pharmaceuticals Inc and Kyowa Hakko Kirin Co Ltd, is an orally active, ATP-competitive, small-mol., quinoline-urea deriv. that inhibits VEGFR tyrosine kinase for the potential treatment of cancer.  In particular, tivozanib is able to markedly inhibit the ligand-induced phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3 at picomolar concns.  In preclin. studies, tivozanib produced a significant inhibition of tumor growth and angiogenesis in several different xenograft tumor models in athymic rats.  In a phase I clin. trial, tivozanib was safe and tolerable when administered at oral doses up to 1.5 mg on a schedule of 4 wk on, 2 wk off treatment.  Results from a phase II clin. trial in patients with advanced renal cell carcinoma reported an overall response rate of 25.4% and a median progression-free survival of 11.8 mo in patients treated with tivozanib as a single agent.  Hypertension and dysphonia were the most frequent adverse events.  At the time of publication, a phase III clin. trial was recruiting patients with advanced renal cancer to assess tivozanib in comparison with sorafenib.  Clin. trials are currently ongoing to evaluate the safety and antitumor activity of tivozanib in breast, lung and colorectal cancer.  Tivozanib might represent a promising anticancer agent in several different tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO2BkRsXc-krVg90H21EOLACvtfcHk0lgzgVkYe_VsCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGjurbL&md5=11c8a0fa9a6a09f982c925952d2369eb</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DNormanno%26aufirst%3DN.%26atitle%3DTivozanib%252C%2520a%2520pan-VEGFR%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520potential%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D636%26epage%3D645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Eskens, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jonge, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhargava, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotreau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomeer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span> </span><span class="NLM_article-title">Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7156</span><span class="NLM_x">–</span> <span class="NLM_lpage">7163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-11-0411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21976547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7156-7163&author=F.+A.+Eskensauthor=M.+J.+de+Jongeauthor=P.+Bhargavaauthor=T.+Isoeauthor=M.+M.+Cotreauauthor=B.+Estevesauthor=K.+Hayashiauthor=H.+Burgerauthor=M.+Thomeerauthor=L+van+Doornauthor=J.+Verweij&title=Biologic+and+clinical+activity+of+tivozanib+%28AV-951%2C+KRN-951%29%2C+a+selective+inhibitor+of+VEGF+receptor-1%2C+-2%2C+and+-3+tyrosine+kinases%2C+in+a+4-week-on%2C+2-week-off+schedule+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Eskens, Ferry A. L. M.; de Jonge, Maja J. A.; Bhargava, Pankaj; Isoe, Toshiyuki; Cotreau, Monette M.; Esteves, Brooke; Hayashi, Kunihiko; Burger, Herman; Thomeer, Maarten; van Doorn, Leni; Verweij, Jaap</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7156-7163</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To assess the max. tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF receptor (VEGFR) tyrosine kinase inhibitor.  Exptl. Design: Dose levels of 1.0, 1.5, and 2.0 mg/d tivozanib for 28 days followed by 14 days of medication were explored in patients with advanced solid tumors.  RESULTS: Forty-one patients were enrolled.  Animal data incorrectly predicted toxicity, resulting in DLTs at the starting dose (2.0 mg) consisting of grade 3 proteinuria and hypertension and grade 3 ataxia.  At 1.0 mg, no DLT was obsd.  At an intermediate dose (1.5 mg), 1 patient experienced DLT consisting of grade 3 hypertension.  This dose was detd. as the MTD.  Of 10 addnl. patients treated at 1.5 mg, 1 patient each experienced grade 3 hypertension and grade 3 fatigue, and 2 patients experienced grade 3 and 4 transaminase elevation.  In 12 addnl. patients treated at 1.0 mg, no DLT was obsd.  Pharmacokinetics displayed long absorption time, dose proportional exposure, and a half-life of 4.7 days.  Plasma levels of VEGF-A and sol. VEGFR-2 showed dose-dependent increases and decreases, resp.  Dynamic contrast-enhanced MRI indicated redn. in tumor perfusion.  Clin. activity was obsd. in renal cell cancer, colorectal cancer, and other tumors.  CONCLUSION: Tivozanib was well tolerated with manageable side effects.  The pharmacokinetics profile revealed that tivozanib was suitable for once-daily dosing.  Encouraging and durable clin. activity was obsd.  The recommended daily dose of tivozanib in a 4-wk-on and 2-wk-off dosing regimen is 1.5 mg.  Clin Cancer Res; 17(22); 7156-63.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH0XTrTm3PZLVg90H21EOLACvtfcHk0lgzgVkYe_VsCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7bJ&md5=553464e342dd352a47c125cb3e84f8ba</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0411%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%26aulast%3DBhargava%26aufirst%3DP.%26aulast%3DIsoe%26aufirst%3DT.%26aulast%3DCotreau%26aufirst%3DM.%2BM.%26aulast%3DEsteves%26aufirst%3DB.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DThomeer%26aufirst%3DM.%26aulast%3Dvan%2BDoorn%26aufirst%3DL%26aulast%3DVerweij%26aufirst%3DJ.%26atitle%3DBiologic%2520and%2520clinical%2520activity%2520of%2520tivozanib%2520%2528AV-951%252C%2520KRN-951%2529%252C%2520a%2520selective%2520inhibitor%2520of%2520VEGF%2520receptor-1%252C%2520-2%252C%2520and%2520-3%2520tyrosine%2520kinases%252C%2520in%2520a%25204-week-on%252C%25202-week-off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7156%26epage%3D7163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Nosov, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipatov, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyulko, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anischenko, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chacko, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doval, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strahs, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slichenmyer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhargava, P.</span><span> </span><span class="NLM_article-title">Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1678</span><span class="NLM_x">–</span> <span class="NLM_lpage">1685</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2011.35.3524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22493422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVKjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1678-1685&author=D.+A.+Nosovauthor=B.+Estevesauthor=O.+N.+Lipatovauthor=A.+A.+Lyulkoauthor=A.+A.+Anischenkoauthor=R.+T.+Chackoauthor=D.+C.+Dovalauthor=A.+Strahsauthor=W.+J.+Slichenmyerauthor=P.+Bhargava&title=Antitumor+activity+and+safety+of+tivozanib+%28AV-951%29+in+a+phase+II+randomized+discontinuation+trial+in+patients+with+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma</span></div><div class="casAuthors">Nosov, Dmitry A.; Esteves, Brooke; Lipatov, Oleg N.; Lyulko, Alexei A.; Anischenko, A. A.; Chacko, Raju T.; Doval, Dinesh C.; Strahs, Andrew; Slichenmyer, William J.; Bhargava, Pankaj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1678-1685</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The antitumor activity and safety of tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, was assessed in patients with advanced/metastatic renal cell carcinoma (RCC).  In this phase II, randomized discontinuation trial, 272 patients received open-label tivozanib 1.5 mg/d (one cycle equaled three treatment weeks followed by a 1-wk break) orally for 16 wk.  Thereafter, 78 patients who demonstrated ≥ 25% tumor shrinkage continued to take tivozanib, and 118 patients with less than 25% tumor change were randomly assigned to receive tivozanib or a placebo in a double-blind manner; patients with ≥ 25% tumor growth were discontinued.  Primary end points included safety, the objective response rate (ORR) at 16 wk, and the percentage of randomly assigned patients who remained progression free after 12 wk of double-blind treatment; secondary end points included progression-free survival (PFS).  Of 272 patients enrolled onto the study, 83% of patients had clear-cell histol., 73% of patients had undergone nephrectomy, and 54% of patients were treatment naive.  The ORR after 16 wk of tivozanib treatment was 18% (95% CI, 14% to 23%).  Of the 118 randomized patients, significantly more patients who were randomly assigned to receive double-blind tivozanib remained progression free after 12 wk vs. patients who received the placebo (49% v 21%; P = .001).  Throughout the study, the ORR was 24% (95% CI, 19% to 30%), and the median PFS was 11.7 mo (95% CI, 8.3 to 14.3 mo) in the overall study population.  The most common grade 3 and 4 treatment-related adverse event was hypertension (12%).  Tivozanib was active and well tolerated in patients with advanced RCC.  These data support addnl. development of tivozanib in advanced RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpenqlk93atmbVg90H21EOLACvtfcHk0lgjS9zjzNO5Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVKjtrY%253D&md5=4ceec72bbd500b3ade59e8573db40b52</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.3524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.3524%26sid%3Dliteratum%253Aachs%26aulast%3DNosov%26aufirst%3DD.%2BA.%26aulast%3DEsteves%26aufirst%3DB.%26aulast%3DLipatov%26aufirst%3DO.%2BN.%26aulast%3DLyulko%26aufirst%3DA.%2BA.%26aulast%3DAnischenko%26aufirst%3DA.%2BA.%26aulast%3DChacko%26aufirst%3DR.%2BT.%26aulast%3DDoval%26aufirst%3DD.%2BC.%26aulast%3DStrahs%26aufirst%3DA.%26aulast%3DSlichenmyer%26aufirst%3DW.%2BJ.%26aulast%3DBhargava%26aufirst%3DP.%26atitle%3DAntitumor%2520activity%2520and%2520safety%2520of%2520tivozanib%2520%2528AV-951%2529%2520in%2520a%2520phase%2520II%2520randomized%2520discontinuation%2520trial%2520in%2520patients%2520with%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1678%26epage%3D1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Matsui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span> </span><span class="NLM_article-title">Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5459</span><span class="NLM_x">–</span> <span class="NLM_lpage">5465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-07-5270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18765537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5459-5465&author=J.+Matsuiauthor=Y.+Funahashiauthor=T.+Uenakaauthor=T.+Watanabeauthor=A.+Tsuruokaauthor=M.+Asada&title=Multi-kinase+inhibitor+E7080+suppresses+lymph+node+and+lung+metastases+of+human+mammary+breast+tumor+MDA-MB-231+via+inhibition+of+vascular+endothelial+growth+factor-receptor+%28VEGF-R%29+2+and+VEGF-R3+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase</span></div><div class="casAuthors">Matsui, Junji; Funahashi, Yasuhiro; Uenaka, Toshimitsu; Watanabe, Tatsuo; Tsuruoka, Akihiko; Asada, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5459-5465</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Vascular endothelial growth factor (VEGF)-C/VEGF-receptor 3 (VEGF-R3) signal plays a significant role in lymphangiogenesis and tumor metastasis based on its effects on lymphatic vessels.  However, little is known about the effect of inhibiting VEGF-R3 on lymphangiogenesis and lymph node metastases using a small-mol. kinase inhibitor.  Exptl. Design: We evaluated the effect of E7080, a potent inhibitor of both VEGF-R2 and VEGF-R3 kinase, and bevacizumab on lymphangiogenesis and angiogenesis in a mammary fat pad xenograft model of human breast cancer using MDA-MB-231 cells that express excessive amts. of VEGF-C.  Lymphangiogenesis was detd. by lymphatic vessel d. (LVD) and angiogenesis by microvessel d. (MVD).  RESULTS: In contrast to MDA-MB-435 cells, which expressed a similar amt. of VEGF to MDA-MB-231 cells with an undetectable amt. of VEGF-C, only MDA-MB-231 exhibited lymphangiogenesis in the primary tumor.  E7080 but not bevacizumab significantly decreased LVD within the MDA-MB-231 tumor.  E7080 and bevacizumab decreased MVD in both the MDA-MB-231 and MDA-MB-435 models.  E7080 significantly suppressed regional lymph nodes and distant lung metastases of MDA-MB-231, whereas bevacizumab significantly inhibited only lung metastases.  E7080 also decreased both MVD and LVD within the metastatic nodules at lymph nodes after resection of the primary tumor.  CONCLUSIONS: Inhibition of VEGF-R3 kinase with E7080 effectively decreased LVD within MDA-MB-231 tumors, which express VEGF-C.  Simultaneous inhibition of both VEGF-R2 and VEGF-R3 kinases by E7080 may be a promising new strategy to control regional lymph node and distant lung metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrBisu80xI7Vg90H21EOLACvtfcHk0lgjS9zjzNO5Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbjP&md5=0a73511c46d0f668f09f84d89c718417</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-5270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-5270%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DAsada%26aufirst%3DM.%26atitle%3DMulti-kinase%2520inhibitor%2520E7080%2520suppresses%2520lymph%2520node%2520and%2520lung%2520metastases%2520of%2520human%2520mammary%2520breast%2520tumor%2520MDA-MB-231%2520via%2520inhibition%2520of%2520vascular%2520endothelial%2520growth%2520factor-receptor%2520%2528VEGF-R%2529%25202%2520and%2520VEGF-R3%2520kinase%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D5459%26epage%3D5465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Ikuta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trung, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanibuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sone, S.</span><span> </span><span class="NLM_article-title">E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7229</span><span class="NLM_x">–</span> <span class="NLM_lpage">7237</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-09-1980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19934291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSnu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=7229-7237&author=K.+Ikutaauthor=S.+Yanoauthor=V.+T.+Trungauthor=M.+Hanibuchiauthor=H.+Gotoauthor=Q.+Liauthor=W.+Wangauthor=T.+Yamadaauthor=H.+Oginoauthor=S.+Kakiuchiauthor=H.+Ueharaauthor=Y.+Sekidoauthor=T.+Uenakaauthor=Y.+Nishiokaauthor=S.+Sone&title=E7080%2C+a+multi-tyrosine+kinase+inhibitor%2C+suppresses+the+progression+of+malignant+pleural+mesothelioma+with+different+proangiogenic+cytokine+production+profiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles</span></div><div class="casAuthors">Ikuta, Kenji; Yano, Seiji; Trung, Van-The; Hanibuchi, Masaki; Goto, Hisatsugu; Li, Qi; Wang, Wei; Yamada, Tadaaki; Ogino, Hirokazu; Kakiuchi, Soji; Uehara, Hisanori; Sekido, Yoshitaka; Uenaka, Toshimitsu; Nishioka, Yasuhiko; Sone, Saburo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7229-7237</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Malignant pleural mesothelioma (MPM) is a biol. heterogeneous malignant disease with a poor prognosis.  We reported previously that the anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, effectively inhibited the progression of VEGF-high-producing (but not VEGF-low-producing) MPM cells in orthotopic implantation models, indicating the need for novel therapeutic strategies to improve the poor prognosis of this disease.  Therefore, we focused on the multi-tyrosine kinase inhibitor E7080 and assessed its therapeutic efficacy against MPM cells with different proangiogenic cytokine prodn. profiles.  Exptl. Design: The efficacy of E7080 was assayed in orthotopic implantation of severe combined immunodeficient mouse models with three human MPM cell lines (MSTO-211H, NCI-H290, and Y-MESO-14).  Results: With regard to proangiogenic cytokine prodn. profiles, MSTO-211H and Y-MESO-14 cells were MPM cells producing high levels of fibroblast growth factor-2 and VEGF, resp.  NCI-H290 cells produced low levels of fibroblast growth factor-2 and VEGF compared with the other two cell lines.  E7080 potently suppressed the phosphorylation of VEGF receptor-2 and FGF receptor 1 and, thus, inhibited proliferation of endothelial cells, but not that of the MPM cell lines, in vitro.  Orthotopically inoculated MSTO-211H cells produced only thoracic tumors, whereas NCI-H290 and Y-MESO-14 cells also developed pleural effusions.  Treatment with E7080 potently inhibited the progression of these three MPM cell lines and markedly prolonged mouse survival, which was assocd. with decreased nos. of tumor-assocd. vessels and proliferating MPM cells in the tumor.  Conclusions: These results strongly suggest broad-spectrum activity of E7080 against MPM with different proangiogenic cytokine prodn. profiles in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe_SW2h8GtULVg90H21EOLACvtfcHk0ljIAW_9wkrWQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSnu7zF&md5=d2951fa3185a26e695d2fd6a95625ebc</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1980%26sid%3Dliteratum%253Aachs%26aulast%3DIkuta%26aufirst%3DK.%26aulast%3DYano%26aufirst%3DS.%26aulast%3DTrung%26aufirst%3DV.%2BT.%26aulast%3DHanibuchi%26aufirst%3DM.%26aulast%3DGoto%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DOgino%26aufirst%3DH.%26aulast%3DKakiuchi%26aufirst%3DS.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DSekido%26aufirst%3DY.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DE7080%252C%2520a%2520multi-tyrosine%2520kinase%2520inhibitor%252C%2520suppresses%2520the%2520progression%2520of%2520malignant%2520pleural%2520mesothelioma%2520with%2520different%2520proangiogenic%2520cytokine%2520production%2520profiles%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D7229%26epage%3D7237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Bruheim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fodstad, Ø.</span><span> </span><span class="NLM_article-title">Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1002%2Fijc.25922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21225632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFGitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=742-750&author=S.+Bruheimauthor=A.+Kristianauthor=T.+Uenakaauthor=Z.+Suoauthor=A.+Tsuruokaauthor=J.+M.+Neslandauthor=%C3%98.+Fodstad&title=Antitumour+activity+of+oral+E7080%2C+a+novel+inhibitor+of+multiple+tyrosine+kinases%2C+in+human+sarcoma+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts</span></div><div class="casAuthors">Bruheim, Skjalg; Kristian, Alexandr; Uenaka, Toshimitsu; Suo, Zhenhe; Tsuruoka, Akihiko; Nesland, Jahn M.; Fodstad, Oystein</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">E7080 is an inhibitor of multiple tyrosine kinases, several of which have pro-angiogenic properties, including receptors for VEGF, FGF, SCF, and PDGF.  We undertook our study to evaluate the preclin. activity of E7080 in human sarcomas.  The antitumor activity of orally administered E7080 was tested in 10 human tumor xenografts representing different sarcoma histotypes.  Concomitant changes in microvessel d. were assayed by immunohistochem. to CD31.  Immunohistochem. was also used to assess the expression of kinases that E7080 is known to inhibit.  The MTS assay was applied to det. effects on tumor cell viability in vitro.  At the Q1D5 × 2 schedule, E7080 (30 mg/kg) was active (T/C<40%) in 7/10 xenografts.  The effects were accompanied by marked decrease in microvessel densities.  Given at the Q1D5 × 4 schedule, E7080 (30, 10, 3 mg/kg) showed antitumor activity in a dose dependent manner in 2 different xenografts.  E7080 growth inhibition did not correlate with the expression of VEGFR1-3, PDGFRA, PDGFRB, FGFR1, or KIT on tumor cells but was significantly correlated with expression of VEGFR2 on tumor microvessels.  In vitro E7080 did not show potent effects on tumor cell viability in 4 different sarcoma cell lines, with IC50 values ≥10 μM.  In conclusion, E7080 showed broad in vivo antitumor activity in sarcoma, mainly attributable to angiogenesis inhibition.  E7080 was also active in xenografts resistant to one or more clin. relevant ref. drugs given at MTD (doxorubicin, cisplatin, or ifosfamide).  The present results encourage further investigation of a potential role of E7080 in sarcoma therapy in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOQpVNIGK-17Vg90H21EOLACvtfcHk0ljIAW_9wkrWQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFGitbw%253D&md5=dd53f080a9d3cc03f94533bd349a7b8a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1002%2Fijc.25922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25922%26sid%3Dliteratum%253Aachs%26aulast%3DBruheim%26aufirst%3DS.%26aulast%3DKristian%26aufirst%3DA.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DSuo%26aufirst%3DZ.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DNesland%26aufirst%3DJ.%2BM.%26aulast%3DFodstad%26aufirst%3D%25C3%2598.%26atitle%3DAntitumour%2520activity%2520of%2520oral%2520E7080%252C%2520a%2520novel%2520inhibitor%2520of%2520multiple%2520tyrosine%2520kinases%252C%2520in%2520human%2520sarcoma%2520xenografts%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D742%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Gild, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clifton-Bligh, R.</span><span> </span><span class="NLM_article-title">Multikinase inhibitors: a new option for the treatment of thyroid cancer</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrendo.2011.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21862995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=617-624&author=M.+L.+Gildauthor=M.+Bullockauthor=B.+G.+Robinsonauthor=R.+Clifton-Bligh&title=Multikinase+inhibitors%3A+a+new+option+for+the+treatment+of+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Multikinase inhibitors: a new option for the treatment of thyroid cancer</span></div><div class="casAuthors">Gild, Matti L.; Bullock, Martyn; Robinson, Bruce G.; Clifton-Bligh, Roderick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">617-624</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Preclin. models have shown that inhibition of kinases in mitogenic and angiogenic signaling pathways can have antitumoral effects.  Starting with a brief synopsis of a malignancy that responds well to kinase inhibition (chronic myeloid leukemia) compared with one with less durable responses as yet (melanoma), this Review highlights challenges that must be overcome in order to successfully translate small-mol. therapies to thyroid cancer in the future.  Thyroid cancer typically has a good outcome following std. treatments, which include surgery, radioactive iodine ablation and treatment with TSH-suppressive levothyroxine.  Thyroid cancers that persist or recur following these therapies have a poorer prognosis.  Activation of mitogenic and angiogenic signaling pathways occurs in these cancers, and preclin. models have shown that inhibition of key kinase steps in these pathways can have antitumoral effects.  Several of these kinase inhibitors have now been tested in phase II and phase III trials, with modestly encouraging results.  Some promising data exist for the use of vandetanib (also known as ZD6474), motesanib, axitinib, cabozantinib (also known as XL184), sorafenib, sunitinib, pazopanib and lenvatinib (also known as E7080) in progressive thyroid cancer of medullary, papillary and follicular subtypes.  These drugs are generally well-tolerated, although dose-limiting toxicities are common, and a few (probable) treatment-related deaths have been reported.  Addnl. phase III trials will be needed to conclusively show that treatment benefit exceeds risk.  Drug resistance can occur via activation of alternate mitogenic signals (pathway switching), as has been reported for the use of kinase inhibitors in other malignancies, such as melanoma.  The hypothesis that combinations of kinase inhibitors targeting different pathways might produce better results is currently being tested in several clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXsZ46UZpqrbVg90H21EOLACvtfcHk0ljIAW_9wkrWQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajsr3F&md5=7ac1c2c3f6693ac567c1c2000eda01c0</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2011.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2011.141%26sid%3Dliteratum%253Aachs%26aulast%3DGild%26aufirst%3DM.%2BL.%26aulast%3DBullock%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DClifton-Bligh%26aufirst%3DR.%26atitle%3DMultikinase%2520inhibitors%253A%2520a%2520new%2520option%2520for%2520the%2520treatment%2520of%2520thyroid%2520cancer%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2011%26volume%3D7%26spage%3D617%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nokihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koizumi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-2638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21372218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2528-2537&author=K.+Yamadaauthor=N.+Yamamotoauthor=Y.+Yamadaauthor=H.+Nokiharaauthor=Y.+Fujiwaraauthor=T.+Hirataauthor=F.+Koizumiauthor=K.+Nishioauthor=N.+Koyamaauthor=T.+Tamura&title=Phase+I+dose-escalation+study+and+biomarker+analysis+of+E7080+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Yamada, Kazuhiko; Yamamoto, Noboru; Yamada, Yasuhide; Nokihara, Hiroshi; Fujiwara, Yutaka; Hirata, Taizo; Koizumi, Fumiaki; Nishio, Kazuto; Koyama, Noriyuki; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2528-2537</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">E7080, an oral multitargeted receptor tyrosine kinase inhibitor, has antiangiogenic and antitumor activity.  This Phase I study investigated max. tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in patients with advanced solid tumors.  In this sequential, dose-escalation, open-label study E7080 was administered orally twice daily in a 2-wk-on/1-wk-off cycle.  Plasma angiogenic proteins, circulating endothelial cells (CEC) and circulating progenitor cells (CEP) were measured for biomarker anal.  27 Patients (median age 53 years, performance status 0/1) were enrolled.  E7080 was escalated from 0.5 to 1, 2, 4, 6, 9, 13, 16, and 20 mg bid by conventional 3-patient cohorts.  During cycle 1, no grade 3/4 toxicity was obsd. up to 13 mg bid.  DLTs included grade 3 AST/ALT increase in 1 patient at 16 mg bid and grade 3 platelet count decrease in 2 patients at 20 mg bid.  The MTD of 13 mg bid was detd.  After repeated doses, Cmax and area under the plasma concn.-time curve increased in a dose-dependent manner.  After 14 days' treatment, c-kit(+) CEPs and CECs significantly decreased in cycle 1, but c-kit(-) CEPs and CECs did not.  Change from baseline in c-kit(+) CEC ratio in cycle 1 and baseline SDF1α, c-kit(+) CEPs and c-kit(+) CEP ratio significantly correlated with the E7080 therapeutic effect.  E7080 has manageable toxicity up to 13 mg bid when administered in a 2-wk-on/1-wk-off cycle and shows preliminary activity for durable disease control.  Biomarker anal. suggested antiangiogenic activity correlated with antitumor activity in patients with a wide range of solid tumors.  Clin Cancer Res; 17(8); 2528-37.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxPI3w_iSeVLVg90H21EOLACvtfcHk0ljEz5Gn-nWOgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgtL8%253D&md5=b64b561784f68928d1ff513143f013c4</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2638%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DKoizumi%26aufirst%3DF.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DKoyama%26aufirst%3DN.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520and%2520biomarker%2520analysis%2520of%2520E7080%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2528%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keesen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tait, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copalu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanders, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. R.</span><span> </span><span class="NLM_article-title">A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1598</span><span class="NLM_x">–</span> <span class="NLM_lpage">1604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fbjc.2012.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22516948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=1598-1604&author=D.+S.+Bossauthor=H.+Glenauthor=J.+H.+Beijnenauthor=M.+Keesenauthor=R.+Morrisonauthor=B.+Taitauthor=W.+Copaluauthor=A.+Mazurauthor=J.+Wandersauthor=J.+P.+O%E2%80%99Brienauthor=J.+H.+Schellensauthor=T.+R.+Evans&title=A+phase+I+study+of+E7080%2C+a+multitargeted+tyrosine+kinase+inhibitor%2C+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours</span></div><div class="casAuthors">Boss, D. S.; Glen, H.; Beijnen, J. H.; Keesen, M.; Morrison, R.; Tait, B.; Copalu, W.; Mazur, A.; Wanders, J.; O'Brien, J. P.; Schellens, J. H. M.; Evans, T. R. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1598-1604</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumors; to det. the max. tolerated dose (MTD) and pharmacokinetics profile of E7080; and to explore preliminary evidence of its anti-tumor efficacy.  Methods: E7080 was administered orally in escalating doses on a once-daily continuous schedule in 28-day cycles to eligible patients.  Samples for pharmacokinetic analyses were collected on days 1, 8, 15 and 22 of cycle 1 and day 1 of cycle 2.  Anti-tumor efficacy was assessed every two cycles.  Results: Eighty-two patients received E7080 in dose cohorts from 0.2 to 32 mg.  Dose-limiting toxicities were grade 3 proteinuria (two patients) at 32 mg, and the MTD was defined as 25 mg.  The most frequently obsd. cumulative toxicities (all grades) were hypertension (40% of patients), diarrhea (45%), nausea (37%), stomatitis (32%) and vomiting (23%).  Seven patients (9%) had a partial response and 38 patients (46%) had stable disease as best response.  E7080 has dose-linear kinetics with no drug accumulation after 4 wk administration.  Conclusion: E7080 is well tolerated at doses up to 25 mg per day.  Encouraging anti-tumor efficacy was obsd. in patients with melanoma and renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhiK54hAkTpbVg90H21EOLACvtfcHk0ljEz5Gn-nWOgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFajsb8%253D&md5=2bb367d69a6dfb5a94cbf1720a52224d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.154%26sid%3Dliteratum%253Aachs%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DGlen%26aufirst%3DH.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DKeesen%26aufirst%3DM.%26aulast%3DMorrison%26aufirst%3DR.%26aulast%3DTait%26aufirst%3DB.%26aulast%3DCopalu%26aufirst%3DW.%26aulast%3DMazur%26aufirst%3DA.%26aulast%3DWanders%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BP.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DT.%2BR.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520E7080%252C%2520a%2520multitargeted%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D106%26spage%3D1598%26epage%3D1604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Bello, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlato, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valbusa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incalci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalletti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camboni, G.</span><span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1396</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1396%26epage%3D1405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Sala, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cereda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incalci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucchetti, M.</span><span> </span><span class="NLM_article-title">Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study</span> <span class="citation_source-journal">J. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=1039-1045&author=F.+Salaauthor=R.+Bagnatiauthor=V.+Liviauthor=R.+Ceredaauthor=M.+D%E2%80%99Incalciauthor=M.+Zucchetti&title=Development+and+validation+of+a+high-performance+liquid+chromatography-tandem+mass+spectrometry+method+for+the+determination+of+the+novel+inhibitor+of+angiogenesis+E-3810+in+human+plasma+and+its+application+in+a+clinical+pharmacokinetic+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSala%26aufirst%3DF.%26aulast%3DBagnati%26aufirst%3DR.%26aulast%3DLivi%26aufirst%3DV.%26aulast%3DCereda%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DZucchetti%26aufirst%3DM.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520high-performance%2520liquid%2520chromatography-tandem%2520mass%2520spectrometry%2520method%2520for%2520the%2520determination%2520of%2520the%2520novel%2520inhibitor%2520of%2520angiogenesis%2520E-3810%2520in%2520human%2520plasma%2520and%2520its%2520application%2520in%2520a%2520clinical%2520pharmacokinetic%2520study%26jtitle%3DJ.%2520Mass%2520Spectrom.%26date%3D2011%26volume%3D46%26spage%3D1039%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Cai, S.; Chou, J.; Harwood, E.; Machajewski, T. D.; Ryckman, D.; Shang, X.; Zhu, S.</span><span> </span><span class="NLM_article-title">Preparation of Benzimidazole Quinolinones and Lactate Salts Thereof for Inhibiting Vascular Endothelial Growth Factor Receptor Tyrosine Kinase</span>. WO 2005046589,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=S.+Cai&author=J.+Chou&author=E.+Harwood&author=T.+D.+Machajewski&author=D.+Ryckman&author=X.+Shang&author=S.+Zhu&title=Preparation+of+Benzimidazole+Quinolinones+and+Lactate+Salts+Thereof+for+Inhibiting+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Benzimidazole%2520Quinolinones%2520and%2520Lactate%2520Salts%2520Thereof%2520for%2520Inhibiting%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Renhowe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machajewski, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonios-McCrea, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aardalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernette-Hammond, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span> </span><span class="NLM_article-title">Design, structure–activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800790t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=278-292&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure%E2%80%93activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+a+novel+class+of+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm800790t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800790t%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure%25E2%2580%2593activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D278%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopes de Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordahl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aukerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelb, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span> </span><span class="NLM_article-title">In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3633</span><span class="NLM_x">–</span> <span class="NLM_lpage">3641</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-04-2129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=15897558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFyrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3633-3641&author=S.+H.+Leeauthor=D.+Lopes+de+Menezesauthor=J.+Voraauthor=A.+Harrisauthor=H.+Yeauthor=L.+Nordahlauthor=E.+Garrettauthor=E.+Samaraauthor=S.+L.+Aukermanauthor=A.+B.+Gelbauthor=C.+Heise&title=In+vivo+target+modulation+and+biological+activity+of+CHIR-258%2C+a+multitargeted+growth+factor+receptor+kinase+inhibitor%2C+in+colon+cancer+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models</span></div><div class="casAuthors">Lee, Sang Hoon; Lopes de Menezes, Daniel; Vora, Jayesh; Harris, Alex; Ye, Helen; Nordahl, Lara; Garrett, Evelyn; Samara, Emil; Aukerman, Sharon Lea; Gelb, Arnold B.; Heise, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3633-3641</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To evaluate the therapeutic and biol. effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases, in colon cancer models.  Exptl. Design: The pharmacol. activity of CHIR-258 was characterized by monitoring target modulation as well as by evaluating the antitumor and antiangiogenic effects in human colon xenograft models.  Results: CHIR-258 inhibits vascular endothelial growth factor receptor 1/2, fibroblast growth factor receptor 1/3, and platelet-derived growth factor receptor β (PDGFRβ) and shows both antitumor and antiangiogenic activities in vivo.  Treatment of KM12L4a human colon cancer cells with CHIR-258 resulted in a dose-dependent inhibition of vascular endothelial growth factor receptor 1 and PDGFRβ phosphorylation and redn. of phosphorylated extracellular signal-regulated kinase (ERK) levels, indicating modulation of target receptors and downstream signaling.  In vivo administration of CHIR-258 resulted in significant tumor growth inhibition and tumor regressions, including large, established tumors (500-1,000 mm3).  Immunohistochem. anal. showed a redn. of phosphorylated PDGFRβ and phosphorylated ERK in tumor cells after oral dosing with CHIR-258 compared with control tumors.  These changes were accompanied by decreased tumor cell proliferation rate and reduced intratumoral microvessel d.  CHIR-258 inhibited the phosphorylation of PDGFRβ and ERK phosphorylation in tumors within 2 h following dosing and the inhibitory activity was sustained for >24 h.  Significant antitumor activity was obsd. with intermittent dosing schedules, indicating a sustained biol. activity.  Conclusion: These studies provide evidence that biol. activity of CHIR-258 in tumors correlates with efficacy and aids in the identification of potential biomarkers of this multitargeted receptor tyrosine kinase inhibitor.  CHIR-258 exhibits properties that make it a promising candidate for clin. development in a variety of solid and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBYM9bzT_QQLVg90H21EOLACvtfcHk0lj6sRz3k5vSmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFyrsb4%253D&md5=eeca79fe190dcdc2db251d6e836ec4ab</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2129%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLopes%2Bde%2BMenezes%26aufirst%3DD.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DNordahl%26aufirst%3DL.%26aulast%3DGarrett%26aufirst%3DE.%26aulast%3DSamara%26aufirst%3DE.%26aulast%3DAukerman%26aufirst%3DS.%2BL.%26aulast%3DGelb%26aufirst%3DA.%2BB.%26aulast%3DHeise%26aufirst%3DC.%26atitle%3DIn%2520vivo%2520target%2520modulation%2520and%2520biological%2520activity%2520of%2520CHIR-258%252C%2520a%2520multitargeted%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%252C%2520in%2520colon%2520cancer%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D3633%26epage%3D3641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Lopes de Menezes, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shephard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldbeck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aukerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span> </span><span class="NLM_article-title">CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5281</span><span class="NLM_x">–</span> <span class="NLM_lpage">5291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-05-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16033847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt12qurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5281-5291&author=D.+E.+Lopes+de+Menezesauthor=J.+Pengauthor=E.+N.+Garrettauthor=S.+G.+Louieauthor=S.+H.+Leeauthor=M.+Wiesmannauthor=Y.+Tangauthor=L.+Shephardauthor=C.+Goldbeckauthor=Y.+Oeiauthor=H.+Yeauthor=S.+L.+Aukermanauthor=C.+Heise&title=CHIR-258%3A+a+potent+inhibitor+of+FLT3+kinase+in+experimental+tumor+xenograft+models+of+human+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia</span></div><div class="casAuthors">Lopes de Menezes, Daniel E.; Peng, Jing; Garrett, Evelyn N.; Louie, Sharianne G.; Lee, Sang H.; Wiesmann, Marion; Tang, Yan; Shephard, Lee; Goldbeck, Cheryl; Oei, Yoko; Ye, Helen; Aukerman, Sharon L.; Heise, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5281-5291</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fms-like tyrosine kinase 3 (FLT3) encodes a receptor tyrosine kinase (RTK) for which activating mutations have been identified in a proportion of acute myelogenous leukemia (AML) patients and assocd. with poor clin. prognosis.  Given the relevance of FLT3 mutations in AML, we investigated the activity of CHIR-258, an orally active, multitargeted small mol., with potent activity against FLT3 kinase and class III, IV, and V RTKs involved in endothelial and tumor cell proliferation in AML models.  Exptl. Design: CHIR-258 was tested on two human leukemic cell lines in vitro and in vivo with differing FLT3 mutational status [MV4;11 cells express FLT3 internal tandem duplications (ITD) vs. RS4;11 cells with wild-type (WT) FLT3].  Results: Antiproliferative activity of CHIR-258 against MV4;11 was ∼24-fold greater compared with RS4;11, indicating more potent inhibition against cells with constitutively activated FLT3 ITD.  Dose-dependent down modulation of receptor phosphorylation and downstream signaling [signal transducer and activator of transcription 5 (STAT5) and extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase] in MV4;11 cells with CHIR-258 confirmed the mol. mechanism of action.  Target modulation of phospho-FLT3, phospho-STAT5, and phospho-ERK in MV4;11 tumors was achieved at biol. active doses of CHIR-258.  Tumor regressions and eradication of AML cells from the bone marrow were shown in s.c. and bone marrow engraftment leukemic xenograft models.  Tumor responses were characterized by decreased cellular proliferation and pos. immunohistochem. staining for active caspase-3 and cleaved poly(ADP-ribose) polymerase, suggesting cell death was mediated in part via apoptosis.  Conclusions: These data indicate that CHIR-258 may be an effective therapy in FLT3-assocd. AML and warrants clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqguTG7oB17arVg90H21EOLACvtfcHk0lhenGZkibZ8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt12qurc%253D&md5=81dc564d120f28420fdd69f685f877c2</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0358%26sid%3Dliteratum%253Aachs%26aulast%3DLopes%2Bde%2BMenezes%26aufirst%3DD.%2BE.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DGarrett%26aufirst%3DE.%2BN.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DShephard%26aufirst%3DL.%26aulast%3DGoldbeck%26aufirst%3DC.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DAukerman%26aufirst%3DS.%2BL.%26aulast%3DHeise%26aufirst%3DC.%26atitle%3DCHIR-258%253A%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520kinase%2520in%2520experimental%2520tumor%2520xenograft%2520models%2520of%2520human%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5281%26epage%3D5291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Xin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbach, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rendahl, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oei, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Embry, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinarski, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryer, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trudel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jallal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. C.</span><span> </span><span class="NLM_article-title">CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4908</span><span class="NLM_x">–</span> <span class="NLM_lpage">4915</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-06-0957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16914579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4908-4915&author=X.+Xinauthor=T.+J.+Abramsauthor=P.+W.+Hollenbachauthor=K.+G.+Rendahlauthor=Y.+Tangauthor=Y.+A.+Oeiauthor=M.+G.+Embryauthor=D.+E.+Swinarskiauthor=E.+N.+Garrettauthor=N.+K.+Pryerauthor=S.+Trudelauthor=B.+Jallalauthor=D.+B.+Mendelauthor=C.+C.+Heise&title=CHIR-258+is+efficacious+in+a+newly+developed+fibroblast+growth+factor+receptor+3-expressing+orthotopic+multiple+myeloma+model+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3-Expressing Orthotopic Multiple Myeloma Model in Mice</span></div><div class="casAuthors">Xin, Xiaohua; Abrams, Tinya J.; Hollenbach, Paul W.; Rendahl, Katherine G.; Tang, Yan; Oei, Yoko A.; Embry, Millicent G.; Swinarski, Debbie E.; Garrett, Evelyn N.; Pryer, Nancy K.; Trudel, Suzanne; Jallal, Bahija; Mendel, Dirk B.; Heise, Carla C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4908-4915</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) results from a t(4;14) chromosomal translocation that occurs in ∼15% of multiple myeloma (MM) patients and confers a particularly poor prognosis.  This study assesses the antimyeloma activity of CHIR-258, a small-mol. inhibitor of multiple receptor tyrosine kinases that is currently in phase I trials, in a newly developed FGFR3-driven preclin. MM animal model.  Exptl. Design: the authors developed an orthotopic MM model in mice using a luciferase-expressing human KMS-11-luc line that expresses mutant FGFR3 (Y373C).  The antimyeloma activity of CHIR-258 was evaluated at doses that inhibited FGFR3 signaling in vivo in this FGFR3-driven animal model.  RESULTS: Noninvasive bioluminescence imaging detected MM lesions in nearly all mice injected with KMS-11-luc cells, which were mainly localized in the spine, skull, and pelvis, resulting in frequent development of paralysis.  Daily oral administration of CHIR-258 at doses that inhibited FGFR3 signaling in KMS-11-luc tumors in vivo resulted in a significant inhibition of KMS-11-luc tumor growth, which translated into a significant improvement in animal survival.  CONCLUSIONS: the authors' data provide a relevant preclin. basis for clin. trials of CHIR-258 in FGFR3-pos. MM patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoitvR-0TUV87Vg90H21EOLACvtfcHk0lhenGZkibZ8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKgt7g%253D&md5=af3f47f59ecf0593cbaf07db17d54fe3</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0957%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DX.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DHollenbach%26aufirst%3DP.%2BW.%26aulast%3DRendahl%26aufirst%3DK.%2BG.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DOei%26aufirst%3DY.%2BA.%26aulast%3DEmbry%26aufirst%3DM.%2BG.%26aulast%3DSwinarski%26aufirst%3DD.%2BE.%26aulast%3DGarrett%26aufirst%3DE.%2BN.%26aulast%3DPryer%26aufirst%3DN.%2BK.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DJallal%26aufirst%3DB.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26atitle%3DCHIR-258%2520is%2520efficacious%2520in%2520a%2520newly%2520developed%2520fibroblast%2520growth%2520factor%2520receptor%25203-expressing%2520orthotopic%2520multiple%2520myeloma%2520model%2520in%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D4908%26epage%3D4915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span> </span><span class="NLM_article-title">Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7451</span><span class="NLM_x">–</span> <span class="NLM_lpage">7461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-11-1747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21976540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7451-7461&author=K.+B.+Kimauthor=J.+Chesneyauthor=D.+Robinsonauthor=H.+Gardnerauthor=M.+M.+Shiauthor=J.+M.+Kirkwood&title=Phase+I%2FII+and+pharmacodynamic+study+of+dovitinib+%28TKI258%29%2C+an+inhibitor+of+fibroblast+growth+factor+receptors+and+VEGF+receptors%2C+in+patients+with+advanced+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma</span></div><div class="casAuthors">Kim, Kevin B.; Chesney, Jason; Robinson, Douglas; Gardner, Humphrey; Shi, Michael M.; Kirkwood, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7451-7461</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Dovitinib (TKI258) is an orally available inhibitor of fibroblast growth factor (FGF), VEGF, and platelet-derived growth factor receptors.  This phase I/II dose-escalation study was conducted to evaluate the safety, pharmacodynamics, and preliminary efficacy of dovitinib in the treatment of advanced melanoma.  Exptl. Design: Patients with advanced melanoma resistant or refractory to std. therapies or for whom no std. therapy was available were enrolled.  Dovitinib was administered at doses ranging from 200 to 500 mg/d.  RESULTS: Forty-seven patients were enrolled.  The most frequently reported adverse events were fatigue (77%; grade ≥3, 28%), diarrhea (77%; grade ≥3, 11%), and nausea (77%; grade ≥3, 9%).  Six dose-limiting toxicities were obsd. in the 400-mg and 500-mg dose cohorts, which consisted of grade 3 nausea, fatigue, and diarrhea and grade 4 fatigue events.  The max. tolerated dose was 400 mg/d.  The best tumor response was stable disease, which was obsd. in 12 patients.  Increases in plasma FGF23, VEGF, and placental growth factor and decreases in sol. VEGF receptor 2 were noted during the first cycle of treatment, consistent with FGF receptor (FGFR) and VEGF receptor (VEGFR) inhibition.  Dynamic contrast-enhanced MRI anal. showed a dose-dependent decrease in tumor blood flow and vascular permeability with dovitinib therapy.  A decrease in FGFR phosphorylation was obsd. in paired tumor biopsy samples from a patient treated with dovitinib at a dose of 400 mg/d.  CONCLUSIONS: At a dose of 400 mg/d, dovitinib showed an acceptable safety profile and limited clin. benefit and inhibited FGFR and VEGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovyP40Cwt1A7Vg90H21EOLACvtfcHk0lhenGZkibZ8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrbF&md5=b477d8c021c7e18ef4d5f3bfb02f8d58</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1747%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DChesney%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DM.%2BM.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26atitle%3DPhase%2520I%252FII%2520and%2520pharmacodynamic%2520study%2520of%2520dovitinib%2520%2528TKI258%2529%252C%2520an%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520and%2520VEGF%2520receptors%252C%2520in%2520patients%2520with%2520advanced%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7451%26epage%3D7461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawver, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">5120</span><span class="NLM_x">–</span> <span class="NLM_lpage">5130</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9904295" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=5120-5130&author=L.+Sunauthor=N.+Tranauthor=C.+Liangauthor=F.+Tangauthor=A.+Riceauthor=R.+Schreckauthor=K.+Waltzauthor=L.+K.+Shawverauthor=G.+McMahonauthor=C.+Tang&title=Design%2C+synthesis%2C+and+evaluations+of+substituted+3-%5B%283-+or+4-carboxyethylpyrrol-2-yl%29methylidenyl%5Dindolin-2-ones+as+inhibitors+of+VEGF%2C+FGF%2C+and+PDGF+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Fjm9904295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9904295%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DRice%26aufirst%3DA.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DWaltz%26aufirst%3DK.%26aulast%3DShawver%26aufirst%3DL.%2BK.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluations%2520of%2520substituted%25203-%255B%25283-%2520or%25204-carboxyethylpyrrol-2-yl%2529methylidenyl%255Dindolin-2-ones%2520as%2520inhibitors%2520of%2520VEGF%252C%2520FGF%252C%2520and%2520PDGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D5120%26epage%3D5130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiramatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, H.</span><span> </span><span class="NLM_article-title">TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model</span> <span class="citation_source-journal">Surg. Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1053</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00595-009-4020-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19997799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFanu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=1046-1053&author=M.+Ohtaauthor=T.+Kawabataauthor=M.+Yamamotoauthor=T.+Tanakaauthor=H.+Kikuchiauthor=Y.+Hiramatsuauthor=K.+Kamiyaauthor=M.+Babaauthor=H.+Konno&title=TSU68%2C+an+antiangiogenic+receptor+tyrosine+kinase+inhibitor%2C+induces+tumor+vascular+normalization+in+a+human+cancer+xenograft+nude+mouse+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model</span></div><div class="casAuthors">Ohta, Manabu; Kawabata, Toshiki; Yamamoto, Masayoshi; Tanaka, Tatsuo; Kikuchi, Hirotoshi; Hiramatsu, Yoshihiro; Kamiya, Kinji; Baba, Megumi; Konno, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Surgery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1046-1053</span>CODEN:
                <span class="NLM_cas:coden">SUTOE5</span>;
        ISSN:<span class="NLM_cas:issn">0941-1291</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">Purpose: Combination therapy using antiangiogenic and cytotoxic agents is a useful strategy for advanced cancer, but the mechanism has not yet been elucidated.  Moreover, there is a persistent paradox that destroying tumor vasculature with antiangiogenic agents disturbs the delivery of cytotoxic agents.  It has been hypothesized that antiangiogenic agents can lead to normalization of tumor vessels that are structurally and functionally abnormal.  The normalization means enhancing the deliver of cytotoxic agents.  Our purpose was to investigate whether TSU68, a multiple receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), would induce the normalization of tumor vessels.  Methods: TSU68 was administered for 7 days to mice with xenografted tumors.  Tumors of interstitial fluid pressure (IFP) were measured before and after administration of agents.  Immunofluorescence double staining for CD31 and α-SMA was performed, and a medical video endoscopy system with narrowband illumination (NBI) was used to visualize the vascular pattern.  Results: TSU68 treatment decreased IFP significantly.  Immunofluorescence double staining showed a significant increase in the fraction of pericyte coverage in the TSU68-treated group.  NBI endoscopy showed that many tumor vessels in TSU68-treated mice were pruned and the diams. of remaining vessels were reduced.  Conclusion: The data supported our hypothesis of tumor vascular normalization by the antiangiogenic agent TSU68.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhs-1N0a5GWLVg90H21EOLACvtfcHk0lj1IU7GeEknTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFanu7fN&md5=62d3aeb3a9967c82973901c6128be203</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1007%2Fs00595-009-4020-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00595-009-4020-y%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DKawabata%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DH.%26aulast%3DHiramatsu%26aufirst%3DY.%26aulast%3DKamiya%26aufirst%3DK.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DKonno%26aufirst%3DH.%26atitle%3DTSU68%252C%2520an%2520antiangiogenic%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520induces%2520tumor%2520vascular%2520normalization%2520in%2520a%2520human%2520cancer%2520xenograft%2520nude%2520mouse%2520model%26jtitle%3DSurg.%2520Today%26date%3D2009%26volume%3D39%26spage%3D1046%26epage%3D1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Klenke, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdollahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewerbeck, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sckell, A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=49-56&author=F.+M.+Klenkeauthor=A.+Abdollahiauthor=E.+Bertlauthor=M.+M.+Gebhardauthor=V.+Ewerbeckauthor=P.+E.+Huberauthor=A.+Sckell&title=Tyrosine+kinase+inhibitor+SU6668+represses+chondrosarcoma+growth+via+antiangiogenesis+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlenke%26aufirst%3DF.%2BM.%26aulast%3DAbdollahi%26aufirst%3DA.%26aulast%3DBertl%26aufirst%3DE.%26aulast%3DGebhard%26aufirst%3DM.%2BM.%26aulast%3DEwerbeck%26aufirst%3DV.%26aulast%3DHuber%26aufirst%3DP.%2BE.%26aulast%3DSckell%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibitor%2520SU6668%2520represses%2520chondrosarcoma%2520growth%2520via%2520antiangiogenesis%2520in%2520vivo%26jtitle%3DBMC%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D49%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiramatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, H.</span><span> </span><span class="NLM_article-title">TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9754</span><span class="NLM_x">–</span> <span class="NLM_lpage">9762</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9754-9762&author=M.+Yamamotoauthor=H.+Kikuchiauthor=M.+Ohtaauthor=T.+Kawabataauthor=Y.+Hiramatsuauthor=K.+Kondoauthor=M.+Babaauthor=K.+Kamiyaauthor=T.+Tanakaauthor=M.+Kitagawaauthor=H.+Konno&title=TSU68+prevents+liver+metastasis+of+colon+cancer+xenografts+by+modulating+the+premetastatic+niche"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DKawabata%26aufirst%3DT.%26aulast%3DHiramatsu%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DKamiya%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKitagawa%26aufirst%3DM.%26aulast%3DKonno%26aufirst%3DH.%26atitle%3DTSU68%2520prevents%2520liver%2520metastasis%2520of%2520colon%2520cancer%2520xenografts%2520by%2520modulating%2520the%2520premetastatic%2520niche%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9754%26epage%3D9762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Kanai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateishi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morizane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okusaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arioka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omata, M.</span><span> </span><span class="NLM_article-title">A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-010-1320-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20390419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1emsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=315-324&author=F.+Kanaiauthor=H.+Yoshidaauthor=R.+Tateishiauthor=S.+Satoauthor=T.+Kawabeauthor=S.+Obiauthor=Y.+Kondoauthor=M.+Taniguchiauthor=K.+Tagawaauthor=M.+Ikedaauthor=C.+Morizaneauthor=T.+Okusakaauthor=H.+Ariokaauthor=S.+Shiinaauthor=M.+Omata&title=A+phase+I%2FII+trial+of+the+oral+antiangiogenic+agent+TSU-68+in+patients+with+advanced+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma</span></div><div class="casAuthors">Kanai, Fumihiko; Yoshida, Haruhiko; Tateishi, Ryosuke; Sato, Shinpei; Kawabe, Takao; Obi, Shuntaro; Kondo, Yuji; Taniguchi, Makoto; Tagawa, Kazumi; Ikeda, Masafumi; Morizane, Chigusa; Okusaka, Takuji; Arioka, Hitoshi; Shiina, Shuichiro; Omata, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">315-324</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We studied the safety and effectiveness of TSU-68, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor and fibroblast growth factor receptor, in patients with advanced hepatocellular carcinoma (HCC).  Patients with unresectable or metastatic HCC were eligible for enrollment.  In phase I, the safety, tolerability and pharmacokinetics were assessed in patients stratified based on liver function, from no cirrhosis to Child-Pugh class B.  The safety and effectiveness were assessed in phase II at the dose detd. in phase I.  Twelve patients were enrolled in phase I. Dose-limiting toxicities were found with TSU-68 at the dose of 400 mg bid in Child-Pugh B patients, and 200 mg bid was established as the phase II dose.  Phase II included 23 addnl. patients, and the safety and efficacy were evaluated in a total of 35 patients.  One patient (2.9%) had a complete response.  Two patients (5.7%) had a partial response, and 15 patients (42.8%) showed a stable disease.  The median time to progression was 2.1 mo, and the median overall survival was 13.1 mo.  Common adverse events were hypoalbuminemia, diarrhea, anorexia, abdominal pain, malaise, edema and AST/ALT elevation.  The anal. of angiogenesis-related parameters suggests that serum-sol. vascular cell adhesion mol.-1 is a possible marker to show the response.  TSU-68 at a dose of 200 mg bid detd. by stratification into liver function, showed promising preliminary efficacy with a high safety profile in patients with HCC who had been heavily pre-treated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi7WlIgieisrVg90H21EOLACvtfcHk0lgNGWn8jZY5MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1emsr8%253D&md5=7e96a1e60b47a63e74414eedeffd7f74</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1007%2Fs00280-010-1320-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-010-1320-2%26sid%3Dliteratum%253Aachs%26aulast%3DKanai%26aufirst%3DF.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DTateishi%26aufirst%3DR.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DKawabe%26aufirst%3DT.%26aulast%3DObi%26aufirst%3DS.%26aulast%3DKondo%26aufirst%3DY.%26aulast%3DTaniguchi%26aufirst%3DM.%26aulast%3DTagawa%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DMorizane%26aufirst%3DC.%26aulast%3DOkusaka%26aufirst%3DT.%26aulast%3DArioka%26aufirst%3DH.%26aulast%3DShiina%26aufirst%3DS.%26aulast%3DOmata%26aufirst%3DM.%26atitle%3DA%2520phase%2520I%252FII%2520trial%2520of%2520the%2520oral%2520antiangiogenic%2520agent%2520TSU-68%2520in%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D67%26spage%3D315%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Toi, M.; Saeki, T.; Iwata, H.; Inoue, K.; Tokuda, Y.; Sato, Y.; Ito, Y.; Aogi, K.; Takatsuka, Y.; Arioka, H.</span><span> </span><span class="NLM_article-title">A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance</span>.  <span class="citation_source-journal">Breast Cancer</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1007/s10147-012-0421-9</span> . Published Online: Mar 2,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs10147-012-0421-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Toi&author=T.+Saeki&author=H.+Iwata&author=K.+Inoue&author=Y.+Tokuda&author=Y.+Sato&author=Y.+Ito&author=K.+Aogi&author=Y.+Takatsuka&author=H.+Arioka&title=A+multicenter+phase+II+study+of+TSU-68%2C+an+oral+multiple+tyrosine+kinase+inhibitor%2C+in+combination+with+docetaxel+in+metastatic+breast+cancer+patients+with+anthracycline+resistance&doi=10.1007%2Fs10147-012-0421-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2Fs10147-012-0421-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10147-012-0421-9%26sid%3Dliteratum%253Aachs%26aulast%3DToi%26aufirst%3DM.%26atitle%3DA%2520multicenter%2520phase%2520II%2520study%2520of%2520TSU-68%252C%2520an%2520oral%2520multiple%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520combination%2520with%2520docetaxel%2520in%2520metastatic%2520breast%2520cancer%2520patients%2520with%2520anthracycline%2520resistance%26jtitle%3DBreast%2520Cancer%26doi%3D10.1007%2Fs10147-012-0421-9%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handschuh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Lintz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4466</span><span class="NLM_x">–</span> <span class="NLM_lpage">4480</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krssak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kautschitsch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommergruber, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span> </span><span class="NLM_article-title">BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">4774</span><span class="NLM_x">–</span> <span class="NLM_lpage">4782</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4774-4782&author=F.+Hilbergauthor=G.+J.+Rothauthor=M.+Krssakauthor=S.+Kautschitschauthor=W.+Sommergruberauthor=U.+Tontsch-Gruntauthor=P.+Garin-Chesaauthor=G.+Baderauthor=A.+Zoephelauthor=J.+Quantauthor=A.+Heckelauthor=W.+J.+Rettig&title=BIBF+1120%3A+triple+angiokinase+inhibitor+with+sustained+receptor+blockade+and+good+antitumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DKrssak%26aufirst%3DM.%26aulast%3DKautschitsch%26aufirst%3DS.%26aulast%3DSommergruber%26aufirst%3DW.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBIBF%25201120%253A%2520triple%2520angiokinase%2520inhibitor%2520with%2520sustained%2520receptor%2520blockade%2520and%2520good%2520antitumor%2520efficacy%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4774%26epage%3D4782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Ledermann, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackshaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabra, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeish, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span> </span><span class="NLM_article-title">Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3798</span><span class="NLM_x">–</span> <span class="NLM_lpage">3804</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2010.33.5208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21859991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWrsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3798-3804&author=J.+A.+Ledermannauthor=A.+Hackshawauthor=S.+Kayeauthor=G.+Jaysonauthor=H.+Gabraauthor=I.+McNeishauthor=H.+Earlauthor=T.+Perrenauthor=M.+Goreauthor=M.+Persicauthor=M.+Adamsauthor=L.+Jamesauthor=G.+Templeauthor=M.+Mergerauthor=G.+Rustin&title=Randomized+phase+II+placebo-controlled+trial+of+maintenance+therapy+using+the+oral+triple+angiokinase+inhibitor+BIBF+1120+after+chemotherapy+for+relapsed+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer</span></div><div class="casAuthors">Ledermann, Jonathan A.; Hackshaw, Allan; Kaye, Stan; Jayson, Gordon; Gabra, Hani; McNeish, Iain; Earl, Helena; Perren, Tim; Gore, Martin; Persic, Mojca; Adams, Malcolm; James, Lindsay; Temple, Graham; Merger, Michael; Rustin, Gordon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3798-3804</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer.  We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease.  Patients and Methods: We conducted a randomized, double-blind, controlled phase II trial in 83 patients who had just completed chemotherapy for relapsed ovarian cancer, with evidence of response, but at high risk of further early recurrence.  The patients were randomly assigned to receive maintenance therapy using BIBF 1120 250 mg or placebo, twice per day, continuously for 36 wk.  End points were progression-free survival (PFS), toxicity, and overall survival.  Results: Thirty-six-week PFS rates were 16.3% and 5.0% in the BIBF 1120 and placebo groups, resp. (hazard ratio, 0.65; 95% CI, 0.42 to 1.02; P = .06).  Four patients continued on BIBF 1120, including two patients for another year or more.  The proportion of patients with any grade 3 or 4 adverse events was similar between the groups (34.9% for BIBF 1120 v 27.5% for placebo; P = .49; mostly grade 3).  However, more patients on BIBF 1120 experienced diarrhea, nausea, or vomiting (mainly grade 1 or 2 and no grade 4).  There was a higher rate of grade 3 or 4 hepatotoxicity in patients on BIBF 1120 (51.2%) compared with patients on placebo (7.5%; P < .001), but this was rarely of clin. significance, and patients continued with the trial treatment.  A single-level dose redn. to 150 mg was made in 15 patients, all on active drug.  Conclusion: BIBF 1120 is well tolerated and assocd. with a potential improvement in PFS.  The obsd. treatment effect is sufficient to justify further study within a large phase III trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZqwdS23hObVg90H21EOLACvtfcHk0lgNGWn8jZY5MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWrsb%252FE&md5=98a6a8e9c2a8c4cbcfa2fbb4f9c21c01</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.5208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.5208%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%2BA.%26aulast%3DHackshaw%26aufirst%3DA.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DJayson%26aufirst%3DG.%26aulast%3DGabra%26aufirst%3DH.%26aulast%3DMcNeish%26aufirst%3DI.%26aulast%3DEarl%26aufirst%3DH.%26aulast%3DPerren%26aufirst%3DT.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DPersic%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DTemple%26aufirst%3DG.%26aulast%3DMerger%26aufirst%3DM.%26aulast%3DRustin%26aufirst%3DG.%26atitle%3DRandomized%2520phase%2520II%2520placebo-controlled%2520trial%2520of%2520maintenance%2520therapy%2520using%2520the%2520oral%2520triple%2520angiokinase%2520inhibitor%2520BIBF%25201120%2520after%2520chemotherapy%2520for%2520relapsed%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3798%26epage%3D3804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Santos, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raez, L. E.</span><span> </span><span class="NLM_article-title">Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1269</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1261-1269&author=E.+S.+Santosauthor=J.+E.+Gomezauthor=L.+E.+Raez&title=Targeting+angiogenesis+from+multiple+pathways+simultaneously%3A+BIBF+1120%2C+an+investigational+novel+triple+angiokinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DE.%2BS.%26aulast%3DGomez%26aufirst%3DJ.%2BE.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26atitle%3DTargeting%2520angiogenesis%2520from%2520multiple%2520pathways%2520simultaneously%253A%2520BIBF%25201120%252C%2520an%2520investigational%2520novel%2520triple%2520angiokinase%2520inhibitor%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D1261%26epage%3D1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wietfeld, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sills, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acemoglu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmenegger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlachter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetterli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2310</span><span class="NLM_x">–</span> <span class="NLM_lpage">2323</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9909443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2310-2323&author=G.+Boldauthor=K.+H.+Altmannauthor=J.+Freiauthor=M.+Langauthor=P.+W.+Manleyauthor=P.+Traxlerauthor=B.+Wietfeldauthor=J.+Bruggenauthor=E.+Buchdungerauthor=R.+Cozensauthor=S.+Ferrariauthor=P.+Furetauthor=F.+Hofmannauthor=G.+Martiny-Baronauthor=J.+Mestanauthor=J.+Roselauthor=M.+Sillsauthor=D.+Stoverauthor=F.+Acemogluauthor=E.+Bossauthor=R.+Emmeneggerauthor=L.+Lasserauthor=E.+Massoauthor=R.+Rothauthor=C.+Schlachterauthor=W.+Vetterliauthor=D.+Wyssauthor=J.+M.+Wood&title=New+anilinophthalazines+as+potent+and+orally+well+absorbed+inhibitors+of+the+VEGF+receptor+tyrosine+kinases+useful+as+antagonists+of+tumor-driven+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm9909443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9909443%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DFrei%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DWietfeld%26aufirst%3DB.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DRosel%26aufirst%3DJ.%26aulast%3DSills%26aufirst%3DM.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DAcemoglu%26aufirst%3DF.%26aulast%3DBoss%26aufirst%3DE.%26aulast%3DEmmenegger%26aufirst%3DR.%26aulast%3DLasser%26aufirst%3DL.%26aulast%3DMasso%26aufirst%3DE.%26aulast%3DRoth%26aufirst%3DR.%26aulast%3DSchlachter%26aufirst%3DC.%26aulast%3DVetterli%26aufirst%3DW.%26aulast%3DWyss%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DNew%2520anilinophthalazines%2520as%2520potent%2520and%2520orally%2520well%2520absorbed%2520inhibitors%2520of%2520the%2520VEGF%2520receptor%2520tyrosine%2520kinases%2520useful%2520as%2520antagonists%2520of%2520tumor-driven%2520angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2310%26epage%3D2323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Jahan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kratzke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindler, H. L.</span><span> </span><span class="NLM_article-title">Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2012&pages=393-396&author=T.+Jahanauthor=L.+Guauthor=R.+Kratzkeauthor=A.+Dudekauthor=G.+A.+Ottersonauthor=X.+Wangauthor=M.+Greenauthor=E.+E.+Vokesauthor=H.+L.+Kindler&title=Vatalanib+in+malignant+mesothelioma%3A+a+phase+II+trial+by+the+Cancer+and+Leukemia+Group+B+%28CALGB+30107%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJahan%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DL.%26aulast%3DKratzke%26aufirst%3DR.%26aulast%3DDudek%26aufirst%3DA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26atitle%3DVatalanib%2520in%2520malignant%2520mesothelioma%253A%2520a%2520phase%2520II%2520trial%2520by%2520the%2520Cancer%2520and%2520Leukemia%2520Group%2520B%2520%2528CALGB%252030107%2529%26jtitle%3DLung%2520Cancer%26date%3D2012%26volume%3D76%26spage%3D393%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Braud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grignagni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitalieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boselli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toffalorio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalava, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aglietta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1686</span><span class="NLM_x">–</span> <span class="NLM_lpage">1690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fbjc.2011.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21540861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFyrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=1686-1690&author=H.+Joensuuauthor=F.+De+Braudauthor=G.+Grignagniauthor=T.+De+Pasauthor=G.+Spitalieriauthor=P.+Cocoauthor=C.+Spreaficoauthor=S.+Boselliauthor=F.+Toffalorioauthor=P.+Bonoauthor=T.+Jalavaauthor=C.+Kappelerauthor=M.+Agliettaauthor=D.+Laurentauthor=P.+G.+Casali&title=Vatalanib+for+metastatic+gastrointestinal+stromal+tumour+%28GIST%29+resistant+to+imatinib%3A+final+results+of+a+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study</span></div><div class="casAuthors">Joensuu, H.; De Braud, F.; Grignagni, G.; De Pas, T.; Spitalieri, G.; Coco, P.; Spreafico, C.; Boselli, S.; Toffalorio, F.; Bono, P.; Jalava, T.; Kappeler, C.; Aglietta, M.; Laurent, D.; Casali, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1686-1690</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs).  We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumor (GIST) resistant to imatinib or both imatinib and sunitinib.  45 Patients whose metastatic GIST had progressed on imatinib were enrolled.  19 (42.2%) Patients had received also prior sunitinib.  Vatalanib 1250 mg was administered orally daily.  18 Patients (40.0%; 95% confidence interval (CI), 25.7-54.3%) had clin. benefit including 2 (4.4%) confirmed partial remissions (PR; duration, 9.6 and 39.4 mo) and 16 (35.6%) stabilized diseases (SDs; median duration, 12.5 mo; range, 6.0-35.6+ months).  12 (46.2%) Out of the 26 patients who had received prior imatinib only achieved either PR or SD compared with 6 (31.6%, all SDs) out of the 19 patients who had received prior imatinib and sunitinib (P = 0.324).  The median time to progression was 5.8 mo (95% CI, 2.9-9.5 mo) in the subset without prior sunitinib and 3.2 (95% CI, 2.1-6.0) months among those with prior imatinib and sunitinib (P = 0.992).  Vatalanib was generally well tolerated.  Vatalanib is active despite its narrow kinome interaction spectrum in patients diagnosed with imatinib-resistant GIST or with imatinib and sunitinib-resistant GIST.  British Journal of Cancer (2011) 104, 1686-1690; doi:10.1038/bjc.2011.151 www.bjcancer.com Published online 3 May 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE-hT4ml3w37Vg90H21EOLACvtfcHk0lhW3A9tRmKfcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFyrsLc%253D&md5=f628eebb274daab934707057dcdcd123</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.151%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DDe%2BBraud%26aufirst%3DF.%26aulast%3DGrignagni%26aufirst%3DG.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DSpitalieri%26aufirst%3DG.%26aulast%3DCoco%26aufirst%3DP.%26aulast%3DSpreafico%26aufirst%3DC.%26aulast%3DBoselli%26aufirst%3DS.%26aulast%3DToffalorio%26aufirst%3DF.%26aulast%3DBono%26aufirst%3DP.%26aulast%3DJalava%26aufirst%3DT.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DAglietta%26aufirst%3DM.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DVatalanib%2520for%2520metastatic%2520gastrointestinal%2520stromal%2520tumour%2520%2528GIST%2529%2520resistant%2520to%2520imatinib%253A%2520final%2520results%2520of%2520a%2520phase%2520II%2520study%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D1686%26epage%3D1690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Gauler, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauguen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meric, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gounant, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeck, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krissel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiainen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, W. E.</span><span> </span><span class="NLM_article-title">Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1093%2Fannonc%2Fmdr255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21617019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADC%252BC383mtFWnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=678-687&author=T.+C.+Gaulerauthor=B.+Besseauthor=A.+Mauguenauthor=J.+B.+Mericauthor=V.+Gounantauthor=B.+Fischerauthor=T.+R.+Overbeckauthor=H.+Krisselauthor=D.+Laurentauthor=M.+Tiainenauthor=F.+Commoauthor=J.+C.+Soriaauthor=W.+E.+Eberhardt&title=Phase+II+trial+of+PTK787%2FZK+222584+%28vatalanib%29+administered+orally+once-daily+or+in+two+divided+daily+doses+as+second-line+monotherapy+in+relapsed+or+progressing+patients+with+stage+IIIB%2FIV+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)</span></div><div class="casAuthors">Gauler T C; Besse B; Mauguen A; Meric J B; Gounant V; Fischer B; Overbeck T R; Krissel H; Laurent D; Tiainen M; Commo F; Soria J C; Eberhardt W E E</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">678-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The objective of this multicenter, prospective uncontrolled phase II trial was to determine efficacy, safety and tolerability of vatalanib, an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor receptors, in the second-line treatment of non-small-cell lung cancer (NSCLC).  PATIENTS AND METHODS:  Patients with stage IIIB/IV NSCLC-proven tumor progression during or after one platinum-based chemotherapy regimen received a fixed dose of 1250 mg vatalanib either once-daily dosing (QD) or two divided daily dosing (TDD: 500 mg a.m. + 750 mg p.m.) until disease progression or unacceptable toxicity.  Primary end point was the disease control rate (DCR) at 12 weeks.  RESULTS:  Fifty-four and 58 patients were enrolled to the QD and TDD arms.  DCR at 12 weeks was 35% in the QD and 37% in the TDD arm.  The best overall response included one (2%) patient with confirmed partial response with QD and three (5%) with TDD.  Median progression-free survival and overall survival were 2.1/7.3 months in the QD arm and 2.8/9.0 months with TDD arm.  This therapy showed a moderate toxicity profile for the majority of patients.  CONCLUSIONS:  In the chosen patient population, vatalanib QD and TDD dosing demonstrated potential benefits in tumor size reduction, DCR, and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8AuRTTo7nR5PlX7E30qdzfW6udTcc2eaCjV0ab_7X5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383mtFWnsQ%253D%253D&md5=3a4808f07c1b22304394337e8420016b</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr255%26sid%3Dliteratum%253Aachs%26aulast%3DGauler%26aufirst%3DT.%2BC.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DMauguen%26aufirst%3DA.%26aulast%3DMeric%26aufirst%3DJ.%2BB.%26aulast%3DGounant%26aufirst%3DV.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DOverbeck%26aufirst%3DT.%2BR.%26aulast%3DKrissel%26aufirst%3DH.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DTiainen%26aufirst%3DM.%26aulast%3DCommo%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.%26atitle%3DPhase%2520II%2520trial%2520of%2520PTK787%252FZK%2520222584%2520%2528vatalanib%2529%2520administered%2520orally%2520once-daily%2520or%2520in%2520two%2520divided%2520daily%2520doses%2520as%2520second-line%2520monotherapy%2520in%2520relapsed%2520or%2520progressing%2520patients%2520with%2520stage%2520IIIB%252FIV%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D678%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Cook, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biswas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kareclas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirohi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mander, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrie, P. G.</span><span> </span><span class="NLM_article-title">A phase 2 study of vatalanib in metastatic melanoma patients</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2671</span><span class="NLM_x">–</span> <span class="NLM_lpage">2673</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=2671-2673&author=N.+Cookauthor=B.+Basuauthor=S.+Biswasauthor=P.+Kareclasauthor=C.+Mannauthor=C.+Palmerauthor=A.+Thomasauthor=S.+Nicholsonauthor=B.+Morganauthor=D.+Lomasauthor=B.+Sirohiauthor=A.+P.+Manderauthor=M.+Middletonauthor=P.+G.+Corrie&title=A+phase+2+study+of+vatalanib+in+metastatic+melanoma+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DN.%26aulast%3DBasu%26aufirst%3DB.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DKareclas%26aufirst%3DP.%26aulast%3DMann%26aufirst%3DC.%26aulast%3DPalmer%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DS.%26aulast%3DMorgan%26aufirst%3DB.%26aulast%3DLomas%26aufirst%3DD.%26aulast%3DSirohi%26aufirst%3DB.%26aulast%3DMander%26aufirst%3DA.%2BP.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DCorrie%26aufirst%3DP.%2BG.%26atitle%3DA%2520phase%25202%2520study%2520of%2520vatalanib%2520in%2520metastatic%2520melanoma%2520patients%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D2671%26epage%3D2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Sobrero, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruzzi, P.</span><span> </span><span class="NLM_article-title">Vatalanib in advanced colorectal cancer: two studies with identical results</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1940</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2010.33.2429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21464409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosF2ktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1938-1940&author=A.+F.+Sobreroauthor=P.+Bruzzi&title=Vatalanib+in+advanced+colorectal+cancer%3A+two+studies+with+identical+results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Vatalanib in advanced colorectal cancer: two studies with identical results</span></div><div class="casAuthors">Sobrero, Alberto F.; Bruzzi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1938-1940</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The research of Hecht et al. (2011) entitled 'Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma' and of Van Cutsem et al. (2011) entitled 'Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK222584 in patients with previously treated metastatic colorectal adenocarcinoma' are reviewed with commentary and refs.  These two studies showed the same hazard ratio (HR) for progression-free survival (PFS; 0.88 and 0.83) and for overall survival (OS; 1.08 and 1.00), the same increased efficacy in the subgroup with high lactate dehydrogenase (HR for PFS = 0.67 and 0.63) and the same lack of effect on the rate of objective responses.  The exposure to the antiangiogenic drug vatalanib (PTK/ZK) or placebo and to the component drugs of infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were similarly reduced (10% to 20%) compared with the controls.  The increased incidence of serious adverse events (SAEs) in the exptl. arms over the control arms was identical (9% and 10%) as was the increased treatment discontinuation proportion due to SAEs (14% and 17%).  The time to deterioration of performance status (HR = 1.55 and 2.23), and the time to more than 5% wt. loss (HR = 1.91 and 1.83) were similarly decreased in the PTK/ZK arms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6-co7G_YgBbVg90H21EOLACvtfcHk0lhlBzuZK6rCpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosF2ktb8%253D&md5=b9ae65e2f7aca941aabad80aec93868d</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.2429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.2429%26sid%3Dliteratum%253Aachs%26aulast%3DSobrero%26aufirst%3DA.%2BF.%26aulast%3DBruzzi%26aufirst%3DP.%26atitle%3DVatalanib%2520in%2520advanced%2520colorectal%2520cancer%253A%2520two%2520studies%2520with%2520identical%2520results%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D1938%26epage%3D1940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Dumas, J. P.; Hatoum-Mokdad, H. N.; Joe, T. K.; Kluender, H. C. E.; Lee, W.; Nagarathnam, D.; Sibley, R. N.; Su, N.; Boyer, S. J.</span><span> </span><span class="NLM_article-title">Substituted Pyridazines and Fused Pyridazines with Angiogenesis Inhibting Activity</span>. WO2001010859,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=J.+P.+Dumas&author=H.+N.+Hatoum-Mokdad&author=T.+K.+Joe&author=H.+C.+E.+Kluender&author=W.+Lee&author=D.+Nagarathnam&author=R.+N.+Sibley&author=N.+Su&author=S.+J.+Boyer&title=Substituted+Pyridazines+and+Fused+Pyridazines+with+Angiogenesis+Inhibting+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDumas%26aufirst%3DJ.%2BP.%26atitle%3DSubstituted%2520Pyridazines%2520and%2520Fused%2520Pyridazines%2520with%2520Angiogenesis%2520Inhibting%2520Activity%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Eskens, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeghs, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloem, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwerkerk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jonge, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nortier, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraetzschmar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span> </span><span class="NLM_article-title">Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4169</span><span class="NLM_x">–</span> <span class="NLM_lpage">4176</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2008.18.8193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19636022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2jtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4169-4176&author=F.+A.+Eskensauthor=N.+Steeghsauthor=J.+Verweijauthor=J.+L.+Bloemauthor=O.+Christensenauthor=L.+van+Doornauthor=J.+Ouwerkerkauthor=M.+J.+de+Jongeauthor=J.+W.+Nortierauthor=J.+Kraetzschmarauthor=P.+Rajagopalanauthor=H.+Gelderblom&title=Phase+I+dose+escalation+study+of+telatinib%2C+a+tyrosine+kinase+inhibitor+of+vascular+endothelial+growth+factor+receptor+2+and+3%2C+platelet-derived+growth+factor+receptor+beta%2C+and+c-Kit%2C+in+patients+with+advanced+or+metastatic+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor β, and c-Kit, in patients with advanced or metastatic solid tumors</span></div><div class="casAuthors">Eskens, Ferry A. L. M.; Steeghs, Neeltje; Verweij, Jaap; Bloem, Johan L.; Christensen, Olaf; van Doorn, Leni; Ouwekerk, Jan; de Jonge, Maja J. A.; Nortier, Johan W. R.; Kraetzschmar, Joern; Rajagopalan, Prabhu; Gelderblom, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4169-4176</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor-β, and c-Kit.  This phase I dose escalation study was conducted to evaluate the safety and tolerability of telatinib, with addnl. pharmacokinetic, pharmacodynamic, and efficacy assessments.  Patients and Methods: Patients with solid tumors refractory to std. therapies or with no std. therapy available were enrolled.  Doses of continuously administered telatinib were escalated from 20 mg once daily to 1,500 mg twice daily.  Results: Fifty-three patients were enrolled.  Most frequently obsd. drug-related adverse events were nausea (26.4%; grade ≥ 3, 0%) and hypertension (20.8%; grade 3, 11.3%; grade 4, 0%).  Two dose-limiting toxicities were obsd.: one poorly controlled hypertension (600 mg twice daily), and one grade 2 wt. loss, anorexia, and fatigue (1,500 mg twice daily).  A formal max.-tolerated dose was not reached.  Telatinib was rapidly absorbed, with median time to peak concn. (tmax) lower than 3 h after dose.  A nearly dose-proportional increase in exposure was obsd. with substantial variability.  Telatinib half-life averaged 5.5 h.  Biomarker analyses showed dose-dependent increase in VEGF levels and decrease in plasma sol. VEGFR-2 levels, with a plateau at 900 mg twice daily.  A decrease in tumor blood flow (Ktrans and IAUC60) was obsd. with dynamic contrast-enhanced magnetic resonance imaging.  Best tumor response was stable disease, obsd. in 50.9% of patients.  Conclusion: Telatinib was safe and well tolerated up to 1,500 mg twice daily.  Based on pharmacodynamic and pharmacokinetic end points, telatinib 900 mg twice daily is the recommended dose for subsequent phase II studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQSW5HnAKUALVg90H21EOLACvtfcHk0lhlDt01blS5hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2jtLrK&md5=187b12f0d2e053352b5b4168d7612753</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.18.8193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.18.8193%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%26aulast%3DSteeghs%26aufirst%3DN.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DBloem%26aufirst%3DJ.%2BL.%26aulast%3DChristensen%26aufirst%3DO.%26aulast%3Dvan%2BDoorn%26aufirst%3DL.%26aulast%3DOuwerkerk%26aufirst%3DJ.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%26aulast%3DNortier%26aufirst%3DJ.%2BW.%26aulast%3DKraetzschmar%26aufirst%3DJ.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26atitle%3DPhase%2520I%2520dose%2520escalation%2520study%2520of%2520telatinib%252C%2520a%2520tyrosine%2520kinase%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520and%25203%252C%2520platelet-derived%2520growth%2520factor%2520receptor%2520beta%252C%2520and%2520c-Kit%252C%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4169%26epage%3D4176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheulen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultheiss, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasol, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büchert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krätzschmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delesen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, O.</span><span> </span><span class="NLM_article-title">Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer</span> <span class="citation_source-journal">Vasc. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1186%2F2045-824X-3-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21801343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SgtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=16&author=K.+Mrossauthor=A.+Frostauthor=M.+E.+Scheulenauthor=J.+Kraussauthor=D.+Strumbergauthor=B.+Schultheissauthor=U.+Fasolauthor=M.+B%C3%BCchertauthor=J.+Kr%C3%A4tzschmerauthor=H.+Delesenauthor=P.+Rajagopalanauthor=O.+Christensen&title=Phase+I+study+of+telatinib+%28BAY+57-9352%29%3A+analysis+of+safety%2C+pharmacokinetics%2C+tumor+efficacy%2C+and+biomarkers+in+patients+with+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer</span></div><div class="casAuthors">Mross, Klaus; Frost, Annette; Scheulen, Max E.; Krauss, Juergen; Strumberg, Dirk; Schultheiss, Beate; Fasol, Ulrike; Buechert, Martin; Kraetzschmer, Jorn; Delesen, Heinz; Rajagopalan, Prabhu; Christensen, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>CODEN:
                <span class="NLM_cas:coden">VCAEAL</span>;
        ISSN:<span class="NLM_cas:issn">2045-824X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Telatinib (BAY 57-9352) is an orally available, small-mol. inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.  Methods: In this multicenter phase I dose-escalation study including a phase II like expansion part, 39 patients with refractory colorectal cancer (CRC) were enrolled into 14 days on/7 days off in repeating cycles of 28 days (n = 11) or continuous dosing groups (n = 28) to receive ≥600 mg telatinib twice-daily (bid).  Results: Hypertension (28%) and diarrhoea (15%) were the most frequent study drug-related adverse events of CTC grade 3.  In this population, no clear relationship between telatinib dose and individual Cmax and AUC was apparent in the 600 mg bid to 1500 mg bid dose range.  No partial remission according to RECIST was reached, but 41% of the patients reached some tumor shrinkage during treatment.  Tumor blood flow measured by dynamic contrast-enhanced magnetic resonance imaging and sVEGFR-2 plasma levels decreased with increasing telatinib AUC(0-12).  Conclusion: Telatinib treatment was well tolerated.  The obsd. single agent antitumor activity in heavily pretreated CRC patients was limited.  Pharmacodynamic results are suggestive for the biol. activity of telatinib justifying a further evaluation of telatinib bid in combination with std. chemotherapy regimens in CRC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQOGoeGHrIIbVg90H21EOLACvtfcHk0lhlDt01blS5hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SgtrnN&md5=6a15ff831e306cfed88d1664a156caa6</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1186%2F2045-824X-3-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2045-824X-3-16%26sid%3Dliteratum%253Aachs%26aulast%3DMross%26aufirst%3DK.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DKrauss%26aufirst%3DJ.%26aulast%3DStrumberg%26aufirst%3DD.%26aulast%3DSchultheiss%26aufirst%3DB.%26aulast%3DFasol%26aufirst%3DU.%26aulast%3DB%25C3%25BCchert%26aufirst%3DM.%26aulast%3DKr%25C3%25A4tzschmer%26aufirst%3DJ.%26aulast%3DDelesen%26aufirst%3DH.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DO.%26atitle%3DPhase%2520I%2520study%2520of%2520telatinib%2520%2528BAY%252057-9352%2529%253A%2520analysis%2520of%2520safety%252C%2520pharmacokinetics%252C%2520tumor%2520efficacy%252C%2520and%2520biomarkers%2520in%2520patients%2520with%2520colorectal%2520cancer%26jtitle%3DVasc.%2520Cell%26date%3D2011%26volume%3D3%26spage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K. H.</span><span> </span><span class="NLM_article-title">Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2967</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2967-2971&author=P.+Furetauthor=G.+Boldauthor=F.+Hofmannauthor=P.+Manleyauthor=T.+Meyerauthor=K.+H.+Altmann&title=Identification+of+a+new+chemical+class+of+potent+angiogenesis+inhibitors+based+on+conformational+considerations+and+database+searching"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26atitle%3DIdentification%2520of%2520a%2520new%2520chemical%2520class%2520of%2520potent%2520angiogenesis%2520inhibitors%2520based%2520on%2520conformational%2520considerations%2520and%2520database%2520searching%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2967%26epage%3D2971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talvenheimo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montestruque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span> </span><span class="NLM_article-title">AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8715</span><span class="NLM_x">–</span> <span class="NLM_lpage">8721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8715-8721&author=A.+Polverinoauthor=A.+Coxonauthor=C.+Starnesauthor=Z.+Diazauthor=T.+DeMelfiauthor=L.+Wangauthor=J.+Breadyauthor=J.+Estradaauthor=R.+Cattleyauthor=S.+Kaufmanauthor=D.+Chenauthor=Y.+Ganauthor=G.+Kumarauthor=J.+Meyerauthor=S.+Neervannanauthor=G.+Alvaauthor=J.+Talvenheimoauthor=S.+Montestruqueauthor=A.+Taskerauthor=V.+Patelauthor=R.+Radinskyauthor=R.+Kendall&title=AMG+706%2C+an+oral%2C+multikinase+inhibitor+that+selectively+targets+vascular+endothelial+growth+factor%2C+platelet-derived+growth+factor%2C+and+kit+receptors%2C+potently+inhibits+angiogenesis+and+induces+regression+in+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DZ.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DCattley%26aufirst%3DR.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DGan%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DAlva%26aufirst%3DG.%26aulast%3DTalvenheimo%26aufirst%3DJ.%26aulast%3DMontestruque%26aufirst%3DS.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26atitle%3DAMG%2520706%252C%2520an%2520oral%252C%2520multikinase%2520inhibitor%2520that%2520selectively%2520targets%2520vascular%2520endothelial%2520growth%2520factor%252C%2520platelet-derived%2520growth%2520factor%252C%2520and%2520kit%2520receptors%252C%2520potently%2520inhibits%2520angiogenesis%2520and%2520induces%2520regression%2520in%2520tumor%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8715%26epage%3D8721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saffran, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span> </span><span class="NLM_article-title">Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-08-1155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19118038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1eltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=110-118&author=A.+Coxonauthor=T.+Bushauthor=D.+Saffranauthor=S.+Kaufmanauthor=B.+Belmontesauthor=K.+Rexauthor=P.+Hughesauthor=S.+Caenepeelauthor=J.+B.+Rottmanauthor=A.+Taskerauthor=V.+Patelauthor=R.+Kendallauthor=R.+Radinskyauthor=A.+Polverino&title=Broad+antitumor+activity+in+breast+cancer+xenografts+by+motesanib%2C+a+highly+selective%2C+oral+inhibitor+of+vascular+endothelial+growth+factor%2C+platelet-derived+growth+factor%2C+and+Kit+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors</span></div><div class="casAuthors">Coxon, Angela; Bush, Tammy; Saffran, Douglas; Kaufman, Stephen; Belmontes, Brian; Rex, Karen; Hughes, Paul; Caenepeel, Sean; Rottman, James B.; Tasker, Andrew; Patel, Vinod; Kendall, Richard; Radinsky, Robert; Polverino, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">110-118</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Angiogenesis plays a crit. role in breast cancer development and progression.  Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that regulates endothelial cell proliferation and survival.  We investigated the effects of motesanib, a novel, oral inhibitor of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit receptor, on the growth of xenografts representing various human breast cancer subtypes.  Athymic nude mice were implanted with MCF-7 (luminal) or MDA-MB-231 (mesenchymal) tumor fragments or Cal-51 (mixed/progenitor) tumor cells.  Once tumors were established, animals were randomized to receive increasing doses of motesanib alone or motesanib plus cytotoxic chemotherapy (docetaxel, doxorubicin, or tamoxifen).  Across all three xenograft models, motesanib treatment resulted in significant dose-dependent redns. in tumor growth, compared with vehicle-treated controls, and in marked redns. in viable tumor fraction and blood vessel d.  No significant effect on body wt. was obsd. with compd. treatment compared with control-treated animals.  Motesanib did not affect the proliferation of tumor cells in vitro.  There was a significantly greater redn. in xenograft tumor growth when motesanib was combined with docetaxel (MDA-MB-231 tumors) or with the estrogen receptor modulator tamoxifen (MCF-7 tumors), compared with either treatment alone, but not when combined with doxorubicin (Cal-51 tumors).  Treatment with motesanib alone or in combination with chemotherapy inhibits tumor growth in vivo in various models of human breast cancer.  These data suggest that motesanib may have broad utility in the treatment of human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkX21dnQZLLVg90H21EOLACvtfcHk0lgj-Jfipi-Wig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1eltg%253D%253D&md5=0a55408655f97efe06156f5cb4ae041c</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1155%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBush%26aufirst%3DT.%26aulast%3DSaffran%26aufirst%3DD.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DRottman%26aufirst%3DJ.%2BB.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DPolverino%26aufirst%3DA.%26atitle%3DBroad%2520antitumor%2520activity%2520in%2520breast%2520cancer%2520xenografts%2520by%2520motesanib%252C%2520a%2520highly%2520selective%252C%2520oral%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%252C%2520platelet-derived%2520growth%2520factor%252C%2520and%2520Kit%2520receptors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D110%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osgood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of motesanib in a medullary thyroid cancer model</span> <span class="citation_source-journal">J. Endocrinol. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=181-190&author=A.+Coxonauthor=J.+Breadyauthor=S.+Kaufmanauthor=J.+Estradaauthor=T.+Osgoodauthor=J.+Canonauthor=L.+Wangauthor=R.+Radinskyauthor=R.+Kendallauthor=P.+Hughesauthor=A.+Polverino&title=Anti-tumor+activity+of+motesanib+in+a+medullary+thyroid+cancer+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DPolverino%26aufirst%3DA.%26atitle%3DAnti-tumor%2520activity%2520of%2520motesanib%2520in%2520a%2520medullary%2520thyroid%2520cancer%2520model%26jtitle%3DJ.%2520Endocrinol.%2520Invest.%26date%3D2012%26volume%3D35%26spage%3D181%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Benjamin, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duyster, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuetze, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skubitz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, L.</span><span> </span><span class="NLM_article-title">Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-010-1431-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20838998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVentrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=69-77&author=R.+S.+Benjaminauthor=P.+Sch%C3%B6ffskiauthor=J.+T.+Hartmannauthor=A.+Van+Oosteromauthor=B.+N.+Buiauthor=J.+Duysterauthor=S.+Schuetzeauthor=J.+Y.+Blayauthor=P.+Reichardtauthor=L.+S.+Rosenauthor=K.+Skubitzauthor=S.+McCoyauthor=Y.+N.+Sunauthor=D.+E.+Stepanauthor=L.+Baker&title=Efficacy+and+safety+of+motesanib%2C+an+oral+inhibitor+of+VEGF%2C+PDGF%2C+and+Kit+receptors%2C+in+patients+with+imatinib-resistant+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors</span></div><div class="casAuthors">Benjamin, Robert S.; Schoeffski, Patrick; Hartmann, Joerg Thomas; Oosterom, Allan; Bui, Binh Nguyen; Duyster, Justus; Schuetze, Scott; Blay, Jean-Yves; Reichardt, Peter; Rosen, Lee S.; Skubitz, Keith; McCoy, Sheryl; Sun, Yu-Nien; Stepan, Daniel E.; Baker, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-77</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: This multicenter phase 2 study assessed the tolerability and efficacy of motesanib, an oral inhibitor of Kit, platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptors (VEGFR), in patients with imatinib-resistant gastrointestinal stromal tumors (GIST).  Methods: Patients with advanced GIST who failed imatinib mesylate after ≥8 wk of treatment with ≥600 mg daily received motesanib 125 mg orally once daily continuously for 48 wk or until unacceptable toxicity or disease progression occurred.  The primary endpoint was confirmed objective tumor response per RECIST and independent review.  Secondary endpoints included progression-free survival (PFS), time to progression (TTP); objective response by 18FDG-PET and by changes in tumor size and/or d. (Choi criteria); pharmacokinetics and safety.  Results: In the patients evaluable for response (N = 102), the objective response rate was 3%; 59% of patients achieved stable disease, with 14% achieving durable stable disease ≥24 wk; 38% had disease progression.  Higher objective response rates were obsd. per 18FDG-PET (N = 91) (30%) and Choi criteria (41%).  The median PFS was 16 wk (95% CI = 14-24 wk); the median TTP was 17 wk (95% CI = 15-24 wk).  The most common motesanib treatment-related grade 3 adverse events included hypertension (23%), fatigue (9%), and diarrhea (5%).  Motesanib did not accumulate with daily dosing.  Conclusions: In this study of patients with imatinib-resistant GIST, motesanib treatment resulted in acceptable tolerability and modest tumor control as evident in the proportion of patients who achieved stable disease and durable stable disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1ymd0N1HF4LVg90H21EOLACvtfcHk0lgau58jpCiTNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVentrY%253D&md5=47d04fa1620603cee06e1a44c2c79082</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2Fs00280-010-1431-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-010-1431-9%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DHartmann%26aufirst%3DJ.%2BT.%26aulast%3DVan%2BOosterom%26aufirst%3DA.%26aulast%3DBui%26aufirst%3DB.%2BN.%26aulast%3DDuyster%26aufirst%3DJ.%26aulast%3DSchuetze%26aufirst%3DS.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DSkubitz%26aufirst%3DK.%26aulast%3DMcCoy%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%2BN.%26aulast%3DStepan%26aufirst%3DD.%2BE.%26aulast%3DBaker%26aufirst%3DL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520motesanib%252C%2520an%2520oral%2520inhibitor%2520of%2520VEGF%252C%2520PDGF%252C%2520and%2520Kit%2520receptors%252C%2520in%2520patients%2520with%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D68%26spage%3D69%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Raghav, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span> </span><span class="NLM_article-title">Motesanib and advanced NSCLC: experiences and expectations</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">–</span> <span class="NLM_lpage">869</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=859-869&author=K.+P.+Raghavauthor=G.+R.+Blumenschein&title=Motesanib+and+advanced+NSCLC%3A+experiences+and+expectations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaghav%26aufirst%3DK.%2BP.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26atitle%3DMotesanib%2520and%2520advanced%2520NSCLC%253A%2520experiences%2520and%2520expectations%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D859%26epage%3D869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Wynne, G. M.; Doyle, K.; Ahmed, S.; Li, A.; Keily, J. F.; Rasamison, C.; Pegg, N. A.; Saba, I.; Thomas, C.; Smyth, D.; Sadiq, S.; Newton, G.; Dawson, G.; Crew, A. P.; Castelano, A. L.</span><span> </span><span class="NLM_article-title">(2-Carboxamido) (3-Amino) Thiophene Compounds</span>. WO2004063330,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+M.+Wynne&author=K.+Doyle&author=S.+Ahmed&author=A.+Li&author=J.+F.+Keily&author=C.+Rasamison&author=N.+A.+Pegg&author=I.+Saba&author=C.+Thomas&author=D.+Smyth&author=S.+Sadiq&author=G.+Newton&author=G.+Dawson&author=A.+P.+Crew&author=A.+L.+Castelano&title=%282-Carboxamido%29+%283-Amino%29+Thiophene+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWynne%26aufirst%3DG.%2BM.%26atitle%3D%25282-Carboxamido%2529%2520%25283-Amino%2529%2520Thiophene%2520Compounds%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crew, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynne, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaldo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bittner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keily, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srebernak, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirrit, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulevic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henninger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennello, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelhano, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span> </span><span class="NLM_article-title">OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1024</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1015-1024&author=A.+J.+Gartonauthor=A.+P.+Crewauthor=M.+Franklinauthor=A.+R.+Cookeauthor=G.+M.+Wynneauthor=L.+Castaldoauthor=J.+Kahlerauthor=S.+L.+Winskiauthor=A.+Franksauthor=E.+N.+Brownauthor=M.+A.+Bittnerauthor=J.+F.+Keilyauthor=P.+Brinerauthor=C.+Hiddenauthor=M.+C.+Srebernakauthor=C.+Pirritauthor=M.+O%E2%80%99Connorauthor=A.+Chanauthor=B.+Vulevicauthor=D.+Henningerauthor=K.+Hartauthor=R.+Sennelloauthor=A.+H.+Liauthor=T.+Zhangauthor=F.+Richardsonauthor=D.+L.+Emersonauthor=A.+L.+Castelhanoauthor=L.+D.+Arnoldauthor=N.+W.+Gibson&title=OSI-930%3A+a+novel+selective+inhibitor+of+Kit+and+kinase+insert+domain+receptor+tyrosine+kinases+with+antitumor+activity+in+mouse+xenograft+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DFranklin%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DA.%2BR.%26aulast%3DWynne%26aufirst%3DG.%2BM.%26aulast%3DCastaldo%26aufirst%3DL.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DFranks%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DE.%2BN.%26aulast%3DBittner%26aufirst%3DM.%2BA.%26aulast%3DKeily%26aufirst%3DJ.%2BF.%26aulast%3DBriner%26aufirst%3DP.%26aulast%3DHidden%26aufirst%3DC.%26aulast%3DSrebernak%26aufirst%3DM.%2BC.%26aulast%3DPirrit%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DVulevic%26aufirst%3DB.%26aulast%3DHenninger%26aufirst%3DD.%26aulast%3DHart%26aufirst%3DK.%26aulast%3DSennello%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BH.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DRichardson%26aufirst%3DF.%26aulast%3DEmerson%26aufirst%3DD.%2BL.%26aulast%3DCastelhano%26aufirst%3DA.%2BL.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26atitle%3DOSI-930%253A%2520a%2520novel%2520selective%2520inhibitor%2520of%2520Kit%2520and%2520kinase%2520insert%2520domain%2520receptor%2520tyrosine%2520kinases%2520with%2520antitumor%2520activity%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1015%26epage%3D1024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical studies of (<i>R</i>)-1-(4-(4-fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5- methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2146</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm051106d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2143-2146&author=R.+S.+Bhideauthor=Z.+W.+Caiauthor=Y.+Z.+Zhangauthor=L.+Qianauthor=D.+Weiauthor=S.+Barbosaauthor=L.+J.+Lombardoauthor=R.+M.+Borzilleriauthor=X.+Zhengauthor=L.+I.+Wuauthor=J.+C.+Barrishauthor=S.+H.+Kimauthor=K.+Leavittauthor=A.+Mathurauthor=L.+Leithauthor=S.+Chaoauthor=B.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+Kukralauthor=J.+T.+Huntauthor=A.+Kamathauthor=A.+Furaauthor=V.+Vyasauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+Fargnoli&title=Discovery+and+preclinical+studies+of+%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-+methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-2-ol+%28BMS-540215%29%2C+an+in+vivo+active+potent+VEGFR-2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm051106d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051106d%26sid%3Dliteratum%253Aachs%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BI.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DVyas%26aufirst%3DV.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DFargnoli%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520studies%2520of%2520%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-%2520methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-2-ol%2520%2528BMS-540215%2529%252C%2520an%2520in%2520vivo%2520active%2520potent%2520VEGFR-2%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2143%26epage%3D2146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukralmgrt, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R. S.</span><span> </span><span class="NLM_article-title">Discovery of brivanib alaninate ((<i>S</i>)-((<i>R</i>)-1-(4-(4-fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5-methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1980</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7013309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1976-1980&author=Z.+W.+Caiauthor=Y.+Zhangauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=S.+Barbosaauthor=D.+Weiauthor=X.+Zhengauthor=L.+Wuauthor=J.+Fanauthor=Z.+Shiauthor=B.+S.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+W.+Kukralmgrtauthor=A.+Kamathauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+C.+Barrishauthor=J.+A.+Roblauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+S.+Bhide&title=Discovery+of+brivanib+alaninate+%28%28S%29-%28%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-2-yl%292-aminopropanoate%29%2C+a+novel+prodrug+of+dual+vascular+endothelial+growth+factor+receptor-2+and+fibroblast+growth+factor+receptor-1+kinase+inhibitor+%28BMS-540215%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm7013309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7013309%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukralmgrt%26aufirst%3DD.%2BW.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520brivanib%2520alaninate%2520%2528%2528S%2529-%2528%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-2-yl%25292-aminopropanoate%2529%252C%2520a%2520novel%2520prodrug%2520of%2520dual%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520fibroblast%2520growth%2520factor%2520receptor-1%2520kinase%2520inhibitor%2520%2528BMS-540215%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1976%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-009-1002-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19396600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFegu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=55-66&author=P.+H.+Maratheauthor=A.+V.+Kamathauthor=Y.+Zhangauthor=C.+D%E2%80%99Arienzoauthor=R.+Bhideauthor=J.+Fargnoli&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+brivanib+%28BMS-540215%29%2C+a+potent+VEGFR2+inhibitor+and+its+alanine+ester+prodrug+brivanib+alaninate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate</span></div><div class="casAuthors">Marathe, Punit H.; Kamath, Amrita V.; Zhang, Yueping; D'Arienzo, Celia; Bhide, Rajeev; Fargnoli, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-66</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas.  In vitro and in vivo studies were conducted to characterize the preclin. pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts.  In vitro studies were conducted in liver and intestinal fractions, plasma and Caco-2 cells to assess the metabolic stability.  Pharmacokinetics of brivanib were detd. in preclin. species after administration of single i.v. or oral doses of both brivanib and brivanib alaninate.  The antitumor efficacy was assessed at equimolar doses in nude mice bearing human tumor xenografts.  Human efficacious dose was predicted based on projected human pharmacokinetic parameters and exposure at efficacious doses in the mouse efficacy models.  In vitro and in vivo studies indicated that brivanib alaninate was efficiently converted to brivanib.  Brivanib showed good brain penetration in rats consistent with its high intrinsic permeability and lack of active efflux in Caco-2 cells.  The oral bioavailability of brivanib varied among species (22-88%) and showed dissoln. rate-limited absorption even when combined with org. co-solvents.  Administration of brivanib as brivanib alaninate allowed completely aq. vehicles, and an improvement in the oral bioavailability (55-97%) was obsd.  The clearance of brivanib in humans is anticipated to be low to intermediate (hepatic extn. ratio < 0.7), while its vol. of distribution is expected to be high.  The min. efficacious dose of brivanib alaninate was detd. to be 60 mg/kg per day.  Brivanib alaninate is rapidly and efficiently converted to the parent, brivanib, as demonstrated both in vitro and in vivo and offers an excellent mode to deliver brivanib orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo32ej0WyxhXbVg90H21EOLACvtfcHk0lgutPcWwammRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFegu77K&md5=d7ca6c43910437a12f64d70fe12c6e9c</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-1002-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-1002-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DBhide%26aufirst%3DR.%26aulast%3DFargnoli%26aufirst%3DJ.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520brivanib%2520%2528BMS-540215%2529%252C%2520a%2520potent%2520VEGFR2%2520inhibitor%2520and%2520its%2520alanine%2520ester%2520prodrug%2520brivanib%2520alaninate%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D65%26spage%3D55%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Huynh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koong, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thng, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, E.</span><span> </span><span class="NLM_article-title">Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6146</span><span class="NLM_x">–</span> <span class="NLM_lpage">6153</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-08-0509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18829493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2nurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6146-6153&author=H.+Huynhauthor=V.+C.+Ngoauthor=J.+Fargnoliauthor=M.+Ayersauthor=K.+C.+Sooauthor=H.+N.+Koongauthor=C.+H.+Thngauthor=H.+S.+Ongauthor=A.+Chungauthor=P.+Chowauthor=P.+Pollockauthor=S.+Byronauthor=E.+Tran&title=Brivanib+alaninate%2C+a+dual+inhibitor+of+vascular+endothelial+growth+factor+receptor+and+fibroblast+growth+factor+receptor+tyrosine+kinases%2C+induces+growth+inhibition+in+mouse+models+of+human+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma</span></div><div class="casAuthors">Huynh, Hung; Ngo, Van Chanh; Fargnoli, Joseph; Ayers, Mark; Soo, Khee Chee; Koong, Heng Nung; Thng, Choon Hua; Ong, Hock Soo; Chung, Alexander; Chow, Pierce; Pollock, Pamela; Byron, Sara; Tran, Evelyn</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6146-6153</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the fifth most common primary neoplasm; surgery is the only curative option but 5-yr survival rates are only 25% to 50%.  Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are known to be involved in growth and neovascularization of HCC.  Therefore, agents that target these pathways may be effective in the treatment of HCC.  The aim of this study was to det. the antineoplastic activity of brivanib alaninate, a dual inhibitor of VEGF receptor (VEGFR) and FGF receptor (FGFR) signaling pathways.  Six different s.c. patient-derived HCC xenografts were implanted into mice.  Tumor growth was evaluated in mice treated with brivanib compared with control.  The effects of brivanib on apoptosis and cell proliferation were evaluated by immunohistochem.  The SK-HEP1 and HepG2 cells were used to investigate the effects of brivanib on the VEGFR-2 and FGFR-1 signaling pathways in vitro.  Western blotting was used to det. changes in proteins in these xenografts and cell lines.  Brivanib significantly suppressed tumor growth in five of six xenograft lines.  Furthermore, brivanib-induced growth inhibition was assocd. with a decrease in phosphorylated VEGFR-2 at Tyr1054/1059, increased apoptosis, reduced microvessel d., inhibition of cell proliferation, and down-regulation of cell cycle regulators.  The levels of FGFR-1 and FGFR-2 expression in these xenograft lines were pos. correlated with its sensitivity to brivanib-induced growth inhibition.  In VEGF-stimulated and basic FGF stimulated SK-HEP1 cells, brivanib significantly inhibited VEGFR-2, FGFR-1, extracellular signal-regulated kinase 1/2, and Akt phosphorylation.  This study provides a strong rationale for clin. investigation of brivanib in patients with HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2l11-dUEyFLVg90H21EOLACvtfcHk0lgutPcWwammRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2nurvK&md5=21fdc03992b6f3a3ac653e313e794e0a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0509%26sid%3Dliteratum%253Aachs%26aulast%3DHuynh%26aufirst%3DH.%26aulast%3DNgo%26aufirst%3DV.%2BC.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DAyers%26aufirst%3DM.%26aulast%3DSoo%26aufirst%3DK.%2BC.%26aulast%3DKoong%26aufirst%3DH.%2BN.%26aulast%3DThng%26aufirst%3DC.%2BH.%26aulast%3DOng%26aufirst%3DH.%2BS.%26aulast%3DChung%26aufirst%3DA.%26aulast%3DChow%26aufirst%3DP.%26aulast%3DPollock%26aufirst%3DP.%26aulast%3DByron%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DE.%26atitle%3DBrivanib%2520alaninate%252C%2520a%2520dual%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520and%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%252C%2520induces%2520growth%2520inhibition%2520in%2520mouse%2520models%2520of%2520human%2520hepatocellular%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D6146%26epage%3D6153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Diaz-Padilla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span> </span><span class="NLM_article-title">Brivanib alaninate for cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=577-586&author=I.+Diaz-Padillaauthor=L.+L.+Siu&title=Brivanib+alaninate+for+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz-Padilla%26aufirst%3DI.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DBrivanib%2520alaninate%2520for%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D577%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulcahy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polite, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudelet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manekas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. W.</span><span> </span><span class="NLM_article-title">Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2090</span><span class="NLM_x">–</span> <span class="NLM_lpage">2098</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-11-1991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22238246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2090-2098&author=R.+S.+Finnauthor=Y.+K.+Kangauthor=M.+Mulcahyauthor=B.+N.+Politeauthor=H.+Y.+Limauthor=I.+Waltersauthor=C.+Baudeletauthor=D.+Manekasauthor=J.+W.+Park&title=Phase+II%2C+open-label+study+of+brivanib+as+second-line+therapy+in+patients+with+advanced+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma</span></div><div class="casAuthors">Finn, Richard S.; Kang, Yoon-Koo; Mulcahy, Mary; Polite, Blase N.; Lim, Ho Yeong; Walters, Ian; Baudelet, Christine; Manekas, Demetrios; Park, Joong-Won</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2090-2098</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC).  This phase II open-label study assessed brivanib as second-line therapy in patients with advanced HCC who had failed prior antiangiogenic treatment.  Exptl. Design: Brivanib was administered orally at a dose of 800 mg once daily.  The primary objectives were tumor response rate, time to response, duration of response, progression-free survival, overall survival (OS), disease control rate, time to progression (TTP), and safety and tolerability.  RESULTS: Forty-six patients were treated.  Best responses to treatment with brivanib (N = 46 patients) using modified World Health Organization criteria were partial responses for two patients (4.3%), stable disease for 19 patients (41.3%), and progressive disease for 19 patients (41.3%).  The tumor response rate was 4.3%; the disease control rate was 45.7%.  Median OS was 9.79 mo.  Median TTP as assessed by study investigators following second-line treatment with brivanib was 2.7 mo.  The most common adverse events were fatigue, decreased appetite, nausea, diarrhea, and hypertension.  CONCLUSION: Brivanib had a manageable safety profile and is one of the first agents to show promising antitumor activity in advanced HCC patients treated with prior sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotRfx03hOZcbVg90H21EOLACvtfcHk0lhe3Z7l9a90xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOls70%253D&md5=e82018cda1daf7417260959cea286064</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1991%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DMulcahy%26aufirst%3DM.%26aulast%3DPolite%26aufirst%3DB.%2BN.%26aulast%3DLim%26aufirst%3DH.%2BY.%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DBaudelet%26aufirst%3DC.%26aulast%3DManekas%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26atitle%3DPhase%2520II%252C%2520open-label%2520study%2520of%2520brivanib%2520as%2520second-line%2520therapy%2520in%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2090%26epage%3D2098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">de La Motte Rouge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olaussen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zermati, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasdemir, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripoche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dessen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araujo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harel-Belan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armand, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span> </span><span class="NLM_article-title">A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6253</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6253-6262&author=T.+de+La+Motte+Rougeauthor=L.+Galluzziauthor=K.+A.+Olaussenauthor=Y.+Zermatiauthor=E.+Tasdemirauthor=T.+Robertauthor=H.+Ripocheauthor=V.+Lazarauthor=P.+Dessenauthor=F.+Harperauthor=G.+Pierronauthor=G.+Pinnaauthor=N.+Araujoauthor=A.+Harel-Belanauthor=J.+P.+Armandauthor=T.+W.+Wongauthor=J.+C.+Soriaauthor=G.+Kroemer&title=A+novel+epidermal+growth+factor+receptor+inhibitor+promotes+apoptosis+in+non-small+cell+lung+cancer+cells+resistant+to+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLa%2BMotte%2BRouge%26aufirst%3DT.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DOlaussen%26aufirst%3DK.%2BA.%26aulast%3DZermati%26aufirst%3DY.%26aulast%3DTasdemir%26aufirst%3DE.%26aulast%3DRobert%26aufirst%3DT.%26aulast%3DRipoche%26aufirst%3DH.%26aulast%3DLazar%26aufirst%3DV.%26aulast%3DDessen%26aufirst%3DP.%26aulast%3DHarper%26aufirst%3DF.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DPinna%26aufirst%3DG.%26aulast%3DAraujo%26aufirst%3DN.%26aulast%3DHarel-Belan%26aufirst%3DA.%26aulast%3DArmand%26aufirst%3DJ.%2BP.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DA%2520novel%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520promotes%2520apoptosis%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%2520resistant%2520to%2520erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6253%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Loriot, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mordant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorvault, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De la motte Rouge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, E.</span><span> </span><span class="NLM_article-title">BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fsj.bjc.6605748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20628392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Oitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=347-353&author=Y.+Loriotauthor=P.+Mordantauthor=N.+Dorvaultauthor=T.+De+la+motte+Rougeauthor=J.+Bourhisauthor=J.+C.+Soriaauthor=E.+Deutsch&title=BMS-690514%2C+a+VEGFR+and+EGFR+tyrosine+kinase+inhibitor%2C+shows+anti-tumoural+activity+on+non-small-cell+lung+cancer+xenografts+and+induces+sequence-dependent+synergistic+effect+with+radiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation</span></div><div class="casAuthors">Loriot, Y.; Mordant, P.; Dorvault, N.; De la motte Rouge, T.; Bourhis, J.; Soria, J.-C.; Deutsch, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-353</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer (NSCLC) is an aggressive disease in which vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) are implicated in tumor growth, tumor resistance to radiation and chemotherapy, and disease relapse.  We have investigated the anti-tumoral effects of BMS-690514, an inhibitor of both vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signalling pathways, as a single agent and in combination with ionising radiation (IR) on several NSCLC cell lines.  Radiosensitization of several NSCLC cell lines by BMS-690514 was assessed in vitro using clonogenic assay and in vivo using nude mice.  In vitro studies showed that BMS-690514 alone decreases clonogenic survival of NSCLC cells lines but no potential enhancement of IR response was obsd. in the combination.  In tumor-bearing mice, BMS-690514 alone inhibits the growth of NSCLC xenografts, including the T790M mutation-harbouring H1975 tumor.  The concomitant combination of BMS-690514 and radiation did not increase mice survival in comparison with treatment with IR alone.  In contrast, BMS-690514 markedly enhances the anti-tumor effect of radiation in a sequential manner on H1299 and H1975 xenografts.  Immunohistochem. revealed a qual. redn. in vessel area after administrations of BMS-690514, compared with vehicle-treated controls, suggesting that revascularisation may explain the schedule dependency of the tumor-growth delay obsd.  The results of assocn. with radiation show that BMS-690514 may be a successful adjuvant to clin. radiotherapy.  These findings are of translational importance because the clin. benefits of anti-EGFR and anti-VEGFR therapy might be schedule dependent.  British Journal of Cancer (2010) 103, 347-353; doi:10.1038/sj.bjc.6605748 www.bjcancer.com Published online 13 July 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWCnV7UYBlYLVg90H21EOLACvtfcHk0ljXXurx1ZNneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Oitrg%253D&md5=82906390bfe03ce3710c457db910eaca</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605748%26sid%3Dliteratum%253Aachs%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DMordant%26aufirst%3DP.%26aulast%3DDorvault%26aufirst%3DN.%26aulast%3DDe%2Bla%2Bmotte%2BRouge%26aufirst%3DT.%26aulast%3DBourhis%26aufirst%3DJ.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DDeutsch%26aufirst%3DE.%26atitle%3DBMS-690514%252C%2520a%2520VEGFR%2520and%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%252C%2520shows%2520anti-tumoural%2520activity%2520on%2520non-small-cell%2520lung%2520cancer%2520xenografts%2520and%2520induces%2520sequence-dependent%2520synergistic%2520effect%2520with%2520radiation%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D103%26spage%3D347%26epage%3D353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malone, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span> </span><span class="NLM_article-title">Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4031</span><span class="NLM_x">–</span> <span class="NLM_lpage">4041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-3417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21531814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4031-4041&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=S.+Emanuelauthor=C.+Fairchildauthor=J.+Fargnoliauthor=B.+Finkauthor=A.+Gavaiauthor=A.+Hammellauthor=B.+Henleyauthor=C.+Hiltauthor=J.+T.+Huntauthor=B.+Krishnanauthor=D.+Kukralauthor=A.+Lewinauthor=H.+Maloneauthor=D.+Norrisauthor=S.+Oppenheimerauthor=G.+Viteauthor=C.+Yu&title=Antitumor+and+antiangiogenic+activities+of+BMS-690514%2C+an+inhibitor+of+human+EGF+and+VEGF+receptor+kinase+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families</span></div><div class="casAuthors">Wong, Tai-W.; Lee, Francis Y.; Emanuel, Stuart; Fairchild, Craig; Fargnoli, Joseph; Fink, Brian; Gavai, Ashvinikumar; Hammell, Amy; Henley, Benjamin; Hilt, Christine; Hunt, John T.; Krishnan, Bala; Kukral, Daniel; Lewin, Anne; Malone, Harold; Norris, Derek; Oppenheimer, Simone; Vite, Gregory; Yu, Chiang</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4031-4041</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The extensive involvement of the HER kinases in epithelial cancer suggests that kinase inhibitors targeting this receptor family have the potential for broad spectrum antitumor activity.  BMS-690514 potently inhibits all three HER kinases, and the VEGF receptor kinases.  This report summarizes data from biochem. and cellular pharmacol. studies, as well as antitumor activity of BMS-690514.  Exptl. Design: The potency and selectivity of BMS-690514 was evaluated by using an extensive array of enzymic and binding assays, as well as cellular assays that measure proliferation and receptor signaling.  Antitumor activity was evaluated by using multiple xenograft models that depend on HER kinase signaling.  The antiangiogenic properties of BMS-690514 were assessed in a matrigel plug assay, and effect on tumor blood flow was measured by dynamic contrast-enhanced MRI.  RESULTS: BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kinases.  It inhibits proliferation of tumor cells with potency that correlates with inhibition of receptor signaling, and induces apoptosis in lung tumor cells that have an activating mutation in EGFR.  Antitumor activity was obsd. with BMS-690514 at multiple doses that are well tolerated in mice.  There was evidence of suppression of tumor angiogenesis and endothelial function by BMS-690514, which may contribute to its efficacy.  CONCLUSIONS: By combining inhibition of two receptor kinase families, BMS-690524 is a novel targeted agent that disrupts signaling in the tumor and its vasculature.  Clin Cancer Res; 17(12); 4031-41.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgvI_vgS8debVg90H21EOLACvtfcHk0ljXXurx1ZNneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKgt78%253D&md5=38fe4d2d2a3a2414888c3f38f72caca4</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3417%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DEmanuel%26aufirst%3DS.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DFink%26aufirst%3DB.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DHammell%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHilt%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKrishnan%26aufirst%3DB.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DLewin%26aufirst%3DA.%26aulast%3DMalone%26aufirst%3DH.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DC.%26atitle%3DAntitumor%2520and%2520antiangiogenic%2520activities%2520of%2520BMS-690514%252C%2520an%2520inhibitor%2520of%2520human%2520EGF%2520and%2520VEGF%2520receptor%2520kinase%2520families%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4031%26epage%3D4041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleczka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">3579</span><span class="NLM_x">–</span> <span class="NLM_lpage">3593</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=3579-3593&author=P.+Maratheauthor=Y.+Tangauthor=B.+Sleczkaauthor=D.+Rodriguesauthor=A.+Gavaiauthor=T.+Wongauthor=L.+Christopherauthor=H.+Zhang&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+BMS-690514%2C+a+potent+inhibitor+of+EGFR+and+VEGFR2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DRodrigues%26aufirst%3DD.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChristopher%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520BMS-690514%252C%2520a%2520potent%2520inhibitor%2520of%2520EGFR%2520and%2520VEGFR2%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D3579%26epage%3D3593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Hong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopher, L. J.</span><span> </span><span class="NLM_article-title">In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1658</span><span class="NLM_x">–</span> <span class="NLM_lpage">1667</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1658-1667&author=H.+Hongauthor=H.+Suauthor=L.+Maauthor=M.+Yaoauthor=R.+A.+Iyerauthor=W.+G.+Humphreysauthor=L.+J.+Christopher&title=In+vitro+characterization+of+the+metabolic+pathways+and+cytochrome+P450+inhibition+and+induction+potential+of+BMS-690514%2C+an+ErbB%2Fvascular+endothelial+growth+factor+receptor+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DR.%2BA.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DChristopher%26aufirst%3DL.%2BJ.%26atitle%3DIn%2520vitro%2520characterization%2520of%2520the%2520metabolic%2520pathways%2520and%2520cytochrome%2520P450%2520inhibition%2520and%2520induction%2520potential%2520of%2520BMS-690514%252C%2520an%2520ErbB%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1658%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(3-amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061280h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1584-1597&author=Y.+Daiauthor=K.+Hartandiauthor=Z.+Jiauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=K.+B.+Glaserauthor=C.+M.+Harrisauthor=D.+Hickmanauthor=J.+Guoauthor=J.+Liauthor=P.+A.+Marcotteauthor=K.+C.+Marshauthor=M.+D.+Moskeyauthor=R.+L.+Martinauthor=A.+M.+Olsonauthor=D.+J.+Osterlingauthor=L.+J.+Peaseauthor=N.+B.+Soniauthor=K.+D.+Stewartauthor=V.+S.+Stollauthor=P.+Tapangauthor=D.+R.+Reuterauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Discovery+of+N-%284-%283-amino-1H-indazol-4-yl%29phenyl%29-N%E2%80%B2-%282-fluoro-5-methylphenyl%29urea+%28ABT-869%29%2C+a+3-aminoindazole-based+orally+active+multitargeted+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm061280h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061280h%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520N-%25284-%25283-amino-1H-indazol-4-yl%2529phenyl%2529-N%25E2%2580%25B2-%25282-fluoro-5-methylphenyl%2529urea%2520%2528ABT-869%2529%252C%2520a%25203-aminoindazole-based%2520orally%2520active%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1584%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magoc, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi-Haack, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukofzer, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niquette, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span> </span><span class="NLM_article-title">Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1535-7163.MCT-05-0410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16648571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=995-1006&author=D.+H.+Albertauthor=P.+Tapangauthor=T.+J.+Magocauthor=L.+J.+Peaseauthor=D.+R.+Reuterauthor=R.+Wieauthor=J.+Liauthor=J.+Guoauthor=P.+F.+Bousquetauthor=N.+S.+Ghoreishi-Haackauthor=B.+Wangauthor=G.+T.+Bukofzerauthor=Y.+C.+Wangauthor=J.+A.+Stavropoulosauthor=K.+Hartandiauthor=A.+L.+Niquetteauthor=N.+Soniauthor=E.+F.+Johnsonauthor=J.+O.+McCallauthor=J.+J.+Bouskaauthor=Y.+Luoauthor=C.+K.+Donawhoauthor=Y.+Daiauthor=P.+A.+Marcotteauthor=K.+B.+Glaserauthor=M.+R.+Michaelidesauthor=S.+K.+Davidsen&title=Preclinical+activity+of+ABT-869%2C+a+multitargeted+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Albert, Daniel H.; Tapang, Paul; Magoc, Terrance J.; Pease, Lori J.; Reuter, David R.; Wei, Ru-Qi; Li, Junling; Guo, Jun; Bousquet, Peter F.; Ghoreishi-Haack, Nayereh S.; Wang, Baole; Bukofzer, Gail T.; Wang, Yi-Chun; Stavropoulos, Jason A.; Hartandi, Kresna; Niquette, Amanda L.; Soni, Nirupama; Johnson, Eric F.; McCall, J. Owen; Bouska, Jennifer J.; Luo, Yanping; Donawho, Cherrie K.; Dai, Yujia; Marcotte, Patrick A.; Glaser, Keith B.; Michaelides, Michael R.; Davidsen, Steven K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">995-1006</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 μmol/L) against unrelated RTKs, sol. tyrosine kinases, or serine/threonine kinases.  The inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 = 2, 4, and 7 nmol/L for PDGFR-β, KDR, and CSF-1R, resp.) and VEGF-stimulated proliferation (IC50 = 0.2 nmol/L for human endothelial cells).  ABT-869 is not a general antiproliferative agent because, in most cancer cells, >1,000-fold higher concns. of ABT-869 are required for inhibition of proliferation.  However, ABT-869 exhibits potent antiproliferative and apoptotic effects on cancer cells whose proliferation is dependent on mutant kinases, such as FLT3.  In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50% inhibition, 15 mg/kg).  In tumor growth studies, ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED50 = 1.5-5 mg/kg, twice daily) and is also effective (>50% inhibition) in orthotopic breast and glioma models.  Redn. in tumor size and tumor regression was obsd. in epidermoid carcinoma and leukemia xenograft models, resp.  In combination, ABT-869 produced at least additive effects when given with cytotoxic therapies.  Based on pharmacokinetic anal. from tumor growth studies, efficacy correlated more strongly with time over a threshold value (cellular KDR IC50 cor. for blood plasma protein binding = 0.08 μg/mL, ≥7 h) than with plasma area under the curve or Cmax.  These results support clin. assessment of ABT-869 as a therapeutic agent for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkn2KBvMa4wrVg90H21EOLACvtfcHk0lim2_m8WMdUtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCkt7g%253D&md5=a5a60b591b4da7a3c589f1618d9cffb9</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0410%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DMagoc%26aufirst%3DT.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DWie%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DGhoreishi-Haack%26aufirst%3DN.%2BS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DBukofzer%26aufirst%3DG.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DStavropoulos%26aufirst%3DJ.%2BA.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DNiquette%26aufirst%3DA.%2BL.%26aulast%3DSoni%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMcCall%26aufirst%3DJ.%2BO.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26atitle%3DPreclinical%2520activity%2520of%2520ABT-869%252C%2520a%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D995%26epage%3D1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Jiang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesniewski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeegan, E. M.</span><span> </span><span class="NLM_article-title">ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1124%2Fjpet.110.178061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21505059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=134-142&author=F.+Jiangauthor=D.+H.+Albertauthor=Y.+Luoauthor=P.+Tapangauthor=K.+Zhangauthor=S.+K.+Davidsenauthor=G.+B.+Foxauthor=R.+Lesniewskiauthor=E.+M.+McKeegan&title=ABT-869%2C+a+multitargeted+receptor+tyrosine+kinase+inhibitor%2C+reduces+tumor+microvascularity+and+improves+vascular+wall+integrity+in+preclinical+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models</span></div><div class="casAuthors">Jiang, Fang; Albert, Daniel H.; Luo, Yanping; Tapang, Paul; Zhang, Ke; Davidsen, Steven K.; Fox, Gerard B.; Lesniewski, Richard; McKeegan, Evelyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-142</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-Me phenyl)-urea (ABT-869) is a novel multitargeted receptor tyrosine kinase inhibitor that demonstrates single-agent activity in preclin. studies and has undergone phase I and II clin. trials.  We characterized the mechanism of action of ABT-869 by examg. vascular changes after treatment (25 mg/kg per day) in HT1080 fibrosarcoma and SW620 colon carcinoma cells, using immunohistochem., dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI), and hypoxic protein detection.  We obsd. the inhibition of vascular endothelial growth factor receptor 2 and platelet-derived growth factor receptor β phosphorylation in both tumors and changes in tumor vasculature.  Redns. in microvessel d. and diam. were obsd.  Vascular-wall integrity was assessed by colocalization of pericytes and basement membrane.  Although both microvessel d. and total no. of pericytes decreased with treatment, the percentage of pericyte coverage on remaining vessels significantly increased.  These data suggest the selective ablation of microvessels lacking pericyte coverage.  Functional vascular measures DCE-MRI and hypoxia formation were also tested.  After 2 days of treatment on the HT1080 model, vascular permeability, Ktrans, was reduced by >60% and hypoxic tumor fraction was significantly decreased, which was also seen in the SW620 tumors after 4 days of treatment.  Taken together, decreases in vascular permeability and changes in vascular integrity obsd. in these studies define the mode of action of ABT-869 and may aid in optimizing the timing of therapeutic window for combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZdOtgsQFEbVg90H21EOLACvtfcHk0lim2_m8WMdUtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu74%253D&md5=8c9eafe6eac51b7433ef7d12951936a9</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178061%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DLesniewski%26aufirst%3DR.%26aulast%3DMcKeegan%26aufirst%3DE.%2BM.%26atitle%3DABT-869%252C%2520a%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520reduces%2520tumor%2520microvascularity%2520and%2520improves%2520vascular%2520wall%2520integrity%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D134%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hradil, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravartty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeegan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G. B.</span><span> </span><span class="NLM_article-title">A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-011-1740-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22080168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVCrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=911-921&author=Y.+Luoauthor=F.+Jiangauthor=T.+B.+Coleauthor=V.+P.+Hradilauthor=D.+Reuterauthor=A.+Chakravarttyauthor=D.+H.+Albertauthor=S.+K.+Davidsenauthor=B.+F.+Coxauthor=E.+M.+McKeeganauthor=G.+B.+Fox&title=A+novel+multi-targeted+tyrosine+kinase+inhibitor%2C+linifanib+%28ABT-869%29%2C+produces+functional+and+structural+changes+in+tumor+vasculature+in+an+orthotopic+rat+glioma+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model</span></div><div class="casAuthors">Luo, Yanping; Jiang, Fang; Cole, Todd B.; Hradil, Vincent P.; Reuter, David; Chakravartty, Arunava; Albert, Daniel H.; Davidsen, Steven K.; Cox, Bryan F.; McKeegan, Evelyn M.; Fox, Gerard B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">911-921</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors represent a class of targeted therapy that has proven to be successful for cancer treatment.  Linifanib is a novel, orally active multi-targeted receptor tyrosine kinase (RTK) inhibitor that exhibits potent antitumor and antiangiogenic activities against a broad spectrum of exptl. tumors and malignancies in patients.  The compd. is currently being evaluated in phase 2 and 3 clin. trials.  To investigate the effectiveness of linifinib against gliomas and the mechanism of drug action, we characterized treatment-induced antitumor and antiangiogenic responses to linifanib in an orthotopic rat glioma model.  The effect of linifanib treatment on tumor growth was detd. by tumor vol. assessment using anatomical magnetic resonance imaging (MRI).  Changes in tumor microvessel function were evaluated with dynamic contrast-enhanced MRI (DCE-MRI).  Immunohistochem. (IHC) was applied to excised tumor samples to examine underlying changes in vascular structures and target receptor expression.  Linifanib (10 mg/kg) given twice daily inhibited tumor growth following treatment for 7 days with tumor vols. being 149 ± 30 and 66 ± 7 mm3 for vehicle-and linifanib-treated groups, resp.  A significant redn. of 37 ± 13% in tumor perfusion and microvessel permeability (measured by K trans) was obsd. as early as 2 h after administration compared with vehicle treatment.  Continuous linifanib administration further reduced K trans at later time points until the end of the study (7 days post-treatment).  At day 7, K trans was reduced by 75 ± 32% for linifanib treatment compared with vehicle treatment.  Significant redn. in total blood vessel d. and improved vessel wall integrity were obsd., and staining for target receptor expression confirmed inhibition of phospho VEGFR-2 and PDGFR-β by linifanib treatment.  These results demonstrate significant antitumor and antiangiogenic activity against gliomas by linifanib, a property that may result from the inhibition of VEGFR-2 and PDGFR-β-mediated vascular changes.  DCE-MRI measured K trans changes at early treatment stages may be a useful pharmacodynamic marker for linifanib activity in clin. trials, and basal K trans may provide predictive value for tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp29ISvhCKMZrVg90H21EOLACvtfcHk0liABkwXzWYXBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVCrsr8%253D&md5=53a832161d9d0ea29b24e556eb81e61c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1740-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1740-7%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DCole%26aufirst%3DT.%2BB.%26aulast%3DHradil%26aufirst%3DV.%2BP.%26aulast%3DReuter%26aufirst%3DD.%26aulast%3DChakravartty%26aufirst%3DA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DMcKeegan%26aufirst%3DE.%2BM.%26aulast%3DFox%26aufirst%3DG.%2BB.%26atitle%3DA%2520novel%2520multi-targeted%2520tyrosine%2520kinase%2520inhibitor%252C%2520linifanib%2520%2528ABT-869%2529%252C%2520produces%2520functional%2520and%2520structural%2520changes%2520in%2520tumor%2520vasculature%2520in%2520an%2520orthotopic%2520rat%2520glioma%2520model%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D911%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Asahina, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nokihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coates, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradhan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeegan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span> </span><span class="NLM_article-title">An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">1486</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-012-1846-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22382879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFOnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1477-1486&author=H.+Asahinaauthor=Y.+Tamuraauthor=H.+Nokiharaauthor=N.+Yamamotoauthor=Y.+Sekiauthor=T.+Shibataauthor=Y.+Gotoauthor=M.+Taniokaauthor=Y.+Yamadaauthor=A.+Coatesauthor=Y.+L.+Chiuauthor=X.+Liauthor=R.+Pradhanauthor=P.+J.+Ansellauthor=E.+M.+McKeeganauthor=M.+D.+McKeeauthor=D.+M.+Carlsonauthor=T.+Tamura&title=An+open-label%2C+phase+1+study+evaluating+safety%2C+tolerability%2C+and+pharmacokinetics+of+linifanib+%28ABT-869%29+in+Japanese+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors</span></div><div class="casAuthors">Asahina, Hajime; Tamura, Yosuke; Nokihara, Hiroshi; Yamamoto, Noboru; Seki, Yoshitaka; Shibata, Takashi; Goto, Yasushi; Tanioka, Maki; Yamada, Yasuhide; Coates, Andrew; Chiu, Yi-Lin; Li, Xiaohui; Pradhan, Rajendra; Ansell, Peter J.; McKeegan, Evelyn M.; McKee, Mark D.; Carlson, Dawn M.; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1477-1486</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose This phase 1 study assessed the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of linifanib in Japanese patients with advanced solid tumors.  Methods Patients were assigned to one of four sequential cohorts (0.05, 0.10, 0.20, or 0.25 mg/kg) of oral, once-daily linifanib on a 21-day cycle.  Adverse events (AEs) were assessed per common terminol. criteria for adverse events v3.0; tumor responses were assessed by response evaluation criteria in solid tumors.  Results Eighteen patients were enrolled.  Eleven (61%) received ≥3 prior therapies.  Dose-limiting toxicities were Grade 3 ALT increase (0.10 mg/kg linifanib) and Grade 1 T-wave inversion (0.25 mg/kg linifanib) requiring dose interruption for >7 days and discontinuation on day 29.  The most common linifanib-related AE was hypertension.  Other significant treatment-related AEs included proteinuria, fatigue, and palmar-plantar erythrodysaesthesia.  Linifanib pharmacokinetics were dose-proportional across 0.10-0.25 mg/kg.  Two patients (11.1%) had confirmed partial responses, 12 had a best response of stable disease (11 had stable disease for ≥12 wk), and four patients were not evaluable due to incomplete data.  Four patients (lung cancer, breast cancer, thymic cancer, sarcoma) have continued linifanib for ≥48 wk (range, 48-96+ weeks).  Conclusion Linifanib was well tolerated with promising preliminary clin. activity in Japanese patients.  Later-phase global studies examg. linifanib efficacy will include Japanese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmFV7_CGfQ3LVg90H21EOLACvtfcHk0liABkwXzWYXBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFOnsLs%253D&md5=f7a06d92da7728b7934ed6ab1d9ad2bc</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1846-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1846-6%26sid%3Dliteratum%253Aachs%26aulast%3DAsahina%26aufirst%3DH.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DTanioka%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DCoates%26aufirst%3DA.%26aulast%3DChiu%26aufirst%3DY.%2BL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DPradhan%26aufirst%3DR.%26aulast%3DAnsell%26aufirst%3DP.%2BJ.%26aulast%3DMcKeegan%26aufirst%3DE.%2BM.%26aulast%3DMcKee%26aufirst%3DM.%2BD.%26aulast%3DCarlson%26aufirst%3DD.%2BM.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DAn%2520open-label%252C%2520phase%25201%2520study%2520evaluating%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520linifanib%2520%2528ABT-869%2529%2520in%2520Japanese%2520patients%2520with%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1477%26epage%3D1486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Tannir, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollmannsberger, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernstoff, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posadas, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coates, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradhan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scappaticci, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricker, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelson, M. D.</span><span> </span><span class="NLM_article-title">Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2706</span><span class="NLM_x">–</span> <span class="NLM_lpage">2714</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=2706-2714&author=N.+M.+Tannirauthor=Y.+N.+Wongauthor=C.+K.+Kollmannsbergerauthor=M.+S.+Ernstoffauthor=D.+J.+Perryauthor=L.+J.+Applemanauthor=E.+M.+Posadasauthor=D.+Choauthor=T.+K.+Choueiriauthor=A.+Coatesauthor=N.+Guptaauthor=R.+Pradhanauthor=J.+Qianauthor=J.+Chenauthor=F.+A.+Scappaticciauthor=J.+L.+Rickerauthor=D.+M.+Carlsonauthor=M.+D.+Michaelson&title=Phase+2+trial+of+linifanib+%28ABT-869%29+in+patients+with+advanced+renal+cell+cancer+after+sunitinib+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTannir%26aufirst%3DN.%2BM.%26aulast%3DWong%26aufirst%3DY.%2BN.%26aulast%3DKollmannsberger%26aufirst%3DC.%2BK.%26aulast%3DErnstoff%26aufirst%3DM.%2BS.%26aulast%3DPerry%26aufirst%3DD.%2BJ.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DCho%26aufirst%3DD.%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DCoates%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DPradhan%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DScappaticci%26aufirst%3DF.%2BA.%26aulast%3DRicker%26aufirst%3DJ.%2BL.%26aulast%3DCarlson%26aufirst%3DD.%2BM.%26aulast%3DMichaelson%26aufirst%3DM.%2BD.%26atitle%3DPhase%25202%2520trial%2520of%2520linifanib%2520%2528ABT-869%2529%2520in%2520patients%2520with%2520advanced%2520renal%2520cell%2520cancer%2520after%2520sunitinib%2520failure%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47%26spage%3D2706%26epage%3D2714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandara, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thertulien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertheim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazieres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hensing, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradhan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scappaticci, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricker, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, R. A.</span><span> </span><span class="NLM_article-title">Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1418</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1097%2FJTO.0b013e318220c93e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21597387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADC%252BC3MfmtVSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1418-1425&author=E.+H.+Tanauthor=G.+D.+Gossauthor=R.+Salgiaauthor=B.+Besseauthor=D.+R.+Gandaraauthor=N.+H.+Hannaauthor=J.+C.+Yangauthor=R.+Thertulienauthor=M.+Wertheimauthor=J.+Mazieresauthor=T.+Hensingauthor=C.+Leeauthor=N.+Guptaauthor=R.+Pradhanauthor=J.+Qianauthor=Q.+Qinauthor=F.+A.+Scappaticciauthor=J.+L.+Rickerauthor=D.+M.+Carlsonauthor=R.+A.+Soo&title=Phase+2+trial+of+linifanib+%28ABT-869%29+in+patients+with+advanced+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer</span></div><div class="casAuthors">Tan Eng-Huat; Goss Glenwood D; Salgia Ravi; Besse Benjamin; Gandara David R; Hanna Nasser H; Yang James Chih-Hsin; Thertulien Raymond; Wertheim Michael; Mazieres Julien; Hensing Thomas; Lee Christa; Gupta Neeraj; Pradhan Rajendra; Qian Jiang; Qin Qin; Scappaticci Frank A; Ricker Justin L; Carlson Dawn M; Soo Ross A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1418-25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  This study assessed activity and safety of linifanib (ABT-869), a selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, in patients with locally advanced or metastatic non-small cell lung cancer.  METHODS:  In this open-label trial (NCT00517790), patients who received one to two prior lines of systemic therapy were randomized to oral linifanib 0.10 mg/kg (low dose) or 0.25 mg/kg (high dose) once daily.  Tumor responses were assessed by independent central imaging review every 8 weeks.  The primary end point was progression-free rate at 16 weeks.  Secondary end points included objective response rate, time to progression, progression-free survival, and overall survival.  Safety was also assessed.  RESULTS:  Between August 2007 and October 2008, 139 patients were enrolled; 60% had two or more prior regimens, and 88% had nonsquamous cell carcinoma.  The objective response rate (low dose and high dose) was 5.0% (3.1 and 6.8%), progression-free rate at 16 weeks was 33.1% (32.3 and 33.8%), median time to progression was 3.6 months (3.6 and 3.7 months), median progression-free survival was 3.6 months (3.5 and 3.6 months), and median overall survival was 9.0 months (10.0 and 8.3 months).  The most common linifanib-related adverse events were fatigue (42%), decreased appetite (38%), hypertension (37%), diarrhea (32%), nausea (27%), palmar-plantar erythrodysesthesia (24%), and proteinuria (22%).  These events were more common in the high-dose group.  The most common linifanib-related grade 3 or 4 adverse event was hypertension (14%).  CONCLUSIONS:  Linifanib is active in advanced non-small cell lung cancer as second- or third-line therapy.  Increased adverse event rates were observed at the high dose of linifanib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0MxtPeEZ78qcY7HFp97qMfW6udTcc2eb3S88fLxOdX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfmtVSltw%253D%253D&md5=71f49f7f3be899090749398888462ad1</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e318220c93e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e318220c93e%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DGoss%26aufirst%3DG.%2BD.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DGandara%26aufirst%3DD.%2BR.%26aulast%3DHanna%26aufirst%3DN.%2BH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DThertulien%26aufirst%3DR.%26aulast%3DWertheim%26aufirst%3DM.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DHensing%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DPradhan%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DScappaticci%26aufirst%3DF.%2BA.%26aulast%3DRicker%26aufirst%3DJ.%2BL.%26aulast%3DCarlson%26aufirst%3DD.%2BM.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26atitle%3DPhase%25202%2520trial%2520of%2520linifanib%2520%2528ABT-869%2529%2520in%2520patients%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D1418%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegrini, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosios, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McSheehy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span> </span><span class="NLM_article-title">AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">4931</span><span class="NLM_x">–</span> <span class="NLM_lpage">4941</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4931-4941&author=P.+Traxlerauthor=P.+R.+Allegriniauthor=B.+Brandtauthor=J.+Brueggenauthor=R.+Cozensauthor=D.+Fabbroauthor=K.+Grosiosauthor=H.+A.+Laneauthor=P.+McSheehyauthor=J.+Mestanauthor=T.+Meyerauthor=C.+Tangauthor=M.+Wartmannauthor=J.+Woodauthor=G.+Caravatti&title=AEE788%3A+a+dual+family+epidermal+growth+factor+receptor%2FErbB2+and+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitor+with+antitumor+and+antiangiogenic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DAllegrini%26aufirst%3DP.%2BR.%26aulast%3DBrandt%26aufirst%3DB.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGrosios%26aufirst%3DK.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DMcSheehy%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DAEE788%253A%2520a%2520dual%2520family%2520epidermal%2520growth%2520factor%2520receptor%252FErbB2%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520with%2520antitumor%2520and%2520antiangiogenic%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4931%26epage%3D4941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neureiter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alinger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissnitzer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sass, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fazio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissniowski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gahr, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlösser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haus, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocker, M.</span><span> </span><span class="NLM_article-title">The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">742</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18813786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KhtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=733-742&author=K.+Okamotoauthor=D.+Neureiterauthor=B.+Alingerauthor=M.+Meissnitzerauthor=G.+Sassauthor=V.+Schmitzauthor=P.+Di+Fazioauthor=T.+Wissniowskiauthor=S.+Gahrauthor=B.+Hohensteinauthor=B.+Kaufmannauthor=A.+Schl%C3%B6sserauthor=U.+Hausauthor=E.+G.+Hahnauthor=C.+Heroldauthor=M.+Ocker&title=The+dual+EGF%2FVEGF+receptor+tyrosine+kinase+inhibitor+AEE788+inhibits+growth+of+human+hepatocellular+carcinoma+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice</span></div><div class="casAuthors">Okamoto, Kinya; Neureiter, Daniel; Alinger, Beate; Meissnitzer, Matthias; Sass, Gabriele; Schmitz, Volker; Di Fazio, Pietro; Wissniowski, Till; Gahr, Susanne; Hohenstein, Bernd; Kaufmann, Bernhard; Schloesser, Axel; Haus, Ulrike; Hahn, Eckhart G.; Herold, Christoph; Ocker, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-742</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">We investigated the effect of AEE788, a novel dual receptor tyrosine kinase inhibitor of the EGF and the VEGF receptor, for treatment of human HCC cell lines and in a s.c. xenograft model.  Cell viability and apoptosis of HepG2 and Hep3B cells incubated with 0.1-100 μM AEE788 were quantified.  In vivo, HepG2 cells were xenografted to NMRI mice and animals were treated orally with 50 mg/kg AEE788 3x/wk.  Immunohistochem. and quant. Western blotting was performed for pathway anal. in vitro and in vivo.  AEE788 reduced growth and induced apoptosis of HCC cells by disrupting mitochondrial transmembrane potentials and inhibiting MAPK phosphorylation.  In the xenografts, AEE788 lead to a reduced tumor growth by reducing proliferation and vascularization.  Except for a reversible skin reaction and wt. loss, no signs of toxicity were obsd.  AEE788 is a promising new option for the treatment of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowl0vYOaiylLVg90H21EOLACvtfcHk0lgEPnl6TpT-WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KhtbbI&md5=aca1665a8d08358a2c297e076bef50fb</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DNeureiter%26aufirst%3DD.%26aulast%3DAlinger%26aufirst%3DB.%26aulast%3DMeissnitzer%26aufirst%3DM.%26aulast%3DSass%26aufirst%3DG.%26aulast%3DSchmitz%26aufirst%3DV.%26aulast%3DDi%2BFazio%26aufirst%3DP.%26aulast%3DWissniowski%26aufirst%3DT.%26aulast%3DGahr%26aufirst%3DS.%26aulast%3DHohenstein%26aufirst%3DB.%26aulast%3DKaufmann%26aufirst%3DB.%26aulast%3DSchl%25C3%25B6sser%26aufirst%3DA.%26aulast%3DHaus%26aufirst%3DU.%26aulast%3DHahn%26aufirst%3DE.%2BG.%26aulast%3DHerold%26aufirst%3DC.%26aulast%3DOcker%26aufirst%3DM.%26atitle%3DThe%2520dual%2520EGF%252FVEGF%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520AEE788%2520inhibits%2520growth%2520of%2520human%2520hepatocellular%2520carcinoma%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2008%26volume%3D33%26spage%3D733%26epage%3D742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Meco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Servidei, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannoni, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prisco, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Waure, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi, R.</span><span> </span><span class="NLM_article-title">Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma</span> <span class="citation_source-journal">Transl. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">335</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1593%2Ftlo.10163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20885895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADC%252BC3cfmvVWiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=326-335&author=D.+Mecoauthor=T.+Servideiauthor=G.+F.+Zannoniauthor=E.+Martinelliauthor=M.+G.+Priscoauthor=C.+de+Waureauthor=R.+Riccardi&title=Dual+inhibitor+AEE788+reduces+tumor+growth+in+preclinical+models+of+medulloblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma</span></div><div class="casAuthors">Meco Daniela; Servidei Tiziana; Zannoni Gian Franco; Martinelli Enrica; Prisco Maria Grazia; de Waure Chiara; Riccardi Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">326-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Medulloblastoma is the most frequent malignant pediatric brain tumor with a dismal prognosis in 30% of cases.  We examined the activity of AEE788, a dual inhibitor of human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2, in medulloblastoma preclinical models.  Established lines (Daoy and D283), chemoresistant (Daoy(Pt)), and ectopically HER2-overexpressing (Daoy(HER2)) cells expressed diverse levels of total and activated AEE788 target receptors.  In vitro, AEE788 inhibited cell proliferation (IC(50) from 1.7 to 3.8 μM) and prevented epidermal growth factor- and neuregulin-induced HER1, HER2, and HER3 activation.  Inhibition of Akt paralleled that of HER receptors.  In vivo, AEE788 growth inhibited Daoy, Daoy(Pt), and Daoy(HER2) xenografts by 51%, 45%, and 72%, respectively.  Immunohistochemical analysis of mock- and HER2-transfected xenografts revealed that the latter showed, along with high HER2 expression, high VEGFR2 staining in tumor and endothelial cells and increased expression of the endothelial marker CD31.  AEE788 reduced the activation of target receptors and angiogenesis.  In 21 primary medulloblastoma, HER2 expression significantly correlated (P < .01) with VEGFR2 (r = 0.56) and VEGF (r = 0.61).  In conclusion, AEE788 shows similar growth-suppressive activities in chemosensitive and chemoresistant medulloblastoma cells in vitro and in vivo.  Ectopic HER2 overexpression sensitizes cells to AEE788 in vivo, but not in vitro, possibly through host-mediated processes.  Together with the experimental data, the finding that HER2 positively correlates with VEGFR2 and VEGF in human medulloblastoma specimens indicates HER2-overexpressing medulloblastoma as the subset that most likely might benefit from AEE788 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcZ4JW-oc_HTMsgLhIoICsfW6udTcc2eY3X5vCjnj6SLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfmvVWiug%253D%253D&md5=dfd2a6b42009efdd77401ea45f53be7f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1593%2Ftlo.10163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Ftlo.10163%26sid%3Dliteratum%253Aachs%26aulast%3DMeco%26aufirst%3DD.%26aulast%3DServidei%26aufirst%3DT.%26aulast%3DZannoni%26aufirst%3DG.%2BF.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DPrisco%26aufirst%3DM.%2BG.%26aulast%3Dde%2BWaure%26aufirst%3DC.%26aulast%3DRiccardi%26aufirst%3DR.%26atitle%3DDual%2520inhibitor%2520AEE788%2520reduces%2520tumor%2520growth%2520in%2520preclinical%2520models%2520of%2520medulloblastoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D326%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Reardon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrad, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prados, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mietlowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yung, W. K.</span><span> </span><span class="NLM_article-title">Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1507</span><span class="NLM_x">–</span> <span class="NLM_lpage">1518</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-012-1854-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22392572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFOnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1507-1518&author=D.+A.+Reardonauthor=C.+A.+Conradauthor=T.+Cloughesyauthor=M.+D.+Pradosauthor=H.+S.+Friedmanauthor=K.+D.+Aldapeauthor=P.+Mischelauthor=J.+Xiaauthor=C.+Dileaauthor=J.+Huangauthor=W.+Mietlowskiauthor=M.+Duganauthor=W.+Chenauthor=W.+K.+Yung&title=Phase+I+study+of+AEE788%2C+a+novel+multitarget+inhibitor+of+ErbB-+and+VEGF-receptor-family+tyrosine+kinases%2C+in+recurrent+glioblastoma+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients</span></div><div class="casAuthors">Reardon, David A.; Conrad, Charles A.; Cloughesy, Timothy; Prados, Michael D.; Friedman, Henry S.; Aldape, Kenneth D.; Mischel, Paul; Xia, Jane; DiLea, Clifford; Huang, Jerry; Mietlowski, William; Dugan, Margaret; Chen, Wei; Yung, W. K. Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1507-1518</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose Vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) play a significant role in glioblastoma angiogenesis and proliferation, making tyrosine kinase (TK) receptors logical targets for treatment.  We evaluated AEE788, a reversible TK inhibitor that inhibits EGFR and VEGFR, in recurrent glioblastoma patients.  Methods In this dose-escalation, phase I study, patients with recurrent glioblastoma received AEE788 once daily in 28-day cycles in stratified subgroups: those receiving (1) non-enzyme-inducing anticonvulsants drugs or no anticonvulsants (Group A) and (2) enzyme-inducing anticonvulsant drugs (Group B).  A dose-expansion phase stratified patients by surgical eligibility.  Primary objectives were to det. dose-limiting toxicity (DLT) and max. tolerated dose; secondary objectives included evaluating (1) safety/tolerability, (2) pharmacokinetics, and (3) preliminary antitumor activity.  Results Sixty-four glioblastoma patients were enrolled.  Two Group A patients experienced DLTs (proteinuria and stomatitis) at 550 mg; 550 mg was, therefore, the highest dose evaluated and dose limiting.  One Group B patient receiving 800 mg experienced a DLT (diarrhea).  The initially recommended dose for dose-expansion phase for Group A was 400 mg; addnl. patients received 250 mg to assess the hepatotoxicity.  Most frequently reported adverse events (AEs) included diarrhea and rash.  Serious AEs, most commonly grade 3/4 liver function test elevations, were responsible for treatment discontinuation in 17% of patients.  AEE788 concns. were reduced by EIACD.  The best overall response was stable disease (17%).  Conclusions Continuous, once-daily AEE788 was assocd. with unacceptable toxicity and minimal activity for the treatment of recurrent glioblastoma.  The study was, therefore, discontinued prematurely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVeHK16CPxbbVg90H21EOLACvtfcHk0lgbJQBSoAEwiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFOnsbY%253D&md5=cd6133b54e9d7e481af1dc42cd4917d2</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1854-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1854-6%26sid%3Dliteratum%253Aachs%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3DConrad%26aufirst%3DC.%2BA.%26aulast%3DCloughesy%26aufirst%3DT.%26aulast%3DPrados%26aufirst%3DM.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DMischel%26aufirst%3DP.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DDilea%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMietlowski%26aufirst%3DW.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DYung%26aufirst%3DW.%2BK.%26atitle%3DPhase%2520I%2520study%2520of%2520AEE788%252C%2520a%2520novel%2520multitarget%2520inhibitor%2520of%2520ErbB-%2520and%2520VEGF-receptor-family%2520tyrosine%2520kinases%252C%2520in%2520recurrent%2520glioblastoma%2520patients%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1507%26epage%3D1518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span> </span><span class="NLM_article-title">Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi101777f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=738-751&author=H.+Iwataauthor=S.+Imamuraauthor=A.+Horiauthor=M.+S.+Hixonauthor=H.+Kimuraauthor=H.+Miki&title=Biochemical+characterization+of+TAK-593%2C+a+novel+VEGFR%2FPDGFR+inhibitor+with+a+two-step+slow+binding+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fbi101777f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi101777f%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DS.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DHixon%26aufirst%3DM.%2BS.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26atitle%3DBiochemical%2520characterization%2520of%2520TAK-593%252C%2520a%2520novel%2520VEGFR%252FPDGFR%2520inhibitor%2520with%2520a%2520two-step%2520slow%2520binding%2520mechanism%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D738%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becknell, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miknyoczki, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">–</span> <span class="NLM_lpage">913</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201449n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=903-913&author=R.+L.+Hudkinsauthor=N.+C.+Becknellauthor=A.+L.+Zulliauthor=T.+L.+Underinerauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=M.+S.+Albomauthor=H.+Changauthor=S.+J.+Miknyoczkiauthor=K.+Hunterauthor=S.+Jones-Bolinauthor=H.+Zhaoauthor=E.+R.+Baconauthor=J.+P.+Mallamoauthor=M.+A.+Atorauthor=B.+A.+Ruggeri&title=Synthesis+and+biological+profile+of+the+pan-vascular+endothelial+growth+factor+receptor%2Ftyrosine+kinase+with+immunoglobulin+and+epidermal+growth+factor-like+homology+domains+2+%28VEGF-R%2FTIE-2%29+inhibitor+11-%282-methylpropyl%29-12%2C13-dihydro-2-methyl-8-%28pyrimidin-2-ylamino%29-4H-indazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazol-4-one+%28CEP-11981%29%3A+a+novel+oncology+therapeutic+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fjm201449n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201449n%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DBecknell%26aufirst%3DN.%2BC.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DMiknyoczki%26aufirst%3DS.%2BJ.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DBacon%26aufirst%3DE.%2BR.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DSynthesis%2520and%2520biological%2520profile%2520of%2520the%2520pan-vascular%2520endothelial%2520growth%2520factor%2520receptor%252Ftyrosine%2520kinase%2520with%2520immunoglobulin%2520and%2520epidermal%2520growth%2520factor-like%2520homology%2520domains%25202%2520%2528VEGF-R%252FTIE-2%2529%2520inhibitor%252011-%25282-methylpropyl%2529-12%252C13-dihydro-2-methyl-8-%2528pyrimidin-2-ylamino%2529-4H-indazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazol-4-one%2520%2528CEP-11981%2529%253A%2520a%2520novel%2520oncology%2520therapeutic%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D903%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Stratmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, K. H.</span><span> </span><span class="NLM_article-title">Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1002%2F1097-0215%28200002%299999%3A9999%3C%3A%3AAID-IJC1054%3E3.0.CO%3B2-Q" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=11169947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsFOktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2001&pages=273-282&author=A.+Stratmannauthor=T.+Ackerauthor=A.+M.+Burgerauthor=K.+Amannauthor=W.+Risauauthor=K.+H.+Plate&title=Differential+inhibition+of+tumor+angiogenesis+by+tie2+and+vascular+endothelial+growth+factor+receptor-2+dominant-negative+receptor+mutants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Differential inhibition of tumor angiogenesis by TIE2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants</span></div><div class="casAuthors">Stratmann, Astrid; Acker, Till; Burger, Angelika M.; Amann, Kerstin; Risau, Werner; Plate, Karl H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-282</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Tumor growth is angiogenesis-dependent.  Current evidence suggests that vascular endothelial growth factor (VEGF), a major regulator of embryonic and hypoxia-mediated angiogenesis, is necessary for tumor angiogenesis.  VEGF is expressed in tumor cells in vivo, and its Tyr kinase receptors VEGFR-1 and VEGFR-2 are up-regulated in the tumor endothelium.  A second endothelial cell-specific ligand/receptor Tyr kinase system, consisting of the tie2 receptor, its activating ligand angiopoietin-1 and the inhibitory ligand angiopoietin-2, was characterized.  The authors have examd. 6 human primary breast-cancer samples and 4 murine breast-cancer cell lines (M6363, M6378, M6444, M6468), transplanted into nude mice, by in situ hybridization and/or Northern anal.  Expression of angiopoietin-1, angiopoietin-2 and tie2 was compared to VEGF and VEGFR-2 expression.  Human tumors expressed VEGFR-2 and tie2 but varied considerably in VEGF and angiopoietin-1/-2 expression.  In the murine tumor models, the authors obsd. high heterogeneity of receptor and ligand expression.  M6363 and M6378 tumors were analyzed in detail because they showed different expression of components of the tie2/angiopoietin signaling system.  M6363 tumors expressed VEGF, VEGFR-2 and angiopoietin-2 but not tie2 or angiopoietin-1, suggesting activation of VEGFR-2 and inhibition of tie2 signaling pathways, whereas M6378 tumors expressed VEGF, VEGFR-2, tie2 and angiopoietin-1 but little angiopoietin-2, suggesting activation of both VEGFR-2 and tie2 signaling pathways.  In vivo studies using truncated dominant-neg. tie2 and VEGFR-2 mutants revealed inhibition of M6363 tumor growth by 15% (truncated tie2) and 36% (truncated VEGFR-2), resp.  In contrast, M6378 tumor growth was inhibited by 57% (truncated tie2) and 47% (truncated VEGFR-2), resp.  These findings support the hypothesis that tumor angiogenesis is dependent on VEGFR-2 but suggest that, in addn., tie2-dependent pathways of tumor angiogenesis may exist.  For adequate application of angiogenesis inhibitors in tumor patients, anal. of prevailing angiogenesis pathways may be a prerequisite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDdiCPRxhiV7Vg90H21EOLACvtfcHk0lg2yji9isg8ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsFOktQ%253D%253D&md5=dcafe52efa95848d38d3381097ab6fc8</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%28200002%299999%3A9999%3C%3A%3AAID-IJC1054%3E3.0.CO%3B2-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%2528200002%25299999%253A9999%253C%253A%253AAID-IJC1054%253E3.0.CO%253B2-Q%26sid%3Dliteratum%253Aachs%26aulast%3DStratmann%26aufirst%3DA.%26aulast%3DAcker%26aufirst%3DT.%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DAmann%26aufirst%3DK.%26aulast%3DRisau%26aufirst%3DW.%26aulast%3DPlate%26aufirst%3DK.%2BH.%26atitle%3DDifferential%2520inhibition%2520of%2520tumor%2520angiogenesis%2520by%2520tie2%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520dominant-negative%2520receptor%2520mutants%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2001%26volume%3D91%26spage%3D273%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madajewicz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgriff, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, D.</span><span> </span><span class="NLM_article-title">A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-006-0352-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17031646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVOgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=81-89&author=R.+B.+Cohenauthor=C.+J.+Langerauthor=G.+R.+Simonauthor=P.+D.+Eisenbergauthor=J.+D.+Hainsworthauthor=S.+Madajewiczauthor=T.+M.+Cosgriffauthor=K.+Pierceauthor=H.+Xuauthor=K.+Liauauthor=D.+Healey&title=A+phase+I%2Frandomized+phase+II%2C+non-comparative%2C+multicenter%2C+open+label+trial+of+CP-547%2C632+in+combination+with+paclitaxel+and+carboplatin+or+paclitaxel+and+carboplatin+alone+as+first-line+treatment+for+advanced+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Cohen, Roger B.; Langer, Corey J.; Simon, George Rajan; Eisenberg, Peter David; Hainsworth, John Daniel; Madajewicz, Stefan; Cosgriff, Thomas Michael; Pierce, Kristen; Xu, Huiping; Liau, Katherine; Healey, Diane</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-89</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate the toxicity profile and pharmacol. properties of oral CP-547,632 alone and in combination with paclitaxel and carboplatin administered every 3 wk, and to assess efficacy as measured by the objective response and progressive disease rates of oral CP-547,632 administered in combination with paclitaxel and carboplatin.  Patients and methods: Patients with stage IIIB/IV or recurrent non-small cell lung cancer receiving first-line chemotherapy were treated with oral daily CP-547,632 in combination with paclitaxel 225 mg/m2 and carboplatin AUC = 6 every 3 wk.  Pharmacokinetics parameters for CP-547,632 and paclitaxel were detd. independently and during co-administration.  Results: Seventy patients were enrolled and 68 patients were treated, 37 in phase 1 and 31 in phase 2 (14 with the combination and 17 with chemotherapy alone).  Dose-limiting toxicity of CP-547,632 250 mg by mouth daily in combination with paclitaxel and carboplatin was grade 3 rash and grade 3 diarrhea despite medical intervention.  CP-547,632 did not significantly affect the pharmacol. profiles of paclitaxel and carboplatin.  No subject had CR.  In phase I, seven subjects (22.6%) had a confirmed partial response.  In phase II, four subjects (28.6%) receiving CP-547,632 plus chemotherapy had a confirmed partial response.  In the phase II chemotherapy alone group, four subjects (25%) had a confirmed partial response.  Conclusion: The combination of CP-547,632 and paclitaxel and carboplatin was well-tolerated at doses up to 200 mg by mouth daily.  Dose-limiting toxicity of CP-547,632 at 250 mg consisted of diarrhea and rash.  CP-547,632 did not increase the objective response rate to chemotherapy alone in patients with advanced non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopzOmygcNSSLVg90H21EOLACvtfcHk0lg2yji9isg8ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVOgsLY%253D&md5=82853265274c80dc446731445b0c7707</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0352-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0352-0%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DSimon%26aufirst%3DG.%2BR.%26aulast%3DEisenberg%26aufirst%3DP.%2BD.%26aulast%3DHainsworth%26aufirst%3DJ.%2BD.%26aulast%3DMadajewicz%26aufirst%3DS.%26aulast%3DCosgriff%26aufirst%3DT.%2BM.%26aulast%3DPierce%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLiau%26aufirst%3DK.%26aulast%3DHealey%26aufirst%3DD.%26atitle%3DA%2520phase%2520I%252Frandomized%2520phase%2520II%252C%2520non-comparative%252C%2520multicenter%252C%2520open%2520label%2520trial%2520of%2520CP-547%252C632%2520in%2520combination%2520with%2520paclitaxel%2520and%2520carboplatin%2520or%2520paclitaxel%2520and%2520carboplatin%2520alone%2520as%2520first-line%2520treatment%2520for%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D81%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Scott, W.; Dumas, J.; Ladouceur, G.; Lynch, M.; Scott, W. J.</span><span> </span><span class="NLM_article-title">Preparation of Diaryl Ureas with Kinase Inhibiting Activity</span>. WO 2004113274,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=W.+Scott&author=J.+Dumas&author=G.+Ladouceur&author=M.+Lynch&author=W.+J.+Scott&title=Preparation+of+Diaryl+Ureas+with+Kinase+Inhibiting+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DW.%26atitle%3DPreparation%2520of%2520Diaryl%2520Ureas%2520with%2520Kinase%2520Inhibiting%2520Activity%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schütz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zopf, D.</span><span> </span><span class="NLM_article-title">Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1002%2Fijc.25864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21170960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=245-255&author=S.+M.+Wilhelmauthor=J.+Dumasauthor=L.+Adnaneauthor=M.+Lynchauthor=C.+A.+Carterauthor=G.+Sch%C3%BCtzauthor=K.+H.+Thierauchauthor=D.+Zopf&title=Regorafenib+%28BAY+73-4506%29%3A+a+new+oral+multikinase+inhibitor+of+angiogenic%2C+stromal+and+oncogenic+receptor+tyrosine+kinases+with+potent+preclinical+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span></div><div class="casAuthors">Wilhelm, Scott M.; Dumas, Jacques; Adnane, Lila; Lynch, Mark; Carter, Christopher A.; Schuetz, Gunnar; Thierauch, Karl-Heinz; Zopf, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-255</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Angiogenesis, a crit. driver of tumor development, is controlled by interconnected signaling pathways.  Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with Ig and epidermal growth factor homol. domain 2 play crucial roles in the biol. of normal and tumor vasculature.  Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochem. and cellular kinase phosphorylation assays.  Furthermore, regorafenib inhibits addnl. angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF.  The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging.  Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts.  In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 h after the last dosing and correlated with tumor growth inhibition (TGI).  A significant redn. in tumor microvessel area was obsd. in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg.  Regorafenib exhibited potent dose-dependent TGI in various preclin. human xenograft models in mice, with tumor shrinkages obsd. in breast MDA-MB-231 and renal 786-O carcinoma models.  Pharmacodynamic analyses of the breast model revealed strong redn. in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2.  These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQpQXfCq04rVg90H21EOLACvtfcHk0lhtRlcr3sukdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D&md5=13eee29ef1f1f03fd1ed311ea613f566</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fijc.25864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25864%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DG.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26aulast%3DZopf%26aufirst%3DD.%26atitle%3DRegorafenib%2520%2528BAY%252073-4506%2529%253A%2520a%2520new%2520oral%2520multikinase%2520inhibitor%2520of%2520angiogenic%252C%2520stromal%2520and%2520oncogenic%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520preclinical%2520antitumor%2520activity%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D245%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbild, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedbom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büchert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasol, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krätzschmar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boix, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, O.</span><span> </span><span class="NLM_article-title">A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2658</span><span class="NLM_x">–</span> <span class="NLM_lpage">2667</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-11-1900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22421192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFeisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2658-2667&author=K.+Mrossauthor=A.+Frostauthor=S.+Steinbildauthor=S.+Hedbomauthor=M.+B%C3%BCchertauthor=U.+Fasolauthor=C.+Ungerauthor=J.+Kr%C3%A4tzschmarauthor=R.+Heinigauthor=O.+Boixauthor=O.+Christensen&title=A+phase+I+dose-escalation+study+of+regorafenib+%28BAY+73-4506%29%2C+an+inhibitor+of+oncogenic%2C+angiogenic%2C+and+stromal+kinases%2C+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Mross, Klaus; Frost, Annette; Steinbild, Simone; Hedbom, Susanne; Buechert, Martin; Fasol, Ulrike; Unger, Clemens; Kraetzschmar, Joern; Heinig, Roland; Boix, Oliver; Christensen, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2658-2667</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF).  This first-in-man, phase I dose-escalation study assessed the safety, pharmacokinetic, pharmacodynamic, and efficacy profiles of regorafenib in patients with advanced solid tumors.  PATIENTS AND METHODS: Patients aged 18 years or older with advanced solid tumors refractory to std. treatment were recruited.  Regorafenib was administered orally for 21 days on/seven days off in repeating cycles, until discontinuation due to toxicity or tumor progression.  Adverse events (AE) were assessed using National Cancer Institute Common Terminol. Criteria for Adverse Events v3.0.  Pharmacokinetic profiles were measured after a single dose and on day 21.  Pharmacodynamic and efficacy evaluations included tumor perfusion assessment using dynamic contrast-enhanced MRI, plasma cytokines, and tumor response using RECIST (v1.0).  RESULTS: Fifty-three patients were enrolled into eight cohorts at dose levels from 10 to 220 mg daily.  The recommended dose for future studies was detd. to be 160 mg daily, with a treatment schedule of 21 days on/seven days off in repeating 28-day cycles.  The most common drug-related grade 3 or 4 AEs were dermatol. AEs (hand-foot skin reaction, rash), hypertension, and diarrhea.  Pharmacokinetic anal. revealed a similar exposure at steady state for the parent compd. and two pharmacol. active metabolites.  Tumor perfusion and plasma cytokine anal. showed biol. activity of regorafenib.  Three of 47 evaluable patients achieved a partial response (renal cell carcinoma, colorectal carcinoma, and osteosarcoma).  CONCLUSION: Regorafenib showed an acceptable safety profile and preliminary evidence of antitumor activity in patients with solid tumors.  Clin Cancer Res; 18(9); 2658-67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozD2QRXhH1irVg90H21EOLACvtfcHk0lhtRlcr3sukdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFeisLk%253D&md5=26b168c1cdb6809a0055f52add91745d</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1900%26sid%3Dliteratum%253Aachs%26aulast%3DMross%26aufirst%3DK.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DSteinbild%26aufirst%3DS.%26aulast%3DHedbom%26aufirst%3DS.%26aulast%3DB%25C3%25BCchert%26aufirst%3DM.%26aulast%3DFasol%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DC.%26aulast%3DKr%25C3%25A4tzschmar%26aufirst%3DJ.%26aulast%3DHeinig%26aufirst%3DR.%26aulast%3DBoix%26aufirst%3DO.%26aulast%3DChristensen%26aufirst%3DO.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520study%2520of%2520regorafenib%2520%2528BAY%252073-4506%2529%252C%2520an%2520inhibitor%2520of%2520oncogenic%252C%2520angiogenic%252C%2520and%2520stromal%2520kinases%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2658%26epage%3D2667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Strumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheulen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultheis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richly, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büchert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boix, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mross, K.</span><span> </span><span class="NLM_article-title">Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study</span> <span class="citation_source-journal">Br. J. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1722</span><span class="NLM_x">–</span> <span class="NLM_lpage">1727</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fbjc.2012.153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22568966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1SntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=1722-1727&author=D.+Strumbergauthor=M.+E.+Scheulenauthor=B.+Schultheisauthor=H.+Richlyauthor=A.+Frostauthor=M.+B%C3%BCchertauthor=O.+Christensenauthor=M.+Jeffersauthor=R.+Heinigauthor=O.+Boixauthor=K.+Mross&title=Regorafenib+%28BAY+73-4506%29+in+advanced+colorectal+cancer%3A+a+phase+I+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study</span></div><div class="casAuthors">Strumberg, D.; Scheulen, M. E.; Schultheis, B.; Richly, H.; Frost, A.; Buechert, M.; Christensen, O.; Jeffers, M.; Heinig, R.; Boix, O.; Mross, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1722-1727</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumor activity in solid tumor patients.  The study was expanded to focus on patients with metastatic colorectal cancer (CRC).  Methods: Patients received oral regorafenib 60-220 mg daily (160 mg daily in the extension cohort) in cycles of 21 days on, 7 days off treatment.  Assessments included toxicity, response, pharmacokinetics and pharmacodynamics.  Results: Thirty-eight patients with heavily pretreated CRC (median 4 prior lines of therapy, range 0-7) were enrolled in the dose-escalation and extension phases; 26 patients received regorafenib 160 mg daily.  Median treatment duration was 53 days (range 7-280 days).  The most common treatment-related toxicities included hand-foot skin reaction, fatigue, voice change and rash.  Twenty-seven patients were evaluable for response: 1 achieved partial response and 19 had stable disease.  Median progression-free survival was 107 days (95% CI, 66-161).  At steady state, regorafenib and its active metabolites had similar systemic exposure.  Pharmacodynamic assessment indicated decreased tumor perfusion in most patients.  Conclusion: Regorafenib showed tolerability and antitumor activity in patients with metastatic CRC.  This expanded-cohort phase I study provided the foundation for further clin. trials of regorafenib in this patient population.  British Journal of Cancer (2012) 106, 1722-1727; doi:10.1038/bjc.2012.153 www.bjcancer.com; published online 8 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxebXIrrEBVLVg90H21EOLACvtfcHk0lhtRlcr3sukdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1SntLs%253D&md5=2be1350accc94d6eac824b273e2079cd</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.153%26sid%3Dliteratum%253Aachs%26aulast%3DStrumberg%26aufirst%3DD.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DSchultheis%26aufirst%3DB.%26aulast%3DRichly%26aufirst%3DH.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DB%25C3%25BCchert%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DO.%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DHeinig%26aufirst%3DR.%26aulast%3DBoix%26aufirst%3DO.%26aulast%3DMross%26aufirst%3DK.%26atitle%3DRegorafenib%2520%2528BAY%252073-4506%2529%2520in%2520advanced%2520colorectal%2520cancer%253A%2520a%2520phase%2520I%2520study%26jtitle%3DBr.%2520J.%2520Cancer.%26date%3D2012%26volume%3D106%26spage%3D1722%26epage%3D1727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationale developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationale+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationale%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Garofalo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemoine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Six, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavatte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goossens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depreux, P.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1189</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2013453" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1189-1204&author=A.+Garofaloauthor=A.+Farceauthor=S.+Ravezauthor=A.+Lemoineauthor=P.+Sixauthor=P.+Chavatteauthor=L.+Goossensauthor=P.+Depreux&title=Synthesis+and+structure%E2%80%93activity+relationships+of+%28aryloxy%29quinazoline+ureas+as+novel%2C+potent%2C+and+selective+vascular+endothelial+growth+factor+receptor-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fjm2013453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013453%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DA.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DRavez%26aufirst%3DS.%26aulast%3DLemoine%26aufirst%3DA.%26aulast%3DSix%26aufirst%3DP.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DGoossens%26aufirst%3DL.%26aulast%3DDepreux%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520%2528aryloxy%2529quinazoline%2520ureas%2520as%2520novel%252C%2520potent%252C%2520and%2520selective%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1189%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4439</span><span class="NLM_x">–</span> <span class="NLM_lpage">4450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-3109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21622720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1SmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4439-4450&author=S.+Zhangauthor=Z.+Caoauthor=H.+Tianauthor=G.+Shenauthor=Y.+Maauthor=H.+Xieauthor=Y.+Liuauthor=C.+Zhaoauthor=S.+Dengauthor=Y.+Yangauthor=R.+Zhengauthor=W.+Liauthor=N.+Zhangauthor=S.+Liuauthor=W.+Wangauthor=L.+Daiauthor=S.+Shiauthor=L.+Chengauthor=Y.+Panauthor=S.+Fengauthor=X.+Zhaoauthor=H.+Dengauthor=S.+Yangauthor=Y.+Wei&title=SKLB1002%2C+a+novel+potent+inhibitor+of+VEGF+receptor+2+signaling%2C+inhibits+angiogenesis+and+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo</span></div><div class="casAuthors">Zhang, Shuang; Cao, Zhixing; Tian, Hongwei; Shen, Guobo; Ma, Yongping; Xie, Huanzhang; Liu, Yalin; Zhao, Chengjian; Deng, Senyi; Yang, Yang; Zheng, Renlin; Li, Weiwei; Zhang, Na; Liu, Shengyong; Wang, Wei; Dai, Lixia; Shi, Shuai; Cheng, Lin; Pan, Youli; Feng, Shan; Zhao, Xia; Deng, Hongxin; Yang, Shengyong; Wei, Yuquan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4439-4450</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment.  However, currently most of these anticancer drugs suffer some adverse effects.  Discovery of novel VEGFR2 inhibitors as anticancer drug candidates is still needed.  Exptl. Design: In this investigation, we adopted a restricted de novo design method to design VEGFR2 inhibitors.  We selected the most potent compd. SKLB1002 and analyzed its inhibitory effects on human umbilical vein endothelial cells (HUVEC) in vitro.  Tumor xenografts in zebrafish and athymic mice were used to examine the in vivo activity of SKLB1002.  RESULTS: The use of the restricted de novo design method indeed led to a new potent VEGFR2 inhibitor, SKLB1002, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation.  Western blot anal. was conducted, which indicated that SKLB1002 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal-regulated kinase, focal adhesion kinase, and Src.  In vivo zebrafish model expts. showed that SKLB1002 remarkably blocked the formation of intersegmental vessels in zebrafish embryos.  It was further found to inhibit a new microvasculature in zebrafish embryos induced by inoculated tumor cells.  Finally, compared with the solvent control, administration of 100 mg/kg/d SKLB1002 reached more than 60% inhibition against human tumor xenografts in athymic mice.  The antiangiogenic effect was indicated by CD31 immunohistochem. staining and alginate-encapsulated tumor cell assay.  CONCLUSIONS: Our findings suggest that SKLB1002 inhibits angiogenesis and may be a potential drug candidate in anticancer therapy.  Clin Cancer Res; 17(13); 4439-50.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgqK6UNG6yrVg90H21EOLACvtfcHk0lgCEgnRPOOWIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1SmtLo%253D&md5=a15e4fe2fd1e62134a8c48cf2d4a2547</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3109%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DSKLB1002%252C%2520a%2520novel%2520potent%2520inhibitor%2520of%2520VEGF%2520receptor%25202%2520signaling%252C%2520inhibits%2520angiogenesis%2520and%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4439%26epage%3D4450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span> </span><span class="NLM_article-title">SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy</span> <span class="citation_source-journal">Neoplasma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=486-493&author=G.+Shenauthor=Y.+Liauthor=T.+Duauthor=G.+Shiauthor=L.+Daiauthor=X.+Chenauthor=R.+Zhengauthor=W.+Liauthor=X.+Suauthor=S.+Zhangauthor=Y.+Weiauthor=S.+Yangauthor=H.+Deng&title=SKLB1002%2C+a+novel+inhibitor+of+VEGF+receptor+2+signaling%2C+induces+vascular+normalization+to+improve+systemically+administered+chemotherapy+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DH.%26atitle%3DSKLB1002%252C%2520a%2520novel%2520inhibitor%2520of%2520VEGF%2520receptor%25202%2520signaling%252C%2520induces%2520vascular%2520normalization%2520to%2520improve%2520systemically%2520administered%2520chemotherapy%2520efficacy%26jtitle%3DNeoplasma%26date%3D2012%26volume%3D59%26spage%3D486%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Yu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. F.</span><span> </span><span class="NLM_article-title">Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=110-114&author=B.+Yuauthor=L.+D.+Tangauthor=Y.+L.+Liauthor=S.+H.+Songauthor=X.+L.+Jiauthor=M.+S.+Linauthor=C.+F.+Wu&title=Design%2C+synthesis+and+antitumor+activity+of+4-aminoquinazoline+derivatives+targeting+VEGFR-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTang%26aufirst%3DL.%2BD.%26aulast%3DLi%26aufirst%3DY.%2BL.%26aulast%3DSong%26aufirst%3DS.%2BH.%26aulast%3DJi%26aufirst%3DX.%2BL.%26aulast%3DLin%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BF.%26atitle%3DDesign%252C%2520synthesis%2520and%2520antitumor%2520activity%2520of%25204-aminoquinazoline%2520derivatives%2520targeting%2520VEGFR-2%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D110%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Plé, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span> </span><span class="NLM_article-title">Discovery of AZD2932, a new quinazoline ether inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=262-266&author=P.+A.+Pl%C3%A9author=F.+Jungauthor=S.+Ashtonauthor=L.+Hennequinauthor=R.+Laineauthor=R.+Morgentinauthor=G.+Pasquetauthor=S.+Taylor&title=Discovery+of+AZD2932%2C+a+new+quinazoline+ether+inhibitor+with+high+affinity+for+VEGFR-2+and+PDGFR+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%2BA.%26aulast%3DJung%26aufirst%3DF.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DHennequin%26aufirst%3DL.%26aulast%3DLaine%26aufirst%3DR.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520AZD2932%252C%2520a%2520new%2520quinazoline%2520ether%2520inhibitor%2520with%2520high%2520affinity%2520for%2520VEGFR-2%2520and%2520PDGFR%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D262%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Oguro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awazu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">7260</span><span class="NLM_x">–</span> <span class="NLM_lpage">7273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=7260-7273&author=Y.+Oguroauthor=N.+Miyamotoauthor=K.+Okadaauthor=T.+Takagiauthor=H.+Iwataauthor=Y.+Awazuauthor=H.+Mikiauthor=A.+Horiauthor=K.+Kamiyamaauthor=S.+Imamura&title=Design%2C+synthesis%2C+and+evaluation+of+5-methyl-4-phenoxy-5H-pyrrolo%5B3%2C2-d%5Dpyrimidine+derivatives%3A+novel+VEGFR2+kinase+inhibitors+binding+to+inactive+kinase+conformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOguro%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DOkada%26aufirst%3DK.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DAwazu%26aufirst%3DY.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DKamiyama%26aufirst%3DK.%26aulast%3DImamura%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%25205-methyl-4-phenoxy-5H-pyrrolo%255B3%252C2-d%255Dpyrimidine%2520derivatives%253A%2520novel%2520VEGFR2%2520kinase%2520inhibitors%2520binding%2520to%2520inactive%2520kinase%2520conformation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D7260%26epage%3D7273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Oguro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awazu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span> </span><span class="NLM_article-title"><i>N</i>-Phenyl-<i>N</i>′-[4-(5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">7150</span><span class="NLM_x">–</span> <span class="NLM_lpage">7163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=7150-7163&author=Y.+Oguroauthor=N.+Miyamotoauthor=T.+Takagiauthor=K.+Okadaauthor=Y.+Awazuauthor=H.+Mikiauthor=A.+Horiauthor=K.+Kamiyamaauthor=S.+Imamura&title=N-Phenyl-N%E2%80%B2-%5B4-%285H-pyrrolo%5B3%2C2-d%5Dpyrimidin-4-yloxy%29phenyl%5Dureas+as+novel+inhibitors+of+VEGFR+and+FGFR+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOguro%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DK.%26aulast%3DAwazu%26aufirst%3DY.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DKamiyama%26aufirst%3DK.%26aulast%3DImamura%26aufirst%3DS.%26atitle%3DN-Phenyl-N%25E2%2580%25B2-%255B4-%25285H-pyrrolo%255B3%252C2-d%255Dpyrimidin-4-yloxy%2529phenyl%255Dureas%2520as%2520novel%2520inhibitors%2520of%2520VEGFR%2520and%2520FGFR%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D7150%26epage%3D7163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurup, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S. S.</span><span> </span><span class="NLM_article-title">Synthesis and biological activity of <i>N</i>(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3575</span><span class="NLM_x">–</span> <span class="NLM_lpage">3587</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=3575-3587&author=A.+Gangjeeauthor=S.+Kurupauthor=M.+A.+Ihnatauthor=J.+E.+Thorpeauthor=S.+S.+Shenoy&title=Synthesis+and+biological+activity+of+N%284%29-phenylsubstituted-6-%282%2C4-dichloro+phenylmethyl%29-7H-pyrrolo%5B2%2C3-d%5Dpyrimidine-2%2C4-diamines+as+vascular+endothelial+growth+factor+receptor-2+inhibitors+and+antiangiogenic+and+antitumor+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DKurup%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DShenoy%26aufirst%3DS.%2BS.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520N%25284%2529-phenylsubstituted-6-%25282%252C4-dichloro%2520phenylmethyl%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidine-2%252C4-diamines%2520as%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520inhibitors%2520and%2520antiangiogenic%2520and%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D3575%26epage%3D3587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Frey, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukofzer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">7-Aminopyrazolo[1,5-<i>a</i>]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3777</span><span class="NLM_x">–</span> <span class="NLM_lpage">3787</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701397k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3777-3787&author=R.+R.+Freyauthor=M.+L.+Curtinauthor=D.+H.+Albertauthor=K.+B.+Glaserauthor=L.+J.+Peaseauthor=N.+B.+Soniauthor=J.+J.+Bouskaauthor=D.+Reuterauthor=K.+D.+Stewartauthor=P.+Marcotteauthor=G.+Bukofzerauthor=J.+Liauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=7-Aminopyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+multitargeted+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Fjm701397k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701397k%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DR.%2BR.%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DReuter%26aufirst%3DD.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DMarcotte%26aufirst%3DP.%26aulast%3DBukofzer%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3D7-Aminopyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3777%26epage%3D3787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Egert-Schmidt, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunkel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohfeld, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehlert, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutschler, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schächtele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubbutat, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunick, C.</span><span> </span><span class="NLM_article-title">Identification of 2-anilino-9-methoxy-5,7-dihydro-6<i>H</i>-pyrimido[5,4-<i>d</i>][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2433</span><span class="NLM_x">–</span> <span class="NLM_lpage">2442</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901388c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2433-2442&author=A.+M.+Egert-Schmidtauthor=J.+Dreherauthor=U.+Dunkelauthor=S.+Kohfeldauthor=L.+Preuauthor=H.+Weberauthor=J.+E.+Ehlertauthor=B.+Mutschlerauthor=F.+Totzkeauthor=C.+Sch%C3%A4chteleauthor=M.+H.+Kubbutatauthor=K.+Baumannauthor=C.+Kunick&title=Identification+of+2-anilino-9-methoxy-5%2C7-dihydro-6H-pyrimido%5B5%2C4-d%5D%5B1%5Dbenzazepin-6-ones+as+dual+PLK1%2FVEGF-R2+kinase+inhibitor+chemotypes+by+structure-based+lead+generation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Fjm901388c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901388c%26sid%3Dliteratum%253Aachs%26aulast%3DEgert-Schmidt%26aufirst%3DA.%2BM.%26aulast%3DDreher%26aufirst%3DJ.%26aulast%3DDunkel%26aufirst%3DU.%26aulast%3DKohfeld%26aufirst%3DS.%26aulast%3DPreu%26aufirst%3DL.%26aulast%3DWeber%26aufirst%3DH.%26aulast%3DEhlert%26aufirst%3DJ.%2BE.%26aulast%3DMutschler%26aufirst%3DB.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%26aulast%3DBaumann%26aufirst%3DK.%26aulast%3DKunick%26aufirst%3DC.%26atitle%3DIdentification%2520of%25202-anilino-9-methoxy-5%252C7-dihydro-6H-pyrimido%255B5%252C4-d%255D%255B1%255Dbenzazepin-6-ones%2520as%2520dual%2520PLK1%252FVEGF-R2%2520kinase%2520inhibitor%2520chemotypes%2520by%2520structure-based%2520lead%2520generation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2433%26epage%3D2442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Strebhardt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Targeting polo-like kinase 1 for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrc1841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16557283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVyqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=321-330&author=K.+Strebhardtauthor=A.+Ullrich&title=Targeting+polo-like+kinase+1+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting polo-like kinase 1 for cancer therapy</span></div><div class="casAuthors">Strebhardt, Klaus; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-330</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Human polo-like kinase 1 (PLK1) is essential during mitosis and in the maintenance of genomic stability.  PLK1 is overexpressed in human tumors and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target.  The use of different PLK1 inhibitors has increased our knowledge of mitotic regulation and allowed us to assess their ability to suppress tumor growth in vivo.  We address the structural features of the kinase domain and the unique polo-box domain of PLK1 that are most suited for drug development and discuss our current understanding of the therapeutic potential of PLK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdeCr1fiAaaLVg90H21EOLACvtfcHk0lgV_9mmlXrMtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVyqtrk%253D&md5=b43638c4eb123292a507734fb87e89ac</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fnrc1841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1841%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DTargeting%2520polo-like%2520kinase%25201%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D321%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Hughes, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnachi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seraj., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes-Pesquera, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruninger, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, D. F.</span><span> </span><span class="NLM_article-title">4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3266</span><span class="NLM_x">–</span> <span class="NLM_lpage">3270</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3266-3270&author=T.+V.+Hughesauthor=S.+L.+Emanuelauthor=A.+K.+Beckauthor=S.+K.+Wetterauthor=P.+J.+Connollyauthor=P.+Karnachiauthor=M.+Reumanauthor=J.+Seraj.author=A.+R.+Fuentes-Pesqueraauthor=R.+H.+Gruningerauthor=S.+A.+Middletonauthor=R.+Linauthor=J.+M.+Davisauthor=D.+F.+Moffat&title=4-Aryl-5-cyano-2-aminopyrimidines+as+VEGF-R2+inhibitors%3A+synthesis+and+biological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DT.%2BV.%26aulast%3DEmanuel%26aufirst%3DS.%2BL.%26aulast%3DBeck%26aufirst%3DA.%2BK.%26aulast%3DWetter%26aufirst%3DS.%2BK.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DKarnachi%26aufirst%3DP.%26aulast%3DReuman%26aufirst%3DM.%26aulast%3DSeraj.%26aufirst%3DJ.%26aulast%3DFuentes-Pesquera%26aufirst%3DA.%2BR.%26aulast%3DGruninger%26aufirst%3DR.%2BH.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26aulast%3DMoffat%26aufirst%3DD.%2BF.%26atitle%3D4-Aryl-5-cyano-2-aminopyrimidines%2520as%2520VEGF-R2%2520inhibitors%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3266%26epage%3D3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Gaudette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaisburg, A.</span><span> </span><span class="NLM_article-title">Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">848</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.bmcl.2009.12.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20071170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=848-852&author=F.+Gaudetteauthor=S.+Raeppelauthor=H.+Nguyenauthor=N.+Beaulieuauthor=C.+Beaulieuauthor=I.+Dupontauthor=A.+R.+Macleodauthor=J.+M.+Bestermanauthor=A.+Vaisburg&title=Identification+of+potent+and+selective+VEGFR+receptor+tyrosine+kinase+inhibitors+having+new+amide+isostere+headgroups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups</span></div><div class="casAuthors">Gaudette, Frederic; Raeppel, Stephane; Nguyen, Hannah; Beaulieu, Normand; Beaulieu, Carole; Dupont, Isabelle; MacLeod, A. Robert; Besterman, Jeffrey M.; Vaisburg, Arkadii</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">848-852</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of malonamide-type dual VEGFR2/c-Met inhibitors in which one of the amide bonds was replaced by an amide isostere-a trifluoroethylamine unit, was designed, synthesized, and evaluated for their enzymic and cellular inhibition of VEGFR2 and c-Met enzymes.  Optimization of these mol. entities resulted in identification of potent and selective inhibitors of VEGFR2 enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom6nM7bV2v7LVg90H21EOLACvtfcHk0lgV_9mmlXrMtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGrurc%253D&md5=4ce25cdb55c553f33a7dab139ee0cc04</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.099%26sid%3Dliteratum%253Aachs%26aulast%3DGaudette%26aufirst%3DF.%26aulast%3DRaeppel%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DBeaulieu%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DI.%26aulast%3DMacleod%26aufirst%3DA.%2BR.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520potent%2520and%2520selective%2520VEGFR%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520having%2520new%2520amide%2520isostere%2520headgroups%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D848%26epage%3D852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaMontagne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, P. J.</span><span> </span><span class="NLM_article-title">4-Aminopyrimidine-5-carbaldehyde oximes as potent VEGFR-2 inhibitors. Part II</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1815</span><span class="NLM_x">–</span> <span class="NLM_lpage">1818</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1815-1818&author=S.+Huangauthor=R.+Liauthor=K.+R.+LaMontagneauthor=L.+M.+Greenbergerauthor=P.+J.+Connolly&title=4-Aminopyrimidine-5-carbaldehyde+oximes+as+potent+VEGFR-2+inhibitors.+Part+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DLaMontagne%26aufirst%3DK.%2BR.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26atitle%3D4-Aminopyrimidine-5-carbaldehyde%2520oximes%2520as%2520potent%2520VEGFR-2%2520inhibitors.%2520Part%2520II%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1815%26epage%3D1818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Sakurai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yashiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirakawa, K.</span><span> </span><span class="NLM_article-title">A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2612</span><span class="NLM_x">–</span> <span class="NLM_lpage">2620</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=2612-2620&author=K.+Sakuraiauthor=N.+Yamadaauthor=M.+Yashiroauthor=T.+Matsuzakiauthor=M.+Komatsuauthor=M.+Ohiraauthor=A.+Miwaauthor=K.+Hirakawa&title=A+novel+angiogenesis+inhibitor%2C+Ki23057%2C+is+useful+for+preventing+the+progression+of+colon+cancer+and+the+spreading+of+cancer+cells+to+the+liver"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakurai%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DYashiro%26aufirst%3DM.%26aulast%3DMatsuzaki%26aufirst%3DT.%26aulast%3DKomatsu%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DMiwa%26aufirst%3DA.%26aulast%3DHirakawa%26aufirst%3DK.%26atitle%3DA%2520novel%2520angiogenesis%2520inhibitor%252C%2520Ki23057%252C%2520is%2520useful%2520for%2520preventing%2520the%2520progression%2520of%2520colon%2520cancer%2520and%2520the%2520spreading%2520of%2520cancer%2520cells%2520to%2520the%2520liver%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D2612%26epage%3D2620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPietro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, R.</span><span> </span><span class="NLM_article-title">Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1667</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701097z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1649-1667&author=J.+C.+Harmangeauthor=M.+M.+Weissauthor=J.+Germainauthor=A.+J.+Polverinoauthor=G.+Borgauthor=J.+Breadyauthor=D.+Chenauthor=D.+Choquetteauthor=A.+Coxonauthor=T.+DeMelfiauthor=L.+DiPietroauthor=N.+Doerrauthor=J.+Estradaauthor=J.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=S.+Kaufmanauthor=D.+S.+Laauthor=A.+Longauthor=M.+W.+Martinauthor=S.+Neervannanauthor=V.+F.+Patelauthor=M.+Potashmanauthor=K.+Regalauthor=P.+M.+Rovetoauthor=M.+L.+Schragauthor=C.+Starnesauthor=A.+Taskerauthor=Y.+Tefferaauthor=L.+Wangauthor=R.+D.+Whiteauthor=D.+A.+Whittingtonauthor=R.+Zanon&title=Naphthamides+as+novel+and+potent+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitors%3A+design%2C+synthesis%2C+and+evaluation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation</span></div><div class="casAuthors">Harmange, Jean-Christophe; Weiss, Matthew M.; Germain, Julie; Polverino, Anthony J.; Borg, George; Bready, James; Chen, Danlin; Choquette, Deborah; Coxon, Angela; DeMelfi, Tom; DiPietro, Lucian; Doerr, Nicholas; Estrada, Juan; Flynn, Julie; Graceffa, Russell F.; Harriman, Shawn P.; Kaufman, Stephen; La, Daniel S.; Long, Alexander; Martin, Matthew W.; Neervannan, Sesha; Patel, Vinod F.; Potashman, Michele; Regal, Kelly; Roveto, Phillip M.; Schrag, Michael L.; Starnes, Charlie; Tasker, Andrew; Teffera, Yohannes; Wang, Ling; White, Ryan D.; Whittington, Douglas A.; Zanon, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1649-1667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of naphthyl-based compds. were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors.  Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family.  Numerous analogs demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compds. possessed favorable pharmacokinetic (PK) profiles.  In particular, compd. I demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice.  A full account of the prepn., structure-activity relationships, pharmacokinetic properties, and pharmacol. of analogs within this series is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1vrmtgp3_m7Vg90H21EOLACvtfcHk0ljESkAohr9suA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D&md5=25685f28450b2ab132ffd278e6c53598</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Fjm701097z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701097z%26sid%3Dliteratum%253Aachs%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DBorg%26aufirst%3DG.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDiPietro%26aufirst%3DL.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLong%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DSchrag%26aufirst%3DM.%2BL.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZanon%26aufirst%3DR.%26atitle%3DNaphthamides%2520as%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1649%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, R.</span><span> </span><span class="NLM_article-title">Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1668</span><span class="NLM_x">–</span> <span class="NLM_lpage">1680</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701098w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1668-1680&author=M.+M.+Weissauthor=J.+C.+Harmangeauthor=A.+J.+Polverinoauthor=D.+Bauerauthor=L.+Berryauthor=V.+Berryauthor=G.+Borgauthor=J.+Breadyauthor=D.+Chenauthor=D.+Choquetteauthor=A.+Coxonauthor=T.+DeMelfiauthor=N.+Doerrauthor=J.+Estradaauthor=J.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=S.+Kaufmanauthor=D.+S.+Laauthor=A.+Longauthor=S.+Neervannanauthor=V.+F.+Patelauthor=M.+Potashmanauthor=K.+Regalauthor=P.+M.+Rovetoauthor=M.+L.+Schragauthor=C.+Starnesauthor=A.+Taskerauthor=Y.+Tefferaauthor=D.+A.+Whittingtonauthor=R.+Zanon&title=Evaluation+of+a+series+of+naphthamides+as+potent%2C+orally+active+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Fjm701098w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701098w%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DV.%26aulast%3DBorg%26aufirst%3DG.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLong%26aufirst%3DA.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DSchrag%26aufirst%3DM.%2BL.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZanon%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520a%2520series%2520of%2520naphthamides%2520as%2520potent%252C%2520orally%2520active%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1668%26epage%3D1680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belzile, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span> </span><span class="NLM_article-title">Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1695</span><span class="NLM_x">–</span> <span class="NLM_lpage">1705</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701129j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1695-1705&author=D.+S.+Laauthor=J.+Belzileauthor=J.+V.+Breadyauthor=A.+Coxonauthor=T.+DeMelfiauthor=N.+Doerrauthor=J.+Estradaauthor=J.+C.+Flynnauthor=S.+R.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=J.+F.+Larrowauthor=A.+M.+Longauthor=M.+W.+Martinauthor=M.+J.+Morrisonauthor=V.+F.+Patelauthor=P.+M.+Rovetoauthor=L.+Wangauthor=M.+M.+Weissauthor=D.+A.+Whittingtonauthor=Y.+Tefferaauthor=Z.+Zhaoauthor=A.+J.+Polverinoauthor=J.+C.+Harmange&title=Novel+2%2C3-dihydro-1%2C4-benzoxazines+as+potent+and+orally+bioavailable+inhibitors+of+tumor-driven+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm701129j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701129j%26sid%3Dliteratum%253Aachs%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DBelzile%26aufirst%3DJ.%26aulast%3DBready%26aufirst%3DJ.%2BV.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%2BC.%26aulast%3DFlynn%26aufirst%3DS.%2BR.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DNovel%25202%252C3-dihydro-1%252C4-benzoxazines%2520as%2520potent%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520tumor-driven%2520angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1695%26epage%3D1705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span> </span><span class="NLM_article-title">Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4844</span><span class="NLM_x">–</span> <span class="NLM_lpage">4848</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4844-4848&author=D.+Bauerauthor=D.+A.+Whittingtonauthor=A.+Coxonauthor=J.+Breadyauthor=S.+P.+Harrimanauthor=V.+F.+Patelauthor=A.+Polverinoauthor=J.+C.+Harmange&title=Evaluation+of+indazole-based+compounds+as+a+new+class+of+potent+KDR%2FVEGFR-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DEvaluation%2520of%2520indazole-based%2520compounds%2520as%2520a%2520new%2520class%2520of%2520potent%2520KDR%252FVEGFR-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4844%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Mannion, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claridge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saavedra, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakovic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déziel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chute, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaisburg, A.</span><span> </span><span class="NLM_article-title"><i>N</i>-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6552</span><span class="NLM_x">–</span> <span class="NLM_lpage">6556</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6552-6556&author=M.+Mannionauthor=S.+Raeppelauthor=S.+Claridgeauthor=N.+Zhouauthor=O.+Saavedraauthor=L.+Isakovicauthor=L.+Zhanauthor=F.+Gaudetteauthor=F.+Raeppelauthor=R.+D%C3%A9zielauthor=N.+Beaulieuauthor=H.+Nguyenauthor=I.+Chuteauthor=C.+Beaulieuauthor=I.+Dupontauthor=M.+F.+Robertauthor=S.+Lefebvreauthor=M.+Dubayauthor=J.+Rahilauthor=J.+Wangauthor=H.+Ste-Croixauthor=R.+A.+Macleodauthor=J.+M.+Bestermanauthor=A.+Vaisburg&title=N-%284-%286%2C7-Disubstituted-quinolin-4-yloxy%29-3-fluorophenyl%29-2-oxo-3-phenylimidazolidine-1-carboxamides%3A+a+novel+series+of+dual+c-Met%2FVEGFR2+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMannion%26aufirst%3DM.%26aulast%3DRaeppel%26aufirst%3DS.%26aulast%3DClaridge%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DSaavedra%26aufirst%3DO.%26aulast%3DIsakovic%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DGaudette%26aufirst%3DF.%26aulast%3DRaeppel%26aufirst%3DF.%26aulast%3DD%25C3%25A9ziel%26aufirst%3DR.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DChute%26aufirst%3DI.%26aulast%3DBeaulieu%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DI.%26aulast%3DRobert%26aufirst%3DM.%2BF.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DDubay%26aufirst%3DM.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DMacleod%26aufirst%3DR.%2BA.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DN-%25284-%25286%252C7-Disubstituted-quinolin-4-yloxy%2529-3-fluorophenyl%2529-2-oxo-3-phenylimidazolidine-1-carboxamides%253A%2520a%2520novel%2520series%2520of%2520dual%2520c-Met%252FVEGFR2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6552%26epage%3D6556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. L.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6653</span><span class="NLM_x">–</span> <span class="NLM_lpage">6656</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6653-6656&author=Y.+Yangauthor=L.+Shiauthor=Y.+Zhouauthor=H.+Q.+Liauthor=Z.+W.+Zhuauthor=H.+L.+Zhu&title=Design%2C+synthesis+and+biological+evaluation+of+quinoline+amide+derivatives+as+novel+VEGFR-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26aulast%3DZhu%26aufirst%3DZ.%2BW.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520quinoline%2520amide%2520derivatives%2520as%2520novel%2520VEGFR-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6653%26epage%3D6656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Rizvi, S. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, I.</span><span> </span><span class="NLM_article-title">Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=942-944&author=S.+U.+Rizviauthor=H.+L.+Siddiquiauthor=M.+Nisarauthor=N.+Khanauthor=I.+Khan&title=Discovery+and+molecular+docking+of+quinolyl-thienyl+chalcones+as+anti-angiogenic+agents+targeting+VEGFR-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRizvi%26aufirst%3DS.%2BU.%26aulast%3DSiddiqui%26aufirst%3DH.%2BL.%26aulast%3DNisar%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DKhan%26aufirst%3DI.%26atitle%3DDiscovery%2520and%2520molecular%2520docking%2520of%2520quinolyl-thienyl%2520chalcones%2520as%2520anti-angiogenic%2520agents%2520targeting%2520VEGFR-2%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D942%26epage%3D944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group">Raeppel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claridge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saavedra, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannion, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakovic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déziel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert Macleod, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaisburg, A.</span><span> </span><span class="NLM_article-title"><i>N</i>-(3-Fluoro-4-(2-arylthieno[3,2-<i>b</i>]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1323</span><span class="NLM_x">–</span> <span class="NLM_lpage">1328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1323-1328&author=S.+Raeppelauthor=S.+Claridgeauthor=O.+Saavedraauthor=F.+Gaudetteauthor=L.+Zhanauthor=M.+Mannionauthor=N.+Zhouauthor=F.+Raeppelauthor=M.+C.+Grangerauthor=L.+Isakovicauthor=R.+D%C3%A9zielauthor=H.+Nguyenauthor=N.+Beaulieuauthor=C.+Beaulieuauthor=I.+Dupontauthor=M.+F.+Robertauthor=S.+Lefebvreauthor=M.+Dubayauthor=J.+Rahilauthor=J.+Wangauthor=H.+Ste-Croixauthor=A.+Robert+Macleodauthor=J.+Bestermanauthor=A.+Vaisburg&title=N-%283-Fluoro-4-%282-arylthieno%5B3%2C2-b%5Dpyridin-7-yloxy%29phenyl%29-2-oxo-3-phenylimidazolidine-1-carboxamides%3A+a+novel+series+of+dual+c-Met%2FVEGFR2+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaeppel%26aufirst%3DS.%26aulast%3DClaridge%26aufirst%3DS.%26aulast%3DSaavedra%26aufirst%3DO.%26aulast%3DGaudette%26aufirst%3DF.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DMannion%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DRaeppel%26aufirst%3DF.%26aulast%3DGranger%26aufirst%3DM.%2BC.%26aulast%3DIsakovic%26aufirst%3DL.%26aulast%3DD%25C3%25A9ziel%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DBeaulieu%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DI.%26aulast%3DRobert%26aufirst%3DM.%2BF.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DDubay%26aufirst%3DM.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DRobert%2BMacleod%26aufirst%3DA.%26aulast%3DBesterman%26aufirst%3DJ.%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DN-%25283-Fluoro-4-%25282-arylthieno%255B3%252C2-b%255Dpyridin-7-yloxy%2529phenyl%2529-2-oxo-3-phenylimidazolidine-1-carboxamides%253A%2520a%2520novel%2520series%2520of%2520dual%2520c-Met%252FVEGFR2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1323%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Saavedra, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claridge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannion, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakovic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déziel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaisburg, A.</span><span> </span><span class="NLM_article-title"><i>N</i><sup>3</sup>-Arylmalonamides: a new series of thieno[3,2-<i>b</i>]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6836</span><span class="NLM_x">–</span> <span class="NLM_lpage">6839</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6836-6839&author=O.+Saavedraauthor=S.+Claridgeauthor=L.+Zhanauthor=F.+Raeppelauthor=M.+C.+Grangerauthor=S.+Raeppelauthor=M.+Mannionauthor=F.+Gaudetteauthor=N.+Zhouauthor=L.+Isakovicauthor=N.+Bernsteinauthor=R.+D%C3%A9zielauthor=H.+Nguyenauthor=N.+Beaulieuauthor=C.+Beaulieuauthor=I.+Dupontauthor=J.+Wangauthor=A.+R.+Macleodauthor=J.+M.+Bestermanauthor=A.+Vaisburg&title=N3-Arylmalonamides%3A+a+new+series+of+thieno%5B3%2C2-b%5Dpyridine+based+inhibitors+of+c-Met+and+VEGFR2+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaavedra%26aufirst%3DO.%26aulast%3DClaridge%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DRaeppel%26aufirst%3DF.%26aulast%3DGranger%26aufirst%3DM.%2BC.%26aulast%3DRaeppel%26aufirst%3DS.%26aulast%3DMannion%26aufirst%3DM.%26aulast%3DGaudette%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DIsakovic%26aufirst%3DL.%26aulast%3DBernstein%26aufirst%3DN.%26aulast%3DD%25C3%25A9ziel%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DBeaulieu%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMacleod%26aufirst%3DA.%2BR.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DN3-Arylmalonamides%253A%2520a%2520new%2520series%2520of%2520thieno%255B3%252C2-b%255Dpyridine%2520based%2520inhibitors%2520of%2520c-Met%2520and%2520VEGFR2%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6836%26epage%3D6839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5330</span><span class="NLM_x">–</span> <span class="NLM_lpage">5341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800476q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5330-5341&author=K.+S.+Kimauthor=L.+Zhangauthor=R.+Schmidtauthor=Z.+W.+Caiauthor=D.+Weiauthor=D.+K.+Williamsauthor=L.+J.+Lombardoauthor=G.+L.+Trainorauthor=D.+Xieauthor=Y.+Zhangauthor=Y.+Anauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=C.+Darienzoauthor=A.+Kamathauthor=P.+Maratheauthor=Y.+Zhangauthor=J.+Lippyauthor=R.+Jeyaseelanauthor=B.+Wautletauthor=B.+Henleyauthor=J.+Gullo-Brownauthor=V.+Manneauthor=J.+T.+Huntauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+pyrrolopyridine-pyridone+based+inhibitors+of+Met+kinase%3A+synthesis%2C+X-ray+crystallographic+analysis%2C+and+biological+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Fjm800476q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800476q%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DDarienzo%26aufirst%3DC.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520pyrrolopyridine-pyridone%2520based%2520inhibitors%2520of%2520Met%2520kinase%253A%2520synthesis%252C%2520X-ray%2520crystallographic%2520analysis%252C%2520and%2520biological%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5330%26epage%3D5341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doktor, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">386</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=386-390&author=Y.+Daiauthor=K.+Hartandiauthor=N.+B.+Soniauthor=L.+J.+Peaseauthor=D.+R.+Reuterauthor=A.+M.+Olsonauthor=D.+J.+Osterlingauthor=S.+Z.+Doktorauthor=D.+H.+Albertauthor=J.+J.+Bouskaauthor=K.+B.+Glaserauthor=P.+A.+Marcotteauthor=K.+D.+Stewartauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Identification+of+aminopyrazolopyridine+ureas+as+potent+VEGFR%2FPDGFR+multitargeted+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DDoktor%26aufirst%3DS.%2BZ.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DIdentification%2520of%2520aminopyrazolopyridine%2520ureas%2520as%2520potent%2520VEGFR%252FPDGFR%2520multitargeted%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D386%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">Kiselyov, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenov, V. V.</span><span> </span><span class="NLM_article-title">3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1195</span><span class="NLM_x">–</span> <span class="NLM_lpage">1198</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1195-1198&author=A.+S.+Kiselyovauthor=M.+Semenovaauthor=V.+V.+Semenov&title=3%2C4-Disubstituted+isothiazoles%3A+novel+potent+inhibitors+of+VEGF+receptors+1+and+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DSemenova%26aufirst%3DM.%26aulast%3DSemenov%26aufirst%3DV.%2BV.%26atitle%3D3%252C4-Disubstituted%2520isothiazoles%253A%2520novel%2520potent%2520inhibitors%2520of%2520VEGF%2520receptors%25201%2520and%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1195%26epage%3D1198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Kiselyov, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenov, V. V.</span><span> </span><span class="NLM_article-title">(1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1344</span><span class="NLM_x">–</span> <span class="NLM_lpage">1348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1344-1348&author=A.+S.+Kiselyovauthor=M.+Semenovaauthor=V.+V.+Semenov&title=%281%2C2%2C3-Triazol-4-yl%29benzenamines%3A+synthesis+and+activity+against+VEGF+receptors+1+and+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DSemenova%26aufirst%3DM.%26aulast%3DSemenov%26aufirst%3DV.%2BV.%26atitle%3D%25281%252C2%252C3-Triazol-4-yl%2529benzenamines%253A%2520synthesis%2520and%2520activity%2520against%2520VEGF%2520receptors%25201%2520and%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1344%26epage%3D1348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">Choi, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paik, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. T.</span><span> </span><span class="NLM_article-title">BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6236</span><span class="NLM_x">–</span> <span class="NLM_lpage">6241</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6236-6241&author=H.+E.+Choiauthor=M.+S.+Yooauthor=J.+H.+Choiauthor=J.+Y.+Leeauthor=J.+H.+Kimauthor=J.+H.+Kimauthor=J.+K.+Leeauthor=G.+I.+Kimauthor=Y.+Parkauthor=Y.+H.+Chiauthor=S.+H.+Paikauthor=J.+H.+Leeauthor=K.+T.+Lee&title=BRN-103%2C+a+novel+nicotinamide+derivative%2C+inhibits+VEGF-induced+angiogenesis+and+proliferation+in+human+umbilical+vein+endothelial+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BE.%26aulast%3DYoo%26aufirst%3DM.%2BS.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DG.%2BI.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DChi%26aufirst%3DY.%2BH.%26aulast%3DPaik%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DK.%2BT.%26atitle%3DBRN-103%252C%2520a%2520novel%2520nicotinamide%2520derivative%252C%2520inhibits%2520VEGF-induced%2520angiogenesis%2520and%2520proliferation%2520in%2520human%2520umbilical%2520vein%2520endothelial%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6236%26epage%3D6241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">Cao, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y. L.</span><span> </span><span class="NLM_article-title">SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth <i>in vivo</i></span> <span class="citation_source-journal">Cell. Physiol. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">574</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1159%2F000329978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21691074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnslensrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2011&pages=565-574&author=Z.+X.+Caoauthor=R.+L.+Zhengauthor=H.+J.+Linauthor=S.+D.+Luoauthor=Y.+Zhouauthor=Y.+Z.+Xuauthor=X.+X.+Zengauthor=Z.+Wangauthor=L.+N.+Zhouauthor=Y.+Q.+Maoauthor=L.+Yangauthor=Y.+Q.+Weiauthor=L.+T.+Yuauthor=S.+Y.+Yangauthor=Y.+L.+Zhao&title=SKLB610%3A+a+novel+potential+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases+inhibits+angiogenesis+and+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB610: A novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo</span></div><div class="casAuthors">Cao, Zhi-Xing; Zheng, Ren-Lin; Lin, Hong-Jun; Luo, Shi-Dong; Zhou, Yan; Xu, You-Zhi; Zeng, Xiu-Xiu; Wang, Zhao; Zhou, Li-Na; Mao, Yong-qiu; Yang, Li; Wei, Yu-Quan; Yu, Luo-Ting; Yang, Sheng-Yong; Zhao, Ying-Lan</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Antagonizing angiogenesis-related receptor tyrosine kinase is a promising therapeutic strategy in oncol.  In present study, we designed and synthesized a novel vascular endothelial growth factor receptor (VEGFR) inhibitor N-methyl-4-(4-(3-(trifluoromethyl) benzamido) phenoxy) picolinamide SKLB610 that potently suppresses human tumor angiogenesis.  SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth factor receptor 2 (FGFR2) and platelet-derived growth factor receptor (PDGFR) at rate of 97%, 65% and 55%, resp., at concn. of 10μM in biochem. kinase assays.  In vitro, SKLB610 showed more selective inhibition of VEGF-stimulated human umbilical vein endothelial cells (HUVECs) proliferation, and this proliferation inhibitory effect was assocd. with decreased phosphorylation of VEGFR2 and p42/44 mitogen-activated protein kinase (p42/44 MAPK).  Antiangiogenic evaluation showed that SKLB610 inhibited the HUVECs capillary-tube formation on Matrigel in vitro and the sub-intestinal vein formation of zebrafish in vivo.  Moreover, SKLB610 inhibited a panel of human cancer cells proliferation in a concn.-dependent manner and human non-small cell lung cancer cell line A549 and human colorectal cancer cell line HCT116 were most sensitive to SKLB610 treatment.  In vivo, chronic i.p. administration of SKLB610 at dose of 50 mg/kg/d resulted in significant inhibition in the growth of established human A549 and HCT116 tumor xenografts in nude mice without exhibit toxicity.  Histol. anal. showed significant redns. in intratumoral microvessel d. (CD31 staining) of 43-55% relative to controls depending on the specific tumor xenografts.  In conclusion, the present study demonstrated that SKLB610 exhibited its antitumor activity as a multi-targeted inhibitor with more potent inhibition of VEGFR2 activity.  Its potential to be a candidate of anticancer agent is worth being further investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0_JmlLdPKLVg90H21EOLACvtfcHk0lhdpdMNLe9SZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnslensrk%253D&md5=c336eca447470eceeb7f5734251f72ac</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1159%2F000329978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000329978%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DZ.%2BX.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DH.%2BJ.%26aulast%3DLuo%26aufirst%3DS.%2BD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%2BZ.%26aulast%3DZeng%26aufirst%3DX.%2BX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYu%26aufirst%3DL.%2BT.%26aulast%3DYang%26aufirst%3DS.%2BY.%26aulast%3DZhao%26aufirst%3DY.%2BL.%26atitle%3DSKLB610%253A%2520a%2520novel%2520potential%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%2520inhibits%2520angiogenesis%2520and%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2011%26volume%3D27%26spage%3D565%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group">Dandu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miknyoczki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Design and synthesis of dihydroindazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1916</span><span class="NLM_x">–</span> <span class="NLM_lpage">1921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1916-1921&author=R.+Danduauthor=A.+L.+Zulliauthor=E.+R.+Baconauthor=T.+Underinerauthor=C.+Robinsonauthor=H.+Changauthor=S.+Miknyoczkiauthor=J.+Grobelnyauthor=B.+A.+Ruggeriauthor=S.+Yangauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=R.+L.+Hudkins&title=Design+and+synthesis+of+dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole+oximes+as+potent+dual+inhibitors+of+TIE-2+and+VEGF-R2+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDandu%26aufirst%3DR.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DBacon%26aufirst%3DE.%2BR.%26aulast%3DUnderiner%26aufirst%3DT.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DGrobelny%26aufirst%3DJ.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole%2520oximes%2520as%2520potent%2520dual%2520inhibitors%2520of%2520TIE-2%2520and%2520VEGF-R2%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1916%26epage%3D1921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A.</span><span> </span><span class="NLM_article-title">TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2368</span><span class="NLM_x">–</span> <span class="NLM_lpage">2372</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2368-2372&author=T.+L.+Underinerauthor=B.+Ruggeriauthor=L.+Aimoneauthor=M.+Albomauthor=T.+Angelesauthor=H.+Changauthor=R.+L.+Hudkinsauthor=K.+Hunterauthor=K.+Josefauthor=C.+Robinsonauthor=L.+Weinbergauthor=S.+Yangauthor=A.+Zulli&title=TIE-2%2FVEGF-R2+SAR+and+in+vitro+activity+of+C3-acyl+dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DAimone%26aufirst%3DL.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DJosef%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DWeinberg%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZulli%26aufirst%3DA.%26atitle%3DTIE-2%252FVEGF-R2%2520SAR%2520and%2520in%2520vitro%2520activity%2520of%2520C3-acyl%2520dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2368%26epage%3D2372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauletti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almo, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">8-THP-DHI analogs as potent type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3356</span><span class="NLM_x">–</span> <span class="NLM_lpage">3360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3356-3360&author=R.+L.+Hudkinsauthor=A.+L.+Zulliauthor=T.+L.+Underinerauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=S.+L.+Meyerauthor=D.+Paulettiauthor=H.+Changauthor=E.+V.+Fedorovauthor=S.+C.+Almoauthor=A.+A.+Fedorovauthor=B.+A.+Ruggeri&title=8-THP-DHI+analogs+as+potent+type+I+dual+TIE-2%2FVEGF-R2+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DPauletti%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DFedorov%26aufirst%3DE.%2BV.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3D8-THP-DHI%2520analogs%2520as%2520potent%2520type%2520I%2520dual%2520TIE-2%252FVEGF-R2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3356%26epage%3D3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group">Peifer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinkel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schächtele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidenreich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Röcken, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schollmeyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel 3-aryl-4-(1<i>H</i>-indole-3yl)-1,5-dihydro-2<i>H</i>-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3814</span><span class="NLM_x">–</span> <span class="NLM_lpage">3824</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8001185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3814-3824&author=C.+Peiferauthor=R.+Seligauthor=K.+Kinkelauthor=D.+Ottauthor=F.+Totzkeauthor=C.+Sch%C3%A4chteleauthor=R.+Heidenreichauthor=M.+R%C3%B6ckenauthor=D.+Schollmeyerauthor=S.+Laufer&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+3-aryl-4-%281H-indole-3yl%29-1%2C5-dihydro-2H-pyrrole-2-ones+as+vascular+endothelial+growth+factor+receptor+%28VEGF-R%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fjm8001185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001185%26sid%3Dliteratum%253Aachs%26aulast%3DPeifer%26aufirst%3DC.%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DKinkel%26aufirst%3DK.%26aulast%3DOtt%26aufirst%3DD.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DHeidenreich%26aufirst%3DR.%26aulast%3DR%25C3%25B6cken%26aufirst%3DM.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%25203-aryl-4-%25281H-indole-3yl%2529-1%252C5-dihydro-2H-pyrrole-2-ones%2520as%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520%2528VEGF-R%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3814%26epage%3D3824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group">Cho, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bing, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiong, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bei, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, M. X.</span><span> </span><span class="NLM_article-title">Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure–activity relationships, and antitumor activities of 2-indolinone derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8140</span><span class="NLM_x">–</span> <span class="NLM_lpage">8149</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8140-8149&author=T.+P.+Choauthor=S.+Y.+Dongauthor=F.+Junauthor=F.+J.+Hongauthor=Y.+J.+Liangauthor=X.+Luauthor=P.+J.+Huaauthor=L.+Y.+Liauthor=Z.+Leiauthor=H.+Bingauthor=Z.+Yingauthor=L.+F.+Qiongauthor=F.+B.+Beiauthor=L.+L.+Guangauthor=G.+A.+Shenauthor=S.+G.+Hongauthor=S.+W.+Hongauthor=M.+X.+Tai&title=Novel+potent+orally+active+multitargeted+receptor+tyrosine+kinase+inhibitors%3A+synthesis%2C+structure%E2%80%93activity+relationships%2C+and+antitumor+activities+of+2-indolinone+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DT.%2BP.%26aulast%3DDong%26aufirst%3DS.%2BY.%26aulast%3DJun%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DF.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%2BJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DP.%2BJ.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DLei%26aufirst%3DZ.%26aulast%3DBing%26aufirst%3DH.%26aulast%3DYing%26aufirst%3DZ.%26aulast%3DQiong%26aufirst%3DL.%2BF.%26aulast%3DBei%26aufirst%3DF.%2BB.%26aulast%3DGuang%26aufirst%3DL.%2BL.%26aulast%3DShen%26aufirst%3DG.%2BA.%26aulast%3DHong%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DS.%2BW.%26aulast%3DTai%26aufirst%3DM.%2BX.%26atitle%3DNovel%2520potent%2520orally%2520active%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520antitumor%2520activities%2520of%25202-indolinone%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8140%26epage%3D8149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span> </span><span class="NLM_article-title">Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-011-1681-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21638122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=173-183&author=D.+Wangauthor=F.+Tangauthor=S.+Wangauthor=Z.+Jiangauthor=L.+Zhang&title=Preclinical+anti-angiogenesis+and+anti-tumor+activity+of+SIM010603%2C+an+oral%2C+multi-targets+receptor+tyrosine+kinases+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor</span></div><div class="casAuthors">Wang, Dongchun; Tang, Feng; Wang, Sen; Jiang, Zhenzhou; Zhang, Luyong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-183</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objective: SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor.  This study investigated the anti-angiogenic and anti-tumor effects of SIM010603.  Methods: A radiometric protein kinase assay was used for measuring the kinase activity of the 32 protein kinases.  Receptor phosphorylation was detd. by ELISA (ELISA).  Cell proliferation was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.  Cell chemotaxis was evaluated by modified Boyden chamber assay.  Effect of SIM010603 on angiogenesis was examd. by mouse cornea angiogenesis assay.  Effect of SIM010603 on xenografts was assessed by tumor growth delay.  Effects of SIM010603 on tumor microvascular d. (MVD), recruitment of pericytes, and pericyte encapsulation of tumor vessels were analyzed by immunofluorescent staining technique.  Results: SIM010603 inhibited stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC50 values between 5.0 and 68.1 nmol/l.  SIM010603 inhibited the phosphorylation of PDGFR-β and VEGFR-2.  Moreover, SIM010603 inhibited endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis.  Although SIM010603 exhibited lower activity in regard to proliferation of NCI-H460, MDA-MB-435, and T241-VEGF-A cells (IC50 > 1 μmol/l), SIM010603 inhibited tumor growth in these xenograft tumor growth models.  SIM010603 reduced tumor MVD in T241-VEGF-A tumor xenograft models and decreased pos. signals of CD31, NG2 in MDA-MB-435, and LLC-SW-44 xenograft tumor models.  Conclusions: These results support the clin. assessment of SIM010603 as a therapeutic agent for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4z0U7U1VXbVg90H21EOLACvtfcHk0liEqCBI-i6Yxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVOntw%253D%253D&md5=7dab0478ef64e82a722254ca06efe457</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1681-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1681-1%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DPreclinical%2520anti-angiogenesis%2520and%2520anti-tumor%2520activity%2520of%2520SIM010603%252C%2520an%2520oral%252C%2520multi-targets%2520receptor%2520tyrosine%2520kinases%2520inhibitor%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D173%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span> </span><span class="NLM_article-title">Synthesis, SAR, and evaluation of 4-[2,4-difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-<i>f</i>][1,2,4]triazine-based VEGFR-2 kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1354</span><span class="NLM_x">–</span> <span class="NLM_lpage">1358</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1354-1358&author=Z.+W.+Caiauthor=D.+Weiauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=A.+Kamathauthor=S.+Mortilloauthor=B.+Wautletauthor=B.+J.+Henleyauthor=R.+Jeyaseelanauthor=J.+Tokarskiauthor=J.+T.+Huntauthor=R.+S.+Bhideauthor=J.+Fargnoliauthor=L.+J.+Lombardo&title=Synthesis%2C+SAR%2C+and+evaluation+of+4-%5B2%2C4-difluoro-5-%28cyclopropylcarbamoyl%29phenylamino%5Dpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazine-based+VEGFR-2+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DHenley%26aufirst%3DB.%2BJ.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26atitle%3DSynthesis%252C%2520SAR%252C%2520and%2520evaluation%2520of%25204-%255B2%252C4-difluoro-5-%2528cyclopropylcarbamoyl%2529phenylamino%255Dpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazine-based%2520VEGFR-2%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1354%26epage%3D1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group">Ruel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">L’Heureux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tejwani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-<i>N</i>-(2-methyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)pyrrolo[2,1-<i>f</i>][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2985</span><span class="NLM_x">–</span> <span class="NLM_lpage">2989</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2985-2989&author=R.+Ruelauthor=C.+Thibeaultauthor=A.+L%E2%80%99Heureuxauthor=A.+Martelauthor=Z.+W.+Caiauthor=D.+Weiauthor=L.+Qianauthor=J.+C.+Barrishauthor=A.+Mathurauthor=C.+D%E2%80%99Arienzoauthor=J.+T.+Huntauthor=A.+Kamathauthor=P.+Maratheauthor=Y.+Zhangauthor=G.+Derbinauthor=B.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=B.+Henleyauthor=R.+Tejwaniauthor=R.+S.+Bhideauthor=G.+L.+Trainorauthor=J.+Fargnoliauthor=L.+J.+Lombardo&title=Discovery+and+preclinical+studies+of+5-isopropyl-6-%285-methyl-1%2C3%2C4-oxadiazol-2-yl%29-N-%282-methyl-1H-pyrrolo%5B2%2C3-b%5Dpyridin-5-yl%29pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-4-amine+%28BMS-645737%29%2C+an+in+vivo+active+potent+VEGFR-2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuel%26aufirst%3DR.%26aulast%3DThibeault%26aufirst%3DC.%26aulast%3DL%25E2%2580%2599Heureux%26aufirst%3DA.%26aulast%3DMartel%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DTejwani%26aufirst%3DR.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520studies%2520of%25205-isopropyl-6-%25285-methyl-1%252C3%252C4-oxadiazol-2-yl%2529-N-%25282-methyl-1H-pyrrolo%255B2%252C3-b%255Dpyridin-5-yl%2529pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-4-amine%2520%2528BMS-645737%2529%252C%2520an%2520in%2520vivo%2520active%2520potent%2520VEGFR-2%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2985%26epage%3D2989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">3-Amino-benzo[<i>d</i>]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701096v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1231-1241&author=Z.+Jiauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=G.+Diazauthor=K.+B.+Glaserauthor=J.+Guoauthor=C.+M.+Harrisauthor=J.+Liauthor=P.+A.+Marcotteauthor=M.+D.+Moskeyauthor=T.+Oieauthor=L.+Peaseauthor=N.+B.+Soniauthor=K.+D.+Stewartauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=3-Amino-benzo%5Bd%5Disoxazoles+as+novel+multitargeted+inhibitors+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Fjm701096v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701096v%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DOie%26aufirst%3DT.%26aulast%3DPease%26aufirst%3DL.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3D3-Amino-benzo%255Bd%255Disoxazoles%2520as%2520novel%2520multitargeted%2520inhibitors%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1231%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group">Abu Thaher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnsmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehlert, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubbutat, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schächtele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">961</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=961-965&author=B.+Abu+Thaherauthor=M.+Arnsmannauthor=F.+Totzkeauthor=J.+E.+Ehlertauthor=M.+H.+Kubbutatauthor=C.+Sch%C3%A4chteleauthor=M.+O.+Zimmermannauthor=P.+Kochauthor=F.+M.+Boecklerauthor=S.+A.+Laufer&title=Tri-+and+tetrasubstituted+pyrazole+derivates%3A+regioisomerism+switches+activity+from+p38MAP+kinase+to+important+cancer+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbu%2BThaher%26aufirst%3DB.%26aulast%3DArnsmann%26aufirst%3DM.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DEhlert%26aufirst%3DJ.%2BE.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DTri-%2520and%2520tetrasubstituted%2520pyrazole%2520derivates%253A%2520regioisomerism%2520switches%2520activity%2520from%2520p38MAP%2520kinase%2520to%2520important%2520cancer%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D961%26epage%3D965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group">Bologna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicentini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pace, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelucci, A.</span><span> </span><span class="NLM_article-title">Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2827</span><span class="NLM_x">–</span> <span class="NLM_lpage">2835</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F092986711796150487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21651496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2rtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2827-2835&author=M.+Bolognaauthor=C.+Vicentiniauthor=P.+Muziauthor=G.+Paceauthor=A.+Angelucci&title=Cancer+multitarget+pharmacology+in+prostate+tumors%3A+tyrosine+kinase+inhibitors+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond</span></div><div class="casAuthors">Bologna, M.; Vicentini, C.; Muzi, P.; Pace, G.; Angelucci, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2827-2835</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinase inhibitors are currently one of the most important classes of cancer drugs, essentially because many kinases and regulators are mols. related to frequently mutated oncogenes and tumor suppressors.  Many expts. and clin. data in different tumors show that better cancer therapy can be obtained by blocking several tumor cell biochem. pathways at once, accurately selecting crit. targets and adjusting drug dosages for the best results.  Through our direct experience in exptl. models of prostate cancer (PCa), we discuss in this review the issues of tyrosine kinase inhibition in neoplastic cells and illustrate the opportunities to extend cancer proliferation control to other key biol. targets of clin. interest, aiming at the realization of better polypharmacol. applications in cancer chemotherapy.  Briefly, in this review the main exptl. evidences on the efficacy of tyrosine kinase inhibitors (TKIs) on PCa are described, together with a reasoned anal. of biol. data which may be useful for a general extension to other clin. areas of cancer multitargeted and possibly individualized polychemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgCr2N6NiCYLVg90H21EOLACvtfcHk0lgvPzcXNRGW_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2rtb8%253D&md5=bd5f67c7bae35fdbc2b688961bb4244c</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.2174%2F092986711796150487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796150487%26sid%3Dliteratum%253Aachs%26aulast%3DBologna%26aufirst%3DM.%26aulast%3DVicentini%26aufirst%3DC.%26aulast%3DMuzi%26aufirst%3DP.%26aulast%3DPace%26aufirst%3DG.%26aulast%3DAngelucci%26aufirst%3DA.%26atitle%3DCancer%2520multitarget%2520pharmacology%2520in%2520prostate%2520tumors%253A%2520tyrosine%2520kinase%2520inhibitors%2520and%2520beyond%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2827%26epage%3D2835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+polypharmacology%3A+discovery+of+dual+inhibitors+of+tyrosine+and+phosphoinositide+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0ljpU_3jslmRjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520polypharmacology%253A%2520discovery%2520of%2520dual%2520inhibitors%2520of%2520tyrosine%2520and%2520phosphoinositide%2520kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 105 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Junting Zhou, Xueyang Jiang, Siyu He, Hongli Jiang, Feng Feng, Wenyuan Liu, Wei Qu, <span class="NLM_string-name hlFld-ContribAuthor">Haopeng Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8881-8914. <a href="https://doi.org/10.1021/acs.jmedchem.9b00017" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Bof%252BMultitarget-Directed%252BLigands%25253A%252BStrategies%252Band%252BEmerging%252BParadigms%26aulast%3DZhou%26aufirst%3DJunting%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04012019%26date%3D28052019%26date%3D13052019%26volume%3D62%26issue%3D20%26spage%3D8881%26epage%3D8914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jie Zang, Xuewu Liang, Yongxue Huang, Yuping Jia, Xiaoyang Li, Wenfang Xu, C. James Chou, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5304-5322. <a href="https://doi.org/10.1021/acs.jmedchem.8b00384" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00384</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPazopanib-Based%252BHDAC%252Band%252BVEGFR%252BDual%252BInhibitors%252BTargeting%252BCancer%252BEpigenetics%252Band%252BAngiogenesis%252BSimultaneously%26aulast%3DZang%26aufirst%3DJie%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09032018%26date%3D07062018%26date%3D22052018%26volume%3D61%26issue%3D12%26spage%3D5304%26epage%3D5322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher M.  Adams</span>, <span class="hlFld-ContribAuthor ">Karen  Anderson</span>, <span class="hlFld-ContribAuthor ">Gerald  Artman, III</span>, <span class="hlFld-ContribAuthor ">Jean-Claude  Bizec</span>, <span class="hlFld-ContribAuthor ">Rosemarie  Cepeda</span>, <span class="hlFld-ContribAuthor ">Jason  Elliott</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Fassbender</span>, <span class="hlFld-ContribAuthor ">Malay  Ghosh</span>, <span class="hlFld-ContribAuthor ">Shawn  Hanks</span>, <span class="hlFld-ContribAuthor ">Leo A.  Hardegger</span>, <span class="hlFld-ContribAuthor ">Vinayak P.  Hosagrahara</span>, <span class="hlFld-ContribAuthor ">Bruce  Jaffee</span>, <span class="hlFld-ContribAuthor ">Keith  Jendza</span>, <span class="hlFld-ContribAuthor ">Nan  Ji</span>, <span class="hlFld-ContribAuthor ">Leland  Johnson</span>, <span class="hlFld-ContribAuthor ">Wendy  Lee</span>, <span class="hlFld-ContribAuthor ">Donglei  Liu</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Debby  Long</span>, <span class="hlFld-ContribAuthor ">Fupeng  Ma</span>, <span class="hlFld-ContribAuthor ">Nello  Mainolfi</span>, <span class="hlFld-ContribAuthor ">Erik L.  Meredith</span>, <span class="hlFld-ContribAuthor ">Karl  Miranda</span>, <span class="hlFld-ContribAuthor ">Yao  Peng</span>, <span class="hlFld-ContribAuthor ">Stephen  Poor</span>, <span class="hlFld-ContribAuthor ">James  Powers</span>, <span class="hlFld-ContribAuthor ">Yubin  Qiu</span>, <span class="hlFld-ContribAuthor ">Chang  Rao</span>, <span class="hlFld-ContribAuthor ">Siyuan  Shen</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Sivak</span>, <span class="hlFld-ContribAuthor ">Catherine  Solovay</span>, <span class="hlFld-ContribAuthor ">Peter  Tarsa</span>, <span class="hlFld-ContribAuthor ">Amber  Woolfenden</span>, <span class="hlFld-ContribAuthor ">Chun  Zhang</span>, and <span class="hlFld-ContribAuthor ">Yiqin  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (4)
                                     , 1622-1635. <a href="https://doi.org/10.1021/acs.jmedchem.7b01731" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01731%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BDiscovery%252Bof%252BN-%2525281-Methyl-5-%252528trifluoromethyl%252529-1H-pyrazol-3-yl%252529-5-%252528%2525286-%252B%252528%252528methylamino%252529methyl%252529pyrimidin-4-yl%252529oxy%252529-1H-indole-1-carboxamide%252B%252528Acrizanib%252529%25252C%252Ba%252BVEGFR-2%252BInhibitor%252BSpecifically%252BDesigned%252Bfor%252BTopical%252BOcular%252BDelivery%25252C%252Bas%252Ba%252BTherapy%252Bfor%252BNeovascular%252BAge-Related%252BMacular%252BDegeneration%26aulast%3DAdams%26aufirst%3DChristopher%2BM.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D28112017%26date%3D05022018%26date%3D22022018%26volume%3D61%26issue%3D4%26spage%3D1622%26epage%3D1635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Danfeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, and <span class="hlFld-ContribAuthor ">Yu  Jiao</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (1)
                                     , 140-157. <a href="https://doi.org/10.1021/acs.jmedchem.7b01091" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01091%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPotent%252BVEGFR-2%252BInhibitors%252BExerting%252BSignificant%252BAntiproliferative%252BActivity%252Bagainst%252BCancer%252BCell%252BLines%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D25072017%26date%3D19122017%26date%3D11012018%26date%3D30112017%26volume%3D61%26issue%3D1%26spage%3D140%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Yu</span>, <span class="hlFld-ContribAuthor ">Jedo  Oh</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Yongseok  Kwon</span>, <span class="hlFld-ContribAuthor ">Hyunkyung  Cho</span>, <span class="hlFld-ContribAuthor ">Jongheon  Shin</span>, <span class="hlFld-ContribAuthor ">Sang Kook  Lee</span>, and <span class="hlFld-ContribAuthor ">Sanghee  Kim</span>  . </span><span class="cited-content_cbyCitation_article-title">New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (10)
                                     , 1066-1071. <a href="https://doi.org/10.1021/acsmedchemlett.7b00281" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00281%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNew%252BScaffold%252Bfor%252BAngiogenesis%252BInhibitors%252BDiscovered%252Bby%252BTargeted%252BChemical%252BTransformations%252Bof%252BWondonin%252BNatural%252BProducts%26aulast%3DYu%26aufirst%3DShuai%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11072017%26date%3D12092017%26date%3D14092017%26date%3D12102017%26date%3D12092017%26volume%3D8%26issue%3D10%26spage%3D1066%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Sartori</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Portioli</span>, <span class="hlFld-ContribAuthor ">Lucia  Battistini</span>, <span class="hlFld-ContribAuthor ">Lido  Calorini</span>, <span class="hlFld-ContribAuthor ">Alberto  Pupi</span>, <span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">Francesca  Bianchini</span>, and <span class="hlFld-ContribAuthor ">Franca  Zanardi</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Novel c(AmpRGD)–Sunitinib Dual Conjugates as Molecular Tools Targeting the αvβ3 Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (1)
                                     , 248-262. <a href="https://doi.org/10.1021/acs.jmedchem.6b01266" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01266%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252BNovel%252Bc%252528AmpRGD%252529%2525E2%252580%252593Sunitinib%252BDual%252BConjugates%252Bas%252BMolecular%252BTools%252BTargeting%252Bthe%252B%2525CE%2525B1v%2525CE%2525B23%252BIntegrin%25252FVEGFR2%252BCouple%252Band%252BImpairing%252BTumor-Associated%252BAngiogenesis%26aulast%3DSartori%26aufirst%3DAndrea%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D25082016%26date%3D20122016%26date%3D12012017%26date%3D06122016%26volume%3D60%26issue%3D1%26spage%3D248%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nello  Mainolfi</span>, <span class="hlFld-ContribAuthor ">Rajeshri  Karki</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, and <span class="hlFld-ContribAuthor ">Karen  Anderson</span>  . </span><span class="cited-content_cbyCitation_article-title">Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (4)
                                     , 363-367. <a href="https://doi.org/10.1021/acsmedchemlett.5b00486" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00486</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00486%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEvolution%252Bof%252Ba%252BNew%252BClass%252Bof%252BVEGFR-2%252BInhibitors%252Bfrom%252BScaffold%252BMorphing%252Band%252BRedesign%26aulast%3DMainolfi%26aufirst%3DNello%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D14122015%26date%3D02022016%26date%3D08022016%26date%3D14042016%26date%3D02022016%26volume%3D7%26issue%3D4%26spage%3D363%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guido  Bold</span>, <span class="hlFld-ContribAuthor ">Christian  Schnell</span>, <span class="hlFld-ContribAuthor ">Pascal  Furet</span>, <span class="hlFld-ContribAuthor ">Paul  McSheehy</span>, <span class="hlFld-ContribAuthor ">Josef  Brüggen</span>, <span class="hlFld-ContribAuthor ">Jürgen  Mestan</span>, <span class="hlFld-ContribAuthor ">Paul W.  Manley</span>, <span class="hlFld-ContribAuthor ">Peter  Drückes</span>, <span class="hlFld-ContribAuthor ">Marion  Burglin</span>, <span class="hlFld-ContribAuthor ">Ursula  Dürler</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Loretan</span>, <span class="hlFld-ContribAuthor ">Robert  Reuter</span>, <span class="hlFld-ContribAuthor ">Markus  Wartmann</span>, <span class="hlFld-ContribAuthor ">Andreas  Theuer</span>, <span class="hlFld-ContribAuthor ">Beatrice  Bauer-Probst</span>, <span class="hlFld-ContribAuthor ">Georg  Martiny-Baron</span>, <span class="hlFld-ContribAuthor ">Peter  Allegrini</span>, <span class="hlFld-ContribAuthor ">Arnaud  Goepfert</span>, <span class="hlFld-ContribAuthor ">Jeanette  Wood</span>, and <span class="hlFld-ContribAuthor ">Amanda  Littlewood-Evans</span>  . </span><span class="cited-content_cbyCitation_article-title">A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 132-146. <a href="https://doi.org/10.1021/acs.jmedchem.5b01582" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01582</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01582%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BNovel%252BPotent%252BOral%252BSeries%252Bof%252BVEGFR2%252BInhibitors%252BAbrogate%252BTumor%252BGrowth%252Bby%252BInhibiting%252BAngiogenesis%26aulast%3DBold%26aufirst%3DGuido%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D21072015%26date%3D21122015%26date%3D14012016%26date%3D02122015%26volume%3D59%26issue%3D1%26spage%3D132%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Sheng  Tian</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Kong</span>, <span class="hlFld-ContribAuthor ">Wenfang  Zhou</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, and <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 via Structure-Based Virtual Screening and Biological Evaluation in in vitro Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (12)
                                     , 2693-2704. <a href="https://doi.org/10.1021/acs.jcim.5b00576" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00576%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Band%252BPreliminary%252BSAR%252BAnalysis%252Bof%252BNovel%252BType-I%252BInhibitors%252Bof%252BTIE-2%252Bvia%252BStructure-Based%252BVirtual%252BScreening%252Band%252BBiological%252BEvaluation%252Bin%252Bin%252Bvitro%252BModels%26aulast%3DPan%26aufirst%3DPeichen%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D18092015%26date%3D15122015%26date%3D28122015%26date%3D30112015%26volume%3D55%26issue%3D12%26spage%3D2693%26epage%3D2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erik L.  Meredith</span>, <span class="hlFld-ContribAuthor ">Nello  Mainolfi</span>, <span class="hlFld-ContribAuthor ">Stephen  Poor</span>, <span class="hlFld-ContribAuthor ">Yubin  Qiu</span>, <span class="hlFld-ContribAuthor ">Karl  Miranda</span>, <span class="hlFld-ContribAuthor ">James  Powers</span>, <span class="hlFld-ContribAuthor ">Donglei  Liu</span>, <span class="hlFld-ContribAuthor ">Fupeng  Ma</span>, <span class="hlFld-ContribAuthor ">Catherine  Solovay</span>, <span class="hlFld-ContribAuthor ">Chang  Rao</span>, <span class="hlFld-ContribAuthor ">Leland  Johnson</span>, <span class="hlFld-ContribAuthor ">Nan  Ji</span>, <span class="hlFld-ContribAuthor ">Gerald  Artman</span>, <span class="hlFld-ContribAuthor ">Leo  Hardegger</span>, <span class="hlFld-ContribAuthor ">Shawn  Hanks</span>, <span class="hlFld-ContribAuthor ">Siyuan  Shen</span>, <span class="hlFld-ContribAuthor ">Amber  Woolfenden</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Fassbender</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Sivak</span>, <span class="hlFld-ContribAuthor ">Yiqin  Zhang</span>, <span class="hlFld-ContribAuthor ">Debby  Long</span>, <span class="hlFld-ContribAuthor ">Rosemarie  Cepeda</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Vinayak P.  Hosagrahara</span>, <span class="hlFld-ContribAuthor ">Wendy  Lee</span>, <span class="hlFld-ContribAuthor ">Peter  Tarsa</span>, <span class="hlFld-ContribAuthor ">Karen  Anderson</span>, <span class="hlFld-ContribAuthor ">Jason  Elliott</span>, and <span class="hlFld-ContribAuthor ">Bruce  Jaffee</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (23)
                                     , 9273-9286. <a href="https://doi.org/10.1021/acs.jmedchem.5b01227" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01227%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BOral%252BVEGFR-2%252BInhibitors%252Bwith%252BProlonged%252BOcular%252BRetention%252BThat%252BAre%252BEfficacious%252Bin%252BModels%252Bof%252BWet%252BAge-Related%252BMacular%252BDegeneration%26aulast%3DMeredith%26aufirst%3DErik%2BL.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D03082015%26date%3D30112015%26date%3D10122015%26date%3D15112015%26volume%3D58%26issue%3D23%26spage%3D9273%26epage%3D9286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Schenone</span>, <span class="hlFld-ContribAuthor ">Marco  Radi</span>, <span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, and <span class="hlFld-ContribAuthor ">Maurizio  Botta</span>  . </span><span class="cited-content_cbyCitation_article-title">Biologically Driven Synthesis of Pyrazolo[3,4-d]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2014,</strong> <em>114 </em>
                                    (14)
                                     , 7189-7238. <a href="https://doi.org/10.1021/cr400270z" title="DOI URL">https://doi.org/10.1021/cr400270z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cr400270z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcr400270z%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DBiologically%252BDriven%252BSynthesis%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyrimidines%252BAs%252BProtein%252BKinase%252BInhibitors%25253A%252BAn%252BOld%252BScaffold%252BAs%252Ba%252BNew%252BTool%252Bfor%252BMedicinal%252BChemistry%252Band%252BChemical%252BBiology%252BStudies%26aulast%3DSchenone%26aufirst%3DSilvia%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D16052013%26date%3D29052014%26date%3D23072014%26volume%3D114%26issue%3D14%26spage%3D7189%26epage%3D7238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongcong  Lv</span>, <span class="hlFld-ContribAuthor ">Mengyuan  Li</span>, <span class="hlFld-ContribAuthor ">Ting  Liu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Lixin  Wei</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, and <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (5)
                                     , 592-597. <a href="https://doi.org/10.1021/ml5000417" title="DOI URL">https://doi.org/10.1021/ml5000417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml5000417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml5000417%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BNew%252BSeries%252Bof%252BNaphthamides%252Bas%252BPotent%252BVEGFR-2%252BKinase%252BInhibitors%26aulast%3DLv%26aufirst%3DYongcong%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D29012014%26date%3D24022014%26date%3D25022014%26date%3D08052014%26date%3D24022014%26volume%3D5%26issue%3D5%26spage%3D592%26epage%3D597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Shangyan  Yang</span>, <span class="hlFld-ContribAuthor ">Yu  Jiao</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Sihui  Yao</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Ke</span>, <span class="hlFld-ContribAuthor ">Jinxing  Xu</span>, <span class="hlFld-ContribAuthor ">Xiao  Xiong</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, and <span class="hlFld-ContribAuthor ">Tao  Lu</span>  . </span><span class="cited-content_cbyCitation_article-title">An Integrated Virtual Screening Approach for VEGFR-2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2013,</strong> <em>53 </em>
                                    (12)
                                     , 3163-3177. <a href="https://doi.org/10.1021/ci400429g" title="DOI URL">https://doi.org/10.1021/ci400429g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci400429g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci400429g%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DAn%252BIntegrated%252BVirtual%252BScreening%252BApproach%252Bfor%252BVEGFR-2%252BInhibitors%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D23072013%26date%3D03122013%26date%3D23122013%26date%3D22112013%26volume%3D53%26issue%3D12%26spage%3D3163%26epage%3D3177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandip B.  Bharate</span>, <span class="hlFld-ContribAuthor ">Sanghapal D.  Sawant</span>, <span class="hlFld-ContribAuthor ">Parvinder Pal  Singh</span>, and <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>  . </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors of Marine Origin. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2013,</strong> <em>113 </em>
                                    (8)
                                     , 6761-6815. <a href="https://doi.org/10.1021/cr300410v" title="DOI URL">https://doi.org/10.1021/cr300410v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cr300410v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcr300410v%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DKinase%252BInhibitors%252Bof%252BMarine%252BOrigin%26aulast%3DBharate%26aufirst%3DSandip%2BB.%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D13102012%26date%3D16052013%26date%3D14082013%26volume%3D113%26issue%3D8%26spage%3D6761%26epage%3D6815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed H.  Hekal</span>, <span class="hlFld-ContribAuthor ">Paula S.  Farag</span>, <span class="hlFld-ContribAuthor ">Magdy M.  Hemdan</span>, <span class="hlFld-ContribAuthor ">Wael M.  El-Sayed</span>. </span><span class="cited-content_cbyCitation_article-title">New N-(1,3,4-thiadiazol-2-yl)furan-2-carboxamide derivatives as potential inhibitors of the VEGFR-2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>115 </em>, 105176. <a href="https://doi.org/10.1016/j.bioorg.2021.105176" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105176%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNew%252BN-%2525281%25252C3%25252C4-thiadiazol-2-yl%252529furan-2-carboxamide%252Bderivatives%252Bas%252Bpotential%252Binhibitors%252Bof%252Bthe%252BVEGFR-2%26aulast%3DHekal%26aufirst%3DMohamed%2BH.%26date%3D2021%26volume%3D115%26spage%3D105176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yara  El-Dash</span>, <span class="hlFld-ContribAuthor ">Emad  Elzayat</span>, <span class="hlFld-ContribAuthor ">Amr M.  Abdou</span>, <span class="hlFld-ContribAuthor ">Rasha A.  Hassan</span>. </span><span class="cited-content_cbyCitation_article-title">Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105137. <a href="https://doi.org/10.1016/j.bioorg.2021.105137" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105137%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252Bthienopyrimidine-aminothiazole%252Bhybrids%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bantimicrobial%252Bscreening%25252C%252Banticancer%252Bactivity%25252C%252Beffects%252Bon%252Bcell%252Bcycle%252Bprofile%25252C%252Bcaspase-3%252Bmediated%252Bapoptosis%252Band%252BVEGFR-2%252Binhibition%26aulast%3DEl-Dash%26aufirst%3DYara%26date%3D2021%26volume%3D114%26spage%3D105137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nitin  Tandon</span>, <span class="hlFld-ContribAuthor ">Vijay  Luxami</span>, <span class="hlFld-ContribAuthor ">Divya  Kant</span>, <span class="hlFld-ContribAuthor ">Runjhun  Tandon</span>, <span class="hlFld-ContribAuthor ">Kamaldeep  Paul</span>. </span><span class="cited-content_cbyCitation_article-title">Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (41)
                                     , 25228-25257. <a href="https://doi.org/10.1039/D1RA03979B" title="DOI URL">https://doi.org/10.1039/D1RA03979B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1RA03979B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1RA03979B%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DCurrent%252Bprogress%25252C%252Bchallenges%252Band%252Bfuture%252Bprospects%252Bof%252Bindazoles%252Bas%252Bprotein%252Bkinase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DTandon%26aufirst%3DNitin%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D41%26spage%3D25228%26epage%3D25257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Souad A.  El-Metwally</span>, <span class="hlFld-ContribAuthor ">Mohsen M.  Abou-El-Regal</span>, <span class="hlFld-ContribAuthor ">Ibrahim H.  Eissa</span>, <span class="hlFld-ContribAuthor ">Ahmed B.M.  Mehany</span>, <span class="hlFld-ContribAuthor ">Hazem A.  Mahdy</span>, <span class="hlFld-ContribAuthor ">Hazem  Elkady</span>, <span class="hlFld-ContribAuthor ">Alaa  Elwan</span>, <span class="hlFld-ContribAuthor ">Eslam B.  Elkaeed</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>112 </em>, 104947. <a href="https://doi.org/10.1016/j.bioorg.2021.104947" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104947%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthieno%25255B2%25252C3-d%25255Dpyrimidine-based%252Bderivatives%252Bas%252Bpotent%252BVEGFR-2%252Bkinase%252Binhibitors%252Band%252Banti-cancer%252Bagents%26aulast%3DEl-Metwally%26aufirst%3DSouad%2BA.%26date%3D2021%26volume%3D112%26spage%3D104947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hasna  Yassine</span>, <span class="hlFld-ContribAuthor ">Jamila  Bouali</span>, <span class="hlFld-ContribAuthor ">Asmaa  Oumessaoud</span>, <span class="hlFld-ContribAuthor ">El Mahdi  Ourhzif</span>, <span class="hlFld-ContribAuthor ">Salha  Hamri</span>, <span class="hlFld-ContribAuthor ">Abderrafia  Hafid</span>, <span class="hlFld-ContribAuthor ">Mostafa  Khouili</span>, <span class="hlFld-ContribAuthor ">Maria Dolors  Pujol</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of New Dialkyl 2,2′-[Carbonylbis(azanediyl)]dibenzoates via Curtius Rearrangement. </span><span class="cited-content_cbyCitation_journal-name">Synthesis</span><span> <strong>2021,</strong> <em>53 </em>
                                    (11)
                                     , 1971-1979. <a href="https://doi.org/10.1055/s-0040-1706643" title="DOI URL">https://doi.org/10.1055/s-0040-1706643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1706643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1706643%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%26atitle%3DSynthesis%252Bof%252BNew%252BDialkyl%252B2%25252C2%2525E2%252580%2525B2-%25255BCarbonylbis%252528azanediyl%252529%25255Ddibenzoates%252Bvia%252BCurtius%252BRearrangement%26aulast%3DYassine%26aufirst%3DHasna%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D11%26spage%3D1971%26epage%3D1979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing-Rong  Wang</span>, <span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Wen-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Kai-Yan  Xu</span>, <span class="hlFld-ContribAuthor ">Xue-Peng  Qiao</span>, <span class="hlFld-ContribAuthor ">Xue-Li  Jing</span>, <span class="hlFld-ContribAuthor ">Zi-Xiao  Wang</span>, <span class="hlFld-ContribAuthor ">Chang-jiang  Yang</span>, <span class="hlFld-ContribAuthor ">Shi-Wu  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113192. <a href="https://doi.org/10.1016/j.ejmech.2021.113192" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113192%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2-%2525284-%2525281H-indazol-6-yl%252529-1H-pyrazol-1-yl%252529acetamide%252Bderivatives%252Bas%252Bpotent%252BVEGFR-2%252Binhibitors%26aulast%3DWang%26aufirst%3DXing-Rong%26date%3D2021%26volume%3D213%26spage%3D113192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem M.  Hazem</span>, <span class="hlFld-ContribAuthor ">Anhar A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Nagat  Ghareb</span>, <span class="hlFld-ContribAuthor ">Eman T.  Mehanna</span>, <span class="hlFld-ContribAuthor ">Noha M.  Mesbah</span>, <span class="hlFld-ContribAuthor ">Dina M.  Abo-Elmatty</span>, <span class="hlFld-ContribAuthor ">Mohamed Saleh  Elgawish</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-cancer activity of two novel heterocyclic compounds through modulation of VEGFR and miR-122 in mice bearing Ehrlich ascites carcinoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2021,</strong> <em>892 </em>, 173747. <a href="https://doi.org/10.1016/j.ejphar.2020.173747" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173747%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DAnti-cancer%252Bactivity%252Bof%252Btwo%252Bnovel%252Bheterocyclic%252Bcompounds%252Bthrough%252Bmodulation%252Bof%252BVEGFR%252Band%252BmiR-122%252Bin%252Bmice%252Bbearing%252BEhrlich%252Bascites%252Bcarcinoma%26aulast%3DHazem%26aufirst%3DReem%2BM.%26date%3D2021%26volume%3D892%26spage%3D173747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ranju  Bansal</span>, <span class="hlFld-ContribAuthor ">Anjleena  Malhotra</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic progression of quinazolines as targeted chemotherapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113016. <a href="https://doi.org/10.1016/j.ejmech.2020.113016" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113016%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTherapeutic%252Bprogression%252Bof%252Bquinazolines%252Bas%252Btargeted%252Bchemotherapeutic%252Bagents%26aulast%3DBansal%26aufirst%3DRanju%26date%3D2021%26volume%3D211%26spage%3D113016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. S.  Shchegravina</span>, <span class="hlFld-ContribAuthor ">A. A.  Sachkova</span>, <span class="hlFld-ContribAuthor ">S. D.  Usova</span>, <span class="hlFld-ContribAuthor ">A. V.  Nyuchev</span>, <span class="hlFld-ContribAuthor ">Yu. A.  Gracheva</span>, <span class="hlFld-ContribAuthor ">A. Yu.  Fedorov</span>. </span><span class="cited-content_cbyCitation_article-title">Carbohydrate Systems in Targeted Drug Delivery: Expectation and Reality. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>47 </em>
                                    (1)
                                     , 71-98. <a href="https://doi.org/10.1134/S1068162021010222" title="DOI URL">https://doi.org/10.1134/S1068162021010222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1068162021010222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1068162021010222%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Bioorganic%2520Chemistry%26atitle%3DCarbohydrate%252BSystems%252Bin%252BTargeted%252BDrug%252BDelivery%25253A%252BExpectation%252Band%252BReality%26aulast%3DShchegravina%26aufirst%3DE.%2BS.%26date%3D2021%26date%3D2021%26volume%3D47%26issue%3D1%26spage%3D71%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaopeng  Peng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Peihua  Kuang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112831. <a href="https://doi.org/10.1016/j.ejmech.2020.112831" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bon%252BHDAC%252Binhibitors%252Bwith%252Bdual%252Btargeting%252Bcapabilities%252Bfor%252Bcancer%252Btreatment%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2020%26volume%3D208%26spage%3D112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ankita  Srivastava</span>, <span class="hlFld-ContribAuthor ">Kaneez  Fatima</span>, <span class="hlFld-ContribAuthor ">Eram  Fatima</span>, <span class="hlFld-ContribAuthor ">Arjun  Singh</span>, <span class="hlFld-ContribAuthor ">Aastha  Singh</span>, <span class="hlFld-ContribAuthor ">Aparna  Shukla</span>, <span class="hlFld-ContribAuthor ">Suaib  Luqman</span>, <span class="hlFld-ContribAuthor ">Karuna  Shanker</span>, <span class="hlFld-ContribAuthor ">Debabrata  Chanda</span>, <span class="hlFld-ContribAuthor ">Feroz  Khan</span>, <span class="hlFld-ContribAuthor ">Arvind S.  Negi</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorinated benzylidene indanone exhibits antiproliferative activity through modulation of microtubule dynamics and antiangiogenic activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>154 </em>, 105513. <a href="https://doi.org/10.1016/j.ejps.2020.105513" title="DOI URL">https://doi.org/10.1016/j.ejps.2020.105513</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2020.105513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2020.105513%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DFluorinated%252Bbenzylidene%252Bindanone%252Bexhibits%252Bantiproliferative%252Bactivity%252Bthrough%252Bmodulation%252Bof%252Bmicrotubule%252Bdynamics%252Band%252Bantiangiogenic%252Bactivity%26aulast%3DSrivastava%26aufirst%3DAnkita%26date%3D2020%26volume%3D154%26spage%3D105513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel J.  Baillache</span>, <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-
              d
              ]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1112-1135. <a href="https://doi.org/10.1039/D0MD00227E" title="DOI URL">https://doi.org/10.1039/D0MD00227E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00227E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00227E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bin%252Banticancer%252Bkinase%252Binhibitors%252Bbased%252Bon%252Bthe%252Bpyrazolo%25255B3%25252C4-%252Bd%252B%25255Dpyrimidine%252Bscaffold%26aulast%3DBaillache%26aufirst%3DDaniel%2BJ.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D10%26spage%3D1112%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vivek  Dave</span>, <span class="hlFld-ContribAuthor ">Rekha  Sharma</span>, <span class="hlFld-ContribAuthor ">Chavi  Gupta</span>, <span class="hlFld-ContribAuthor ">Srija  Sur</span>. </span><span class="cited-content_cbyCitation_article-title">Folic acid modified gold nanoparticle for targeted delivery of Sorafenib tosylate towards the treatment of diabetic retinopathy. </span><span class="cited-content_cbyCitation_journal-name">Colloids and Surfaces B: Biointerfaces</span><span> <strong>2020,</strong> <em>194 </em>, 111151. <a href="https://doi.org/10.1016/j.colsurfb.2020.111151" title="DOI URL">https://doi.org/10.1016/j.colsurfb.2020.111151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.colsurfb.2020.111151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.colsurfb.2020.111151%26sid%3Dliteratum%253Aachs%26jtitle%3DColloids%2520and%2520Surfaces%2520B%253A%2520Biointerfaces%26atitle%3DFolic%252Bacid%252Bmodified%252Bgold%252Bnanoparticle%252Bfor%252Btargeted%252Bdelivery%252Bof%252BSorafenib%252Btosylate%252Btowards%252Bthe%252Btreatment%252Bof%252Bdiabetic%252Bretinopathy%26aulast%3DDave%26aufirst%3DVivek%26date%3D2020%26volume%3D194%26spage%3D111151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soha R. Abd El  Hadi</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Dalia H.  Soliman</span>, <span class="hlFld-ContribAuthor ">Eman Z.  Elrazaz</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 103961. <a href="https://doi.org/10.1016/j.bioorg.2020.103961" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103961%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DScaffold%252Bhopping%252Band%252Bredesign%252Bapproaches%252Bfor%252Bquinazoline%252Bbased%252Burea%252Bderivatives%252Bas%252Bpotent%252BVEGFR-2%252Binhibitors%26aulast%3DHadi%26aufirst%3DSoha%2BR.%2BAbd%2BEl%26date%3D2020%26volume%3D101%26spage%3D103961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">Velma Ganga  Reddy</span>, <span class="hlFld-ContribAuthor ">Sonal  Bhandari</span>, <span class="hlFld-ContribAuthor ">T. Srinivasa  Reddy</span>, <span class="hlFld-ContribAuthor ">Ramya  Tokala</span>, <span class="hlFld-ContribAuthor ">Akash P.  Sakla</span>, <span class="hlFld-ContribAuthor ">Suresh K.  Bhargava</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112457. <a href="https://doi.org/10.1016/j.ejmech.2020.112457" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112457%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploration%252Bof%252Bcarbamide%252Bderived%252Bpyrimidine-thioindole%252Bconjugates%252Bas%252Bpotential%252BVEGFR-2%252Binhibitors%252Bwith%252Banti-angiogenesis%252Beffect%26aulast%3DSana%26aufirst%3DSravani%26date%3D2020%26volume%3D200%26spage%3D112457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chelliah  Selvam</span>, <span class="hlFld-ContribAuthor ">Charlotta D.  Mock</span>, <span class="hlFld-ContribAuthor ">Omana P.  Mathew</span>, <span class="hlFld-ContribAuthor ">Kasturi  Ranganna</span>, <span class="hlFld-ContribAuthor ">Ramasamy  Thilagavathi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Vascular Endothelial Growth Factor Receptor‐2 (VEGFR‐2) Inhibitors by Ligand‐based Virtual High Throughput Screening. </span><span class="cited-content_cbyCitation_journal-name">Molecular Informatics</span><span> <strong>2020,</strong> <em>39 </em>
                                    (7)
                                     , 1900150. <a href="https://doi.org/10.1002/minf.201900150" title="DOI URL">https://doi.org/10.1002/minf.201900150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/minf.201900150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fminf.201900150%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Informatics%26atitle%3DDiscovery%252Bof%252BVascular%252BEndothelial%252BGrowth%252BFactor%252BReceptor%2525E2%252580%2525902%252B%252528VEGFR%2525E2%252580%2525902%252529%252BInhibitors%252Bby%252BLigand%2525E2%252580%252590based%252BVirtual%252BHigh%252BThroughput%252BScreening%26aulast%3DSelvam%26aufirst%3DChelliah%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D7%26spage%3D1900150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atukuri  Dorababu</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacology Profile of Recently Developed Multi‐Functional Azoles; SAR‐Based Predictive Structural Modification. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (22)
                                     , 6730-6758. <a href="https://doi.org/10.1002/slct.202000294" title="DOI URL">https://doi.org/10.1002/slct.202000294</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202000294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202000294%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DPharmacology%252BProfile%252Bof%252BRecently%252BDeveloped%252BMulti%2525E2%252580%252590Functional%252BAzoles%25253B%252BSAR%2525E2%252580%252590Based%252BPredictive%252BStructural%252BModification%26aulast%3DDorababu%26aufirst%3DAtukuri%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D22%26spage%3D6730%26epage%3D6758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingliang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuchen  Wang</span>, <span class="hlFld-ContribAuthor ">Yuanrong  Fan</span>, <span class="hlFld-ContribAuthor ">Xingye  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Yi  Hua</span>, <span class="hlFld-ContribAuthor ">Wuchen  Xie</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Protein–ligand interaction-guided discovery of novel VEGFR-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>38 </em>
                                    (9)
                                     , 2559-2574. <a href="https://doi.org/10.1080/07391102.2019.1635915" title="DOI URL">https://doi.org/10.1080/07391102.2019.1635915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1635915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1635915%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DProtein%2525E2%252580%252593ligand%252Binteraction-guided%252Bdiscovery%252Bof%252Bnovel%252BVEGFR-2%252Binhibitors%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D9%26spage%3D2559%26epage%3D2574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asmaa E.  Kassab</span>, <span class="hlFld-ContribAuthor ">Yara  El‐Dash</span>, <span class="hlFld-ContribAuthor ">Ehab M.  Gedawy</span>. </span><span class="cited-content_cbyCitation_article-title">Novel pyrazolopyrimidine urea derivatives: Synthesis, antiproliferative activity, VEGFR‐2 inhibition, and effects on the cell cycle profile. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2020,</strong> <em>353 </em>
                                    (4)
                                     , 1900319. <a href="https://doi.org/10.1002/ardp.201900319" title="DOI URL">https://doi.org/10.1002/ardp.201900319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201900319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201900319%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DNovel%252Bpyrazolopyrimidine%252Burea%252Bderivatives%25253A%252BSynthesis%25252C%252Bantiproliferative%252Bactivity%25252C%252BVEGFR%2525E2%252580%2525902%252Binhibition%25252C%252Band%252Beffects%252Bon%252Bthe%252Bcell%252Bcycle%252Bprofile%26aulast%3DKassab%26aufirst%3DAsmaa%2BE.%26date%3D2020%26volume%3D353%26issue%3D4%26spage%3D1900319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba T.  Abdel-Mohsen</span>, <span class="hlFld-ContribAuthor ">Mona A.  Abdullaziz</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  El Kerdawy</span>, <span class="hlFld-ContribAuthor ">Fatma A. F.  Ragab</span>, <span class="hlFld-ContribAuthor ">Keith J.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Abeer E. E.  Mahmoud</span>, <span class="hlFld-ContribAuthor ">Mamdouh M.  Ali</span>, <span class="hlFld-ContribAuthor ">Hoda I.  El Diwani</span>, <span class="hlFld-ContribAuthor ">Mathias O.  Senge</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (4)
                                     , 770. <a href="https://doi.org/10.3390/molecules25040770" title="DOI URL">https://doi.org/10.3390/molecules25040770</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25040770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25040770%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTargeting%252BReceptor%252BTyrosine%252BKinase%252BVEGFR-2%252Bin%252BHepatocellular%252BCancer%25253A%252BRational%252BDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252B1%25252C2-Disubstituted%252BBenzimidazoles%26aulast%3DAbdel-Mohsen%26aufirst%3DHeba%2BT.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D4%26spage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marco  Tjakra</span>, <span class="hlFld-ContribAuthor ">Yeqi  Wang</span>, <span class="hlFld-ContribAuthor ">Vicki  Vania</span>, <span class="hlFld-ContribAuthor ">Zhengjun  Hou</span>, <span class="hlFld-ContribAuthor ">Colm  Durkan</span>, <span class="hlFld-ContribAuthor ">Nan  Wang</span>, <span class="hlFld-ContribAuthor ">Guixue  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Crosstalk Between Multiple Factor of Transcytosis in Blood Brain Barrier. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neuroscience</span><span> <strong>2020,</strong> <em>13 </em><a href="https://doi.org/10.3389/fnins.2019.01436" title="DOI URL">https://doi.org/10.3389/fnins.2019.01436</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnins.2019.01436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnins.2019.01436%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neuroscience%26atitle%3DOverview%252Bof%252BCrosstalk%252BBetween%252BMultiple%252BFactor%252Bof%252BTranscytosis%252Bin%252BBlood%252BBrain%252BBarrier%26aulast%3DTjakra%26aufirst%3DMarco%26date%3D2020%26date%3D2020%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koroush  Mashayekh</span>, <span class="hlFld-ContribAuthor ">Pezhman  Shiri</span>. </span><span class="cited-content_cbyCitation_article-title">An Overview of Recent Advances in the Applications of Click Chemistry in the Synthesis of Bioconjugates with Anticancer Activities. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (46)
                                     , 13459-13478. <a href="https://doi.org/10.1002/slct.201902362" title="DOI URL">https://doi.org/10.1002/slct.201902362</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201902362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201902362%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DAn%252BOverview%252Bof%252BRecent%252BAdvances%252Bin%252Bthe%252BApplications%252Bof%252BClick%252BChemistry%252Bin%252Bthe%252BSynthesis%252Bof%252BBioconjugates%252Bwith%252BAnticancer%252BActivities%26aulast%3DMashayekh%26aufirst%3DKoroush%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D46%26spage%3D13459%26epage%3D13478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ekta  Rathi</span>, <span class="hlFld-ContribAuthor ">Avinash  Kumar</span>, <span class="hlFld-ContribAuthor ">Suvarna G.  Kini</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2019,</strong> <em>39 </em>
                                    (5-6)
                                     , 415-433. <a href="https://doi.org/10.1080/10799893.2019.1690509" title="DOI URL">https://doi.org/10.1080/10799893.2019.1690509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2019.1690509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2019.1690509%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DMolecular%252Bdynamics%252Bguided%252Binsight%25252C%252Bbinding%252Bfree%252Benergy%252Bcalculations%252Band%252Bpharmacophore-based%252Bvirtual%252Bscreening%252Bfor%252Bthe%252Bidentification%252Bof%252Bpotential%252BVEGFR2%252Binhibitors%26aulast%3DRathi%26aufirst%3DEkta%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D5-6%26spage%3D415%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahitab K.  Sobhy</span>, <span class="hlFld-ContribAuthor ">Samar  Mowafy</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Nahla A.  Farag</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>89 </em>, 102988. <a href="https://doi.org/10.1016/j.bioorg.2019.102988" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.102988</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.102988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.102988%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3D3D-QSAR%252Bpharmacophore%252Bmodelling%25252C%252Bvirtual%252Bscreening%252Band%252Bdocking%252Bstudies%252Bfor%252Blead%252Bdiscovery%252Bof%252Ba%252Bnovel%252Bscaffold%252Bfor%252BVEGFR%252B2%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DSobhy%26aufirst%3DMahitab%2BK.%26date%3D2019%26volume%3D89%26spage%3D102988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amany S.  Mostafa</span>, <span class="hlFld-ContribAuthor ">Waleed A.  Bayoumi</span>, <span class="hlFld-ContribAuthor ">Mohamed  El-Mesery</span>, <span class="hlFld-ContribAuthor ">Abdelaziz  Elgaml</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (3)
                                     , 310-322. <a href="https://doi.org/10.2174/1871520618666180717125906" title="DOI URL">https://doi.org/10.2174/1871520618666180717125906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520618666180717125906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520618666180717125906%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252BDesign%252Band%252BSynthesis%252Bof%252BNew%252B3%25252C4-Dihydropyrimidin-2%2525281H%252529-Ones%252Bas%252BPotential%252BAnticancer%252BAgents%252Bwith%252BVEGFR-2%252BInhibiting%252BActivity%26aulast%3DMostafa%26aufirst%3DAmany%2BS.%26date%3D2019%26volume%3D19%26issue%3D3%26spage%3D310%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samantha L.  Cooper</span>, <span class="hlFld-ContribAuthor ">Joanne J.  Carter</span>, <span class="hlFld-ContribAuthor ">Julie  March</span>, <span class="hlFld-ContribAuthor ">Jeanette  Woolard</span>. </span><span class="cited-content_cbyCitation_article-title">Long‐term cardiovascular effects of vandetanib and pazopanib in normotensive rats. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Research & Perspectives</span><span> <strong>2019,</strong> <em>7 </em>
                                    (3)
                                     , e00477. <a href="https://doi.org/10.1002/prp2.477" title="DOI URL">https://doi.org/10.1002/prp2.477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/prp2.477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fprp2.477%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Research%2520%2526%2520Perspectives%26atitle%3DLong%2525E2%252580%252590term%252Bcardiovascular%252Beffects%252Bof%252Bvandetanib%252Band%252Bpazopanib%252Bin%252Bnormotensive%252Brats%26aulast%3DCooper%26aufirst%3DSamantha%2BL.%26date%3D2019%26date%3D2019%26volume%3D7%26issue%3D3%26spage%3De00477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura E.  Kilpatrick</span>, <span class="hlFld-ContribAuthor ">Diana C.  Alcobia</span>, <span class="hlFld-ContribAuthor ">Carl W.  White</span>, <span class="hlFld-ContribAuthor ">Chloe J.  Peach</span>, <span class="hlFld-ContribAuthor ">Jackie R.  Glenn</span>, <span class="hlFld-ContribAuthor ">Kris  Zimmerman</span>, <span class="hlFld-ContribAuthor ">Alexander  Kondrashov</span>, <span class="hlFld-ContribAuthor ">Kevin D.G.  Pfleger</span>, <span class="hlFld-ContribAuthor ">Rachel Friedman  Ohana</span>, <span class="hlFld-ContribAuthor ">Matthew B.  Robers</span>, <span class="hlFld-ContribAuthor ">Keith V.  Wood</span>, <span class="hlFld-ContribAuthor ">Erica K.  Sloan</span>, <span class="hlFld-ContribAuthor ">Jeanette  Woolard</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Hill</span>. </span><span class="cited-content_cbyCitation_article-title">Complex Formation between VEGFR2 and the β2-Adrenoceptor. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2019,</strong> <em>26 </em>
                                    (6)
                                     , 830-841.e9. <a href="https://doi.org/10.1016/j.chembiol.2019.02.014" title="DOI URL">https://doi.org/10.1016/j.chembiol.2019.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2019.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2019.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DComplex%252BFormation%252Bbetween%252BVEGFR2%252Band%252Bthe%252B%2525CE%2525B22-Adrenoceptor%26aulast%3DKilpatrick%26aufirst%3DLaura%2BE.%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D830%26epage%3D841.e9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>170 </em>, 55-72. <a href="https://doi.org/10.1016/j.ejmech.2019.03.004" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvancements%252Bof%252B4-aminoquinazoline%252Bderivatives%252Bas%252Bkinase%252Binhibitors%252Band%252Btheir%252Bapplications%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2019%26volume%3D170%26spage%3D55%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Zanella</span>, <span class="hlFld-ContribAuthor ">Gianfranco  Bocchinfuso</span>, <span class="hlFld-ContribAuthor ">Marta  De Zotti</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">Franca  Marino</span>, <span class="hlFld-ContribAuthor ">Stefano  Raniolo</span>, <span class="hlFld-ContribAuthor ">Luca  Pignataro</span>, <span class="hlFld-ContribAuthor ">Giovanni  Sacco</span>, <span class="hlFld-ContribAuthor ">Antonio  Palleschi</span>, <span class="hlFld-ContribAuthor ">Alvaro S.  Siano</span>, <span class="hlFld-ContribAuthor ">Umberto  Piarulli</span>, <span class="hlFld-ContribAuthor ">Laura  Belvisi</span>, <span class="hlFld-ContribAuthor ">Fernando  Formaggio</span>, <span class="hlFld-ContribAuthor ">Cesare  Gennari</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Stella</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Antiangiogenic Helical Oligopeptides Targeting the Vascular Endothelial Growth Factor Receptors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2019,</strong> <em>7 </em><a href="https://doi.org/10.3389/fchem.2019.00170" title="DOI URL">https://doi.org/10.3389/fchem.2019.00170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2019.00170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2019.00170%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DRational%252BDesign%252Bof%252BAntiangiogenic%252BHelical%252BOligopeptides%252BTargeting%252Bthe%252BVascular%252BEndothelial%252BGrowth%252BFactor%252BReceptors%26aulast%3DZanella%26aufirst%3DSimone%26date%3D2019%26date%3D2019%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikil  Purushotham</span>, <span class="hlFld-ContribAuthor ">Boja  Poojary</span>, <span class="hlFld-ContribAuthor ">Vaishali  Rai</span>, <span class="hlFld-ContribAuthor ">Sowmya Padejjar  Vasantha</span>. </span><span class="cited-content_cbyCitation_article-title">A preliminary study on quinazolinylaminobenzoyl monopeptide esters as effective Gram-positive bacteriostatic agents. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (5)
                                     , 407-422. <a href="https://doi.org/10.4155/fmc-2018-0275" title="DOI URL">https://doi.org/10.4155/fmc-2018-0275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0275%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DA%252Bpreliminary%252Bstudy%252Bon%252Bquinazolinylaminobenzoyl%252Bmonopeptide%252Besters%252Bas%252Beffective%252BGram-positive%252Bbacteriostatic%252Bagents%26aulast%3DPurushotham%26aufirst%3DNikil%26date%3D2019%26volume%3D11%26issue%3D5%26spage%3D407%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nevine M.Y.  Elsayed</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Mai F.  Tolba</span>, <span class="hlFld-ContribAuthor ">Marawan  Ahmed</span>, <span class="hlFld-ContribAuthor ">Khaled  Barakat</span>, <span class="hlFld-ContribAuthor ">Dalal A.  Abou El Ella</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>82 </em>, 340-359. <a href="https://doi.org/10.1016/j.bioorg.2018.10.071" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.071%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bdynamics%252Bsimulation%252Bof%252Bindazole%252Bderivatives%252Bwith%252Bantiangiogenic%252Band%252Bantiproliferative%252Banticancer%252Bactivity%26aulast%3DElsayed%26aufirst%3DNevine%2BM.Y.%26date%3D2019%26volume%3D82%26spage%3D340%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth Michele  Davies</span>, <span class="hlFld-ContribAuthor ">Rajendra  Gurung</span>, <span class="hlFld-ContribAuthor ">Kai Qin  Le</span>, <span class="hlFld-ContribAuthor ">Christina Anne  Mitchell</span>. </span><span class="cited-content_cbyCitation_article-title">Effective angiogenesis requires regulation of phosphoinositide signaling. </span><span class="cited-content_cbyCitation_journal-name">Advances in Biological Regulation</span><span> <strong>2019,</strong> <em>71 </em>, 69-78. <a href="https://doi.org/10.1016/j.jbior.2018.11.008" title="DOI URL">https://doi.org/10.1016/j.jbior.2018.11.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jbior.2018.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jbior.2018.11.008%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvances%2520in%2520Biological%2520Regulation%26atitle%3DEffective%252Bangiogenesis%252Brequires%252Bregulation%252Bof%252Bphosphoinositide%252Bsignaling%26aulast%3DDavies%26aufirst%3DElizabeth%2BMichele%26date%3D2019%26volume%3D71%26spage%3D69%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aml E.-S.  Mghwary</span>, <span class="hlFld-ContribAuthor ">Ehab M.  Gedawy</span>, <span class="hlFld-ContribAuthor ">Aliaa M.  Kamal</span>, <span class="hlFld-ContribAuthor ">Suzan M.  Abuel-Maaty</span>. </span><span class="cited-content_cbyCitation_article-title">Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 838-852. <a href="https://doi.org/10.1080/14756366.2019.1593160" title="DOI URL">https://doi.org/10.1080/14756366.2019.1593160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1593160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1593160%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bthienopyrimidine%252Bderivatives%252Bas%252Bdual%252BEGFR%252Band%252BVEGFR-2%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%25252C%252Banticancer%252Bactivity%252Band%252Beffect%252Bon%252Bcell%252Bcycle%252Bprofile%26aulast%3DMghwary%26aufirst%3DAml%2BE.-S.%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D838%26epage%3D852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Salwa  Elmeligie</span>, <span class="hlFld-ContribAuthor ">Asmaa M.  Aboul-Magd</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Tamer M.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Tamer M.  Abdelghany</span>, <span class="hlFld-ContribAuthor ">Sohair M.  Khojah</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 1347-1367. <a href="https://doi.org/10.1080/14756366.2019.1642883" title="DOI URL">https://doi.org/10.1080/14756366.2019.1642883</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1642883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1642883%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bphthalazine-based%252Bcompounds%252Bas%252Bpotent%252Banticancer%252Bagents%252Bwith%252Bpotential%252Bantiangiogenic%252Bactivity%252Bvia%252BVEGFR-2%252Binhibition%26aulast%3DElmeligie%26aufirst%3DSalwa%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1347%26epage%3D1367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teresa  Glomb</span>, <span class="hlFld-ContribAuthor ">Karolina  Szymankiewicz</span>, <span class="hlFld-ContribAuthor ">Piotr  Świątek</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-Cancer Activity of Derivatives of 1,3,4-Oxadiazole. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (12)
                                     , 3361. <a href="https://doi.org/10.3390/molecules23123361" title="DOI URL">https://doi.org/10.3390/molecules23123361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23123361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23123361%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAnti-Cancer%252BActivity%252Bof%252BDerivatives%252Bof%252B1%25252C3%25252C4-Oxadiazole%26aulast%3DGlomb%26aufirst%3DTeresa%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D12%26spage%3D3361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rossella  Di Stasi</span>, <span class="hlFld-ContribAuthor ">Donatella  Diana</span>, <span class="hlFld-ContribAuthor ">Domenica  Capasso</span>, <span class="hlFld-ContribAuthor ">Sonia  Di Gaetano</span>, <span class="hlFld-ContribAuthor ">Lucia  De Rosa</span>, <span class="hlFld-ContribAuthor ">Veronica  Celentano</span>, <span class="hlFld-ContribAuthor ">Carla  Isernia</span>, <span class="hlFld-ContribAuthor ">Roberto  Fattorusso</span>, <span class="hlFld-ContribAuthor ">Luca D.  D'Andrea</span>. </span><span class="cited-content_cbyCitation_article-title">VEGFR Recognition Interface of a Proangiogenic VEGF-Mimetic Peptide Determined In Vitro and in the Presence of Endothelial Cells by NMR Spectroscopy. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2018,</strong> <em>24 </em>
                                    (44)
                                     , 11461-11466. <a href="https://doi.org/10.1002/chem.201802117" title="DOI URL">https://doi.org/10.1002/chem.201802117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201802117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201802117%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DVEGFR%252BRecognition%252BInterface%252Bof%252Ba%252BProangiogenic%252BVEGF-Mimetic%252BPeptide%252BDetermined%252BIn%252BVitro%252Band%252Bin%252Bthe%252BPresence%252Bof%252BEndothelial%252BCells%252Bby%252BNMR%252BSpectroscopy%26aulast%3DDi%25E2%2580%2585Stasi%26aufirst%3DRossella%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D44%26spage%3D11461%26epage%3D11466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kranthi Kumar  Konidala</span>, <span class="hlFld-ContribAuthor ">Uma Devi  Bommu</span>, <span class="hlFld-ContribAuthor ">Neeraja  Pabbaraju</span>. </span><span class="cited-content_cbyCitation_article-title">In silico
              insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2018,</strong> <em>38 </em>
                                    (4)
                                     , 372-383. <a href="https://doi.org/10.1080/10799893.2018.1531891" title="DOI URL">https://doi.org/10.1080/10799893.2018.1531891</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2018.1531891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2018.1531891%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DIn%252Bsilico%252Binsights%252Binto%252Bthe%252Bidentification%252Bof%252Bpotential%252Bnovel%252Bangiogenic%252Binhibitors%252Bagainst%252Bhuman%252BVEGFR-2%25253A%252Ba%252Bnew%252BSAR-based%252Bhierarchical%252Bclustering%252Bapproach%26aulast%3DKonidala%26aufirst%3DKranthi%2BKumar%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D4%26spage%3D372%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Yu  Fu</span>, <span class="hlFld-ContribAuthor ">Guangfa  Wang</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 210-228. <a href="https://doi.org/10.1016/j.ejmech.2018.05.054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.05.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.05.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.05.054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bmodeling%252Bof%252Bnovel%252B1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252BBRAFV600E%252Band%252BVEGFR-2%252Bdual%252Binhibitors%26aulast%3DWang%26aufirst%3DYuanyuan%26date%3D2018%26volume%3D155%26spage%3D210%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianqiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Tongyang  Liu</span>, <span class="hlFld-ContribAuthor ">Mei  Chen</span>, <span class="hlFld-ContribAuthor ">Feifei  Liu</span>, <span class="hlFld-ContribAuthor ">Xingyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Jihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Yi  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Indole-2-carbohydrazide Derivatives as Anticancer Agents with Anti-angiogenic and Antiproliferative Activities. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (12)
                                     , 1181-1192. <a href="https://doi.org/10.1002/cmdc.201800033" title="DOI URL">https://doi.org/10.1002/cmdc.201800033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800033%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BIndole-2-carbohydrazide%252BDerivatives%252Bas%252BAnticancer%252BAgents%252Bwith%252BAnti-angiogenic%252Band%252BAntiproliferative%252BActivities%26aulast%3DZhang%26aufirst%3DJianqiang%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D12%26spage%3D1181%26epage%3D1192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ángel C.  Roman</span>, <span class="hlFld-ContribAuthor ">José M.  Carvajal-Gonzalez</span>, <span class="hlFld-ContribAuthor ">Jaime M.  Merino</span>, <span class="hlFld-ContribAuthor ">Sonia  Mulero-Navarro</span>, <span class="hlFld-ContribAuthor ">Pedro M.  Fernández-Salguero</span>. </span><span class="cited-content_cbyCitation_article-title">The aryl hydrocarbon receptor in the crossroad of signalling networks with therapeutic value. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>185 </em>, 50-63. <a href="https://doi.org/10.1016/j.pharmthera.2017.12.003" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DThe%252Baryl%252Bhydrocarbon%252Breceptor%252Bin%252Bthe%252Bcrossroad%252Bof%252Bsignalling%252Bnetworks%252Bwith%252Btherapeutic%252Bvalue%26aulast%3DRoman%26aufirst%3D%25C3%2581ngel%2BC.%26date%3D2018%26volume%3D185%26spage%3D50%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Salerno</span>, <span class="hlFld-ContribAuthor ">Aída Nelly  García-Argáez</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Barresi</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Francesca  Simorini</span>, <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>, <span class="hlFld-ContribAuthor ">Giorgio  Amendola</span>, <span class="hlFld-ContribAuthor ">Stefano  Tomassi</span>, <span class="hlFld-ContribAuthor ">Sandro  Cosconati</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Federico  Da Settimo</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Marini</span>, <span class="hlFld-ContribAuthor ">Lisa Dalla  Via</span>. </span><span class="cited-content_cbyCitation_article-title">New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>150 </em>, 446-456. <a href="https://doi.org/10.1016/j.ejmech.2018.03.013" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.013%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Binsights%252Bin%252Bthe%252Bstructure-activity%252Brelationships%252Bof%252B2-phenylamino-substituted%252Bbenzothiopyrano%25255B4%25252C3-d%25255Dpyrimidines%252Bas%252Bkinase%252Binhibitors%26aulast%3DSalerno%26aufirst%3DSilvia%26date%3D2018%26volume%3D150%26spage%3D446%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingliang  Wang</span>, <span class="hlFld-ContribAuthor ">Jilai  Han</span>, <span class="hlFld-ContribAuthor ">Xiaojia  Si</span>, <span class="hlFld-ContribAuthor ">Yimin  Hu</span>, <span class="hlFld-ContribAuthor ">Jidong  Zhu</span>, <span class="hlFld-ContribAuthor ">Xun  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Effective approach to ureas through organocatalyzed one-pot process. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (17)
                                     , 1614-1618. <a href="https://doi.org/10.1016/j.tetlet.2017.11.030" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.11.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.11.030%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DEffective%252Bapproach%252Bto%252Bureas%252Bthrough%252Borganocatalyzed%252Bone-pot%252Bprocess%26aulast%3DWang%26aufirst%3DMingliang%26date%3D2018%26volume%3D59%26issue%3D17%26spage%3D1614%26epage%3D1618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Biaryls. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 83-154. <a href="https://doi.org/10.1002/9781118686263.ch4" title="DOI URL">https://doi.org/10.1002/9781118686263.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DBiaryls%26date%3D2018%26date%3D2018%26spage%3D83%26epage%3D154%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.  Requejo</span>, <span class="hlFld-ContribAuthor ">J. A.  Ruiz-Ortega</span>, <span class="hlFld-ContribAuthor ">H.  Bengoetxea</span>, <span class="hlFld-ContribAuthor ">S.  Bulnes</span>, <span class="hlFld-ContribAuthor ">L.  Ugedo</span>, <span class="hlFld-ContribAuthor ">J. V.  Lafuente</span>. </span><span class="cited-content_cbyCitation_article-title">Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecular Neurobiology</span><span> <strong>2018,</strong> <em>55 </em>
                                    (1)
                                     , 201-212. <a href="https://doi.org/10.1007/s12035-017-0733-x" title="DOI URL">https://doi.org/10.1007/s12035-017-0733-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12035-017-0733-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12035-017-0733-x%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Neurobiology%26atitle%3DDeleterious%252BEffects%252Bof%252BVEGFR2%252Band%252BRET%252BInhibition%252Bin%252Ba%252BPreclinical%252BModel%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DRequejo%26aufirst%3DC.%26date%3D2018%26date%3D2017%26volume%3D55%26issue%3D1%26spage%3D201%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eman F.  Abdelhaleem</span>, <span class="hlFld-ContribAuthor ">Mohammed K.  Abdelhameid</span>, <span class="hlFld-ContribAuthor ">Asmaa E.  Kassab</span>, <span class="hlFld-ContribAuthor ">Manal M.  Kandeel</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1807-1825. <a href="https://doi.org/10.1016/j.ejmech.2017.10.075" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.075%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bthienopyrimidine%252Burea%252Bderivatives%252Bwith%252Bpotential%252Bcytotoxic%252Band%252Bpro-apoptotic%252Bactivity%252Bagainst%252Bbreast%252Bcancer%252Bcell%252Bline%252BMCF-7%26aulast%3DAbdelhaleem%26aufirst%3DEman%2BF.%26date%3D2018%26volume%3D143%26spage%3D1807%26epage%3D1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Ye  Tian</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Sun</span>, <span class="hlFld-ContribAuthor ">Simiao  Yu</span>, <span class="hlFld-ContribAuthor ">Juanjuan  Xia</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Haotian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>139 </em>, 492-502. <a href="https://doi.org/10.1016/j.ejmech.2017.08.031" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.031%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bmethyl%252Bindolinone-6-carboxylates%252Bcontaining%252Ban%252Bindole%252Bmoiety%252Bas%252Bangiokinase%252Binhibitors%26aulast%3DQin%26aufirst%3DMingze%26date%3D2017%26volume%3D139%26spage%3D492%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenjing  Ye</span>, <span class="hlFld-ContribAuthor ">Qi  Yao</span>, <span class="hlFld-ContribAuthor ">Simiao  Yu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Antitumor Activity of Triazole-Containing Sorafenib Analogs. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (10)
                                     , 1759. <a href="https://doi.org/10.3390/molecules22101759" title="DOI URL">https://doi.org/10.3390/molecules22101759</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22101759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22101759%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BAntitumor%252BActivity%252Bof%252BTriazole-Containing%252BSorafenib%252BAnalogs%26aulast%3DYe%26aufirst%3DWenjing%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D10%26spage%3D1759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fan-Wei  Peng</span>, <span class="hlFld-ContribAuthor ">Da-Ke  Liu</span>, <span class="hlFld-ContribAuthor ">Qing-Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Yun-Gen  Xu</span>, <span class="hlFld-ContribAuthor ">Lei  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (9)
                                     , 987-1004. <a href="https://doi.org/10.1080/13543776.2017.1344215" title="DOI URL">https://doi.org/10.1080/13543776.2017.1344215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1344215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1344215%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DVEGFR-2%252Binhibitors%252Band%252Bthe%252Btherapeutic%252Bapplications%252Bthereof%25253A%252Ba%252Bpatent%252Breview%252B%2525282012-2016%252529%26aulast%3DPeng%26aufirst%3DFan-Wei%26date%3D2017%26date%3D2017%26volume%3D27%26issue%3D9%26spage%3D987%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yinping  Tian</span>, <span class="hlFld-ContribAuthor ">Wenhui  Lv</span>, <span class="hlFld-ContribAuthor ">Qiuyue  Meng</span>, <span class="hlFld-ContribAuthor ">Xuewei  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Zeng</span>, <span class="hlFld-ContribAuthor ">Yaxin  Lu</span>, <span class="hlFld-ContribAuthor ">Peng G.  Wang</span>, <span class="hlFld-ContribAuthor ">Jin  Jin</span>, <span class="hlFld-ContribAuthor ">Jie  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Replacing triazole with diazole to optimize physicochemical properties of a click-based lead compound. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2017,</strong> <em>26 </em>
                                    (9)
                                     , 2007-2014. <a href="https://doi.org/10.1007/s00044-017-1903-0" title="DOI URL">https://doi.org/10.1007/s00044-017-1903-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-017-1903-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-017-1903-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DReplacing%252Btriazole%252Bwith%252Bdiazole%252Bto%252Boptimize%252Bphysicochemical%252Bproperties%252Bof%252Ba%252Bclick-based%252Blead%252Bcompound%26aulast%3DTian%26aufirst%3DYinping%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D9%26spage%3D2007%26epage%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleksandar  Pavic</span>, <span class="hlFld-ContribAuthor ">Biljana Đ.  Glišić</span>, <span class="hlFld-ContribAuthor ">Sandra  Vojnovic</span>, <span class="hlFld-ContribAuthor ">Beata  Warżajtis</span>, <span class="hlFld-ContribAuthor ">Nada D.  Savić</span>, <span class="hlFld-ContribAuthor ">Marija  Antić</span>, <span class="hlFld-ContribAuthor ">Slavko  Radenković</span>, <span class="hlFld-ContribAuthor ">Goran V.  Janjić</span>, <span class="hlFld-ContribAuthor ">Jasmina  Nikodinovic-Runic</span>, <span class="hlFld-ContribAuthor ">Urszula  Rychlewska</span>, <span class="hlFld-ContribAuthor ">Miloš I.  Djuran</span>. </span><span class="cited-content_cbyCitation_article-title">Mononuclear gold(III) complexes with phenanthroline ligands as efficient inhibitors of angiogenesis: A comparative study with auranofin and sunitinib. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2017,</strong> <em>174 </em>, 156-168. <a href="https://doi.org/10.1016/j.jinorgbio.2017.06.009" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2017.06.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2017.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2017.06.009%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DMononuclear%252Bgold%252528III%252529%252Bcomplexes%252Bwith%252Bphenanthroline%252Bligands%252Bas%252Befficient%252Binhibitors%252Bof%252Bangiogenesis%25253A%252BA%252Bcomparative%252Bstudy%252Bwith%252Bauranofin%252Band%252Bsunitinib%26aulast%3DPavic%26aufirst%3DAleksandar%26date%3D2017%26volume%3D174%26spage%3D156%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura E.  Kilpatrick</span>, <span class="hlFld-ContribAuthor ">Rachel  Friedman-Ohana</span>, <span class="hlFld-ContribAuthor ">Diana C.  Alcobia</span>, <span class="hlFld-ContribAuthor ">Kristin  Riching</span>, <span class="hlFld-ContribAuthor ">Chloe J.  Peach</span>, <span class="hlFld-ContribAuthor ">Amanda J.  Wheal</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Briddon</span>, <span class="hlFld-ContribAuthor ">Matthew B.  Robers</span>, <span class="hlFld-ContribAuthor ">Kris  Zimmerman</span>, <span class="hlFld-ContribAuthor ">Thomas  Machleidt</span>, <span class="hlFld-ContribAuthor ">Keith V.  Wood</span>, <span class="hlFld-ContribAuthor ">Jeanette  Woolard</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Hill</span>. </span><span class="cited-content_cbyCitation_article-title">Real-time analysis of the binding of fluorescent VEGF 165 a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2017,</strong> <em>136 </em>, 62-75. <a href="https://doi.org/10.1016/j.bcp.2017.04.006" title="DOI URL">https://doi.org/10.1016/j.bcp.2017.04.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2017.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2017.04.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DReal-time%252Banalysis%252Bof%252Bthe%252Bbinding%252Bof%252Bfluorescent%252BVEGF%252B165%252Ba%252Bto%252BVEGFR2%252Bin%252Bliving%252Bcells%25253A%252BEffect%252Bof%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Band%252Bfate%252Bof%252Binternalized%252Bagonist-receptor%252Bcomplexes%26aulast%3DKilpatrick%26aufirst%3DLaura%2BE.%26date%3D2017%26volume%3D136%26spage%3D62%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Panduga  Ramaraju</span>, <span class="hlFld-ContribAuthor ">Nisar A.  Mir</span>, <span class="hlFld-ContribAuthor ">Deepika  Singh</span>, <span class="hlFld-ContribAuthor ">Preetika  Sharma</span>, <span class="hlFld-ContribAuthor ">Rajni  Kant</span>, <span class="hlFld-ContribAuthor ">Indresh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">An Unprecedented Pseudo-[3+2] Annulation between
              N
              -(4-Methoxyphenyl)aldimines and Aqueous Glutaraldehyde: Direct Synthesis of Pyrrole-2,4-dialdehydes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>2017 </em>
                                    (24)
                                     , 3461-3465. <a href="https://doi.org/10.1002/ejoc.201700500" title="DOI URL">https://doi.org/10.1002/ejoc.201700500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201700500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201700500%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAn%252BUnprecedented%252BPseudo-%25255B3%25252B2%25255D%252BAnnulation%252Bbetween%252BN%252B-%2525284-Methoxyphenyl%252529aldimines%252Band%252BAqueous%252BGlutaraldehyde%25253A%252BDirect%252BSynthesis%252Bof%252BPyrrole-2%25252C4-dialdehydes%26aulast%3DRamaraju%26aufirst%3DPanduga%26date%3D2017%26date%3D2017%26volume%3D2017%26issue%3D24%26spage%3D3461%26epage%3D3465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antineoplastic and Immunomodulating Agents (L). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-56. <a href="https://doi.org/10.1002/14356007.a05_001.pub3" title="DOI URL">https://doi.org/10.1002/14356007.a05_001.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.a05_001.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.a05_001.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DAntineoplastic%252Band%252BImmunomodulating%252BAgents%252B%252528L%252529%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2017%26date%3D2017%26spage%3D1%26epage%3D56%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Shuang  Yan</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Haotian  Zhang</span>, <span class="hlFld-ContribAuthor ">Ye  Tian</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (6)
                                     , 1778-1786. <a href="https://doi.org/10.1016/j.bmc.2017.01.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.01.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.01.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B6-methoxycarbonyl%252Bindolinones%252Bbearing%252Ba%252Bpyrrole%252BMannich%252Bbase%252Bmoiety%252Bas%252Bangiokinase%252Binhibitors%26aulast%3DQin%26aufirst%3DMingze%26date%3D2017%26volume%3D25%26issue%3D6%26spage%3D1778%26epage%3D1786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanne J.  Carter</span>, <span class="hlFld-ContribAuthor ">Laurice V.  Fretwell</span>, <span class="hlFld-ContribAuthor ">Jeanette  Woolard</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats. </span><span class="cited-content_cbyCitation_journal-name">The FASEB Journal</span><span> <strong>2017,</strong> <em>31 </em>
                                    (3)
                                     , 1193-1203. <a href="https://doi.org/10.1096/fj.201600749R" title="DOI URL">https://doi.org/10.1096/fj.201600749R</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1096/fj.201600749R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1096%2Ffj.201600749R%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FASEB%2520Journal%26atitle%3DEffects%252Bof%252B4%252Bmultitargeted%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Bon%252Bregional%252Bhemodynamics%252Bin%252Bconscious%25252C%252Bfreely%252Bmoving%252Brats%26aulast%3DCarter%26aufirst%3DJoanne%2BJ.%26date%3D2017%26date%3D2016%26volume%3D31%26issue%3D3%26spage%3D1193%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hendra  Gunosewoyo</span>, <span class="hlFld-ContribAuthor ">Lifang  Yu</span>, <span class="hlFld-ContribAuthor ">Lenka  Munoz</span>, <span class="hlFld-ContribAuthor ">Michael  Kassiou</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase targets in CNS drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (3)
                                     , 303-314. <a href="https://doi.org/10.4155/fmc-2016-0214" title="DOI URL">https://doi.org/10.4155/fmc-2016-0214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0214%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DKinase%252Btargets%252Bin%252BCNS%252Bdrug%252Bdiscovery%26aulast%3DGunosewoyo%26aufirst%3DHendra%26date%3D2017%26volume%3D9%26issue%3D3%26spage%3D303%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Fei-Hu  Gong</span>, <span class="hlFld-ContribAuthor ">Ji-Qing  Ye</span>, <span class="hlFld-ContribAuthor ">Chi  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Chuan-Gui  Li</span>, <span class="hlFld-ContribAuthor ">Yun-Gen  Xu</span>, <span class="hlFld-ContribAuthor ">Li-Ping  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>125 </em>, 245-254. <a href="https://doi.org/10.1016/j.ejmech.2016.09.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.09.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.09.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.09.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bdiscovery%252Bof%252B4-anilinoquinazoline-urea%252Bderivatives%252Bas%252Bdual%252BTK%252Binhibitors%252Bof%252BEGFR%252Band%252BVEGFR-2%26aulast%3DZhang%26aufirst%3DHai-Qi%26date%3D2017%26volume%3D125%26spage%3D245%26epage%3D254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Wenfang  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Kong</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, <span class="hlFld-ContribAuthor ">Huidong  Yu</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2016,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep37628" title="DOI URL">https://doi.org/10.1038/srep37628</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep37628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep37628%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DIn%252BSilico%252BExploration%252Bfor%252BNovel%252BType-I%252BInhibitors%252Bof%252BTie-2%25252FTEK%25253A%252BThe%252BPerformance%252Bof%252BDifferent%252BSelection%252BStrategy%252Bin%252BSelecting%252BVirtual%252BScreening%252BCandidates%26aulast%3DPan%26aufirst%3DPeichen%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lilian  Saryeddine</span>, <span class="hlFld-ContribAuthor ">Kazem  Zibara</span>, <span class="hlFld-ContribAuthor ">Nouhad  Kassem</span>, <span class="hlFld-ContribAuthor ">Bassam  Badran</span>, <span class="hlFld-ContribAuthor ">Nabil  El-Zein</span>, . </span><span class="cited-content_cbyCitation_article-title">EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2016,</strong> <em>11 </em>
                                    (11)
                                     , e0165876. <a href="https://doi.org/10.1371/journal.pone.0165876" title="DOI URL">https://doi.org/10.1371/journal.pone.0165876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0165876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0165876%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DEGF-Induced%252BVEGF%252BExerts%252Ba%252BPI3K-Dependent%252BPositive%252BFeedback%252Bon%252BERK%252Band%252BAKT%252Bthrough%252BVEGFR2%252Bin%252BHematological%252BIn%252BVitro%252BModels%26aulast%3DSaryeddine%26aufirst%3DLilian%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D11%26spage%3De0165876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Michailidou</span>, <span class="hlFld-ContribAuthor ">Vassiliki  Giannouli</span>, <span class="hlFld-ContribAuthor ">Vasilios  Kotsikoris</span>, <span class="hlFld-ContribAuthor ">Olga  Papadodima</span>, <span class="hlFld-ContribAuthor ">Georgia  Kontogianni</span>, <span class="hlFld-ContribAuthor ">Ioannis K.  Kostakis</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Lougiakis</span>, <span class="hlFld-ContribAuthor ">Aristotelis  Chatziioannou</span>, <span class="hlFld-ContribAuthor ">Fragiskos N.  Kolisis</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Marakos</span>, <span class="hlFld-ContribAuthor ">Nicole  Pouli</span>, <span class="hlFld-ContribAuthor ">Heleni  Loutrari</span>. </span><span class="cited-content_cbyCitation_article-title">Novel pyrazolopyridine derivatives as potential angiogenesis inhibitors: Synthesis, biological evaluation and transcriptome-based mechanistic analysis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>121 </em>, 143-157. <a href="https://doi.org/10.1016/j.ejmech.2016.05.035" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.05.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.05.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.05.035%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bpyrazolopyridine%252Bderivatives%252Bas%252Bpotential%252Bangiogenesis%252Binhibitors%25253A%252BSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Btranscriptome-based%252Bmechanistic%252Banalysis%26aulast%3DMichailidou%26aufirst%3DMaria%26date%3D2016%26volume%3D121%26spage%3D143%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-zhou  Liu</span>, <span class="hlFld-ContribAuthor ">Xiao-li  Wang</span>, <span class="hlFld-ContribAuthor ">Xin-ying  Wang</span>, <span class="hlFld-ContribAuthor ">Ri-lei  Yu</span>, <span class="hlFld-ContribAuthor ">Dong-qing  Liu</span>, <span class="hlFld-ContribAuthor ">Cong-min  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2016,</strong> <em>22 </em>
                                    (9)
                                     <a href="https://doi.org/10.1007/s00894-016-3088-8" title="DOI URL">https://doi.org/10.1007/s00894-016-3088-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-016-3088-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-016-3088-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DDe%252Bnovo%252Bdesign%252Bof%252BVEGFR-2%252Btyrosine%252Bkinase%252Binhibitors%252Bbased%252Bon%252Ba%252Blinked-fragment%252Bapproach%26aulast%3DLiu%26aufirst%3DYi-zhou%26date%3D2016%26date%3D2016%26volume%3D22%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingya  Zhang</span>, <span class="hlFld-ContribAuthor ">Linna  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanyou  Wang</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2016,</strong> <em>77 </em>
                                    (5)
                                     , 905-926. <a href="https://doi.org/10.1007/s00280-016-2961-6" title="DOI URL">https://doi.org/10.1007/s00280-016-2961-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-016-2961-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-016-2961-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DDevelopment%252Bof%252Banti-angiogenic%252Btyrosine%252Bkinases%252Binhibitors%25253A%252Bmolecular%252Bstructures%252Band%252Bbinding%252Bmodes%26aulast%3DZhang%26aufirst%3DJingya%26date%3D2016%26date%3D2016%26volume%3D77%26issue%3D5%26spage%3D905%26epage%3D926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Zhaoru  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Wang</span>, <span class="hlFld-ContribAuthor ">Sufen  Cao</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Zhou</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (5)
                                     , 694-703. <a href="https://doi.org/10.1111/cbdd.12703" title="DOI URL">https://doi.org/10.1111/cbdd.12703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12703%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDiscovery%252Bof%252B1%25252C3-Diaryl-pyridones%252Bas%252BPotent%252BVEGFR-2%252BInhibitors%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%26aulast%3DYan%26aufirst%3DWei%26date%3D2016%26date%3D2016%26volume%3D87%26issue%3D5%26spage%3D694%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leilei  Shi</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Zhou</span>, <span class="hlFld-ContribAuthor ">Jifeng  Wu</span>, <span class="hlFld-ContribAuthor ">Junya  Cao</span>, <span class="hlFld-ContribAuthor ">Yuemao  Shen</span>, <span class="hlFld-ContribAuthor ">Hua  Zhou</span>, <span class="hlFld-ContribAuthor ">Xun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (8)
                                     , 1840-1852. <a href="https://doi.org/10.1016/j.bmc.2016.03.008" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.03.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.03.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DQuinoxalinone%252B%252528Part%252BII%252529.%252BDiscovery%252Bof%252B%252528Z%252529-3-%2525282-%252528pyridin-4-yl%252529vinyl%252529quinoxalinone%252Bderivates%252Bas%252Bpotent%252BVEGFR-2%252Bkinase%252Binhibitors%26aulast%3DShi%26aufirst%3DLeilei%26date%3D2016%26volume%3D24%26issue%3D8%26spage%3D1840%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nevine M. Y.  Elsayed</span>, <span class="hlFld-ContribAuthor ">Dalal A.  Abou El Ella</span>, <span class="hlFld-ContribAuthor ">Rabah A. T.  Serya</span>, <span class="hlFld-ContribAuthor ">Mai F.  Tolba</span>, <span class="hlFld-ContribAuthor ">Raed  Shalaby</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of indazole–pyrimidine based derivatives as anticancer agents with anti-angiogenic and antiproliferative activities. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2016,</strong> <em>7 </em>
                                    (5)
                                     , 881-899. <a href="https://doi.org/10.1039/C5MD00602C" title="DOI URL">https://doi.org/10.1039/C5MD00602C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5MD00602C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5MD00602C%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bindazole%2525E2%252580%252593pyrimidine%252Bbased%252Bderivatives%252Bas%252Banticancer%252Bagents%252Bwith%252Banti-angiogenic%252Band%252Bantiproliferative%252Bactivities%26aulast%3DElsayed%26aufirst%3DNevine%2BM.%2BY.%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D5%26spage%3D881%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naoyuki  Kotoku</span>, <span class="hlFld-ContribAuthor ">Masayoshi  Arai</span>, <span class="hlFld-ContribAuthor ">Motomasa  Kobayashi</span>. </span><span class="cited-content_cbyCitation_article-title">Search for Anti-angiogenic Substances from Natural Sources. </span><span class="cited-content_cbyCitation_journal-name">CHEMICAL & PHARMACEUTICAL BULLETIN</span><span> <strong>2016,</strong> <em>64 </em>
                                    (2)
                                     , 128-134. <a href="https://doi.org/10.1248/cpb.c15-00744" title="DOI URL">https://doi.org/10.1248/cpb.c15-00744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c15-00744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c15-00744%26sid%3Dliteratum%253Aachs%26jtitle%3DCHEMICAL%2520%2526%2520PHARMACEUTICAL%2520BULLETIN%26atitle%3DSearch%252Bfor%252BAnti-angiogenic%252BSubstances%252Bfrom%252BNatural%252BSources%26aulast%3DKotoku%26aufirst%3DNaoyuki%26date%3D2016%26volume%3D64%26issue%3D2%26spage%3D128%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang  Lu</span>, <span class="hlFld-ContribAuthor ">Ting-Ting  Zhao</span>, <span class="hlFld-ContribAuthor ">Tian-Bao  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Xue  Sun</span>, <span class="hlFld-ContribAuthor ">Chen  Xu</span>, <span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2. </span><span class="cited-content_cbyCitation_journal-name">CHEMICAL & PHARMACEUTICAL BULLETIN</span><span> <strong>2016,</strong> <em>64 </em>
                                    (11)
                                     , 1570-1575. <a href="https://doi.org/10.1248/cpb.c16-00386" title="DOI URL">https://doi.org/10.1248/cpb.c16-00386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c16-00386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c16-00386%26sid%3Dliteratum%253Aachs%26jtitle%3DCHEMICAL%2520%2526%2520PHARMACEUTICAL%2520BULLETIN%26atitle%3DSynthesis%25252C%252BMolecular%252BModeling%252Band%252BBiological%252BEvaluation%252Bof%252B4-Alkoxyquinazoline%252BDerivatives%252Bas%252BNovel%252BInhibitors%252Bof%252BVEGFR2%26aulast%3DLu%26aufirst%3DLiang%26date%3D2016%26volume%3D64%26issue%3D11%26spage%3D1570%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Jiao</span>, <span class="hlFld-ContribAuthor ">Xiao  Xiong</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Jinxing  Xu</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Anyang  Xu</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Xin  Qiao</span>, <span class="hlFld-ContribAuthor ">Zhihao  Shi</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment virtual screening based on Bayesian categorization for discovering novel VEGFR-2 scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2015,</strong> <em>19 </em>
                                    (4)
                                     , 895-913. <a href="https://doi.org/10.1007/s11030-015-9592-4" title="DOI URL">https://doi.org/10.1007/s11030-015-9592-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-015-9592-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-015-9592-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DFragment%252Bvirtual%252Bscreening%252Bbased%252Bon%252BBayesian%252Bcategorization%252Bfor%252Bdiscovering%252Bnovel%252BVEGFR-2%252Bscaffolds%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2015%26date%3D2015%26volume%3D19%26issue%3D4%26spage%3D895%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ge  Meng</span>, <span class="hlFld-ContribAuthor ">Chunyan  Liu</span>, <span class="hlFld-ContribAuthor ">Shidong  Qin</span>, <span class="hlFld-ContribAuthor ">Mengshu  Dong</span>, <span class="hlFld-ContribAuthor ">Xiaomi  Wei</span>, <span class="hlFld-ContribAuthor ">Meilin  Zheng</span>, <span class="hlFld-ContribAuthor ">Liwen  Qin</span>, <span class="hlFld-ContribAuthor ">Huihui  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoshuang  He</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An improved synthesis of sunitinib malate via a solvent-free decarboxylation process. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2015,</strong> <em>41 </em>
                                    (11)
                                     , 8941-8954. <a href="https://doi.org/10.1007/s11164-015-1939-z" title="DOI URL">https://doi.org/10.1007/s11164-015-1939-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-015-1939-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-015-1939-z%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DAn%252Bimproved%252Bsynthesis%252Bof%252Bsunitinib%252Bmalate%252Bvia%252Ba%252Bsolvent-free%252Bdecarboxylation%252Bprocess%26aulast%3DMeng%26aufirst%3DGe%26date%3D2015%26date%3D2015%26volume%3D41%26issue%3D11%26spage%3D8941%26epage%3D8954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Séverine  Ravez</span>, <span class="hlFld-ContribAuthor ">Stéphane  Arsenlis</span>, <span class="hlFld-ContribAuthor ">Amélie  Barczyk</span>, <span class="hlFld-ContribAuthor ">Anthony  Dupont</span>, <span class="hlFld-ContribAuthor ">Raphaël  Frédérick</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Hesse</span>, <span class="hlFld-ContribAuthor ">Gilbert  Kirsch</span>, <span class="hlFld-ContribAuthor ">Patrick  Depreux</span>, <span class="hlFld-ContribAuthor ">Laurence  Goossens</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (22)
                                     , 7340-7347. <a href="https://doi.org/10.1016/j.bmc.2015.10.035" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.10.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.10.035%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bdi-aryl%252Burea%252Bderivatives%252Bas%252Bc-Kit%252Binhibitors%26aulast%3DRavez%26aufirst%3DS%25C3%25A9verine%26date%3D2015%26volume%3D23%26issue%3D22%26spage%3D7340%26epage%3D7347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Zanella</span>, <span class="hlFld-ContribAuthor ">Michele  Mingozzi</span>, <span class="hlFld-ContribAuthor ">Alberto  Dal Corso</span>, <span class="hlFld-ContribAuthor ">Roberto  Fanelli</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">Marco  Cosentino</span>, <span class="hlFld-ContribAuthor ">Laura  Schembri</span>, <span class="hlFld-ContribAuthor ">Franca  Marino</span>, <span class="hlFld-ContribAuthor ">Marta  De Zotti</span>, <span class="hlFld-ContribAuthor ">Fernando  Formaggio</span>, <span class="hlFld-ContribAuthor ">Luca  Pignataro</span>, <span class="hlFld-ContribAuthor ">Laura  Belvisi</span>, <span class="hlFld-ContribAuthor ">Umberto  Piarulli</span>, <span class="hlFld-ContribAuthor ">Cesare  Gennari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Characterization, and Biological Evaluation of a Dual-Action Ligand Targeting α
              v
              β
              3
              Integrin and VEGF Receptors. </span><span class="cited-content_cbyCitation_journal-name">ChemistryOpen</span><span> <strong>2015,</strong> <em>4 </em>
                                    (5)
                                     , 633-641. <a href="https://doi.org/10.1002/open.201500062" title="DOI URL">https://doi.org/10.1002/open.201500062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/open.201500062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fopen.201500062%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistryOpen%26atitle%3DSynthesis%25252C%252BCharacterization%25252C%252Band%252BBiological%252BEvaluation%252Bof%252Ba%252BDual-Action%252BLigand%252BTargeting%252B%2525CE%2525B1%252Bv%252B%2525CE%2525B2%252B3%252BIntegrin%252Band%252BVEGF%252BReceptors%26aulast%3DZanella%26aufirst%3DSimone%26date%3D2015%26date%3D2015%26volume%3D4%26issue%3D5%26spage%3D633%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Salerno</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Marini</span>, <span class="hlFld-ContribAuthor ">Giacomo  Fornaciari</span>, <span class="hlFld-ContribAuthor ">Francesca  Simorini</span>, <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Stefania  Sartini</span>, <span class="hlFld-ContribAuthor ">Federico  Da Settimo</span>, <span class="hlFld-ContribAuthor ">Aída Nelly  García-Argáez</span>, <span class="hlFld-ContribAuthor ">Ornella  Gia</span>, <span class="hlFld-ContribAuthor ">Sandro  Cosconati</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Pilar  D'Ocon</span>, <span class="hlFld-ContribAuthor ">Anna  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Paola  Orlandi</span>, <span class="hlFld-ContribAuthor ">Guido  Bocci</span>, <span class="hlFld-ContribAuthor ">Lisa  Dalla Via</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>103 </em>, 29-43. <a href="https://doi.org/10.1016/j.ejmech.2015.08.027" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.08.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.08.027%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInvestigation%252Bof%252Bnew%252B2-aryl%252Bsubstituted%252BBenzothiopyrano%25255B4%25252C3-d%25255Dpyrimidines%252Bas%252Bkinase%252Binhibitors%252Btargeting%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor%252B2%26aulast%3DSalerno%26aufirst%3DSilvia%26date%3D2015%26volume%3D103%26spage%3D29%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasmine M.  Abdel Aziz</span>, <span class="hlFld-ContribAuthor ">Mohamed M.  Said</span>, <span class="hlFld-ContribAuthor ">Hosam A.  El Shihawy</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel tricyclic pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-amine derivatives as VEGFR-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2015,</strong> <em>60 </em>, 1-12. <a href="https://doi.org/10.1016/j.bioorg.2015.03.004" title="DOI URL">https://doi.org/10.1016/j.bioorg.2015.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2015.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2015.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Btricyclic%252Bpyrido%25255B3%2525E2%252580%2525B2%25252C2%2525E2%252580%2525B2%25253A4%25252C5%25255Dthieno%25255B3%25252C2-d%25255Dpyrimidin-4-amine%252Bderivatives%252Bas%252BVEGFR-2%252Binhibitors%26aulast%3DAbdel%2BAziz%26aufirst%3DYasmine%2BM.%26date%3D2015%26volume%3D60%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanne J  Carter</span>, <span class="hlFld-ContribAuthor ">Amanda J  Wheal</span>, <span class="hlFld-ContribAuthor ">Stephen J  Hill</span>, <span class="hlFld-ContribAuthor ">Jeanette  Woolard</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of receptor tyrosine kinase inhibitors on VEGF
              165
              a- and VEGF
              165
              b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2015,</strong> <em>172 </em>
                                    (12)
                                     , 3141-3150. <a href="https://doi.org/10.1111/bph.13116" title="DOI URL">https://doi.org/10.1111/bph.13116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.13116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.13116%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DEffects%252Bof%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Bon%252BVEGF%252B165%252Ba-%252Band%252BVEGF%252B165%252Bb-stimulated%252Bgene%252Btranscription%252Bin%252BHEK-293%252Bcells%252Bexpressing%252Bhuman%252BVEGFR2%26aulast%3DCarter%26aufirst%3DJoanne%2BJ%26date%3D2015%26date%3D2015%26volume%3D172%26issue%3D12%26spage%3D3141%26epage%3D3150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yali  Zhang</span>, <span class="hlFld-ContribAuthor ">Lili  Dong</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Lingfeng  Chen</span>, <span class="hlFld-ContribAuthor ">Dandan  Liang</span>, <span class="hlFld-ContribAuthor ">Dengjian  Shi</span>, <span class="hlFld-ContribAuthor ">Xiaoou  Shan</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Quinazoline Derivatives as Anti-inflammatory Agents against Lipopolysaccharide-induced Acute Lung Injury in Rats. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2015,</strong> <em>85 </em>
                                    (6)
                                     , 672-684. <a href="https://doi.org/10.1111/cbdd.12454" title="DOI URL">https://doi.org/10.1111/cbdd.12454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12454%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BQuinazoline%252BDerivatives%252Bas%252BAnti-inflammatory%252BAgents%252Bagainst%252BLipopolysaccharide-induced%252BAcute%252BLung%252BInjury%252Bin%252BRats%26aulast%3DHu%26aufirst%3DJie%26date%3D2015%26date%3D2014%26volume%3D85%26issue%3D6%26spage%3D672%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Desogus</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Cristina  Tintori</span>, <span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>. </span><span class="cited-content_cbyCitation_article-title">Bcr-Abl tyrosine kinase inhibitors: a patent review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2015,</strong> <em>25 </em>
                                    (4)
                                     , 397-412. <a href="https://doi.org/10.1517/13543776.2015.1012155" title="DOI URL">https://doi.org/10.1517/13543776.2015.1012155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2015.1012155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2015.1012155%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DBcr-Abl%252Btyrosine%252Bkinase%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%26aulast%3DDesogus%26aufirst%3DAndrea%26date%3D2015%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D397%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guanhua  Ai</span>, <span class="hlFld-ContribAuthor ">Caiping  Tian</span>, <span class="hlFld-ContribAuthor ">Dawei  Deng</span>, <span class="hlFld-ContribAuthor ">Guissi  Fida</span>, <span class="hlFld-ContribAuthor ">Haiyan  Chen</span>, <span class="hlFld-ContribAuthor ">Yuxiang  Ma</span>, <span class="hlFld-ContribAuthor ">Li  Ding</span>, <span class="hlFld-ContribAuthor ">Yueqing  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Drugs</span><span> <strong>2015,</strong> <em>26 </em>
                                    (4)
                                     , 399-409. <a href="https://doi.org/10.1097/CAD.0000000000000199" title="DOI URL">https://doi.org/10.1097/CAD.0000000000000199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CAD.0000000000000199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCAD.0000000000000199%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Drugs%26atitle%3DA%252Bcombination%252Bof%252B2D%252Bsimilarity%252Bsearch%25252C%252Bpharmacophore%25252C%252Band%252Bmolecular%252Bdocking%252Btechniques%252Bfor%252Bthe%252Bidentification%252Bof%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor-2%252Binhibitors%26aulast%3DAi%26aufirst%3DGuanhua%26date%3D2015%26volume%3D26%26issue%3D4%26spage%3D399%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen'kii</span>, <span class="hlFld-ContribAuthor ">Yu B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XIII, 2012–2013. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 193-363. <a href="https://doi.org/10.1016/bs.aihch.2015.04.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2015.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2015.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2015.04.002%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXIII%25252C%252B2012%2525E2%252580%2525932013%26aulast%3DBelen%2527kii%26aufirst%3DLeonid%2BI.%26date%3D2015%26spage%3D193%26epage%3D363%26pub%3DElsevier%26date%3D2015%26volume%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fang  Qiao</span>, <span class="hlFld-ContribAuthor ">Yong  Yin</span>, <span class="hlFld-ContribAuthor ">Yu-Ning  Shen</span>, <span class="hlFld-ContribAuthor ">She-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Shao  Sha</span>, <span class="hlFld-ContribAuthor ">Xun  Wu</span>, <span class="hlFld-ContribAuthor ">Ai-Min  Lu</span>, <span class="hlFld-ContribAuthor ">Chen  Xu</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, molecular modeling, and biological evaluation of quinazoline derivatives containing the 1,3,4-oxadiazole scaffold as novel inhibitors of VEGFR2. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (26)
                                     , 19914-19923. <a href="https://doi.org/10.1039/C4RA11780H" title="DOI URL">https://doi.org/10.1039/C4RA11780H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4RA11780H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4RA11780H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%25252C%252Bmolecular%252Bmodeling%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bquinazoline%252Bderivatives%252Bcontaining%252Bthe%252B1%25252C3%25252C4-oxadiazole%252Bscaffold%252Bas%252Bnovel%252Binhibitors%252Bof%252BVEGFR2%26aulast%3DQiao%26aufirst%3DFang%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D26%26spage%3D19914%26epage%3D19923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongcong  Lv</span>, <span class="hlFld-ContribAuthor ">Mengyuan  Li</span>, <span class="hlFld-ContribAuthor ">Sufen  Cao</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Lixin  Wei</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2015,</strong> <em>6 </em>
                                    (7)
                                     , 1375-1380. <a href="https://doi.org/10.1039/C5MD00191A" title="DOI URL">https://doi.org/10.1039/C5MD00191A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5MD00191A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5MD00191A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDiscovery%252Bof%252Banilinopyrimidine-based%252Bnaphthamide%252Bderivatives%252Bas%252Bpotent%252BVEGFR-2%252Binhibitors%26aulast%3DLv%26aufirst%3DYongcong%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D7%26spage%3D1375%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akihiko  Tsuruoka</span>, <span class="hlFld-ContribAuthor ">Junji  Matsui</span>, <span class="hlFld-ContribAuthor ">Takuya  Suzuki</span>, <span class="hlFld-ContribAuthor ">Noriyuki  Koyama</span>, <span class="hlFld-ContribAuthor ">Tatsuo  Watanabe</span>, <span class="hlFld-ContribAuthor ">Yasuhiro  Funahashi</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Folia Pharmacologica Japonica</span><span> <strong>2015,</strong> <em>146 </em>
                                    (5)
                                     , 283-290. <a href="https://doi.org/10.1254/fpj.146.283" title="DOI URL">https://doi.org/10.1254/fpj.146.283</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1254/fpj.146.283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1254%2Ffpj.146.283%26sid%3Dliteratum%253Aachs%26jtitle%3DFolia%2520Pharmacologica%2520Japonica%26atitle%3DPreclinical%252Band%252Bclinical%252Bresearches%252Bof%252Blenvatinib%252Bmesylate%252B%252528Lenvima%252Bcapsule%252529%25252C%252Ba%252Bnovel%252Bantitumor%252Bagent%252Bapproved%252Bfor%252Bthyroid%252Bcancer%252Btreatment%26aulast%3DTsuruoka%26aufirst%3DAkihiko%26date%3D2015%26volume%3D146%26issue%3D5%26spage%3D283%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Ding</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingli  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu Zong  Chen</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Ying  Tan</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2014,</strong> <em>6 </em>
                                    (16)
                                     , 1771-1789. <a href="https://doi.org/10.4155/fmc.14.112" title="DOI URL">https://doi.org/10.4155/fmc.14.112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.14.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.14.112%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DMultitarget%252Binhibitors%252Bderived%252Bfrom%252Bcrosstalk%252Bmechanism%252Binvolving%252BVEGFR2%26aulast%3DDing%26aufirst%3DChao%26date%3D2014%26volume%3D6%26issue%3D16%26spage%3D1771%26epage%3D1789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Shi</span>, <span class="hlFld-ContribAuthor ">Ting-Ting  Wu</span>, <span class="hlFld-ContribAuthor ">Zhi  Wang</span>, <span class="hlFld-ContribAuthor ">Jia-Yu  Xue</span>, <span class="hlFld-ContribAuthor ">Yun-Gen  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>84 </em>, 698-707. <a href="https://doi.org/10.1016/j.ejmech.2014.07.071" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.071%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%2525282-phenyl-1H-benzo%25255Bd%25255Dimidazol-5-yl%252529quinolin-4-amine%252Bderivatives%252Bas%252Bnovel%252BVEGFR-2%252Bkinase%252Binhibitors%26aulast%3DShi%26aufirst%3DLei%26date%3D2014%26volume%3D84%26spage%3D698%26epage%3D707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Sudhir  Raghavan</span>, <span class="hlFld-ContribAuthor ">Michael  Ihnat</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Disch</span>, <span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Lora C.  Bailey-Downs</span>, <span class="hlFld-ContribAuthor ">Nicholas F.  Dybdal-Hargreaves</span>, <span class="hlFld-ContribAuthor ">Cristina C.  Rohena</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (14)
                                     , 3753-3772. <a href="https://doi.org/10.1016/j.bmc.2014.04.049" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.04.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bdesign%252Band%252Bdiscovery%252Bof%252Bwater%252Bsoluble%252B4-substituted-2%25252C6-dimethylfuro%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bmultitargeted%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Band%252Bmicrotubule%252Btargeting%252Bantitumor%252Bagents%26aulast%3DZhang%26aufirst%3DXin%26date%3D2014%26volume%3D22%26issue%3D14%26spage%3D3753%26epage%3D3772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Séverine  Ravez</span>, <span class="hlFld-ContribAuthor ">Amélie  Barczyk</span>, <span class="hlFld-ContribAuthor ">Perrine  Six</span>, <span class="hlFld-ContribAuthor ">Aurélie  Cagnon</span>, <span class="hlFld-ContribAuthor ">Antonio  Garofalo</span>, <span class="hlFld-ContribAuthor ">Laurence  Goossens</span>, <span class="hlFld-ContribAuthor ">Patrick  Depreux</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of tumor cell growth and angiogenesis by 7-Aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>79 </em>, 369-381. <a href="https://doi.org/10.1016/j.ejmech.2014.04.007" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.04.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.04.007%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInhibition%252Bof%252Btumor%252Bcell%252Bgrowth%252Band%252Bangiogenesis%252Bby%252B7-Aminoalkoxy-4-aryloxy-quinazoline%252Bureas%25252C%252Ba%252Bnovel%252Bseries%252Bof%252Bmulti-tyrosine%252Bkinase%252Binhibitors%26aulast%3DRavez%26aufirst%3DS%25C3%25A9verine%26date%3D2014%26volume%3D79%26spage%3D369%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">MENG  YANG</span>, <span class="hlFld-ContribAuthor ">XIAOCONG  KUANG</span>, <span class="hlFld-ContribAuthor ">YANBIN  PAN</span>, <span class="hlFld-ContribAuthor ">MEILE  TAN</span>, <span class="hlFld-ContribAuthor ">BINZHU  LU</span>, <span class="hlFld-ContribAuthor ">JIAN  LU</span>, <span class="hlFld-ContribAuthor ">QIUMEI  CHENG</span>, <span class="hlFld-ContribAuthor ">JIANMIN  LI</span>. </span><span class="cited-content_cbyCitation_article-title">Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: A meta-analysis. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Clinical Oncology</span><span> <strong>2014,</strong> <em>2 </em>
                                    (3)
                                     , 363-368. <a href="https://doi.org/10.3892/mco.2014.247" title="DOI URL">https://doi.org/10.3892/mco.2014.247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/mco.2014.247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fmco.2014.247%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Clinical%2520Oncology%26atitle%3DClinicopathological%252Bcharacteristics%252Bof%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Bexpression%252Bin%252Buveal%252Bmelanoma%25253A%252BA%252Bmeta-analysis%26aulast%3DYANG%26aufirst%3DMENG%26date%3D2014%26date%3D2014%26volume%3D2%26issue%3D3%26spage%3D363%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm301085w&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Fjm301085w%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=105&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0019.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of VEGER structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. VEGFR/multitargeted inhibitors approved for clinical use.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Quinazoline and quinoline derivatives in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Other derivatives in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Other derivatives in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic representation of hydrogen bonds (dotted lines) between <b>22</b> and VEGFR-2 catalytic site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Quinazolines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pyrrolopyrimidines and other fused pyrimidines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Graphical representation of the binding mode of compound <b>32</b> (sticks) into the ATP binding site of VEGFR-2. For sake of clarity, only a few residues are labeled, nonpolar hydrogen atoms are omitted, and hydrogen bond interactions are represented by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Nonfused pyrimidines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Quinolines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Graphical representation of the binding mode of compound <b>41</b> (sticks) into the ATP binding site of VEGFR-2. For sake of clarity, only a few residues are labeled, nonpolar hydrogen atoms are omitted, and hydrogen bond interactions are represented by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Fused pyridines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Nonfused pyridines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Pyrrolocarbazoles, indolopyrrolones, and indolinones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Schematic representation of hydrogen bonds (dotted lines) between <b>59</b> and VEGFR-2 catalytic site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/medium/jm-2012-01085w_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Miscellaneous compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301085w/production/images/large/jm-2012-01085w_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301085w&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13380" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13380" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 211 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Folkman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amore, P.</span><span> </span><span class="NLM_article-title">Blood vessel formation: what is its molecular basis?</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1996&pages=1153-1155&author=J.+Folkmanauthor=P.+D%E2%80%99Amore&title=Blood+vessel+formation%3A+what+is+its+molecular+basis%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%26atitle%3DBlood%2520vessel%2520formation%253A%2520what%2520is%2520its%2520molecular%2520basis%253F%26jtitle%3DCell%26date%3D1996%26volume%3D87%26spage%3D1153%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Risau, W.</span><span> </span><span class="NLM_article-title">Mechanisms of angiogenesis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2F386671a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=9109485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADyaK2s3mtlGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=1997&pages=671-674&author=W.+Risau&title=Mechanisms+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of angiogenesis</span></div><div class="casAuthors">Risau W</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">6626</span>),
    <span class="NLM_cas:pages">671-4</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">After the developing embryo has formed a primary vascular plexus by a process termed vasculogenesis, further blood vessels are generated by both sprouting and non-sprouting angiogenesis, which are progressively pruned and remodelled into a functional adult circulatory system.  Recent results, particularly from the study of mice lacking some of the signalling systems involved, have greatly improved our understanding of the molecular basis underlying these events, and may suggest new approaches for treating conditions such as cancer that depend on angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRN2kGUT2MdEH3Rlp_k91zfW6udTcc2eZMFyFKfbE7mLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3mtlGksg%253D%253D&md5=748146a1cf56ccaf4894573d0687a402</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F386671a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F386671a0%26sid%3Dliteratum%253Aachs%26aulast%3DRisau%26aufirst%3DW.%26atitle%3DMechanisms%2520of%2520angiogenesis%26jtitle%3DNature%26date%3D1997%26volume%3D386%26spage%3D671%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Klagsbrun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moses, M. A.</span><span> </span><span class="NLM_article-title">Molecular angiogenesis</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">R217</span><span class="NLM_x">–</span> <span class="NLM_lpage">R224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2FS1074-5521%2899%2980081-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=10421764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVynsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=R217-R224&author=M.+Klagsbrunauthor=M.+A.+Moses&title=Molecular+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular angiogenesis</span></div><div class="casAuthors">Klagsbrun, Michael; Moses, Marsha A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">R217-R224</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">A review with 70 refs.  New insights into the mechanisms by which blood vessels develop (angiogenesis) have been gained recently, primarily by the identification of factors that inhibit and promote this process.  Angiogenesis-stimulating factors are being used to promote growth of new blood vessels in ischemic disease.  In contrast, anti-angiogenesis factors are being used as inhibitors of neovascularization to control tumor growth and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol1lP42oGX-7Vg90H21EOLACvtfcHk0lixO3GTkh0vww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVynsLk%253D&md5=7deec4953a842556064ce4d002b72d6d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2899%2980081-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252899%252980081-7%26sid%3Dliteratum%253Aachs%26aulast%3DKlagsbrun%26aufirst%3DM.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26atitle%3DMolecular%2520angiogenesis%26jtitle%3DChem.%2520Biol.%26date%3D1999%26volume%3D6%26spage%3DR217%26epage%3DR224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, B. M.</span><span> </span><span class="NLM_article-title">An overview of small-molecule inhibitors of VEGFR signalling</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">569</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrclinonc.2009.130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19736552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=569-579&author=S.+P.+Ivyauthor=J.+Y.+Wickauthor=B.+M.+Kaufman&title=An+overview+of+small-molecule+inhibitors+of+VEGFR+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of small-molecule inhibitors of VEGFR signaling</span></div><div class="casAuthors">Ivy, S. Percy; Wick, Jeannette Y.; Kaufman, Bennett M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">569-579</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The VEGFR small-mol. inhibitors of angiogenesis show promise for oncol. patients.  These rationally designed inhibitors are being tailored for use in specific malignancies and will have a pivotal role in personalized medicine.  The authors discuss the potential of these agents for treating tumors such as metastatic renal-cell carcinoma, GIST and hepatocellular carcinoma.  VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma, gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a no. of other oncol. indications, including colorectal cancer, non-small-cell lung cancer, pancreatic cancer, thyroid malignancies, ovarian cancer, breast cancer and sarcomas.  This Review outlines the structure-activity relationships of the 44 VEGFR inhibitors currently in development.  An overview of the pharmacokinetic profile of each mol. and its stage in development is provided.  Phase III clin. trials being conducted for licensing of these agents for specific indications and phase III developmental efficacy trials are described in detailed tables that include the disease studied, trial design including combination therapy, study end points, and projected or final accrual.  The relative frequency of on-target and off-target adverse events obsd. in 3,060 patients is described for a subset of agents in development in clin. trials sponsored by the National Cancer Institute.  No interagent comparisons were undertaken and no data from pharmaceutical pharmacovigilance databases were used.  The on-target effects seem to be mechanistically based and predicted by VEGFR inhibition.  Small-mol. inhibitors of angiogenesis are active in a wide variety of malignancies and fill a unique niche for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN-w_SDT-UfrVg90H21EOLACvtfcHk0lixO3GTkh0vww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbI&md5=6ae67a681df0729bda1fa06a2aa391eb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2009.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2009.130%26sid%3Dliteratum%253Aachs%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DWick%26aufirst%3DJ.%2BY.%26aulast%3DKaufman%26aufirst%3DB.%2BM.%26atitle%3DAn%2520overview%2520of%2520small-molecule%2520inhibitors%2520of%2520VEGFR%2520signalling%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D6%26spage%3D569%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor as a target for anticancer therapy</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=2-10&author=N.+Ferrara&title=Vascular+endothelial+growth+factor+as+a+target+for+anticancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520as%2520a%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DOncologist%26date%3D2004%26volume%3D9%26spage%3D2%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Potente, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhardt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Basic and therapeutic aspects of angiogenesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">887</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2011&pages=873-887&author=M.+Potenteauthor=H.+Gerhardtauthor=P.+Carmeliet&title=Basic+and+therapeutic+aspects+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPotente%26aufirst%3DM.%26aulast%3DGerhardt%26aufirst%3DH.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DBasic%2520and%2520therapeutic%2520aspects%2520of%2520angiogenesis%26jtitle%3DCell%26date%3D2011%26volume%3D146%26spage%3D873%26epage%3D887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Tumor angiogenesis: therapeutic implications</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">1182</span><span class="NLM_x">–</span> <span class="NLM_lpage">1186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1056%2FNEJM197111182852108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=4938153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1971&pages=1182-1186&author=J.+Folkman&title=Tumor+angiogenesis%3A+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor angiogenesis: therapeutic implications</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1182-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA0C6odtE1LPxQvRxYU81tfW6udTcc2ebzZSQo4FN-Hbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D&md5=efdddcba0c04be542edd51fef2ef27b9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJM197111182852108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197111182852108%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DTumor%2520angiogenesis%253A%2520therapeutic%2520implications%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1971%26volume%3D285%26spage%3D1182%26epage%3D1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1996&pages=353-364&author=D.+Hanahanauthor=J.+Folkman&title=Patterns+and+emerging+mechanisms+of+the+angiogenic+switch+during+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DPatterns%2520and%2520emerging%2520mechanisms%2520of%2520the%2520angiogenic%2520switch%2520during%2520tumorigenesis%26jtitle%3DCell%26date%3D1996%26volume%3D86%26spage%3D353%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Tumor angiogenesis: past, present and the near future</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">–</span> <span class="NLM_lpage">515</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=501-515&author=R.+S.+Kerbel&title=Tumor+angiogenesis%3A+past%2C+present+and+the+near+future"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DTumor%2520angiogenesis%253A%2520past%252C%2520present%2520and%2520the%2520near%2520future%26jtitle%3DCarcinogenesis%26date%3D2000%26volume%3D21%26spage%3D501%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Sharpe, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maupin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teleron, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pyle, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. P.</span><span> </span><span class="NLM_article-title">VEGF and PIGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularisation</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1495</span><span class="NLM_x">–</span> <span class="NLM_lpage">1497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=1495-1497&author=E.+E.+Sharpeauthor=A.+B.+Maupinauthor=A.+A.+Teleronauthor=A.+L.+Pyleauthor=P.+Carmelietauthor=P.+P.+Young&title=VEGF+and+PIGF+promote+adult+vasculogenesis+by+enhancing+EPC+recruitment+and+vessel+formation+at+the+site+of+tumor+neovascularisation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharpe%26aufirst%3DE.%2BE.%26aulast%3DMaupin%26aufirst%3DA.%2BB.%26aulast%3DTeleron%26aufirst%3DA.%2BA.%26aulast%3DPyle%26aufirst%3DA.%2BL.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DP.%2BP.%26atitle%3DVEGF%2520and%2520PIGF%2520promote%2520adult%2520vasculogenesis%2520by%2520enhancing%2520EPC%2520recruitment%2520and%2520vessel%2520formation%2520at%2520the%2520site%2520of%2520tumor%2520neovascularisation%26jtitle%3DFASEB%2520J.%26date%3D2006%26volume%3D20%26spage%3D1495%26epage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Angiogenesis in life, disease and medicine</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnature04478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16355210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=932-936&author=P.+Carmeliet&title=Angiogenesis+in+life%2C+disease+and+medicine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in life, disease and medicine</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">7070</span>),
    <span class="NLM_cas:pages">932-936</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair.  An imbalance in this process contributes to numerous malignant, inflammatory, ischemic, infectious and immune disorders.  Recently, the first anti-angiogenic agents have been approved for the treatment of cancer and blindness.  Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5NqkaUGRfrVg90H21EOLACvtfcHk0lg8D4OdrHrJsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF&md5=e196d7203fa60d5ecd9182fa023cd30e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature04478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04478%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAngiogenesis%2520in%2520life%252C%2520disease%2520and%2520medicine%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D932%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Leung, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cachianes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goeddel, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor is a secreted angiogenic mitogen</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">246</span><span class="NLM_x">, </span> <span class="NLM_fpage">1306</span><span class="NLM_x">–</span> <span class="NLM_lpage">1309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1989&pages=1306-1309&author=D.+W.+Leungauthor=G.+Cachianesauthor=W.+J.+Kuangauthor=D.+V.+Goeddelauthor=N.+Ferrara&title=Vascular+endothelial+growth+factor+is+a+secreted+angiogenic+mitogen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DD.%2BW.%26aulast%3DCachianes%26aufirst%3DG.%26aulast%3DKuang%26aufirst%3DW.%2BJ.%26aulast%3DGoeddel%26aufirst%3DD.%2BV.%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520is%2520a%2520secreted%2520angiogenic%2520mitogen%26jtitle%3DScience%26date%3D1989%26volume%3D246%26spage%3D1306%26epage%3D1309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Holmes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, M. J.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.cellsig.2007.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17658244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=2003-2012&author=K.+Holmesauthor=O.+L.+Robertsauthor=A.+M.+Thomasauthor=M.+J.+Cross&title=Vascular+endothelial+growth+factor+receptor-2%3A+structure%2C+function%2C+intracellular+signalling+and+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span></div><div class="casAuthors">Holmes, Katherine; Roberts, Owain Ll; Thomas, Angharad M.; Cross, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2003-2012</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a no. of receptors.  VEGFR-1 is required for the recruitment of hematopoietic stem cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function.  Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signaling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response.  Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a no. of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTYxPMokVV57Vg90H21EOLACvtfcHk0lhXKmIcNcuSSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D&md5=44a935f36d29b000d2a9ff514709e9c2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2007.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2007.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DO.%2BL.%26aulast%3DThomas%26aufirst%3DA.%2BM.%26aulast%3DCross%26aufirst%3DM.%2BJ.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-2%253A%2520structure%252C%2520function%252C%2520intracellular%2520signalling%2520and%2520therapeutic%2520inhibition%26jtitle%3DCell.%2520Signalling%26date%3D2007%26volume%3D19%26spage%3D2003%26epage%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Stuttfeld, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballmer-Hofer, K.</span><span> </span><span class="NLM_article-title">Structure and function of VEGF receptors</span> <span class="citation_source-journal">IUBMB Life</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=915-922&author=E.+Stuttfeldauthor=K.+Ballmer-Hofer&title=Structure+and+function+of+VEGF+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStuttfeld%26aufirst%3DE.%26aulast%3DBallmer-Hofer%26aufirst%3DK.%26atitle%3DStructure%2520and%2520function%2520of%2520VEGF%2520receptors%26jtitle%3DIUBMB%2520Life%26date%3D2009%26volume%3D61%26spage%3D915%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">VEGF receptor protein-tyrosine kinases: structure and regulation</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2008&pages=287-291&author=R.+Roskoski&title=VEGF+receptor+protein-tyrosine+kinases%3A+structure+and+regulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DVEGF%2520receptor%2520protein-tyrosine%2520kinases%253A%2520structure%2520and%2520regulation%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2008%26volume%3D375%26spage%3D287%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Koch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tugues, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gualandi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claesson-Welsh, L.</span><span> </span><span class="NLM_article-title">Signal transduction by vascular endothelial growth factor receptors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">437</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1042%2FBJ20110301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21711246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFSmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=437&publication_year=2011&pages=169-183&author=S.+Kochauthor=S.+Tuguesauthor=X.+Liauthor=L.+Gualandiauthor=L.+Claesson-Welsh&title=Signal+transduction+by+vascular+endothelial+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction by vascular endothelial growth factor receptors</span></div><div class="casAuthors">Koch, Sina; Tugues, Sonia; Li, Xiujuan; Gualandi, Laura; Claesson-Welsh, Lena</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">437</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-183</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  VEGFs (vascular endothelial growth factors) control vascular development during embryogenesis and the function of blood vessels and lymphatic vessels in the adult.  There are five related mammalian ligands, which act through three receptor tyrosine kinases.  Signaling is modulated through neuropilins, which act as VEGF co-receptors.  Heparan sulfate and integrins are also important modulators of VEGF signaling.  Therapeutic agents that interfere with VEGF signaling have been developed with the aim of decreasing angiogenesis in diseases that involve tissue growth and inflammation, such as cancer.  The present review will outline the current understanding and consequent biol. of VEGF receptor signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeC7nB3SWcmrVg90H21EOLACvtfcHk0lhXKmIcNcuSSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFSmtbo%253D&md5=fa31c9c345be1b5004c9d8052f6d29ae</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1042%2FBJ20110301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110301%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DTugues%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGualandi%26aufirst%3DL.%26aulast%3DClaesson-Welsh%26aufirst%3DL.%26atitle%3DSignal%2520transduction%2520by%2520vascular%2520endothelial%2520growth%2520factor%2520receptors%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D437%26spage%3D169%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Morabito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Maio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normanno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, F.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=753-764&author=A.+Morabitoauthor=E.+De+Maioauthor=M.+Di+Maioauthor=N.+Normannoauthor=F.+Perrone&title=Tyrosine+kinase+inhibitors+of+vascular+endothelial+growth+factor+receptors+in+clinical+trials%3A+current+status+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorabito%26aufirst%3DA.%26aulast%3DDe%2BMaio%26aufirst%3DE.%26aulast%3DDi%2BMaio%26aufirst%3DM.%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DPerrone%26aufirst%3DF.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptors%2520in%2520clinical%2520trials%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DOncologist%26date%3D2006%26volume%3D17%26spage%3D753%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kappert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böhmer, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostman, A.</span><span> </span><span class="NLM_article-title">Tyrosine phosphatases in vessel wall signaling</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.cardiores.2004.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=15664385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsVKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=587-598&author=K.+Kappertauthor=K.+G.+Petersauthor=F.+D.+B%C3%B6hmerauthor=A.+Ostman&title=Tyrosine+phosphatases+in+vessel+wall+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine phosphatases in vessel wall signaling</span></div><div class="casAuthors">Kappert, Kai; Peters, Kevin G.; Boehmer, Frank D.; Oestman, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-598</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein tyrosine phosphatases (PTPs) are crit. regulators of cellular processes like migration, proliferation and differentiation that are involved in physiol. and pathol. vessel wall function.  In this review, we summarize the biochem. of this enzyme family, discuss the present knowledge concerning the identity and involvement of PTPs in vascular cells and in pathways of relevance to cardiovascular diseases.  We also briefly introduce ongoing efforts to develop inhibitors of PTPs, and finally point to some opportunities for use of such agents in novel treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYLeFet4ZcbVg90H21EOLACvtfcHk0lhXKmIcNcuSSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsVKmuw%253D%253D&md5=87f37d332a2b6f60fbade9fedb9c7b4c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2004.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2004.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DKappert%26aufirst%3DK.%26aulast%3DPeters%26aufirst%3DK.%2BG.%26aulast%3DB%25C3%25B6hmer%26aufirst%3DF.%2BD.%26aulast%3DOstman%26aufirst%3DA.%26atitle%3DTyrosine%2520phosphatases%2520in%2520vessel%2520wall%2520signaling%26jtitle%3DCardiovasc.%2520Res.%26date%3D2005%26volume%3D65%26spage%3D587%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Bruce, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, P. H.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: Where do we go from here?</span> <span class="citation_source-journal">Cell Commun. Adhes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22017472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsF2ltbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=85-103&author=D.+Bruceauthor=P.+H.+Tan&title=Vascular+endothelial+growth+factor+receptors+and+the+therapeutic+targeting+of+angiogenesis+in+cancer%3A+Where+do+we+go+from+here%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?</span></div><div class="casAuthors">Bruce, David; Tan, Peng H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Communication & Adhesion</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">85-103</span>CODEN:
                <span class="NLM_cas:coden">CCAEBH</span>;
        ISSN:<span class="NLM_cas:issn">1541-9061</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Vascular Endothelial Growth Factor receptors (VEGFRs), the interactions with their ligands and the subsequent signalling pathways are known to play a vital role in tumor angiogenesis.  Initial clin. trials of VEGFR inhibitors were disappointing but over the past decade some therapies have been successfully brought to market.  At present, VEGFR inhibitors appear to be most promising as adjuvants to conventional chemotherapy.  However, several interacting signalling mols. and downstream pathways have recently been shown to interact with VEGFR signalling and provide promising novel targets, such as the platelet-derived growth factor (PDGF), epithelial growth factor (EGF), human epithelial receptor-2, (HER-2) Tie-2 and estrogen receptors.  Elucidation of this web of signalling pathways may identify new therapeutic strategies which may be used in combination with VEGFR inhibitors to augment the efficacy of anti-angiogenic cancer treatments.  This review assesses the role of modulating VEGFR activity in cancer and systematically examines current evidence and trials in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS2hGQkpX8wbVg90H21EOLACvtfcHk0liMwNS0TNaQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsF2ltbnE&md5=e1e997c8fdb55c025ff5d5bb4afd72cb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DP.%2BH.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptors%2520and%2520the%2520therapeutic%2520targeting%2520of%2520angiogenesis%2520in%2520cancer%253A%2520Where%2520do%2520we%2520go%2520from%2520here%253F%26jtitle%3DCell%2520Commun.%2520Adhes.%26date%3D2011%26volume%3D18%26spage%3D85%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christinger, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vos, A. M.</span><span> </span><span class="NLM_article-title">Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2FS0092-8674%2800%2980456-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=9393862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1997&pages=695-704&author=C.+Wiesmannauthor=G.+Fuhauthor=H.+W.+Christingerauthor=C.+Eigenbrotauthor=J.+A.+Wellsauthor=A.+M.+de+Vos&title=Crystal+structure+at+1.7+%C3%85+resolution+of+VEGF+in+complex+with+domain+2+of+the+Flt-1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor</span></div><div class="casAuthors">Wiesmann, Christian; Fuh, Germaine; Christinger, Hans W.; Eigenbrot, Charles; Wells, James A.; De Vos, Abraham M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-704</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) is a homodimeric hormone that induces proliferation of endothelial cells through binding to the kinase domain receptor and the Fms-like tyrosine kinase receptor (Flt-1), the extracellular portions of which consist of seven Ig domains.  We show that the second and third domains of Flt-1 are necessary and sufficient for binding VEGF with near-native affinity, and that domain 2 alone binds only 60-fold less tightly than wild-type.  The crystal structure of the complex between VEGF and the second domain of Flt-1 shows domain 2 in a predominantly hydrophobic interaction with the "poles" of the VEGF dimer.  Based on this structure and on mutational data, we present a model of VEGF bound to the first four domains of Flt-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZYD3KG--Kg7Vg90H21EOLACvtfcHk0liMwNS0TNaQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWrtr4%253D&md5=0775fe6ced8d68e2db5d2900a2d5c3e4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980456-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980456-0%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DFuh%26aufirst%3DG.%26aulast%3DChristinger%26aufirst%3DH.%2BW.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26atitle%3DCrystal%2520structure%2520at%25201.7%2520%25C3%2585%2520resolution%2520of%2520VEGF%2520in%2520complex%2520with%2520domain%25202%2520of%2520the%2520Flt-1%2520receptor%26jtitle%3DCell%26date%3D1997%26volume%3D91%26spage%3D695%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Maharaj, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saint-Geniez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maldonado, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amore, P. A.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor localization in the adult</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">168</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2353%2Fajpath.2006.050834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16436677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1agu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2006&pages=639-648&author=A.+S.+Maharajauthor=M.+Saint-Geniezauthor=A.+E.+Maldonadoauthor=P.+A.+D%E2%80%99Amore&title=Vascular+endothelial+growth+factor+localization+in+the+adult"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor localization in the adult</span></div><div class="casAuthors">Maharaj, Arindel S. R.; Saint-Geniez, Magali; Maldonado, Angel E.; D'Amore, Patricia A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">639-648</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Although vascular endothelial growth factor (VEGF) has been well studied in both developmental and pathol. angiogenesis, its role in mature blood vessels is poorly understood.  A growing body of observations, including the side effects of anti-VEGF therapies as well as the role of sol. VEGFR1 in preeclampsia, points to an important role for VEGF in maintenance of stable blood vessels.  To better understand the potential function of VEGF in mature vessels, a survey of VEGF localization in adult mice was conducted.  In adult VEGF-lacZ mice, VEGF was expressed in a cell-specific manner by cells overlying fenestrated and sinusoidal blood vessels, including podocytes, choroid plexus epithelium, and hepatocytes, as well as in tissues with high metabolic demands or with secretory functions, such as cardiac and skeletal myocytes, Leydig cells, prostatic epithelium, and salivary serous epithelium.  VEGF was not detected in most endothelium but was specifically expressed by aortic endothelial cells where VEGFR2 was found to be phosphorylated, indicating an autocrine loop.  Addnl., VEGFR2 was constitutively phosphorylated in the liver, lung, adipose, and kidney in vivo, providing evidence consistent with a role for VEGF in adult tissues.  These observations support the concept that VEGF acts in the adult to stabilize mature vessels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnrvmXDoCBbVg90H21EOLACvtfcHk0liMwNS0TNaQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1agu7c%253D&md5=eaab361f5f9a869b528202b7845519dc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2006.050834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2006.050834%26sid%3Dliteratum%253Aachs%26aulast%3DMaharaj%26aufirst%3DA.%2BS.%26aulast%3DSaint-Geniez%26aufirst%3DM.%26aulast%3DMaldonado%26aufirst%3DA.%2BE.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520localization%2520in%2520the%2520adult%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2006%26volume%3D168%26spage%3D639%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Shibuya, M.</span><span> </span><span class="NLM_article-title">Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1177%2F1947601910392987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21779435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFamt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=1119-1123&author=M.+Shibuya&title=Tyrosine+kinase+receptor+Flt%2FVEGFR+family%3A+its+characterization+related+to+angiogenesis+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer</span></div><div class="casAuthors">Shibuya, Masabumi</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ligands and their tyrosine kinase (TK) receptors regulate a variety of biol. systems in animals.  Vascular endothelial growth factor (VEGF) and its receptor (Flt/VEGFR family) system play a crucial role not only in physiol. but also in most parts of pathol. angiogenesis including cancer.  Flt-1/VEGFR-1 and KDR/VEGFR-2 bind VEGF-A but have different functions on angiogenesis at early embryogenesis: Flt-1 has a neg. role by trapping ligands, whereas KDR (Flk1 in mice) exerts a strong pos. signal, resulting in a balance in blood vessel formation.  At adult stages, however, both VEGFRs contribute to pathol. angiogenesis either directly or through stimulation of migration/activation of macrophage lineage cells and stimulate tumor growth, metastasis, and inflammation.  VEGFRs activate downstream signaling of the phospholipase Cγ-protein kinase C-MAP kinase pathway but not Ras pathway for cell proliferation.  The VEGF-C/D and Flt-4/VEGFR-3 system regulates lymphangiogenesis.  Thus, VEGFs as well as these receptor TKs are attractive targets for suppressing pathol. angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0TbJ-wxIJY7Vg90H21EOLACvtfcHk0lh92UK7zUObOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFamt7g%253D&md5=320ffe17a8a3d4d5468d5784e428a8f3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F1947601910392987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601910392987%26sid%3Dliteratum%253Aachs%26aulast%3DShibuya%26aufirst%3DM.%26atitle%3DTyrosine%2520kinase%2520receptor%2520Flt%252FVEGFR%2520family%253A%2520its%2520characterization%2520related%2520to%2520angiogenesis%2520and%2520cancer%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26spage%3D1119%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Rahimi, N.</span><span> </span><span class="NLM_article-title">VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy</span> <span class="citation_source-journal">Front. Biosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2741%2F1839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16146773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=818-829&author=N.+Rahimi&title=VEGFR-1+and+VEGFR-2%3A+two+non-identical+twins+with+a+unique+physiognomy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy</span></div><div class="casAuthors">Rahimi, Nader</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">818-829</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Angiogenesis involves endothelial cell differentiation, proliferation, migration and cord formation, which lead to tubulogenesis to form vessels.  One group of growth factor receptors implicated in angiogenesis is the VEGFR family of receptor tyrosine kinases.  VEGFR-1 and VEGFR-2 are closely related receptor tyrosine kinases and have both common and specific ligands.  VEGFR-1 is a kinase-impaired RTK whereas VEGFR-2 is a highly active kinase.  Despite their differential kinase activation potentials, both VEGFR-1 and VEGFR-2 are required for normal development and angiogenesis.  VEGFR-1 regulates angiogenesis by mechanisms that involve ligand-trapping, receptor homo- and heterodimerization.  VEGFR-2 stimulates variety of signaling pathways and broad biol. responses in vitro.  The mechanisms that govern VEGFR-2 activation, its ability to recruit signaling proteins and to undergo downregulation are highly regulated by its carboxyl terminus.  This review highlights recent insights into the mechanism of activation of VEGFR-1 and VEGFR-2, and focuses on the signaling pathways employed by VEGFR-1 and VEGFR-2 that regulate angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxIaYxenHinbVg90H21EOLACvtfcHk0lh92UK7zUObOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrurnN&md5=36552ed71bde50aa5e04a7180e6101d7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2741%2F1839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F1839%26sid%3Dliteratum%253Aachs%26aulast%3DRahimi%26aufirst%3DN.%26atitle%3DVEGFR-1%2520and%2520VEGFR-2%253A%2520two%2520non-identical%2520twins%2520with%2520a%2520unique%2520physiognomy%26jtitle%3DFront.%2520Biosci.%26date%3D2006%26volume%3D11%26spage%3D818%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moons, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Compernolle, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Mol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Palma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewerchin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalmans, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandendriessche, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponten, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foidart, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaper, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charnock Jones, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persico, M. G.</span><span> </span><span class="NLM_article-title">Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2F87904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=11329059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVakurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=575-583&author=P.+Carmelietauthor=L.+Moonsauthor=A.+Luttunauthor=V.+Vincentiauthor=V.+Compernolleauthor=M.+De+Molauthor=Y.+Wuauthor=F.+Bonoauthor=L.+Devyauthor=H.+Beckauthor=D.+Scholzauthor=T.+Ackerauthor=T.+Di+Palmaauthor=M.+Dewerchinauthor=A.+Noelauthor=I.+Stalmansauthor=A.+Barraauthor=S.+Blacherauthor=T.+Vandendriesscheauthor=A.+Pontenauthor=U.+Erikssonauthor=K.+H.+Plateauthor=J.+M.+Foidartauthor=W.+Schaperauthor=D.+S.+Charnock+Jonesauthor=D.+J.+Hicklinauthor=J.+M.+Herbertauthor=D.+Collenauthor=M.+G.+Persico&title=Synergism+between+vascular+endothelial+growth+factor+and+placental+growth+factor+contributes+to+angiogenesis+and+plasma+extravasation+in+pathological+conditions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions</span></div><div class="casAuthors">Carmeliet, Peter; Moons, Lieve; Luttun, Aernout; Vincenti, Valeria; Compernolle, Veerle; De Mol, Maria; Wu, Yan; Bono, Francoise; Devy, Laetitia; Beck, Heike; Scholz, Dimitri; Acker, Till; DiPalma, Tina; Dewerchin, Mieke; Noel, Agnes; Stalmans, Ingeborg; Barra, Adriano; Blacher, Sylvia; Vandendriessche, Thierry; Ponten, Annica; Eriksson, Ulf; Plate, Karl H.; Foidart, Jean-Michel; Schaper, Wolfgang; Charnock-Jones, D. Stephen; Hicklin, Daniel J.; Herbert, Jean-Marc; Collen, Desire; Persico, M. Graziella</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">575-583</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating VEGF receptor-2 (VEGFR-2).  The role of its homolog, placental growth factor (PIGF), remains unknown.  Both VEGF and PIGF bind to VEGF receptor-1 (VEGFR-1), but it is unknown whether VEGFR-1, which exists as a sol. or a membrane-bound type, is an inert decoy or a signaling receptor for PIGF during angiogenesis.  Here, we report that embryonic angiogenesis in mice was not affected by deficiency of PIGF (Pgf-/-).  VEGF-B, another ligand of VEGFR-1, did not rescue development in Pgf-/- mice.  However, loss of PIGF impaired angiogenesis, plasma extravasation and collateral growth during ischemia, inflammation, wound healing and cancer.  Transplantation of wild-type bone marrow rescued the impaired angiogenesis and collateral growth in Pgf-/- mice, indicating that PIGF might have contributed to vessel growth in the adult by mobilizing bone-marrow-derived cells.  The synergism between PIGF and VEGF was specific, as PIGF deficiency impaired the response to VEGF, but not to bFGF or histamine.  VEGFR-1 was activated by PIGF, given that anti-VEGFR-1 antibodies and a Src-kinase inhibitor blocked the endothelial response to PIGF or VEGF/PIGF.  By upregulating PIGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the "angiogenic switch" in many pathol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsnFRJnUk7e7Vg90H21EOLACvtfcHk0lh92UK7zUObOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVakurc%253D&md5=ae49f22810ca45ba84f02a8238d7b5a4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2F87904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F87904%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DMoons%26aufirst%3DL.%26aulast%3DLuttun%26aufirst%3DA.%26aulast%3DVincenti%26aufirst%3DV.%26aulast%3DCompernolle%26aufirst%3DV.%26aulast%3DDe%2BMol%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DDevy%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DH.%26aulast%3DScholz%26aufirst%3DD.%26aulast%3DAcker%26aufirst%3DT.%26aulast%3DDi%2BPalma%26aufirst%3DT.%26aulast%3DDewerchin%26aufirst%3DM.%26aulast%3DNoel%26aufirst%3DA.%26aulast%3DStalmans%26aufirst%3DI.%26aulast%3DBarra%26aufirst%3DA.%26aulast%3DBlacher%26aufirst%3DS.%26aulast%3DVandendriessche%26aufirst%3DT.%26aulast%3DPonten%26aufirst%3DA.%26aulast%3DEriksson%26aufirst%3DU.%26aulast%3DPlate%26aufirst%3DK.%2BH.%26aulast%3DFoidart%26aufirst%3DJ.%2BM.%26aulast%3DSchaper%26aufirst%3DW.%26aulast%3DCharnock%2BJones%26aufirst%3DD.%2BS.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DCollen%26aufirst%3DD.%26aulast%3DPersico%26aufirst%3DM.%2BG.%26atitle%3DSynergism%2520between%2520vascular%2520endothelial%2520growth%2520factor%2520and%2520placental%2520growth%2520factor%2520contributes%2520to%2520angiogenesis%2520and%2520plasma%2520extravasation%2520in%2520pathological%2520conditions%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D575%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egashira, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiasa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishibashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeshita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunagawa, K.</span><span> </span><span class="NLM_article-title">Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury</span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2284</span><span class="NLM_x">–</span> <span class="NLM_lpage">2289</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1161%2F01.ATV.0000147161.42956.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=15472126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVaisrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=2284-2289&author=Q.+Zhaoauthor=K.+Egashiraauthor=K.+Hiasaauthor=M.+Ishibashiauthor=S.+Inoueauthor=K.+Ohtaniauthor=C.+Tanauthor=M.+Shibuyaauthor=A.+Takeshitaauthor=K.+Sunagawa&title=Essential+role+of+vascular+endothelial+growth+factor+and+Flt-1+signals+in+neointimal+formation+after+periadventitial+injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of vascular endothelial growth factor and Flt-1 Signals in neointimal formation after periadventitial injury</span></div><div class="casAuthors">Zhao, Qingwei; Egashira, Kensuke; Hiasa, Ken-ichi; Ishibashi, Minako; Inoue, Shujiro; Ohtani, Kisho; Tan, Chunyan; Shibuya, Masabumi; Takeshita, Akira; Sunagawa, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2284-2289</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) is upregulated after arterial injury.  Its role in the pathogenesis of neointimal formation after periadventitial injury, however, has not been addressed.  Expression of VEGF and its receptors but not that of placental growth factor markedly increased with the development of neointimal formation in hypercholesterolemic mice after cuff-induced periarterial injury.  Transfection with the murine sol. Flt-1 (sFlt-1) gene to block VEGF in vivo in mice inhibited early inflammation and later neointimal formation.  The sFlt-1 gene transfer did not affect plasma lipid levels but attenuated increased expression of VEGF, Flt-1, Flk-1, monocyte chemoattractant protein-1, and other inflammation-promoting factors.  Mice with Flt-1 kinase deficiency also displayed reduced neointimal formation.  Thus, inflammatory changes mediated by VEGF and Flt-1 signals play an important role in the pathogenesis of neointimal formation after cuff-induced periadventitial injury.  VEGF might promote neointimal formation by acting as a proinflammatory cytokine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuWZSmJhFVALVg90H21EOLACvtfcHk0lj2uhE5Vtv7jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVaisrvM&md5=8a48242d9808c10de0cab0e775048067</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1161%2F01.ATV.0000147161.42956.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.ATV.0000147161.42956.80%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DEgashira%26aufirst%3DK.%26aulast%3DHiasa%26aufirst%3DK.%26aulast%3DIshibashi%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DOhtani%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DSunagawa%26aufirst%3DK.%26atitle%3DEssential%2520role%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520and%2520Flt-1%2520signals%2520in%2520neointimal%2520formation%2520after%2520periadventitial%2520injury%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D2284%26epage%3D2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Jackson, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckford, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricciardelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsfall, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tilley, W. D.</span><span> </span><span class="NLM_article-title">A potential autocrine role for vascular endothelial growth factor in prostate cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">854</span><span class="NLM_x">–</span> <span class="NLM_lpage">859</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=854-859&author=M.+W.+Jacksonauthor=J.+S.+Robertsauthor=S.+E.+Heckfordauthor=C.+Ricciardelliauthor=J.+Stahlauthor=C.+Choongauthor=D.+J.+Horsfallauthor=W.+D.+Tilley&title=A+potential+autocrine+role+for+vascular+endothelial+growth+factor+in+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DM.%2BW.%26aulast%3DRoberts%26aufirst%3DJ.%2BS.%26aulast%3DHeckford%26aufirst%3DS.%2BE.%26aulast%3DRicciardelli%26aufirst%3DC.%26aulast%3DStahl%26aufirst%3DJ.%26aulast%3DChoong%26aufirst%3DC.%26aulast%3DHorsfall%26aufirst%3DD.%2BJ.%26aulast%3DTilley%26aufirst%3DW.%2BD.%26atitle%3DA%2520potential%2520autocrine%2520role%2520for%2520vascular%2520endothelial%2520growth%2520factor%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D854%26epage%3D859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Yang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camp, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somcio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L. M.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=46-51&author=A.+D.+Yangauthor=E.+R.+Campauthor=F.+Fanauthor=L.+Shenauthor=M.+J.+Grayauthor=W.+Liuauthor=R.+Somcioauthor=T.+W.+Bauerauthor=Y.+Wuauthor=D.+J.+Hicklinauthor=L.+M.+Ellis&title=Vascular+endothelial+growth+factor+receptor-1+activation+mediates+epithelial+to+mesenchymal+transition+in+human+pancreatic+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DA.%2BD.%26aulast%3DCamp%26aufirst%3DE.%2BR.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSomcio%26aufirst%3DR.%26aulast%3DBauer%26aufirst%3DT.%2BW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DEllis%26aufirst%3DL.%2BM.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-1%2520activation%2520mediates%2520epithelial%2520to%2520mesenchymal%2520transition%2520in%2520human%2520pancreatic%2520carcinoma%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D46%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Frank, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schatton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saab, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osherov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widlund, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waaga-Gasser, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupper, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, M. H.</span><span> </span><span class="NLM_article-title">VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1474</span><span class="NLM_x">–</span> <span class="NLM_lpage">1485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1474-1485&author=N.+Y.+Frankauthor=T.+Schattonauthor=S.+Kimauthor=Q.+Zhanauthor=B.+J.+Wilsonauthor=J.+Maauthor=K.+R.+Saabauthor=V.+Osherovauthor=H.+R.+Widlundauthor=M.+Gasserauthor=A.+M.+Waaga-Gasserauthor=T.+S.+Kupperauthor=G.+F.+Murphyauthor=M.+H.+Frank&title=VEGFR-1+expressed+by+malignant+melanoma-initiating+cells+is+required+for+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DN.%2BY.%26aulast%3DSchatton%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DQ.%26aulast%3DWilson%26aufirst%3DB.%2BJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DSaab%26aufirst%3DK.%2BR.%26aulast%3DOsherov%26aufirst%3DV.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26aulast%3DGasser%26aufirst%3DM.%26aulast%3DWaaga-Gasser%26aufirst%3DA.%2BM.%26aulast%3DKupper%26aufirst%3DT.%2BS.%26aulast%3DMurphy%26aufirst%3DG.%2BF.%26aulast%3DFrank%26aufirst%3DM.%2BH.%26atitle%3DVEGFR-1%2520expressed%2520by%2520malignant%2520melanoma-initiating%2520cells%2520is%2520required%2520for%2520tumor%2520growth%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1474%26epage%3D1485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Roybal, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thilaganathan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saintigny, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurie, J. M.</span><span> </span><span class="NLM_article-title">miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1</span> <span class="citation_source-journal">Mol Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1541-7786.MCR-10-0497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21115742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=25-35&author=J.+D.+Roybalauthor=Y.+Zangauthor=Y.+H.+Ahnauthor=Y.+Yangauthor=D.+L.+Gibbonsauthor=B.+N.+Bairdauthor=C.+Alvarezauthor=N.+Thilaganathanauthor=D.+D.+Liuauthor=P.+Saintignyauthor=J.+V.+Heymachauthor=C.+J.+Creightonauthor=J.+M.+Kurie&title=miR-200+Inhibits+lung+adenocarcinoma+cell+invasion+and+metastasis+by+targeting+Flt1%2FVEGFR1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1</span></div><div class="casAuthors">Roybal, Jonathon D.; Zang, Yi; Ahn, Young-Ho; Yang, Yanan; Gibbons, Don L.; Baird, Brandi N.; Alvarez, Cristina; Thilaganathan, Nishan; Liu, Diane D.; Saintigny, Pierre; Heymach, John V.; Creighton, Chad J.; Kurie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-35</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The microRNA-200 (miR-200) family is part of a gene expression signature that predicts poor prognosis in lung cancer patients.  In a mouse model of K-ras/p53-mutant lung adenocarcinoma, miR-200 levels are suppressed in metastasis-prone tumor cells, and forced miR-200 expression inhibits tumor growth and metastasis, but the miR-200 target genes that drive lung tumorigenesis have not been fully elucidated.  Here, we scanned the genome for putative miR-200 binding sites and found them in the 3'-untranslated region (3'-UTR) of 35 genes that are amplified in human cancer.  Mining of a database of resected human lung adenocarcinomas revealed that the levels of one of these genes, Flt1/VEGFR1, correlate inversely with duration of survival.  Forced miR-200 expression suppressed Flt1 levels in metastasis-prone lung adenocarcinoma cells derived from K-ras/p53-mutant mice, and neg. regulated the Flt1 3'-UTR in reporter assays.  Cancer-assocd. fibroblasts (CAFs) isolated from murine lung adenocarcinomas secreted abundant VEGF and enhanced tumor cell invasion in coculture studies.  CAF-induced tumor cell invasion was abrogated by VEGF neutralization or Flt1 knockdown in tumor cells.  Flt1 knockdown decreased the growth and metastasis of tumor cells in syngeneic mice.  We conclude that miR-200 suppresses lung tumorigenesis by targeting Flt1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_JXl7KJozGbVg90H21EOLACvtfcHk0lgAxbchUib36Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGruw%253D%253D&md5=d7400afc42a03a43f016a583c8cd50e2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-10-0497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-10-0497%26sid%3Dliteratum%253Aachs%26aulast%3DRoybal%26aufirst%3DJ.%2BD.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DY.%2BH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DBaird%26aufirst%3DB.%2BN.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DThilaganathan%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DD.%2BD.%26aulast%3DSaintigny%26aufirst%3DP.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DKurie%26aufirst%3DJ.%2BM.%26atitle%3DmiR-200%2520Inhibits%2520lung%2520adenocarcinoma%2520cell%2520invasion%2520and%2520metastasis%2520by%2520targeting%2520Flt1%252FVEGFR1%26jtitle%3DMol%2520Cancer%2520Res.%26date%3D2011%26volume%3D9%26spage%3D25%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Kaplan, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riba, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharoulis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bramley, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shido, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Port, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altorki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Port, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shmelkov, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyden, D.</span><span> </span><span class="NLM_article-title">VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">820</span><span class="NLM_x">–</span> <span class="NLM_lpage">827</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=820-827&author=R.+N.+Kaplanauthor=R.+D.+Ribaauthor=S.+Zacharoulisauthor=A.+H.+Bramleyauthor=L.+Vincentauthor=C.+Costaauthor=D.+D.+MacDonaldauthor=D.+K.+Jinauthor=K.+Shidoauthor=S.+A.+Kernsauthor=Z.+Zhuauthor=D.+Hicklinauthor=Y.+Wuauthor=J.+L.+Portauthor=N.+Altorkiauthor=E.+R.+Portauthor=D.+Ruggeroauthor=S.+V.+Shmelkovauthor=K.+K.+Jensenauthor=S.+Rafiiauthor=D.+Lyden&title=VEGFR1-positive+haematopoietic+bone+marrow+progenitors+initiate+the+pre-metastatic+niche"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaplan%26aufirst%3DR.%2BN.%26aulast%3DRiba%26aufirst%3DR.%2BD.%26aulast%3DZacharoulis%26aufirst%3DS.%26aulast%3DBramley%26aufirst%3DA.%2BH.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DMacDonald%26aufirst%3DD.%2BD.%26aulast%3DJin%26aufirst%3DD.%2BK.%26aulast%3DShido%26aufirst%3DK.%26aulast%3DKerns%26aufirst%3DS.%2BA.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DPort%26aufirst%3DJ.%2BL.%26aulast%3DAltorki%26aufirst%3DN.%26aulast%3DPort%26aufirst%3DE.%2BR.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DShmelkov%26aufirst%3DS.%2BV.%26aulast%3DJensen%26aufirst%3DK.%2BK.%26aulast%3DRafii%26aufirst%3DS.%26aulast%3DLyden%26aufirst%3DD.%26atitle%3DVEGFR1-positive%2520haematopoietic%2520bone%2520marrow%2520progenitors%2520initiate%2520the%2520pre-metastatic%2520niche%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D820%26epage%3D827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Premetastatic lung “niche”: Is vascular endothelial growth factor receptor 1 activation required?</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">5670</span><span class="NLM_x">–</span> <span class="NLM_lpage">5673</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=5670-5673&author=D.+G.+Dudaauthor=R.+K.+Jain&title=Premetastatic+lung+%E2%80%9Cniche%E2%80%9D%3A+Is+vascular+endothelial+growth+factor+receptor+1+activation+required%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DPremetastatic%2520lung%2520%25E2%2580%259Cniche%25E2%2580%259D%253A%2520Is%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25201%2520activation%2520required%253F%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D5670%26epage%3D5673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Wu, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanini, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mac Gabhann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontos, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annex, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popel, A. S.</span><span> </span><span class="NLM_article-title">A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use</span> <span class="citation_source-journal">J. Cell. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19840194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1yktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=528-552&author=F.+T.+Wuauthor=M.+O.+Stefaniniauthor=F.+Mac+Gabhannauthor=C.+D.+Kontosauthor=B.+H.+Annexauthor=A.+S.+Popel&title=A+systems+biology+perspective+on+sVEGFR1%3A+its+biological+function%2C+pathogenic+role+and+therapeutic+use"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use</span></div><div class="casAuthors">Wu, Florence T. H.; Stefanini, Marianne O.; MacGabhann, Feilim; Kontos, Christopher D.; Annex, Brian H.; Popel, Aleksander S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">528-552</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-1838</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is the growth of new capillaries from pre-existent microvasculature.  A wide range of pathol. conditions, from atherosclerosis to cancer, can be attributed to either excessive or deficient angiogenesis.  Central to the physiol. regulation of angiogenesis is the vascular endothelial growth factor (VEGF) system - its ligands and receptors (VEGFRs) are thus prime mol. targets of pro-angiogenic and anti-angiogenic therapies.  Of growing interest as a prognostic marker and therapeutic target in angiogenesis-dependent diseases is sol. VEGF receptor-1 (sVEGFR1, also known as sFlt-1) - a truncated version of the cell membrane-spanning VEGFR1.  For instance, it is known that sVEGFR1 is involved in the endothelial dysfunction characterizing the pregnancy disorder of pre-eclampsia, and sVEGFR1's therapeutic potential as an anti-angiogenic agent is being evaluated in pre-clin. models of cancer.  This mini review begins with an examn. of the protein domain structure and biomol. interactions of sVEGFR1 in relation to the full-length VEGFR1.  A synopsis of known and inferred physiol. and pathol. roles of sVEGFR1 is then given, with emphasis on the utility of computational systems biol. models in deciphering the mol. mechanisms by which sVEGFR1's purported biol. functions occur.  Finally, we present the need for a systems biol. perspective in interpreting circulating VEGF and sVEGFR1 concns. as surrogate markers of angiogenic status in angiogenesis-dependent diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAGxoi9cHujLVg90H21EOLACvtfcHk0lgAxbchUib36Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1yktr4%253D&md5=dc58194306c54f32e12cdc7c55194fe8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.%2BT.%26aulast%3DStefanini%26aufirst%3DM.%2BO.%26aulast%3DMac%2BGabhann%26aufirst%3DF.%26aulast%3DKontos%26aufirst%3DC.%2BD.%26aulast%3DAnnex%26aufirst%3DB.%2BH.%26aulast%3DPopel%26aufirst%3DA.%2BS.%26atitle%3DA%2520systems%2520biology%2520perspective%2520on%2520sVEGFR1%253A%2520its%2520biological%2520function%252C%2520pathogenic%2520role%2520and%2520therapeutic%2520use%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2010%26volume%3D14%26spage%3D528%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kowanetz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor signaling pathways: therapeutic perspective</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">5018</span><span class="NLM_x">–</span> <span class="NLM_lpage">5022</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-06-1520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16951216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XovF2huro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5018-5022&author=M.+Kowanetzauthor=N.+Ferrara&title=Vascular+endothelial+growth+factor+signaling+pathways%3A+therapeutic+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective</span></div><div class="casAuthors">Kowanetz, Marcin; Ferrara, Napoleone</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5018-5022</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The establishment of a vascular supply is one of the earliest and most important events occurring during embryonic development.  Growth and maturation of a functional vascular network are complex and still incompletely understood processes involving orchestrated activation of vascular progenitors in the early stages of embryonic development followed by vasculogenesis and angiogenesis.  These processes require a tightly regulated activation of several growth factors and their receptors.  The role of vascular endothelial growth factors (VEGF) and their receptors has been studied extensively due to their prominent role during blood vessel formation.  Mice deficient in various VEGF ligands or receptors show serious defects in vascular formation and maturation.  Moreover, members of the VEGF family are involved in other significant biol. processes, including lymphangiogenesis, vascular permeability, and hematopoiesis.  Importantly, VEGF is released by tumor cells and induces tumor neovascularization.  It is now well established that the VEGF axis represents an important target for antitumor therapy.  Aberrant VEGF signaling is also a feature of several other pathol. conditions, such as age-related macular degeneration and rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDW6gq9KzrR7Vg90H21EOLACvtfcHk0ljp9eZcvO_IbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovF2huro%253D&md5=6b7523714e6d601ffc9c9b0a8f8edd44</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1520%26sid%3Dliteratum%253Aachs%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520signaling%2520pathways%253A%2520therapeutic%2520perspective%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5018%26epage%3D5022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Wang, F. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barfield, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pua, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishman, D. A.</span><span> </span><span class="NLM_article-title">VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.ygyno.2009.08.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=414-423&author=F.+Q.+Wangauthor=E.+Barfieldauthor=S.+Duttaauthor=T.+Puaauthor=D.+A.+Fishman&title=VEGFR-2+silencing+by+small+interference+RNA+%28siRNA%29+suppresses+LPA-induced+epithelial+ovarian+cancer+%28EOC%29+invasion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2009.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2009.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%2BQ.%26aulast%3DBarfield%26aufirst%3DE.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DPua%26aufirst%3DT.%26aulast%3DFishman%26aufirst%3DD.%2BA.%26atitle%3DVEGFR-2%2520silencing%2520by%2520small%2520interference%2520RNA%2520%2528siRNA%2529%2520suppresses%2520LPA-induced%2520epithelial%2520ovarian%2520cancer%2520%2528EOC%2529%2520invasion%26jtitle%3DGynecol.%2520Oncol.%26date%3D2009%26volume%3D15%26spage%3D414%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Rodríguez-Antona, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero-Conde, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglada-Pérez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelblanco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leskelä, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leandro-García, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Jiménez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letón, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascón, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carralero, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauricio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cigudosa, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matias-Guiu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robledo, M.</span><span> </span><span class="NLM_article-title">Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=7-16&author=C.+Rodr%C3%ADguez-Antonaauthor=J.+Pallaresauthor=C.+Montero-Condeauthor=L.+Inglada-P%C3%A9rezauthor=E.+Castelblancoauthor=I.+Landaauthor=S.+Leskel%C3%A4author=L.+J.+Leandro-Garc%C3%ADaauthor=E.+L%C3%B3pez-Jim%C3%A9nezauthor=R.+Let%C3%B3nauthor=A.+Casc%C3%B3nauthor=E.+Lermaauthor=M.+C.+Martinauthor=M.+C.+Carraleroauthor=D.+Mauricioauthor=J.+C.+Cigudosaauthor=X.+Matias-Guiuauthor=M.+Robledo&title=Overexpression+and+activation+of+EGFR+and+VEGFR2+in+medullary+thyroid+carcinomas+is+related+to+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez-Antona%26aufirst%3DC.%26aulast%3DPallares%26aufirst%3DJ.%26aulast%3DMontero-Conde%26aufirst%3DC.%26aulast%3DInglada-P%25C3%25A9rez%26aufirst%3DL.%26aulast%3DCastelblanco%26aufirst%3DE.%26aulast%3DLanda%26aufirst%3DI.%26aulast%3DLeskel%25C3%25A4%26aufirst%3DS.%26aulast%3DLeandro-Garc%25C3%25ADa%26aufirst%3DL.%2BJ.%26aulast%3DL%25C3%25B3pez-Jim%25C3%25A9nez%26aufirst%3DE.%26aulast%3DLet%25C3%25B3n%26aufirst%3DR.%26aulast%3DCasc%25C3%25B3n%26aufirst%3DA.%26aulast%3DLerma%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DM.%2BC.%26aulast%3DCarralero%26aufirst%3DM.%2BC.%26aulast%3DMauricio%26aufirst%3DD.%26aulast%3DCigudosa%26aufirst%3DJ.%2BC.%26aulast%3DMatias-Guiu%26aufirst%3DX.%26aulast%3DRobledo%26aufirst%3DM.%26atitle%3DOverexpression%2520and%2520activation%2520of%2520EGFR%2520and%2520VEGFR2%2520in%2520medullary%2520thyroid%2520carcinomas%2520is%2520related%2520to%2520metastasis%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2010%26volume%3D17%26spage%3D7%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Graells, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinyals, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llorens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoval, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabra, A.</span><span> </span><span class="NLM_article-title">Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1151</span><span class="NLM_x">–</span> <span class="NLM_lpage">1161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2004&pages=1151-1161&author=J.+Graellsauthor=A.+Vinyalsauthor=A.+Figuerasauthor=A.+Llorensauthor=A.+Morenoauthor=J.+Marcovalauthor=F.+J.+Gonzalezauthor=A.+Fabra&title=Overproduction+of+VEGF+concomitantly+expressed+with+its+receptors+promotes+growth+and+survival+of+melanoma+cells+through+MAPK+and+PI3K+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGraells%26aufirst%3DJ.%26aulast%3DVinyals%26aufirst%3DA.%26aulast%3DFigueras%26aufirst%3DA.%26aulast%3DLlorens%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DA.%26aulast%3DMarcoval%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DF.%2BJ.%26aulast%3DFabra%26aufirst%3DA.%26atitle%3DOverproduction%2520of%2520VEGF%2520concomitantly%2520expressed%2520with%2520its%2520receptors%2520promotes%2520growth%2520and%2520survival%2520of%2520melanoma%2520cells%2520through%2520MAPK%2520and%2520PI3K%2520signaling%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2004%26volume%3D123%26spage%3D1151%26epage%3D1161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Blom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roselli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Häyry, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tynninen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartiovaara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korja, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordfors, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haapasalo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nupponen, N. N.</span><span> </span><span class="NLM_article-title">Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs11060-009-0014-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19779861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFygsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2010&pages=217-224&author=T.+Blomauthor=A.+Roselliauthor=V.+H%C3%A4yryauthor=O.+Tynninenauthor=K.+Wartiovaaraauthor=M.+Korjaauthor=K.+Nordforsauthor=H.+Haapasaloauthor=N.+N.+Nupponen&title=Amplification+and+overexpression+of+KIT%2C+PDGFRA%2C+and+VEGFR2+in+medulloblastomas+and+primitive+neuroectodermal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors</span></div><div class="casAuthors">Blom, Tea; Roselli, Annariikka; Haeyry, Valtteri; Tynninen, Olli; Wartiovaara, Kirmo; Korja, Miikka; Nordfors, Kristiina; Haapasalo, Hannu; Nupponen, Nina N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Medulloblastomas (MB) and primitive neuroectodermal tumors (PNET) are the most common malignant brain tumors in children.  These two tumor types are histol. similar, but have different genetic backgrounds and clin. outcomes.  Other brain tumors, such as gliomas, frequently have coamplification and overexpression of receptor tyrosine kinases KIT, platelet-derived growth factor receptor alpha (PDGFRA), and vascular endothelial growth factor receptor 2 (VEGFR2).  We investigated protein expression and gene copy nos. of KIT, PDGFRA, and VEGFR2 in 41 MB and 11 PNET samples by immunohistochem. (IHC) and chromogenic in situ hybridization (CISH).  KIT and PDGFRA expression was detected in both MBs and PNETs, whereas VEGFR2 expression was weak in these tumors.  KIT, PDGFRA, and VEGFR2 amplifications were all present in 4% of MBs/PNETs, and KIT amplification was assocd. with concurrent PDGFRA and VEGFR2 amplifications (P ≤ 0.001).  Most strikingly, increased gene copy no. of PDGFRA was assocd. with poor overall survival (P = 0.027).  We suggest that coamplification of PDGFRA or VEGFR2 with KIT may be clin. useful novel mol. markers in MBs and PNETs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJe7WLUMZwdLVg90H21EOLACvtfcHk0ljp9eZcvO_IbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFygsLc%253D&md5=4642469bca80265ef2c6f3e5b1bed5ce</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs11060-009-0014-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-009-0014-2%26sid%3Dliteratum%253Aachs%26aulast%3DBlom%26aufirst%3DT.%26aulast%3DRoselli%26aufirst%3DA.%26aulast%3DH%25C3%25A4yry%26aufirst%3DV.%26aulast%3DTynninen%26aufirst%3DO.%26aulast%3DWartiovaara%26aufirst%3DK.%26aulast%3DKorja%26aufirst%3DM.%26aulast%3DNordfors%26aufirst%3DK.%26aulast%3DHaapasalo%26aufirst%3DH.%26aulast%3DNupponen%26aufirst%3DN.%2BN.%26atitle%3DAmplification%2520and%2520overexpression%2520of%2520KIT%252C%2520PDGFRA%252C%2520and%2520VEGFR2%2520in%2520medulloblastomas%2520and%2520primitive%2520neuroectodermal%2520tumors%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2010%26volume%3D97%26spage%3D217%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratcliffe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womack, C.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3548</span><span class="NLM_x">–</span> <span class="NLM_lpage">3561</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-09-2797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20606037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovVansb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3548-3561&author=N.+R.+Smithauthor=D.+Bakerauthor=N.+H.+Jamesauthor=K.+Ratcliffeauthor=M.+Jenkinsauthor=S.+E.+Ashtonauthor=G.+Sproatauthor=R.+Swannauthor=N.+Grayauthor=A.+Ryanauthor=J.+M.+J%C3%BCrgensmeierauthor=C.+Womack&title=Vascular+endothelial+growth+factor+receptors+VEGFR-2+and+VEGFR-3+are+localized+primarily+to+the+vasculature+in+human+primary+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers</span></div><div class="casAuthors">Smith, Neil R.; Baker, Dawn; James, Neil H.; Ratcliffe, Kirsty; Jenkins, Martin; Ashton, Susan E.; Sproat, Graham; Swann, Ruth; Gray, Neil; Ryan, Anderson; Juergensmeier, Juliane M.; Womack, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3548-3561</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Vascular endothelial growth factor (VEGF) signaling is key to tumor angiogenesis and is an important target in the development of anticancer drugs.  However, VEGF receptor (VEGFR) expression in human cancers, particularly the relative expression of VEGFR-2 and VEGFR-3 in tumor vasculature vs. tumor cells, is poorly defined.  Exptl. Design: VEGFR-2- and VEGFR-3-specific antibodies were identified and used in the immunohistochem. anal. of human primary cancers and normal tissue.  The relative vascular localization of both receptors in colorectal and breast cancers was detd. by coimmunofluorescence with vascular markers.  RESULTS: VEGFR-2 and VEGFR-3 were expressed on vascular endothelium but not on malignant cells in 13 common human solid tumor types (n > 400, bladder, breast, colorectal, head and neck, liver, lung, skin, ovarian, pancreatic, prostate, renal, stomach, and thyroid).  The signal intensity of both receptors was significantly greater in vessels assocd. with malignant colorectal, lung, and breast than adjacent nontumor tissue.  In colorectal cancers, VEGFR-2 was expressed on both intratumoral blood and lymphatic vessels, whereas VEGFR-3 was found predominantly on lymphatic vessels.  In breast cancers, both receptors were localized to and upregulated on blood vessels.  CONCLUSIONS: VEGFR-2 and VEGFR-3 are primarily localized to, and significantly upregulated on, tumor vasculature (blood and/or lymphatic) supporting the majority of solid cancers.  The primary clin. mechanism of action of VEGF signaling inhibitors is likely to be through the targeting of tumor vessels rather than tumor cells.  The upregulation of VEGFR-3 on tumor blood vessels indicates a potential addnl. antiangiogenic effect for dual VEGFR-2/VEGFR-3-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHdbIUcIe27Vg90H21EOLACvtfcHk0lgw0LhbU_FtSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovVansb4%253D&md5=8a2b2d865a14202dfd539a74ec700e3f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-2797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-2797%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DRatcliffe%26aufirst%3DK.%26aulast%3DJenkins%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DSproat%26aufirst%3DG.%26aulast%3DSwann%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DA.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DWomack%26aufirst%3DC.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptors%2520VEGFR-2%2520and%2520VEGFR-3%2520are%2520localized%2520primarily%2520to%2520the%2520vasculature%2520in%2520human%2520primary%2520solid%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3548%26epage%3D3561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Mäkinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veikkola, T</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustjoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karpanen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catimel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nice, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerjaschki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stacker, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Achen, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4762</span><span class="NLM_x">–</span> <span class="NLM_lpage">4773</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=4762-4773&author=T.+M%C3%A4kinenauthor=T+Veikkolaauthor=S.+Mustjokiauthor=T.+Karpanenauthor=B.+Catimelauthor=E.+C.+Niceauthor=L.+Wiseauthor=A.+Mercerauthor=H.+Kowalskiauthor=D.+Kerjaschkiauthor=S.+A.+Stackerauthor=M.+G.+Achenauthor=K.+Alitalo&title=Isolated+lymphatic+endothelial+cells+transduce+growth%2C+survival+and+migratory+signals+via+the+VEGF-C%2FD+receptor+VEGFR-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A4kinen%26aufirst%3DT.%26aulast%3DVeikkola%26aufirst%3DT%26aulast%3DMustjoki%26aufirst%3DS.%26aulast%3DKarpanen%26aufirst%3DT.%26aulast%3DCatimel%26aufirst%3DB.%26aulast%3DNice%26aufirst%3DE.%2BC.%26aulast%3DWise%26aufirst%3DL.%26aulast%3DMercer%26aufirst%3DA.%26aulast%3DKowalski%26aufirst%3DH.%26aulast%3DKerjaschki%26aufirst%3DD.%26aulast%3DStacker%26aufirst%3DS.%2BA.%26aulast%3DAchen%26aufirst%3DM.%2BG.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DIsolated%2520lymphatic%2520endothelial%2520cells%2520transduce%2520growth%252C%2520survival%2520and%2520migratory%2520signals%2520via%2520the%2520VEGF-C%252FD%2520receptor%2520VEGFR-3%26jtitle%3DEMBO%2520J.%26date%3D2001%26volume%3D20%26spage%3D4762%26epage%3D4773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Su, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuang, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, M. L.</span><span> </span><span class="NLM_article-title">The role of the VEGF-C/VEGFR-3 axis in cancer progression</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fsj.bjc.6603487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17164762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvV2jsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=541-545&author=J.+L.+Suauthor=C.+J.+Yenauthor=P.+S.+Chenauthor=S.+E.+Chuangauthor=C.+C.+Hongauthor=I.+H.+Kuoauthor=H.+Y.+Chenauthor=M.+C.+Hungauthor=M.+L.+Kuo&title=The+role+of+the+VEGF-C%2FVEGFR-3+axis+in+cancer+progression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the VEGF-C/VEGFR-3 axis in cancer progression</span></div><div class="casAuthors">Su, J.-L.; Yen, C.-J.; Chen, P.-S.; Chuang, S.-E.; Hong, C.-C.; Kuo, I.-H.; Chen, H.-Y.; Hung, M.-C.; Kuo, M.-L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">541-545</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C, which promotes cancer progression.  The VEGF-C/VEGFR-3 axis is expressed not only by lymphatic endothelial cells but also by a variety of human tumor cells.  Activation of the VEGF-C/VEGFR-3 axis in lymphatic endothelial cells can facilitate metastasis by increasing the formation of lymphatic vessels (lymph angiogenesis) within and around tumors.  The VEGF-C/VEGFR-3 axis plays a crit. role in leukemic cell proliferation, survival, and resistance to chemotherapy.  Moreover, activation of the VEGF-C/VEGFR-3 axis in several types of solid tumors enhances cancer cell mobility and invasion capabilities, promoting cancer cell metastasis.  In this review, we discuss the novel function and mol. mechanism of the VEGF-C/VEGFR-3 axis in cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_-GCr7Ijs7Vg90H21EOLACvtfcHk0lgw0LhbU_FtSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvV2jsbg%253D&md5=5e18e8c62f846a218e9275352fbc307f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603487%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DJ.%2BL.%26aulast%3DYen%26aufirst%3DC.%2BJ.%26aulast%3DChen%26aufirst%3DP.%2BS.%26aulast%3DChuang%26aufirst%3DS.%2BE.%26aulast%3DHong%26aufirst%3DC.%2BC.%26aulast%3DKuo%26aufirst%3DI.%2BH.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DKuo%26aufirst%3DM.%2BL.%26atitle%3DThe%2520role%2520of%2520the%2520VEGF-C%252FVEGFR-3%2520axis%2520in%2520cancer%2520progression%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D96%26spage%3D541%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Achen, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stacker, S. A.</span><span> </span><span class="NLM_article-title">Targeting lymphangiogenesis to prevent tumour metastasis</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fsj.bjc.6603120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16641900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=1355-1360&author=M.+G.+Achenauthor=G.+B.+Mannauthor=S.+A.+Stacker&title=Targeting+lymphangiogenesis+to+prevent+tumour+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting lymphangiogenesis to prevent tumour metastasis</span></div><div class="casAuthors">Achen, M. G.; Mann, G. B.; Stacker, S. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1355-1360</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent studies involving animal models of cancer and clinicopathol. analyses of human tumors suggest that the growth of lymphatic vessels (lymphangiogenesis) in or nearby tumors is assocd. with the metastatic spread of cancer.  The best validated mol. signalling system for tumor lymphangiogenesis involves the secreted proteins vascular endothelial growth factor-C (VEGF-C) and VEGF-D that induce growth of lymphatic vessels via activation of VEGF receptor-3 (VEGFR-3) localized on the surface of lymphatic endothelial cells.  In this review, we discuss the evidence supporting a role for this signalling system in the spread of cancer and potential approaches for blocking this system to prevent tumor metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOLXx0f0rdcbVg90H21EOLACvtfcHk0lhh9vgwowckRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKnur0%253D&md5=9e5d3355aec24711990a68992e587c15</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603120%26sid%3Dliteratum%253Aachs%26aulast%3DAchen%26aufirst%3DM.%2BG.%26aulast%3DMann%26aufirst%3DG.%2BB.%26aulast%3DStacker%26aufirst%3DS.%2BA.%26atitle%3DTargeting%2520lymphangiogenesis%2520to%2520prevent%2520tumour%2520metastasis%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D94%26spage%3D1355%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Boyer, S. J.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F1568026023393273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=12171566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVOitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=973-1000&author=S.+J.+Boyer&title=Small+molecule+inhibitors+of+KDR+%28VEGFR-2%29+kinase%3A+an+overview+of+structure+activity+relationships"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships</span></div><div class="casAuthors">Boyer, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">973-1000</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Kinase insert Domain contg. Receptor (KDR), alternatively referred to as VEGFR-2, is a receptor for Vascular Endothelial Growth Factors (VEGFs) and functions as a key regulator of angiogenesis, the process by which new capillaries are created from preexisting blood vessels.  The induction of angiogenesis, or the "angiogenic switch," is a crit. step in tumor progression, and inhibitors of KDR have been demonstrated both to induce tumor regression and reduce metastatic potential in preclin. models.  In the last few years, medicinal chemists have expanded the kinase selectivity profile of known inhibitor classes to include KDR, and also identified novel classes of KDR inhibitors.  This review presents structure activity relationships (SAR) of small mol. inhibitors of KDR, with an emphasis on the pharmacophore elements of the scaffolds employed.  Binding hypotheses based on x-ray crystallog. analyses will also be described.  Addnl., the efficacy of representative compds. in in vitro and in vivo models of tumor progression and angiogenesis are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8iX5xdLgktLVg90H21EOLACvtfcHk0lhh9vgwowckRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVOitbw%253D&md5=4c4445eac589bded1baed3140b918be8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F1568026023393273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026023393273%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DS.%2BJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520KDR%2520%2528VEGFR-2%2529%2520kinase%253A%2520an%2520overview%2520of%2520structure%2520activity%2520relationships%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2002%26volume%3D2%26spage%3D973%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondavalli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Antiangiogenic agents: an update on small molecule VEGFR inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2495</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F092986707782023622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17979703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKqtrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=2495-2516&author=S.+Schenoneauthor=F.+Bondavalliauthor=M.+Botta&title=Antiangiogenic+agents%3A+an+update+on+small+molecule+VEGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic agents: an update on small molecule VEGFR inhibitors</span></div><div class="casAuthors">Schenone, S.; Bondavalli, F.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2495-2516</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels sprouting from pre-existing microvasculature and occurs in limited physiol. conditions or under pathol. situations such as retinopathies, arthritis, endometriosis and cancer.  Blockade of angiogenesis is an attractive approach for the treatment of such diseases.  Particularly in malignancies, antiangiogenic therapy should be less toxic in comparison with conventional treatments such as chemotherapy, as angiogenesis is a process relatively restricted to the growing tumor.  Vascular endothelial growth factor (VEGF) is one of the most important inducers of angiogenesis and exerts its cellular effects mainly by interacting with two high-affinity transmembrane tyrosine kinase receptors: VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1).  It has been proven that inhibition of VEGF receptor activity reduces angiogenesis.  For these reasons, the inhibition of VEGF or its receptor signaling system is an attractive target for therapeutic intervention.  The most studied and developed inhibitors are monoclonal antibodies that neutralize VEGF, ribozymes, and small mol. VEGFR kinase inhibitors.  Many important reviews dealing with VEGF-induced angiogenesis and its inhibition through the block of VEGF receptors have been reported, esp. from a biol. point of view.  Here, we will review small synthetic VEGFR inhibitors that have appeared in literature in the last few years, focusing our attention on their medicinal chem. in terms of chem. structure, mechanisms of action and structure-activity relationships.  In fact, there have been an increased no. of tyrosine kinase inhibitors in the most recent literature reports; their biol. profile is extremely interesting and could be of great importance to medicinal chemists working in this area in improving their efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7o_mKLGN1mLVg90H21EOLACvtfcHk0lhh9vgwowckRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKqtrbN&md5=1cb7ea6cf7867e796f2333e5d304220c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F092986707782023622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707782023622%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBondavalli%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DAntiangiogenic%2520agents%253A%2520an%2520update%2520on%2520small%2520molecule%2520VEGFR%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D2495%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Gille, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidenreich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehme, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henschler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breier, G.</span><span> </span><span class="NLM_article-title">Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation</span> <span class="citation_source-journal">Int. J. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">1899</span><span class="NLM_x">–</span> <span class="NLM_lpage">908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1002%2Fijc.22531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17230507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVCqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2007&pages=1899-908&author=J.+Gilleauthor=R.+Heidenreichauthor=A.+Pinterauthor=J.+Schmitzauthor=B.+Boehmeauthor=D.+J.+Hicklinauthor=R.+Henschlerauthor=G.+Breier&title=Simultaneous+blockade+of+VEGFR-1+and+VEGFR-2+activation+is+necessary+to+efficiently+inhibit+experimental+melanoma+growth+and+metastasis+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation</span></div><div class="casAuthors">Gille, Jens; Heidenreich, Regina; Pinter, Andreas; Schmitz, Judith; Boehme, Beatrice; Hicklin, Daniel J.; Henschler, Reinhard; Breier, Georg</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1899-1908</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Metastasis continues to be the major cause of morbidity and mortality in malignant melanoma.  In our study, we explored whether inhibition of VEGFR-1 or VEGFR-2 signaling conveys distinct suppressive effects on B16 melanoma s.c. growth and metastasis formation.  The inhibition of VEGFR-1 or -2 alone had no significant influence on both melanoma growth and metastasis formation.  In contrast, simultaneous blockade of VEGFR-1 and -2 signaling strongly suppressed progression in both B16 tumor models.  There was no expression of VEGFR-1 or -2 detectable on the B16 cells used, excluding the melanoma cells as direct therapeutic targets.  Analyzing the contribution of progenitor-like cells during melanoma metastasis formation, we obsd. an enhanced proliferation and mobilization of VEGFR-1+ myeloid and VEGFR-2+ endothelial cells with progenitor potential by the induction of melanoma lung metastasis, which was not influenced by interference with VEGFR signaling.  These results indicate that the antimetastatic effects exerted by combined inhibition of VEGFR-1 and -2 signaling were mediated via targeting cell populations other than progenitors only.  Sole inhibition of VEGFR-1 signaling led to a strong redn. of the CD45-pos. inflammatory infiltrate in the tumor tissue.  However, the formation of lung metastasis was not affected, indicating that inhibition of the inflammatory response was not sufficient to efficiently block B16 melanoma metastasis development.  Taken together,these data suggest that in the utilized B16 tumor models the blockade of both the inflammatory and the VEGFR-2-dependent angiogenic response are necessary to effectively inhibit solid tumor growth and formation of lung metastasis by B16 melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1p1K_RkddibVg90H21EOLACvtfcHk0lhh9vgwowckRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVCqsLw%253D&md5=6b304bd8a5792206c910c8bbe1db4445</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fijc.22531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22531%26sid%3Dliteratum%253Aachs%26aulast%3DGille%26aufirst%3DJ.%26aulast%3DHeidenreich%26aufirst%3DR.%26aulast%3DPinter%26aufirst%3DA.%26aulast%3DSchmitz%26aufirst%3DJ.%26aulast%3DBoehme%26aufirst%3DB.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DHenschler%26aufirst%3DR.%26aulast%3DBreier%26aufirst%3DG.%26atitle%3DSimultaneous%2520blockade%2520of%2520VEGFR-1%2520and%2520VEGFR-2%2520activation%2520is%2520necessary%2520to%2520efficiently%2520inhibit%2520experimental%2520melanoma%2520growth%2520and%2520metastasis%2520formation%26jtitle%3DInt.%2520J.%2520Cancer.%26date%3D2007%26volume%3D120%26spage%3D1899%26epage%3D908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">Clinical applications of angiogenic growth factors and their inhibitors</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2F70928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=10581076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADyaK1MXnvFCqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=1359-1364&author=N.+Ferraraauthor=K.+Alitalo&title=Clinical+applications+of+angiogenic+growth+factors+and+their+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical applications of angiogenic growth factors and their inhibitors</span></div><div class="casAuthors">Ferrara, Napoleone; Alitalo, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1359-1364</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">A review with 97 refs. is given on promoting the formation of new collateral vessels in ischemic tissues (therapeutic angiogenesis) using angiogenic factors like vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) and inhibition of key regulators of angiogenesis as an approach for the treatment of solid tumors and intraocular neovascular syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-M0EbeAZm8LVg90H21EOLACvtfcHk0lggrDAqWy_JwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnvFCqtrw%253D&md5=2c16b63492d564151b64a8a75151cbe3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2F70928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F70928%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DClinical%2520applications%2520of%2520angiogenic%2520growth%2520factors%2520and%2520their%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D1999%26volume%3D5%26spage%3D1359%26epage%3D1364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Kanda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanetake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smithgall, T. E.</span><span> </span><span class="NLM_article-title">Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17549397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1KqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=113-121&author=S.+Kandaauthor=Y.+Miyataauthor=H.+Kanetakeauthor=T.+E.+Smithgall&title=Non-receptor+protein-tyrosine+kinases+as+molecular+targets+for+antiangiogenic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review)</span></div><div class="casAuthors">Kanda, Shigeru; Miyata, Yasuyoshi; Kanetake, Hiroshi; Smithgall, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-121</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Molecular Medicine</span>)
        </div><div class="casAbstract">A review.  Antiangiogenic therapy, including blockade of vascular endothelial growth factor (VEGF) signaling, was highly anticipated to improve the prognosis for patients with advanced cancers following the success of preclin. animal models.  However, antiangiogenic monotherapy with VEGF antagonists has produced disappointing results in clin. trials to date.  One of the reasons for this poor outcome is that angiogenesis is not solely regulated by VEGF.  Inhibition of VEGF signaling, therefore, may select for tumor cell populations that stimulate angiogenesis through VEGF-independent pathways.  Successful antiangiogenic therapy, therefore, may require simultaneous blockade of signaling downstream from multiple proangiogenic factor receptors.  Recently, we found that non-receptor protein-tyrosine kinases, including members of the Src and Fes families, play vital roles in the responses of cultured endothelial cells to several proangiogenic factors.  In this review, we summarize the contributions of these kinase families to angiogenic pathways in endothelial cells, and discuss the potential of these kinases as new targets for antiangiogenic drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpljqPGMyZFIrVg90H21EOLACvtfcHk0lggrDAqWy_JwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1KqtLo%253D&md5=a223598e45fe1982b33886d630432c36</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DS.%26aulast%3DMiyata%26aufirst%3DY.%26aulast%3DKanetake%26aufirst%3DH.%26aulast%3DSmithgall%26aufirst%3DT.%2BE.%26atitle%3DNon-receptor%2520protein-tyrosine%2520kinases%2520as%2520molecular%2520targets%2520for%2520antiangiogenic%2520therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2007%26volume%3D20%26spage%3D113%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Casanovas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span> </span><span class="NLM_article-title">Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=299-309&author=O.+Casanovasauthor=D.+J.+Hicklinauthor=G.+Bergersauthor=D.+Hanahan&title=Drug+resistance+by+evasion+of+antiangiogenic+targeting+of+VEGF+signaling+in+late-stage+pancreatic+islet+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasanovas%26aufirst%3DO.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBergers%26aufirst%3DG.%26aulast%3DHanahan%26aufirst%3DD.%26atitle%3DDrug%2520resistance%2520by%2520evasion%2520of%2520antiangiogenic%2520targeting%2520of%2520VEGF%2520signaling%2520in%2520late-stage%2520pancreatic%2520islet%2520tumors%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D299%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Shibuya, M.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis</span> <span class="citation_source-journal">BMB Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.5483%2FBMBRep.2008.41.4.278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18452647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFelsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=278-286&author=M.+Shibuya&title=Vascular+endothelial+growth+factor-dependent+and+-independent+regulation+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis</span></div><div class="casAuthors">Shibuya, Masabumi</div><div class="citationInfo"><span class="NLM_cas:title">BMB Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">278-286</span>CODEN:
                <span class="NLM_cas:coden">BRMEC2</span>;
        ISSN:<span class="NLM_cas:issn">1976-6696</span>.
    
            (<span class="NLM_cas:orgname">Korean Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review on the roles of VEGF and VEGFRs for formation, maintenance, and pathol. of blood vessels, the clin. application of VEGF-VEGFR inhibitors to treat cancer and macular degeneration, the adverse effects of and resistance to VEGF-VEGFR inhibitors.  The author also discussed VEGF-independent regulation of angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnudmVpbvuMbVg90H21EOLACvtfcHk0lggrDAqWy_JwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFelsL0%253D&md5=691e39eebfae3534a2a9772816cb392a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.5483%2FBMBRep.2008.41.4.278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5483%252FBMBRep.2008.41.4.278%26sid%3Dliteratum%253Aachs%26aulast%3DShibuya%26aufirst%3DM.%26atitle%3DVascular%2520endothelial%2520growth%2520factor-dependent%2520and%2520-independent%2520regulation%2520of%2520angiogenesis%26jtitle%3DBMB%2520Rep.%26date%3D2008%26volume%3D41%26spage%3D278%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyhack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1697</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=17-27&author=P.+W.+Manleyauthor=G.+Boldauthor=J.+Bruggenauthor=G.+Fendrichauthor=P.+Furetauthor=J.+Mestanauthor=C.+Schnellauthor=B.+Stolzauthor=T.+Meyerauthor=B.+Meyhackauthor=W.+Starkauthor=A.+Straussauthor=J.+Wood&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+VEGF-R+kinase+inhibitors+for+the+treatment+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DStolz%26aufirst%3DB.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DMeyhack%26aufirst%3DB.%26aulast%3DStark%26aufirst%3DW.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520VEGF-R%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520angiogenesis%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2004%26volume%3D1697%26spage%3D17%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrd3455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21629292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvVegurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=417-427&author=P.+Carmelietauthor=R.+K.+Jain&title=Principles+and+mechanisms+of+vessel+normalization+for+cancer+and+other+angiogenic+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases</span></div><div class="casAuthors">Carmeliet, Peter; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417-427</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite having an abundant no. of vessels, tumors are usually hypoxic and nutrient-deprived because their vessels malfunction.  Such abnormal milieu can fuel disease progression and resistance to treatment.  Traditional anti-angiogenesis strategies attempt to reduce the tumor vascular supply, but their success is restricted by insufficient efficacy or development of resistance.  Preclin. and initial clin. evidence reveal that normalization of the vascular abnormalities is emerging as a complementary therapeutic paradigm for cancer and other vascular disorders, which affect more than half a billion people worldwide.  Here, we discuss the mechanisms, benefits, limitations and possible clin. translation of vessel normalization for cancer and other angiogenic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodLcTmRH7e2bVg90H21EOLACvtfcHk0lgPvbv4chNUWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvVegurs%253D&md5=e32f1e9d69ff314d20af6bdcca745981</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrd3455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3455%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DPrinciples%2520and%2520mechanisms%2520of%2520vessel%2520normalization%2520for%2520cancer%2520and%2520other%2520angiogenic%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D417%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Rosen, L. S.</span><span> </span><span class="NLM_article-title">VEGF-targeted therapy: therapeutic potential and recent advances</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">382</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=382-391&author=L.+S.+Rosen&title=VEGF-targeted+therapy%3A+therapeutic+potential+and+recent+advances"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DL.%2BS.%26atitle%3DVEGF-targeted%2520therapy%253A%2520therapeutic%2520potential%2520and%2520recent%2520advances%26jtitle%3DOncologist%26date%3D2005%26volume%3D10%26spage%3D382%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Van der Veldt, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubberink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walraven, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Boer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greuter, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrikse, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windhorst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postmus, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheul, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serné, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammertsma, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span> </span><span class="NLM_article-title">Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=82-91&author=A.+A.+Van+der+Veldtauthor=M.+Lubberinkauthor=I.+Bahceauthor=M.+Walravenauthor=M.+P.+de+Boerauthor=H.+N.+Greuterauthor=N.+H.+Hendrikseauthor=J.+Erikssonauthor=A.+D.+Windhorstauthor=P.+E.+Postmusauthor=H.+M.+Verheulauthor=E.+H.+Sern%C3%A9author=A.+A.+Lammertsmaauthor=E.+F.+Smit&title=Rapid+decrease+in+delivery+of+chemotherapy+to+tumors+after+anti-VEGF+therapy%3A+implications+for+scheduling+of+anti-angiogenic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BVeldt%26aufirst%3DA.%2BA.%26aulast%3DLubberink%26aufirst%3DM.%26aulast%3DBahce%26aufirst%3DI.%26aulast%3DWalraven%26aufirst%3DM.%26aulast%3Dde%2BBoer%26aufirst%3DM.%2BP.%26aulast%3DGreuter%26aufirst%3DH.%2BN.%26aulast%3DHendrikse%26aufirst%3DN.%2BH.%26aulast%3DEriksson%26aufirst%3DJ.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3DVerheul%26aufirst%3DH.%2BM.%26aulast%3DSern%25C3%25A9%26aufirst%3DE.%2BH.%26aulast%3DLammertsma%26aufirst%3DA.%2BA.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26atitle%3DRapid%2520decrease%2520in%2520delivery%2520of%2520chemotherapy%2520to%2520tumors%2520after%2520anti-VEGF%2520therapy%253A%2520implications%2520for%2520scheduling%2520of%2520anti-angiogenic%2520drugs%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D82%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Antiangiogenic therapy: a universal chemosensitization strategy for cancer?</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1175</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2006&pages=1171-1175&author=R.+S.+Kerbel&title=Antiangiogenic+therapy%3A+a+universal+chemosensitization+strategy+for+cancer%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DAntiangiogenic%2520therapy%253A%2520a%2520universal%2520chemosensitization%2520strategy%2520for%2520cancer%253F%26jtitle%3DScience%26date%3D2006%26volume%3D312%26spage%3D1171%26epage%3D1175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Kerbel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Clinical translation of angiogenesis inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrc905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=12360276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVGrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=727-739&author=R.+Kerbelauthor=J.+Folkman&title=Clinical+translation+of+angiogenesis+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical translation of angiogenesis inhibitors</span></div><div class="casAuthors">Kerbel, Robert; Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">727-739</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply.  The successful translation of angiogenesis inhibitors to clin. application depends partly on the transfer of expertise from scientists who are familiar with the biol. of angiogenesis to clinicians.  What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDKNdHthr-NrVg90H21EOLACvtfcHk0lgPvbv4chNUWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVGrtb0%253D&md5=db07af200e8842cc5a66a1bb41c6cd57</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrc905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc905%26sid%3Dliteratum%253Aachs%26aulast%3DKerbel%26aufirst%3DR.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DClinical%2520translation%2520of%2520angiogenesis%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D727%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1220</span><span class="NLM_x">–</span> <span class="NLM_lpage">1245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F092986710790936310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20166937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFeht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1220-1245&author=S.+Schenoneauthor=C.+Brulloauthor=M.+Botta&title=New+opportunities+to+treat+the+T315I-Bcr-Abl+mutant+in+chronic+myeloid+leukaemia%3A+tyrosine+kinase+inhibitors+and+molecules+that+act+by+alternative+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms</span></div><div class="casAuthors">Schenone, S.; Brullo, C.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1220-1245</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Resistance to the Bcr-Abl inhibitors approved for the treatment of chronic myeloid leukemia (CML) may arise from different mechanisms, including Bcr-Abl amino acid mutations, gene amplification and mechanisms independent of Bcr-Abl.  The T315I mutation at the gatekeeper residue is very frequent in advanced phases of the disease and is one of the main causes of resistance, disrupting important contact points between the inhibitors and the enzyme.  Different strategies have been implemented to overcome this resistance, including the synthesis of new Bcr-Abl ATP-competitive or non-ATP-competitive inhibitors, dual Aurora/Bcr-Abl inhibitors and multi-targeted kinase inhibitors.  An alternative approach is the use of other compds. that do not bind directly to the Bcr-Abl protein; instead, these mols. act on several downstream pathways, regulated by or linked in different ways to Bcr-Abl, that lead to the malignant transformation of the cells.  For this reason, farnesyl transferase inhibitors, MAPK inhibitors, Rac guanosine triphosphatase inhibitors, PI3K inhibitors, JAK inhibitors, Hsp90 inhibitors, mTOR inhibitors, PP2A activators and apoptosis inducers have been tested, alone or in combination with ATP-competitive inhibitors, against CML cell lines.  This review discusses compds. that act on Bcr-Abl or different cell pathways and reports on the mols. active against the T315I mutation, particularly the most recent findings in this field.  New mols. that are claimed by recent patents to be active on this mutation are also reported.  When possible, the review will focus on medicinal chem. in terms of chem. structure, mechanism of action and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzJF4D0f3TnrVg90H21EOLACvtfcHk0lgXV4m76nPLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFeht7k%253D&md5=b169ec458fa04fd2870501e42753381e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F092986710790936310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710790936310%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DNew%2520opportunities%2520to%2520treat%2520the%2520T315I-Bcr-Abl%2520mutant%2520in%2520chronic%2520myeloid%2520leukaemia%253A%2520tyrosine%2520kinase%2520inhibitors%2520and%2520molecules%2520that%2520act%2520by%2520alternative%2520mechanisms%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D1220%26epage%3D1245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Marx, J.</span><span> </span><span class="NLM_article-title">Cancer research. Obstacle for promising cancer therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">1444</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2002&pages=1444&author=J.+Marx&title=Cancer+research.+Obstacle+for+promising+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarx%26aufirst%3DJ.%26atitle%3DCancer%2520research.%2520Obstacle%2520for%2520promising%2520cancer%2520therapy%26jtitle%3DScience%26date%3D2002%26volume%3D295%26spage%3D1444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Lee, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouhi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl Jensen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauptmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span> </span><span class="NLM_article-title">Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">19485</span><span class="NLM_x">–</span> <span class="NLM_lpage">19490</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=19485-19490&author=S.+L.+Leeauthor=P.+Rouhiauthor=L.+Dahl+Jensenauthor=D.+Zhangauthor=H.+Jiauthor=G.+Hauptmannauthor=P.+Inghamauthor=Y.+Cao&title=Hypoxia-induced+pathological+angiogenesis+mediates+tumor+cell+dissemination%2C+invasion%2C+and+metastasis+in+a+zebrafish+tumor+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BL.%26aulast%3DRouhi%26aufirst%3DP.%26aulast%3DDahl%2BJensen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DHauptmann%26aufirst%3DG.%26aulast%3DIngham%26aufirst%3DP.%26aulast%3DCao%26aufirst%3DY.%26atitle%3DHypoxia-induced%2520pathological%2520angiogenesis%2520mediates%2520tumor%2520cell%2520dissemination%252C%2520invasion%252C%2520and%2520metastasis%2520in%2520a%2520zebrafish%2520tumor%2520model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D19485%26epage%3D19490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Rapisarda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melillo, G.</span><span> </span><span class="NLM_article-title">Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrclinonc.2012.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22525710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVSgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=378-390&author=A.+Rapisardaauthor=G.+Melillo&title=Overcoming+disappointing+results+with+antiangiogenic+therapy+by+targeting+hypoxia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia</span></div><div class="casAuthors">Rapisarda, Annamaria A.; Melillo, Giovanni G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">378-390</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer cells rely on angiogenesis to fulfil their need for oxygen and nutrients; hence, agents targeting angiogenic pathways and mediators have been investigated as potential cancer drugs.  However, a significant no. of patients either do not respond to antiangiogenic agents or fairly rapidly develop resistance to them, which raises questions about how resistance develops and how it can be overcome.  In this Review, the authors examine the evidence linking antiangiogenic agents and intratumor hypoxia by providing an overview of the preclin. and clin. data, focusing on the possibility of exploiting intratumor hypoxia as a means to improve the therapeutic response to antiangiogenic agents.  Cancer cells rely on angiogenesis to fulfil their need for oxygen and nutrients; hence, agents targeting angiogenic pathways and mediators have been investigated as potential cancer drugs.  Although this strategy has demonstrated delayed tumor progression-leading to progression-free survival and overall survival benefits compared with std. therapy-in some patients, the results are more modest than predicted.  A significant no. of patients either do not respond to antiangiogenic agents or fairly rapidly develop resistance to them, which raises questions about how resistance develops and how it can be overcome.  Furthermore, whether cancers, once they develop resistance, become more invasive or lead to metastatic disease remains unclear.  Several mechanisms of resistance have been recently proposed and emerging evidence indicates that, under certain exptl. conditions, antiangiogenic agents increase intratumor hypoxia by promoting vessel pruning and inhibiting neoangiogenesis.  Indeed, several studies have highlighted the possibility that inhibitors of VEGF (and its receptors) can promote an invasive metastatic switch, in part by creating an increasingly hypoxic tumor microenvironment.  As a potential remedy, a no. of therapeutic approaches have been investigated that target the hypoxic tumor compartment to improve the clin. outcome of antiangiogenic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXtTq_ScREzrVg90H21EOLACvtfcHk0lgXV4m76nPLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVSgt74%253D&md5=a0362341d4f472cc25b778a1effb765f</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.64%26sid%3Dliteratum%253Aachs%26aulast%3DRapisarda%26aufirst%3DA.%26aulast%3DMelillo%26aufirst%3DG.%26atitle%3DOvercoming%2520disappointing%2520results%2520with%2520antiangiogenic%2520therapy%2520by%2520targeting%2520hypoxia%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D378%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Force, T.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2010&pages=21-34&author=H.+Chengauthor=T.+Force&title=Molecular+mechanisms+of+cardiovascular+toxicity+of+targeted+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DForce%26aufirst%3DT.%26atitle%3DMolecular%2520mechanisms%2520of%2520cardiovascular%2520toxicity%2520of%2520targeted%2520cancer%2520therapeutics%26jtitle%3DCirc.%2520Res.%26date%3D2010%26volume%3D106%26spage%3D21%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Jain, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeffler, J. S.</span><span> </span><span class="NLM_article-title">Lessons from phase III clinical trials on anti-VEGF therapy for cancer</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fncponc0403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16407877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVynsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=24-40&author=R.+K.+Jainauthor=D.+G.+Dudaauthor=J.+W.+Clarkauthor=J.+S.+Loeffler&title=Lessons+from+phase+III+clinical+trials+on+anti-VEGF+therapy+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from phase III clinical trials on anti-VEGF therapy for cancer</span></div><div class="casAuthors">Jain, Rakesh K.; Duda, Dan G.; Clark, Jeffrey W.; Loeffler, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-40</span>CODEN:
                <span class="NLM_cas:coden">NCPOB5</span>;
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer.  In one approach, the addn. of bevacizumab, a VEGF-specific antibody, to std. chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients.  In the second approach, multitargeted tyrosine kinase inhibitors that block VEGF receptor and other kinases in both endothelial and cancer cells, demonstrated survival benefit in gastrointestinal stromal tumor and renal-cell-carcinoma patients.  By contrast, adding bevacizumab to chemotherapy failed to increase survival in patients with previously treated and refractory metastatic breast cancer.  Furthermore, addn. of vatalanib, a kinase inhibitor developed as a VEGF receptor-selective agent, to chemotherapy did not show a similar benefit in metastatic colorectal cancer patients.  These contrasting responses raise crit. questions about how these agents work and how to combine them optimally.  We summarize three of the many potential mechanisms of action of anti-VEGF agents, and also discuss progress relating to the identification of potential biomarkers for anti-VEGF-agent efficacy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzdONgbUWNUrVg90H21EOLACvtfcHk0lgXV4m76nPLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVynsL0%253D&md5=dfcfbf8ab8060df6b65c359b0bf8ef77</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fncponc0403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0403%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DLoeffler%26aufirst%3DJ.%2BS.%26atitle%3DLessons%2520from%2520phase%2520III%2520clinical%2520trials%2520on%2520anti-VEGF%2520therapy%2520for%2520cancer%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2006%26volume%3D3%26spage%3D24%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0ljOyllU9RCa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Woo, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, J.</span><span> </span><span class="NLM_article-title">Sorafenib in liver cancer</span> <span class="citation_source-journal">Exp. Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1059</span><span class="NLM_x">–</span> <span class="NLM_lpage">1067</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1517%2F14656566.2012.679930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22519770" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1059-1067&author=H.+Y.+Wooauthor=J.+Heo&title=Sorafenib+in+liver+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1517%2F14656566.2012.679930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2012.679930%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DH.%2BY.%26aulast%3DHeo%26aufirst%3DJ.%26atitle%3DSorafenib%2520in%2520liver%2520cancer%26jtitle%3DExp.%2520Opin.%2520Pharmacother.%26date%3D2012%26volume%3D13%26spage%3D1059%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Calvisi, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conner, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Factor, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorgeirsson, S. S.</span><span> </span><span class="NLM_article-title">Ubiquitous activation of Ras and Jak/Stat pathways in human HCC</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1128</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2006&pages=1117-1128&author=D.+F.+Calvisiauthor=S.+Laduauthor=A.+Gordenauthor=M.+Farinaauthor=E.+A.+Connerauthor=J.+S.+Leeauthor=V.+M.+Factorauthor=S.+S.+Thorgeirsson&title=Ubiquitous+activation+of+Ras+and+Jak%2FStat+pathways+in+human+HCC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCalvisi%26aufirst%3DD.%2BF.%26aulast%3DLadu%26aufirst%3DS.%26aulast%3DGorden%26aufirst%3DA.%26aulast%3DFarina%26aufirst%3DM.%26aulast%3DConner%26aufirst%3DE.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DFactor%26aufirst%3DV.%2BM.%26aulast%3DThorgeirsson%26aufirst%3DS.%2BS.%26atitle%3DUbiquitous%2520activation%2520of%2520Ras%2520and%2520Jak%252FStat%2520pathways%2520in%2520human%2520HCC%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D130%26spage%3D1117%26epage%3D1128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Gedaly, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creasy, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spear, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hundley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daily, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, B. M.</span><span> </span><span class="NLM_article-title">The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2531</span><span class="NLM_x">–</span> <span class="NLM_lpage">2536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22753710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aks73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=2531-2536&author=R.+Gedalyauthor=P.+Anguloauthor=C.+Chenauthor=K.+T.+Creasyauthor=B.+T.+Spearauthor=J.+Hundleyauthor=M.+F.+Dailyauthor=M.+Shahauthor=B.+M.+Evers&title=The+role+of+PI3K%2FmTOR+inhibition+in+combination+with+sorafenib+in+hepatocellular+carcinoma+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment</span></div><div class="casAuthors">Gedaly, Roberto; Angulo, Paul; Chen, Changguo; Creasy, Kate Townsend; Spear, Brett T.; Hundley, Jonathan; Daily, Michael F.; Shah, Malay; Evers, B. Mark</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2531-2536</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Deregulated RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC).  This study aimed to test the inhibitory effects of PI-103 (a small mol. inhibitor of PI3K and mTOR) and sorafenib as single agents and in combination on HCC tumorigenesis in an in vivo xenograft model.  Materials and Methods: In vitro study: Huh7 proliferation was assayed by 3H-thymidine incorporation and by thiazolyl blue tetrazolium bromide (MTT) assay.  Western blots were used to detect phosphorylation of the key enzymes in the two pathways.  In vivo study: Human HCC cell line Huh7 was inoculated into nude mice s.c. and the mice were treated with sorafenib (20 mg/kg/day) and PI-103 (5 mg/kg, every 4 days).  Tumor size was measured every other day.  Tumors were isolated for western blot and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay detection of apoptosis and signaling pathway enzymes.  Results: Our in vitro study found that combination of sorafenib and PI-103 additively inhibited Huh7 proliferation as compared to single-agent treatment.  Sorafenib and PI-103 as single agents differentially inhibited or activated key enzymes (MEK, ERK, AKT, mTOR, and S6K) in P13K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.  Combination of sorafenib and PI-103 inhibited all the key enzymes in the two pathways.  Our in vivo study demonstrated significant differences between control group, mono-drug groups and drug-combination group (p<0.05).  Combination of Sorafenib and PI-103 more efficiently inhibited tumorigenesis as compared to mono-drug treatments (p<0.032).  Conclusion: The combination of PI-103 and sorafenib has the advantage over mono-drug therapy on inhibition of HCC cell proliferation and tumorigenesis by inhibiting both PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCZFrpeD720LVg90H21EOLACvtfcHk0ljOyllU9RCa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aks73I&md5=921829aacb25e09d9261364e3806b111</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGedaly%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCreasy%26aufirst%3DK.%2BT.%26aulast%3DSpear%26aufirst%3DB.%2BT.%26aulast%3DHundley%26aufirst%3DJ.%26aulast%3DDaily%26aufirst%3DM.%2BF.%26aulast%3DShah%26aufirst%3DM.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DThe%2520role%2520of%2520PI3K%252FmTOR%2520inhibition%2520in%2520combination%2520with%2520sorafenib%2520in%2520hepatocellular%2520carcinoma%2520treatment%26jtitle%3DAnticancer%2520Res.%26date%3D2012%26volume%3D32%26spage%3D2531%26epage%3D2536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Small molecules ATP-competitive inhibitors of FLT3: a chemical overview</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3113</span><span class="NLM_x">–</span> <span class="NLM_lpage">3132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F092986708786848613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19075657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptV2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=3113-3132&author=S.+Schenoneauthor=C.+Brulloauthor=M.+Botta&title=Small+molecules+ATP-competitive+inhibitors+of+FLT3%3A+a+chemical+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules ATP-competitive inhibitors of FLT3: a chemical overview</span></div><div class="casAuthors">Schenone, S.; Brullo, C.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3113-3132</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3 is a tyrosine kinase (TK), member of the class III TK receptor family, normally expressed in hematopoietic, immune and neural systems, also playing an important role in the pathogenesis of acute leukemias, particularly acute myeloid leukemia (AML), where it is present in constitutively activated mutated forms, correlated with poor prognosis, in a notable percentage of patients.  For these reasons FLT3 soon appeared as a promising target for the therapeutic intervention for this severe and aggressive malignancy; the recent detn. of the crystal structure of the autoinhibited form of FLT3 gave new trend for the design and the synthesis of potent inhibitors.  Small mols. tyrosine kinase inhibitors represent one of the largest drug family currently targeted by pharmaceutical companies for the treatment of cancer.  Exciting examples of such mols. have reached advanced clin. trials and have been recently approved by FDA for the treatment of different solid or hematol. tumors.  Usually TK inhibitors share common features, namely two hydrophobic/arom. regions bearing one or more hydrogen bonding substituents.  These two regions can be connected by different spacers and almost all the mols. contain a component resembling the ATP purine structure.  This review will deal with FLT3 synthetic inhibitors, reporting not only the most important mols. that are in clin. trials, but also the new compds. that have appeared in literature in the last few years.  Our attention will be focused on chem. structures, mechanisms of action and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMaEJysVaMAbVg90H21EOLACvtfcHk0ljOyllU9RCa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptV2gsA%253D%253D&md5=f0d577bdb45e35fb063b98f35d9329d1</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2174%2F092986708786848613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708786848613%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520ATP-competitive%2520inhibitors%2520of%2520FLT3%253A%2520a%2520chemical%2520overview%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D3113%26epage%3D3132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=323-328&author=R.+Roskoski&title=Sunitinib%3A+a+VEGF+and+PDGF+receptor+protein+kinase+and+angiogenesis+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DSunitinib%253A%2520a%2520VEGF%2520and%2520PDGF%2520receptor%2520protein%2520kinase%2520and%2520angiogenesis%2520inhibitor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D356%26spage%3D323%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boloor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epperly, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N. ,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudeman, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-dimethyl-2<i>H</i>-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4632</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.++Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28pazopanib%29%2C+a+novel+and+potent+vascular+endothelial+growth+factor+receptor+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528pazopanib%2529%252C%2520a%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Pazopanib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=17-18&author=R.+M.+Bukowskiauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Pazopanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DPazopanib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D17%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Morabito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccirillo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandomenico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carillio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryce, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotenuto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rocca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normanno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, F.</span><span> </span><span class="NLM_article-title">Vandetanib: an overview of its clinical development in NSCLC and other tumors</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1358%2Fdot.2010.46.9.1516989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Wms7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=683-698&author=A.+Morabitoauthor=M.+C.+Piccirilloauthor=R.+Costanzoauthor=C.+Sandomenicoauthor=G.+Carillioauthor=G.+Danieleauthor=P.+Giordanoauthor=J.+Bryceauthor=P.+Carotenutoauthor=A.+La+Roccaauthor=M.+Di+Maioauthor=N.+Normannoauthor=G.+Roccoauthor=F.+Perrone&title=Vandetanib%3A+an+overview+of+its+clinical+development+in+NSCLC+and+other+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib: an overview of its clinical development in NSCLC and other tumors</span></div><div class="casAuthors">Morabito, A.; Piccirillo, M. C.; Costanzo, R.; Sandomenico, C.; Carillio, G.; Daniele, G.; Giordano, P.; Bryce, J.; Carotenuto, P.; La Rocca, A.; Di Maio, M.; Normanno, N.; Rocco, G.; Perrone, F.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">683-698</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Vandetanib is an oral inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR) and Ret tyrosine kinases involved in tumor growth, progression and angiogenesis.  Phase I studies indicated that the recommended dose of vandetanib as a single agent is 300 mg/day.  Rash, diarrhea, hypertension and asymptomatic Q-Tc prolongation were the most common adverse events.  Four randomized phase III clin. trials evaluated the efficacy of vandetanib in non-small cell lung cancer (NSCLC) in combination with docetaxel (ZODIAC), pemetrexed (ZEAL) or as a single agent (ZEST and ZEPHYR).  Only the ZODIAC trial met its primary endpoint (progression-free survival [PFS]), while no study showed an advantage in overall survival with vandetanib.  No significant antitumor activity has been obsd. in small cell lung cancer, advanced ovarian, colorectal, breast, prostate cancer and multiple myeloma.  In advanced metastatic medullary thyroid cancer, one randomized phase III clin. trial has demonstrated that vandetanib can significantly improve response rate, PFS and time to worsening of pain.  Several key questions remain to be addressed regarding the identification of clin. or mol. biomarkers predictive of response, the choice of the optimal dose or schedule of vandetanib and the safety of long-term administration.  The results of ongoing trials in untreated patients with advanced NSCLC and other tumors should better define the optimal clin. application of vandetanib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeMQRrol1lKbVg90H21EOLACvtfcHk0li1HD35SAgRPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Wms7vE&md5=fed11f7d0dfbe7e6717384d5de86fa77</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1358%2Fdot.2010.46.9.1516989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2010.46.9.1516989%26sid%3Dliteratum%253Aachs%26aulast%3DMorabito%26aufirst%3DA.%26aulast%3DPiccirillo%26aufirst%3DM.%2BC.%26aulast%3DCostanzo%26aufirst%3DR.%26aulast%3DSandomenico%26aufirst%3DC.%26aulast%3DCarillio%26aufirst%3DG.%26aulast%3DDaniele%26aufirst%3DG.%26aulast%3DGiordano%26aufirst%3DP.%26aulast%3DBryce%26aufirst%3DJ.%26aulast%3DCarotenuto%26aufirst%3DP.%26aulast%3DLa%2BRocca%26aufirst%3DA.%26aulast%3DDi%2BMaio%26aufirst%3DM.%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DRocco%26aufirst%3DG.%26aulast%3DPerrone%26aufirst%3DF.%26atitle%3DVandetanib%253A%2520an%2520overview%2520of%2520its%2520clinical%2520development%2520in%2520NSCLC%2520and%2520other%2520tumors%26jtitle%3DDrugs%2520Today%26date%3D2010%26volume%3D46%26spage%3D683%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Commander, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteside, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, C.</span><span> </span><span class="NLM_article-title">Vandetanib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2165%2F11595310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21770481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlakurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1355-1365&author=H.+Commanderauthor=G.+Whitesideauthor=C.+Perry&title=Vandetanib%3A+first+global+approval"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib: first global approval</span></div><div class="casAuthors">Commander, Helen; Whiteside, Glenn; Perry, Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1355-1365</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC).  Regulatory submissions for this indication have been filed in the EU and Canada, with clin. development in malignant MTC ongoing in several other countries.  Vandetanib is being developed by AstraZeneca, and is also in phase II development for biliary, breast and prostate cancer.  Earlier, AstraZeneca withdrew regulatory filings for non-small cell lung cancer (NSCLC) in the US and EU, and later discontinued development.  This article summarizes the milestones in the development of vandetanib leading to this first approval in malignant MTC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsc9DGAyJOZ7Vg90H21EOLACvtfcHk0lhaqTFqU28pGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlakurzJ&md5=ffb345f58f8c488b3752dc43554054af</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2165%2F11595310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11595310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DCommander%26aufirst%3DH.%26aulast%3DWhiteside%26aufirst%3DG.%26aulast%3DPerry%26aufirst%3DC.%26atitle%3DVandetanib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D1355%26epage%3D1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjaer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibáñez, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span> </span><span class="NLM_article-title">Structure and chemical inhibition of the RET tyrosine kinase domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">33577</span><span class="NLM_x">–</span> <span class="NLM_lpage">33587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kjaerauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ib%C3%A1%C3%B1ezauthor=N.+Q.+McDonald&title=Structure+and+chemical+inhibition+of+the+RET+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0lhaqTFqU28pGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520chemical%2520inhibition%2520of%2520the%2520RET%2520tyrosine%2520kinase%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Ho, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonasch, E.</span><span> </span><span class="NLM_article-title">Axitinib in the treatment of metastatic renal cell carcinoma</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2217%2Ffon.11.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22044199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=1247-1253&author=T.+H.+Hoauthor=E.+Jonasch&title=Axitinib+in+the+treatment+of+metastatic+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Axitinib in the treatment of metastatic renal cell carcinoma</span></div><div class="casAuthors">Ho, Thai H.; Jonasch, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1247-1253</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Axitinib, an oral small-mol. tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma.  Common side effects include hypertension, fatigue and dysphonia.  Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma.  Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9XhyXJ5T84LVg90H21EOLACvtfcHk0lhaqTFqU28pGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtbrI&md5=60a0a2879cb1fb633c9fb84d89e8c07c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2217%2Ffon.11.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.11.107%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BH.%26aulast%3DJonasch%26aufirst%3DE.%26atitle%3DAxitinib%2520in%2520the%2520treatment%2520of%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DFuture%2520Oncol.%26date%3D2011%26volume%3D7%26spage%3D1247%26epage%3D1253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobbs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7019</span><span class="NLM_x">–</span> <span class="NLM_lpage">7031</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900522y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=7019-7031&author=J.+Solowiejauthor=S.+Bergqvistauthor=M.+A.+McTigueauthor=T.+Marroneauthor=T.+Quenzerauthor=M.+Cobbsauthor=K.+Ryanauthor=R.+S.+Kaniaauthor=W.+Diehlauthor=B.+W.+Murray&title=Characterizing+the+effects+of+the+juxtamembrane+domain+on+vascular+endothelial+growth+factor+receptor-2+enzymatic+activity%2C+autophosphorylation%2C+and+inhibition+by+axitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fbi900522y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900522y%26sid%3Dliteratum%253Aachs%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DMarrone%26aufirst%3DT.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DCobbs%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCharacterizing%2520the%2520effects%2520of%2520the%2520juxtamembrane%2520domain%2520on%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520enzymatic%2520activity%252C%2520autophosphorylation%252C%2520and%2520inhibition%2520by%2520axitinib%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D7019%26epage%3D7031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musumeci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Novel dual Src/Abl inhibitors for hematologic and solid malignancies</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">931</span><span class="NLM_x">–</span> <span class="NLM_lpage">945</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=931-945&author=S.+Schenoneauthor=C.+Brulloauthor=F.+Musumeciauthor=M.+Botta&title=Novel+dual+Src%2FAbl+inhibitors+for+hematologic+and+solid+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DNovel%2520dual%2520Src%252FAbl%2520inhibitors%2520for%2520hematologic%2520and%2520solid%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D931%26epage%3D945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boffey, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilburn, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span> </span><span class="NLM_article-title">AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4389</span><span class="NLM_x">–</span> <span class="NLM_lpage">4400</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4389-4400&author=S.+R.+Wedgeauthor=J.+Kendrewauthor=L.+F.+Hennequinauthor=P.+J.+Valentineauthor=S.+T.+Barryauthor=S.+R.+Braveauthor=N.+R.+Smithauthor=N.+H.+Jamesauthor=M.+Dukesauthor=J.+O.+Curwenauthor=R.+Chesterauthor=J.+A.+Jacksonauthor=S.+J.+Boffeyauthor=L.+L.+Kilburnauthor=S.+Barnettauthor=G.+H.+Richmondauthor=P.+F.+Wadsworthauthor=M.+Walkerauthor=A.+L.+Bigleyauthor=S.+T.+Taylorauthor=L.+Cooperauthor=S.+Beckauthor=J.+M.+Jurgensmeierauthor=D.+J.+Ogilvie&title=AZD2171%3A+a+highly+potent%2C+orally+bioavailable%2C+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DValentine%26aufirst%3DP.%2BJ.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DChester%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DJ.%2BA.%26aulast%3DBoffey%26aufirst%3DS.%2BJ.%26aulast%3DKilburn%26aufirst%3DL.%2BL.%26aulast%3DBarnett%26aufirst%3DS.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DWadsworth%26aufirst%3DP.%2BF.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DBigley%26aufirst%3DA.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%2BT.%26aulast%3DCooper%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DJurgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26atitle%3DAZD2171%253A%2520a%2520highly%2520potent%252C%2520orally%2520bioavailable%252C%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4389%26epage%3D4400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Lindsay, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacPherson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassidy, J.</span><span> </span><span class="NLM_article-title">Current status of cediranib: the rapid development of a novel anti-angiogenic therapy</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2217%2Ffon.09.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19450171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtF2qu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=421-432&author=C.+R.+Lindsayauthor=I.+R.+MacPhersonauthor=J.+Cassidy&title=Current+status+of+cediranib%3A+the+rapid+development+of+a+novel+anti-angiogenic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of Cediranib: the rapid development of a novel anti-angiogenic therapy</span></div><div class="casAuthors">Lindsay, Colin R.; MacPherson, Iain RJ; Cassidy, Jim</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">421-432</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and metastasis, is a pivotal event in tumorigenesis.  It is tightly regulated by the VEGF system.  Cediranib (AZD2171, Recentin; AstraZeneca, London, UK) is a novel and potent small-mol. inhibitor of VEGF signaling, with activity against the three VEGF receptors, as well as other targets.  This article provides a comprehensive and up-to-date synopsis of all pertinent preclin. and clin. studies detailing this promising new therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj-x6JwTlXIbVg90H21EOLACvtfcHk0ljNwOnS3dO4eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtF2qu7c%253D&md5=0f60b2d1bb1ac6379dcee0787d220830</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.2217%2Ffon.09.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.09.18%26sid%3Dliteratum%253Aachs%26aulast%3DLindsay%26aufirst%3DC.%2BR.%26aulast%3DMacPherson%26aufirst%3DI.%2BR.%26aulast%3DCassidy%26aufirst%3DJ.%26atitle%3DCurrent%2520status%2520of%2520cediranib%253A%2520the%2520rapid%2520development%2520of%2520a%2520novel%2520anti-angiogenic%2520therapy%26jtitle%3DFuture%2520Oncol.%26date%3D2009%26volume%3D5%26spage%3D421%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Batchelor, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">di Tomaso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancukiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotkin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichler, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drappatz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochberg, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chea, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Exarhopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeffler, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moses, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2817</span><span class="NLM_x">–</span> <span class="NLM_lpage">2823</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2009.26.3988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20458050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFKmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2817-2823&author=T.+T.+Batchelorauthor=D.+G.+Dudaauthor=E.+di+Tomasoauthor=M.+Ancukiewiczauthor=S.+R.+Plotkinauthor=E.+Gerstnerauthor=A.+F.+Eichlerauthor=J.+Drappatzauthor=F.+H.+Hochbergauthor=T.+Bennerauthor=D.+N.+Louisauthor=K.+S.+Cohenauthor=H.+Cheaauthor=A.+Exarhopoulosauthor=J.+S.+Loefflerauthor=M.+A.+Mosesauthor=P.+Ivyauthor=A.+G.+Sorensenauthor=P.+Y.+Wenauthor=R.+K.+Jain&title=Phase+II+study+of+cediranib%2C+an+oral+pan-vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+in+patients+with+recurrent+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma</span></div><div class="casAuthors">Batchelor, Tracy T.; Duda, Dan G.; di Tomaso, Emmanuelle; Ancukiewicz, Marek; Plotkin, Scott R.; Gerstner, Elizabeth; Eichler, April F.; Drappatz, Jan; Hochberg, Fred H.; Benner, Thomas; Louis, David N.; Cohen, Kenneth S.; Chea, Houng; Exarhopoulos, Alexis; Loeffler, Jay S.; Moses, Marsha A.; Ivy, Percy; Sorensen, A. Gregory; Wen, Patrick Y.; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2817-2823</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF).  We performed a phase II study of cediranib in patients with recurrent glioblastoma.  Methods: Cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, was administered (45 mg/d) until progression or unacceptable toxicity to patients with recurrent glioblastoma.  The primary end point was the proportion of patients alive and progression free at 6 mo (APF6).  We performed magnetic resonance imaging (MRI) and plasma and urinary biomarker evaluations at multiple time points.  Results: Thirty-one patients with recurrent glioblastoma were accrued.  APF6 after cediranib was 25.8%.  Radiog. partial responses were obsd. by MRI in 17 (56.7%) of 30 evaluable patients using three-dimensional measurements and in eight (27%) of 30 evaluable patients using two-dimensional measurements.  For the 15 patients who entered the study taking corticosteroids, the dose was reduced (n = 10) or discontinued (n = 5).  Toxicities were manageable.  Grade 3/4 toxicities included hypertension (four of 31; 12.9%); diarrhea (two of 31; 6.4%); and fatigue (six of 31; 19.4%).  Fifteen (48.4%) of 31 patients required at least one dose redn. and 15 patients required temporary drug interruptions due to toxicity.  Drug interruptions were not assocd. with outcome.  Changes in plasma placental growth factor, basic fibroblast growth factor, matrix metalloproteinase (MMP) -2, sol. VEGF receptor 1, stromal cell-derived factor-1α, and sol. Tek/Tie2 receptor and in urinary MMP-9/neutrophil gelatinase-assocd. lipocalin activity after cediranib were assocd. with radiog. response or survival.  Conclusion: Cediranib monotherapy for recurrent glioblastoma is assocd. with encouraging proportions of radiog. response, 6-mo progression-free survival, and a steroid-sparing effect with manageable toxicity.  We identified early changes in circulating mols. as potential biomarkers of response to cediranib.  The efficacy of cediranib and the predictive value of these candidate biomarkers will be explored in prospective trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJbFlYzveoHrVg90H21EOLACvtfcHk0ljNwOnS3dO4eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFKmu78%253D&md5=b8f902095ea92608bdd4ef376acbfb50</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.3988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.3988%26sid%3Dliteratum%253Aachs%26aulast%3DBatchelor%26aufirst%3DT.%2BT.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3Ddi%2BTomaso%26aufirst%3DE.%26aulast%3DAncukiewicz%26aufirst%3DM.%26aulast%3DPlotkin%26aufirst%3DS.%2BR.%26aulast%3DGerstner%26aufirst%3DE.%26aulast%3DEichler%26aufirst%3DA.%2BF.%26aulast%3DDrappatz%26aufirst%3DJ.%26aulast%3DHochberg%26aufirst%3DF.%2BH.%26aulast%3DBenner%26aufirst%3DT.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DCohen%26aufirst%3DK.%2BS.%26aulast%3DChea%26aufirst%3DH.%26aulast%3DExarhopoulos%26aufirst%3DA.%26aulast%3DLoeffler%26aufirst%3DJ.%2BS.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DSorensen%26aufirst%3DA.%2BG.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DPhase%2520II%2520study%2520of%2520cediranib%252C%2520an%2520oral%2520pan-vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D2817%26epage%3D2823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">di Tomaso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snuderl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamoun, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auluck, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazlollahi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andronesi, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frosch, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotkin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley-Whyte, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=19-28&author=E.+di+Tomasoauthor=M.+Snuderlauthor=W.+S.+Kamounauthor=D.+G.+Dudaauthor=P.+K.+Auluckauthor=L.+Fazlollahiauthor=O.+C.+Andronesiauthor=M.+P.+Froschauthor=P.+Y.+Wenauthor=S.+R.+Plotkinauthor=E.+T.+Hedley-Whyteauthor=A.+G.+Sorensenauthor=T.+T.+Batchelorauthor=R.+K.+Jain&title=Glioblastoma+recurrence+after+cediranib+therapy+in+patients%3A+lack+of+%E2%80%9Crebound%E2%80%9D+revascularization+as+mode+of+escape"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Ddi%2BTomaso%26aufirst%3DE.%26aulast%3DSnuderl%26aufirst%3DM.%26aulast%3DKamoun%26aufirst%3DW.%2BS.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3DAuluck%26aufirst%3DP.%2BK.%26aulast%3DFazlollahi%26aufirst%3DL.%26aulast%3DAndronesi%26aufirst%3DO.%2BC.%26aulast%3DFrosch%26aufirst%3DM.%2BP.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DPlotkin%26aufirst%3DS.%2BR.%26aulast%3DHedley-Whyte%26aufirst%3DE.%2BT.%26aulast%3DSorensen%26aufirst%3DA.%2BG.%26aulast%3DBatchelor%26aufirst%3DT.%2BT.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DGlioblastoma%2520recurrence%2520after%2520cediranib%2520therapy%2520in%2520patients%253A%2520lack%2520of%2520%25E2%2580%259Crebound%25E2%2580%259D%2520revascularization%2520as%2520mode%2520of%2520escape%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D19%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Sorensen, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emblem, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polaskova, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancukiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=402-407&author=A.+G.+Sorensenauthor=K.+E.+Emblemauthor=P.+Polaskovaauthor=D.+Jenningsauthor=H.+Kimauthor=M.+Ancukiewiczauthor=M.+Wangauthor=P.+Y.+Wenauthor=P.+Ivyauthor=T.+T.+Batchelorauthor=R.+K.+Jain&title=Increased+survival+of+glioblastoma+patients+who+respond+to+antiangiogenic+therapy+with+elevated+blood+perfusion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DA.%2BG.%26aulast%3DEmblem%26aufirst%3DK.%2BE.%26aulast%3DPolaskova%26aufirst%3DP.%26aulast%3DJennings%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DAncukiewicz%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DBatchelor%26aufirst%3DT.%2BT.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DIncreased%2520survival%2520of%2520glioblastoma%2520patients%2520who%2520respond%2520to%2520antiangiogenic%2520therapy%2520with%2520elevated%2520blood%2520perfusion%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D402%26epage%3D407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Mulders, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jong, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osanto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porfiri, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protheroe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Herpen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mookerjee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M. E.</span><span> </span><span class="NLM_article-title">Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=527-537&author=P.+Muldersauthor=R.+Hawkinsauthor=P.+Nathanauthor=I.+de+Jongauthor=S.+Osantoauthor=E.+Porfiriauthor=A.+Protheroeauthor=C.+M.+van+Herpenauthor=B.+Mookerjeeauthor=L.+Pikeauthor=J.+M.+J%C3%BCrgensmeierauthor=M.+E.+Gore&title=Cediranib+monotherapy+in+patients+with+advanced+renal+cell+carcinoma%3A+results+of+a+randomised+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMulders%26aufirst%3DP.%26aulast%3DHawkins%26aufirst%3DR.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3Dde%2BJong%26aufirst%3DI.%26aulast%3DOsanto%26aufirst%3DS.%26aulast%3DPorfiri%26aufirst%3DE.%26aulast%3DProtheroe%26aufirst%3DA.%26aulast%3Dvan%2BHerpen%26aufirst%3DC.%2BM.%26aulast%3DMookerjee%26aufirst%3DB.%26aulast%3DPike%26aufirst%3DL.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DGore%26aufirst%3DM.%2BE.%26atitle%3DCediranib%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520renal%2520cell%2520carcinoma%253A%2520results%2520of%2520a%2520randomised%2520phase%2520II%2520study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2012%26volume%3D48%26spage%3D527%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Garland, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chansky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verschraegen, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dasilva, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandara, D. R.</span><span> </span><span class="NLM_article-title">Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1945</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1097%2FJTO.0b013e318229586e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21964533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADC%252BC3MbhvVCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1938-1945&author=L.+L.+Garlandauthor=K.+Chanskyauthor=A.+J.+Wozniakauthor=A.+S.+Tsaoauthor=S.+M.+Gadgeelauthor=C.+F.+Verschraegenauthor=M.+A.+Dasilvaauthor=M.+Redmanauthor=D.+R.+Gandara&title=Phase+II+study+of+cediranib+in+patients+with+malignant+pleural+mesothelioma%3A+SWOG+S0509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509</span></div><div class="casAuthors">Garland Linda L; Chansky Kari; Wozniak Antoinette J; Tsao Anne S; Gadgeel Shirish M; Verschraegen Claire F; Dasilva Marco A; Redman Mary; Gandara David R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1938-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Malignant pleural mesothelioma (MPM) tumors express vascular epithelial growth factor (VEGF) and VEGF receptors.  We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy.  METHODS:  Patients with MPM previously treated with a platinum-containing chemotherapy regimen and a performance status 0 to 2 were eligible for enrollment.  Cediranib 45 mg/d was administered until progression or unacceptable toxicity.  The primary end point was response rate.  Tumor measurements were made by RECIST criteria, with a subset analysis conducted using modified RECIST.  A two-stage design with an early stopping rule based on response rate was used.  RESULTS:  Fifty-four patients were enrolled.  Of 47 evaluable patients, 4 patients (9%) had objective responses, 16 patients (34%) had stable disease, 20 patients (43%) had disease progression, 2 patients (4%) had symptomatic deterioration, and 1 patient (2%) had early death.  The most common toxicities were fatigue (64%), diarrhea (64%), and hypertension (70%); 91% of patients required a dose reduction.  Median overall survival was 9.5 months, 1-year survival was 36%, and median progression-free survival was 2.6 months.  CONCLUSION:  Cediranib monotherapy has modest single-agent activity in MPM after platinum-based therapy.  However, some patient tumors were highly sensitive to cediranib.  This study provides a rationale for further testing of cediranib plus chemotherapy in MPM and highlights the need to identify a predictive biomarker for cediranib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbY1bR_QwPCLZpSb_XWfMrfW6udTcc2eb24ya4l-wWybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbhvVCmug%253D%253D&md5=4b201c6827c3aed78d507efae97800e5</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e318229586e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e318229586e%26sid%3Dliteratum%253Aachs%26aulast%3DGarland%26aufirst%3DL.%2BL.%26aulast%3DChansky%26aufirst%3DK.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DTsao%26aufirst%3DA.%2BS.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVerschraegen%26aufirst%3DC.%2BF.%26aulast%3DDasilva%26aufirst%3DM.%2BA.%26aulast%3DRedman%26aufirst%3DM.%26aulast%3DGandara%26aufirst%3DD.%2BR.%26atitle%3DPhase%2520II%2520study%2520of%2520cediranib%2520in%2520patients%2520with%2520malignant%2520pleural%2520mesothelioma%253A%2520SWOG%2520S0509%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D1938%26epage%3D1945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Alberts, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitch, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morlan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakhil, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, S.</span><span> </span><span class="NLM_article-title">Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II north central cancer treatment troup clinical trial</span> <span class="citation_source-journal">Am. J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1097%2FCOC.0b013e3182118cdf" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21422991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=329-333&author=S.+R.+Albertsauthor=T.+R.+Fitchauthor=G.+P.+Kimauthor=B.+W.+Morlanauthor=S.+R.+Dakhilauthor=H.+M.+Grossauthor=S.+Nair&title=Cediranib+%28AZD2171%29+in+patients+with+advanced+hepatocellular+carcinoma%3A+a+phase+II+north+central+cancer+treatment+troup+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial</span></div><div class="casAuthors">Alberts, Steven Robert; Fitch, Tom R.; Kim, George P.; Morlan, Bruce W.; Dakhil, Shaker R.; Gross, Howard M.; Nair, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">329-333</span>CODEN:
                <span class="NLM_cas:coden">AJCODI</span>;
        ISSN:<span class="NLM_cas:issn">0277-3732</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objectives: Vascular endothelial growth factor has been shown to be overexpressed in several studies of hepatocellular carcinoma (HCC).  Cediranib is a potent inhibitor of vascular endothelial growth factor signaling.  We assessed the efficacy and toxicity of cediranib in patients with HCC.  Methods: Twenty-eight patients with unresectable or metastatic HCC were enrolled in this study.  Patients received 45 mg of cediranib orally, once daily, for 28-day cycles.  The primary objective of this phase II study was to assess 6-mo survival.  Secondary objectives were to assess tumor response, time to progression, and toxicity.  Results: All 28 patients were evaluable for efficacy outcomes.  Twelve patients (42.9%) survived 6 mo, 15 (53.6%) died within 6 mo, and 1 (3.6%) was lost to follow-up before 6 mo.  The median overall survival was 5.8 mo (95% confidence interval, 3.4-7.3 mo).  No patients experienced confirmed response.  The median time to progression was 2.8 mo (95% confidence interval, 2.3-4.4 mo).  Twenty-six patients (93%) experienced a grade 3+ adverse event with the most common adverse event s being fatigue (46%), anorexia (25%), hypertension (21%), and elevated alanine aminotransferase (18%).  Conclusions: Owing to the toxicity, cediranib at this dose and schedule is not an effective treatment in patients with unresectable or metastatic HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgnvCvkgPvtrVg90H21EOLACvtfcHk0lhYIq5Ys_TpUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOjsbfL&md5=1f23cf888e84d1af813d1f154c5c2c7b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1097%2FCOC.0b013e3182118cdf&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOC.0b013e3182118cdf%26sid%3Dliteratum%253Aachs%26aulast%3DAlberts%26aufirst%3DS.%2BR.%26aulast%3DFitch%26aufirst%3DT.%2BR.%26aulast%3DKim%26aufirst%3DG.%2BP.%26aulast%3DMorlan%26aufirst%3DB.%2BW.%26aulast%3DDakhil%26aufirst%3DS.%2BR.%26aulast%3DGross%26aufirst%3DH.%2BM.%26aulast%3DNair%26aufirst%3DS.%26atitle%3DCediranib%2520%2528AZD2171%2529%2520in%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%253A%2520a%2520phase%2520II%2520north%2520central%2520cancer%2520treatment%2520troup%2520clinical%2520trial%26jtitle%3DAm.%2520J.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D35%26spage%3D329%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesters, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehninger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zirrgiebel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puchalski, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span> </span><span class="NLM_article-title">An open-label, phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">196</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.leukres.2009.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19674789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=196-202&author=W.+Fiedlerauthor=R.+Mestersauthor=M.+Heuserauthor=G.+Ehningerauthor=W.+E.+Berdelauthor=U.+Zirrgiebelauthor=J.+D.+Robertsonauthor=T.+A.+Puchalskiauthor=B.+Collinsauthor=J.+M.+J%C3%BCrgensmeierauthor=H.+Serve&title=An+open-label%2C+phase+I+study+of+cediranib+%28RECENTIN%29+in+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia</span></div><div class="casAuthors">Fiedler, Walter; Mesters, Rolf; Heuser, Michael; Ehninger, Gerhard; Berdel, Wolfgang E.; Zirrgiebel, Ute; Robertson, Jane D.; Puchalski, Tom A.; Collins, Barbara; Juergensmeier, Juliane M.; Serve, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-202</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">VEGFR and c-Kit signaling pathways may contribute to the pathophysiol. of acute myeloid leukemia (AML).  Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of ≤30 mg/day.  The most common adverse events were diarrhea, hypertension and fatigue.  Six patients experienced an objective response (3 each at 20 and 30 mg).  Dose- and time-dependent redns. in sVEGFR-2 were obsd., and there was a pos. correlation between cediranib exposure and the change in plasma VEGF levels from baseline.  Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNJ2lmgszE5LVg90H21EOLACvtfcHk0ljs0lNn8dTtlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgt7c%253D&md5=110f783b4ed226182786615af2860586</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2009.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2009.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DMesters%26aufirst%3DR.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DZirrgiebel%26aufirst%3DU.%26aulast%3DRobertson%26aufirst%3DJ.%2BD.%26aulast%3DPuchalski%26aufirst%3DT.%2BA.%26aulast%3DCollins%26aufirst%3DB.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DServe%26aufirst%3DH.%26atitle%3DAn%2520open-label%252C%2520phase%2520I%2520study%2520of%2520cediranib%2520%2528RECENTIN%2529%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2010%26volume%3D34%26spage%3D196%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2298</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0ljs0lNn8dTtlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guessous, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kofman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abounader, R.</span><span> </span><span class="NLM_article-title">XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20127563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1ylt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=112-121&author=Y.+Zhangauthor=F.+Guessousauthor=A.+Kofmanauthor=D.+Schiffauthor=R.+Abounader&title=XL-184%2C+a+MET%2C+VEGFR-2+and+RET+kinase+inhibitor+for+the+treatment+of+thyroid+cancer%2C+glioblastoma+multiforme+and+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC</span></div><div class="casAuthors">Zhang, Ying; Guessous, Fadila; Kofman, Alex; Schiff, David; Abounader, Roger</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-121</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  XL-184 (BMS-907351), under development by Exelixis Inc and Bristol-Myers Squibb Co, is a pan-tyrosine kinase inhibitor for the potential oral treatment of medullary thyroid cancer, glioblastoma multiforme and NSCLC.  The prinicipal targets of XL-184 are MET, VEGFR-2 and RET, but the drug is also reported to display inhibitory activity against KIT, FLT3 and TEK.  Preclin. studies demonstrated that XL-184 potently inhibited multiple receptor tyrosine kinases in various cancer cell lines and animal xenograft models, and that the drug exhibited significant oral bioavailability and blood-brain barrier penetration.  A phase I clin. trial in patients with advanced solid malignancies indicated that XL-184 accumulated dose-dependently in the plasma and had a long terminal half-life.  A phase II trial in patients with progressive or recurrent glioblastoma revealed modest but promising median progression-free survival.  Toxicity and side effects for the drug have generally been of low-to-moderate severity.  At the time of publication, three addnl. trials of XL-184 were recruiting patients, including a phase I trial in combination with std. of care in patients with glioblastoma, a phase I/II trial in combination with erlotinib in patients with NSCLC, and a phase III trial in patients with medullary thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Fd_mnBA3mrVg90H21EOLACvtfcHk0ljs0lNn8dTtlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1ylt7s%253D&md5=fe00ddc171497cc2dff787db6d430208</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuessous%26aufirst%3DF.%26aulast%3DKofman%26aufirst%3DA.%26aulast%3DSchiff%26aufirst%3DD.%26aulast%3DAbounader%26aufirst%3DR.%26atitle%3DXL-184%252C%2520a%2520MET%252C%2520VEGFR-2%2520and%2520RET%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520thyroid%2520cancer%252C%2520glioblastoma%2520multiforme%2520and%2520NSCLC%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D112%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Bowles, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span> </span><span class="NLM_article-title">Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib)</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">868</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1358%2Fdot.2011.47.11.1688487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsleitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=857-868&author=D.+W.+Bowlesauthor=E.+R.+Kesslerauthor=A.+Jimeno&title=Multi-targeted+tyrosine+kinase+inhibitors+in+clinical+development%3A+focus+on+XL-184+%28cabozantinib%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib)</span></div><div class="casAuthors">Bowles, D. W.; Kessler, E. R.; Jimeno, A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">857-868</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">XL-184 (cabozantinib) is a novel, small-mol., multi-targeted receptor tyrosine kinase inhibitor with particular activity against hepatocyte growth factor receptor (tyrosine-protein kinase Met), vascular endothelial growth factor receptor 2 (VEGFR-2) and proto-oncogene tyrosine-protein kinase receptor Ret.  There is ample evidence of Met, VEGFR-2 and Ret signaling in several tumor types.  Preclin. data suggest that XL-184 has activity in tumors derived from both epithelial and mesenchymal origins.  Phase I and II clin. studies support significant antitumor activity, particularly in medullary thyroid cancer and cancers metastatic to the bone.  This review will evaluate XL-184's preclin. pharmacol., pharmacokinetics, drug interactions and clin. activity in phase I through phase III studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonPoiYaPWFU7Vg90H21EOLACvtfcHk0liDDBCDiKr8vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsleitL0%253D&md5=02ecf3a4628b7204e8cd74a48b62a0a3</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1358%2Fdot.2011.47.11.1688487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2011.47.11.1688487%26sid%3Dliteratum%253Aachs%26aulast%3DBowles%26aufirst%3DD.%2BW.%26aulast%3DKessler%26aufirst%3DE.%2BR.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DMulti-targeted%2520tyrosine%2520kinase%2520inhibitors%2520in%2520clinical%2520development%253A%2520focus%2520on%2520XL-184%2520%2528cabozantinib%2529%26jtitle%3DDrugs%2520Today%26date%3D2011%26volume%3D47%26spage%3D857%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Durante, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrienti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filetti, S.</span><span> </span><span class="NLM_article-title">XL184 (cabozantinib) for medullary thyroid carcinoma</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">413</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=407-413&author=C.+Duranteauthor=D.+Russoauthor=A.+Verrientiauthor=S.+Filetti&title=XL184+%28cabozantinib%29+for+medullary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurante%26aufirst%3DC.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DVerrienti%26aufirst%3DA.%26aulast%3DFiletti%26aufirst%3DS.%26atitle%3DXL184%2520%2528cabozantinib%2529%2520for%2520medullary%2520thyroid%2520carcinoma%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D407%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Zillhardt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, I. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montag, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengyel, E.</span><span> </span><span class="NLM_article-title">Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4042</span><span class="NLM_x">–</span> <span class="NLM_lpage">4051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-3387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21551255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4042-4051&author=M.+Zillhardtauthor=S.+M.+Parkauthor=I.+L.+Romeroauthor=K.+Sawadaauthor=A.+Montagauthor=T.+Krauszauthor=S.+D.+Yamadaauthor=M.+E.+Peterauthor=E.+Lengyel&title=Foretinib+%28GSK1363089%29%2C+an+orally+available+multikinase+inhibitor+of+c-Met+and+VEGFR-2%2C+blocks+proliferation%2C+induces+anoikis%2C+and+impairs+ovarian+cancer+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis</span></div><div class="casAuthors">Zillhardt, Marion; Park, Sun-Mi; Romero, Iris L.; Sawada, Kenjiro; Montag, Anthony; Krausz, Thomas; Yamada, S. Diane; Peter, Marcus E.; Lengyel, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4042-4051</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Currently, there are no approved targeted therapies for the treatment of ovarian cancer, despite the fact that it is the most lethal gynecol. malignancy.  One proposed target is c-Met, which has been shown to be an important prognostic indicator in a no. of malignancies, including ovarian cancer.  The objective of this study was to det. whether an orally available multikinase inhibitor of c-Met and vascular endothelial growth factor receptor-2 (foretinib, GSK1363089) blocks ovarian cancer growth.  Exptl. Design: The effect of foretinib was tested in a genetic mouse model of endometrioid ovarian cancer, several ovarian cancer cell lines, and an organotypic 3D model of the human omentum.  RESULTS: In the genetic mouse model, treatment with foretinib prevented the progression of primary tumors to invasive adenocarcinoma.  Invasion through the basement membrane was completely blocked in treated mice, whereas in control mice, invasive tumors entirely replaced the normal ovary.  In 2 xenograft mouse models using human ovarian cancer cell lines, the inhibitor reduced overall tumor burden (86% inhibition, P < 0.0001) and metastasis (67% inhibition, P < 0.0001).  The mechanism of inhibition by foretinib involved (a) inhibition of c-Met activation and downstream signaling, (b) redn. of ovarian cancer cell adhesion, (c) a block in migration and invasion, (d) reduced proliferation mediated by a G2-M cell-cycle arrest, and (e) induction of anoikis.  CONCLUSIONS: This study shows that foretinib blocks tumorigenesis and reduces invasive tumor growth in different models of ovarian cancer by affecting several crit. tumor functions.  We believe that it provides a rationale for the further clin. development of foretinib for the treatment of ovarian cancer.  Clin Cancer Res; 17(12); 4042-51.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWG7ScxztDR7Vg90H21EOLACvtfcHk0liDDBCDiKr8vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKgt70%253D&md5=c38fa90e323957636493972d340cad83</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3387%26sid%3Dliteratum%253Aachs%26aulast%3DZillhardt%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DS.%2BM.%26aulast%3DRomero%26aufirst%3DI.%2BL.%26aulast%3DSawada%26aufirst%3DK.%26aulast%3DMontag%26aufirst%3DA.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DS.%2BD.%26aulast%3DPeter%26aufirst%3DM.%2BE.%26aulast%3DLengyel%26aufirst%3DE.%26atitle%3DForetinib%2520%2528GSK1363089%2529%252C%2520an%2520orally%2520available%2520multikinase%2520inhibitor%2520of%2520c-Met%2520and%2520VEGFR-2%252C%2520blocks%2520proliferation%252C%2520induces%2520anoikis%252C%2520and%2520impairs%2520ovarian%2520cancer%2520metastasis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4042%26epage%3D4051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Huynh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, K. C.</span><span> </span><span class="NLM_article-title">Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma</span> <span class="citation_source-journal">Angiogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=59-70&author=H.+Huynhauthor=R.+Ongauthor=K.+C.+Soo&title=Foretinib+demonstrates+anti-tumor+activity+and+improves+overall+survival+in+preclinical+models+of+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuynh%26aufirst%3DH.%26aulast%3DOng%26aufirst%3DR.%26aulast%3DSoo%26aufirst%3DK.%2BC.%26atitle%3DForetinib%2520demonstrates%2520anti-tumor%2520activity%2520and%2520improves%2520overall%2520survival%2520in%2520preclinical%2520models%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DAngiogenesis%26date%3D2012%26volume%3D15%26spage%3D59%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock-Bryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3507</span><span class="NLM_x">–</span> <span class="NLM_lpage">3516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-0574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20472683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3507-3516&author=J.+P.+Ederauthor=G.+I.+Shapiroauthor=L.+J.+Applemanauthor=A.+X.+Zhuauthor=D.+Milesauthor=H.+Keerauthor=B.+Cancillaauthor=F.+Chuauthor=S.+Hitchcock-Bryanauthor=L.+Shermanauthor=S.+McCallumauthor=E.+I.+Heathauthor=S.+A.+Boernerauthor=P.+M.+LoRusso&title=A+phase+I+study+of+foretinib%2C+a+multi-targeted+inhibitor+of+c-Met+and+vascular+endothelial+growth+factor+receptor+2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2</span></div><div class="casAuthors">Eder, Joseph Paul; Shapiro, Geoffrey I.; Appleman, Leonard J.; Zhu, Andrew X.; Miles, Dale; Keer, Harold; Cancilla, Belinda; Chu, Felix; Hitchcock-Bryan, Suzanne; Sherman, Laurie; McCallum, Stewart; Heath, Elisabeth I.; Boerner, Scott A.; Lo Russo, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3507-3516</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor.  We conducted a phase I, first-time-in-human, clin. trial using escalating doses of oral foretinib.  The primary objectives are to identify a max. tolerated dose and det. the safety profile of foretinib.  Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity.  Exptl. Design: Patients had histol. confirmed metastatic or unresectable solid tumors for which no std. measures exist.  All patients received foretinib orally for 5 consecutive days every 14 days.  Dose escalation followed a conventional "3+3" design.  RESULTS: Forty patients were treated in eight dose cohorts.  The max. tolerated dose was defined as 3.6 mg/kg, with a max. administered dose of 4.5 mg/kg.  Dose-limiting toxicities included grade 3 elevations in aspartate aminotransferase and lipase.  Addnl. non-dose-limiting adverse events included hypertension, fatigue, diarrhea, vomiting, proteinuria, and hematuria.  Responses were obsd. in two patients with papillary renal cell cancer and one patient with medullary thyroid cancer.  Stable disease was identified in 22 patients.  Foretinib pharmacokinetics increased linearly with dose.  Pharmacodynamic evaluation indicated inhibition of MET phosphorylation and decreased proliferation in select tumor biopsies at submaximal doses.  CONCLUSIONS: The recommended dose of foretinib was detd. to be 240 mg, given on the first 5 days of a 14-day cycle.  This dose and schedule were identified as having acceptable safety and pharmacokinetics, and will be the dose used in subsequent phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LAL1xiRe-rVg90H21EOLACvtfcHk0liOcZQDp0Q39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D&md5=d37b24383a08fdde5f78ed40b077963b</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0574%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DKeer%26aufirst%3DH.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DHitchcock-Bryan%26aufirst%3DS.%26aulast%3DSherman%26aufirst%3DL.%26aulast%3DMcCallum%26aufirst%3DS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520foretinib%252C%2520a%2520multi-targeted%2520inhibitor%2520of%2520c-Met%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3507%26epage%3D3516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Dumas, J.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors from the urea class</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">718</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2002&pages=718-727&author=J.+Dumas&title=Protein+kinase+inhibitors+from+the+urea+class"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDumas%26aufirst%3DJ.%26atitle%3DProtein%2520kinase%2520inhibitors%2520from%2520the%2520urea%2520class%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2002%26volume%3D5%26spage%3D718%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bichat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilbaud, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span> </span><span class="NLM_article-title">KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9134</span><span class="NLM_x">–</span> <span class="NLM_lpage">9142</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9134-9142&author=K.+Nakamuraauthor=E.+Taguchiauthor=T.+Miuraauthor=A.+Yamamotoauthor=K.+Takahashiauthor=F.+Bichatauthor=N.+Guilbaudauthor=K.+Hasegawaauthor=K.+Kuboauthor=Y.+Fujiwaraauthor=R.+Suzukiauthor=K.+Kuboauthor=M.+Shibuyaauthor=T.+Isoe&title=KRN951%2C+a+highly+potent+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases%2C+has+antitumor+activities+and+affects+functional+vascular+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DTaguchi%26aufirst%3DE.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DBichat%26aufirst%3DF.%26aulast%3DGuilbaud%26aufirst%3DN.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DKRN951%252C%2520a%2520highly%2520potent%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%252C%2520has%2520antitumor%2520activities%2520and%2520affects%2520functional%2520vascular%2520properties%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9134%26epage%3D9142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Eskens, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span> </span><span class="NLM_article-title">An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2034</span><div class="note"><p class="first last">; Asco Meeting Abstracts</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2034&author=F.+A.+Eskensauthor=A.+Plantingauthor=L.+Van+Doornauthor=T.+Isoeauthor=K.+Hayashiauthor=S.+Hussainauthor=L.+Ekmanauthor=H.+Burgerauthor=J.+Verweij&title=An+open-label+phase+I+dose+escalation+study+of+KRN951%2C+a+tyrosine+kinase+inhibitor+of+vascular+endothelial+growth+factor+receptor+2+and+1+in+a+4+week+on%2C+2+week+off+schedule+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%26aulast%3DPlanting%26aufirst%3DA.%26aulast%3DVan%2BDoorn%26aufirst%3DL.%26aulast%3DIsoe%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DEkman%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DVerweij%26aufirst%3DJ.%26atitle%3DAn%2520open-label%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520KRN951%252C%2520a%2520tyrosine%2520kinase%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520and%25201%2520in%2520a%25204%2520week%2520on%252C%25202%2520week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">De Luca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normanno, N.</span><span> </span><span class="NLM_article-title">Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20799147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGjurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=636-645&author=A.+De+Lucaauthor=N.+Normanno&title=Tivozanib%2C+a+pan-VEGFR+tyrosine+kinase+inhibitor+for+the+potential+treatment+of+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors</span></div><div class="casAuthors">De Luca, Antonella; Normanno, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">636-645</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Tivozanib (AV-951; KRN-951), being developed by AVEO Pharmaceuticals Inc and Kyowa Hakko Kirin Co Ltd, is an orally active, ATP-competitive, small-mol., quinoline-urea deriv. that inhibits VEGFR tyrosine kinase for the potential treatment of cancer.  In particular, tivozanib is able to markedly inhibit the ligand-induced phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3 at picomolar concns.  In preclin. studies, tivozanib produced a significant inhibition of tumor growth and angiogenesis in several different xenograft tumor models in athymic rats.  In a phase I clin. trial, tivozanib was safe and tolerable when administered at oral doses up to 1.5 mg on a schedule of 4 wk on, 2 wk off treatment.  Results from a phase II clin. trial in patients with advanced renal cell carcinoma reported an overall response rate of 25.4% and a median progression-free survival of 11.8 mo in patients treated with tivozanib as a single agent.  Hypertension and dysphonia were the most frequent adverse events.  At the time of publication, a phase III clin. trial was recruiting patients with advanced renal cancer to assess tivozanib in comparison with sorafenib.  Clin. trials are currently ongoing to evaluate the safety and antitumor activity of tivozanib in breast, lung and colorectal cancer.  Tivozanib might represent a promising anticancer agent in several different tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO2BkRsXc-krVg90H21EOLACvtfcHk0lh-FwVxm6KwJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGjurbL&md5=11c8a0fa9a6a09f982c925952d2369eb</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DNormanno%26aufirst%3DN.%26atitle%3DTivozanib%252C%2520a%2520pan-VEGFR%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520potential%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D636%26epage%3D645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Eskens, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jonge, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhargava, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotreau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomeer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span> </span><span class="NLM_article-title">Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7156</span><span class="NLM_x">–</span> <span class="NLM_lpage">7163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-11-0411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21976547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7156-7163&author=F.+A.+Eskensauthor=M.+J.+de+Jongeauthor=P.+Bhargavaauthor=T.+Isoeauthor=M.+M.+Cotreauauthor=B.+Estevesauthor=K.+Hayashiauthor=H.+Burgerauthor=M.+Thomeerauthor=L+van+Doornauthor=J.+Verweij&title=Biologic+and+clinical+activity+of+tivozanib+%28AV-951%2C+KRN-951%29%2C+a+selective+inhibitor+of+VEGF+receptor-1%2C+-2%2C+and+-3+tyrosine+kinases%2C+in+a+4-week-on%2C+2-week-off+schedule+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Eskens, Ferry A. L. M.; de Jonge, Maja J. A.; Bhargava, Pankaj; Isoe, Toshiyuki; Cotreau, Monette M.; Esteves, Brooke; Hayashi, Kunihiko; Burger, Herman; Thomeer, Maarten; van Doorn, Leni; Verweij, Jaap</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7156-7163</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To assess the max. tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF receptor (VEGFR) tyrosine kinase inhibitor.  Exptl. Design: Dose levels of 1.0, 1.5, and 2.0 mg/d tivozanib for 28 days followed by 14 days of medication were explored in patients with advanced solid tumors.  RESULTS: Forty-one patients were enrolled.  Animal data incorrectly predicted toxicity, resulting in DLTs at the starting dose (2.0 mg) consisting of grade 3 proteinuria and hypertension and grade 3 ataxia.  At 1.0 mg, no DLT was obsd.  At an intermediate dose (1.5 mg), 1 patient experienced DLT consisting of grade 3 hypertension.  This dose was detd. as the MTD.  Of 10 addnl. patients treated at 1.5 mg, 1 patient each experienced grade 3 hypertension and grade 3 fatigue, and 2 patients experienced grade 3 and 4 transaminase elevation.  In 12 addnl. patients treated at 1.0 mg, no DLT was obsd.  Pharmacokinetics displayed long absorption time, dose proportional exposure, and a half-life of 4.7 days.  Plasma levels of VEGF-A and sol. VEGFR-2 showed dose-dependent increases and decreases, resp.  Dynamic contrast-enhanced MRI indicated redn. in tumor perfusion.  Clin. activity was obsd. in renal cell cancer, colorectal cancer, and other tumors.  CONCLUSION: Tivozanib was well tolerated with manageable side effects.  The pharmacokinetics profile revealed that tivozanib was suitable for once-daily dosing.  Encouraging and durable clin. activity was obsd.  The recommended daily dose of tivozanib in a 4-wk-on and 2-wk-off dosing regimen is 1.5 mg.  Clin Cancer Res; 17(22); 7156-63.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH0XTrTm3PZLVg90H21EOLACvtfcHk0lh-FwVxm6KwJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7bJ&md5=553464e342dd352a47c125cb3e84f8ba</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0411%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%26aulast%3DBhargava%26aufirst%3DP.%26aulast%3DIsoe%26aufirst%3DT.%26aulast%3DCotreau%26aufirst%3DM.%2BM.%26aulast%3DEsteves%26aufirst%3DB.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DThomeer%26aufirst%3DM.%26aulast%3Dvan%2BDoorn%26aufirst%3DL%26aulast%3DVerweij%26aufirst%3DJ.%26atitle%3DBiologic%2520and%2520clinical%2520activity%2520of%2520tivozanib%2520%2528AV-951%252C%2520KRN-951%2529%252C%2520a%2520selective%2520inhibitor%2520of%2520VEGF%2520receptor-1%252C%2520-2%252C%2520and%2520-3%2520tyrosine%2520kinases%252C%2520in%2520a%25204-week-on%252C%25202-week-off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7156%26epage%3D7163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Nosov, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipatov, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyulko, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anischenko, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chacko, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doval, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strahs, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slichenmyer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhargava, P.</span><span> </span><span class="NLM_article-title">Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1678</span><span class="NLM_x">–</span> <span class="NLM_lpage">1685</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2011.35.3524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22493422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVKjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1678-1685&author=D.+A.+Nosovauthor=B.+Estevesauthor=O.+N.+Lipatovauthor=A.+A.+Lyulkoauthor=A.+A.+Anischenkoauthor=R.+T.+Chackoauthor=D.+C.+Dovalauthor=A.+Strahsauthor=W.+J.+Slichenmyerauthor=P.+Bhargava&title=Antitumor+activity+and+safety+of+tivozanib+%28AV-951%29+in+a+phase+II+randomized+discontinuation+trial+in+patients+with+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma</span></div><div class="casAuthors">Nosov, Dmitry A.; Esteves, Brooke; Lipatov, Oleg N.; Lyulko, Alexei A.; Anischenko, A. A.; Chacko, Raju T.; Doval, Dinesh C.; Strahs, Andrew; Slichenmyer, William J.; Bhargava, Pankaj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1678-1685</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The antitumor activity and safety of tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, was assessed in patients with advanced/metastatic renal cell carcinoma (RCC).  In this phase II, randomized discontinuation trial, 272 patients received open-label tivozanib 1.5 mg/d (one cycle equaled three treatment weeks followed by a 1-wk break) orally for 16 wk.  Thereafter, 78 patients who demonstrated ≥ 25% tumor shrinkage continued to take tivozanib, and 118 patients with less than 25% tumor change were randomly assigned to receive tivozanib or a placebo in a double-blind manner; patients with ≥ 25% tumor growth were discontinued.  Primary end points included safety, the objective response rate (ORR) at 16 wk, and the percentage of randomly assigned patients who remained progression free after 12 wk of double-blind treatment; secondary end points included progression-free survival (PFS).  Of 272 patients enrolled onto the study, 83% of patients had clear-cell histol., 73% of patients had undergone nephrectomy, and 54% of patients were treatment naive.  The ORR after 16 wk of tivozanib treatment was 18% (95% CI, 14% to 23%).  Of the 118 randomized patients, significantly more patients who were randomly assigned to receive double-blind tivozanib remained progression free after 12 wk vs. patients who received the placebo (49% v 21%; P = .001).  Throughout the study, the ORR was 24% (95% CI, 19% to 30%), and the median PFS was 11.7 mo (95% CI, 8.3 to 14.3 mo) in the overall study population.  The most common grade 3 and 4 treatment-related adverse event was hypertension (12%).  Tivozanib was active and well tolerated in patients with advanced RCC.  These data support addnl. development of tivozanib in advanced RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpenqlk93atmbVg90H21EOLACvtfcHk0lh-FwVxm6KwJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVKjtrY%253D&md5=4ceec72bbd500b3ade59e8573db40b52</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.3524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.3524%26sid%3Dliteratum%253Aachs%26aulast%3DNosov%26aufirst%3DD.%2BA.%26aulast%3DEsteves%26aufirst%3DB.%26aulast%3DLipatov%26aufirst%3DO.%2BN.%26aulast%3DLyulko%26aufirst%3DA.%2BA.%26aulast%3DAnischenko%26aufirst%3DA.%2BA.%26aulast%3DChacko%26aufirst%3DR.%2BT.%26aulast%3DDoval%26aufirst%3DD.%2BC.%26aulast%3DStrahs%26aufirst%3DA.%26aulast%3DSlichenmyer%26aufirst%3DW.%2BJ.%26aulast%3DBhargava%26aufirst%3DP.%26atitle%3DAntitumor%2520activity%2520and%2520safety%2520of%2520tivozanib%2520%2528AV-951%2529%2520in%2520a%2520phase%2520II%2520randomized%2520discontinuation%2520trial%2520in%2520patients%2520with%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1678%26epage%3D1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Matsui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span> </span><span class="NLM_article-title">Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5459</span><span class="NLM_x">–</span> <span class="NLM_lpage">5465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-07-5270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18765537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5459-5465&author=J.+Matsuiauthor=Y.+Funahashiauthor=T.+Uenakaauthor=T.+Watanabeauthor=A.+Tsuruokaauthor=M.+Asada&title=Multi-kinase+inhibitor+E7080+suppresses+lymph+node+and+lung+metastases+of+human+mammary+breast+tumor+MDA-MB-231+via+inhibition+of+vascular+endothelial+growth+factor-receptor+%28VEGF-R%29+2+and+VEGF-R3+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase</span></div><div class="casAuthors">Matsui, Junji; Funahashi, Yasuhiro; Uenaka, Toshimitsu; Watanabe, Tatsuo; Tsuruoka, Akihiko; Asada, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5459-5465</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Vascular endothelial growth factor (VEGF)-C/VEGF-receptor 3 (VEGF-R3) signal plays a significant role in lymphangiogenesis and tumor metastasis based on its effects on lymphatic vessels.  However, little is known about the effect of inhibiting VEGF-R3 on lymphangiogenesis and lymph node metastases using a small-mol. kinase inhibitor.  Exptl. Design: We evaluated the effect of E7080, a potent inhibitor of both VEGF-R2 and VEGF-R3 kinase, and bevacizumab on lymphangiogenesis and angiogenesis in a mammary fat pad xenograft model of human breast cancer using MDA-MB-231 cells that express excessive amts. of VEGF-C.  Lymphangiogenesis was detd. by lymphatic vessel d. (LVD) and angiogenesis by microvessel d. (MVD).  RESULTS: In contrast to MDA-MB-435 cells, which expressed a similar amt. of VEGF to MDA-MB-231 cells with an undetectable amt. of VEGF-C, only MDA-MB-231 exhibited lymphangiogenesis in the primary tumor.  E7080 but not bevacizumab significantly decreased LVD within the MDA-MB-231 tumor.  E7080 and bevacizumab decreased MVD in both the MDA-MB-231 and MDA-MB-435 models.  E7080 significantly suppressed regional lymph nodes and distant lung metastases of MDA-MB-231, whereas bevacizumab significantly inhibited only lung metastases.  E7080 also decreased both MVD and LVD within the metastatic nodules at lymph nodes after resection of the primary tumor.  CONCLUSIONS: Inhibition of VEGF-R3 kinase with E7080 effectively decreased LVD within MDA-MB-231 tumors, which express VEGF-C.  Simultaneous inhibition of both VEGF-R2 and VEGF-R3 kinases by E7080 may be a promising new strategy to control regional lymph node and distant lung metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrBisu80xI7Vg90H21EOLACvtfcHk0livXqKk-No3LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbjP&md5=0a73511c46d0f668f09f84d89c718417</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-5270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-5270%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DAsada%26aufirst%3DM.%26atitle%3DMulti-kinase%2520inhibitor%2520E7080%2520suppresses%2520lymph%2520node%2520and%2520lung%2520metastases%2520of%2520human%2520mammary%2520breast%2520tumor%2520MDA-MB-231%2520via%2520inhibition%2520of%2520vascular%2520endothelial%2520growth%2520factor-receptor%2520%2528VEGF-R%2529%25202%2520and%2520VEGF-R3%2520kinase%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D5459%26epage%3D5465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Ikuta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trung, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanibuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sone, S.</span><span> </span><span class="NLM_article-title">E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7229</span><span class="NLM_x">–</span> <span class="NLM_lpage">7237</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-09-1980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19934291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSnu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=7229-7237&author=K.+Ikutaauthor=S.+Yanoauthor=V.+T.+Trungauthor=M.+Hanibuchiauthor=H.+Gotoauthor=Q.+Liauthor=W.+Wangauthor=T.+Yamadaauthor=H.+Oginoauthor=S.+Kakiuchiauthor=H.+Ueharaauthor=Y.+Sekidoauthor=T.+Uenakaauthor=Y.+Nishiokaauthor=S.+Sone&title=E7080%2C+a+multi-tyrosine+kinase+inhibitor%2C+suppresses+the+progression+of+malignant+pleural+mesothelioma+with+different+proangiogenic+cytokine+production+profiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles</span></div><div class="casAuthors">Ikuta, Kenji; Yano, Seiji; Trung, Van-The; Hanibuchi, Masaki; Goto, Hisatsugu; Li, Qi; Wang, Wei; Yamada, Tadaaki; Ogino, Hirokazu; Kakiuchi, Soji; Uehara, Hisanori; Sekido, Yoshitaka; Uenaka, Toshimitsu; Nishioka, Yasuhiko; Sone, Saburo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7229-7237</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Malignant pleural mesothelioma (MPM) is a biol. heterogeneous malignant disease with a poor prognosis.  We reported previously that the anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, effectively inhibited the progression of VEGF-high-producing (but not VEGF-low-producing) MPM cells in orthotopic implantation models, indicating the need for novel therapeutic strategies to improve the poor prognosis of this disease.  Therefore, we focused on the multi-tyrosine kinase inhibitor E7080 and assessed its therapeutic efficacy against MPM cells with different proangiogenic cytokine prodn. profiles.  Exptl. Design: The efficacy of E7080 was assayed in orthotopic implantation of severe combined immunodeficient mouse models with three human MPM cell lines (MSTO-211H, NCI-H290, and Y-MESO-14).  Results: With regard to proangiogenic cytokine prodn. profiles, MSTO-211H and Y-MESO-14 cells were MPM cells producing high levels of fibroblast growth factor-2 and VEGF, resp.  NCI-H290 cells produced low levels of fibroblast growth factor-2 and VEGF compared with the other two cell lines.  E7080 potently suppressed the phosphorylation of VEGF receptor-2 and FGF receptor 1 and, thus, inhibited proliferation of endothelial cells, but not that of the MPM cell lines, in vitro.  Orthotopically inoculated MSTO-211H cells produced only thoracic tumors, whereas NCI-H290 and Y-MESO-14 cells also developed pleural effusions.  Treatment with E7080 potently inhibited the progression of these three MPM cell lines and markedly prolonged mouse survival, which was assocd. with decreased nos. of tumor-assocd. vessels and proliferating MPM cells in the tumor.  Conclusions: These results strongly suggest broad-spectrum activity of E7080 against MPM with different proangiogenic cytokine prodn. profiles in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe_SW2h8GtULVg90H21EOLACvtfcHk0livXqKk-No3LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSnu7zF&md5=d2951fa3185a26e695d2fd6a95625ebc</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1980%26sid%3Dliteratum%253Aachs%26aulast%3DIkuta%26aufirst%3DK.%26aulast%3DYano%26aufirst%3DS.%26aulast%3DTrung%26aufirst%3DV.%2BT.%26aulast%3DHanibuchi%26aufirst%3DM.%26aulast%3DGoto%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DOgino%26aufirst%3DH.%26aulast%3DKakiuchi%26aufirst%3DS.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DSekido%26aufirst%3DY.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DE7080%252C%2520a%2520multi-tyrosine%2520kinase%2520inhibitor%252C%2520suppresses%2520the%2520progression%2520of%2520malignant%2520pleural%2520mesothelioma%2520with%2520different%2520proangiogenic%2520cytokine%2520production%2520profiles%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D7229%26epage%3D7237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Bruheim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fodstad, Ø.</span><span> </span><span class="NLM_article-title">Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1002%2Fijc.25922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21225632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFGitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=742-750&author=S.+Bruheimauthor=A.+Kristianauthor=T.+Uenakaauthor=Z.+Suoauthor=A.+Tsuruokaauthor=J.+M.+Neslandauthor=%C3%98.+Fodstad&title=Antitumour+activity+of+oral+E7080%2C+a+novel+inhibitor+of+multiple+tyrosine+kinases%2C+in+human+sarcoma+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts</span></div><div class="casAuthors">Bruheim, Skjalg; Kristian, Alexandr; Uenaka, Toshimitsu; Suo, Zhenhe; Tsuruoka, Akihiko; Nesland, Jahn M.; Fodstad, Oystein</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">E7080 is an inhibitor of multiple tyrosine kinases, several of which have pro-angiogenic properties, including receptors for VEGF, FGF, SCF, and PDGF.  We undertook our study to evaluate the preclin. activity of E7080 in human sarcomas.  The antitumor activity of orally administered E7080 was tested in 10 human tumor xenografts representing different sarcoma histotypes.  Concomitant changes in microvessel d. were assayed by immunohistochem. to CD31.  Immunohistochem. was also used to assess the expression of kinases that E7080 is known to inhibit.  The MTS assay was applied to det. effects on tumor cell viability in vitro.  At the Q1D5 × 2 schedule, E7080 (30 mg/kg) was active (T/C<40%) in 7/10 xenografts.  The effects were accompanied by marked decrease in microvessel densities.  Given at the Q1D5 × 4 schedule, E7080 (30, 10, 3 mg/kg) showed antitumor activity in a dose dependent manner in 2 different xenografts.  E7080 growth inhibition did not correlate with the expression of VEGFR1-3, PDGFRA, PDGFRB, FGFR1, or KIT on tumor cells but was significantly correlated with expression of VEGFR2 on tumor microvessels.  In vitro E7080 did not show potent effects on tumor cell viability in 4 different sarcoma cell lines, with IC50 values ≥10 μM.  In conclusion, E7080 showed broad in vivo antitumor activity in sarcoma, mainly attributable to angiogenesis inhibition.  E7080 was also active in xenografts resistant to one or more clin. relevant ref. drugs given at MTD (doxorubicin, cisplatin, or ifosfamide).  The present results encourage further investigation of a potential role of E7080 in sarcoma therapy in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOQpVNIGK-17Vg90H21EOLACvtfcHk0livXqKk-No3LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFGitbw%253D&md5=dd53f080a9d3cc03f94533bd349a7b8a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1002%2Fijc.25922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25922%26sid%3Dliteratum%253Aachs%26aulast%3DBruheim%26aufirst%3DS.%26aulast%3DKristian%26aufirst%3DA.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DSuo%26aufirst%3DZ.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DNesland%26aufirst%3DJ.%2BM.%26aulast%3DFodstad%26aufirst%3D%25C3%2598.%26atitle%3DAntitumour%2520activity%2520of%2520oral%2520E7080%252C%2520a%2520novel%2520inhibitor%2520of%2520multiple%2520tyrosine%2520kinases%252C%2520in%2520human%2520sarcoma%2520xenografts%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D742%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Gild, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clifton-Bligh, R.</span><span> </span><span class="NLM_article-title">Multikinase inhibitors: a new option for the treatment of thyroid cancer</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrendo.2011.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21862995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=617-624&author=M.+L.+Gildauthor=M.+Bullockauthor=B.+G.+Robinsonauthor=R.+Clifton-Bligh&title=Multikinase+inhibitors%3A+a+new+option+for+the+treatment+of+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Multikinase inhibitors: a new option for the treatment of thyroid cancer</span></div><div class="casAuthors">Gild, Matti L.; Bullock, Martyn; Robinson, Bruce G.; Clifton-Bligh, Roderick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">617-624</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Preclin. models have shown that inhibition of kinases in mitogenic and angiogenic signaling pathways can have antitumoral effects.  Starting with a brief synopsis of a malignancy that responds well to kinase inhibition (chronic myeloid leukemia) compared with one with less durable responses as yet (melanoma), this Review highlights challenges that must be overcome in order to successfully translate small-mol. therapies to thyroid cancer in the future.  Thyroid cancer typically has a good outcome following std. treatments, which include surgery, radioactive iodine ablation and treatment with TSH-suppressive levothyroxine.  Thyroid cancers that persist or recur following these therapies have a poorer prognosis.  Activation of mitogenic and angiogenic signaling pathways occurs in these cancers, and preclin. models have shown that inhibition of key kinase steps in these pathways can have antitumoral effects.  Several of these kinase inhibitors have now been tested in phase II and phase III trials, with modestly encouraging results.  Some promising data exist for the use of vandetanib (also known as ZD6474), motesanib, axitinib, cabozantinib (also known as XL184), sorafenib, sunitinib, pazopanib and lenvatinib (also known as E7080) in progressive thyroid cancer of medullary, papillary and follicular subtypes.  These drugs are generally well-tolerated, although dose-limiting toxicities are common, and a few (probable) treatment-related deaths have been reported.  Addnl. phase III trials will be needed to conclusively show that treatment benefit exceeds risk.  Drug resistance can occur via activation of alternate mitogenic signals (pathway switching), as has been reported for the use of kinase inhibitors in other malignancies, such as melanoma.  The hypothesis that combinations of kinase inhibitors targeting different pathways might produce better results is currently being tested in several clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXsZ46UZpqrbVg90H21EOLACvtfcHk0lhYZ-WgQe_hXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajsr3F&md5=7ac1c2c3f6693ac567c1c2000eda01c0</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2011.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2011.141%26sid%3Dliteratum%253Aachs%26aulast%3DGild%26aufirst%3DM.%2BL.%26aulast%3DBullock%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DClifton-Bligh%26aufirst%3DR.%26atitle%3DMultikinase%2520inhibitors%253A%2520a%2520new%2520option%2520for%2520the%2520treatment%2520of%2520thyroid%2520cancer%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2011%26volume%3D7%26spage%3D617%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nokihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koizumi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-2638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21372218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2528-2537&author=K.+Yamadaauthor=N.+Yamamotoauthor=Y.+Yamadaauthor=H.+Nokiharaauthor=Y.+Fujiwaraauthor=T.+Hirataauthor=F.+Koizumiauthor=K.+Nishioauthor=N.+Koyamaauthor=T.+Tamura&title=Phase+I+dose-escalation+study+and+biomarker+analysis+of+E7080+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Yamada, Kazuhiko; Yamamoto, Noboru; Yamada, Yasuhide; Nokihara, Hiroshi; Fujiwara, Yutaka; Hirata, Taizo; Koizumi, Fumiaki; Nishio, Kazuto; Koyama, Noriyuki; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2528-2537</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">E7080, an oral multitargeted receptor tyrosine kinase inhibitor, has antiangiogenic and antitumor activity.  This Phase I study investigated max. tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in patients with advanced solid tumors.  In this sequential, dose-escalation, open-label study E7080 was administered orally twice daily in a 2-wk-on/1-wk-off cycle.  Plasma angiogenic proteins, circulating endothelial cells (CEC) and circulating progenitor cells (CEP) were measured for biomarker anal.  27 Patients (median age 53 years, performance status 0/1) were enrolled.  E7080 was escalated from 0.5 to 1, 2, 4, 6, 9, 13, 16, and 20 mg bid by conventional 3-patient cohorts.  During cycle 1, no grade 3/4 toxicity was obsd. up to 13 mg bid.  DLTs included grade 3 AST/ALT increase in 1 patient at 16 mg bid and grade 3 platelet count decrease in 2 patients at 20 mg bid.  The MTD of 13 mg bid was detd.  After repeated doses, Cmax and area under the plasma concn.-time curve increased in a dose-dependent manner.  After 14 days' treatment, c-kit(+) CEPs and CECs significantly decreased in cycle 1, but c-kit(-) CEPs and CECs did not.  Change from baseline in c-kit(+) CEC ratio in cycle 1 and baseline SDF1α, c-kit(+) CEPs and c-kit(+) CEP ratio significantly correlated with the E7080 therapeutic effect.  E7080 has manageable toxicity up to 13 mg bid when administered in a 2-wk-on/1-wk-off cycle and shows preliminary activity for durable disease control.  Biomarker anal. suggested antiangiogenic activity correlated with antitumor activity in patients with a wide range of solid tumors.  Clin Cancer Res; 17(8); 2528-37.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxPI3w_iSeVLVg90H21EOLACvtfcHk0lhYZ-WgQe_hXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgtL8%253D&md5=b64b561784f68928d1ff513143f013c4</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2638%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DKoizumi%26aufirst%3DF.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DKoyama%26aufirst%3DN.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520and%2520biomarker%2520analysis%2520of%2520E7080%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2528%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keesen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tait, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copalu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanders, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. R.</span><span> </span><span class="NLM_article-title">A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1598</span><span class="NLM_x">–</span> <span class="NLM_lpage">1604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fbjc.2012.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22516948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=1598-1604&author=D.+S.+Bossauthor=H.+Glenauthor=J.+H.+Beijnenauthor=M.+Keesenauthor=R.+Morrisonauthor=B.+Taitauthor=W.+Copaluauthor=A.+Mazurauthor=J.+Wandersauthor=J.+P.+O%E2%80%99Brienauthor=J.+H.+Schellensauthor=T.+R.+Evans&title=A+phase+I+study+of+E7080%2C+a+multitargeted+tyrosine+kinase+inhibitor%2C+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours</span></div><div class="casAuthors">Boss, D. S.; Glen, H.; Beijnen, J. H.; Keesen, M.; Morrison, R.; Tait, B.; Copalu, W.; Mazur, A.; Wanders, J.; O'Brien, J. P.; Schellens, J. H. M.; Evans, T. R. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1598-1604</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumors; to det. the max. tolerated dose (MTD) and pharmacokinetics profile of E7080; and to explore preliminary evidence of its anti-tumor efficacy.  Methods: E7080 was administered orally in escalating doses on a once-daily continuous schedule in 28-day cycles to eligible patients.  Samples for pharmacokinetic analyses were collected on days 1, 8, 15 and 22 of cycle 1 and day 1 of cycle 2.  Anti-tumor efficacy was assessed every two cycles.  Results: Eighty-two patients received E7080 in dose cohorts from 0.2 to 32 mg.  Dose-limiting toxicities were grade 3 proteinuria (two patients) at 32 mg, and the MTD was defined as 25 mg.  The most frequently obsd. cumulative toxicities (all grades) were hypertension (40% of patients), diarrhea (45%), nausea (37%), stomatitis (32%) and vomiting (23%).  Seven patients (9%) had a partial response and 38 patients (46%) had stable disease as best response.  E7080 has dose-linear kinetics with no drug accumulation after 4 wk administration.  Conclusion: E7080 is well tolerated at doses up to 25 mg per day.  Encouraging anti-tumor efficacy was obsd. in patients with melanoma and renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhiK54hAkTpbVg90H21EOLACvtfcHk0lhYZ-WgQe_hXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFajsb8%253D&md5=2bb367d69a6dfb5a94cbf1720a52224d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.154%26sid%3Dliteratum%253Aachs%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DGlen%26aufirst%3DH.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DKeesen%26aufirst%3DM.%26aulast%3DMorrison%26aufirst%3DR.%26aulast%3DTait%26aufirst%3DB.%26aulast%3DCopalu%26aufirst%3DW.%26aulast%3DMazur%26aufirst%3DA.%26aulast%3DWanders%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BP.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DT.%2BR.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520E7080%252C%2520a%2520multitargeted%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D106%26spage%3D1598%26epage%3D1604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Bello, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlato, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valbusa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incalci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalletti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camboni, G.</span><span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1396</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1396%26epage%3D1405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Sala, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cereda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incalci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucchetti, M.</span><span> </span><span class="NLM_article-title">Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study</span> <span class="citation_source-journal">J. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=1039-1045&author=F.+Salaauthor=R.+Bagnatiauthor=V.+Liviauthor=R.+Ceredaauthor=M.+D%E2%80%99Incalciauthor=M.+Zucchetti&title=Development+and+validation+of+a+high-performance+liquid+chromatography-tandem+mass+spectrometry+method+for+the+determination+of+the+novel+inhibitor+of+angiogenesis+E-3810+in+human+plasma+and+its+application+in+a+clinical+pharmacokinetic+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSala%26aufirst%3DF.%26aulast%3DBagnati%26aufirst%3DR.%26aulast%3DLivi%26aufirst%3DV.%26aulast%3DCereda%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DZucchetti%26aufirst%3DM.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520high-performance%2520liquid%2520chromatography-tandem%2520mass%2520spectrometry%2520method%2520for%2520the%2520determination%2520of%2520the%2520novel%2520inhibitor%2520of%2520angiogenesis%2520E-3810%2520in%2520human%2520plasma%2520and%2520its%2520application%2520in%2520a%2520clinical%2520pharmacokinetic%2520study%26jtitle%3DJ.%2520Mass%2520Spectrom.%26date%3D2011%26volume%3D46%26spage%3D1039%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Cai, S.; Chou, J.; Harwood, E.; Machajewski, T. D.; Ryckman, D.; Shang, X.; Zhu, S.</span><span> </span><span class="NLM_article-title">Preparation of Benzimidazole Quinolinones and Lactate Salts Thereof for Inhibiting Vascular Endothelial Growth Factor Receptor Tyrosine Kinase</span>. WO 2005046589,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=S.+Cai&author=J.+Chou&author=E.+Harwood&author=T.+D.+Machajewski&author=D.+Ryckman&author=X.+Shang&author=S.+Zhu&title=Preparation+of+Benzimidazole+Quinolinones+and+Lactate+Salts+Thereof+for+Inhibiting+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Benzimidazole%2520Quinolinones%2520and%2520Lactate%2520Salts%2520Thereof%2520for%2520Inhibiting%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Renhowe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machajewski, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonios-McCrea, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aardalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernette-Hammond, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span> </span><span class="NLM_article-title">Design, structure–activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800790t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=278-292&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure%E2%80%93activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+a+novel+class+of+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm800790t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800790t%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure%25E2%2580%2593activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D278%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopes de Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordahl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aukerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelb, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span> </span><span class="NLM_article-title">In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3633</span><span class="NLM_x">–</span> <span class="NLM_lpage">3641</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-04-2129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=15897558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFyrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3633-3641&author=S.+H.+Leeauthor=D.+Lopes+de+Menezesauthor=J.+Voraauthor=A.+Harrisauthor=H.+Yeauthor=L.+Nordahlauthor=E.+Garrettauthor=E.+Samaraauthor=S.+L.+Aukermanauthor=A.+B.+Gelbauthor=C.+Heise&title=In+vivo+target+modulation+and+biological+activity+of+CHIR-258%2C+a+multitargeted+growth+factor+receptor+kinase+inhibitor%2C+in+colon+cancer+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models</span></div><div class="casAuthors">Lee, Sang Hoon; Lopes de Menezes, Daniel; Vora, Jayesh; Harris, Alex; Ye, Helen; Nordahl, Lara; Garrett, Evelyn; Samara, Emil; Aukerman, Sharon Lea; Gelb, Arnold B.; Heise, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3633-3641</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To evaluate the therapeutic and biol. effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases, in colon cancer models.  Exptl. Design: The pharmacol. activity of CHIR-258 was characterized by monitoring target modulation as well as by evaluating the antitumor and antiangiogenic effects in human colon xenograft models.  Results: CHIR-258 inhibits vascular endothelial growth factor receptor 1/2, fibroblast growth factor receptor 1/3, and platelet-derived growth factor receptor β (PDGFRβ) and shows both antitumor and antiangiogenic activities in vivo.  Treatment of KM12L4a human colon cancer cells with CHIR-258 resulted in a dose-dependent inhibition of vascular endothelial growth factor receptor 1 and PDGFRβ phosphorylation and redn. of phosphorylated extracellular signal-regulated kinase (ERK) levels, indicating modulation of target receptors and downstream signaling.  In vivo administration of CHIR-258 resulted in significant tumor growth inhibition and tumor regressions, including large, established tumors (500-1,000 mm3).  Immunohistochem. anal. showed a redn. of phosphorylated PDGFRβ and phosphorylated ERK in tumor cells after oral dosing with CHIR-258 compared with control tumors.  These changes were accompanied by decreased tumor cell proliferation rate and reduced intratumoral microvessel d.  CHIR-258 inhibited the phosphorylation of PDGFRβ and ERK phosphorylation in tumors within 2 h following dosing and the inhibitory activity was sustained for >24 h.  Significant antitumor activity was obsd. with intermittent dosing schedules, indicating a sustained biol. activity.  Conclusion: These studies provide evidence that biol. activity of CHIR-258 in tumors correlates with efficacy and aids in the identification of potential biomarkers of this multitargeted receptor tyrosine kinase inhibitor.  CHIR-258 exhibits properties that make it a promising candidate for clin. development in a variety of solid and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBYM9bzT_QQLVg90H21EOLACvtfcHk0li_wnqyaCsgIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFyrsb4%253D&md5=eeca79fe190dcdc2db251d6e836ec4ab</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2129%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLopes%2Bde%2BMenezes%26aufirst%3DD.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DNordahl%26aufirst%3DL.%26aulast%3DGarrett%26aufirst%3DE.%26aulast%3DSamara%26aufirst%3DE.%26aulast%3DAukerman%26aufirst%3DS.%2BL.%26aulast%3DGelb%26aufirst%3DA.%2BB.%26aulast%3DHeise%26aufirst%3DC.%26atitle%3DIn%2520vivo%2520target%2520modulation%2520and%2520biological%2520activity%2520of%2520CHIR-258%252C%2520a%2520multitargeted%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%252C%2520in%2520colon%2520cancer%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D3633%26epage%3D3641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Lopes de Menezes, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shephard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldbeck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aukerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span> </span><span class="NLM_article-title">CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5281</span><span class="NLM_x">–</span> <span class="NLM_lpage">5291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-05-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16033847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt12qurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5281-5291&author=D.+E.+Lopes+de+Menezesauthor=J.+Pengauthor=E.+N.+Garrettauthor=S.+G.+Louieauthor=S.+H.+Leeauthor=M.+Wiesmannauthor=Y.+Tangauthor=L.+Shephardauthor=C.+Goldbeckauthor=Y.+Oeiauthor=H.+Yeauthor=S.+L.+Aukermanauthor=C.+Heise&title=CHIR-258%3A+a+potent+inhibitor+of+FLT3+kinase+in+experimental+tumor+xenograft+models+of+human+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia</span></div><div class="casAuthors">Lopes de Menezes, Daniel E.; Peng, Jing; Garrett, Evelyn N.; Louie, Sharianne G.; Lee, Sang H.; Wiesmann, Marion; Tang, Yan; Shephard, Lee; Goldbeck, Cheryl; Oei, Yoko; Ye, Helen; Aukerman, Sharon L.; Heise, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5281-5291</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fms-like tyrosine kinase 3 (FLT3) encodes a receptor tyrosine kinase (RTK) for which activating mutations have been identified in a proportion of acute myelogenous leukemia (AML) patients and assocd. with poor clin. prognosis.  Given the relevance of FLT3 mutations in AML, we investigated the activity of CHIR-258, an orally active, multitargeted small mol., with potent activity against FLT3 kinase and class III, IV, and V RTKs involved in endothelial and tumor cell proliferation in AML models.  Exptl. Design: CHIR-258 was tested on two human leukemic cell lines in vitro and in vivo with differing FLT3 mutational status [MV4;11 cells express FLT3 internal tandem duplications (ITD) vs. RS4;11 cells with wild-type (WT) FLT3].  Results: Antiproliferative activity of CHIR-258 against MV4;11 was ∼24-fold greater compared with RS4;11, indicating more potent inhibition against cells with constitutively activated FLT3 ITD.  Dose-dependent down modulation of receptor phosphorylation and downstream signaling [signal transducer and activator of transcription 5 (STAT5) and extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase] in MV4;11 cells with CHIR-258 confirmed the mol. mechanism of action.  Target modulation of phospho-FLT3, phospho-STAT5, and phospho-ERK in MV4;11 tumors was achieved at biol. active doses of CHIR-258.  Tumor regressions and eradication of AML cells from the bone marrow were shown in s.c. and bone marrow engraftment leukemic xenograft models.  Tumor responses were characterized by decreased cellular proliferation and pos. immunohistochem. staining for active caspase-3 and cleaved poly(ADP-ribose) polymerase, suggesting cell death was mediated in part via apoptosis.  Conclusions: These data indicate that CHIR-258 may be an effective therapy in FLT3-assocd. AML and warrants clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqguTG7oB17arVg90H21EOLACvtfcHk0lil_yxAyB0wdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt12qurc%253D&md5=81dc564d120f28420fdd69f685f877c2</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0358%26sid%3Dliteratum%253Aachs%26aulast%3DLopes%2Bde%2BMenezes%26aufirst%3DD.%2BE.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DGarrett%26aufirst%3DE.%2BN.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DShephard%26aufirst%3DL.%26aulast%3DGoldbeck%26aufirst%3DC.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DAukerman%26aufirst%3DS.%2BL.%26aulast%3DHeise%26aufirst%3DC.%26atitle%3DCHIR-258%253A%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520kinase%2520in%2520experimental%2520tumor%2520xenograft%2520models%2520of%2520human%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5281%26epage%3D5291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Xin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbach, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rendahl, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oei, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Embry, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinarski, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryer, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trudel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jallal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. C.</span><span> </span><span class="NLM_article-title">CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4908</span><span class="NLM_x">–</span> <span class="NLM_lpage">4915</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-06-0957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16914579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4908-4915&author=X.+Xinauthor=T.+J.+Abramsauthor=P.+W.+Hollenbachauthor=K.+G.+Rendahlauthor=Y.+Tangauthor=Y.+A.+Oeiauthor=M.+G.+Embryauthor=D.+E.+Swinarskiauthor=E.+N.+Garrettauthor=N.+K.+Pryerauthor=S.+Trudelauthor=B.+Jallalauthor=D.+B.+Mendelauthor=C.+C.+Heise&title=CHIR-258+is+efficacious+in+a+newly+developed+fibroblast+growth+factor+receptor+3-expressing+orthotopic+multiple+myeloma+model+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3-Expressing Orthotopic Multiple Myeloma Model in Mice</span></div><div class="casAuthors">Xin, Xiaohua; Abrams, Tinya J.; Hollenbach, Paul W.; Rendahl, Katherine G.; Tang, Yan; Oei, Yoko A.; Embry, Millicent G.; Swinarski, Debbie E.; Garrett, Evelyn N.; Pryer, Nancy K.; Trudel, Suzanne; Jallal, Bahija; Mendel, Dirk B.; Heise, Carla C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4908-4915</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) results from a t(4;14) chromosomal translocation that occurs in ∼15% of multiple myeloma (MM) patients and confers a particularly poor prognosis.  This study assesses the antimyeloma activity of CHIR-258, a small-mol. inhibitor of multiple receptor tyrosine kinases that is currently in phase I trials, in a newly developed FGFR3-driven preclin. MM animal model.  Exptl. Design: the authors developed an orthotopic MM model in mice using a luciferase-expressing human KMS-11-luc line that expresses mutant FGFR3 (Y373C).  The antimyeloma activity of CHIR-258 was evaluated at doses that inhibited FGFR3 signaling in vivo in this FGFR3-driven animal model.  RESULTS: Noninvasive bioluminescence imaging detected MM lesions in nearly all mice injected with KMS-11-luc cells, which were mainly localized in the spine, skull, and pelvis, resulting in frequent development of paralysis.  Daily oral administration of CHIR-258 at doses that inhibited FGFR3 signaling in KMS-11-luc tumors in vivo resulted in a significant inhibition of KMS-11-luc tumor growth, which translated into a significant improvement in animal survival.  CONCLUSIONS: the authors' data provide a relevant preclin. basis for clin. trials of CHIR-258 in FGFR3-pos. MM patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoitvR-0TUV87Vg90H21EOLACvtfcHk0lil_yxAyB0wdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKgt7g%253D&md5=af3f47f59ecf0593cbaf07db17d54fe3</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0957%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DX.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DHollenbach%26aufirst%3DP.%2BW.%26aulast%3DRendahl%26aufirst%3DK.%2BG.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DOei%26aufirst%3DY.%2BA.%26aulast%3DEmbry%26aufirst%3DM.%2BG.%26aulast%3DSwinarski%26aufirst%3DD.%2BE.%26aulast%3DGarrett%26aufirst%3DE.%2BN.%26aulast%3DPryer%26aufirst%3DN.%2BK.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DJallal%26aufirst%3DB.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26atitle%3DCHIR-258%2520is%2520efficacious%2520in%2520a%2520newly%2520developed%2520fibroblast%2520growth%2520factor%2520receptor%25203-expressing%2520orthotopic%2520multiple%2520myeloma%2520model%2520in%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D4908%26epage%3D4915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span> </span><span class="NLM_article-title">Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7451</span><span class="NLM_x">–</span> <span class="NLM_lpage">7461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-11-1747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21976540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7451-7461&author=K.+B.+Kimauthor=J.+Chesneyauthor=D.+Robinsonauthor=H.+Gardnerauthor=M.+M.+Shiauthor=J.+M.+Kirkwood&title=Phase+I%2FII+and+pharmacodynamic+study+of+dovitinib+%28TKI258%29%2C+an+inhibitor+of+fibroblast+growth+factor+receptors+and+VEGF+receptors%2C+in+patients+with+advanced+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma</span></div><div class="casAuthors">Kim, Kevin B.; Chesney, Jason; Robinson, Douglas; Gardner, Humphrey; Shi, Michael M.; Kirkwood, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7451-7461</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Dovitinib (TKI258) is an orally available inhibitor of fibroblast growth factor (FGF), VEGF, and platelet-derived growth factor receptors.  This phase I/II dose-escalation study was conducted to evaluate the safety, pharmacodynamics, and preliminary efficacy of dovitinib in the treatment of advanced melanoma.  Exptl. Design: Patients with advanced melanoma resistant or refractory to std. therapies or for whom no std. therapy was available were enrolled.  Dovitinib was administered at doses ranging from 200 to 500 mg/d.  RESULTS: Forty-seven patients were enrolled.  The most frequently reported adverse events were fatigue (77%; grade ≥3, 28%), diarrhea (77%; grade ≥3, 11%), and nausea (77%; grade ≥3, 9%).  Six dose-limiting toxicities were obsd. in the 400-mg and 500-mg dose cohorts, which consisted of grade 3 nausea, fatigue, and diarrhea and grade 4 fatigue events.  The max. tolerated dose was 400 mg/d.  The best tumor response was stable disease, which was obsd. in 12 patients.  Increases in plasma FGF23, VEGF, and placental growth factor and decreases in sol. VEGF receptor 2 were noted during the first cycle of treatment, consistent with FGF receptor (FGFR) and VEGF receptor (VEGFR) inhibition.  Dynamic contrast-enhanced MRI anal. showed a dose-dependent decrease in tumor blood flow and vascular permeability with dovitinib therapy.  A decrease in FGFR phosphorylation was obsd. in paired tumor biopsy samples from a patient treated with dovitinib at a dose of 400 mg/d.  CONCLUSIONS: At a dose of 400 mg/d, dovitinib showed an acceptable safety profile and limited clin. benefit and inhibited FGFR and VEGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovyP40Cwt1A7Vg90H21EOLACvtfcHk0lil_yxAyB0wdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrbF&md5=b477d8c021c7e18ef4d5f3bfb02f8d58</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1747%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DChesney%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DM.%2BM.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26atitle%3DPhase%2520I%252FII%2520and%2520pharmacodynamic%2520study%2520of%2520dovitinib%2520%2528TKI258%2529%252C%2520an%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520and%2520VEGF%2520receptors%252C%2520in%2520patients%2520with%2520advanced%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7451%26epage%3D7461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawver, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">5120</span><span class="NLM_x">–</span> <span class="NLM_lpage">5130</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9904295" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=5120-5130&author=L.+Sunauthor=N.+Tranauthor=C.+Liangauthor=F.+Tangauthor=A.+Riceauthor=R.+Schreckauthor=K.+Waltzauthor=L.+K.+Shawverauthor=G.+McMahonauthor=C.+Tang&title=Design%2C+synthesis%2C+and+evaluations+of+substituted+3-%5B%283-+or+4-carboxyethylpyrrol-2-yl%29methylidenyl%5Dindolin-2-ones+as+inhibitors+of+VEGF%2C+FGF%2C+and+PDGF+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Fjm9904295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9904295%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DRice%26aufirst%3DA.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DWaltz%26aufirst%3DK.%26aulast%3DShawver%26aufirst%3DL.%2BK.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluations%2520of%2520substituted%25203-%255B%25283-%2520or%25204-carboxyethylpyrrol-2-yl%2529methylidenyl%255Dindolin-2-ones%2520as%2520inhibitors%2520of%2520VEGF%252C%2520FGF%252C%2520and%2520PDGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D5120%26epage%3D5130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiramatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, H.</span><span> </span><span class="NLM_article-title">TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model</span> <span class="citation_source-journal">Surg. Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1053</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00595-009-4020-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19997799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFanu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=1046-1053&author=M.+Ohtaauthor=T.+Kawabataauthor=M.+Yamamotoauthor=T.+Tanakaauthor=H.+Kikuchiauthor=Y.+Hiramatsuauthor=K.+Kamiyaauthor=M.+Babaauthor=H.+Konno&title=TSU68%2C+an+antiangiogenic+receptor+tyrosine+kinase+inhibitor%2C+induces+tumor+vascular+normalization+in+a+human+cancer+xenograft+nude+mouse+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model</span></div><div class="casAuthors">Ohta, Manabu; Kawabata, Toshiki; Yamamoto, Masayoshi; Tanaka, Tatsuo; Kikuchi, Hirotoshi; Hiramatsu, Yoshihiro; Kamiya, Kinji; Baba, Megumi; Konno, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Surgery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1046-1053</span>CODEN:
                <span class="NLM_cas:coden">SUTOE5</span>;
        ISSN:<span class="NLM_cas:issn">0941-1291</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">Purpose: Combination therapy using antiangiogenic and cytotoxic agents is a useful strategy for advanced cancer, but the mechanism has not yet been elucidated.  Moreover, there is a persistent paradox that destroying tumor vasculature with antiangiogenic agents disturbs the delivery of cytotoxic agents.  It has been hypothesized that antiangiogenic agents can lead to normalization of tumor vessels that are structurally and functionally abnormal.  The normalization means enhancing the deliver of cytotoxic agents.  Our purpose was to investigate whether TSU68, a multiple receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), would induce the normalization of tumor vessels.  Methods: TSU68 was administered for 7 days to mice with xenografted tumors.  Tumors of interstitial fluid pressure (IFP) were measured before and after administration of agents.  Immunofluorescence double staining for CD31 and α-SMA was performed, and a medical video endoscopy system with narrowband illumination (NBI) was used to visualize the vascular pattern.  Results: TSU68 treatment decreased IFP significantly.  Immunofluorescence double staining showed a significant increase in the fraction of pericyte coverage in the TSU68-treated group.  NBI endoscopy showed that many tumor vessels in TSU68-treated mice were pruned and the diams. of remaining vessels were reduced.  Conclusion: The data supported our hypothesis of tumor vascular normalization by the antiangiogenic agent TSU68.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhs-1N0a5GWLVg90H21EOLACvtfcHk0lgFl1lhPWvmWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFanu7fN&md5=62d3aeb3a9967c82973901c6128be203</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1007%2Fs00595-009-4020-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00595-009-4020-y%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DKawabata%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DH.%26aulast%3DHiramatsu%26aufirst%3DY.%26aulast%3DKamiya%26aufirst%3DK.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DKonno%26aufirst%3DH.%26atitle%3DTSU68%252C%2520an%2520antiangiogenic%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520induces%2520tumor%2520vascular%2520normalization%2520in%2520a%2520human%2520cancer%2520xenograft%2520nude%2520mouse%2520model%26jtitle%3DSurg.%2520Today%26date%3D2009%26volume%3D39%26spage%3D1046%26epage%3D1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Klenke, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdollahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewerbeck, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sckell, A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=49-56&author=F.+M.+Klenkeauthor=A.+Abdollahiauthor=E.+Bertlauthor=M.+M.+Gebhardauthor=V.+Ewerbeckauthor=P.+E.+Huberauthor=A.+Sckell&title=Tyrosine+kinase+inhibitor+SU6668+represses+chondrosarcoma+growth+via+antiangiogenesis+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlenke%26aufirst%3DF.%2BM.%26aulast%3DAbdollahi%26aufirst%3DA.%26aulast%3DBertl%26aufirst%3DE.%26aulast%3DGebhard%26aufirst%3DM.%2BM.%26aulast%3DEwerbeck%26aufirst%3DV.%26aulast%3DHuber%26aufirst%3DP.%2BE.%26aulast%3DSckell%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibitor%2520SU6668%2520represses%2520chondrosarcoma%2520growth%2520via%2520antiangiogenesis%2520in%2520vivo%26jtitle%3DBMC%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D49%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiramatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, H.</span><span> </span><span class="NLM_article-title">TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9754</span><span class="NLM_x">–</span> <span class="NLM_lpage">9762</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9754-9762&author=M.+Yamamotoauthor=H.+Kikuchiauthor=M.+Ohtaauthor=T.+Kawabataauthor=Y.+Hiramatsuauthor=K.+Kondoauthor=M.+Babaauthor=K.+Kamiyaauthor=T.+Tanakaauthor=M.+Kitagawaauthor=H.+Konno&title=TSU68+prevents+liver+metastasis+of+colon+cancer+xenografts+by+modulating+the+premetastatic+niche"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DKawabata%26aufirst%3DT.%26aulast%3DHiramatsu%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DKamiya%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKitagawa%26aufirst%3DM.%26aulast%3DKonno%26aufirst%3DH.%26atitle%3DTSU68%2520prevents%2520liver%2520metastasis%2520of%2520colon%2520cancer%2520xenografts%2520by%2520modulating%2520the%2520premetastatic%2520niche%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9754%26epage%3D9762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Kanai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateishi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morizane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okusaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arioka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omata, M.</span><span> </span><span class="NLM_article-title">A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-010-1320-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20390419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1emsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=315-324&author=F.+Kanaiauthor=H.+Yoshidaauthor=R.+Tateishiauthor=S.+Satoauthor=T.+Kawabeauthor=S.+Obiauthor=Y.+Kondoauthor=M.+Taniguchiauthor=K.+Tagawaauthor=M.+Ikedaauthor=C.+Morizaneauthor=T.+Okusakaauthor=H.+Ariokaauthor=S.+Shiinaauthor=M.+Omata&title=A+phase+I%2FII+trial+of+the+oral+antiangiogenic+agent+TSU-68+in+patients+with+advanced+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma</span></div><div class="casAuthors">Kanai, Fumihiko; Yoshida, Haruhiko; Tateishi, Ryosuke; Sato, Shinpei; Kawabe, Takao; Obi, Shuntaro; Kondo, Yuji; Taniguchi, Makoto; Tagawa, Kazumi; Ikeda, Masafumi; Morizane, Chigusa; Okusaka, Takuji; Arioka, Hitoshi; Shiina, Shuichiro; Omata, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">315-324</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We studied the safety and effectiveness of TSU-68, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor and fibroblast growth factor receptor, in patients with advanced hepatocellular carcinoma (HCC).  Patients with unresectable or metastatic HCC were eligible for enrollment.  In phase I, the safety, tolerability and pharmacokinetics were assessed in patients stratified based on liver function, from no cirrhosis to Child-Pugh class B.  The safety and effectiveness were assessed in phase II at the dose detd. in phase I.  Twelve patients were enrolled in phase I. Dose-limiting toxicities were found with TSU-68 at the dose of 400 mg bid in Child-Pugh B patients, and 200 mg bid was established as the phase II dose.  Phase II included 23 addnl. patients, and the safety and efficacy were evaluated in a total of 35 patients.  One patient (2.9%) had a complete response.  Two patients (5.7%) had a partial response, and 15 patients (42.8%) showed a stable disease.  The median time to progression was 2.1 mo, and the median overall survival was 13.1 mo.  Common adverse events were hypoalbuminemia, diarrhea, anorexia, abdominal pain, malaise, edema and AST/ALT elevation.  The anal. of angiogenesis-related parameters suggests that serum-sol. vascular cell adhesion mol.-1 is a possible marker to show the response.  TSU-68 at a dose of 200 mg bid detd. by stratification into liver function, showed promising preliminary efficacy with a high safety profile in patients with HCC who had been heavily pre-treated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi7WlIgieisrVg90H21EOLACvtfcHk0lhJbJVkrwVrKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1emsr8%253D&md5=7e96a1e60b47a63e74414eedeffd7f74</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1007%2Fs00280-010-1320-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-010-1320-2%26sid%3Dliteratum%253Aachs%26aulast%3DKanai%26aufirst%3DF.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DTateishi%26aufirst%3DR.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DKawabe%26aufirst%3DT.%26aulast%3DObi%26aufirst%3DS.%26aulast%3DKondo%26aufirst%3DY.%26aulast%3DTaniguchi%26aufirst%3DM.%26aulast%3DTagawa%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DMorizane%26aufirst%3DC.%26aulast%3DOkusaka%26aufirst%3DT.%26aulast%3DArioka%26aufirst%3DH.%26aulast%3DShiina%26aufirst%3DS.%26aulast%3DOmata%26aufirst%3DM.%26atitle%3DA%2520phase%2520I%252FII%2520trial%2520of%2520the%2520oral%2520antiangiogenic%2520agent%2520TSU-68%2520in%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D67%26spage%3D315%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Toi, M.; Saeki, T.; Iwata, H.; Inoue, K.; Tokuda, Y.; Sato, Y.; Ito, Y.; Aogi, K.; Takatsuka, Y.; Arioka, H.</span><span> </span><span class="NLM_article-title">A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance</span>.  <span class="citation_source-journal">Breast Cancer</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1007/s10147-012-0421-9</span> . Published Online: Mar 2,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs10147-012-0421-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Toi&author=T.+Saeki&author=H.+Iwata&author=K.+Inoue&author=Y.+Tokuda&author=Y.+Sato&author=Y.+Ito&author=K.+Aogi&author=Y.+Takatsuka&author=H.+Arioka&title=A+multicenter+phase+II+study+of+TSU-68%2C+an+oral+multiple+tyrosine+kinase+inhibitor%2C+in+combination+with+docetaxel+in+metastatic+breast+cancer+patients+with+anthracycline+resistance&doi=10.1007%2Fs10147-012-0421-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2Fs10147-012-0421-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10147-012-0421-9%26sid%3Dliteratum%253Aachs%26aulast%3DToi%26aufirst%3DM.%26atitle%3DA%2520multicenter%2520phase%2520II%2520study%2520of%2520TSU-68%252C%2520an%2520oral%2520multiple%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520combination%2520with%2520docetaxel%2520in%2520metastatic%2520breast%2520cancer%2520patients%2520with%2520anthracycline%2520resistance%26jtitle%3DBreast%2520Cancer%26doi%3D10.1007%2Fs10147-012-0421-9%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handschuh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Lintz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4466</span><span class="NLM_x">–</span> <span class="NLM_lpage">4480</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krssak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kautschitsch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommergruber, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span> </span><span class="NLM_article-title">BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">4774</span><span class="NLM_x">–</span> <span class="NLM_lpage">4782</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4774-4782&author=F.+Hilbergauthor=G.+J.+Rothauthor=M.+Krssakauthor=S.+Kautschitschauthor=W.+Sommergruberauthor=U.+Tontsch-Gruntauthor=P.+Garin-Chesaauthor=G.+Baderauthor=A.+Zoephelauthor=J.+Quantauthor=A.+Heckelauthor=W.+J.+Rettig&title=BIBF+1120%3A+triple+angiokinase+inhibitor+with+sustained+receptor+blockade+and+good+antitumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DKrssak%26aufirst%3DM.%26aulast%3DKautschitsch%26aufirst%3DS.%26aulast%3DSommergruber%26aufirst%3DW.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBIBF%25201120%253A%2520triple%2520angiokinase%2520inhibitor%2520with%2520sustained%2520receptor%2520blockade%2520and%2520good%2520antitumor%2520efficacy%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4774%26epage%3D4782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Ledermann, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackshaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabra, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeish, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span> </span><span class="NLM_article-title">Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3798</span><span class="NLM_x">–</span> <span class="NLM_lpage">3804</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2010.33.5208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21859991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWrsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3798-3804&author=J.+A.+Ledermannauthor=A.+Hackshawauthor=S.+Kayeauthor=G.+Jaysonauthor=H.+Gabraauthor=I.+McNeishauthor=H.+Earlauthor=T.+Perrenauthor=M.+Goreauthor=M.+Persicauthor=M.+Adamsauthor=L.+Jamesauthor=G.+Templeauthor=M.+Mergerauthor=G.+Rustin&title=Randomized+phase+II+placebo-controlled+trial+of+maintenance+therapy+using+the+oral+triple+angiokinase+inhibitor+BIBF+1120+after+chemotherapy+for+relapsed+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer</span></div><div class="casAuthors">Ledermann, Jonathan A.; Hackshaw, Allan; Kaye, Stan; Jayson, Gordon; Gabra, Hani; McNeish, Iain; Earl, Helena; Perren, Tim; Gore, Martin; Persic, Mojca; Adams, Malcolm; James, Lindsay; Temple, Graham; Merger, Michael; Rustin, Gordon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3798-3804</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer.  We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease.  Patients and Methods: We conducted a randomized, double-blind, controlled phase II trial in 83 patients who had just completed chemotherapy for relapsed ovarian cancer, with evidence of response, but at high risk of further early recurrence.  The patients were randomly assigned to receive maintenance therapy using BIBF 1120 250 mg or placebo, twice per day, continuously for 36 wk.  End points were progression-free survival (PFS), toxicity, and overall survival.  Results: Thirty-six-week PFS rates were 16.3% and 5.0% in the BIBF 1120 and placebo groups, resp. (hazard ratio, 0.65; 95% CI, 0.42 to 1.02; P = .06).  Four patients continued on BIBF 1120, including two patients for another year or more.  The proportion of patients with any grade 3 or 4 adverse events was similar between the groups (34.9% for BIBF 1120 v 27.5% for placebo; P = .49; mostly grade 3).  However, more patients on BIBF 1120 experienced diarrhea, nausea, or vomiting (mainly grade 1 or 2 and no grade 4).  There was a higher rate of grade 3 or 4 hepatotoxicity in patients on BIBF 1120 (51.2%) compared with patients on placebo (7.5%; P < .001), but this was rarely of clin. significance, and patients continued with the trial treatment.  A single-level dose redn. to 150 mg was made in 15 patients, all on active drug.  Conclusion: BIBF 1120 is well tolerated and assocd. with a potential improvement in PFS.  The obsd. treatment effect is sufficient to justify further study within a large phase III trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZqwdS23hObVg90H21EOLACvtfcHk0lhJbJVkrwVrKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWrsb%252FE&md5=98a6a8e9c2a8c4cbcfa2fbb4f9c21c01</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.5208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.5208%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%2BA.%26aulast%3DHackshaw%26aufirst%3DA.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DJayson%26aufirst%3DG.%26aulast%3DGabra%26aufirst%3DH.%26aulast%3DMcNeish%26aufirst%3DI.%26aulast%3DEarl%26aufirst%3DH.%26aulast%3DPerren%26aufirst%3DT.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DPersic%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DTemple%26aufirst%3DG.%26aulast%3DMerger%26aufirst%3DM.%26aulast%3DRustin%26aufirst%3DG.%26atitle%3DRandomized%2520phase%2520II%2520placebo-controlled%2520trial%2520of%2520maintenance%2520therapy%2520using%2520the%2520oral%2520triple%2520angiokinase%2520inhibitor%2520BIBF%25201120%2520after%2520chemotherapy%2520for%2520relapsed%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3798%26epage%3D3804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Santos, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raez, L. E.</span><span> </span><span class="NLM_article-title">Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1269</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1261-1269&author=E.+S.+Santosauthor=J.+E.+Gomezauthor=L.+E.+Raez&title=Targeting+angiogenesis+from+multiple+pathways+simultaneously%3A+BIBF+1120%2C+an+investigational+novel+triple+angiokinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DE.%2BS.%26aulast%3DGomez%26aufirst%3DJ.%2BE.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26atitle%3DTargeting%2520angiogenesis%2520from%2520multiple%2520pathways%2520simultaneously%253A%2520BIBF%25201120%252C%2520an%2520investigational%2520novel%2520triple%2520angiokinase%2520inhibitor%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D1261%26epage%3D1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wietfeld, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sills, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acemoglu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmenegger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlachter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetterli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2310</span><span class="NLM_x">–</span> <span class="NLM_lpage">2323</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9909443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2310-2323&author=G.+Boldauthor=K.+H.+Altmannauthor=J.+Freiauthor=M.+Langauthor=P.+W.+Manleyauthor=P.+Traxlerauthor=B.+Wietfeldauthor=J.+Bruggenauthor=E.+Buchdungerauthor=R.+Cozensauthor=S.+Ferrariauthor=P.+Furetauthor=F.+Hofmannauthor=G.+Martiny-Baronauthor=J.+Mestanauthor=J.+Roselauthor=M.+Sillsauthor=D.+Stoverauthor=F.+Acemogluauthor=E.+Bossauthor=R.+Emmeneggerauthor=L.+Lasserauthor=E.+Massoauthor=R.+Rothauthor=C.+Schlachterauthor=W.+Vetterliauthor=D.+Wyssauthor=J.+M.+Wood&title=New+anilinophthalazines+as+potent+and+orally+well+absorbed+inhibitors+of+the+VEGF+receptor+tyrosine+kinases+useful+as+antagonists+of+tumor-driven+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm9909443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9909443%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DFrei%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DWietfeld%26aufirst%3DB.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DRosel%26aufirst%3DJ.%26aulast%3DSills%26aufirst%3DM.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DAcemoglu%26aufirst%3DF.%26aulast%3DBoss%26aufirst%3DE.%26aulast%3DEmmenegger%26aufirst%3DR.%26aulast%3DLasser%26aufirst%3DL.%26aulast%3DMasso%26aufirst%3DE.%26aulast%3DRoth%26aufirst%3DR.%26aulast%3DSchlachter%26aufirst%3DC.%26aulast%3DVetterli%26aufirst%3DW.%26aulast%3DWyss%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DNew%2520anilinophthalazines%2520as%2520potent%2520and%2520orally%2520well%2520absorbed%2520inhibitors%2520of%2520the%2520VEGF%2520receptor%2520tyrosine%2520kinases%2520useful%2520as%2520antagonists%2520of%2520tumor-driven%2520angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2310%26epage%3D2323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Jahan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kratzke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindler, H. L.</span><span> </span><span class="NLM_article-title">Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2012&pages=393-396&author=T.+Jahanauthor=L.+Guauthor=R.+Kratzkeauthor=A.+Dudekauthor=G.+A.+Ottersonauthor=X.+Wangauthor=M.+Greenauthor=E.+E.+Vokesauthor=H.+L.+Kindler&title=Vatalanib+in+malignant+mesothelioma%3A+a+phase+II+trial+by+the+Cancer+and+Leukemia+Group+B+%28CALGB+30107%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJahan%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DL.%26aulast%3DKratzke%26aufirst%3DR.%26aulast%3DDudek%26aufirst%3DA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26atitle%3DVatalanib%2520in%2520malignant%2520mesothelioma%253A%2520a%2520phase%2520II%2520trial%2520by%2520the%2520Cancer%2520and%2520Leukemia%2520Group%2520B%2520%2528CALGB%252030107%2529%26jtitle%3DLung%2520Cancer%26date%3D2012%26volume%3D76%26spage%3D393%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Braud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grignagni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitalieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boselli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toffalorio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalava, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aglietta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1686</span><span class="NLM_x">–</span> <span class="NLM_lpage">1690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fbjc.2011.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21540861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFyrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=1686-1690&author=H.+Joensuuauthor=F.+De+Braudauthor=G.+Grignagniauthor=T.+De+Pasauthor=G.+Spitalieriauthor=P.+Cocoauthor=C.+Spreaficoauthor=S.+Boselliauthor=F.+Toffalorioauthor=P.+Bonoauthor=T.+Jalavaauthor=C.+Kappelerauthor=M.+Agliettaauthor=D.+Laurentauthor=P.+G.+Casali&title=Vatalanib+for+metastatic+gastrointestinal+stromal+tumour+%28GIST%29+resistant+to+imatinib%3A+final+results+of+a+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study</span></div><div class="casAuthors">Joensuu, H.; De Braud, F.; Grignagni, G.; De Pas, T.; Spitalieri, G.; Coco, P.; Spreafico, C.; Boselli, S.; Toffalorio, F.; Bono, P.; Jalava, T.; Kappeler, C.; Aglietta, M.; Laurent, D.; Casali, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1686-1690</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs).  We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumor (GIST) resistant to imatinib or both imatinib and sunitinib.  45 Patients whose metastatic GIST had progressed on imatinib were enrolled.  19 (42.2%) Patients had received also prior sunitinib.  Vatalanib 1250 mg was administered orally daily.  18 Patients (40.0%; 95% confidence interval (CI), 25.7-54.3%) had clin. benefit including 2 (4.4%) confirmed partial remissions (PR; duration, 9.6 and 39.4 mo) and 16 (35.6%) stabilized diseases (SDs; median duration, 12.5 mo; range, 6.0-35.6+ months).  12 (46.2%) Out of the 26 patients who had received prior imatinib only achieved either PR or SD compared with 6 (31.6%, all SDs) out of the 19 patients who had received prior imatinib and sunitinib (P = 0.324).  The median time to progression was 5.8 mo (95% CI, 2.9-9.5 mo) in the subset without prior sunitinib and 3.2 (95% CI, 2.1-6.0) months among those with prior imatinib and sunitinib (P = 0.992).  Vatalanib was generally well tolerated.  Vatalanib is active despite its narrow kinome interaction spectrum in patients diagnosed with imatinib-resistant GIST or with imatinib and sunitinib-resistant GIST.  British Journal of Cancer (2011) 104, 1686-1690; doi:10.1038/bjc.2011.151 www.bjcancer.com Published online 3 May 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE-hT4ml3w37Vg90H21EOLACvtfcHk0liUys2TMVJ7ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFyrsLc%253D&md5=f628eebb274daab934707057dcdcd123</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.151%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DDe%2BBraud%26aufirst%3DF.%26aulast%3DGrignagni%26aufirst%3DG.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DSpitalieri%26aufirst%3DG.%26aulast%3DCoco%26aufirst%3DP.%26aulast%3DSpreafico%26aufirst%3DC.%26aulast%3DBoselli%26aufirst%3DS.%26aulast%3DToffalorio%26aufirst%3DF.%26aulast%3DBono%26aufirst%3DP.%26aulast%3DJalava%26aufirst%3DT.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DAglietta%26aufirst%3DM.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DVatalanib%2520for%2520metastatic%2520gastrointestinal%2520stromal%2520tumour%2520%2528GIST%2529%2520resistant%2520to%2520imatinib%253A%2520final%2520results%2520of%2520a%2520phase%2520II%2520study%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D1686%26epage%3D1690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Gauler, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauguen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meric, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gounant, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeck, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krissel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiainen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, W. E.</span><span> </span><span class="NLM_article-title">Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1093%2Fannonc%2Fmdr255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21617019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADC%252BC383mtFWnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=678-687&author=T.+C.+Gaulerauthor=B.+Besseauthor=A.+Mauguenauthor=J.+B.+Mericauthor=V.+Gounantauthor=B.+Fischerauthor=T.+R.+Overbeckauthor=H.+Krisselauthor=D.+Laurentauthor=M.+Tiainenauthor=F.+Commoauthor=J.+C.+Soriaauthor=W.+E.+Eberhardt&title=Phase+II+trial+of+PTK787%2FZK+222584+%28vatalanib%29+administered+orally+once-daily+or+in+two+divided+daily+doses+as+second-line+monotherapy+in+relapsed+or+progressing+patients+with+stage+IIIB%2FIV+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)</span></div><div class="casAuthors">Gauler T C; Besse B; Mauguen A; Meric J B; Gounant V; Fischer B; Overbeck T R; Krissel H; Laurent D; Tiainen M; Commo F; Soria J C; Eberhardt W E E</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">678-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The objective of this multicenter, prospective uncontrolled phase II trial was to determine efficacy, safety and tolerability of vatalanib, an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor receptors, in the second-line treatment of non-small-cell lung cancer (NSCLC).  PATIENTS AND METHODS:  Patients with stage IIIB/IV NSCLC-proven tumor progression during or after one platinum-based chemotherapy regimen received a fixed dose of 1250 mg vatalanib either once-daily dosing (QD) or two divided daily dosing (TDD: 500 mg a.m. + 750 mg p.m.) until disease progression or unacceptable toxicity.  Primary end point was the disease control rate (DCR) at 12 weeks.  RESULTS:  Fifty-four and 58 patients were enrolled to the QD and TDD arms.  DCR at 12 weeks was 35% in the QD and 37% in the TDD arm.  The best overall response included one (2%) patient with confirmed partial response with QD and three (5%) with TDD.  Median progression-free survival and overall survival were 2.1/7.3 months in the QD arm and 2.8/9.0 months with TDD arm.  This therapy showed a moderate toxicity profile for the majority of patients.  CONCLUSIONS:  In the chosen patient population, vatalanib QD and TDD dosing demonstrated potential benefits in tumor size reduction, DCR, and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8AuRTTo7nR5PlX7E30qdzfW6udTcc2ebMJYmNR9oKw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383mtFWnsQ%253D%253D&md5=3a4808f07c1b22304394337e8420016b</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr255%26sid%3Dliteratum%253Aachs%26aulast%3DGauler%26aufirst%3DT.%2BC.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DMauguen%26aufirst%3DA.%26aulast%3DMeric%26aufirst%3DJ.%2BB.%26aulast%3DGounant%26aufirst%3DV.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DOverbeck%26aufirst%3DT.%2BR.%26aulast%3DKrissel%26aufirst%3DH.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DTiainen%26aufirst%3DM.%26aulast%3DCommo%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.%26atitle%3DPhase%2520II%2520trial%2520of%2520PTK787%252FZK%2520222584%2520%2528vatalanib%2529%2520administered%2520orally%2520once-daily%2520or%2520in%2520two%2520divided%2520daily%2520doses%2520as%2520second-line%2520monotherapy%2520in%2520relapsed%2520or%2520progressing%2520patients%2520with%2520stage%2520IIIB%252FIV%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D678%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Cook, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biswas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kareclas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirohi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mander, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrie, P. G.</span><span> </span><span class="NLM_article-title">A phase 2 study of vatalanib in metastatic melanoma patients</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2671</span><span class="NLM_x">–</span> <span class="NLM_lpage">2673</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=2671-2673&author=N.+Cookauthor=B.+Basuauthor=S.+Biswasauthor=P.+Kareclasauthor=C.+Mannauthor=C.+Palmerauthor=A.+Thomasauthor=S.+Nicholsonauthor=B.+Morganauthor=D.+Lomasauthor=B.+Sirohiauthor=A.+P.+Manderauthor=M.+Middletonauthor=P.+G.+Corrie&title=A+phase+2+study+of+vatalanib+in+metastatic+melanoma+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DN.%26aulast%3DBasu%26aufirst%3DB.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DKareclas%26aufirst%3DP.%26aulast%3DMann%26aufirst%3DC.%26aulast%3DPalmer%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DS.%26aulast%3DMorgan%26aufirst%3DB.%26aulast%3DLomas%26aufirst%3DD.%26aulast%3DSirohi%26aufirst%3DB.%26aulast%3DMander%26aufirst%3DA.%2BP.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DCorrie%26aufirst%3DP.%2BG.%26atitle%3DA%2520phase%25202%2520study%2520of%2520vatalanib%2520in%2520metastatic%2520melanoma%2520patients%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D2671%26epage%3D2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Sobrero, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruzzi, P.</span><span> </span><span class="NLM_article-title">Vatalanib in advanced colorectal cancer: two studies with identical results</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1940</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2010.33.2429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21464409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosF2ktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1938-1940&author=A.+F.+Sobreroauthor=P.+Bruzzi&title=Vatalanib+in+advanced+colorectal+cancer%3A+two+studies+with+identical+results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Vatalanib in advanced colorectal cancer: two studies with identical results</span></div><div class="casAuthors">Sobrero, Alberto F.; Bruzzi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1938-1940</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The research of Hecht et al. (2011) entitled 'Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma' and of Van Cutsem et al. (2011) entitled 'Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK222584 in patients with previously treated metastatic colorectal adenocarcinoma' are reviewed with commentary and refs.  These two studies showed the same hazard ratio (HR) for progression-free survival (PFS; 0.88 and 0.83) and for overall survival (OS; 1.08 and 1.00), the same increased efficacy in the subgroup with high lactate dehydrogenase (HR for PFS = 0.67 and 0.63) and the same lack of effect on the rate of objective responses.  The exposure to the antiangiogenic drug vatalanib (PTK/ZK) or placebo and to the component drugs of infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were similarly reduced (10% to 20%) compared with the controls.  The increased incidence of serious adverse events (SAEs) in the exptl. arms over the control arms was identical (9% and 10%) as was the increased treatment discontinuation proportion due to SAEs (14% and 17%).  The time to deterioration of performance status (HR = 1.55 and 2.23), and the time to more than 5% wt. loss (HR = 1.91 and 1.83) were similarly decreased in the PTK/ZK arms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6-co7G_YgBbVg90H21EOLACvtfcHk0lhOBzXhippDyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosF2ktb8%253D&md5=b9ae65e2f7aca941aabad80aec93868d</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.2429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.2429%26sid%3Dliteratum%253Aachs%26aulast%3DSobrero%26aufirst%3DA.%2BF.%26aulast%3DBruzzi%26aufirst%3DP.%26atitle%3DVatalanib%2520in%2520advanced%2520colorectal%2520cancer%253A%2520two%2520studies%2520with%2520identical%2520results%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D1938%26epage%3D1940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Dumas, J. P.; Hatoum-Mokdad, H. N.; Joe, T. K.; Kluender, H. C. E.; Lee, W.; Nagarathnam, D.; Sibley, R. N.; Su, N.; Boyer, S. J.</span><span> </span><span class="NLM_article-title">Substituted Pyridazines and Fused Pyridazines with Angiogenesis Inhibting Activity</span>. WO2001010859,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=J.+P.+Dumas&author=H.+N.+Hatoum-Mokdad&author=T.+K.+Joe&author=H.+C.+E.+Kluender&author=W.+Lee&author=D.+Nagarathnam&author=R.+N.+Sibley&author=N.+Su&author=S.+J.+Boyer&title=Substituted+Pyridazines+and+Fused+Pyridazines+with+Angiogenesis+Inhibting+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDumas%26aufirst%3DJ.%2BP.%26atitle%3DSubstituted%2520Pyridazines%2520and%2520Fused%2520Pyridazines%2520with%2520Angiogenesis%2520Inhibting%2520Activity%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Eskens, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeghs, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloem, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwerkerk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jonge, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nortier, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraetzschmar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span> </span><span class="NLM_article-title">Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4169</span><span class="NLM_x">–</span> <span class="NLM_lpage">4176</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1200%2FJCO.2008.18.8193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19636022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2jtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4169-4176&author=F.+A.+Eskensauthor=N.+Steeghsauthor=J.+Verweijauthor=J.+L.+Bloemauthor=O.+Christensenauthor=L.+van+Doornauthor=J.+Ouwerkerkauthor=M.+J.+de+Jongeauthor=J.+W.+Nortierauthor=J.+Kraetzschmarauthor=P.+Rajagopalanauthor=H.+Gelderblom&title=Phase+I+dose+escalation+study+of+telatinib%2C+a+tyrosine+kinase+inhibitor+of+vascular+endothelial+growth+factor+receptor+2+and+3%2C+platelet-derived+growth+factor+receptor+beta%2C+and+c-Kit%2C+in+patients+with+advanced+or+metastatic+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor β, and c-Kit, in patients with advanced or metastatic solid tumors</span></div><div class="casAuthors">Eskens, Ferry A. L. M.; Steeghs, Neeltje; Verweij, Jaap; Bloem, Johan L.; Christensen, Olaf; van Doorn, Leni; Ouwekerk, Jan; de Jonge, Maja J. A.; Nortier, Johan W. R.; Kraetzschmar, Joern; Rajagopalan, Prabhu; Gelderblom, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4169-4176</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor-β, and c-Kit.  This phase I dose escalation study was conducted to evaluate the safety and tolerability of telatinib, with addnl. pharmacokinetic, pharmacodynamic, and efficacy assessments.  Patients and Methods: Patients with solid tumors refractory to std. therapies or with no std. therapy available were enrolled.  Doses of continuously administered telatinib were escalated from 20 mg once daily to 1,500 mg twice daily.  Results: Fifty-three patients were enrolled.  Most frequently obsd. drug-related adverse events were nausea (26.4%; grade ≥ 3, 0%) and hypertension (20.8%; grade 3, 11.3%; grade 4, 0%).  Two dose-limiting toxicities were obsd.: one poorly controlled hypertension (600 mg twice daily), and one grade 2 wt. loss, anorexia, and fatigue (1,500 mg twice daily).  A formal max.-tolerated dose was not reached.  Telatinib was rapidly absorbed, with median time to peak concn. (tmax) lower than 3 h after dose.  A nearly dose-proportional increase in exposure was obsd. with substantial variability.  Telatinib half-life averaged 5.5 h.  Biomarker analyses showed dose-dependent increase in VEGF levels and decrease in plasma sol. VEGFR-2 levels, with a plateau at 900 mg twice daily.  A decrease in tumor blood flow (Ktrans and IAUC60) was obsd. with dynamic contrast-enhanced magnetic resonance imaging.  Best tumor response was stable disease, obsd. in 50.9% of patients.  Conclusion: Telatinib was safe and well tolerated up to 1,500 mg twice daily.  Based on pharmacodynamic and pharmacokinetic end points, telatinib 900 mg twice daily is the recommended dose for subsequent phase II studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQSW5HnAKUALVg90H21EOLACvtfcHk0ljzXpZTUGRi8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2jtLrK&md5=187b12f0d2e053352b5b4168d7612753</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.18.8193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.18.8193%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%26aulast%3DSteeghs%26aufirst%3DN.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DBloem%26aufirst%3DJ.%2BL.%26aulast%3DChristensen%26aufirst%3DO.%26aulast%3Dvan%2BDoorn%26aufirst%3DL.%26aulast%3DOuwerkerk%26aufirst%3DJ.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%26aulast%3DNortier%26aufirst%3DJ.%2BW.%26aulast%3DKraetzschmar%26aufirst%3DJ.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26atitle%3DPhase%2520I%2520dose%2520escalation%2520study%2520of%2520telatinib%252C%2520a%2520tyrosine%2520kinase%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520and%25203%252C%2520platelet-derived%2520growth%2520factor%2520receptor%2520beta%252C%2520and%2520c-Kit%252C%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4169%26epage%3D4176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheulen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultheiss, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasol, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büchert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krätzschmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delesen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, O.</span><span> </span><span class="NLM_article-title">Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer</span> <span class="citation_source-journal">Vasc. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1186%2F2045-824X-3-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21801343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SgtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=16&author=K.+Mrossauthor=A.+Frostauthor=M.+E.+Scheulenauthor=J.+Kraussauthor=D.+Strumbergauthor=B.+Schultheissauthor=U.+Fasolauthor=M.+B%C3%BCchertauthor=J.+Kr%C3%A4tzschmerauthor=H.+Delesenauthor=P.+Rajagopalanauthor=O.+Christensen&title=Phase+I+study+of+telatinib+%28BAY+57-9352%29%3A+analysis+of+safety%2C+pharmacokinetics%2C+tumor+efficacy%2C+and+biomarkers+in+patients+with+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer</span></div><div class="casAuthors">Mross, Klaus; Frost, Annette; Scheulen, Max E.; Krauss, Juergen; Strumberg, Dirk; Schultheiss, Beate; Fasol, Ulrike; Buechert, Martin; Kraetzschmer, Jorn; Delesen, Heinz; Rajagopalan, Prabhu; Christensen, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>CODEN:
                <span class="NLM_cas:coden">VCAEAL</span>;
        ISSN:<span class="NLM_cas:issn">2045-824X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Telatinib (BAY 57-9352) is an orally available, small-mol. inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.  Methods: In this multicenter phase I dose-escalation study including a phase II like expansion part, 39 patients with refractory colorectal cancer (CRC) were enrolled into 14 days on/7 days off in repeating cycles of 28 days (n = 11) or continuous dosing groups (n = 28) to receive ≥600 mg telatinib twice-daily (bid).  Results: Hypertension (28%) and diarrhoea (15%) were the most frequent study drug-related adverse events of CTC grade 3.  In this population, no clear relationship between telatinib dose and individual Cmax and AUC was apparent in the 600 mg bid to 1500 mg bid dose range.  No partial remission according to RECIST was reached, but 41% of the patients reached some tumor shrinkage during treatment.  Tumor blood flow measured by dynamic contrast-enhanced magnetic resonance imaging and sVEGFR-2 plasma levels decreased with increasing telatinib AUC(0-12).  Conclusion: Telatinib treatment was well tolerated.  The obsd. single agent antitumor activity in heavily pretreated CRC patients was limited.  Pharmacodynamic results are suggestive for the biol. activity of telatinib justifying a further evaluation of telatinib bid in combination with std. chemotherapy regimens in CRC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQOGoeGHrIIbVg90H21EOLACvtfcHk0ljzXpZTUGRi8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SgtrnN&md5=6a15ff831e306cfed88d1664a156caa6</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1186%2F2045-824X-3-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2045-824X-3-16%26sid%3Dliteratum%253Aachs%26aulast%3DMross%26aufirst%3DK.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DKrauss%26aufirst%3DJ.%26aulast%3DStrumberg%26aufirst%3DD.%26aulast%3DSchultheiss%26aufirst%3DB.%26aulast%3DFasol%26aufirst%3DU.%26aulast%3DB%25C3%25BCchert%26aufirst%3DM.%26aulast%3DKr%25C3%25A4tzschmer%26aufirst%3DJ.%26aulast%3DDelesen%26aufirst%3DH.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DO.%26atitle%3DPhase%2520I%2520study%2520of%2520telatinib%2520%2528BAY%252057-9352%2529%253A%2520analysis%2520of%2520safety%252C%2520pharmacokinetics%252C%2520tumor%2520efficacy%252C%2520and%2520biomarkers%2520in%2520patients%2520with%2520colorectal%2520cancer%26jtitle%3DVasc.%2520Cell%26date%3D2011%26volume%3D3%26spage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K. H.</span><span> </span><span class="NLM_article-title">Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2967</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2967-2971&author=P.+Furetauthor=G.+Boldauthor=F.+Hofmannauthor=P.+Manleyauthor=T.+Meyerauthor=K.+H.+Altmann&title=Identification+of+a+new+chemical+class+of+potent+angiogenesis+inhibitors+based+on+conformational+considerations+and+database+searching"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26atitle%3DIdentification%2520of%2520a%2520new%2520chemical%2520class%2520of%2520potent%2520angiogenesis%2520inhibitors%2520based%2520on%2520conformational%2520considerations%2520and%2520database%2520searching%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2967%26epage%3D2971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talvenheimo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montestruque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span> </span><span class="NLM_article-title">AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8715</span><span class="NLM_x">–</span> <span class="NLM_lpage">8721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8715-8721&author=A.+Polverinoauthor=A.+Coxonauthor=C.+Starnesauthor=Z.+Diazauthor=T.+DeMelfiauthor=L.+Wangauthor=J.+Breadyauthor=J.+Estradaauthor=R.+Cattleyauthor=S.+Kaufmanauthor=D.+Chenauthor=Y.+Ganauthor=G.+Kumarauthor=J.+Meyerauthor=S.+Neervannanauthor=G.+Alvaauthor=J.+Talvenheimoauthor=S.+Montestruqueauthor=A.+Taskerauthor=V.+Patelauthor=R.+Radinskyauthor=R.+Kendall&title=AMG+706%2C+an+oral%2C+multikinase+inhibitor+that+selectively+targets+vascular+endothelial+growth+factor%2C+platelet-derived+growth+factor%2C+and+kit+receptors%2C+potently+inhibits+angiogenesis+and+induces+regression+in+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DZ.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DCattley%26aufirst%3DR.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DGan%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DAlva%26aufirst%3DG.%26aulast%3DTalvenheimo%26aufirst%3DJ.%26aulast%3DMontestruque%26aufirst%3DS.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26atitle%3DAMG%2520706%252C%2520an%2520oral%252C%2520multikinase%2520inhibitor%2520that%2520selectively%2520targets%2520vascular%2520endothelial%2520growth%2520factor%252C%2520platelet-derived%2520growth%2520factor%252C%2520and%2520kit%2520receptors%252C%2520potently%2520inhibits%2520angiogenesis%2520and%2520induces%2520regression%2520in%2520tumor%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8715%26epage%3D8721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saffran, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span> </span><span class="NLM_article-title">Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-08-1155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19118038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1eltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=110-118&author=A.+Coxonauthor=T.+Bushauthor=D.+Saffranauthor=S.+Kaufmanauthor=B.+Belmontesauthor=K.+Rexauthor=P.+Hughesauthor=S.+Caenepeelauthor=J.+B.+Rottmanauthor=A.+Taskerauthor=V.+Patelauthor=R.+Kendallauthor=R.+Radinskyauthor=A.+Polverino&title=Broad+antitumor+activity+in+breast+cancer+xenografts+by+motesanib%2C+a+highly+selective%2C+oral+inhibitor+of+vascular+endothelial+growth+factor%2C+platelet-derived+growth+factor%2C+and+Kit+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors</span></div><div class="casAuthors">Coxon, Angela; Bush, Tammy; Saffran, Douglas; Kaufman, Stephen; Belmontes, Brian; Rex, Karen; Hughes, Paul; Caenepeel, Sean; Rottman, James B.; Tasker, Andrew; Patel, Vinod; Kendall, Richard; Radinsky, Robert; Polverino, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">110-118</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Angiogenesis plays a crit. role in breast cancer development and progression.  Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that regulates endothelial cell proliferation and survival.  We investigated the effects of motesanib, a novel, oral inhibitor of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit receptor, on the growth of xenografts representing various human breast cancer subtypes.  Athymic nude mice were implanted with MCF-7 (luminal) or MDA-MB-231 (mesenchymal) tumor fragments or Cal-51 (mixed/progenitor) tumor cells.  Once tumors were established, animals were randomized to receive increasing doses of motesanib alone or motesanib plus cytotoxic chemotherapy (docetaxel, doxorubicin, or tamoxifen).  Across all three xenograft models, motesanib treatment resulted in significant dose-dependent redns. in tumor growth, compared with vehicle-treated controls, and in marked redns. in viable tumor fraction and blood vessel d.  No significant effect on body wt. was obsd. with compd. treatment compared with control-treated animals.  Motesanib did not affect the proliferation of tumor cells in vitro.  There was a significantly greater redn. in xenograft tumor growth when motesanib was combined with docetaxel (MDA-MB-231 tumors) or with the estrogen receptor modulator tamoxifen (MCF-7 tumors), compared with either treatment alone, but not when combined with doxorubicin (Cal-51 tumors).  Treatment with motesanib alone or in combination with chemotherapy inhibits tumor growth in vivo in various models of human breast cancer.  These data suggest that motesanib may have broad utility in the treatment of human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkX21dnQZLLVg90H21EOLACvtfcHk0lgS2giPFMJ-XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1eltg%253D%253D&md5=0a55408655f97efe06156f5cb4ae041c</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1155%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBush%26aufirst%3DT.%26aulast%3DSaffran%26aufirst%3DD.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DRottman%26aufirst%3DJ.%2BB.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DPolverino%26aufirst%3DA.%26atitle%3DBroad%2520antitumor%2520activity%2520in%2520breast%2520cancer%2520xenografts%2520by%2520motesanib%252C%2520a%2520highly%2520selective%252C%2520oral%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%252C%2520platelet-derived%2520growth%2520factor%252C%2520and%2520Kit%2520receptors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D110%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osgood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of motesanib in a medullary thyroid cancer model</span> <span class="citation_source-journal">J. Endocrinol. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=181-190&author=A.+Coxonauthor=J.+Breadyauthor=S.+Kaufmanauthor=J.+Estradaauthor=T.+Osgoodauthor=J.+Canonauthor=L.+Wangauthor=R.+Radinskyauthor=R.+Kendallauthor=P.+Hughesauthor=A.+Polverino&title=Anti-tumor+activity+of+motesanib+in+a+medullary+thyroid+cancer+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DPolverino%26aufirst%3DA.%26atitle%3DAnti-tumor%2520activity%2520of%2520motesanib%2520in%2520a%2520medullary%2520thyroid%2520cancer%2520model%26jtitle%3DJ.%2520Endocrinol.%2520Invest.%26date%3D2012%26volume%3D35%26spage%3D181%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Benjamin, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duyster, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuetze, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skubitz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, L.</span><span> </span><span class="NLM_article-title">Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-010-1431-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20838998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVentrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=69-77&author=R.+S.+Benjaminauthor=P.+Sch%C3%B6ffskiauthor=J.+T.+Hartmannauthor=A.+Van+Oosteromauthor=B.+N.+Buiauthor=J.+Duysterauthor=S.+Schuetzeauthor=J.+Y.+Blayauthor=P.+Reichardtauthor=L.+S.+Rosenauthor=K.+Skubitzauthor=S.+McCoyauthor=Y.+N.+Sunauthor=D.+E.+Stepanauthor=L.+Baker&title=Efficacy+and+safety+of+motesanib%2C+an+oral+inhibitor+of+VEGF%2C+PDGF%2C+and+Kit+receptors%2C+in+patients+with+imatinib-resistant+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors</span></div><div class="casAuthors">Benjamin, Robert S.; Schoeffski, Patrick; Hartmann, Joerg Thomas; Oosterom, Allan; Bui, Binh Nguyen; Duyster, Justus; Schuetze, Scott; Blay, Jean-Yves; Reichardt, Peter; Rosen, Lee S.; Skubitz, Keith; McCoy, Sheryl; Sun, Yu-Nien; Stepan, Daniel E.; Baker, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-77</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: This multicenter phase 2 study assessed the tolerability and efficacy of motesanib, an oral inhibitor of Kit, platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptors (VEGFR), in patients with imatinib-resistant gastrointestinal stromal tumors (GIST).  Methods: Patients with advanced GIST who failed imatinib mesylate after ≥8 wk of treatment with ≥600 mg daily received motesanib 125 mg orally once daily continuously for 48 wk or until unacceptable toxicity or disease progression occurred.  The primary endpoint was confirmed objective tumor response per RECIST and independent review.  Secondary endpoints included progression-free survival (PFS), time to progression (TTP); objective response by 18FDG-PET and by changes in tumor size and/or d. (Choi criteria); pharmacokinetics and safety.  Results: In the patients evaluable for response (N = 102), the objective response rate was 3%; 59% of patients achieved stable disease, with 14% achieving durable stable disease ≥24 wk; 38% had disease progression.  Higher objective response rates were obsd. per 18FDG-PET (N = 91) (30%) and Choi criteria (41%).  The median PFS was 16 wk (95% CI = 14-24 wk); the median TTP was 17 wk (95% CI = 15-24 wk).  The most common motesanib treatment-related grade 3 adverse events included hypertension (23%), fatigue (9%), and diarrhea (5%).  Motesanib did not accumulate with daily dosing.  Conclusions: In this study of patients with imatinib-resistant GIST, motesanib treatment resulted in acceptable tolerability and modest tumor control as evident in the proportion of patients who achieved stable disease and durable stable disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1ymd0N1HF4LVg90H21EOLACvtfcHk0lgS2giPFMJ-XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVentrY%253D&md5=47d04fa1620603cee06e1a44c2c79082</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2Fs00280-010-1431-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-010-1431-9%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DHartmann%26aufirst%3DJ.%2BT.%26aulast%3DVan%2BOosterom%26aufirst%3DA.%26aulast%3DBui%26aufirst%3DB.%2BN.%26aulast%3DDuyster%26aufirst%3DJ.%26aulast%3DSchuetze%26aufirst%3DS.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DSkubitz%26aufirst%3DK.%26aulast%3DMcCoy%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%2BN.%26aulast%3DStepan%26aufirst%3DD.%2BE.%26aulast%3DBaker%26aufirst%3DL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520motesanib%252C%2520an%2520oral%2520inhibitor%2520of%2520VEGF%252C%2520PDGF%252C%2520and%2520Kit%2520receptors%252C%2520in%2520patients%2520with%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D68%26spage%3D69%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Raghav, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span> </span><span class="NLM_article-title">Motesanib and advanced NSCLC: experiences and expectations</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">–</span> <span class="NLM_lpage">869</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=859-869&author=K.+P.+Raghavauthor=G.+R.+Blumenschein&title=Motesanib+and+advanced+NSCLC%3A+experiences+and+expectations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaghav%26aufirst%3DK.%2BP.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26atitle%3DMotesanib%2520and%2520advanced%2520NSCLC%253A%2520experiences%2520and%2520expectations%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D859%26epage%3D869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Wynne, G. M.; Doyle, K.; Ahmed, S.; Li, A.; Keily, J. F.; Rasamison, C.; Pegg, N. A.; Saba, I.; Thomas, C.; Smyth, D.; Sadiq, S.; Newton, G.; Dawson, G.; Crew, A. P.; Castelano, A. L.</span><span> </span><span class="NLM_article-title">(2-Carboxamido) (3-Amino) Thiophene Compounds</span>. WO2004063330,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+M.+Wynne&author=K.+Doyle&author=S.+Ahmed&author=A.+Li&author=J.+F.+Keily&author=C.+Rasamison&author=N.+A.+Pegg&author=I.+Saba&author=C.+Thomas&author=D.+Smyth&author=S.+Sadiq&author=G.+Newton&author=G.+Dawson&author=A.+P.+Crew&author=A.+L.+Castelano&title=%282-Carboxamido%29+%283-Amino%29+Thiophene+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWynne%26aufirst%3DG.%2BM.%26atitle%3D%25282-Carboxamido%2529%2520%25283-Amino%2529%2520Thiophene%2520Compounds%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crew, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynne, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaldo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bittner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keily, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srebernak, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirrit, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulevic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henninger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennello, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelhano, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span> </span><span class="NLM_article-title">OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1024</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1015-1024&author=A.+J.+Gartonauthor=A.+P.+Crewauthor=M.+Franklinauthor=A.+R.+Cookeauthor=G.+M.+Wynneauthor=L.+Castaldoauthor=J.+Kahlerauthor=S.+L.+Winskiauthor=A.+Franksauthor=E.+N.+Brownauthor=M.+A.+Bittnerauthor=J.+F.+Keilyauthor=P.+Brinerauthor=C.+Hiddenauthor=M.+C.+Srebernakauthor=C.+Pirritauthor=M.+O%E2%80%99Connorauthor=A.+Chanauthor=B.+Vulevicauthor=D.+Henningerauthor=K.+Hartauthor=R.+Sennelloauthor=A.+H.+Liauthor=T.+Zhangauthor=F.+Richardsonauthor=D.+L.+Emersonauthor=A.+L.+Castelhanoauthor=L.+D.+Arnoldauthor=N.+W.+Gibson&title=OSI-930%3A+a+novel+selective+inhibitor+of+Kit+and+kinase+insert+domain+receptor+tyrosine+kinases+with+antitumor+activity+in+mouse+xenograft+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DFranklin%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DA.%2BR.%26aulast%3DWynne%26aufirst%3DG.%2BM.%26aulast%3DCastaldo%26aufirst%3DL.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DFranks%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DE.%2BN.%26aulast%3DBittner%26aufirst%3DM.%2BA.%26aulast%3DKeily%26aufirst%3DJ.%2BF.%26aulast%3DBriner%26aufirst%3DP.%26aulast%3DHidden%26aufirst%3DC.%26aulast%3DSrebernak%26aufirst%3DM.%2BC.%26aulast%3DPirrit%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DVulevic%26aufirst%3DB.%26aulast%3DHenninger%26aufirst%3DD.%26aulast%3DHart%26aufirst%3DK.%26aulast%3DSennello%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BH.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DRichardson%26aufirst%3DF.%26aulast%3DEmerson%26aufirst%3DD.%2BL.%26aulast%3DCastelhano%26aufirst%3DA.%2BL.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26atitle%3DOSI-930%253A%2520a%2520novel%2520selective%2520inhibitor%2520of%2520Kit%2520and%2520kinase%2520insert%2520domain%2520receptor%2520tyrosine%2520kinases%2520with%2520antitumor%2520activity%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1015%26epage%3D1024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical studies of (<i>R</i>)-1-(4-(4-fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5- methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2146</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm051106d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2143-2146&author=R.+S.+Bhideauthor=Z.+W.+Caiauthor=Y.+Z.+Zhangauthor=L.+Qianauthor=D.+Weiauthor=S.+Barbosaauthor=L.+J.+Lombardoauthor=R.+M.+Borzilleriauthor=X.+Zhengauthor=L.+I.+Wuauthor=J.+C.+Barrishauthor=S.+H.+Kimauthor=K.+Leavittauthor=A.+Mathurauthor=L.+Leithauthor=S.+Chaoauthor=B.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+Kukralauthor=J.+T.+Huntauthor=A.+Kamathauthor=A.+Furaauthor=V.+Vyasauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+Fargnoli&title=Discovery+and+preclinical+studies+of+%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-+methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-2-ol+%28BMS-540215%29%2C+an+in+vivo+active+potent+VEGFR-2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm051106d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051106d%26sid%3Dliteratum%253Aachs%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BI.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DVyas%26aufirst%3DV.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DFargnoli%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520studies%2520of%2520%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-%2520methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-2-ol%2520%2528BMS-540215%2529%252C%2520an%2520in%2520vivo%2520active%2520potent%2520VEGFR-2%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2143%26epage%3D2146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukralmgrt, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R. S.</span><span> </span><span class="NLM_article-title">Discovery of brivanib alaninate ((<i>S</i>)-((<i>R</i>)-1-(4-(4-fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5-methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1980</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7013309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1976-1980&author=Z.+W.+Caiauthor=Y.+Zhangauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=S.+Barbosaauthor=D.+Weiauthor=X.+Zhengauthor=L.+Wuauthor=J.+Fanauthor=Z.+Shiauthor=B.+S.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+W.+Kukralmgrtauthor=A.+Kamathauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+C.+Barrishauthor=J.+A.+Roblauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+S.+Bhide&title=Discovery+of+brivanib+alaninate+%28%28S%29-%28%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-2-yl%292-aminopropanoate%29%2C+a+novel+prodrug+of+dual+vascular+endothelial+growth+factor+receptor-2+and+fibroblast+growth+factor+receptor-1+kinase+inhibitor+%28BMS-540215%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm7013309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7013309%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukralmgrt%26aufirst%3DD.%2BW.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520brivanib%2520alaninate%2520%2528%2528S%2529-%2528%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-2-yl%25292-aminopropanoate%2529%252C%2520a%2520novel%2520prodrug%2520of%2520dual%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520and%2520fibroblast%2520growth%2520factor%2520receptor-1%2520kinase%2520inhibitor%2520%2528BMS-540215%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1976%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-009-1002-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=19396600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFegu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=55-66&author=P.+H.+Maratheauthor=A.+V.+Kamathauthor=Y.+Zhangauthor=C.+D%E2%80%99Arienzoauthor=R.+Bhideauthor=J.+Fargnoli&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+brivanib+%28BMS-540215%29%2C+a+potent+VEGFR2+inhibitor+and+its+alanine+ester+prodrug+brivanib+alaninate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate</span></div><div class="casAuthors">Marathe, Punit H.; Kamath, Amrita V.; Zhang, Yueping; D'Arienzo, Celia; Bhide, Rajeev; Fargnoli, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-66</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas.  In vitro and in vivo studies were conducted to characterize the preclin. pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts.  In vitro studies were conducted in liver and intestinal fractions, plasma and Caco-2 cells to assess the metabolic stability.  Pharmacokinetics of brivanib were detd. in preclin. species after administration of single i.v. or oral doses of both brivanib and brivanib alaninate.  The antitumor efficacy was assessed at equimolar doses in nude mice bearing human tumor xenografts.  Human efficacious dose was predicted based on projected human pharmacokinetic parameters and exposure at efficacious doses in the mouse efficacy models.  In vitro and in vivo studies indicated that brivanib alaninate was efficiently converted to brivanib.  Brivanib showed good brain penetration in rats consistent with its high intrinsic permeability and lack of active efflux in Caco-2 cells.  The oral bioavailability of brivanib varied among species (22-88%) and showed dissoln. rate-limited absorption even when combined with org. co-solvents.  Administration of brivanib as brivanib alaninate allowed completely aq. vehicles, and an improvement in the oral bioavailability (55-97%) was obsd.  The clearance of brivanib in humans is anticipated to be low to intermediate (hepatic extn. ratio < 0.7), while its vol. of distribution is expected to be high.  The min. efficacious dose of brivanib alaninate was detd. to be 60 mg/kg per day.  Brivanib alaninate is rapidly and efficiently converted to the parent, brivanib, as demonstrated both in vitro and in vivo and offers an excellent mode to deliver brivanib orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo32ej0WyxhXbVg90H21EOLACvtfcHk0ljNotCNy-CNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFegu77K&md5=d7ca6c43910437a12f64d70fe12c6e9c</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-1002-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-1002-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DBhide%26aufirst%3DR.%26aulast%3DFargnoli%26aufirst%3DJ.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520brivanib%2520%2528BMS-540215%2529%252C%2520a%2520potent%2520VEGFR2%2520inhibitor%2520and%2520its%2520alanine%2520ester%2520prodrug%2520brivanib%2520alaninate%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D65%26spage%3D55%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Huynh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koong, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thng, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, E.</span><span> </span><span class="NLM_article-title">Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6146</span><span class="NLM_x">–</span> <span class="NLM_lpage">6153</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-08-0509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18829493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2nurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6146-6153&author=H.+Huynhauthor=V.+C.+Ngoauthor=J.+Fargnoliauthor=M.+Ayersauthor=K.+C.+Sooauthor=H.+N.+Koongauthor=C.+H.+Thngauthor=H.+S.+Ongauthor=A.+Chungauthor=P.+Chowauthor=P.+Pollockauthor=S.+Byronauthor=E.+Tran&title=Brivanib+alaninate%2C+a+dual+inhibitor+of+vascular+endothelial+growth+factor+receptor+and+fibroblast+growth+factor+receptor+tyrosine+kinases%2C+induces+growth+inhibition+in+mouse+models+of+human+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma</span></div><div class="casAuthors">Huynh, Hung; Ngo, Van Chanh; Fargnoli, Joseph; Ayers, Mark; Soo, Khee Chee; Koong, Heng Nung; Thng, Choon Hua; Ong, Hock Soo; Chung, Alexander; Chow, Pierce; Pollock, Pamela; Byron, Sara; Tran, Evelyn</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6146-6153</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the fifth most common primary neoplasm; surgery is the only curative option but 5-yr survival rates are only 25% to 50%.  Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are known to be involved in growth and neovascularization of HCC.  Therefore, agents that target these pathways may be effective in the treatment of HCC.  The aim of this study was to det. the antineoplastic activity of brivanib alaninate, a dual inhibitor of VEGF receptor (VEGFR) and FGF receptor (FGFR) signaling pathways.  Six different s.c. patient-derived HCC xenografts were implanted into mice.  Tumor growth was evaluated in mice treated with brivanib compared with control.  The effects of brivanib on apoptosis and cell proliferation were evaluated by immunohistochem.  The SK-HEP1 and HepG2 cells were used to investigate the effects of brivanib on the VEGFR-2 and FGFR-1 signaling pathways in vitro.  Western blotting was used to det. changes in proteins in these xenografts and cell lines.  Brivanib significantly suppressed tumor growth in five of six xenograft lines.  Furthermore, brivanib-induced growth inhibition was assocd. with a decrease in phosphorylated VEGFR-2 at Tyr1054/1059, increased apoptosis, reduced microvessel d., inhibition of cell proliferation, and down-regulation of cell cycle regulators.  The levels of FGFR-1 and FGFR-2 expression in these xenograft lines were pos. correlated with its sensitivity to brivanib-induced growth inhibition.  In VEGF-stimulated and basic FGF stimulated SK-HEP1 cells, brivanib significantly inhibited VEGFR-2, FGFR-1, extracellular signal-regulated kinase 1/2, and Akt phosphorylation.  This study provides a strong rationale for clin. investigation of brivanib in patients with HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2l11-dUEyFLVg90H21EOLACvtfcHk0ljNotCNy-CNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2nurvK&md5=21fdc03992b6f3a3ac653e313e794e0a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0509%26sid%3Dliteratum%253Aachs%26aulast%3DHuynh%26aufirst%3DH.%26aulast%3DNgo%26aufirst%3DV.%2BC.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DAyers%26aufirst%3DM.%26aulast%3DSoo%26aufirst%3DK.%2BC.%26aulast%3DKoong%26aufirst%3DH.%2BN.%26aulast%3DThng%26aufirst%3DC.%2BH.%26aulast%3DOng%26aufirst%3DH.%2BS.%26aulast%3DChung%26aufirst%3DA.%26aulast%3DChow%26aufirst%3DP.%26aulast%3DPollock%26aufirst%3DP.%26aulast%3DByron%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DE.%26atitle%3DBrivanib%2520alaninate%252C%2520a%2520dual%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520and%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%252C%2520induces%2520growth%2520inhibition%2520in%2520mouse%2520models%2520of%2520human%2520hepatocellular%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D6146%26epage%3D6153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Diaz-Padilla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span> </span><span class="NLM_article-title">Brivanib alaninate for cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=577-586&author=I.+Diaz-Padillaauthor=L.+L.+Siu&title=Brivanib+alaninate+for+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz-Padilla%26aufirst%3DI.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DBrivanib%2520alaninate%2520for%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D577%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulcahy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polite, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudelet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manekas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. W.</span><span> </span><span class="NLM_article-title">Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2090</span><span class="NLM_x">–</span> <span class="NLM_lpage">2098</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-11-1991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22238246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2090-2098&author=R.+S.+Finnauthor=Y.+K.+Kangauthor=M.+Mulcahyauthor=B.+N.+Politeauthor=H.+Y.+Limauthor=I.+Waltersauthor=C.+Baudeletauthor=D.+Manekasauthor=J.+W.+Park&title=Phase+II%2C+open-label+study+of+brivanib+as+second-line+therapy+in+patients+with+advanced+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma</span></div><div class="casAuthors">Finn, Richard S.; Kang, Yoon-Koo; Mulcahy, Mary; Polite, Blase N.; Lim, Ho Yeong; Walters, Ian; Baudelet, Christine; Manekas, Demetrios; Park, Joong-Won</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2090-2098</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC).  This phase II open-label study assessed brivanib as second-line therapy in patients with advanced HCC who had failed prior antiangiogenic treatment.  Exptl. Design: Brivanib was administered orally at a dose of 800 mg once daily.  The primary objectives were tumor response rate, time to response, duration of response, progression-free survival, overall survival (OS), disease control rate, time to progression (TTP), and safety and tolerability.  RESULTS: Forty-six patients were treated.  Best responses to treatment with brivanib (N = 46 patients) using modified World Health Organization criteria were partial responses for two patients (4.3%), stable disease for 19 patients (41.3%), and progressive disease for 19 patients (41.3%).  The tumor response rate was 4.3%; the disease control rate was 45.7%.  Median OS was 9.79 mo.  Median TTP as assessed by study investigators following second-line treatment with brivanib was 2.7 mo.  The most common adverse events were fatigue, decreased appetite, nausea, diarrhea, and hypertension.  CONCLUSION: Brivanib had a manageable safety profile and is one of the first agents to show promising antitumor activity in advanced HCC patients treated with prior sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotRfx03hOZcbVg90H21EOLACvtfcHk0ljWMeVOwjX5sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOls70%253D&md5=e82018cda1daf7417260959cea286064</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1991%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DMulcahy%26aufirst%3DM.%26aulast%3DPolite%26aufirst%3DB.%2BN.%26aulast%3DLim%26aufirst%3DH.%2BY.%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DBaudelet%26aufirst%3DC.%26aulast%3DManekas%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26atitle%3DPhase%2520II%252C%2520open-label%2520study%2520of%2520brivanib%2520as%2520second-line%2520therapy%2520in%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2090%26epage%3D2098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">de La Motte Rouge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olaussen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zermati, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasdemir, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripoche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dessen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araujo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harel-Belan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armand, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span> </span><span class="NLM_article-title">A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6253</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6253-6262&author=T.+de+La+Motte+Rougeauthor=L.+Galluzziauthor=K.+A.+Olaussenauthor=Y.+Zermatiauthor=E.+Tasdemirauthor=T.+Robertauthor=H.+Ripocheauthor=V.+Lazarauthor=P.+Dessenauthor=F.+Harperauthor=G.+Pierronauthor=G.+Pinnaauthor=N.+Araujoauthor=A.+Harel-Belanauthor=J.+P.+Armandauthor=T.+W.+Wongauthor=J.+C.+Soriaauthor=G.+Kroemer&title=A+novel+epidermal+growth+factor+receptor+inhibitor+promotes+apoptosis+in+non-small+cell+lung+cancer+cells+resistant+to+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLa%2BMotte%2BRouge%26aufirst%3DT.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DOlaussen%26aufirst%3DK.%2BA.%26aulast%3DZermati%26aufirst%3DY.%26aulast%3DTasdemir%26aufirst%3DE.%26aulast%3DRobert%26aufirst%3DT.%26aulast%3DRipoche%26aufirst%3DH.%26aulast%3DLazar%26aufirst%3DV.%26aulast%3DDessen%26aufirst%3DP.%26aulast%3DHarper%26aufirst%3DF.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DPinna%26aufirst%3DG.%26aulast%3DAraujo%26aufirst%3DN.%26aulast%3DHarel-Belan%26aufirst%3DA.%26aulast%3DArmand%26aufirst%3DJ.%2BP.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DA%2520novel%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520promotes%2520apoptosis%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%2520resistant%2520to%2520erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6253%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Loriot, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mordant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorvault, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De la motte Rouge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, E.</span><span> </span><span class="NLM_article-title">BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fsj.bjc.6605748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20628392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Oitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=347-353&author=Y.+Loriotauthor=P.+Mordantauthor=N.+Dorvaultauthor=T.+De+la+motte+Rougeauthor=J.+Bourhisauthor=J.+C.+Soriaauthor=E.+Deutsch&title=BMS-690514%2C+a+VEGFR+and+EGFR+tyrosine+kinase+inhibitor%2C+shows+anti-tumoural+activity+on+non-small-cell+lung+cancer+xenografts+and+induces+sequence-dependent+synergistic+effect+with+radiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation</span></div><div class="casAuthors">Loriot, Y.; Mordant, P.; Dorvault, N.; De la motte Rouge, T.; Bourhis, J.; Soria, J.-C.; Deutsch, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-353</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer (NSCLC) is an aggressive disease in which vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) are implicated in tumor growth, tumor resistance to radiation and chemotherapy, and disease relapse.  We have investigated the anti-tumoral effects of BMS-690514, an inhibitor of both vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signalling pathways, as a single agent and in combination with ionising radiation (IR) on several NSCLC cell lines.  Radiosensitization of several NSCLC cell lines by BMS-690514 was assessed in vitro using clonogenic assay and in vivo using nude mice.  In vitro studies showed that BMS-690514 alone decreases clonogenic survival of NSCLC cells lines but no potential enhancement of IR response was obsd. in the combination.  In tumor-bearing mice, BMS-690514 alone inhibits the growth of NSCLC xenografts, including the T790M mutation-harbouring H1975 tumor.  The concomitant combination of BMS-690514 and radiation did not increase mice survival in comparison with treatment with IR alone.  In contrast, BMS-690514 markedly enhances the anti-tumor effect of radiation in a sequential manner on H1299 and H1975 xenografts.  Immunohistochem. revealed a qual. redn. in vessel area after administrations of BMS-690514, compared with vehicle-treated controls, suggesting that revascularisation may explain the schedule dependency of the tumor-growth delay obsd.  The results of assocn. with radiation show that BMS-690514 may be a successful adjuvant to clin. radiotherapy.  These findings are of translational importance because the clin. benefits of anti-EGFR and anti-VEGFR therapy might be schedule dependent.  British Journal of Cancer (2010) 103, 347-353; doi:10.1038/sj.bjc.6605748 www.bjcancer.com Published online 13 July 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWCnV7UYBlYLVg90H21EOLACvtfcHk0ljWMeVOwjX5sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Oitrg%253D&md5=82906390bfe03ce3710c457db910eaca</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605748%26sid%3Dliteratum%253Aachs%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DMordant%26aufirst%3DP.%26aulast%3DDorvault%26aufirst%3DN.%26aulast%3DDe%2Bla%2Bmotte%2BRouge%26aufirst%3DT.%26aulast%3DBourhis%26aufirst%3DJ.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DDeutsch%26aufirst%3DE.%26atitle%3DBMS-690514%252C%2520a%2520VEGFR%2520and%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%252C%2520shows%2520anti-tumoural%2520activity%2520on%2520non-small-cell%2520lung%2520cancer%2520xenografts%2520and%2520induces%2520sequence-dependent%2520synergistic%2520effect%2520with%2520radiation%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D103%26spage%3D347%26epage%3D353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malone, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span> </span><span class="NLM_article-title">Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4031</span><span class="NLM_x">–</span> <span class="NLM_lpage">4041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-3417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21531814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4031-4041&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=S.+Emanuelauthor=C.+Fairchildauthor=J.+Fargnoliauthor=B.+Finkauthor=A.+Gavaiauthor=A.+Hammellauthor=B.+Henleyauthor=C.+Hiltauthor=J.+T.+Huntauthor=B.+Krishnanauthor=D.+Kukralauthor=A.+Lewinauthor=H.+Maloneauthor=D.+Norrisauthor=S.+Oppenheimerauthor=G.+Viteauthor=C.+Yu&title=Antitumor+and+antiangiogenic+activities+of+BMS-690514%2C+an+inhibitor+of+human+EGF+and+VEGF+receptor+kinase+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families</span></div><div class="casAuthors">Wong, Tai-W.; Lee, Francis Y.; Emanuel, Stuart; Fairchild, Craig; Fargnoli, Joseph; Fink, Brian; Gavai, Ashvinikumar; Hammell, Amy; Henley, Benjamin; Hilt, Christine; Hunt, John T.; Krishnan, Bala; Kukral, Daniel; Lewin, Anne; Malone, Harold; Norris, Derek; Oppenheimer, Simone; Vite, Gregory; Yu, Chiang</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4031-4041</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The extensive involvement of the HER kinases in epithelial cancer suggests that kinase inhibitors targeting this receptor family have the potential for broad spectrum antitumor activity.  BMS-690514 potently inhibits all three HER kinases, and the VEGF receptor kinases.  This report summarizes data from biochem. and cellular pharmacol. studies, as well as antitumor activity of BMS-690514.  Exptl. Design: The potency and selectivity of BMS-690514 was evaluated by using an extensive array of enzymic and binding assays, as well as cellular assays that measure proliferation and receptor signaling.  Antitumor activity was evaluated by using multiple xenograft models that depend on HER kinase signaling.  The antiangiogenic properties of BMS-690514 were assessed in a matrigel plug assay, and effect on tumor blood flow was measured by dynamic contrast-enhanced MRI.  RESULTS: BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kinases.  It inhibits proliferation of tumor cells with potency that correlates with inhibition of receptor signaling, and induces apoptosis in lung tumor cells that have an activating mutation in EGFR.  Antitumor activity was obsd. with BMS-690514 at multiple doses that are well tolerated in mice.  There was evidence of suppression of tumor angiogenesis and endothelial function by BMS-690514, which may contribute to its efficacy.  CONCLUSIONS: By combining inhibition of two receptor kinase families, BMS-690524 is a novel targeted agent that disrupts signaling in the tumor and its vasculature.  Clin Cancer Res; 17(12); 4031-41.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgvI_vgS8debVg90H21EOLACvtfcHk0lgYIn1lT_7nnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKgt78%253D&md5=38fe4d2d2a3a2414888c3f38f72caca4</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3417%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DEmanuel%26aufirst%3DS.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DFink%26aufirst%3DB.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DHammell%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHilt%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKrishnan%26aufirst%3DB.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DLewin%26aufirst%3DA.%26aulast%3DMalone%26aufirst%3DH.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DC.%26atitle%3DAntitumor%2520and%2520antiangiogenic%2520activities%2520of%2520BMS-690514%252C%2520an%2520inhibitor%2520of%2520human%2520EGF%2520and%2520VEGF%2520receptor%2520kinase%2520families%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4031%26epage%3D4041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleczka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">3579</span><span class="NLM_x">–</span> <span class="NLM_lpage">3593</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=3579-3593&author=P.+Maratheauthor=Y.+Tangauthor=B.+Sleczkaauthor=D.+Rodriguesauthor=A.+Gavaiauthor=T.+Wongauthor=L.+Christopherauthor=H.+Zhang&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+BMS-690514%2C+a+potent+inhibitor+of+EGFR+and+VEGFR2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DRodrigues%26aufirst%3DD.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChristopher%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520BMS-690514%252C%2520a%2520potent%2520inhibitor%2520of%2520EGFR%2520and%2520VEGFR2%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D3579%26epage%3D3593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Hong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopher, L. J.</span><span> </span><span class="NLM_article-title">In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1658</span><span class="NLM_x">–</span> <span class="NLM_lpage">1667</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1658-1667&author=H.+Hongauthor=H.+Suauthor=L.+Maauthor=M.+Yaoauthor=R.+A.+Iyerauthor=W.+G.+Humphreysauthor=L.+J.+Christopher&title=In+vitro+characterization+of+the+metabolic+pathways+and+cytochrome+P450+inhibition+and+induction+potential+of+BMS-690514%2C+an+ErbB%2Fvascular+endothelial+growth+factor+receptor+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DR.%2BA.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DChristopher%26aufirst%3DL.%2BJ.%26atitle%3DIn%2520vitro%2520characterization%2520of%2520the%2520metabolic%2520pathways%2520and%2520cytochrome%2520P450%2520inhibition%2520and%2520induction%2520potential%2520of%2520BMS-690514%252C%2520an%2520ErbB%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1658%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(3-amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061280h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1584-1597&author=Y.+Daiauthor=K.+Hartandiauthor=Z.+Jiauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=K.+B.+Glaserauthor=C.+M.+Harrisauthor=D.+Hickmanauthor=J.+Guoauthor=J.+Liauthor=P.+A.+Marcotteauthor=K.+C.+Marshauthor=M.+D.+Moskeyauthor=R.+L.+Martinauthor=A.+M.+Olsonauthor=D.+J.+Osterlingauthor=L.+J.+Peaseauthor=N.+B.+Soniauthor=K.+D.+Stewartauthor=V.+S.+Stollauthor=P.+Tapangauthor=D.+R.+Reuterauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Discovery+of+N-%284-%283-amino-1H-indazol-4-yl%29phenyl%29-N%E2%80%B2-%282-fluoro-5-methylphenyl%29urea+%28ABT-869%29%2C+a+3-aminoindazole-based+orally+active+multitargeted+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm061280h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061280h%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520N-%25284-%25283-amino-1H-indazol-4-yl%2529phenyl%2529-N%25E2%2580%25B2-%25282-fluoro-5-methylphenyl%2529urea%2520%2528ABT-869%2529%252C%2520a%25203-aminoindazole-based%2520orally%2520active%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1584%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magoc, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi-Haack, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukofzer, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niquette, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span> </span><span class="NLM_article-title">Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1535-7163.MCT-05-0410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16648571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=995-1006&author=D.+H.+Albertauthor=P.+Tapangauthor=T.+J.+Magocauthor=L.+J.+Peaseauthor=D.+R.+Reuterauthor=R.+Wieauthor=J.+Liauthor=J.+Guoauthor=P.+F.+Bousquetauthor=N.+S.+Ghoreishi-Haackauthor=B.+Wangauthor=G.+T.+Bukofzerauthor=Y.+C.+Wangauthor=J.+A.+Stavropoulosauthor=K.+Hartandiauthor=A.+L.+Niquetteauthor=N.+Soniauthor=E.+F.+Johnsonauthor=J.+O.+McCallauthor=J.+J.+Bouskaauthor=Y.+Luoauthor=C.+K.+Donawhoauthor=Y.+Daiauthor=P.+A.+Marcotteauthor=K.+B.+Glaserauthor=M.+R.+Michaelidesauthor=S.+K.+Davidsen&title=Preclinical+activity+of+ABT-869%2C+a+multitargeted+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Albert, Daniel H.; Tapang, Paul; Magoc, Terrance J.; Pease, Lori J.; Reuter, David R.; Wei, Ru-Qi; Li, Junling; Guo, Jun; Bousquet, Peter F.; Ghoreishi-Haack, Nayereh S.; Wang, Baole; Bukofzer, Gail T.; Wang, Yi-Chun; Stavropoulos, Jason A.; Hartandi, Kresna; Niquette, Amanda L.; Soni, Nirupama; Johnson, Eric F.; McCall, J. Owen; Bouska, Jennifer J.; Luo, Yanping; Donawho, Cherrie K.; Dai, Yujia; Marcotte, Patrick A.; Glaser, Keith B.; Michaelides, Michael R.; Davidsen, Steven K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">995-1006</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 μmol/L) against unrelated RTKs, sol. tyrosine kinases, or serine/threonine kinases.  The inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 = 2, 4, and 7 nmol/L for PDGFR-β, KDR, and CSF-1R, resp.) and VEGF-stimulated proliferation (IC50 = 0.2 nmol/L for human endothelial cells).  ABT-869 is not a general antiproliferative agent because, in most cancer cells, >1,000-fold higher concns. of ABT-869 are required for inhibition of proliferation.  However, ABT-869 exhibits potent antiproliferative and apoptotic effects on cancer cells whose proliferation is dependent on mutant kinases, such as FLT3.  In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50% inhibition, 15 mg/kg).  In tumor growth studies, ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED50 = 1.5-5 mg/kg, twice daily) and is also effective (>50% inhibition) in orthotopic breast and glioma models.  Redn. in tumor size and tumor regression was obsd. in epidermoid carcinoma and leukemia xenograft models, resp.  In combination, ABT-869 produced at least additive effects when given with cytotoxic therapies.  Based on pharmacokinetic anal. from tumor growth studies, efficacy correlated more strongly with time over a threshold value (cellular KDR IC50 cor. for blood plasma protein binding = 0.08 μg/mL, ≥7 h) than with plasma area under the curve or Cmax.  These results support clin. assessment of ABT-869 as a therapeutic agent for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkn2KBvMa4wrVg90H21EOLACvtfcHk0lgv3uEEPekZGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCkt7g%253D&md5=a5a60b591b4da7a3c589f1618d9cffb9</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0410%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DMagoc%26aufirst%3DT.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DWie%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DGhoreishi-Haack%26aufirst%3DN.%2BS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DBukofzer%26aufirst%3DG.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DStavropoulos%26aufirst%3DJ.%2BA.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DNiquette%26aufirst%3DA.%2BL.%26aulast%3DSoni%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMcCall%26aufirst%3DJ.%2BO.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26atitle%3DPreclinical%2520activity%2520of%2520ABT-869%252C%2520a%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D995%26epage%3D1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Jiang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesniewski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeegan, E. M.</span><span> </span><span class="NLM_article-title">ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1124%2Fjpet.110.178061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21505059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=134-142&author=F.+Jiangauthor=D.+H.+Albertauthor=Y.+Luoauthor=P.+Tapangauthor=K.+Zhangauthor=S.+K.+Davidsenauthor=G.+B.+Foxauthor=R.+Lesniewskiauthor=E.+M.+McKeegan&title=ABT-869%2C+a+multitargeted+receptor+tyrosine+kinase+inhibitor%2C+reduces+tumor+microvascularity+and+improves+vascular+wall+integrity+in+preclinical+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models</span></div><div class="casAuthors">Jiang, Fang; Albert, Daniel H.; Luo, Yanping; Tapang, Paul; Zhang, Ke; Davidsen, Steven K.; Fox, Gerard B.; Lesniewski, Richard; McKeegan, Evelyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-142</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-Me phenyl)-urea (ABT-869) is a novel multitargeted receptor tyrosine kinase inhibitor that demonstrates single-agent activity in preclin. studies and has undergone phase I and II clin. trials.  We characterized the mechanism of action of ABT-869 by examg. vascular changes after treatment (25 mg/kg per day) in HT1080 fibrosarcoma and SW620 colon carcinoma cells, using immunohistochem., dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI), and hypoxic protein detection.  We obsd. the inhibition of vascular endothelial growth factor receptor 2 and platelet-derived growth factor receptor β phosphorylation in both tumors and changes in tumor vasculature.  Redns. in microvessel d. and diam. were obsd.  Vascular-wall integrity was assessed by colocalization of pericytes and basement membrane.  Although both microvessel d. and total no. of pericytes decreased with treatment, the percentage of pericyte coverage on remaining vessels significantly increased.  These data suggest the selective ablation of microvessels lacking pericyte coverage.  Functional vascular measures DCE-MRI and hypoxia formation were also tested.  After 2 days of treatment on the HT1080 model, vascular permeability, Ktrans, was reduced by >60% and hypoxic tumor fraction was significantly decreased, which was also seen in the SW620 tumors after 4 days of treatment.  Taken together, decreases in vascular permeability and changes in vascular integrity obsd. in these studies define the mode of action of ABT-869 and may aid in optimizing the timing of therapeutic window for combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZdOtgsQFEbVg90H21EOLACvtfcHk0lgv3uEEPekZGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu74%253D&md5=8c9eafe6eac51b7433ef7d12951936a9</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178061%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DLesniewski%26aufirst%3DR.%26aulast%3DMcKeegan%26aufirst%3DE.%2BM.%26atitle%3DABT-869%252C%2520a%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520reduces%2520tumor%2520microvascularity%2520and%2520improves%2520vascular%2520wall%2520integrity%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D134%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hradil, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravartty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeegan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G. B.</span><span> </span><span class="NLM_article-title">A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-011-1740-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22080168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVCrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=911-921&author=Y.+Luoauthor=F.+Jiangauthor=T.+B.+Coleauthor=V.+P.+Hradilauthor=D.+Reuterauthor=A.+Chakravarttyauthor=D.+H.+Albertauthor=S.+K.+Davidsenauthor=B.+F.+Coxauthor=E.+M.+McKeeganauthor=G.+B.+Fox&title=A+novel+multi-targeted+tyrosine+kinase+inhibitor%2C+linifanib+%28ABT-869%29%2C+produces+functional+and+structural+changes+in+tumor+vasculature+in+an+orthotopic+rat+glioma+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model</span></div><div class="casAuthors">Luo, Yanping; Jiang, Fang; Cole, Todd B.; Hradil, Vincent P.; Reuter, David; Chakravartty, Arunava; Albert, Daniel H.; Davidsen, Steven K.; Cox, Bryan F.; McKeegan, Evelyn M.; Fox, Gerard B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">911-921</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors represent a class of targeted therapy that has proven to be successful for cancer treatment.  Linifanib is a novel, orally active multi-targeted receptor tyrosine kinase (RTK) inhibitor that exhibits potent antitumor and antiangiogenic activities against a broad spectrum of exptl. tumors and malignancies in patients.  The compd. is currently being evaluated in phase 2 and 3 clin. trials.  To investigate the effectiveness of linifinib against gliomas and the mechanism of drug action, we characterized treatment-induced antitumor and antiangiogenic responses to linifanib in an orthotopic rat glioma model.  The effect of linifanib treatment on tumor growth was detd. by tumor vol. assessment using anatomical magnetic resonance imaging (MRI).  Changes in tumor microvessel function were evaluated with dynamic contrast-enhanced MRI (DCE-MRI).  Immunohistochem. (IHC) was applied to excised tumor samples to examine underlying changes in vascular structures and target receptor expression.  Linifanib (10 mg/kg) given twice daily inhibited tumor growth following treatment for 7 days with tumor vols. being 149 ± 30 and 66 ± 7 mm3 for vehicle-and linifanib-treated groups, resp.  A significant redn. of 37 ± 13% in tumor perfusion and microvessel permeability (measured by K trans) was obsd. as early as 2 h after administration compared with vehicle treatment.  Continuous linifanib administration further reduced K trans at later time points until the end of the study (7 days post-treatment).  At day 7, K trans was reduced by 75 ± 32% for linifanib treatment compared with vehicle treatment.  Significant redn. in total blood vessel d. and improved vessel wall integrity were obsd., and staining for target receptor expression confirmed inhibition of phospho VEGFR-2 and PDGFR-β by linifanib treatment.  These results demonstrate significant antitumor and antiangiogenic activity against gliomas by linifanib, a property that may result from the inhibition of VEGFR-2 and PDGFR-β-mediated vascular changes.  DCE-MRI measured K trans changes at early treatment stages may be a useful pharmacodynamic marker for linifanib activity in clin. trials, and basal K trans may provide predictive value for tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp29ISvhCKMZrVg90H21EOLACvtfcHk0lgv3uEEPekZGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVCrsr8%253D&md5=53a832161d9d0ea29b24e556eb81e61c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1740-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1740-7%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DCole%26aufirst%3DT.%2BB.%26aulast%3DHradil%26aufirst%3DV.%2BP.%26aulast%3DReuter%26aufirst%3DD.%26aulast%3DChakravartty%26aufirst%3DA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DMcKeegan%26aufirst%3DE.%2BM.%26aulast%3DFox%26aufirst%3DG.%2BB.%26atitle%3DA%2520novel%2520multi-targeted%2520tyrosine%2520kinase%2520inhibitor%252C%2520linifanib%2520%2528ABT-869%2529%252C%2520produces%2520functional%2520and%2520structural%2520changes%2520in%2520tumor%2520vasculature%2520in%2520an%2520orthotopic%2520rat%2520glioma%2520model%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D911%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Asahina, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nokihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coates, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradhan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeegan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span> </span><span class="NLM_article-title">An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">1486</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-012-1846-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22382879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFOnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1477-1486&author=H.+Asahinaauthor=Y.+Tamuraauthor=H.+Nokiharaauthor=N.+Yamamotoauthor=Y.+Sekiauthor=T.+Shibataauthor=Y.+Gotoauthor=M.+Taniokaauthor=Y.+Yamadaauthor=A.+Coatesauthor=Y.+L.+Chiuauthor=X.+Liauthor=R.+Pradhanauthor=P.+J.+Ansellauthor=E.+M.+McKeeganauthor=M.+D.+McKeeauthor=D.+M.+Carlsonauthor=T.+Tamura&title=An+open-label%2C+phase+1+study+evaluating+safety%2C+tolerability%2C+and+pharmacokinetics+of+linifanib+%28ABT-869%29+in+Japanese+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors</span></div><div class="casAuthors">Asahina, Hajime; Tamura, Yosuke; Nokihara, Hiroshi; Yamamoto, Noboru; Seki, Yoshitaka; Shibata, Takashi; Goto, Yasushi; Tanioka, Maki; Yamada, Yasuhide; Coates, Andrew; Chiu, Yi-Lin; Li, Xiaohui; Pradhan, Rajendra; Ansell, Peter J.; McKeegan, Evelyn M.; McKee, Mark D.; Carlson, Dawn M.; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1477-1486</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose This phase 1 study assessed the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of linifanib in Japanese patients with advanced solid tumors.  Methods Patients were assigned to one of four sequential cohorts (0.05, 0.10, 0.20, or 0.25 mg/kg) of oral, once-daily linifanib on a 21-day cycle.  Adverse events (AEs) were assessed per common terminol. criteria for adverse events v3.0; tumor responses were assessed by response evaluation criteria in solid tumors.  Results Eighteen patients were enrolled.  Eleven (61%) received ≥3 prior therapies.  Dose-limiting toxicities were Grade 3 ALT increase (0.10 mg/kg linifanib) and Grade 1 T-wave inversion (0.25 mg/kg linifanib) requiring dose interruption for >7 days and discontinuation on day 29.  The most common linifanib-related AE was hypertension.  Other significant treatment-related AEs included proteinuria, fatigue, and palmar-plantar erythrodysaesthesia.  Linifanib pharmacokinetics were dose-proportional across 0.10-0.25 mg/kg.  Two patients (11.1%) had confirmed partial responses, 12 had a best response of stable disease (11 had stable disease for ≥12 wk), and four patients were not evaluable due to incomplete data.  Four patients (lung cancer, breast cancer, thymic cancer, sarcoma) have continued linifanib for ≥48 wk (range, 48-96+ weeks).  Conclusion Linifanib was well tolerated with promising preliminary clin. activity in Japanese patients.  Later-phase global studies examg. linifanib efficacy will include Japanese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmFV7_CGfQ3LVg90H21EOLACvtfcHk0ljbRg-824TgjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFOnsLs%253D&md5=f7a06d92da7728b7934ed6ab1d9ad2bc</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1846-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1846-6%26sid%3Dliteratum%253Aachs%26aulast%3DAsahina%26aufirst%3DH.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DTanioka%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DCoates%26aufirst%3DA.%26aulast%3DChiu%26aufirst%3DY.%2BL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DPradhan%26aufirst%3DR.%26aulast%3DAnsell%26aufirst%3DP.%2BJ.%26aulast%3DMcKeegan%26aufirst%3DE.%2BM.%26aulast%3DMcKee%26aufirst%3DM.%2BD.%26aulast%3DCarlson%26aufirst%3DD.%2BM.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DAn%2520open-label%252C%2520phase%25201%2520study%2520evaluating%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520linifanib%2520%2528ABT-869%2529%2520in%2520Japanese%2520patients%2520with%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1477%26epage%3D1486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Tannir, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollmannsberger, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernstoff, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posadas, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coates, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradhan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scappaticci, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricker, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelson, M. D.</span><span> </span><span class="NLM_article-title">Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2706</span><span class="NLM_x">–</span> <span class="NLM_lpage">2714</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=2706-2714&author=N.+M.+Tannirauthor=Y.+N.+Wongauthor=C.+K.+Kollmannsbergerauthor=M.+S.+Ernstoffauthor=D.+J.+Perryauthor=L.+J.+Applemanauthor=E.+M.+Posadasauthor=D.+Choauthor=T.+K.+Choueiriauthor=A.+Coatesauthor=N.+Guptaauthor=R.+Pradhanauthor=J.+Qianauthor=J.+Chenauthor=F.+A.+Scappaticciauthor=J.+L.+Rickerauthor=D.+M.+Carlsonauthor=M.+D.+Michaelson&title=Phase+2+trial+of+linifanib+%28ABT-869%29+in+patients+with+advanced+renal+cell+cancer+after+sunitinib+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTannir%26aufirst%3DN.%2BM.%26aulast%3DWong%26aufirst%3DY.%2BN.%26aulast%3DKollmannsberger%26aufirst%3DC.%2BK.%26aulast%3DErnstoff%26aufirst%3DM.%2BS.%26aulast%3DPerry%26aufirst%3DD.%2BJ.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DCho%26aufirst%3DD.%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DCoates%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DPradhan%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DScappaticci%26aufirst%3DF.%2BA.%26aulast%3DRicker%26aufirst%3DJ.%2BL.%26aulast%3DCarlson%26aufirst%3DD.%2BM.%26aulast%3DMichaelson%26aufirst%3DM.%2BD.%26atitle%3DPhase%25202%2520trial%2520of%2520linifanib%2520%2528ABT-869%2529%2520in%2520patients%2520with%2520advanced%2520renal%2520cell%2520cancer%2520after%2520sunitinib%2520failure%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47%26spage%3D2706%26epage%3D2714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandara, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thertulien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertheim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazieres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hensing, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradhan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scappaticci, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricker, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, R. A.</span><span> </span><span class="NLM_article-title">Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1418</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1097%2FJTO.0b013e318220c93e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21597387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADC%252BC3MfmtVSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1418-1425&author=E.+H.+Tanauthor=G.+D.+Gossauthor=R.+Salgiaauthor=B.+Besseauthor=D.+R.+Gandaraauthor=N.+H.+Hannaauthor=J.+C.+Yangauthor=R.+Thertulienauthor=M.+Wertheimauthor=J.+Mazieresauthor=T.+Hensingauthor=C.+Leeauthor=N.+Guptaauthor=R.+Pradhanauthor=J.+Qianauthor=Q.+Qinauthor=F.+A.+Scappaticciauthor=J.+L.+Rickerauthor=D.+M.+Carlsonauthor=R.+A.+Soo&title=Phase+2+trial+of+linifanib+%28ABT-869%29+in+patients+with+advanced+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer</span></div><div class="casAuthors">Tan Eng-Huat; Goss Glenwood D; Salgia Ravi; Besse Benjamin; Gandara David R; Hanna Nasser H; Yang James Chih-Hsin; Thertulien Raymond; Wertheim Michael; Mazieres Julien; Hensing Thomas; Lee Christa; Gupta Neeraj; Pradhan Rajendra; Qian Jiang; Qin Qin; Scappaticci Frank A; Ricker Justin L; Carlson Dawn M; Soo Ross A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1418-25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  This study assessed activity and safety of linifanib (ABT-869), a selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, in patients with locally advanced or metastatic non-small cell lung cancer.  METHODS:  In this open-label trial (NCT00517790), patients who received one to two prior lines of systemic therapy were randomized to oral linifanib 0.10 mg/kg (low dose) or 0.25 mg/kg (high dose) once daily.  Tumor responses were assessed by independent central imaging review every 8 weeks.  The primary end point was progression-free rate at 16 weeks.  Secondary end points included objective response rate, time to progression, progression-free survival, and overall survival.  Safety was also assessed.  RESULTS:  Between August 2007 and October 2008, 139 patients were enrolled; 60% had two or more prior regimens, and 88% had nonsquamous cell carcinoma.  The objective response rate (low dose and high dose) was 5.0% (3.1 and 6.8%), progression-free rate at 16 weeks was 33.1% (32.3 and 33.8%), median time to progression was 3.6 months (3.6 and 3.7 months), median progression-free survival was 3.6 months (3.5 and 3.6 months), and median overall survival was 9.0 months (10.0 and 8.3 months).  The most common linifanib-related adverse events were fatigue (42%), decreased appetite (38%), hypertension (37%), diarrhea (32%), nausea (27%), palmar-plantar erythrodysesthesia (24%), and proteinuria (22%).  These events were more common in the high-dose group.  The most common linifanib-related grade 3 or 4 adverse event was hypertension (14%).  CONCLUSIONS:  Linifanib is active in advanced non-small cell lung cancer as second- or third-line therapy.  Increased adverse event rates were observed at the high dose of linifanib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0MxtPeEZ78qcY7HFp97qMfW6udTcc2eafHr2xDzmRrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfmtVSltw%253D%253D&md5=71f49f7f3be899090749398888462ad1</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e318220c93e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e318220c93e%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DGoss%26aufirst%3DG.%2BD.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DGandara%26aufirst%3DD.%2BR.%26aulast%3DHanna%26aufirst%3DN.%2BH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DThertulien%26aufirst%3DR.%26aulast%3DWertheim%26aufirst%3DM.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DHensing%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DPradhan%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DScappaticci%26aufirst%3DF.%2BA.%26aulast%3DRicker%26aufirst%3DJ.%2BL.%26aulast%3DCarlson%26aufirst%3DD.%2BM.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26atitle%3DPhase%25202%2520trial%2520of%2520linifanib%2520%2528ABT-869%2529%2520in%2520patients%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D1418%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegrini, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosios, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McSheehy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span> </span><span class="NLM_article-title">AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">4931</span><span class="NLM_x">–</span> <span class="NLM_lpage">4941</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4931-4941&author=P.+Traxlerauthor=P.+R.+Allegriniauthor=B.+Brandtauthor=J.+Brueggenauthor=R.+Cozensauthor=D.+Fabbroauthor=K.+Grosiosauthor=H.+A.+Laneauthor=P.+McSheehyauthor=J.+Mestanauthor=T.+Meyerauthor=C.+Tangauthor=M.+Wartmannauthor=J.+Woodauthor=G.+Caravatti&title=AEE788%3A+a+dual+family+epidermal+growth+factor+receptor%2FErbB2+and+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitor+with+antitumor+and+antiangiogenic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DAllegrini%26aufirst%3DP.%2BR.%26aulast%3DBrandt%26aufirst%3DB.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGrosios%26aufirst%3DK.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DMcSheehy%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DAEE788%253A%2520a%2520dual%2520family%2520epidermal%2520growth%2520factor%2520receptor%252FErbB2%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520with%2520antitumor%2520and%2520antiangiogenic%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4931%26epage%3D4941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neureiter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alinger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissnitzer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sass, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fazio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissniowski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gahr, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlösser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haus, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocker, M.</span><span> </span><span class="NLM_article-title">The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">742</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18813786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KhtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=733-742&author=K.+Okamotoauthor=D.+Neureiterauthor=B.+Alingerauthor=M.+Meissnitzerauthor=G.+Sassauthor=V.+Schmitzauthor=P.+Di+Fazioauthor=T.+Wissniowskiauthor=S.+Gahrauthor=B.+Hohensteinauthor=B.+Kaufmannauthor=A.+Schl%C3%B6sserauthor=U.+Hausauthor=E.+G.+Hahnauthor=C.+Heroldauthor=M.+Ocker&title=The+dual+EGF%2FVEGF+receptor+tyrosine+kinase+inhibitor+AEE788+inhibits+growth+of+human+hepatocellular+carcinoma+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice</span></div><div class="casAuthors">Okamoto, Kinya; Neureiter, Daniel; Alinger, Beate; Meissnitzer, Matthias; Sass, Gabriele; Schmitz, Volker; Di Fazio, Pietro; Wissniowski, Till; Gahr, Susanne; Hohenstein, Bernd; Kaufmann, Bernhard; Schloesser, Axel; Haus, Ulrike; Hahn, Eckhart G.; Herold, Christoph; Ocker, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-742</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">We investigated the effect of AEE788, a novel dual receptor tyrosine kinase inhibitor of the EGF and the VEGF receptor, for treatment of human HCC cell lines and in a s.c. xenograft model.  Cell viability and apoptosis of HepG2 and Hep3B cells incubated with 0.1-100 μM AEE788 were quantified.  In vivo, HepG2 cells were xenografted to NMRI mice and animals were treated orally with 50 mg/kg AEE788 3x/wk.  Immunohistochem. and quant. Western blotting was performed for pathway anal. in vitro and in vivo.  AEE788 reduced growth and induced apoptosis of HCC cells by disrupting mitochondrial transmembrane potentials and inhibiting MAPK phosphorylation.  In the xenografts, AEE788 lead to a reduced tumor growth by reducing proliferation and vascularization.  Except for a reversible skin reaction and wt. loss, no signs of toxicity were obsd.  AEE788 is a promising new option for the treatment of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowl0vYOaiylLVg90H21EOLACvtfcHk0lgzv2ccDdEhYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KhtbbI&md5=aca1665a8d08358a2c297e076bef50fb</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DNeureiter%26aufirst%3DD.%26aulast%3DAlinger%26aufirst%3DB.%26aulast%3DMeissnitzer%26aufirst%3DM.%26aulast%3DSass%26aufirst%3DG.%26aulast%3DSchmitz%26aufirst%3DV.%26aulast%3DDi%2BFazio%26aufirst%3DP.%26aulast%3DWissniowski%26aufirst%3DT.%26aulast%3DGahr%26aufirst%3DS.%26aulast%3DHohenstein%26aufirst%3DB.%26aulast%3DKaufmann%26aufirst%3DB.%26aulast%3DSchl%25C3%25B6sser%26aufirst%3DA.%26aulast%3DHaus%26aufirst%3DU.%26aulast%3DHahn%26aufirst%3DE.%2BG.%26aulast%3DHerold%26aufirst%3DC.%26aulast%3DOcker%26aufirst%3DM.%26atitle%3DThe%2520dual%2520EGF%252FVEGF%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520AEE788%2520inhibits%2520growth%2520of%2520human%2520hepatocellular%2520carcinoma%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2008%26volume%3D33%26spage%3D733%26epage%3D742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Meco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Servidei, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannoni, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prisco, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Waure, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi, R.</span><span> </span><span class="NLM_article-title">Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma</span> <span class="citation_source-journal">Transl. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">335</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1593%2Ftlo.10163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20885895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A280%3ADC%252BC3cfmvVWiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=326-335&author=D.+Mecoauthor=T.+Servideiauthor=G.+F.+Zannoniauthor=E.+Martinelliauthor=M.+G.+Priscoauthor=C.+de+Waureauthor=R.+Riccardi&title=Dual+inhibitor+AEE788+reduces+tumor+growth+in+preclinical+models+of+medulloblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma</span></div><div class="casAuthors">Meco Daniela; Servidei Tiziana; Zannoni Gian Franco; Martinelli Enrica; Prisco Maria Grazia; de Waure Chiara; Riccardi Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">326-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Medulloblastoma is the most frequent malignant pediatric brain tumor with a dismal prognosis in 30% of cases.  We examined the activity of AEE788, a dual inhibitor of human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2, in medulloblastoma preclinical models.  Established lines (Daoy and D283), chemoresistant (Daoy(Pt)), and ectopically HER2-overexpressing (Daoy(HER2)) cells expressed diverse levels of total and activated AEE788 target receptors.  In vitro, AEE788 inhibited cell proliferation (IC(50) from 1.7 to 3.8 μM) and prevented epidermal growth factor- and neuregulin-induced HER1, HER2, and HER3 activation.  Inhibition of Akt paralleled that of HER receptors.  In vivo, AEE788 growth inhibited Daoy, Daoy(Pt), and Daoy(HER2) xenografts by 51%, 45%, and 72%, respectively.  Immunohistochemical analysis of mock- and HER2-transfected xenografts revealed that the latter showed, along with high HER2 expression, high VEGFR2 staining in tumor and endothelial cells and increased expression of the endothelial marker CD31.  AEE788 reduced the activation of target receptors and angiogenesis.  In 21 primary medulloblastoma, HER2 expression significantly correlated (P < .01) with VEGFR2 (r = 0.56) and VEGF (r = 0.61).  In conclusion, AEE788 shows similar growth-suppressive activities in chemosensitive and chemoresistant medulloblastoma cells in vitro and in vivo.  Ectopic HER2 overexpression sensitizes cells to AEE788 in vivo, but not in vitro, possibly through host-mediated processes.  Together with the experimental data, the finding that HER2 positively correlates with VEGFR2 and VEGF in human medulloblastoma specimens indicates HER2-overexpressing medulloblastoma as the subset that most likely might benefit from AEE788 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcZ4JW-oc_HTMsgLhIoICsfW6udTcc2ebfrbWv-7DUjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfmvVWiug%253D%253D&md5=dfd2a6b42009efdd77401ea45f53be7f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1593%2Ftlo.10163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Ftlo.10163%26sid%3Dliteratum%253Aachs%26aulast%3DMeco%26aufirst%3DD.%26aulast%3DServidei%26aufirst%3DT.%26aulast%3DZannoni%26aufirst%3DG.%2BF.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DPrisco%26aufirst%3DM.%2BG.%26aulast%3Dde%2BWaure%26aufirst%3DC.%26aulast%3DRiccardi%26aufirst%3DR.%26atitle%3DDual%2520inhibitor%2520AEE788%2520reduces%2520tumor%2520growth%2520in%2520preclinical%2520models%2520of%2520medulloblastoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D326%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Reardon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrad, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prados, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mietlowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yung, W. K.</span><span> </span><span class="NLM_article-title">Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1507</span><span class="NLM_x">–</span> <span class="NLM_lpage">1518</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-012-1854-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22392572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFOnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1507-1518&author=D.+A.+Reardonauthor=C.+A.+Conradauthor=T.+Cloughesyauthor=M.+D.+Pradosauthor=H.+S.+Friedmanauthor=K.+D.+Aldapeauthor=P.+Mischelauthor=J.+Xiaauthor=C.+Dileaauthor=J.+Huangauthor=W.+Mietlowskiauthor=M.+Duganauthor=W.+Chenauthor=W.+K.+Yung&title=Phase+I+study+of+AEE788%2C+a+novel+multitarget+inhibitor+of+ErbB-+and+VEGF-receptor-family+tyrosine+kinases%2C+in+recurrent+glioblastoma+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients</span></div><div class="casAuthors">Reardon, David A.; Conrad, Charles A.; Cloughesy, Timothy; Prados, Michael D.; Friedman, Henry S.; Aldape, Kenneth D.; Mischel, Paul; Xia, Jane; DiLea, Clifford; Huang, Jerry; Mietlowski, William; Dugan, Margaret; Chen, Wei; Yung, W. K. Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1507-1518</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose Vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) play a significant role in glioblastoma angiogenesis and proliferation, making tyrosine kinase (TK) receptors logical targets for treatment.  We evaluated AEE788, a reversible TK inhibitor that inhibits EGFR and VEGFR, in recurrent glioblastoma patients.  Methods In this dose-escalation, phase I study, patients with recurrent glioblastoma received AEE788 once daily in 28-day cycles in stratified subgroups: those receiving (1) non-enzyme-inducing anticonvulsants drugs or no anticonvulsants (Group A) and (2) enzyme-inducing anticonvulsant drugs (Group B).  A dose-expansion phase stratified patients by surgical eligibility.  Primary objectives were to det. dose-limiting toxicity (DLT) and max. tolerated dose; secondary objectives included evaluating (1) safety/tolerability, (2) pharmacokinetics, and (3) preliminary antitumor activity.  Results Sixty-four glioblastoma patients were enrolled.  Two Group A patients experienced DLTs (proteinuria and stomatitis) at 550 mg; 550 mg was, therefore, the highest dose evaluated and dose limiting.  One Group B patient receiving 800 mg experienced a DLT (diarrhea).  The initially recommended dose for dose-expansion phase for Group A was 400 mg; addnl. patients received 250 mg to assess the hepatotoxicity.  Most frequently reported adverse events (AEs) included diarrhea and rash.  Serious AEs, most commonly grade 3/4 liver function test elevations, were responsible for treatment discontinuation in 17% of patients.  AEE788 concns. were reduced by EIACD.  The best overall response was stable disease (17%).  Conclusions Continuous, once-daily AEE788 was assocd. with unacceptable toxicity and minimal activity for the treatment of recurrent glioblastoma.  The study was, therefore, discontinued prematurely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVeHK16CPxbbVg90H21EOLACvtfcHk0liKPRfawV7c2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFOnsbY%253D&md5=cd6133b54e9d7e481af1dc42cd4917d2</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1854-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1854-6%26sid%3Dliteratum%253Aachs%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3DConrad%26aufirst%3DC.%2BA.%26aulast%3DCloughesy%26aufirst%3DT.%26aulast%3DPrados%26aufirst%3DM.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DMischel%26aufirst%3DP.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DDilea%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMietlowski%26aufirst%3DW.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DYung%26aufirst%3DW.%2BK.%26atitle%3DPhase%2520I%2520study%2520of%2520AEE788%252C%2520a%2520novel%2520multitarget%2520inhibitor%2520of%2520ErbB-%2520and%2520VEGF-receptor-family%2520tyrosine%2520kinases%252C%2520in%2520recurrent%2520glioblastoma%2520patients%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1507%26epage%3D1518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span> </span><span class="NLM_article-title">Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi101777f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=738-751&author=H.+Iwataauthor=S.+Imamuraauthor=A.+Horiauthor=M.+S.+Hixonauthor=H.+Kimuraauthor=H.+Miki&title=Biochemical+characterization+of+TAK-593%2C+a+novel+VEGFR%2FPDGFR+inhibitor+with+a+two-step+slow+binding+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fbi101777f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi101777f%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DS.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DHixon%26aufirst%3DM.%2BS.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26atitle%3DBiochemical%2520characterization%2520of%2520TAK-593%252C%2520a%2520novel%2520VEGFR%252FPDGFR%2520inhibitor%2520with%2520a%2520two-step%2520slow%2520binding%2520mechanism%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D738%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becknell, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miknyoczki, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">–</span> <span class="NLM_lpage">913</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201449n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=903-913&author=R.+L.+Hudkinsauthor=N.+C.+Becknellauthor=A.+L.+Zulliauthor=T.+L.+Underinerauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=M.+S.+Albomauthor=H.+Changauthor=S.+J.+Miknyoczkiauthor=K.+Hunterauthor=S.+Jones-Bolinauthor=H.+Zhaoauthor=E.+R.+Baconauthor=J.+P.+Mallamoauthor=M.+A.+Atorauthor=B.+A.+Ruggeri&title=Synthesis+and+biological+profile+of+the+pan-vascular+endothelial+growth+factor+receptor%2Ftyrosine+kinase+with+immunoglobulin+and+epidermal+growth+factor-like+homology+domains+2+%28VEGF-R%2FTIE-2%29+inhibitor+11-%282-methylpropyl%29-12%2C13-dihydro-2-methyl-8-%28pyrimidin-2-ylamino%29-4H-indazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazol-4-one+%28CEP-11981%29%3A+a+novel+oncology+therapeutic+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fjm201449n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201449n%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DBecknell%26aufirst%3DN.%2BC.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DMiknyoczki%26aufirst%3DS.%2BJ.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DBacon%26aufirst%3DE.%2BR.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DSynthesis%2520and%2520biological%2520profile%2520of%2520the%2520pan-vascular%2520endothelial%2520growth%2520factor%2520receptor%252Ftyrosine%2520kinase%2520with%2520immunoglobulin%2520and%2520epidermal%2520growth%2520factor-like%2520homology%2520domains%25202%2520%2528VEGF-R%252FTIE-2%2529%2520inhibitor%252011-%25282-methylpropyl%2529-12%252C13-dihydro-2-methyl-8-%2528pyrimidin-2-ylamino%2529-4H-indazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazol-4-one%2520%2528CEP-11981%2529%253A%2520a%2520novel%2520oncology%2520therapeutic%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D903%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Stratmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plate, K. H.</span><span> </span><span class="NLM_article-title">Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1002%2F1097-0215%28200002%299999%3A9999%3C%3A%3AAID-IJC1054%3E3.0.CO%3B2-Q" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=11169947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsFOktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2001&pages=273-282&author=A.+Stratmannauthor=T.+Ackerauthor=A.+M.+Burgerauthor=K.+Amannauthor=W.+Risauauthor=K.+H.+Plate&title=Differential+inhibition+of+tumor+angiogenesis+by+tie2+and+vascular+endothelial+growth+factor+receptor-2+dominant-negative+receptor+mutants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Differential inhibition of tumor angiogenesis by TIE2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants</span></div><div class="casAuthors">Stratmann, Astrid; Acker, Till; Burger, Angelika M.; Amann, Kerstin; Risau, Werner; Plate, Karl H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-282</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Tumor growth is angiogenesis-dependent.  Current evidence suggests that vascular endothelial growth factor (VEGF), a major regulator of embryonic and hypoxia-mediated angiogenesis, is necessary for tumor angiogenesis.  VEGF is expressed in tumor cells in vivo, and its Tyr kinase receptors VEGFR-1 and VEGFR-2 are up-regulated in the tumor endothelium.  A second endothelial cell-specific ligand/receptor Tyr kinase system, consisting of the tie2 receptor, its activating ligand angiopoietin-1 and the inhibitory ligand angiopoietin-2, was characterized.  The authors have examd. 6 human primary breast-cancer samples and 4 murine breast-cancer cell lines (M6363, M6378, M6444, M6468), transplanted into nude mice, by in situ hybridization and/or Northern anal.  Expression of angiopoietin-1, angiopoietin-2 and tie2 was compared to VEGF and VEGFR-2 expression.  Human tumors expressed VEGFR-2 and tie2 but varied considerably in VEGF and angiopoietin-1/-2 expression.  In the murine tumor models, the authors obsd. high heterogeneity of receptor and ligand expression.  M6363 and M6378 tumors were analyzed in detail because they showed different expression of components of the tie2/angiopoietin signaling system.  M6363 tumors expressed VEGF, VEGFR-2 and angiopoietin-2 but not tie2 or angiopoietin-1, suggesting activation of VEGFR-2 and inhibition of tie2 signaling pathways, whereas M6378 tumors expressed VEGF, VEGFR-2, tie2 and angiopoietin-1 but little angiopoietin-2, suggesting activation of both VEGFR-2 and tie2 signaling pathways.  In vivo studies using truncated dominant-neg. tie2 and VEGFR-2 mutants revealed inhibition of M6363 tumor growth by 15% (truncated tie2) and 36% (truncated VEGFR-2), resp.  In contrast, M6378 tumor growth was inhibited by 57% (truncated tie2) and 47% (truncated VEGFR-2), resp.  These findings support the hypothesis that tumor angiogenesis is dependent on VEGFR-2 but suggest that, in addn., tie2-dependent pathways of tumor angiogenesis may exist.  For adequate application of angiogenesis inhibitors in tumor patients, anal. of prevailing angiogenesis pathways may be a prerequisite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDdiCPRxhiV7Vg90H21EOLACvtfcHk0lh8GnHGXC-APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsFOktQ%253D%253D&md5=dcafe52efa95848d38d3381097ab6fc8</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%28200002%299999%3A9999%3C%3A%3AAID-IJC1054%3E3.0.CO%3B2-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%2528200002%25299999%253A9999%253C%253A%253AAID-IJC1054%253E3.0.CO%253B2-Q%26sid%3Dliteratum%253Aachs%26aulast%3DStratmann%26aufirst%3DA.%26aulast%3DAcker%26aufirst%3DT.%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DAmann%26aufirst%3DK.%26aulast%3DRisau%26aufirst%3DW.%26aulast%3DPlate%26aufirst%3DK.%2BH.%26atitle%3DDifferential%2520inhibition%2520of%2520tumor%2520angiogenesis%2520by%2520tie2%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520dominant-negative%2520receptor%2520mutants%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2001%26volume%3D91%26spage%3D273%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madajewicz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgriff, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, D.</span><span> </span><span class="NLM_article-title">A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-006-0352-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=17031646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVOgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=81-89&author=R.+B.+Cohenauthor=C.+J.+Langerauthor=G.+R.+Simonauthor=P.+D.+Eisenbergauthor=J.+D.+Hainsworthauthor=S.+Madajewiczauthor=T.+M.+Cosgriffauthor=K.+Pierceauthor=H.+Xuauthor=K.+Liauauthor=D.+Healey&title=A+phase+I%2Frandomized+phase+II%2C+non-comparative%2C+multicenter%2C+open+label+trial+of+CP-547%2C632+in+combination+with+paclitaxel+and+carboplatin+or+paclitaxel+and+carboplatin+alone+as+first-line+treatment+for+advanced+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Cohen, Roger B.; Langer, Corey J.; Simon, George Rajan; Eisenberg, Peter David; Hainsworth, John Daniel; Madajewicz, Stefan; Cosgriff, Thomas Michael; Pierce, Kristen; Xu, Huiping; Liau, Katherine; Healey, Diane</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-89</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate the toxicity profile and pharmacol. properties of oral CP-547,632 alone and in combination with paclitaxel and carboplatin administered every 3 wk, and to assess efficacy as measured by the objective response and progressive disease rates of oral CP-547,632 administered in combination with paclitaxel and carboplatin.  Patients and methods: Patients with stage IIIB/IV or recurrent non-small cell lung cancer receiving first-line chemotherapy were treated with oral daily CP-547,632 in combination with paclitaxel 225 mg/m2 and carboplatin AUC = 6 every 3 wk.  Pharmacokinetics parameters for CP-547,632 and paclitaxel were detd. independently and during co-administration.  Results: Seventy patients were enrolled and 68 patients were treated, 37 in phase 1 and 31 in phase 2 (14 with the combination and 17 with chemotherapy alone).  Dose-limiting toxicity of CP-547,632 250 mg by mouth daily in combination with paclitaxel and carboplatin was grade 3 rash and grade 3 diarrhea despite medical intervention.  CP-547,632 did not significantly affect the pharmacol. profiles of paclitaxel and carboplatin.  No subject had CR.  In phase I, seven subjects (22.6%) had a confirmed partial response.  In phase II, four subjects (28.6%) receiving CP-547,632 plus chemotherapy had a confirmed partial response.  In the phase II chemotherapy alone group, four subjects (25%) had a confirmed partial response.  Conclusion: The combination of CP-547,632 and paclitaxel and carboplatin was well-tolerated at doses up to 200 mg by mouth daily.  Dose-limiting toxicity of CP-547,632 at 250 mg consisted of diarrhea and rash.  CP-547,632 did not increase the objective response rate to chemotherapy alone in patients with advanced non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopzOmygcNSSLVg90H21EOLACvtfcHk0lh8GnHGXC-APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVOgsLY%253D&md5=82853265274c80dc446731445b0c7707</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0352-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0352-0%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DSimon%26aufirst%3DG.%2BR.%26aulast%3DEisenberg%26aufirst%3DP.%2BD.%26aulast%3DHainsworth%26aufirst%3DJ.%2BD.%26aulast%3DMadajewicz%26aufirst%3DS.%26aulast%3DCosgriff%26aufirst%3DT.%2BM.%26aulast%3DPierce%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLiau%26aufirst%3DK.%26aulast%3DHealey%26aufirst%3DD.%26atitle%3DA%2520phase%2520I%252Frandomized%2520phase%2520II%252C%2520non-comparative%252C%2520multicenter%252C%2520open%2520label%2520trial%2520of%2520CP-547%252C632%2520in%2520combination%2520with%2520paclitaxel%2520and%2520carboplatin%2520or%2520paclitaxel%2520and%2520carboplatin%2520alone%2520as%2520first-line%2520treatment%2520for%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D81%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Scott, W.; Dumas, J.; Ladouceur, G.; Lynch, M.; Scott, W. J.</span><span> </span><span class="NLM_article-title">Preparation of Diaryl Ureas with Kinase Inhibiting Activity</span>. WO 2004113274,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=W.+Scott&author=J.+Dumas&author=G.+Ladouceur&author=M.+Lynch&author=W.+J.+Scott&title=Preparation+of+Diaryl+Ureas+with+Kinase+Inhibiting+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DW.%26atitle%3DPreparation%2520of%2520Diaryl%2520Ureas%2520with%2520Kinase%2520Inhibiting%2520Activity%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schütz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zopf, D.</span><span> </span><span class="NLM_article-title">Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1002%2Fijc.25864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21170960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=245-255&author=S.+M.+Wilhelmauthor=J.+Dumasauthor=L.+Adnaneauthor=M.+Lynchauthor=C.+A.+Carterauthor=G.+Sch%C3%BCtzauthor=K.+H.+Thierauchauthor=D.+Zopf&title=Regorafenib+%28BAY+73-4506%29%3A+a+new+oral+multikinase+inhibitor+of+angiogenic%2C+stromal+and+oncogenic+receptor+tyrosine+kinases+with+potent+preclinical+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span></div><div class="casAuthors">Wilhelm, Scott M.; Dumas, Jacques; Adnane, Lila; Lynch, Mark; Carter, Christopher A.; Schuetz, Gunnar; Thierauch, Karl-Heinz; Zopf, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-255</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Angiogenesis, a crit. driver of tumor development, is controlled by interconnected signaling pathways.  Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with Ig and epidermal growth factor homol. domain 2 play crucial roles in the biol. of normal and tumor vasculature.  Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochem. and cellular kinase phosphorylation assays.  Furthermore, regorafenib inhibits addnl. angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF.  The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging.  Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts.  In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 h after the last dosing and correlated with tumor growth inhibition (TGI).  A significant redn. in tumor microvessel area was obsd. in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg.  Regorafenib exhibited potent dose-dependent TGI in various preclin. human xenograft models in mice, with tumor shrinkages obsd. in breast MDA-MB-231 and renal 786-O carcinoma models.  Pharmacodynamic analyses of the breast model revealed strong redn. in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2.  These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQpQXfCq04rVg90H21EOLACvtfcHk0lh8GnHGXC-APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D&md5=13eee29ef1f1f03fd1ed311ea613f566</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fijc.25864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25864%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DG.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26aulast%3DZopf%26aufirst%3DD.%26atitle%3DRegorafenib%2520%2528BAY%252073-4506%2529%253A%2520a%2520new%2520oral%2520multikinase%2520inhibitor%2520of%2520angiogenic%252C%2520stromal%2520and%2520oncogenic%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520preclinical%2520antitumor%2520activity%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D245%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbild, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedbom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büchert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasol, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krätzschmar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boix, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, O.</span><span> </span><span class="NLM_article-title">A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2658</span><span class="NLM_x">–</span> <span class="NLM_lpage">2667</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-11-1900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22421192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFeisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2658-2667&author=K.+Mrossauthor=A.+Frostauthor=S.+Steinbildauthor=S.+Hedbomauthor=M.+B%C3%BCchertauthor=U.+Fasolauthor=C.+Ungerauthor=J.+Kr%C3%A4tzschmarauthor=R.+Heinigauthor=O.+Boixauthor=O.+Christensen&title=A+phase+I+dose-escalation+study+of+regorafenib+%28BAY+73-4506%29%2C+an+inhibitor+of+oncogenic%2C+angiogenic%2C+and+stromal+kinases%2C+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Mross, Klaus; Frost, Annette; Steinbild, Simone; Hedbom, Susanne; Buechert, Martin; Fasol, Ulrike; Unger, Clemens; Kraetzschmar, Joern; Heinig, Roland; Boix, Oliver; Christensen, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2658-2667</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF).  This first-in-man, phase I dose-escalation study assessed the safety, pharmacokinetic, pharmacodynamic, and efficacy profiles of regorafenib in patients with advanced solid tumors.  PATIENTS AND METHODS: Patients aged 18 years or older with advanced solid tumors refractory to std. treatment were recruited.  Regorafenib was administered orally for 21 days on/seven days off in repeating cycles, until discontinuation due to toxicity or tumor progression.  Adverse events (AE) were assessed using National Cancer Institute Common Terminol. Criteria for Adverse Events v3.0.  Pharmacokinetic profiles were measured after a single dose and on day 21.  Pharmacodynamic and efficacy evaluations included tumor perfusion assessment using dynamic contrast-enhanced MRI, plasma cytokines, and tumor response using RECIST (v1.0).  RESULTS: Fifty-three patients were enrolled into eight cohorts at dose levels from 10 to 220 mg daily.  The recommended dose for future studies was detd. to be 160 mg daily, with a treatment schedule of 21 days on/seven days off in repeating 28-day cycles.  The most common drug-related grade 3 or 4 AEs were dermatol. AEs (hand-foot skin reaction, rash), hypertension, and diarrhea.  Pharmacokinetic anal. revealed a similar exposure at steady state for the parent compd. and two pharmacol. active metabolites.  Tumor perfusion and plasma cytokine anal. showed biol. activity of regorafenib.  Three of 47 evaluable patients achieved a partial response (renal cell carcinoma, colorectal carcinoma, and osteosarcoma).  CONCLUSION: Regorafenib showed an acceptable safety profile and preliminary evidence of antitumor activity in patients with solid tumors.  Clin Cancer Res; 18(9); 2658-67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozD2QRXhH1irVg90H21EOLACvtfcHk0lh5XhV78i9NBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFeisLk%253D&md5=26b168c1cdb6809a0055f52add91745d</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1900%26sid%3Dliteratum%253Aachs%26aulast%3DMross%26aufirst%3DK.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DSteinbild%26aufirst%3DS.%26aulast%3DHedbom%26aufirst%3DS.%26aulast%3DB%25C3%25BCchert%26aufirst%3DM.%26aulast%3DFasol%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DC.%26aulast%3DKr%25C3%25A4tzschmar%26aufirst%3DJ.%26aulast%3DHeinig%26aufirst%3DR.%26aulast%3DBoix%26aufirst%3DO.%26aulast%3DChristensen%26aufirst%3DO.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520study%2520of%2520regorafenib%2520%2528BAY%252073-4506%2529%252C%2520an%2520inhibitor%2520of%2520oncogenic%252C%2520angiogenic%252C%2520and%2520stromal%2520kinases%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2658%26epage%3D2667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Strumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheulen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultheis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richly, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büchert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boix, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mross, K.</span><span> </span><span class="NLM_article-title">Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study</span> <span class="citation_source-journal">Br. J. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1722</span><span class="NLM_x">–</span> <span class="NLM_lpage">1727</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fbjc.2012.153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=22568966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1SntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=1722-1727&author=D.+Strumbergauthor=M.+E.+Scheulenauthor=B.+Schultheisauthor=H.+Richlyauthor=A.+Frostauthor=M.+B%C3%BCchertauthor=O.+Christensenauthor=M.+Jeffersauthor=R.+Heinigauthor=O.+Boixauthor=K.+Mross&title=Regorafenib+%28BAY+73-4506%29+in+advanced+colorectal+cancer%3A+a+phase+I+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study</span></div><div class="casAuthors">Strumberg, D.; Scheulen, M. E.; Schultheis, B.; Richly, H.; Frost, A.; Buechert, M.; Christensen, O.; Jeffers, M.; Heinig, R.; Boix, O.; Mross, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1722-1727</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumor activity in solid tumor patients.  The study was expanded to focus on patients with metastatic colorectal cancer (CRC).  Methods: Patients received oral regorafenib 60-220 mg daily (160 mg daily in the extension cohort) in cycles of 21 days on, 7 days off treatment.  Assessments included toxicity, response, pharmacokinetics and pharmacodynamics.  Results: Thirty-eight patients with heavily pretreated CRC (median 4 prior lines of therapy, range 0-7) were enrolled in the dose-escalation and extension phases; 26 patients received regorafenib 160 mg daily.  Median treatment duration was 53 days (range 7-280 days).  The most common treatment-related toxicities included hand-foot skin reaction, fatigue, voice change and rash.  Twenty-seven patients were evaluable for response: 1 achieved partial response and 19 had stable disease.  Median progression-free survival was 107 days (95% CI, 66-161).  At steady state, regorafenib and its active metabolites had similar systemic exposure.  Pharmacodynamic assessment indicated decreased tumor perfusion in most patients.  Conclusion: Regorafenib showed tolerability and antitumor activity in patients with metastatic CRC.  This expanded-cohort phase I study provided the foundation for further clin. trials of regorafenib in this patient population.  British Journal of Cancer (2012) 106, 1722-1727; doi:10.1038/bjc.2012.153 www.bjcancer.com; published online 8 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxebXIrrEBVLVg90H21EOLACvtfcHk0lh5XhV78i9NBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1SntLs%253D&md5=2be1350accc94d6eac824b273e2079cd</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.153%26sid%3Dliteratum%253Aachs%26aulast%3DStrumberg%26aufirst%3DD.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DSchultheis%26aufirst%3DB.%26aulast%3DRichly%26aufirst%3DH.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DB%25C3%25BCchert%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DO.%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DHeinig%26aufirst%3DR.%26aulast%3DBoix%26aufirst%3DO.%26aulast%3DMross%26aufirst%3DK.%26atitle%3DRegorafenib%2520%2528BAY%252073-4506%2529%2520in%2520advanced%2520colorectal%2520cancer%253A%2520a%2520phase%2520I%2520study%26jtitle%3DBr.%2520J.%2520Cancer.%26date%3D2012%26volume%3D106%26spage%3D1722%26epage%3D1727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationale developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationale+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationale%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Garofalo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemoine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Six, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavatte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goossens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depreux, P.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1189</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2013453" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1189-1204&author=A.+Garofaloauthor=A.+Farceauthor=S.+Ravezauthor=A.+Lemoineauthor=P.+Sixauthor=P.+Chavatteauthor=L.+Goossensauthor=P.+Depreux&title=Synthesis+and+structure%E2%80%93activity+relationships+of+%28aryloxy%29quinazoline+ureas+as+novel%2C+potent%2C+and+selective+vascular+endothelial+growth+factor+receptor-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fjm2013453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013453%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DA.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DRavez%26aufirst%3DS.%26aulast%3DLemoine%26aufirst%3DA.%26aulast%3DSix%26aufirst%3DP.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DGoossens%26aufirst%3DL.%26aulast%3DDepreux%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520%2528aryloxy%2529quinazoline%2520ureas%2520as%2520novel%252C%2520potent%252C%2520and%2520selective%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1189%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4439</span><span class="NLM_x">–</span> <span class="NLM_lpage">4450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1158%2F1078-0432.CCR-10-3109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21622720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1SmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4439-4450&author=S.+Zhangauthor=Z.+Caoauthor=H.+Tianauthor=G.+Shenauthor=Y.+Maauthor=H.+Xieauthor=Y.+Liuauthor=C.+Zhaoauthor=S.+Dengauthor=Y.+Yangauthor=R.+Zhengauthor=W.+Liauthor=N.+Zhangauthor=S.+Liuauthor=W.+Wangauthor=L.+Daiauthor=S.+Shiauthor=L.+Chengauthor=Y.+Panauthor=S.+Fengauthor=X.+Zhaoauthor=H.+Dengauthor=S.+Yangauthor=Y.+Wei&title=SKLB1002%2C+a+novel+potent+inhibitor+of+VEGF+receptor+2+signaling%2C+inhibits+angiogenesis+and+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo</span></div><div class="casAuthors">Zhang, Shuang; Cao, Zhixing; Tian, Hongwei; Shen, Guobo; Ma, Yongping; Xie, Huanzhang; Liu, Yalin; Zhao, Chengjian; Deng, Senyi; Yang, Yang; Zheng, Renlin; Li, Weiwei; Zhang, Na; Liu, Shengyong; Wang, Wei; Dai, Lixia; Shi, Shuai; Cheng, Lin; Pan, Youli; Feng, Shan; Zhao, Xia; Deng, Hongxin; Yang, Shengyong; Wei, Yuquan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4439-4450</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment.  However, currently most of these anticancer drugs suffer some adverse effects.  Discovery of novel VEGFR2 inhibitors as anticancer drug candidates is still needed.  Exptl. Design: In this investigation, we adopted a restricted de novo design method to design VEGFR2 inhibitors.  We selected the most potent compd. SKLB1002 and analyzed its inhibitory effects on human umbilical vein endothelial cells (HUVEC) in vitro.  Tumor xenografts in zebrafish and athymic mice were used to examine the in vivo activity of SKLB1002.  RESULTS: The use of the restricted de novo design method indeed led to a new potent VEGFR2 inhibitor, SKLB1002, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation.  Western blot anal. was conducted, which indicated that SKLB1002 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal-regulated kinase, focal adhesion kinase, and Src.  In vivo zebrafish model expts. showed that SKLB1002 remarkably blocked the formation of intersegmental vessels in zebrafish embryos.  It was further found to inhibit a new microvasculature in zebrafish embryos induced by inoculated tumor cells.  Finally, compared with the solvent control, administration of 100 mg/kg/d SKLB1002 reached more than 60% inhibition against human tumor xenografts in athymic mice.  The antiangiogenic effect was indicated by CD31 immunohistochem. staining and alginate-encapsulated tumor cell assay.  CONCLUSIONS: Our findings suggest that SKLB1002 inhibits angiogenesis and may be a potential drug candidate in anticancer therapy.  Clin Cancer Res; 17(13); 4439-50.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgqK6UNG6yrVg90H21EOLACvtfcHk0ljtqcINI4-7_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1SmtLo%253D&md5=a15e4fe2fd1e62134a8c48cf2d4a2547</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3109%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DSKLB1002%252C%2520a%2520novel%2520potent%2520inhibitor%2520of%2520VEGF%2520receptor%25202%2520signaling%252C%2520inhibits%2520angiogenesis%2520and%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4439%26epage%3D4450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span> </span><span class="NLM_article-title">SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy</span> <span class="citation_source-journal">Neoplasma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=486-493&author=G.+Shenauthor=Y.+Liauthor=T.+Duauthor=G.+Shiauthor=L.+Daiauthor=X.+Chenauthor=R.+Zhengauthor=W.+Liauthor=X.+Suauthor=S.+Zhangauthor=Y.+Weiauthor=S.+Yangauthor=H.+Deng&title=SKLB1002%2C+a+novel+inhibitor+of+VEGF+receptor+2+signaling%2C+induces+vascular+normalization+to+improve+systemically+administered+chemotherapy+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DH.%26atitle%3DSKLB1002%252C%2520a%2520novel%2520inhibitor%2520of%2520VEGF%2520receptor%25202%2520signaling%252C%2520induces%2520vascular%2520normalization%2520to%2520improve%2520systemically%2520administered%2520chemotherapy%2520efficacy%26jtitle%3DNeoplasma%26date%3D2012%26volume%3D59%26spage%3D486%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Yu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. F.</span><span> </span><span class="NLM_article-title">Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=110-114&author=B.+Yuauthor=L.+D.+Tangauthor=Y.+L.+Liauthor=S.+H.+Songauthor=X.+L.+Jiauthor=M.+S.+Linauthor=C.+F.+Wu&title=Design%2C+synthesis+and+antitumor+activity+of+4-aminoquinazoline+derivatives+targeting+VEGFR-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTang%26aufirst%3DL.%2BD.%26aulast%3DLi%26aufirst%3DY.%2BL.%26aulast%3DSong%26aufirst%3DS.%2BH.%26aulast%3DJi%26aufirst%3DX.%2BL.%26aulast%3DLin%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BF.%26atitle%3DDesign%252C%2520synthesis%2520and%2520antitumor%2520activity%2520of%25204-aminoquinazoline%2520derivatives%2520targeting%2520VEGFR-2%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D110%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Plé, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span> </span><span class="NLM_article-title">Discovery of AZD2932, a new quinazoline ether inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=262-266&author=P.+A.+Pl%C3%A9author=F.+Jungauthor=S.+Ashtonauthor=L.+Hennequinauthor=R.+Laineauthor=R.+Morgentinauthor=G.+Pasquetauthor=S.+Taylor&title=Discovery+of+AZD2932%2C+a+new+quinazoline+ether+inhibitor+with+high+affinity+for+VEGFR-2+and+PDGFR+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%2BA.%26aulast%3DJung%26aufirst%3DF.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DHennequin%26aufirst%3DL.%26aulast%3DLaine%26aufirst%3DR.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520AZD2932%252C%2520a%2520new%2520quinazoline%2520ether%2520inhibitor%2520with%2520high%2520affinity%2520for%2520VEGFR-2%2520and%2520PDGFR%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D262%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Oguro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awazu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">7260</span><span class="NLM_x">–</span> <span class="NLM_lpage">7273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=7260-7273&author=Y.+Oguroauthor=N.+Miyamotoauthor=K.+Okadaauthor=T.+Takagiauthor=H.+Iwataauthor=Y.+Awazuauthor=H.+Mikiauthor=A.+Horiauthor=K.+Kamiyamaauthor=S.+Imamura&title=Design%2C+synthesis%2C+and+evaluation+of+5-methyl-4-phenoxy-5H-pyrrolo%5B3%2C2-d%5Dpyrimidine+derivatives%3A+novel+VEGFR2+kinase+inhibitors+binding+to+inactive+kinase+conformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOguro%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DOkada%26aufirst%3DK.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DAwazu%26aufirst%3DY.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DKamiyama%26aufirst%3DK.%26aulast%3DImamura%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%25205-methyl-4-phenoxy-5H-pyrrolo%255B3%252C2-d%255Dpyrimidine%2520derivatives%253A%2520novel%2520VEGFR2%2520kinase%2520inhibitors%2520binding%2520to%2520inactive%2520kinase%2520conformation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D7260%26epage%3D7273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Oguro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awazu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span> </span><span class="NLM_article-title"><i>N</i>-Phenyl-<i>N</i>′-[4-(5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">7150</span><span class="NLM_x">–</span> <span class="NLM_lpage">7163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=7150-7163&author=Y.+Oguroauthor=N.+Miyamotoauthor=T.+Takagiauthor=K.+Okadaauthor=Y.+Awazuauthor=H.+Mikiauthor=A.+Horiauthor=K.+Kamiyamaauthor=S.+Imamura&title=N-Phenyl-N%E2%80%B2-%5B4-%285H-pyrrolo%5B3%2C2-d%5Dpyrimidin-4-yloxy%29phenyl%5Dureas+as+novel+inhibitors+of+VEGFR+and+FGFR+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOguro%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DK.%26aulast%3DAwazu%26aufirst%3DY.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DKamiyama%26aufirst%3DK.%26aulast%3DImamura%26aufirst%3DS.%26atitle%3DN-Phenyl-N%25E2%2580%25B2-%255B4-%25285H-pyrrolo%255B3%252C2-d%255Dpyrimidin-4-yloxy%2529phenyl%255Dureas%2520as%2520novel%2520inhibitors%2520of%2520VEGFR%2520and%2520FGFR%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D7150%26epage%3D7163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurup, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S. S.</span><span> </span><span class="NLM_article-title">Synthesis and biological activity of <i>N</i>(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3575</span><span class="NLM_x">–</span> <span class="NLM_lpage">3587</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=3575-3587&author=A.+Gangjeeauthor=S.+Kurupauthor=M.+A.+Ihnatauthor=J.+E.+Thorpeauthor=S.+S.+Shenoy&title=Synthesis+and+biological+activity+of+N%284%29-phenylsubstituted-6-%282%2C4-dichloro+phenylmethyl%29-7H-pyrrolo%5B2%2C3-d%5Dpyrimidine-2%2C4-diamines+as+vascular+endothelial+growth+factor+receptor-2+inhibitors+and+antiangiogenic+and+antitumor+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DKurup%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DShenoy%26aufirst%3DS.%2BS.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520N%25284%2529-phenylsubstituted-6-%25282%252C4-dichloro%2520phenylmethyl%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidine-2%252C4-diamines%2520as%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520inhibitors%2520and%2520antiangiogenic%2520and%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D3575%26epage%3D3587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Frey, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukofzer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">7-Aminopyrazolo[1,5-<i>a</i>]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3777</span><span class="NLM_x">–</span> <span class="NLM_lpage">3787</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701397k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3777-3787&author=R.+R.+Freyauthor=M.+L.+Curtinauthor=D.+H.+Albertauthor=K.+B.+Glaserauthor=L.+J.+Peaseauthor=N.+B.+Soniauthor=J.+J.+Bouskaauthor=D.+Reuterauthor=K.+D.+Stewartauthor=P.+Marcotteauthor=G.+Bukofzerauthor=J.+Liauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=7-Aminopyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+multitargeted+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Fjm701397k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701397k%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DR.%2BR.%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DReuter%26aufirst%3DD.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DMarcotte%26aufirst%3DP.%26aulast%3DBukofzer%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3D7-Aminopyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3777%26epage%3D3787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Egert-Schmidt, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunkel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohfeld, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehlert, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutschler, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schächtele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubbutat, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunick, C.</span><span> </span><span class="NLM_article-title">Identification of 2-anilino-9-methoxy-5,7-dihydro-6<i>H</i>-pyrimido[5,4-<i>d</i>][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2433</span><span class="NLM_x">–</span> <span class="NLM_lpage">2442</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901388c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2433-2442&author=A.+M.+Egert-Schmidtauthor=J.+Dreherauthor=U.+Dunkelauthor=S.+Kohfeldauthor=L.+Preuauthor=H.+Weberauthor=J.+E.+Ehlertauthor=B.+Mutschlerauthor=F.+Totzkeauthor=C.+Sch%C3%A4chteleauthor=M.+H.+Kubbutatauthor=K.+Baumannauthor=C.+Kunick&title=Identification+of+2-anilino-9-methoxy-5%2C7-dihydro-6H-pyrimido%5B5%2C4-d%5D%5B1%5Dbenzazepin-6-ones+as+dual+PLK1%2FVEGF-R2+kinase+inhibitor+chemotypes+by+structure-based+lead+generation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Fjm901388c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901388c%26sid%3Dliteratum%253Aachs%26aulast%3DEgert-Schmidt%26aufirst%3DA.%2BM.%26aulast%3DDreher%26aufirst%3DJ.%26aulast%3DDunkel%26aufirst%3DU.%26aulast%3DKohfeld%26aufirst%3DS.%26aulast%3DPreu%26aufirst%3DL.%26aulast%3DWeber%26aufirst%3DH.%26aulast%3DEhlert%26aufirst%3DJ.%2BE.%26aulast%3DMutschler%26aufirst%3DB.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%26aulast%3DBaumann%26aufirst%3DK.%26aulast%3DKunick%26aufirst%3DC.%26atitle%3DIdentification%2520of%25202-anilino-9-methoxy-5%252C7-dihydro-6H-pyrimido%255B5%252C4-d%255D%255B1%255Dbenzazepin-6-ones%2520as%2520dual%2520PLK1%252FVEGF-R2%2520kinase%2520inhibitor%2520chemotypes%2520by%2520structure-based%2520lead%2520generation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2433%26epage%3D2442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Strebhardt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Targeting polo-like kinase 1 for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnrc1841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=16557283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVyqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=321-330&author=K.+Strebhardtauthor=A.+Ullrich&title=Targeting+polo-like+kinase+1+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting polo-like kinase 1 for cancer therapy</span></div><div class="casAuthors">Strebhardt, Klaus; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-330</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Human polo-like kinase 1 (PLK1) is essential during mitosis and in the maintenance of genomic stability.  PLK1 is overexpressed in human tumors and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target.  The use of different PLK1 inhibitors has increased our knowledge of mitotic regulation and allowed us to assess their ability to suppress tumor growth in vivo.  We address the structural features of the kinase domain and the unique polo-box domain of PLK1 that are most suited for drug development and discuss our current understanding of the therapeutic potential of PLK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdeCr1fiAaaLVg90H21EOLACvtfcHk0lgcAnaivRUbog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVyqtrk%253D&md5=b43638c4eb123292a507734fb87e89ac</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fnrc1841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1841%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DTargeting%2520polo-like%2520kinase%25201%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D321%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Hughes, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnachi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seraj., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes-Pesquera, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruninger, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, D. F.</span><span> </span><span class="NLM_article-title">4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3266</span><span class="NLM_x">–</span> <span class="NLM_lpage">3270</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3266-3270&author=T.+V.+Hughesauthor=S.+L.+Emanuelauthor=A.+K.+Beckauthor=S.+K.+Wetterauthor=P.+J.+Connollyauthor=P.+Karnachiauthor=M.+Reumanauthor=J.+Seraj.author=A.+R.+Fuentes-Pesqueraauthor=R.+H.+Gruningerauthor=S.+A.+Middletonauthor=R.+Linauthor=J.+M.+Davisauthor=D.+F.+Moffat&title=4-Aryl-5-cyano-2-aminopyrimidines+as+VEGF-R2+inhibitors%3A+synthesis+and+biological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DT.%2BV.%26aulast%3DEmanuel%26aufirst%3DS.%2BL.%26aulast%3DBeck%26aufirst%3DA.%2BK.%26aulast%3DWetter%26aufirst%3DS.%2BK.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DKarnachi%26aufirst%3DP.%26aulast%3DReuman%26aufirst%3DM.%26aulast%3DSeraj.%26aufirst%3DJ.%26aulast%3DFuentes-Pesquera%26aufirst%3DA.%2BR.%26aulast%3DGruninger%26aufirst%3DR.%2BH.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26aulast%3DMoffat%26aufirst%3DD.%2BF.%26atitle%3D4-Aryl-5-cyano-2-aminopyrimidines%2520as%2520VEGF-R2%2520inhibitors%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3266%26epage%3D3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Gaudette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaisburg, A.</span><span> </span><span class="NLM_article-title">Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">848</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1016%2Fj.bmcl.2009.12.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=20071170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=848-852&author=F.+Gaudetteauthor=S.+Raeppelauthor=H.+Nguyenauthor=N.+Beaulieuauthor=C.+Beaulieuauthor=I.+Dupontauthor=A.+R.+Macleodauthor=J.+M.+Bestermanauthor=A.+Vaisburg&title=Identification+of+potent+and+selective+VEGFR+receptor+tyrosine+kinase+inhibitors+having+new+amide+isostere+headgroups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups</span></div><div class="casAuthors">Gaudette, Frederic; Raeppel, Stephane; Nguyen, Hannah; Beaulieu, Normand; Beaulieu, Carole; Dupont, Isabelle; MacLeod, A. Robert; Besterman, Jeffrey M.; Vaisburg, Arkadii</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">848-852</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of malonamide-type dual VEGFR2/c-Met inhibitors in which one of the amide bonds was replaced by an amide isostere-a trifluoroethylamine unit, was designed, synthesized, and evaluated for their enzymic and cellular inhibition of VEGFR2 and c-Met enzymes.  Optimization of these mol. entities resulted in identification of potent and selective inhibitors of VEGFR2 enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom6nM7bV2v7LVg90H21EOLACvtfcHk0lgcAnaivRUbog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGrurc%253D&md5=4ce25cdb55c553f33a7dab139ee0cc04</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.099%26sid%3Dliteratum%253Aachs%26aulast%3DGaudette%26aufirst%3DF.%26aulast%3DRaeppel%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DBeaulieu%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DI.%26aulast%3DMacleod%26aufirst%3DA.%2BR.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520potent%2520and%2520selective%2520VEGFR%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520having%2520new%2520amide%2520isostere%2520headgroups%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D848%26epage%3D852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaMontagne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, P. J.</span><span> </span><span class="NLM_article-title">4-Aminopyrimidine-5-carbaldehyde oximes as potent VEGFR-2 inhibitors. Part II</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1815</span><span class="NLM_x">–</span> <span class="NLM_lpage">1818</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1815-1818&author=S.+Huangauthor=R.+Liauthor=K.+R.+LaMontagneauthor=L.+M.+Greenbergerauthor=P.+J.+Connolly&title=4-Aminopyrimidine-5-carbaldehyde+oximes+as+potent+VEGFR-2+inhibitors.+Part+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DLaMontagne%26aufirst%3DK.%2BR.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26atitle%3D4-Aminopyrimidine-5-carbaldehyde%2520oximes%2520as%2520potent%2520VEGFR-2%2520inhibitors.%2520Part%2520II%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1815%26epage%3D1818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Sakurai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yashiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirakawa, K.</span><span> </span><span class="NLM_article-title">A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2612</span><span class="NLM_x">–</span> <span class="NLM_lpage">2620</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=2612-2620&author=K.+Sakuraiauthor=N.+Yamadaauthor=M.+Yashiroauthor=T.+Matsuzakiauthor=M.+Komatsuauthor=M.+Ohiraauthor=A.+Miwaauthor=K.+Hirakawa&title=A+novel+angiogenesis+inhibitor%2C+Ki23057%2C+is+useful+for+preventing+the+progression+of+colon+cancer+and+the+spreading+of+cancer+cells+to+the+liver"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakurai%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DYashiro%26aufirst%3DM.%26aulast%3DMatsuzaki%26aufirst%3DT.%26aulast%3DKomatsu%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DMiwa%26aufirst%3DA.%26aulast%3DHirakawa%26aufirst%3DK.%26atitle%3DA%2520novel%2520angiogenesis%2520inhibitor%252C%2520Ki23057%252C%2520is%2520useful%2520for%2520preventing%2520the%2520progression%2520of%2520colon%2520cancer%2520and%2520the%2520spreading%2520of%2520cancer%2520cells%2520to%2520the%2520liver%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D2612%26epage%3D2620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPietro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, R.</span><span> </span><span class="NLM_article-title">Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1667</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701097z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1649-1667&author=J.+C.+Harmangeauthor=M.+M.+Weissauthor=J.+Germainauthor=A.+J.+Polverinoauthor=G.+Borgauthor=J.+Breadyauthor=D.+Chenauthor=D.+Choquetteauthor=A.+Coxonauthor=T.+DeMelfiauthor=L.+DiPietroauthor=N.+Doerrauthor=J.+Estradaauthor=J.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=S.+Kaufmanauthor=D.+S.+Laauthor=A.+Longauthor=M.+W.+Martinauthor=S.+Neervannanauthor=V.+F.+Patelauthor=M.+Potashmanauthor=K.+Regalauthor=P.+M.+Rovetoauthor=M.+L.+Schragauthor=C.+Starnesauthor=A.+Taskerauthor=Y.+Tefferaauthor=L.+Wangauthor=R.+D.+Whiteauthor=D.+A.+Whittingtonauthor=R.+Zanon&title=Naphthamides+as+novel+and+potent+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitors%3A+design%2C+synthesis%2C+and+evaluation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation</span></div><div class="casAuthors">Harmange, Jean-Christophe; Weiss, Matthew M.; Germain, Julie; Polverino, Anthony J.; Borg, George; Bready, James; Chen, Danlin; Choquette, Deborah; Coxon, Angela; DeMelfi, Tom; DiPietro, Lucian; Doerr, Nicholas; Estrada, Juan; Flynn, Julie; Graceffa, Russell F.; Harriman, Shawn P.; Kaufman, Stephen; La, Daniel S.; Long, Alexander; Martin, Matthew W.; Neervannan, Sesha; Patel, Vinod F.; Potashman, Michele; Regal, Kelly; Roveto, Phillip M.; Schrag, Michael L.; Starnes, Charlie; Tasker, Andrew; Teffera, Yohannes; Wang, Ling; White, Ryan D.; Whittington, Douglas A.; Zanon, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1649-1667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of naphthyl-based compds. were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors.  Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family.  Numerous analogs demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compds. possessed favorable pharmacokinetic (PK) profiles.  In particular, compd. I demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice.  A full account of the prepn., structure-activity relationships, pharmacokinetic properties, and pharmacol. of analogs within this series is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1vrmtgp3_m7Vg90H21EOLACvtfcHk0lgHLs07zsnJ4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D&md5=25685f28450b2ab132ffd278e6c53598</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Fjm701097z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701097z%26sid%3Dliteratum%253Aachs%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DBorg%26aufirst%3DG.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDiPietro%26aufirst%3DL.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLong%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DSchrag%26aufirst%3DM.%2BL.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZanon%26aufirst%3DR.%26atitle%3DNaphthamides%2520as%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1649%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, R.</span><span> </span><span class="NLM_article-title">Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1668</span><span class="NLM_x">–</span> <span class="NLM_lpage">1680</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701098w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1668-1680&author=M.+M.+Weissauthor=J.+C.+Harmangeauthor=A.+J.+Polverinoauthor=D.+Bauerauthor=L.+Berryauthor=V.+Berryauthor=G.+Borgauthor=J.+Breadyauthor=D.+Chenauthor=D.+Choquetteauthor=A.+Coxonauthor=T.+DeMelfiauthor=N.+Doerrauthor=J.+Estradaauthor=J.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=S.+Kaufmanauthor=D.+S.+Laauthor=A.+Longauthor=S.+Neervannanauthor=V.+F.+Patelauthor=M.+Potashmanauthor=K.+Regalauthor=P.+M.+Rovetoauthor=M.+L.+Schragauthor=C.+Starnesauthor=A.+Taskerauthor=Y.+Tefferaauthor=D.+A.+Whittingtonauthor=R.+Zanon&title=Evaluation+of+a+series+of+naphthamides+as+potent%2C+orally+active+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Fjm701098w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701098w%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DV.%26aulast%3DBorg%26aufirst%3DG.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLong%26aufirst%3DA.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DSchrag%26aufirst%3DM.%2BL.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZanon%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520a%2520series%2520of%2520naphthamides%2520as%2520potent%252C%2520orally%2520active%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1668%26epage%3D1680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belzile, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span> </span><span class="NLM_article-title">Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1695</span><span class="NLM_x">–</span> <span class="NLM_lpage">1705</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701129j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1695-1705&author=D.+S.+Laauthor=J.+Belzileauthor=J.+V.+Breadyauthor=A.+Coxonauthor=T.+DeMelfiauthor=N.+Doerrauthor=J.+Estradaauthor=J.+C.+Flynnauthor=S.+R.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=J.+F.+Larrowauthor=A.+M.+Longauthor=M.+W.+Martinauthor=M.+J.+Morrisonauthor=V.+F.+Patelauthor=P.+M.+Rovetoauthor=L.+Wangauthor=M.+M.+Weissauthor=D.+A.+Whittingtonauthor=Y.+Tefferaauthor=Z.+Zhaoauthor=A.+J.+Polverinoauthor=J.+C.+Harmange&title=Novel+2%2C3-dihydro-1%2C4-benzoxazines+as+potent+and+orally+bioavailable+inhibitors+of+tumor-driven+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm701129j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701129j%26sid%3Dliteratum%253Aachs%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DBelzile%26aufirst%3DJ.%26aulast%3DBready%26aufirst%3DJ.%2BV.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%2BC.%26aulast%3DFlynn%26aufirst%3DS.%2BR.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DNovel%25202%252C3-dihydro-1%252C4-benzoxazines%2520as%2520potent%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520tumor-driven%2520angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1695%26epage%3D1705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span> </span><span class="NLM_article-title">Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4844</span><span class="NLM_x">–</span> <span class="NLM_lpage">4848</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4844-4848&author=D.+Bauerauthor=D.+A.+Whittingtonauthor=A.+Coxonauthor=J.+Breadyauthor=S.+P.+Harrimanauthor=V.+F.+Patelauthor=A.+Polverinoauthor=J.+C.+Harmange&title=Evaluation+of+indazole-based+compounds+as+a+new+class+of+potent+KDR%2FVEGFR-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DEvaluation%2520of%2520indazole-based%2520compounds%2520as%2520a%2520new%2520class%2520of%2520potent%2520KDR%252FVEGFR-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4844%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Mannion, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claridge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saavedra, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakovic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déziel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chute, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaisburg, A.</span><span> </span><span class="NLM_article-title"><i>N</i>-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6552</span><span class="NLM_x">–</span> <span class="NLM_lpage">6556</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6552-6556&author=M.+Mannionauthor=S.+Raeppelauthor=S.+Claridgeauthor=N.+Zhouauthor=O.+Saavedraauthor=L.+Isakovicauthor=L.+Zhanauthor=F.+Gaudetteauthor=F.+Raeppelauthor=R.+D%C3%A9zielauthor=N.+Beaulieuauthor=H.+Nguyenauthor=I.+Chuteauthor=C.+Beaulieuauthor=I.+Dupontauthor=M.+F.+Robertauthor=S.+Lefebvreauthor=M.+Dubayauthor=J.+Rahilauthor=J.+Wangauthor=H.+Ste-Croixauthor=R.+A.+Macleodauthor=J.+M.+Bestermanauthor=A.+Vaisburg&title=N-%284-%286%2C7-Disubstituted-quinolin-4-yloxy%29-3-fluorophenyl%29-2-oxo-3-phenylimidazolidine-1-carboxamides%3A+a+novel+series+of+dual+c-Met%2FVEGFR2+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMannion%26aufirst%3DM.%26aulast%3DRaeppel%26aufirst%3DS.%26aulast%3DClaridge%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DSaavedra%26aufirst%3DO.%26aulast%3DIsakovic%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DGaudette%26aufirst%3DF.%26aulast%3DRaeppel%26aufirst%3DF.%26aulast%3DD%25C3%25A9ziel%26aufirst%3DR.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DChute%26aufirst%3DI.%26aulast%3DBeaulieu%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DI.%26aulast%3DRobert%26aufirst%3DM.%2BF.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DDubay%26aufirst%3DM.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DMacleod%26aufirst%3DR.%2BA.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DN-%25284-%25286%252C7-Disubstituted-quinolin-4-yloxy%2529-3-fluorophenyl%2529-2-oxo-3-phenylimidazolidine-1-carboxamides%253A%2520a%2520novel%2520series%2520of%2520dual%2520c-Met%252FVEGFR2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6552%26epage%3D6556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. L.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6653</span><span class="NLM_x">–</span> <span class="NLM_lpage">6656</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6653-6656&author=Y.+Yangauthor=L.+Shiauthor=Y.+Zhouauthor=H.+Q.+Liauthor=Z.+W.+Zhuauthor=H.+L.+Zhu&title=Design%2C+synthesis+and+biological+evaluation+of+quinoline+amide+derivatives+as+novel+VEGFR-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26aulast%3DZhu%26aufirst%3DZ.%2BW.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520quinoline%2520amide%2520derivatives%2520as%2520novel%2520VEGFR-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6653%26epage%3D6656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Rizvi, S. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, I.</span><span> </span><span class="NLM_article-title">Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=942-944&author=S.+U.+Rizviauthor=H.+L.+Siddiquiauthor=M.+Nisarauthor=N.+Khanauthor=I.+Khan&title=Discovery+and+molecular+docking+of+quinolyl-thienyl+chalcones+as+anti-angiogenic+agents+targeting+VEGFR-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRizvi%26aufirst%3DS.%2BU.%26aulast%3DSiddiqui%26aufirst%3DH.%2BL.%26aulast%3DNisar%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DKhan%26aufirst%3DI.%26atitle%3DDiscovery%2520and%2520molecular%2520docking%2520of%2520quinolyl-thienyl%2520chalcones%2520as%2520anti-angiogenic%2520agents%2520targeting%2520VEGFR-2%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D942%26epage%3D944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group">Raeppel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claridge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saavedra, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannion, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakovic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déziel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert Macleod, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaisburg, A.</span><span> </span><span class="NLM_article-title"><i>N</i>-(3-Fluoro-4-(2-arylthieno[3,2-<i>b</i>]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1323</span><span class="NLM_x">–</span> <span class="NLM_lpage">1328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1323-1328&author=S.+Raeppelauthor=S.+Claridgeauthor=O.+Saavedraauthor=F.+Gaudetteauthor=L.+Zhanauthor=M.+Mannionauthor=N.+Zhouauthor=F.+Raeppelauthor=M.+C.+Grangerauthor=L.+Isakovicauthor=R.+D%C3%A9zielauthor=H.+Nguyenauthor=N.+Beaulieuauthor=C.+Beaulieuauthor=I.+Dupontauthor=M.+F.+Robertauthor=S.+Lefebvreauthor=M.+Dubayauthor=J.+Rahilauthor=J.+Wangauthor=H.+Ste-Croixauthor=A.+Robert+Macleodauthor=J.+Bestermanauthor=A.+Vaisburg&title=N-%283-Fluoro-4-%282-arylthieno%5B3%2C2-b%5Dpyridin-7-yloxy%29phenyl%29-2-oxo-3-phenylimidazolidine-1-carboxamides%3A+a+novel+series+of+dual+c-Met%2FVEGFR2+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaeppel%26aufirst%3DS.%26aulast%3DClaridge%26aufirst%3DS.%26aulast%3DSaavedra%26aufirst%3DO.%26aulast%3DGaudette%26aufirst%3DF.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DMannion%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DRaeppel%26aufirst%3DF.%26aulast%3DGranger%26aufirst%3DM.%2BC.%26aulast%3DIsakovic%26aufirst%3DL.%26aulast%3DD%25C3%25A9ziel%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DBeaulieu%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DI.%26aulast%3DRobert%26aufirst%3DM.%2BF.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DDubay%26aufirst%3DM.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DRobert%2BMacleod%26aufirst%3DA.%26aulast%3DBesterman%26aufirst%3DJ.%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DN-%25283-Fluoro-4-%25282-arylthieno%255B3%252C2-b%255Dpyridin-7-yloxy%2529phenyl%2529-2-oxo-3-phenylimidazolidine-1-carboxamides%253A%2520a%2520novel%2520series%2520of%2520dual%2520c-Met%252FVEGFR2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1323%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Saavedra, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claridge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeppel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannion, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakovic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déziel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaisburg, A.</span><span> </span><span class="NLM_article-title"><i>N</i><sup>3</sup>-Arylmalonamides: a new series of thieno[3,2-<i>b</i>]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6836</span><span class="NLM_x">–</span> <span class="NLM_lpage">6839</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6836-6839&author=O.+Saavedraauthor=S.+Claridgeauthor=L.+Zhanauthor=F.+Raeppelauthor=M.+C.+Grangerauthor=S.+Raeppelauthor=M.+Mannionauthor=F.+Gaudetteauthor=N.+Zhouauthor=L.+Isakovicauthor=N.+Bernsteinauthor=R.+D%C3%A9zielauthor=H.+Nguyenauthor=N.+Beaulieuauthor=C.+Beaulieuauthor=I.+Dupontauthor=J.+Wangauthor=A.+R.+Macleodauthor=J.+M.+Bestermanauthor=A.+Vaisburg&title=N3-Arylmalonamides%3A+a+new+series+of+thieno%5B3%2C2-b%5Dpyridine+based+inhibitors+of+c-Met+and+VEGFR2+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaavedra%26aufirst%3DO.%26aulast%3DClaridge%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DRaeppel%26aufirst%3DF.%26aulast%3DGranger%26aufirst%3DM.%2BC.%26aulast%3DRaeppel%26aufirst%3DS.%26aulast%3DMannion%26aufirst%3DM.%26aulast%3DGaudette%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DIsakovic%26aufirst%3DL.%26aulast%3DBernstein%26aufirst%3DN.%26aulast%3DD%25C3%25A9ziel%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DBeaulieu%26aufirst%3DC.%26aulast%3DDupont%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMacleod%26aufirst%3DA.%2BR.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DN3-Arylmalonamides%253A%2520a%2520new%2520series%2520of%2520thieno%255B3%252C2-b%255Dpyridine%2520based%2520inhibitors%2520of%2520c-Met%2520and%2520VEGFR2%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6836%26epage%3D6839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5330</span><span class="NLM_x">–</span> <span class="NLM_lpage">5341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800476q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5330-5341&author=K.+S.+Kimauthor=L.+Zhangauthor=R.+Schmidtauthor=Z.+W.+Caiauthor=D.+Weiauthor=D.+K.+Williamsauthor=L.+J.+Lombardoauthor=G.+L.+Trainorauthor=D.+Xieauthor=Y.+Zhangauthor=Y.+Anauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=C.+Darienzoauthor=A.+Kamathauthor=P.+Maratheauthor=Y.+Zhangauthor=J.+Lippyauthor=R.+Jeyaseelanauthor=B.+Wautletauthor=B.+Henleyauthor=J.+Gullo-Brownauthor=V.+Manneauthor=J.+T.+Huntauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+pyrrolopyridine-pyridone+based+inhibitors+of+Met+kinase%3A+synthesis%2C+X-ray+crystallographic+analysis%2C+and+biological+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Fjm800476q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800476q%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DDarienzo%26aufirst%3DC.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520pyrrolopyridine-pyridone%2520based%2520inhibitors%2520of%2520Met%2520kinase%253A%2520synthesis%252C%2520X-ray%2520crystallographic%2520analysis%252C%2520and%2520biological%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5330%26epage%3D5341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doktor, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">386</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=386-390&author=Y.+Daiauthor=K.+Hartandiauthor=N.+B.+Soniauthor=L.+J.+Peaseauthor=D.+R.+Reuterauthor=A.+M.+Olsonauthor=D.+J.+Osterlingauthor=S.+Z.+Doktorauthor=D.+H.+Albertauthor=J.+J.+Bouskaauthor=K.+B.+Glaserauthor=P.+A.+Marcotteauthor=K.+D.+Stewartauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Identification+of+aminopyrazolopyridine+ureas+as+potent+VEGFR%2FPDGFR+multitargeted+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DDoktor%26aufirst%3DS.%2BZ.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DIdentification%2520of%2520aminopyrazolopyridine%2520ureas%2520as%2520potent%2520VEGFR%252FPDGFR%2520multitargeted%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D386%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">Kiselyov, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenov, V. V.</span><span> </span><span class="NLM_article-title">3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1195</span><span class="NLM_x">–</span> <span class="NLM_lpage">1198</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1195-1198&author=A.+S.+Kiselyovauthor=M.+Semenovaauthor=V.+V.+Semenov&title=3%2C4-Disubstituted+isothiazoles%3A+novel+potent+inhibitors+of+VEGF+receptors+1+and+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DSemenova%26aufirst%3DM.%26aulast%3DSemenov%26aufirst%3DV.%2BV.%26atitle%3D3%252C4-Disubstituted%2520isothiazoles%253A%2520novel%2520potent%2520inhibitors%2520of%2520VEGF%2520receptors%25201%2520and%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1195%26epage%3D1198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Kiselyov, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenov, V. V.</span><span> </span><span class="NLM_article-title">(1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1344</span><span class="NLM_x">–</span> <span class="NLM_lpage">1348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1344-1348&author=A.+S.+Kiselyovauthor=M.+Semenovaauthor=V.+V.+Semenov&title=%281%2C2%2C3-Triazol-4-yl%29benzenamines%3A+synthesis+and+activity+against+VEGF+receptors+1+and+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DSemenova%26aufirst%3DM.%26aulast%3DSemenov%26aufirst%3DV.%2BV.%26atitle%3D%25281%252C2%252C3-Triazol-4-yl%2529benzenamines%253A%2520synthesis%2520and%2520activity%2520against%2520VEGF%2520receptors%25201%2520and%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1344%26epage%3D1348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">Choi, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paik, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. T.</span><span> </span><span class="NLM_article-title">BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6236</span><span class="NLM_x">–</span> <span class="NLM_lpage">6241</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6236-6241&author=H.+E.+Choiauthor=M.+S.+Yooauthor=J.+H.+Choiauthor=J.+Y.+Leeauthor=J.+H.+Kimauthor=J.+H.+Kimauthor=J.+K.+Leeauthor=G.+I.+Kimauthor=Y.+Parkauthor=Y.+H.+Chiauthor=S.+H.+Paikauthor=J.+H.+Leeauthor=K.+T.+Lee&title=BRN-103%2C+a+novel+nicotinamide+derivative%2C+inhibits+VEGF-induced+angiogenesis+and+proliferation+in+human+umbilical+vein+endothelial+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BE.%26aulast%3DYoo%26aufirst%3DM.%2BS.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DG.%2BI.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DChi%26aufirst%3DY.%2BH.%26aulast%3DPaik%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DK.%2BT.%26atitle%3DBRN-103%252C%2520a%2520novel%2520nicotinamide%2520derivative%252C%2520inhibits%2520VEGF-induced%2520angiogenesis%2520and%2520proliferation%2520in%2520human%2520umbilical%2520vein%2520endothelial%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6236%26epage%3D6241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">Cao, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y. L.</span><span> </span><span class="NLM_article-title">SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth <i>in vivo</i></span> <span class="citation_source-journal">Cell. Physiol. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">574</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1159%2F000329978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21691074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnslensrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2011&pages=565-574&author=Z.+X.+Caoauthor=R.+L.+Zhengauthor=H.+J.+Linauthor=S.+D.+Luoauthor=Y.+Zhouauthor=Y.+Z.+Xuauthor=X.+X.+Zengauthor=Z.+Wangauthor=L.+N.+Zhouauthor=Y.+Q.+Maoauthor=L.+Yangauthor=Y.+Q.+Weiauthor=L.+T.+Yuauthor=S.+Y.+Yangauthor=Y.+L.+Zhao&title=SKLB610%3A+a+novel+potential+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases+inhibits+angiogenesis+and+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB610: A novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo</span></div><div class="casAuthors">Cao, Zhi-Xing; Zheng, Ren-Lin; Lin, Hong-Jun; Luo, Shi-Dong; Zhou, Yan; Xu, You-Zhi; Zeng, Xiu-Xiu; Wang, Zhao; Zhou, Li-Na; Mao, Yong-qiu; Yang, Li; Wei, Yu-Quan; Yu, Luo-Ting; Yang, Sheng-Yong; Zhao, Ying-Lan</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Antagonizing angiogenesis-related receptor tyrosine kinase is a promising therapeutic strategy in oncol.  In present study, we designed and synthesized a novel vascular endothelial growth factor receptor (VEGFR) inhibitor N-methyl-4-(4-(3-(trifluoromethyl) benzamido) phenoxy) picolinamide SKLB610 that potently suppresses human tumor angiogenesis.  SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth factor receptor 2 (FGFR2) and platelet-derived growth factor receptor (PDGFR) at rate of 97%, 65% and 55%, resp., at concn. of 10μM in biochem. kinase assays.  In vitro, SKLB610 showed more selective inhibition of VEGF-stimulated human umbilical vein endothelial cells (HUVECs) proliferation, and this proliferation inhibitory effect was assocd. with decreased phosphorylation of VEGFR2 and p42/44 mitogen-activated protein kinase (p42/44 MAPK).  Antiangiogenic evaluation showed that SKLB610 inhibited the HUVECs capillary-tube formation on Matrigel in vitro and the sub-intestinal vein formation of zebrafish in vivo.  Moreover, SKLB610 inhibited a panel of human cancer cells proliferation in a concn.-dependent manner and human non-small cell lung cancer cell line A549 and human colorectal cancer cell line HCT116 were most sensitive to SKLB610 treatment.  In vivo, chronic i.p. administration of SKLB610 at dose of 50 mg/kg/d resulted in significant inhibition in the growth of established human A549 and HCT116 tumor xenografts in nude mice without exhibit toxicity.  Histol. anal. showed significant redns. in intratumoral microvessel d. (CD31 staining) of 43-55% relative to controls depending on the specific tumor xenografts.  In conclusion, the present study demonstrated that SKLB610 exhibited its antitumor activity as a multi-targeted inhibitor with more potent inhibition of VEGFR2 activity.  Its potential to be a candidate of anticancer agent is worth being further investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0_JmlLdPKLVg90H21EOLACvtfcHk0lihbSAdaNKgKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnslensrk%253D&md5=c336eca447470eceeb7f5734251f72ac</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1159%2F000329978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000329978%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DZ.%2BX.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DH.%2BJ.%26aulast%3DLuo%26aufirst%3DS.%2BD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%2BZ.%26aulast%3DZeng%26aufirst%3DX.%2BX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYu%26aufirst%3DL.%2BT.%26aulast%3DYang%26aufirst%3DS.%2BY.%26aulast%3DZhao%26aufirst%3DY.%2BL.%26atitle%3DSKLB610%253A%2520a%2520novel%2520potential%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%2520inhibits%2520angiogenesis%2520and%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2011%26volume%3D27%26spage%3D565%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group">Dandu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miknyoczki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Design and synthesis of dihydroindazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1916</span><span class="NLM_x">–</span> <span class="NLM_lpage">1921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1916-1921&author=R.+Danduauthor=A.+L.+Zulliauthor=E.+R.+Baconauthor=T.+Underinerauthor=C.+Robinsonauthor=H.+Changauthor=S.+Miknyoczkiauthor=J.+Grobelnyauthor=B.+A.+Ruggeriauthor=S.+Yangauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=R.+L.+Hudkins&title=Design+and+synthesis+of+dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole+oximes+as+potent+dual+inhibitors+of+TIE-2+and+VEGF-R2+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDandu%26aufirst%3DR.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DBacon%26aufirst%3DE.%2BR.%26aulast%3DUnderiner%26aufirst%3DT.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DGrobelny%26aufirst%3DJ.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole%2520oximes%2520as%2520potent%2520dual%2520inhibitors%2520of%2520TIE-2%2520and%2520VEGF-R2%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1916%26epage%3D1921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josef, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A.</span><span> </span><span class="NLM_article-title">TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2368</span><span class="NLM_x">–</span> <span class="NLM_lpage">2372</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2368-2372&author=T.+L.+Underinerauthor=B.+Ruggeriauthor=L.+Aimoneauthor=M.+Albomauthor=T.+Angelesauthor=H.+Changauthor=R.+L.+Hudkinsauthor=K.+Hunterauthor=K.+Josefauthor=C.+Robinsonauthor=L.+Weinbergauthor=S.+Yangauthor=A.+Zulli&title=TIE-2%2FVEGF-R2+SAR+and+in+vitro+activity+of+C3-acyl+dihydroindazolo%5B5%2C4-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DAimone%26aufirst%3DL.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DJosef%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DWeinberg%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZulli%26aufirst%3DA.%26atitle%3DTIE-2%252FVEGF-R2%2520SAR%2520and%2520in%2520vitro%2520activity%2520of%2520C3-acyl%2520dihydroindazolo%255B5%252C4-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2368%26epage%3D2372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauletti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almo, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">8-THP-DHI analogs as potent type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3356</span><span class="NLM_x">–</span> <span class="NLM_lpage">3360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3356-3360&author=R.+L.+Hudkinsauthor=A.+L.+Zulliauthor=T.+L.+Underinerauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=S.+L.+Meyerauthor=D.+Paulettiauthor=H.+Changauthor=E.+V.+Fedorovauthor=S.+C.+Almoauthor=A.+A.+Fedorovauthor=B.+A.+Ruggeri&title=8-THP-DHI+analogs+as+potent+type+I+dual+TIE-2%2FVEGF-R2+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DPauletti%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DFedorov%26aufirst%3DE.%2BV.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DFedorov%26aufirst%3DA.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3D8-THP-DHI%2520analogs%2520as%2520potent%2520type%2520I%2520dual%2520TIE-2%252FVEGF-R2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3356%26epage%3D3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group">Peifer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinkel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schächtele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidenreich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Röcken, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schollmeyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel 3-aryl-4-(1<i>H</i>-indole-3yl)-1,5-dihydro-2<i>H</i>-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3814</span><span class="NLM_x">–</span> <span class="NLM_lpage">3824</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8001185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3814-3824&author=C.+Peiferauthor=R.+Seligauthor=K.+Kinkelauthor=D.+Ottauthor=F.+Totzkeauthor=C.+Sch%C3%A4chteleauthor=R.+Heidenreichauthor=M.+R%C3%B6ckenauthor=D.+Schollmeyerauthor=S.+Laufer&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+3-aryl-4-%281H-indole-3yl%29-1%2C5-dihydro-2H-pyrrole-2-ones+as+vascular+endothelial+growth+factor+receptor+%28VEGF-R%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fjm8001185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001185%26sid%3Dliteratum%253Aachs%26aulast%3DPeifer%26aufirst%3DC.%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DKinkel%26aufirst%3DK.%26aulast%3DOtt%26aufirst%3DD.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DHeidenreich%26aufirst%3DR.%26aulast%3DR%25C3%25B6cken%26aufirst%3DM.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%25203-aryl-4-%25281H-indole-3yl%2529-1%252C5-dihydro-2H-pyrrole-2-ones%2520as%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520%2528VEGF-R%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3814%26epage%3D3824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group">Cho, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bing, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiong, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bei, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, M. X.</span><span> </span><span class="NLM_article-title">Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure–activity relationships, and antitumor activities of 2-indolinone derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8140</span><span class="NLM_x">–</span> <span class="NLM_lpage">8149</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8140-8149&author=T.+P.+Choauthor=S.+Y.+Dongauthor=F.+Junauthor=F.+J.+Hongauthor=Y.+J.+Liangauthor=X.+Luauthor=P.+J.+Huaauthor=L.+Y.+Liauthor=Z.+Leiauthor=H.+Bingauthor=Z.+Yingauthor=L.+F.+Qiongauthor=F.+B.+Beiauthor=L.+L.+Guangauthor=G.+A.+Shenauthor=S.+G.+Hongauthor=S.+W.+Hongauthor=M.+X.+Tai&title=Novel+potent+orally+active+multitargeted+receptor+tyrosine+kinase+inhibitors%3A+synthesis%2C+structure%E2%80%93activity+relationships%2C+and+antitumor+activities+of+2-indolinone+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DT.%2BP.%26aulast%3DDong%26aufirst%3DS.%2BY.%26aulast%3DJun%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DF.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%2BJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DP.%2BJ.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DLei%26aufirst%3DZ.%26aulast%3DBing%26aufirst%3DH.%26aulast%3DYing%26aufirst%3DZ.%26aulast%3DQiong%26aufirst%3DL.%2BF.%26aulast%3DBei%26aufirst%3DF.%2BB.%26aulast%3DGuang%26aufirst%3DL.%2BL.%26aulast%3DShen%26aufirst%3DG.%2BA.%26aulast%3DHong%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DS.%2BW.%26aulast%3DTai%26aufirst%3DM.%2BX.%26atitle%3DNovel%2520potent%2520orally%2520active%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520antitumor%2520activities%2520of%25202-indolinone%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8140%26epage%3D8149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span> </span><span class="NLM_article-title">Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1007%2Fs00280-011-1681-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21638122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=173-183&author=D.+Wangauthor=F.+Tangauthor=S.+Wangauthor=Z.+Jiangauthor=L.+Zhang&title=Preclinical+anti-angiogenesis+and+anti-tumor+activity+of+SIM010603%2C+an+oral%2C+multi-targets+receptor+tyrosine+kinases+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor</span></div><div class="casAuthors">Wang, Dongchun; Tang, Feng; Wang, Sen; Jiang, Zhenzhou; Zhang, Luyong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-183</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objective: SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor.  This study investigated the anti-angiogenic and anti-tumor effects of SIM010603.  Methods: A radiometric protein kinase assay was used for measuring the kinase activity of the 32 protein kinases.  Receptor phosphorylation was detd. by ELISA (ELISA).  Cell proliferation was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.  Cell chemotaxis was evaluated by modified Boyden chamber assay.  Effect of SIM010603 on angiogenesis was examd. by mouse cornea angiogenesis assay.  Effect of SIM010603 on xenografts was assessed by tumor growth delay.  Effects of SIM010603 on tumor microvascular d. (MVD), recruitment of pericytes, and pericyte encapsulation of tumor vessels were analyzed by immunofluorescent staining technique.  Results: SIM010603 inhibited stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC50 values between 5.0 and 68.1 nmol/l.  SIM010603 inhibited the phosphorylation of PDGFR-β and VEGFR-2.  Moreover, SIM010603 inhibited endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis.  Although SIM010603 exhibited lower activity in regard to proliferation of NCI-H460, MDA-MB-435, and T241-VEGF-A cells (IC50 > 1 μmol/l), SIM010603 inhibited tumor growth in these xenograft tumor growth models.  SIM010603 reduced tumor MVD in T241-VEGF-A tumor xenograft models and decreased pos. signals of CD31, NG2 in MDA-MB-435, and LLC-SW-44 xenograft tumor models.  Conclusions: These results support the clin. assessment of SIM010603 as a therapeutic agent for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4z0U7U1VXbVg90H21EOLACvtfcHk0lghUNu9iMx4mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVOntw%253D%253D&md5=7dab0478ef64e82a722254ca06efe457</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1681-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1681-1%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DPreclinical%2520anti-angiogenesis%2520and%2520anti-tumor%2520activity%2520of%2520SIM010603%252C%2520an%2520oral%252C%2520multi-targets%2520receptor%2520tyrosine%2520kinases%2520inhibitor%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D173%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span> </span><span class="NLM_article-title">Synthesis, SAR, and evaluation of 4-[2,4-difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-<i>f</i>][1,2,4]triazine-based VEGFR-2 kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1354</span><span class="NLM_x">–</span> <span class="NLM_lpage">1358</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1354-1358&author=Z.+W.+Caiauthor=D.+Weiauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=A.+Kamathauthor=S.+Mortilloauthor=B.+Wautletauthor=B.+J.+Henleyauthor=R.+Jeyaseelanauthor=J.+Tokarskiauthor=J.+T.+Huntauthor=R.+S.+Bhideauthor=J.+Fargnoliauthor=L.+J.+Lombardo&title=Synthesis%2C+SAR%2C+and+evaluation+of+4-%5B2%2C4-difluoro-5-%28cyclopropylcarbamoyl%29phenylamino%5Dpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazine-based+VEGFR-2+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DHenley%26aufirst%3DB.%2BJ.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26atitle%3DSynthesis%252C%2520SAR%252C%2520and%2520evaluation%2520of%25204-%255B2%252C4-difluoro-5-%2528cyclopropylcarbamoyl%2529phenylamino%255Dpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazine-based%2520VEGFR-2%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1354%26epage%3D1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group">Ruel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">L’Heureux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tejwani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-<i>N</i>-(2-methyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)pyrrolo[2,1-<i>f</i>][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2985</span><span class="NLM_x">–</span> <span class="NLM_lpage">2989</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2985-2989&author=R.+Ruelauthor=C.+Thibeaultauthor=A.+L%E2%80%99Heureuxauthor=A.+Martelauthor=Z.+W.+Caiauthor=D.+Weiauthor=L.+Qianauthor=J.+C.+Barrishauthor=A.+Mathurauthor=C.+D%E2%80%99Arienzoauthor=J.+T.+Huntauthor=A.+Kamathauthor=P.+Maratheauthor=Y.+Zhangauthor=G.+Derbinauthor=B.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=B.+Henleyauthor=R.+Tejwaniauthor=R.+S.+Bhideauthor=G.+L.+Trainorauthor=J.+Fargnoliauthor=L.+J.+Lombardo&title=Discovery+and+preclinical+studies+of+5-isopropyl-6-%285-methyl-1%2C3%2C4-oxadiazol-2-yl%29-N-%282-methyl-1H-pyrrolo%5B2%2C3-b%5Dpyridin-5-yl%29pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-4-amine+%28BMS-645737%29%2C+an+in+vivo+active+potent+VEGFR-2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuel%26aufirst%3DR.%26aulast%3DThibeault%26aufirst%3DC.%26aulast%3DL%25E2%2580%2599Heureux%26aufirst%3DA.%26aulast%3DMartel%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DTejwani%26aufirst%3DR.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520studies%2520of%25205-isopropyl-6-%25285-methyl-1%252C3%252C4-oxadiazol-2-yl%2529-N-%25282-methyl-1H-pyrrolo%255B2%252C3-b%255Dpyridin-5-yl%2529pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-4-amine%2520%2528BMS-645737%2529%252C%2520an%2520in%2520vivo%2520active%2520potent%2520VEGFR-2%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2985%26epage%3D2989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">3-Amino-benzo[<i>d</i>]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701096v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1231-1241&author=Z.+Jiauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=G.+Diazauthor=K.+B.+Glaserauthor=J.+Guoauthor=C.+M.+Harrisauthor=J.+Liauthor=P.+A.+Marcotteauthor=M.+D.+Moskeyauthor=T.+Oieauthor=L.+Peaseauthor=N.+B.+Soniauthor=K.+D.+Stewartauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=3-Amino-benzo%5Bd%5Disoxazoles+as+novel+multitargeted+inhibitors+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Fjm701096v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701096v%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DOie%26aufirst%3DT.%26aulast%3DPease%26aufirst%3DL.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3D3-Amino-benzo%255Bd%255Disoxazoles%2520as%2520novel%2520multitargeted%2520inhibitors%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1231%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group">Abu Thaher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnsmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehlert, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubbutat, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schächtele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">961</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=961-965&author=B.+Abu+Thaherauthor=M.+Arnsmannauthor=F.+Totzkeauthor=J.+E.+Ehlertauthor=M.+H.+Kubbutatauthor=C.+Sch%C3%A4chteleauthor=M.+O.+Zimmermannauthor=P.+Kochauthor=F.+M.+Boecklerauthor=S.+A.+Laufer&title=Tri-+and+tetrasubstituted+pyrazole+derivates%3A+regioisomerism+switches+activity+from+p38MAP+kinase+to+important+cancer+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbu%2BThaher%26aufirst%3DB.%26aulast%3DArnsmann%26aufirst%3DM.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DEhlert%26aufirst%3DJ.%2BE.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DTri-%2520and%2520tetrasubstituted%2520pyrazole%2520derivates%253A%2520regioisomerism%2520switches%2520activity%2520from%2520p38MAP%2520kinase%2520to%2520important%2520cancer%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D961%26epage%3D965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group">Bologna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicentini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pace, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelucci, A.</span><span> </span><span class="NLM_article-title">Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2827</span><span class="NLM_x">–</span> <span class="NLM_lpage">2835</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.2174%2F092986711796150487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=21651496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2rtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2827-2835&author=M.+Bolognaauthor=C.+Vicentiniauthor=P.+Muziauthor=G.+Paceauthor=A.+Angelucci&title=Cancer+multitarget+pharmacology+in+prostate+tumors%3A+tyrosine+kinase+inhibitors+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond</span></div><div class="casAuthors">Bologna, M.; Vicentini, C.; Muzi, P.; Pace, G.; Angelucci, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2827-2835</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinase inhibitors are currently one of the most important classes of cancer drugs, essentially because many kinases and regulators are mols. related to frequently mutated oncogenes and tumor suppressors.  Many expts. and clin. data in different tumors show that better cancer therapy can be obtained by blocking several tumor cell biochem. pathways at once, accurately selecting crit. targets and adjusting drug dosages for the best results.  Through our direct experience in exptl. models of prostate cancer (PCa), we discuss in this review the issues of tyrosine kinase inhibition in neoplastic cells and illustrate the opportunities to extend cancer proliferation control to other key biol. targets of clin. interest, aiming at the realization of better polypharmacol. applications in cancer chemotherapy.  Briefly, in this review the main exptl. evidences on the efficacy of tyrosine kinase inhibitors (TKIs) on PCa are described, together with a reasoned anal. of biol. data which may be useful for a general extension to other clin. areas of cancer multitargeted and possibly individualized polychemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgCr2N6NiCYLVg90H21EOLACvtfcHk0liX4_BX9yyizg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2rtb8%253D&md5=bd5f67c7bae35fdbc2b688961bb4244c</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.2174%2F092986711796150487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796150487%26sid%3Dliteratum%253Aachs%26aulast%3DBologna%26aufirst%3DM.%26aulast%3DVicentini%26aufirst%3DC.%26aulast%3DMuzi%26aufirst%3DP.%26aulast%3DPace%26aufirst%3DG.%26aulast%3DAngelucci%26aufirst%3DA.%26atitle%3DCancer%2520multitarget%2520pharmacology%2520in%2520prostate%2520tumors%253A%2520tyrosine%2520kinase%2520inhibitors%2520and%2520beyond%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2827%26epage%3D2835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Fjm301085w&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Fjm301085w&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Fjm301085w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+polypharmacology%3A+discovery+of+dual+inhibitors+of+tyrosine+and+phosphoinositide+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0liX4_BX9yyizg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520polypharmacology%253A%2520discovery%2520of%2520dual%2520inhibitors%2520of%2520tyrosine%2520and%2520phosphoinositide%2520kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VHE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VHE','PDB','3VHE'); return false;">PDB: 3VHE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8Q','PDB','3B8Q'); return false;">PDB: 3B8Q</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301085w&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Fjm301085w%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301085w" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a5343fc8c248d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
